Year,Brand Name,Generic Name,Application Number,SPL Set ID,Review Document URL,Review Document Title
1984,POTASSIUM ACETATE,POTASSIUM ACETATE,NDA018896,c58f8112-d587-493a-91b7-2b48c80bb7bf,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/18896Orig1s012.pdf,
1984,POTASSIUM ACETATE,POTASSIUM ACETATE,NDA018896,c58f8112-d587-493a-91b7-2b48c80bb7bf,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/18896Orig1s011.pdf,
2015,SAVAYSA,EDOXABAN TOSYLATE,NDA206316,e77d3400-56ad-11e3-949a-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206316Orig1Orig2s000TOC.cfm,
2015,SAVAYSA,EDOXABAN TOSYLATE,NDA206316,e77d3400-56ad-11e3-949a-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206316Orig1Orig2s000SumR.pdf,
2013,UMECLIDINIUM AND VILANTEROL ELLIPTA,UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE,NDA203975,6de414b1-f707-4b98-9e4b-742032ec90af,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203975Orig1s000TOC.cfm,
2013,UMECLIDINIUM AND VILANTEROL ELLIPTA,UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE,NDA203975,6de414b1-f707-4b98-9e4b-742032ec90af,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203975Orig1s000SumR.pdf,
2014,TRIUMEQ,"ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE",NDA205551,2997739a-aa91-42aa-a206-a70e2db7b84f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205551Orig1s000TOC.cfm,
2014,TRIUMEQ,"ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE",NDA205551,2997739a-aa91-42aa-a206-a70e2db7b84f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/209_205551S11_clinical prea.pdf,
2014,TRIUMEQ,"ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE",NDA205551,2997739a-aa91-42aa-a206-a70e2db7b84f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/210_205551S11_clinpharm prea.pdf,
2017,GLEOLAN,AMINOLEVULINIC ACID HYDROCHLORIDE,NDA208630,4873911e-a5d7-47e3-9679-fa5c95999323,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208630Orig1s000TOC.cfm,
2018,BRYHALI,HALOBETASOL PROPIONATE,NDA209355,d4bbb66a-3f9d-4091-b1b0-1cbc908432d3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209355Orig1s000TOC.cfm,
1993,OMNISCAN,GADODIAMIDE,NDA020123,1e9a37e2-f28a-4373-bf0f-3e9b60f42d8a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020123_s015.pdf,
2019,SOVALDI,SOFOSBUVIR,NDA212480,80beab2c-396e-4a37-a4dc-40fdb62859cf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212480Orig1s000TOC.cfm,
2020,N/A,N/A,NDA212860,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212860Orig1s000TOC.cfm,
2021,N/A,N/A,NDA215358,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/215358Orig1s008TOC.cfm,
2021,N/A,N/A,NDA215358,N/A,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215358Orig1s000,Orig2s000TOC.cfm",
2011,N/A,N/A,NDA022494,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022494Orig1s000TOC.cfm,
2011,N/A,N/A,NDA022494,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022494Orig1s000SumR.pdf,
2022,REZVOGLAR KWIKPEN,INSULIN GLARGINE-AGLR,BLA761215,f6af8706-2058-4fe1-99c8-43684c20bfa2,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761215Orig2s000TOC.cfm,
2022,REZVOGLAR KWIKPEN,INSULIN GLARGINE-AGLR,BLA761215,f6af8706-2058-4fe1-99c8-43684c20bfa2,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761215Orig1s000TOC.cfm,
1999,N/A,N/A,NDA021040,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/021040_s000_OrthoPrefestTOC.cfm,
2003,N/A,N/A,NDA021371,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-371_Estrasorb.cfm,
2005,N/A,N/A,NDA021726,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021726s000_NiravamTOC.cfm,
2009,VECTICAL,CALCITRIOL,NDA022087,a1567da9-af74-4afd-9ac5-8b53ec5d7cbf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022087s000_SumR.pdf,
2009,VECTICAL,CALCITRIOL,NDA022087,a1567da9-af74-4afd-9ac5-8b53ec5d7cbf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022087_vectical_toc.cfm,
1967,N/A,N/A,NDA016131,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/016131Orig1s028.pdf,
1967,N/A,N/A,NDA016131,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/016131Orig1s026.pdf,
2012,CEFIXIME,CEFIXIME,NDA203195,6d68dbd9-7d75-4ff1-91db-79ff8ae879ec,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203195_suprax_toc.cfm,
2012,CEFIXIME,CEFIXIME,NDA203195,6d68dbd9-7d75-4ff1-91db-79ff8ae879ec,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203195Orig1s000SumR.pdf,
1988,CYTOTEC,MISOPROSTOL,NDA019268,4ab12da7-5731-4e06-bf1c-bc3f2e711f12,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/019268Orig1s000.pdf,
2010,KRYSTEXXA,PEGLOTICASE,BLA125293,6e566303-d93a-4130-b764-25749829aa95,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125293s0000TOC.cfm,
2010,KRYSTEXXA,PEGLOTICASE,BLA125293,6e566303-d93a-4130-b764-25749829aa95,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125293Orig1s000SumR.pdf,
1986,KLOR-CON,POTASSIUM CHLORIDE,NDA019123,1ff53330-065c-4213-9c0c-ac498621d09d,http://www.accessdata.fda.gov/drugsatfda_docs/NDA/pre96/019123_s000.pdf,
2016,DOXYCYCLINE HYCLATE,DOXYCYCLINE HYCLATE,NDA208253,fad03768-f1d2-459f-965e-0ec29f189f1f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208253Orig1s000TOC.cfm,
2016,DOXYCYCLINE HYCLATE,DOXYCYCLINE HYCLATE,NDA208253,fad03768-f1d2-459f-965e-0ec29f189f1f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208253Orig1s000SumR.pdf,
2025,DAWNZERA,DONIDALORSEN,NDA219407,3ff501e0-f75f-07da-e063-6294a90a0cb7,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219407Orig1s000TOC.cfm,
2023,POMBILITI ATGA,CIPAGLUCOSIDASE ALFA-ATGA,BLA761204,d77aa596-910d-516b-e053-2995a90a0839,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761204Orig1s000TOC.cfm,
1999,PRECEDEX,DEXMEDETOMIDINE HYDROCHLORIDE,NDA021038,4419162d-81d4-49bd-96de-1729440bdb74,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021038s022, s021 dexmedetomidine Precedex clinical bpca.pdf",
1999,PRECEDEX,DEXMEDETOMIDINE HYDROCHLORIDE,NDA021038,4419162d-81d4-49bd-96de-1729440bdb74,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021038s022, s021 dexmedetomidine Precedex clinpharm bpca.pdf",
1999,PRECEDEX,DEXMEDETOMIDINE HYDROCHLORIDE,NDA021038,4419162d-81d4-49bd-96de-1729440bdb74,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021038s022, s021 dexmedetomidine Precedex statistical bpca.pdf",
1999,PRECEDEX,DEXMEDETOMIDINE HYDROCHLORIDE,NDA021038,4419162d-81d4-49bd-96de-1729440bdb74,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021038Orig1s020.pdf,
1999,PRECEDEX,DEXMEDETOMIDINE HYDROCHLORIDE,NDA021038,4419162d-81d4-49bd-96de-1729440bdb74,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21-038_Precedex.cfm,
1999,PRECEDEX,DEXMEDETOMIDINE HYDROCHLORIDE,NDA021038,4419162d-81d4-49bd-96de-1729440bdb74,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021038Orig1s017.pdf,
2003,CIALIS,TADALAFIL,NDA021368,bcd8f8ab-81a2-4891-83db-24a0b0e25895,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-368_Cialis.cfm,
2003,CIALIS,TADALAFIL,NDA021368,bcd8f8ab-81a2-4891-83db-24a0b0e25895,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/245_21368S30 tadalafil clinical bpca.pdf,
2003,CIALIS,TADALAFIL,NDA021368,bcd8f8ab-81a2-4891-83db-24a0b0e25895,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/244_21368S30 tadalafil clinpharm bpca.pdf,
2003,CIALIS,TADALAFIL,NDA021368,bcd8f8ab-81a2-4891-83db-24a0b0e25895,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021368Orig1s020.pdf,
2012,N/A,N/A,BLA125294,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125294Orig1s000SumR.pdf,
2012,N/A,N/A,BLA125294,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125294Orig1s000TOC.cfm,
2012,N/A,N/A,BLA125294,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/312_125294S45-Tbo-filgrastim-clinical-bpca.pdf,
2012,N/A,N/A,BLA125294,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/311_125294S45-Tbo-filgrastim-CDTL-bpca.pdf,
2012,N/A,N/A,BLA125294,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/313_125294S45-Tbo-filgrastim-clinpharm-bpca.pdf,
2013,N/A,N/A,NDA204736,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204736_aciphex_toc.cfm,
2013,N/A,N/A,NDA204736,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/UCM350720.pdf,
2013,N/A,N/A,NDA204736,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/UCM350721.pdf,
2013,N/A,N/A,NDA204736,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/UCM350723.pdf,
2017,RHOPRESSA,NETARSUDIL,NDA208254,7d4f0e3a-5b86-4c43-982a-813b22ae7e22,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208254Orig1s000TOC.cfm,
2018,N/A,N/A,NDA208627,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208627Orig1s000TOC.cfm,
2018,N/A,N/A,NDA208627,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/208627Orig1s007.pdf,
2016,SELZENTRY,MARAVIROC,NDA208984,46f30ac5-c96b-429e-976d-8c5ee1c0761b,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208984Orig1s000,022128Orig1s017TOC.cfm",
2016,SELZENTRY,MARAVIROC,NDA208984,46f30ac5-c96b-429e-976d-8c5ee1c0761b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/35_208984 maraviroc clinical prea.pdf,
2016,SELZENTRY,MARAVIROC,NDA208984,46f30ac5-c96b-429e-976d-8c5ee1c0761b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/36_208984 maraviroc clinpharm prea.pdf,
2018,ALTRENO,TRETINOIN,NDA209353,1412aba5-71aa-4cce-8db4-c189bed1852c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209353Orig1s000TOC.cfm,
2021,TAVNEOS,AVACOPAN,NDA214487,c93cbc0b-29a3-46a5-9c85-41815ea5cf4a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214487Orig1s000TOC.cfm,
2019,HARVONI,LEDIPASVIR AND SOFOSBUVIR,NDA212477,f4ec77e4-bae8-4db0-b3d5-bde09c5fa075,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212477Orig1s000TOC.cfm,
2021,TWYNEO,TRETINOIN AND BENZOYL PEROXIDE,NDA214902,27208dff-e376-4c18-b56e-0a260f685a39,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214902Orig1s000TOC.cfm,
2024,DAPTOMYCIN,DAPTOMYCIN,NDA217630,c1d47001-5e0f-46a3-b220-53f46b4fd6ac,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/217630Orig1s000TOC.cfm,
2011,N/A,N/A,NDA022485,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022485_argatroban_toc.cfm,
2011,N/A,N/A,NDA022485,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022485Orig1s000SumR.pdf,
2021,TIVDAK,TISOTUMAB VEDOTIN,BLA761208,c9fe3f32-4219-466e-acb9-3f609b4f4df1,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761208Orig1s000TOC.cfm,
1956,N/A,N/A,NDA010515,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/010515Orig1s031.pdf,
1956,N/A,N/A,NDA010515,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/010515Orig1s023.pdf,
1956,N/A,N/A,NDA010515,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/010515Orig1s024.pdf,
1956,N/A,N/A,NDA010515,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/10515s022_Isuprel.pdf,
2007,RIVASTIGMINE,RIVASTIGMINE,NDA022083,92a58ebb-748d-49f4-bf11-ecbcf5424152,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022083Orig1s016.pdf,
2007,RIVASTIGMINE,RIVASTIGMINE,NDA022083,92a58ebb-748d-49f4-bf11-ecbcf5424152,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022083_exelon_toc.cfm,
2009,ILARIS,CANAKINUMAB,BLA125319,7d271f3b-e4f9-4d80-8dcf-28d49123f80e,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125319Orig1s085,086,087TOC.cfm",
2009,ILARIS,CANAKINUMAB,BLA125319,7d271f3b-e4f9-4d80-8dcf-28d49123f80e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/125319s000TOC.cfm,
2009,ILARIS,CANAKINUMAB,BLA125319,7d271f3b-e4f9-4d80-8dcf-28d49123f80e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/125319s000_SumR.pdf,
2009,ILARIS,CANAKINUMAB,BLA125319,7d271f3b-e4f9-4d80-8dcf-28d49123f80e,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125319Orig1s085,086,087TOC.cfm",
2009,ILARIS,CANAKINUMAB,BLA125319,7d271f3b-e4f9-4d80-8dcf-28d49123f80e,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125319Orig1s085,086,087TOC.cfm",
2016,N/A,N/A,NDA205103,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205103Orig1s000TOC.cfm,
2015,IBRANCE,PALBOCICLIB,NDA207103,e0e6412f-50b4-4fd4-9364-62818d121a07,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207103Orig1s000SumR.pdf,
2015,IBRANCE,PALBOCICLIB,NDA207103,e0e6412f-50b4-4fd4-9364-62818d121a07,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207103Orig1s000TOC.cfm,
2015,IBRANCE,PALBOCICLIB,NDA207103,e0e6412f-50b4-4fd4-9364-62818d121a07,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/207103Orig1s008.pdf,
2015,IBRANCE,PALBOCICLIB,NDA207103,e0e6412f-50b4-4fd4-9364-62818d121a07,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/207103Orig1s004.pdf,
2015,IBRANCE,PALBOCICLIB,NDA207103,e0e6412f-50b4-4fd4-9364-62818d121a07,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/207103Orig1s002.pdf,
2018,SYMFI LO,"EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE",NDA208255,86aad85d-5460-4c38-9761-a225e6bce190,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208255Orig1s000TOC.cfm,
2018,SYMFI LO,"EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE",NDA208255,86aad85d-5460-4c38-9761-a225e6bce190,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/234_208255-efavirenz-lamivudine-tenofovir-clinical-prea.pdf,
2018,SYMFI LO,"EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE",NDA208255,86aad85d-5460-4c38-9761-a225e6bce190,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/233_208255-efavirenz-lamivudine-tenofovir-clinpharm-prea.pdf,
2019,DUOBRII,HALOBETASOL PROPIONATE AND TAZAROTENE,NDA209354,b3f0cdc0-69fd-43d1-baf2-d776a3a20715,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209354Orig1s000TOC.cfm,
2023,AIRSUPRA,ALBUTEROL SULFATE AND BUDESONIDE,NDA214070,e60aa9f9-5139-44df-b886-ebddc3c7eb13,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/214070Orig1s000TOC.cfm,
1996,ELMIRON,PENTOSAN POLYSULFATE SODIUM,NDA020193,f0ba651e-3d8a-11df-8fbe-119855d89593,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/020193Orig1s014.pdf,
1996,ELMIRON,PENTOSAN POLYSULFATE SODIUM,NDA020193,f0ba651e-3d8a-11df-8fbe-119855d89593,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020193Orig1s000rev.pdf,
1996,ELMIRON,PENTOSAN POLYSULFATE SODIUM,NDA020193,f0ba651e-3d8a-11df-8fbe-119855d89593,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/020193Orig1s015.pdf,
1996,ELMIRON,PENTOSAN POLYSULFATE SODIUM,NDA020193,f0ba651e-3d8a-11df-8fbe-119855d89593,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020193Orig1s002.pdf,
2021,N/A,N/A,NDA212125,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/212125Orig1s000TOC.cfm,
2022,JYLAMVO,METHOTREXATE,NDA212479,96e931f5-51ae-4bdf-a441-bb0dd26d4c0e,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/212479Orig1,Orig2,Orig3,Orig4s000TOC.cfm",
2022,JYLAMVO,METHOTREXATE,NDA212479,96e931f5-51ae-4bdf-a441-bb0dd26d4c0e,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/212479Orig1,Orig2,Orig3,Orig4s000TOC.cfm",
2022,JYLAMVO,METHOTREXATE,NDA212479,96e931f5-51ae-4bdf-a441-bb0dd26d4c0e,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/212479Orig1,Orig2,Orig3,Orig4s000TOC.cfm",
2022,JYLAMVO,METHOTREXATE,NDA212479,96e931f5-51ae-4bdf-a441-bb0dd26d4c0e,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/212479Orig1,Orig2,Orig3,Orig4s000TOC.cfm",
2021,CYTALUX,PAFOLACIANINE INJECTION,NDA214907,d21952b9-7c4e-3a56-e053-2a95a90a0ab0,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000TOC.cfm,
2023,MIEBO,PERFLUOROHEXYLOCTANE,NDA216675,6b283c02-7df4-4c00-951b-555cddffe77c,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216675Orig1s000TOC.cfm,
2010,LYRICA,PREGABALIN,NDA022488,60185c88-ecfd-46f9-adb9-b97c6b00a553,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022488_lyrica_toc.cfm,
2010,LYRICA,PREGABALIN,NDA022488,60185c88-ecfd-46f9-adb9-b97c6b00a553,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022488s000sumr.pdf,
2010,LYRICA,PREGABALIN,NDA022488,60185c88-ecfd-46f9-adb9-b97c6b00a553,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/285_22488S13 pregabalin clinical and statistical both.pdf,
2010,LYRICA,PREGABALIN,NDA022488,60185c88-ecfd-46f9-adb9-b97c6b00a553,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/286_22488S13 pregabalin clinpharm both.pdf,
2010,LYRICA,PREGABALIN,NDA022488,60185c88-ecfd-46f9-adb9-b97c6b00a553,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/435_21446S36 pregabalin clinical prea.pdf,
2010,LYRICA,PREGABALIN,NDA022488,60185c88-ecfd-46f9-adb9-b97c6b00a553,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/436_21446S36 pregabalin CDTL prea.pdf,
2010,LYRICA,PREGABALIN,NDA022488,60185c88-ecfd-46f9-adb9-b97c6b00a553,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/437_21446S36 pregabalin clinipharm prea.pdf,
2010,LYRICA,PREGABALIN,NDA022488,60185c88-ecfd-46f9-adb9-b97c6b00a553,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/438_21446S36 pregabalin statistical prea.pdf,
2021,RYBREVANT,AMIVANTAMAB,BLA761210,1466c070-9f97-4fa4-a955-6a6b59981fb8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761210Orig1s000TOC.cfm,
1984,N/A,N/A,NDA050564,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/050564s022_augmentin.pdf,
2001,CAMPATH,ALEMTUZUMAB,BLA103948,4f5f7255-7abc-4328-bd1a-ceaf139ef3e0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/103948Orig1s5151.pdf,
2001,CAMPATH,ALEMTUZUMAB,BLA103948,4f5f7255-7abc-4328-bd1a-ceaf139ef3e0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/103948s000_CampathTOC.cfm,
2019,FLUORODOPA F18,FLUORODOPA F18,NDA200655,262503e7-de09-4b42-9963-ec00cbc7c35c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/200655Orig1s000TOC.cfm,
2012,N/A,N/A,NDA202799,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202799_Omontys_Orig1s000TOC.cfm,
2012,N/A,N/A,NDA202088,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202088Origs1s000SumR.pdf,
2012,N/A,N/A,NDA202088,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202088_suprenza_toc.cfm,
2012,N/A,N/A,NDA202088,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088_suprenza_toc.cfm,
2012,N/A,N/A,NDA202088,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000SumR.pdf,
2017,N/A,N/A,NDA204325,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/183_204325 amphetamine clinical prea.pdf,
2017,N/A,N/A,NDA204325,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/182_204325 amphetamine clinpharm prea.pdf,
2017,N/A,N/A,NDA204325,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/204325Orig1s000TOC.cfm,
2014,NATESTO NASAL GEL,TESTOSTERONE,NDA205488,dea6bed1-eaca-11e3-ac10-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205488Orig1s000SumR.pdf,
2014,NATESTO NASAL GEL,TESTOSTERONE,NDA205488,dea6bed1-eaca-11e3-ac10-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205488Orig1s000TOC.cfm,
2024,ITOVEBI,INAVOLISIB,NDA219249,5de59f5b-e5db-410f-b692-658686ef4107,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/219249Orig1s000TOC.cfm,
2022,ROLVEDON,EFLAPEGRASTIM-XNST,BLA761148,6e436115-62e7-4729-aeb0-ff78ea685206,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761148Orig1s000TOC.cfm,
1996,N/A,N/A,NDA020613,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-490s007_Alphagan.cfm,
1996,N/A,N/A,NDA020613,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020613Orig1s000rev.pdf,
2005,N/A,N/A,NDA020645,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020645s000TOC.cfm,
2023,RYZUMVI,PHENTOLAMINE MESYLATE,NDA217064,96bb1e53-c2cc-4e60-a21a-db0269c371bf,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217064Orig1s000TOC.cfm,
2013,ALOGLIPTIN AND PIOGLITAZONE,ALOGLIPTIN BENZOATE AND PIOGLITAZONE HYDROCHLORIDE,NDA022426,642b1e90-701e-42f2-bac6-a4918738e2c9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022426Orig1s000TOC.cfm,
2000,NOVOLOG,INSULIN ASPART,BLA020986,3a1e73a2-3009-40d0-876c-b4cb2be56fc5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-986se3003_Novolog.cfm,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2000,NOVOLOG,INSULIN ASPART,BLA020986,3a1e73a2-3009-40d0-876c-b4cb2be56fc5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-986SE3003_NovoLog_Approv.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2000,NOVOLOG,INSULIN ASPART,BLA020986,3a1e73a2-3009-40d0-876c-b4cb2be56fc5,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/020986Orig1s040.pdf,
2000,NOVOLOG,INSULIN ASPART,BLA020986,3a1e73a2-3009-40d0-876c-b4cb2be56fc5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020986Orig1s002.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2000,NOVOLOG,INSULIN ASPART,BLA020986,3a1e73a2-3009-40d0-876c-b4cb2be56fc5,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/020986Orig1s047.pdf,
2000,NOVOLOG,INSULIN ASPART,BLA020986,3a1e73a2-3009-40d0-876c-b4cb2be56fc5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/020986Orig1s061.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2000,NOVOLOG,INSULIN ASPART,BLA020986,3a1e73a2-3009-40d0-876c-b4cb2be56fc5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20986_Insulin-Aspart_Clinical_PREA.pdf,
2000,NOVOLOG,INSULIN ASPART,BLA020986,3a1e73a2-3009-40d0-876c-b4cb2be56fc5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20986_Insulin-Aspart_Clinpharm_PREA.pdf,
2000,NOVOLOG,INSULIN ASPART,BLA020986,3a1e73a2-3009-40d0-876c-b4cb2be56fc5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20986_Insulin-Aspart_Statistical_PREA.pdf,
2000,NOVOLOG,INSULIN ASPART,BLA020986,3a1e73a2-3009-40d0-876c-b4cb2be56fc5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-986_NovoLog.cfm,
2000,NOVOLOG,INSULIN ASPART,BLA020986,3a1e73a2-3009-40d0-876c-b4cb2be56fc5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020986s033_insulin aspart_Novolog-MedRev.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2000,NOVOLOG,INSULIN ASPART,BLA020986,3a1e73a2-3009-40d0-876c-b4cb2be56fc5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20986_Insulin Aspart_Statistical_PREA.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2001,AVODART,DUTASTERIDE,NDA021319,960797b3-09b1-4d6a-8ece-8b5d918e93e4,http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/021319se1-014_SUMR.pdf,
2001,AVODART,DUTASTERIDE,NDA021319,960797b3-09b1-4d6a-8ece-8b5d918e93e4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21319_Duagen.cfm,
2005,CHLORHEXIDINE GLUCONATE,CHLORHEXIDINE GLUCONATE,NDA021669,bdb6a012-37e5-4664-84a3-134bea284744,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21669s000TOC.cfm,
2005,CHLORHEXIDINE GLUCONATE,CHLORHEXIDINE GLUCONATE,NDA021669,bdb6a012-37e5-4664-84a3-134bea284744,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021669_s006_chlorhexidine gluconate.pdf,
2008,N/A,N/A,NDA022033,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022033TOC.cfm,
2008,N/A,N/A,NDA022033,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022033s000_SumR.pdf,
2000,MYOBLOC,RIMABOTULINUMTOXINB,BLA103846,675cb354-9d13-482e-8ac2-22f709c58b4f,https://web.archive.org/web/20170201030814/http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080661.htm,
1992,N/A,N/A,NDA019982,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/19982-S5_Zebeta.pdf,
1992,N/A,N/A,NDA019982,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/19982-S3_Zebeta.pdf,
1992,N/A,N/A,NDA019982,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/19982-S1_Zebeta.pdf,
1992,N/A,N/A,NDA019982,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/19982_Zebeta.cfm,
1992,N/A,N/A,NDA019982,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/19982-S6_Zebeta.pdf,
1992,N/A,N/A,NDA019982,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/19982-S4_Zebeta.pdf,
1998,SUCRAID,SACROSIDASE,BLA020772,d613bb7f-c3f4-462e-81a2-da2347cc4b6b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20772.cfm,
1998,ATACAND,CANDESARTAN CILEXETIL,NDA020838,94a59260-d2b6-464a-b5b9-bbc599e57e10,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20838s015_Atacand.cfm,
1998,ATACAND,CANDESARTAN CILEXETIL,NDA020838,94a59260-d2b6-464a-b5b9-bbc599e57e10,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20838-s008_atacand.pdf,
1998,ATACAND,CANDESARTAN CILEXETIL,NDA020838,94a59260-d2b6-464a-b5b9-bbc599e57e10,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020838_Candesartan_Clinical_BPCA.pdf,
1998,ATACAND,CANDESARTAN CILEXETIL,NDA020838,94a59260-d2b6-464a-b5b9-bbc599e57e10,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020838_Candesartan_Clinpharm_BPCA.pdf,
1998,ATACAND,CANDESARTAN CILEXETIL,NDA020838,94a59260-d2b6-464a-b5b9-bbc599e57e10,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020838_Candesartan_Statisitical_BPCA.pdf,
1998,ATACAND,CANDESARTAN CILEXETIL,NDA020838,94a59260-d2b6-464a-b5b9-bbc599e57e10,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20838_Atacand.cfm,
2024,N/A,N/A,NDA214835,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/214835Orig1s000TOC.cfm,
2022,VTAMA,TAPINAROF,NDA215272,9309d20f-8cd4-4c96-93fa-7f730e83c7ab,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215272Orig1s000TOC.cfm,
2024,COBENFY,XANOMELINE AND TROSPIUM CHLORIDE,NDA216158,8f0e73bf-6025-44f6-ab64-0983322de0df,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/216158Orig1s000TOC.cfm,
2010,N/A,N/A,NDA022421,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022421s000TOC.cfm,
2010,N/A,N/A,NDA022421,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022421s000SumR.pdf,
2001,VENTOLIN HFA,ALBUTEROL SULFATE,NDA020983,d92c5d6b-ff10-4087-36a2-1cfc464cb967,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-983_Ventolin-HFA.cfm,
2001,VENTOLIN HFA,ALBUTEROL SULFATE,NDA020983,d92c5d6b-ff10-4087-36a2-1cfc464cb967,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020983s013_Albuterol_Clinical_BPCA.pdf,
2001,VENTOLIN HFA,ALBUTEROL SULFATE,NDA020983,d92c5d6b-ff10-4087-36a2-1cfc464cb967,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020983s013_Albuterol_Clinpharm_BPCA.pdf,
2001,VENTOLIN HFA,ALBUTEROL SULFATE,NDA020983,d92c5d6b-ff10-4087-36a2-1cfc464cb967,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020983s013_Albuterol_Statistical_BPCA.pdf,
2001,VENTOLIN HFA,ALBUTEROL SULFATE,NDA020983,d92c5d6b-ff10-4087-36a2-1cfc464cb967,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020983Orig1s009Approv.pdf,
2002,ALTOPREV,LOVASTATIN,NDA021316,8c0db100-5df9-49c3-8af9-1bc03ae609b9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021316_S006_ALTOCAR_TABLETS_AP.pdf,
2002,ALTOPREV,LOVASTATIN,NDA021316,8c0db100-5df9-49c3-8af9-1bc03ae609b9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021316_S001_ALTOCOR_AP.pdf,
2002,ALTOPREV,LOVASTATIN,NDA021316,8c0db100-5df9-49c3-8af9-1bc03ae609b9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021316_altocor.cfm,
2005,N/A,N/A,NDA021664,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021664Orig1s013.pdf,
2005,N/A,N/A,NDA021664,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021664s000TOC.cfm,
2008,SALONPAS PAIN RELIEF,"MENTHOL, METHYL SALICYLATE",NDA022029,724bc4d3-0bc1-4275-a23b-4bbc62fbc0d2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022029TOC.cfm,
2008,SALONPAS PAIN RELIEF,"MENTHOL, METHYL SALICYLATE",NDA022029,724bc4d3-0bc1-4275-a23b-4bbc62fbc0d2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022029s000sumr.pdf,
2008,SALONPAS PAIN RELIEF,"MENTHOL, METHYL SALICYLATE",NDA022029,724bc4d3-0bc1-4275-a23b-4bbc62fbc0d2,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22029 methyl salicylate clinical prea.pdf,
2008,SALONPAS PAIN RELIEF,"MENTHOL, METHYL SALICYLATE",NDA022029,724bc4d3-0bc1-4275-a23b-4bbc62fbc0d2,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22029 methyl salicylate clinical2 prea.pdf,
2008,SALONPAS PAIN RELIEF,"MENTHOL, METHYL SALICYLATE",NDA022029,724bc4d3-0bc1-4275-a23b-4bbc62fbc0d2,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22029 methyl salicylate clinpharm prea.pdf,
2008,SALONPAS PAIN RELIEF,"MENTHOL, METHYL SALICYLATE",NDA022029,724bc4d3-0bc1-4275-a23b-4bbc62fbc0d2,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22029 methy salicylate statistical prea.pdf,
1965,KENALOG-40,TRIAMCINOLONE ACETONIDE,NDA014901,cf970688-cd77-b95c-4bd9-c541590e9722,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/014901_S029_Kenalog_40.pdf,
1965,KENALOG-40,TRIAMCINOLONE ACETONIDE,NDA014901,cf970688-cd77-b95c-4bd9-c541590e9722,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/014901Orig1s043.pdf,
1965,KENALOG-40,TRIAMCINOLONE ACETONIDE,NDA014901,cf970688-cd77-b95c-4bd9-c541590e9722,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/014901_S009_Kenalog_40.pdf,
1965,KENALOG-40,TRIAMCINOLONE ACETONIDE,NDA014901,cf970688-cd77-b95c-4bd9-c541590e9722,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/014901_S028_Kenalog.pdf,
1965,KENALOG-40,TRIAMCINOLONE ACETONIDE,NDA014901,cf970688-cd77-b95c-4bd9-c541590e9722,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/014901_S034_Kenalog_40.pdf,
1965,KENALOG-40,TRIAMCINOLONE ACETONIDE,NDA014901,cf970688-cd77-b95c-4bd9-c541590e9722,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/014901_S010_Kenalog_40.pdf,
1974,N/A,N/A,NDA017516,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/017516_OriginalApprovalPackage.pdf,
1985,N/A,N/A,NDA018644,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/018644a_s010_s012_s013.pdf,
1985,N/A,N/A,NDA018644,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/018644a_s010_s012_s013.pdf,
1985,N/A,N/A,NDA018644,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018644Orig1s000rev.pdf,
1985,N/A,N/A,NDA018644,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/018644Orig1s047.pdf,
1985,N/A,N/A,NDA018644,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/018644a_s010_s012_s013.pdf,
1985,N/A,N/A,NDA018644,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/018644Orig1s046.pdf,
1985,N/A,N/A,NDA018644,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/018644s027s028,020358s031s032,021515s006s007_WellbutrinTOC.cfm",
1985,N/A,N/A,NDA018644,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/018644Orig1s034.pdf,
1985,QUAZEPAM,QUAZEPAM,NDA018708,f7d63f3f-5303-48ab-bce2-35fd62c45799,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018708Orig1s000rev.pdf,
2013,DOCETAXEL,DOCETAXEL,NDA203551,2c806400-5fdc-4398-8475-37f700b3191f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203551_docetaxel_toc.cfm,
2013,DOCETAXEL,DOCETAXEL,NDA203551,2c806400-5fdc-4398-8475-37f700b3191f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203551Orig1s000SumR.pdf,
2000,TNKASE,TENECTEPLASE,BLA103909,e647640d-c395-4b4b-a0be-1162f9c21d84,https://web.archive.org/web/20090119110643/http://www.fda.gov/cder/biologics/products/tenegen060200.htm,
2018,YONSA,ABIRATERONE ACETATE,NDA210308,b8967e10-f768-47ce-ac9e-2324c8390132,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210308Orig1s000TOC.cfm,
1989,N/A,N/A,NDA019909,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/19909S003_Zovirax.pdf,
2018,TAVALISSE,FOSTAMATINIB,NDA209299,21149cc3-049b-43e2-b141-c9499160556c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209299Orig1s000TOC.cfm,
2020,EPHEDRINE SULFATE,EPHEDRINE SULFATE,NDA213994,2c203482-8a04-40fc-93d2-74b30dec7742,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213994Orig1s000TOC.cfm,
2024,ZURNAI,NALMEFENE HYDROCHLORIDE,NDA218590,a59a5847-9fe4-4341-a203-be0a5e6d3e36,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/218590Orig1s000TOC.cfm,
1998,CIPRO HC,CIPROFLOXACIN HYDROCHLORIDE AND HYDROCORTISONE,NDA020805,eff6ee40-6e52-4f61-b54d-edc612543f71,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20805.cfm,
2020,DARZALEX FASPRO,DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT),BLA761145,4bb241af-4299-4373-8762-2d6709515db0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761145Orig1s000TOC.cfm,
1999,CUROSURF,PORACTANT ALFA,BLA020744,99bef307-00bd-4379-9f45-ede1380e74d4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20744_Curosurf.cfm,
2015,N/A,N/A,NDA022424,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022424Orig1s000TOC.cfm,
2015,N/A,N/A,NDA022424,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022424Orig1s000SumR.pdf,
1999,N/A,N/A,NDA020984,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20984_Raplon.cfm,
2004,AMPHADASE,HYALURONIDASE,BLA021665,8396ea96-7cb5-4e26-87a4-90bca9c3c6dd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-665_Amphadase.cfm,
2008,TOVIAZ,FESOTERODINE FUMARATE,NDA022030,4f01dced-195a-4712-a614-d68012bc29df,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022030s000TOC.cfm,
2008,TOVIAZ,FESOTERODINE FUMARATE,NDA022030,4f01dced-195a-4712-a614-d68012bc29df,http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/022030s000_SumR.pdf,
2002,ELITEK,RASBURICASE,BLA103946,0ae10bc4-6b65-402f-9db5-2d7753054922,https://web.archive.org/web/20120303004138/http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080525.htm,
2014,NEURACEQ,FLORBETABEN F 18,NDA204677,b0915068-cfd4-4d72-b9f8-7e31fe83cd1e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204677Orig1s000TOC.cfm,
2014,NEURACEQ,FLORBETABEN F 18,NDA204677,b0915068-cfd4-4d72-b9f8-7e31fe83cd1e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204677Orig1s000SumR.pdf,
2022,EPINEPHRINE,EPINEPHRINE,NDA211363,f2b5f15b-8541-466a-a27a-ee57bc4aac67,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/211363Orig1s000TOC.cfm,
2020,KLISYRI,TIRBANIBULIN,NDA213189,589c8de8-b773-4d47-b60c-48471806cccc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213189Orig1s000TOC.cfm,
2024,ENTRESTO,SACUBITRIL AND VALSARTAN,NDA218591,000dc81d-ab91-450c-8eae-8eb74e72296f,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/218591Orig1s000,207620Orig1s025TOC.cfm",
2020,N/A,N/A,BLA761146,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761146Orig1s000TOC.cfm,
2022,RUGBY MOMETASONE FUROATE NASAL,MOMETASONE FUROATE,NDA215712,b4c43535-ad22-44c2-b04f-df4348a6c485,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215712Orig1s000TOC.cfm,
1996,N/A,N/A,NDA020682,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020682orig1s000rev.pdf,
1996,N/A,N/A,NDA020682,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020682S001_Glyset.cfm,
1997,N/A,N/A,NDA020711,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-711s12_Zyban.cfm,
1997,N/A,N/A,NDA020711,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020711_s002s004_ZybanTOC.cfm,
1997,N/A,N/A,NDA020711,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020711_s002s004_ZybanTOC.cfm,
1997,N/A,N/A,NDA020711,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020711_S015_ZYBAN.pdf,
1997,N/A,N/A,NDA020711,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020711_zyban_toc.cfm,
2009,MULTAQ,DRONEDARONE,NDA022425,7fa41601-7fb5-4155-8e50-2ae903f0d2d6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_SumR.pdf,
2009,MULTAQ,DRONEDARONE,NDA022425,7fa41601-7fb5-4155-8e50-2ae903f0d2d6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000TOC.cfm,
2000,FLUOROURACIL,"FLUOROURACIL CREAM, 0.5%",NDA020985,37dcfb83-0e7d-d23d-9cd5-afa5bdc30628,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/carac_20985.cfm,
2002,TERIPARATIDE,TERIPARATIDE,NDA021318,ab322675-4769-45b0-b146-14fbaa3135d0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-318_Forteo.cfm,
2002,TERIPARATIDE,TERIPARATIDE,NDA021318,ab322675-4769-45b0-b146-14fbaa3135d0,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/021318Orig1s056.pdf,
2002,TERIPARATIDE,TERIPARATIDE,NDA021318,ab322675-4769-45b0-b146-14fbaa3135d0,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/021318Orig1s054.pdf,
2002,TERIPARATIDE,TERIPARATIDE,NDA021318,ab322675-4769-45b0-b146-14fbaa3135d0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021318Orig1s016.pdf,
2002,TERIPARATIDE,TERIPARATIDE,NDA021318,ab322675-4769-45b0-b146-14fbaa3135d0,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/021318Orig1s053.pdf,
2004,N/A,N/A,NDA021667,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-667_NutreStroe.cfm,
2007,GOOD NEIGHBOR PHARMACY OMEPRAZOLE,OMEPRAZOLE,NDA022032,5ee3cb79-5c0c-456f-b5d5-d5a008bbd118,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022032s000_SumR.pdf,
2007,GOOD NEIGHBOR PHARMACY OMEPRAZOLE,OMEPRAZOLE,NDA022032,5ee3cb79-5c0c-456f-b5d5-d5a008bbd118,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022032_omeprazole_toc.cfm,
2007,GOOD NEIGHBOR PHARMACY OMEPRAZOLE,OMEPRAZOLE,NDA022032,5ee3cb79-5c0c-456f-b5d5-d5a008bbd118,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/022032Orig1s024_Approval_Pkg.pdf,
2012,CHOLINE C 11,CHOLINE C-11,NDA203155,8e046642-5038-4094-b1bb-a1915558fb1c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203155Orig1s000TOC.cfm,
2012,CHOLINE C 11,CHOLINE C-11,NDA203155,8e046642-5038-4094-b1bb-a1915558fb1c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203155Orig1s000SumR.pdf,
2002,PEGASYS,PEGINTERFERON ALFA-2A,BLA103964,d9290e5b-6d40-2318-e053-2995a90a9916,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21511 ribavirin clinical prea-Dawn.pdf,
2002,PEGASYS,PEGINTERFERON ALFA-2A,BLA103964,d9290e5b-6d40-2318-e053-2995a90a9916,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/196_103964S5270 peginterferon clinpharm prea.pdf,
2002,PEGASYS,PEGINTERFERON ALFA-2A,BLA103964,d9290e5b-6d40-2318-e053-2995a90a9916,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/197_103964S5270 peginterferon statistical prea.pdf,
2002,PEGASYS,PEGINTERFERON ALFA-2A,BLA103964,d9290e5b-6d40-2318-e053-2995a90a9916,https://web.archive.org/web/20170113111452/http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080721.htm,
2013,N/A,N/A,NDA204683,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204683Orig1s000SumR.pdf,
2013,N/A,N/A,NDA204683,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204683Orig1s000TOC.cfm,
2017,ENDARI,GLUTAMINE,NDA208587,d5a783f4-12ef-4326-8faa-40018e45ba3b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208587Orig1s000TOC.cfm,
1995,CAVERJECT,ALPROSTADIL,NDA020379,a295fc1e-d82c-4f44-bc2d-a552bf594c98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20379-s009_caverject.pdf,
2020,ADALIMUMAB,ADALIMUMAB-FKJP,BLA761154,e94548f8-6a95-4159-9db8-6e734febbea0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761154Orig1s000TOC.cfm,
2021,OPZELURA,RUXOLITINIB,NDA215309,24da5509-6631-4795-9d42-273faecd08e7,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215309Orig1s000TOC.cfm,
2009,ZYRTEC,CETIRIZINE HYDROCHLORIDE,NDA022429,605adf29-734f-451a-8ff3-74be7b5814a6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022429_cetirizine_hydrochloride_toc.cfm,
1999,SERTRALINE HYDROCHLORIDE,SERTRALINE HYDROCHLORIDE,NDA020990,1a58062b-e635-431a-908d-2651c6a4a21c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/19-839S35_Zoloft.cfm,
1999,SERTRALINE HYDROCHLORIDE,SERTRALINE HYDROCHLORIDE,NDA020990,1a58062b-e635-431a-908d-2651c6a4a21c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20990_Zoloft.cfm,
1999,SERTRALINE HYDROCHLORIDE,SERTRALINE HYDROCHLORIDE,NDA020990,1a58062b-e635-431a-908d-2651c6a4a21c,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/019839s044,020990s010_ZoloftTOC.cfm",
2001,BUDESONIDE,BUDESONIDE,NDA021324,3a18d5a7-04c5-4137-8155-70a8adc0a48b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021324Orig1s008.pdf,
2001,BUDESONIDE,BUDESONIDE,NDA021324,3a18d5a7-04c5-4137-8155-70a8adc0a48b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/021324Orig1s018.pdf,
2001,BUDESONIDE,BUDESONIDE,NDA021324,3a18d5a7-04c5-4137-8155-70a8adc0a48b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21324 budesonide Entocort_clinical prea.pdf,
2001,BUDESONIDE,BUDESONIDE,NDA021324,3a18d5a7-04c5-4137-8155-70a8adc0a48b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21324 budesonide_Entocort_ statistical prea.pdf,
2001,BUDESONIDE,BUDESONIDE,NDA021324,3a18d5a7-04c5-4137-8155-70a8adc0a48b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-324_Entocort.cfm,
2001,BUDESONIDE,BUDESONIDE,NDA021324,3a18d5a7-04c5-4137-8155-70a8adc0a48b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21324 budesonide Entocort_clinical prea.pdf,
1981,N/A,N/A,NDA018401,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/018401_s014_BuprenexTOC.cfm,
1981,N/A,N/A,NDA018401,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/018401_S015_Buprenex Injectable_APPROVAL PACKAGE.pdf,
2001,N/A,N/A,BLA103949,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/103949s5002_PEGIntronTOC.cfm,
2001,N/A,N/A,BLA103949,N/A,https://web.archive.org/web/20160402193205/http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080727.htm,
2001,N/A,N/A,BLA103949,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/0103949s5171_peginterferon_(Rebetol)_Clinical_PREA.pdf,
2001,N/A,N/A,BLA103949,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/0103949s5171-Peginterferon-ClinPharm-PREA.pdf,
2001,N/A,N/A,BLA103949,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/103949Orig1s5259.pdf,
2014,KABIVEN,"DEXTROSE, SOYBEAN OIL, ELECTROLYTES, LYSINE, PHENYLALANINE, LEUCINE, VALINE, THREONINE, METHIONINE, ISOLEUCINE, TRYPTOPHAN, ALANINE, ARGININE, GLYCINE, PROLINE, HISTIDINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID AND TYROSINE",NDA200656,afeb4837-a759-4484-a76e-e04611c459e7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/200656Orig1s000TOC.cfm,
2011,N/A,N/A,NDA202439,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/202439Orig1s035.pdf,
2011,N/A,N/A,NDA202439,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202439toc.cfm,
2012,SODIUM NITRITE,SODIUM NITRITE,NDA203922,52f01c6e-172a-47a9-98a6-9eab7651a032,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203922_sodium_nitrite_toc.cfm,
2012,SODIUM NITRITE,SODIUM NITRITE,NDA203922,52f01c6e-172a-47a9-98a6-9eab7651a032,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203922Orig1s000SumR.pdf,
2016,AMPHETAMINE EXTENDED-RELEASE,AMPHETAMINE EXTENDED-RELEASE,NDA204326,48d0f55c-f847-4d26-b2ed-94b5a2770228,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/204326Orig1_toc.cfm,
2016,AMPHETAMINE EXTENDED-RELEASE,AMPHETAMINE EXTENDED-RELEASE,NDA204326,48d0f55c-f847-4d26-b2ed-94b5a2770228,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/204326 amphetamine clinical prea.pdf,
2016,AMPHETAMINE EXTENDED-RELEASE,AMPHETAMINE EXTENDED-RELEASE,NDA204326,48d0f55c-f847-4d26-b2ed-94b5a2770228,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/204326 amphetamine clinpharm prea.pdf,
2017,COTEMPLA XR-ODT,METHYLPHENIDATE,NDA205489,33f70f58-c871-42c8-8adb-345caeafefcd,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/143_205489 methylphenidate clinical prea.pdf,
2017,COTEMPLA XR-ODT,METHYLPHENIDATE,NDA205489,33f70f58-c871-42c8-8adb-345caeafefcd,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/145_205489 methylphenidate clinpharm prea.pdf,
2017,COTEMPLA XR-ODT,METHYLPHENIDATE,NDA205489,33f70f58-c871-42c8-8adb-345caeafefcd,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/146_205489 methylphenidate clinpharm resubmission prea.pdf,
2017,COTEMPLA XR-ODT,METHYLPHENIDATE,NDA205489,33f70f58-c871-42c8-8adb-345caeafefcd,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/148_205489 methylphenidate statistical prea.pdf,
2017,COTEMPLA XR-ODT,METHYLPHENIDATE,NDA205489,33f70f58-c871-42c8-8adb-345caeafefcd,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/147_205489 methylphenidate stat resubmission prea.pdf,
2017,COTEMPLA XR-ODT,METHYLPHENIDATE,NDA205489,33f70f58-c871-42c8-8adb-345caeafefcd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/205489Orig1s000TOC.cfm,
2017,ALTAFLUOR,FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE,NDA208582,54017304-e680-4129-b52a-69cb9810af76,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208582Orig1s000TOC.cfm,
2019,SLYND,DROSPIRENONE,NDA211367,db32bc55-f295-4d87-9dbb-0a2f45573dcf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211367Orig1s000TOC.cfm,
2019,IBRANCE,PALBOCICLIB,NDA212436,89a142d5-7e61-48bf-9e77-e2cd124c4792,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212436Orig1s000TOC.cfm,
2020,ENSPRYNG,SATRALIZUMAB,BLA761149,64c156a4-9bad-4d45-a294-0733c141f47b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761149Orig1s000TOC.cfm,
2009,ACUVAIL,KETOROLAC TROMETHAMINE,NDA022427,3cea5803-a446-4d2c-9747-f3fb034332c8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022427_acuvail_toc.cfm,
2009,ACUVAIL,KETOROLAC TROMETHAMINE,NDA022427,3cea5803-a446-4d2c-9747-f3fb034332c8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022427s000_SumR.pdf,
2000,PROTONIX DELAYED-RELEASE,PANTOPRAZOLE SODIUM,NDA020987,08098cb2-c048-4640-f387-6beec4a38936,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-987s007_Protonix.cfm,
2000,PROTONIX DELAYED-RELEASE,PANTOPRAZOLE SODIUM,NDA020987,08098cb2-c048-4640-f387-6beec4a38936,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix.cfm,
2004,VISIONBLUE,TRYPAN BLUE,NDA021670,a44bc2ef-3d7f-4125-a7f7-c5969b1b4142,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-670_VisionBlue.cfm,
2010,SILENOR,DOXEPIN HYDROCHLORIDE,NDA022036,1bec1223-5239-4eb6-a9e8-62444106d2c0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022036Orig1s000SumR.pdf,
2010,SILENOR,DOXEPIN HYDROCHLORIDE,NDA022036,1bec1223-5239-4eb6-a9e8-62444106d2c0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022036s000_silenor_toc.cfm,
2001,KINERET,ANAKINRA,BLA103950,d9d74915-6606-4570-9c52-c4001d3177de,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/103950-0_Kineret.cfm,
2013,N/A,N/A,NDA202091,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202091Orig1s000TOC.cfm,
2013,N/A,N/A,NDA202091,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202091Orig1s000SumR.pdf,
2012,SODIUM THIOSULFATE,SODIUM THIOSULFATE,NDA203923,82f55408-2de9-463d-85e8-b39c3b259f0b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203923_sodium_thiosulfate_toc.cfm,
2012,SODIUM THIOSULFATE,SODIUM THIOSULFATE,NDA203923,82f55408-2de9-463d-85e8-b39c3b259f0b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203923Orig1s000SumR.pdf,
2022,FUROSCIX,FUROSEMIDE INJECTION 80 MG/ 10 ML,NDA209988,eac958dd-8d43-e44e-e053-2995a90a4d5e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/209988Orig1s000TOC.cfm,
2016,XULTOPHY 100/3.6,INSULIN DEGLUDEC AND LIRAGLUTIDE,BLA208583,21335fe4-d395-4501-ac2a-2f20d7520da9,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=faq.page#nda_bla,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2017,N/A,N/A,NDA209305,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209305Orig1s000TOC.cfm,
1995,MAGNESIUM SULFATE IN DEXTROSE,MAGNESIUM SULFATE IN DEXTROSE,NDA020488,03ebeabb-8386-4af4-3086-bdf3c3fc4a5a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020488_original_approval.pdf,
2003,N/A,N/A,NDA020452,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/20-452_Paraplatin.cfm,
2020,ISTURISA,OSILODROSTAT,NDA212801,f3a5ec24-63c3-4d83-b1c0-6c550fbe7ae2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212801Orig1s000TOC.cfm,
2020,MARGENZA,MARGETUXIMAB-CMKB,BLA761150,6a6d50c7-06ea-479c-83cc-f197a9e428c9,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761150Orig1s000TOC.cfm,
1995,N/A,N/A,NDA020520,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020520_S015_ZANTAC.pdf,
1995,N/A,N/A,NDA020520,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20520s1_Zantac.pdf,
2024,N/A,N/A,NDA216165,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/216165Orig1s000TOC.cfm,
2010,N/A,N/A,NDA022428,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022428s000MedRPREA.pdf,
2010,N/A,N/A,NDA022428,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022428s000ClinPharm PREA.pdf,
2010,N/A,N/A,NDA022428,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022428s000StatRPREA.pdf,
2010,N/A,N/A,NDA022428,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022428_moxeza_toc.cfm,
2010,N/A,N/A,NDA022428,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022428Orig1s000SumR.pdf,
2001,PROTONIX I.V.,PANTOPRAZOLE SODIUM,NDA020988,51e4144a-489e-436c-609a-39305f8f56ba,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20988_Protonix.cfm,
2002,EXTRANEAL,"ICODEXTRIN, SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE",NDA021321,d5b85158-b0d6-4855-9d07-8d1b3ad9ab71,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21321_Extraneal.cfm,
2009,INTUNIV,GUANFACINE,NDA022037,b972af81-3a37-40be-9fe1-3ddf59852528,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22037 S011 guanfacine clinical prea.pdf,
2009,INTUNIV,GUANFACINE,NDA022037,b972af81-3a37-40be-9fe1-3ddf59852528,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22037 S011 guanfacine clinpharm prea.pdf,
2009,INTUNIV,GUANFACINE,NDA022037,b972af81-3a37-40be-9fe1-3ddf59852528,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22037 S011 guanfacine statistical prea.pdf,
2009,INTUNIV,GUANFACINE,NDA022037,b972af81-3a37-40be-9fe1-3ddf59852528,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22037 guanfacine clinical both (2).pdf,
2009,INTUNIV,GUANFACINE,NDA022037,b972af81-3a37-40be-9fe1-3ddf59852528,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22037 guanfacine CDTL clinical both.pdf,
2009,INTUNIV,GUANFACINE,NDA022037,b972af81-3a37-40be-9fe1-3ddf59852528,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22037 guanfacine statistical both.pdf,
2009,INTUNIV,GUANFACINE,NDA022037,b972af81-3a37-40be-9fe1-3ddf59852528,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022037_intuniv_toc.cfm,
2009,INTUNIV,GUANFACINE,NDA022037,b972af81-3a37-40be-9fe1-3ddf59852528,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22037_guanfacine_Clinical_PREA.pdf,
2009,INTUNIV,GUANFACINE,NDA022037,b972af81-3a37-40be-9fe1-3ddf59852528,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22037_guanfacine_DDmemo_PREA.pdf,
2009,INTUNIV,GUANFACINE,NDA022037,b972af81-3a37-40be-9fe1-3ddf59852528,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22037_guanfacine_DD memo1_PREA.pdf,
2009,INTUNIV,GUANFACINE,NDA022037,b972af81-3a37-40be-9fe1-3ddf59852528,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22037_guanfacine_cliinpharm_PREA.pdf,
2009,INTUNIV,GUANFACINE,NDA022037,b972af81-3a37-40be-9fe1-3ddf59852528,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22037_guanfacine_Statistical_PREA.pdf,
2009,INTUNIV,GUANFACINE,NDA022037,b972af81-3a37-40be-9fe1-3ddf59852528,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022037_ Intuniv_Clinical_PREA.pdf,
2009,INTUNIV,GUANFACINE,NDA022037,b972af81-3a37-40be-9fe1-3ddf59852528,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022037_Intuniv_ClinPharm_PREA.pdf,
2009,INTUNIV,GUANFACINE,NDA022037,b972af81-3a37-40be-9fe1-3ddf59852528,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022037_Intuniv_Statistical_PREA.pdf,
2009,INTUNIV,GUANFACINE,NDA022037,b972af81-3a37-40be-9fe1-3ddf59852528,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022037_ Intuniv_Clinical_PREA.pdf,
2009,INTUNIV,GUANFACINE,NDA022037,b972af81-3a37-40be-9fe1-3ddf59852528,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022037_Intuniv_ClinPharm_PREA.pdf,
2009,INTUNIV,GUANFACINE,NDA022037,b972af81-3a37-40be-9fe1-3ddf59852528,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022037_Intuniv_Statistical_PREA.pdf,
2009,INTUNIV,GUANFACINE,NDA022037,b972af81-3a37-40be-9fe1-3ddf59852528,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022037_ Intuniv_Clinical_PREA.pdf,
2009,INTUNIV,GUANFACINE,NDA022037,b972af81-3a37-40be-9fe1-3ddf59852528,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022037_Intuniv_ClinPharm_PREA.pdf,
2009,INTUNIV,GUANFACINE,NDA022037,b972af81-3a37-40be-9fe1-3ddf59852528,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022037_Intuniv_Statistical_PREA.pdf,
2009,INTUNIV,GUANFACINE,NDA022037,b972af81-3a37-40be-9fe1-3ddf59852528,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022037s000sumr.pdf,
2001,ARANESP,DARBEPOETIN ALFA,BLA103951,0fd36cb9-c4f6-4167-93c9-8530865db3f9,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/103951s5363 darbepoetin clinical bpca.pdf,
2001,ARANESP,DARBEPOETIN ALFA,BLA103951,0fd36cb9-c4f6-4167-93c9-8530865db3f9,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/103951s5363 darbepoetin statistical bpca.pdf,
2001,ARANESP,DARBEPOETIN ALFA,BLA103951,0fd36cb9-c4f6-4167-93c9-8530865db3f9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/103951_aranesp_toc.cfm,
2001,ARANESP,DARBEPOETIN ALFA,BLA103951,0fd36cb9-c4f6-4167-93c9-8530865db3f9,http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103951Orig1s5173SumR.pdf,
2001,ARANESP,DARBEPOETIN ALFA,BLA103951,0fd36cb9-c4f6-4167-93c9-8530865db3f9,http://www.accessdata.fda.gov/drugsatfda_docs/bla/2002/103951Orig1s5001.pdf,
2001,ARANESP,DARBEPOETIN ALFA,BLA103951,0fd36cb9-c4f6-4167-93c9-8530865db3f9,https://web.archive.org/web/20160317023707/http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080442.htm,
2015,N/A,N/A,NDA200671,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/200671Orig1s000TOC.cfm,
1988,IMODIUM A-D,LOPERAMIDE HYDROCHLORIDE,NDA019487,76a976d5-8bee-4158-a94d-7fbfc5544fd4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/019487_S022_IMODIUM_A-D LIQUID.pdf,
1988,IMODIUM A-D,LOPERAMIDE HYDROCHLORIDE,NDA019487,76a976d5-8bee-4158-a94d-7fbfc5544fd4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/019487_s023_IMODIUM A-D LIQUID.pdf,
1988,IMODIUM A-D,LOPERAMIDE HYDROCHLORIDE,NDA019487,76a976d5-8bee-4158-a94d-7fbfc5544fd4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/019487_S021_IMODIUM A-D LIQUID.pdf,
2020,TAZVERIK,TAZEMETOSTAT,NDA211723,7db07b5f-4e22-467c-9c0a-f830b08dbb1d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/211723Orig1s000TOC.cfm,
2023,BIMZELX,BIMEKIZUMAB,BLA761151,26b88358-871f-4c80-9d80-b2fb16477f81,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761151Orig1s000TOC.cfm,
2000,EVOXAC,CEVIMELINE HYDROCHLORIDE,NDA020989,dac32a9b-05b8-42c2-9a29-d885a9279456,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-989_Evoxac.cfm,
2002,LEXAPRO,ESCITALOPRAM,NDA021323,13bb8267-1cab-43e5-acae-55a4d957630a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021323_S003&021365_S004_LEXAPRO_TABS.pdf,
2002,LEXAPRO,ESCITALOPRAM,NDA021323,13bb8267-1cab-43e5-acae-55a4d957630a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21323_Escitalopram_clinpharm_PREA.pdf,
2002,LEXAPRO,ESCITALOPRAM,NDA021323,13bb8267-1cab-43e5-acae-55a4d957630a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21323_Escitalopram_statistical_PREA.pdf,
2002,LEXAPRO,ESCITALOPRAM,NDA021323,13bb8267-1cab-43e5-acae-55a4d957630a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-440_21323s1_Lexapro.cfm,
2002,LEXAPRO,ESCITALOPRAM,NDA021323,13bb8267-1cab-43e5-acae-55a4d957630a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323_Lexapro.cfm,
2002,LEXAPRO,ESCITALOPRAM,NDA021323,13bb8267-1cab-43e5-acae-55a4d957630a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21323_escitalopram_clinical_PREA.pdf,
2002,LEXAPRO,ESCITALOPRAM,NDA021323,13bb8267-1cab-43e5-acae-55a4d957630a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21323_Escitalopram_clinpharm_PREA.pdf,
2002,LEXAPRO,ESCITALOPRAM,NDA021323,13bb8267-1cab-43e5-acae-55a4d957630a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21323_Escitalopram_statistical_PREA.pdf,
2002,LEXAPRO,ESCITALOPRAM,NDA021323,13bb8267-1cab-43e5-acae-55a4d957630a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021323Orig1S030_s031.pdf,
2002,LEXAPRO,ESCITALOPRAM,NDA021323,13bb8267-1cab-43e5-acae-55a4d957630a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021323Orig1S030_s031.pdf,
2002,LEXAPRO,ESCITALOPRAM,NDA021323,13bb8267-1cab-43e5-acae-55a4d957630a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021323_S007&021365_S001_LEXAPRO_TABS.pdf,
2004,N/A,N/A,NDA021673,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021673_clofarabine_Clolar-Med&StatsRev.pdf,
2004,N/A,N/A,NDA021673,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021673_clofarabine_Clolar-ClinPharmRev.pdf,
2004,N/A,N/A,NDA021673,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021673_clofarabine_Clolar-Med&StatsRev.pdf,
2004,N/A,N/A,NDA021673,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-673_Clolar.cfm,
2007,DIVIGEL,ESTRADIOL,NDA022038,59e610dc-883e-4f07-9ec6-a5841b0bf9fb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022038s000_divigel_toc.cfm,
2007,DIVIGEL,ESTRADIOL,NDA022038,59e610dc-883e-4f07-9ec6-a5841b0bf9fb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022038s000_SUMR.pdf,
1978,N/A,N/A,NDA050517,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/50-517S039_Mefoxin.pdf,
1978,N/A,N/A,NDA050517,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/50-517s031_50-581s020_Mefoxin.cfm,
1978,N/A,N/A,NDA050517,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-517s038_Mefoxin.cfm,
2016,INVOKAMET XR,CANAGLIFLOZIN AND METFORMIN HYDROCHLORIDE,NDA205879,6868666b-c25e-40d1-9d1f-306bbe9390c1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205879Orig1s000TOC.cfm,
1991,N/A,N/A,NDA020036,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20-036s001,002,005_ltr_lbl.pdf",
1991,N/A,N/A,NDA020036,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20036s015_Aredia.cfm,
1991,N/A,N/A,NDA020036,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20-036s001,002,005_ltr_lbl.pdf",
1991,N/A,N/A,NDA020036,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20-036s003_ltr_lbl.pdf,
1991,N/A,N/A,NDA020036,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20-036s001,002,005_ltr_lbl.pdf",
1991,N/A,N/A,NDA020036,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020036_aredia_toc.cfm,
1991,N/A,N/A,NDA020036,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020036_S028_AREDIA.pdf,
1991,N/A,N/A,NDA020036,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-036S024_Aredia.pdf,
1991,N/A,N/A,NDA020036,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20036s016.cfm,
1991,N/A,N/A,NDA020036,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020036_s030_Aredia.pdf,
1991,N/A,N/A,NDA020036,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020036_S020_AREDIA.pdf,
1991,N/A,N/A,NDA020036,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20-036s004_pkg.pdf,
2017,GOCOVRI,AMANTADINE,NDA208944,82ff865f-78f3-4c94-b6a9-727a54944b28,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208944Orig1s000TOC.cfm,
2021,LEQVIO,INCLISIRAN,NDA214012,6fc0afca-4513-4c35-b594-6544aee29a44,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214012Orig1s000TOC.cfm,
2021,LEQVIO,INCLISIRAN,NDA214012,6fc0afca-4513-4c35-b594-6544aee29a44,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/214012Orig1s009.pdf,
1997,PLAVIX,CLOPIDOGREL,NDA020839,de8b0b67-eb25-4684-83b5-7ad785314227,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020-839_S-016.PDF,
1997,PLAVIX,CLOPIDOGREL,NDA020839,de8b0b67-eb25-4684-83b5-7ad785314227,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020-839_S-014.PDF,
1997,PLAVIX,CLOPIDOGREL,NDA020839,de8b0b67-eb25-4684-83b5-7ad785314227,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020839_s000.pdf,
1997,PLAVIX,CLOPIDOGREL,NDA020839,de8b0b67-eb25-4684-83b5-7ad785314227,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020-839_S-020.PDF,
1997,PLAVIX,CLOPIDOGREL,NDA020839,de8b0b67-eb25-4684-83b5-7ad785314227,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020-839_S-010.PDF,
1997,PLAVIX,CLOPIDOGREL,NDA020839,de8b0b67-eb25-4684-83b5-7ad785314227,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020839Orig1s051TOC.cfm,
1997,PLAVIX,CLOPIDOGREL,NDA020839,de8b0b67-eb25-4684-83b5-7ad785314227,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20839s051 clopidogrel statistical BPCA.pdf,
1997,PLAVIX,CLOPIDOGREL,NDA020839,de8b0b67-eb25-4684-83b5-7ad785314227,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20839s051 clopidogrel Clinical BPCA.pdf,
1997,PLAVIX,CLOPIDOGREL,NDA020839,de8b0b67-eb25-4684-83b5-7ad785314227,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20839s051 clopidogrel clinpharm BPCA_CORRECTED.pdf,
1997,PLAVIX,CLOPIDOGREL,NDA020839,de8b0b67-eb25-4684-83b5-7ad785314227,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020839Orig1s051SumR.pdf,
1997,PLAVIX,CLOPIDOGREL,NDA020839,de8b0b67-eb25-4684-83b5-7ad785314227,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020-839_S-006.PDF,
1997,PLAVIX,CLOPIDOGREL,NDA020839,de8b0b67-eb25-4684-83b5-7ad785314227,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020-839_S-004.PDF,
1997,PLAVIX,CLOPIDOGREL,NDA020839,de8b0b67-eb25-4684-83b5-7ad785314227,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-839s019_ClopidogrelPlavix.cfm,
1997,PLAVIX,CLOPIDOGREL,NDA020839,de8b0b67-eb25-4684-83b5-7ad785314227,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020-839_S-002.PDF,
1997,PLAVIX,CLOPIDOGREL,NDA020839,de8b0b67-eb25-4684-83b5-7ad785314227,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020-839_S-017.PDF,
1997,PLAVIX,CLOPIDOGREL,NDA020839,de8b0b67-eb25-4684-83b5-7ad785314227,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020-839_S-015.PDF,
1997,PLAVIX,CLOPIDOGREL,NDA020839,de8b0b67-eb25-4684-83b5-7ad785314227,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020-839_S-013.PDF,
1997,PLAVIX,CLOPIDOGREL,NDA020839,de8b0b67-eb25-4684-83b5-7ad785314227,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020-839_S-011.PDF,
1997,PLAVIX,CLOPIDOGREL,NDA020839,de8b0b67-eb25-4684-83b5-7ad785314227,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020-839_S-009.PDF,
1997,PLAVIX,CLOPIDOGREL,NDA020839,de8b0b67-eb25-4684-83b5-7ad785314227,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/020839Orig1s038.pdf,
1997,PLAVIX,CLOPIDOGREL,NDA020839,de8b0b67-eb25-4684-83b5-7ad785314227,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020-839_S-007.PDF,
1997,PLAVIX,CLOPIDOGREL,NDA020839,de8b0b67-eb25-4684-83b5-7ad785314227,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020-839_S-005.PDF,
1997,PLAVIX,CLOPIDOGREL,NDA020839,de8b0b67-eb25-4684-83b5-7ad785314227,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/020839Orig1s042.pdf,
1997,PLAVIX,CLOPIDOGREL,NDA020839,de8b0b67-eb25-4684-83b5-7ad785314227,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020-839_S-003.PDF,
1997,PLAVIX,CLOPIDOGREL,NDA020839,de8b0b67-eb25-4684-83b5-7ad785314227,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020839_s034_plavix.pdf,
1997,PLAVIX,CLOPIDOGREL,NDA020839,de8b0b67-eb25-4684-83b5-7ad785314227,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020-839_S-001.PDF,
1997,PLAVIX,CLOPIDOGREL,NDA020839,de8b0b67-eb25-4684-83b5-7ad785314227,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020-839_S-018.PDF,
2011,N/A,N/A,NDA022434,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022434_argatroban_toc.cfm,
2011,N/A,N/A,NDA022434,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022434Orig1s000SumR.pdf,
1998,CELEBREX,CELECOXIB,NDA020998,2d6675e4-5859-4be2-8037-a20ce9f707aa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020998_S006_CELEBREX.pdf,
1998,CELEBREX,CELECOXIB,NDA020998,2d6675e4-5859-4be2-8037-a20ce9f707aa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020998_S004_CELEBREX.pdf,
1998,CELEBREX,CELECOXIB,NDA020998,2d6675e4-5859-4be2-8037-a20ce9f707aa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20998.cfm,
1998,CELEBREX,CELECOXIB,NDA020998,2d6675e4-5859-4be2-8037-a20ce9f707aa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020998_s016_CelebrexTOC.cfm,
1998,CELEBREX,CELECOXIB,NDA020998,2d6675e4-5859-4be2-8037-a20ce9f707aa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020998_S014_CELEBREXTOC.cfm,
1998,CELEBREX,CELECOXIB,NDA020998,2d6675e4-5859-4be2-8037-a20ce9f707aa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-998s009_Celebrex.cfm,
1998,CELEBREX,CELECOXIB,NDA020998,2d6675e4-5859-4be2-8037-a20ce9f707aa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21156-S007_Celebrex.cfm,
1998,CELEBREX,CELECOXIB,NDA020998,2d6675e4-5859-4be2-8037-a20ce9f707aa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-998s010_Celebrex.cfm,
1998,CELEBREX,CELECOXIB,NDA020998,2d6675e4-5859-4be2-8037-a20ce9f707aa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020998_S001_CELEBREX.pdf,
1998,CELEBREX,CELECOXIB,NDA020998,2d6675e4-5859-4be2-8037-a20ce9f707aa,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020998s021_celecoxib_Celebrex-MedRev.pdf,
1998,CELEBREX,CELECOXIB,NDA020998,2d6675e4-5859-4be2-8037-a20ce9f707aa,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020998s021_celecoxib_Celebrex-ClinPharmRev.pdf,
1998,CELEBREX,CELECOXIB,NDA020998,2d6675e4-5859-4be2-8037-a20ce9f707aa,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020998s021_celecoxib_Celebrex-StatsRev.pdf,
1998,CELEBREX,CELECOXIB,NDA020998,2d6675e4-5859-4be2-8037-a20ce9f707aa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-998s013_Celebrex.cfm,
1998,CELEBREX,CELECOXIB,NDA020998,2d6675e4-5859-4be2-8037-a20ce9f707aa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020998_S008_CELEBREX.pdf,
2002,N/A,N/A,NDA021333,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021333s000_MinirinTOC.cfm,
2007,JANUMET,SITAGLIPTIN AND METFORMIN HYDROCHLORIDE,NDA022044,d19c7ed0-ad5c-426e-b2df-722508f97d67,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022044TOC.cfm,
1978,N/A,N/A,NDA018060,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/18-060S055.pdf,
2003,XOLAIR,OMALIZUMAB,BLA103976,7f6a2191-adfb-48b9-9bfa-0d9920479f0d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/103976 omalizumab clinical prea.pdf,
2003,XOLAIR,OMALIZUMAB,BLA103976,7f6a2191-adfb-48b9-9bfa-0d9920479f0d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/103976 omalizumab clinpharm-prea.pdf,
2003,XOLAIR,OMALIZUMAB,BLA103976,7f6a2191-adfb-48b9-9bfa-0d9920479f0d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/103976 omalizumab statistical-prea.pdf,
2003,XOLAIR,OMALIZUMAB,BLA103976,7f6a2191-adfb-48b9-9bfa-0d9920479f0d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/103976Orig1s5231.pdf,
2003,XOLAIR,OMALIZUMAB,BLA103976,7f6a2191-adfb-48b9-9bfa-0d9920479f0d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/103976Orig1s5211.pdf,
2003,XOLAIR,OMALIZUMAB,BLA103976,7f6a2191-adfb-48b9-9bfa-0d9920479f0d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/103976 omalizumab clinical prea.pdf,
2003,XOLAIR,OMALIZUMAB,BLA103976,7f6a2191-adfb-48b9-9bfa-0d9920479f0d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/103976 omalizumab clinpharm prea.pdf,
2003,XOLAIR,OMALIZUMAB,BLA103976,7f6a2191-adfb-48b9-9bfa-0d9920479f0d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/103976 omalizumab statistical prea.pdf,
2003,XOLAIR,OMALIZUMAB,BLA103976,7f6a2191-adfb-48b9-9bfa-0d9920479f0d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/Omalizumab---Xolair-Clinical-Pharmacology-Review--New-Genentech--Inc.-and-Novartis-Pharmaceuticals-Corp..pdf,
2003,XOLAIR,OMALIZUMAB,BLA103976,7f6a2191-adfb-48b9-9bfa-0d9920479f0d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/Omalizumab---Xolair--Statistical-Review-Memo-New-Genentech--Inc.-and-Novartis-Pharmaceuticals-Corp.pdf,
2003,XOLAIR,OMALIZUMAB,BLA103976,7f6a2191-adfb-48b9-9bfa-0d9920479f0d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/103976-Omalizumab-multidisciplinary-prea.pdf,
2003,XOLAIR,OMALIZUMAB,BLA103976,7f6a2191-adfb-48b9-9bfa-0d9920479f0d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/103976 omalizumab clinical prea.pdf,
2003,XOLAIR,OMALIZUMAB,BLA103976,7f6a2191-adfb-48b9-9bfa-0d9920479f0d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/103976 omalizumab clinpharm prea.pdf,
2003,XOLAIR,OMALIZUMAB,BLA103976,7f6a2191-adfb-48b9-9bfa-0d9920479f0d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/103976 omalizumab statistical prea.pdf,
2003,XOLAIR,OMALIZUMAB,BLA103976,7f6a2191-adfb-48b9-9bfa-0d9920479f0d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/103976s5149_Omalizumab_Clinical_PREA.pdf,
2003,XOLAIR,OMALIZUMAB,BLA103976,7f6a2191-adfb-48b9-9bfa-0d9920479f0d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/103976s5149_Omalizumab_Clinical2_PREA.pdf,
2003,XOLAIR,OMALIZUMAB,BLA103976,7f6a2191-adfb-48b9-9bfa-0d9920479f0d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/103976s5149_Omalizumab_ClinPharm_PREA.pdf,
2003,XOLAIR,OMALIZUMAB,BLA103976,7f6a2191-adfb-48b9-9bfa-0d9920479f0d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/103976s5149_Omalizumab_Statistical_PREA.pdf,
2014,FERRIC CITRATE,FERRIC CITRATE,NDA205874,8e8396fa-288b-402e-82b0-b1007d1b571f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205874Orig1s000SumR.pdf,
2014,FERRIC CITRATE,FERRIC CITRATE,NDA205874,8e8396fa-288b-402e-82b0-b1007d1b571f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205874Orig1s000TOC.cfm,
2014,IMPAVIDO,MILTEFOSINE,NDA204684,bcb387ac-2e90-4f5e-94b2-d3635190678e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204684Orig1s000TOC.cfm,
2013,NOXAFIL,POSACONAZOLE,NDA205053,b073b082-7b57-4423-8c06-4fd4263d6f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205053Orig1s000SumR.pdf,
2013,NOXAFIL,POSACONAZOLE,NDA205053,b073b082-7b57-4423-8c06-4fd4263d6f84,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205053Orig1s000_posaconazole Noxafil_Statistical prea.pdf,
2013,NOXAFIL,POSACONAZOLE,NDA205053,b073b082-7b57-4423-8c06-4fd4263d6f84,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205053Orig1s000_ posaconazole Noxafil_Clinical prea.pdf,
2013,NOXAFIL,POSACONAZOLE,NDA205053,b073b082-7b57-4423-8c06-4fd4263d6f84,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205053Orig1s000_posaconazole Noxafil_Clinpharm prea.pdf,
2013,NOXAFIL,POSACONAZOLE,NDA205053,b073b082-7b57-4423-8c06-4fd4263d6f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205053Orig1s000TOC.cfm,
2014,CERDELGA,ELIGLUSTAT,NDA205494,819f828a-b888-4e46-83fc-94d774a28a83,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205494Orig1s000TOC.cfm,
2014,CERDELGA,ELIGLUSTAT,NDA205494,819f828a-b888-4e46-83fc-94d774a28a83,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205494Orig1s000SumR.pdf,
2019,N/A,N/A,NDA211371,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211371Orig1s000TOC.cfm,
1996,N/A,N/A,NDA020254,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020254Orig1s016.pdf,
2020,SOGROYA,SOMAPACITAN-BECO,BLA761156,eadd03b4-adc3-4b88-8a24-9d205c5b85aa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761156Orig1s000TOC.cfm,
2021,N/A,N/A,NDA215310,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215310Orig1s000TOC.cfm,
2021,MYFEMBREE,"RELUGOLIX, ESTRADIOL HEMIHYDRATE, AND NORETHINDRONE ACETATE",NDA214846,fc3feb73-cc84-43a8-aa32-b262460495e8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000TOC.cfm,
2023,N/A,N/A,NDA215721,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/215721Orig1s000TOC.cfm,
2009,TRANEXAMIC ACID,TRANEXAMIC ACID,NDA022430,031bf7c2-3b07-469d-bc5a-31fc6238e25f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/022430Orig1s002.pdf,
2009,TRANEXAMIC ACID,TRANEXAMIC ACID,NDA022430,031bf7c2-3b07-469d-bc5a-31fc6238e25f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022430_lysteda_toc.cfm,
2009,TRANEXAMIC ACID,TRANEXAMIC ACID,NDA022430,031bf7c2-3b07-469d-bc5a-31fc6238e25f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022430 tranexamic acid Lysteda clinpharm prea.pdf,
2009,TRANEXAMIC ACID,TRANEXAMIC ACID,NDA022430,031bf7c2-3b07-469d-bc5a-31fc6238e25f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022430s000sumr.pdf,
2006,CYANOKIT,HYDROXOCOBALAMIN,NDA022041,d56fcc8d-bd64-46ab-b0c0-2124bd745a6b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022041_cyanokit_toc.cfm,
2013,SKYLA,LEVONORGESTREL,NDA203159,9f44ff35-e052-49cd-a1c2-0bfd87d49309,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203159Orig1s000SumR.pdf,
2013,SKYLA,LEVONORGESTREL,NDA203159,9f44ff35-e052-49cd-a1c2-0bfd87d49309,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/UCM350706.pdf,
2013,SKYLA,LEVONORGESTREL,NDA203159,9f44ff35-e052-49cd-a1c2-0bfd87d49309,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/UCM350707.pdf,
2013,SKYLA,LEVONORGESTREL,NDA203159,9f44ff35-e052-49cd-a1c2-0bfd87d49309,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/UCM350708.pdf,
2013,SKYLA,LEVONORGESTREL,NDA203159,9f44ff35-e052-49cd-a1c2-0bfd87d49309,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203159_skyla_toc.cfm,
2003,FABRAZYME,AGALSIDASE BETA,BLA103979,988513ab-b06f-4dd0-93f7-d2d4531dcce4,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/103979Orig1s5309.pdf,
2003,FABRAZYME,AGALSIDASE BETA,BLA103979,988513ab-b06f-4dd0-93f7-d2d4531dcce4,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/103979_toc.cfm,
1985,N/A,N/A,NDA018972,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/18972-s019_cordarone.pdf,
1985,N/A,N/A,NDA018972,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/18972-s019_cordarone.pdf,
1985,N/A,N/A,NDA018972,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/18972S015S017.cfm,
1985,N/A,N/A,NDA018972,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/18972S015S017.cfm,
1985,N/A,N/A,NDA018972,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/18-972_Cardarone.cfm,
1985,N/A,N/A,NDA018972,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/18972-S014_Cordarone.pdf,
1985,N/A,N/A,NDA018972,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/18972-S014_Cordarone.pdf,
1985,N/A,N/A,NDA018972,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/018972s030_Cordarone.cfm,
1985,N/A,N/A,NDA018972,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/18972-S014_Cordarone.pdf,
2018,LUTRATE DEPOT,LEUPROLIDE ACETATE,NDA205054,3a6d1373-17d9-4289-b62f-d299ffe55831,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/205054Orig1s000TOC.cfm,
2016,N/A,N/A,NDA206679,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206679Orig1s000TOC.cfm,
2016,N/A,N/A,NDA206679,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206679Orig1s000SumR.pdf,
2023,ELFABRIO,PEGUNIGALSIDASE ALFA,BLA761161,6fb674bf-744e-431f-92ef-b2a5a66c8cf3,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761161Orig1s000TOC.cfm,
2023,FRUZAQLA,FRUQUINTINIB,NDA217564,186d786e-dc8a-45f2-b5e1-01ac0201879f,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217564Orig1s000TOC.cfm,
2024,OJEMDA,TOVORAFENIB,NDA218033,ea3a9631-3a66-6a7c-e053-2995a90ae2ad,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217700Orig1s000, 218033Orig1s000TOC.cfm",
2010,N/A,N/A,NDA022432,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022432_hp_acthar_gel_toc.cfm,
2010,N/A,N/A,NDA022432,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022432Orig1s0900SumR.pdf,
1999,N/A,N/A,NDA020992,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020992_S016_CENESTINTOC.cfm,
1999,N/A,N/A,NDA020992,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20992.cfm,
2002,NICORETTE,NICOTINE POLACRILEX,NDA021330,f350e050-2173-43e0-8738-848382ce0700,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/021330Orig1s021.pdf,
2002,NICORETTE,NICOTINE POLACRILEX,NDA021330,f350e050-2173-43e0-8738-848382ce0700,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021330Orig1s007.pdf,
2002,NICORETTE,NICOTINE POLACRILEX,NDA021330,f350e050-2173-43e0-8738-848382ce0700,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021330Orig1s013.pdf,
2002,NICORETTE,NICOTINE POLACRILEX,NDA021330,f350e050-2173-43e0-8738-848382ce0700,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-330_Commit.cfm,
2002,NICORETTE,NICOTINE POLACRILEX,NDA021330,f350e050-2173-43e0-8738-848382ce0700,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021330Orig1S014.pdf,
2002,NICORETTE,NICOTINE POLACRILEX,NDA021330,f350e050-2173-43e0-8738-848382ce0700,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021330Orig1s004.pdf,
2002,NICORETTE,NICOTINE POLACRILEX,NDA021330,f350e050-2173-43e0-8738-848382ce0700,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021330Orig1s002.pdf,
2006,YAZ,DROSPIRENONE AND ETHINYL ESTRADIOL,NDA021676,065f33e4-b587-4e66-b896-ca9ab7b7c876,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021676s000TOC.cfm,
2006,YAZ,DROSPIRENONE AND ETHINYL ESTRADIOL,NDA021676,065f33e4-b587-4e66-b896-ca9ab7b7c876,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021676Orig1s012.pdf,
1976,N/A,N/A,NDA017802,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/18-782S023.pdf,
2012,TUDORZA PRESSAIR,ACLIDINIUM BROMIDE,NDA202450,6f92cceb-a63f-4470-99b6-56179d98f10f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000TOC.cfm,
2012,TUDORZA PRESSAIR,ACLIDINIUM BROMIDE,NDA202450,6f92cceb-a63f-4470-99b6-56179d98f10f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000SumR.pdf,
2013,TAFINLAR,DABRAFENIB,NDA202806,fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/202806Orig1s002.pdf,
2013,TAFINLAR,DABRAFENIB,NDA202806,fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202806Orig1s000TOC.cfm,
2013,TAFINLAR,DABRAFENIB,NDA202806,fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea,http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202806Orig1s000SumR.pdf,
2017,EPHEDRINE SULFATE,EPHEDRINE SULFATE,NDA208943,3e43cc8e-bf4e-44ef-a07d-4336367b9bdb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208943Orig1s000TOC.cfm,
2017,SINUVA,MOMETASONE FUROATE,NDA209310,e33c1b23-cdc6-4f64-94ba-24b0b42c09bf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209310Orig1s000TOC.cfm,
2021,FEXINIDAZOLE,FEXINIDAZOLE,NDA214429,74a611bc-9977-46bb-b626-0370b3031628,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214429Orig1s000TOC.cfm,
2020,FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE,FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE,NDA211039,1797c5ef-66c4-4cf8-b62d-b484242be2ee,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/211039Orig1s000TOC.cfm,
2020,JELMYTO,MITOMYCIN,NDA211728,3d3d5053-5427-4a68-a40b-edb60699521e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/211728Orig1s000TOC.cfm,
2025,EVRYSDI,RISDIPLAM,NDA219285,eceb9a99-7191-4be5-87c3-0102707cf98e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219285Orig1s000TOC.cfm,
2020,MONJUVI,TAFASITAMAB-CXIX,BLA761163,ec13ac6b-bfde-4e84-907a-83bd69584d95,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761163Orig1s000TOC.cfm,
2011,BRILINTA,TICAGRELOR,NDA022433,f7b3f443-e83d-4bf2-0e96-023448fed9a8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/022433Orig1s028.pdf,
2011,BRILINTA,TICAGRELOR,NDA022433,f7b3f443-e83d-4bf2-0e96-023448fed9a8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022433Orig1s000TOC.cfm,
2011,BRILINTA,TICAGRELOR,NDA022433,f7b3f443-e83d-4bf2-0e96-023448fed9a8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022433Orig1s000SumR.pdf,
2011,BRILINTA,TICAGRELOR,NDA022433,f7b3f443-e83d-4bf2-0e96-023448fed9a8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022433Orig1s015TOC.cfm,
2005,SYMLINPEN,PRAMLINTIDE ACETATE,NDA021332,4aea30ff-eb0d-45c1-b114-3127966328ff,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21-332_Symlin.cfm,
2003,ALDURAZYME,LARONIDASE,BLA125058,a80ac249-cae4-41f3-88bb-344088b20e60,https://web.archive.org/web/20170118085125/http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080438.htm,
2011,N/A,N/A,NDA201517,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201517_morphine_toc.cfm,
2011,N/A,N/A,NDA201517,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201517Orig1s000SumR.pdf,
2012,QNASL,BECLOMETHASONE DIPROPIONATE,NDA202813,4b8d8e84-b5d2-4e56-97ec-4f72971465c5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000SumR.pdf,
2012,QNASL,BECLOMETHASONE DIPROPIONATE,NDA202813,4b8d8e84-b5d2-4e56-97ec-4f72971465c5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813_qnasl_toc.cfm,
2012,QNASL,BECLOMETHASONE DIPROPIONATE,NDA202813,4b8d8e84-b5d2-4e56-97ec-4f72971465c5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/139_202813 beclomethasone clinical prea.pdf,
2012,QNASL,BECLOMETHASONE DIPROPIONATE,NDA202813,4b8d8e84-b5d2-4e56-97ec-4f72971465c5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202813 beclomethasone clinpharm prea.pdf,
2012,QNASL,BECLOMETHASONE DIPROPIONATE,NDA202813,4b8d8e84-b5d2-4e56-97ec-4f72971465c5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202813 beclomethasone statistical prea.pdf,
2016,AZACITIDINE,AZACITIDINE,NDA208216,5f0f9ee3-a5b1-4a25-a34c-7f38c8433f4a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208216Orig1s000TOC.cfm,
2020,ADVIL DUAL ACTION WITH ACETAMINOPHEN,"IBUPROFEN, ACETAMINOPHEN",NDA211733,f5ea858e-76d9-4777-b3dc-5d614f66d485,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/211733Orig1s000TOC.cfm,
2020,INMAZEB,"ATOLTIVIMAB, MAFTIVIMAB, AND ODESIVIMAB-EBGN",BLA761169,0536b6fe-6fe5-4fd6-8cc6-1b481945c1fa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761169Orig1s000TOC.cfm,
2024,ONTRALFY,TIZANIDINE HYDROCHLORIDE,NDA216190,51d392ee-6907-4472-bd9c-12ca59dadb1b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/216190Orig1s000TOC.cfm,
2011,N/A,N/A,NDA022442,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022442_rezira_toc.cfm,
2011,N/A,N/A,NDA022442,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022442Orig1s000SumR.pdf,
2000,N/A,N/A,NDA021005,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21005_Solaraze.cfm,
2001,ERTAPENEM,ERTAPENEM SODIUM,NDA021337,41304b1d-7db4-468a-ab1d-04e56fb50de4,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021337_ertapenem-InVanz-MedRev.pdf,
2001,ERTAPENEM,ERTAPENEM SODIUM,NDA021337,41304b1d-7db4-468a-ab1d-04e56fb50de4,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021337_ertapenem-InVanz-ClinPharmRev.pdf,
2001,ERTAPENEM,ERTAPENEM SODIUM,NDA021337,41304b1d-7db4-468a-ab1d-04e56fb50de4,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021337_ertapenem-InVanz-StatRev.pdf,
2001,ERTAPENEM,ERTAPENEM SODIUM,NDA021337,41304b1d-7db4-468a-ab1d-04e56fb50de4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21337_Invanz.cfm,
2001,ERTAPENEM,ERTAPENEM SODIUM,NDA021337,41304b1d-7db4-468a-ab1d-04e56fb50de4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021337Orig1s021.pdf,
2004,SENSIPAR,CINACALCET HYDROCHLORIDE,NDA021688,45028573-13c4-4c8b-ae62-6c75bba97c81,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688_Sensipar.cfm,
2004,SENSIPAR,CINACALCET HYDROCHLORIDE,NDA021688,45028573-13c4-4c8b-ae62-6c75bba97c81,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/160_209962 cinacalcet CDTL clinical  bpca.pdf,
2004,SENSIPAR,CINACALCET HYDROCHLORIDE,NDA021688,45028573-13c4-4c8b-ae62-6c75bba97c81,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/161_209962 cinacalcet clinical  bpca.pdf,
2004,SENSIPAR,CINACALCET HYDROCHLORIDE,NDA021688,45028573-13c4-4c8b-ae62-6c75bba97c81,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/162_209962 cinacalcet clinpharm bpca.pdf,
2004,SENSIPAR,CINACALCET HYDROCHLORIDE,NDA021688,45028573-13c4-4c8b-ae62-6c75bba97c81,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/163_209962 cinacalcet statistical bpca.pdf,
2007,TRIESENCE,TRIAMCINOLONE ACETONIDE,NDA022048,2267978c-72ad-9229-e063-6394a90a09d0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022048s000_022223s000_TOC.cfm,
2007,TRIESENCE,TRIAMCINOLONE ACETONIDE,NDA022048,2267978c-72ad-9229-e063-6394a90a09d0,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022048_Acetonide_Clinical_PREA.pdf,
2007,TRIESENCE,TRIAMCINOLONE ACETONIDE,NDA022048,2267978c-72ad-9229-e063-6394a90a09d0,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022048_Acetonide_Clinpharm_PREA.pdf,
2007,TRIESENCE,TRIAMCINOLONE ACETONIDE,NDA022048,2267978c-72ad-9229-e063-6394a90a09d0,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022048_Acetonide_Statistical_PREA.pdf,
2013,INJECTAFER,FERRIC CARBOXYMALTOSE INJECTION,NDA203565,517b4a19-45b3-4286-9f6a-ced4e10447de,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203565Orig1s000SumR.pdf,
2013,INJECTAFER,FERRIC CARBOXYMALTOSE INJECTION,NDA203565,517b4a19-45b3-4286-9f6a-ced4e10447de,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203565Orig1s000TOC.cfm,
2002,ZEVALIN,IBRITUMOMAB TIUXETAN,BLA125019,25d367dc-da65-44c9-a844-1bf15339c285,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/125019_0000_ZevalinTOC.cfm,
2012,SIGNIFOR,PASIREOTIDE,NDA200677,a09a25fc-a5a3-0c82-e053-2995a90a5d74,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/200677Orig1s000TOC.cfm,
2012,SIGNIFOR,PASIREOTIDE,NDA200677,a09a25fc-a5a3-0c82-e053-2995a90a5d74,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/200677Orig1s000SumR.pdf,
1989,RETROVIR,ZIDOVUDINE,NDA019910,6df09f15-b102-431c-adde-d7aeef6f5d84,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/019910s033_Zidovudine (RETROVIR)_Clinical_PREA.pdf,
1989,RETROVIR,ZIDOVUDINE,NDA019910,6df09f15-b102-431c-adde-d7aeef6f5d84,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/19910 zidovudine clinpharm prea.pdf,
1989,RETROVIR,ZIDOVUDINE,NDA019910,6df09f15-b102-431c-adde-d7aeef6f5d84,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/019910 zidovudine clinpharm prea.pdf,
1989,RETROVIR,ZIDOVUDINE,NDA019910,6df09f15-b102-431c-adde-d7aeef6f5d84,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/019910 zidovudine clinical prea.pdf,
1989,RETROVIR,ZIDOVUDINE,NDA019910,6df09f15-b102-431c-adde-d7aeef6f5d84,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/019910 zidovudine clinical prea.pdf,
1989,RETROVIR,ZIDOVUDINE,NDA019910,6df09f15-b102-431c-adde-d7aeef6f5d84,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/019910s033_Zidovudine (RETROVIR)_Clinical_PREA.pdf,
1989,RETROVIR,ZIDOVUDINE,NDA019910,6df09f15-b102-431c-adde-d7aeef6f5d84,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/019910s033_Zidovudine (RETROVIR)_Clinpharm_PREA.pdf,
1989,RETROVIR,ZIDOVUDINE,NDA019910,6df09f15-b102-431c-adde-d7aeef6f5d84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/019655s032_019910s021_020518s004_Retrovir.cfm,
2018,JORNAY PM EXTENDED-RELEASE,METHYLPHENIDATE HYDROCHLORIDE,NDA209311,d95dede0-b1ff-4489-8f91-3bbe122852bf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209311Orig1s000TOC.cfm,
2022,ATROPINE SULFATE,ATROPINE SULFATE,NDA213581,e294ce2b-6bb5-4f84-8a6d-ce2402ed926d,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/213581Orig1s000TOC.cfm,
2019,HEMADY,DEXAMETHASONE,NDA211379,aec60743-f925-4d91-a865-064696a9f9e6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211379Orig1s000TOC.cfm,
1997,VISIPAQUE,IODIXANOL,NDA020808,2d964c13-88ad-43be-88d4-a3a7ea4d5b5e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/020808Orig1s025.pdf,
1997,VISIPAQUE,IODIXANOL,NDA020808,2d964c13-88ad-43be-88d4-a3a7ea4d5b5e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20808-S1_Visipaque.pdf,
2022,ENJAYMO,SUTIMLIMAB-JOME,BLA761164,0a25363a-7781-d9f8-cb1c-be22987bf03b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761164Orig1s000TOC.cfm,
2023,MOTPOLY XR,LACOSAMIDE,NDA216185,fb8235b4-4cd3-6f22-e053-6294a90a545c,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216185Orig1s000TOC.cfm,
2023,VASOPRESSIN IN 0.9% SODIUM CHLORIDE,VASOPRESSIN IN 0.9% SODIUM CHLORIDE,NDA217569,b5b2c367-6b7e-40be-a296-c4632f3e783f,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217569Orig1s000TOC.cfm,
2009,XERESE,ACYCLOVIR AND HYDROCORTISONE,NDA022436,3b6ac164-0f1e-4f36-94a1-1fdb07d710f5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022436 acyclovir clinical prea.pdf,
2009,XERESE,ACYCLOVIR AND HYDROCORTISONE,NDA022436,3b6ac164-0f1e-4f36-94a1-1fdb07d710f5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022436_acyclovir_hydrocortisone_toc.cfm,
2009,XERESE,ACYCLOVIR AND HYDROCORTISONE,NDA022436,3b6ac164-0f1e-4f36-94a1-1fdb07d710f5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022436s000_SumR.pdf,
2009,XERESE,ACYCLOVIR AND HYDROCORTISONE,NDA022436,3b6ac164-0f1e-4f36-94a1-1fdb07d710f5,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022436_acyclovir, hydrocortisone_combined clinical_PREA.pdf",
2009,XERESE,ACYCLOVIR AND HYDROCORTISONE,NDA022436,3b6ac164-0f1e-4f36-94a1-1fdb07d710f5,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022436_acyclovir, hydrocortisone_clinpharm_PREA.pdf",
2009,XERESE,ACYCLOVIR AND HYDROCORTISONE,NDA022436,3b6ac164-0f1e-4f36-94a1-1fdb07d710f5,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022436_acyclovir, hydrocortisone_combined clinica_stats_PREA.pdf",
2001,N/A,N/A,NDA021001,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21001_Axert.cfm,
2001,N/A,N/A,NDA021001,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021001se5-011_Almotriptan_Clinical_BPCA.pdf,
2001,N/A,N/A,NDA021001,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021001se5-011_Almotriptan_Clinpharm_BPCA.pdf,
1967,N/A,N/A,NDA015034,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/015034_S034_PONSTEL.pdf,
1967,N/A,N/A,NDA015034,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/015034_S032_PONSTEL.pdf,
1985,CESAMET,NABILONE,NDA018677,83c7ac15-ece9-47de-b83c-d575544fa449,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018677Orig1s000rev.pdf,
2014,JUBLIA,EFINACONAZOLE,NDA203567,922d4d25-c530-11e1-9b21-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203567_jublia_toc.cfm,
2014,JUBLIA,EFINACONAZOLE,NDA203567,922d4d25-c530-11e1-9b21-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203567Orig1s000SumR.pdf,
2002,N/A,N/A,BLA125031,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/0125031s105_Pegfilgrastim_Clinical_PREA.pdf,
2002,N/A,N/A,BLA125031,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/0125031s105_Pegfilgrastim_Clinpharm_PREA.pdf,
2002,N/A,N/A,BLA125031,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/125031_0000_NeulastaTOC.cfm,
2002,N/A,N/A,BLA125031,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/125031Orig1s175.pdf,
2002,N/A,N/A,BLA125031,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/125031Orig1s203_LabelingR.pdf,
2002,N/A,N/A,BLA125031,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125031Orig1s181.pdf,
2002,N/A,N/A,BLA125031,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125031Orig1s180.pdf,
2010,KOMBIGLYZE XR,SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE,NDA200678,fbd25da4-ebe6-45c9-beb8-93523d11a0b4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200678Orig1s000SumR.pdf,
2010,KOMBIGLYZE XR,SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE,NDA200678,fbd25da4-ebe6-45c9-beb8-93523d11a0b4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200678_kombiglyze_xr_toc.cfm,
2012,OXTELLAR XR,OXCARBAZEPINE,NDA202810,aa610e56-1d1d-11e1-8bc2-0800200c9a66,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202810 oxcarbazepine clinical prea.pdf,
2012,OXTELLAR XR,OXCARBAZEPINE,NDA202810,aa610e56-1d1d-11e1-8bc2-0800200c9a66,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202810 oxcarbazepine clinpharm prea.pdf,
2012,OXTELLAR XR,OXCARBAZEPINE,NDA202810,aa610e56-1d1d-11e1-8bc2-0800200c9a66,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202810 oxcarbazepine statistical prea.pdf,
2012,OXTELLAR XR,OXCARBAZEPINE,NDA202810,aa610e56-1d1d-11e1-8bc2-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202810_oxtellarxr_toc.cfm,
2012,OXTELLAR XR,OXCARBAZEPINE,NDA202810,aa610e56-1d1d-11e1-8bc2-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202810Orig1s000SumR.pdf,
2012,QUILLIVANT XR,METHYLPHENIDATE HYDROCHLORIDE,NDA202100,c2dc2109-44a6-4797-b04e-18761dd9d45a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202100_quillivantxr_toc.cfm,
2012,QUILLIVANT XR,METHYLPHENIDATE HYDROCHLORIDE,NDA202100,c2dc2109-44a6-4797-b04e-18761dd9d45a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202100 methylphenidate clinical prea.pdf,
2012,QUILLIVANT XR,METHYLPHENIDATE HYDROCHLORIDE,NDA202100,c2dc2109-44a6-4797-b04e-18761dd9d45a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202100 methylphenidate clinpharm prea.pdf,
2012,QUILLIVANT XR,METHYLPHENIDATE HYDROCHLORIDE,NDA202100,c2dc2109-44a6-4797-b04e-18761dd9d45a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202100 methylphenidate statistical prea.pdf,
2012,QUILLIVANT XR,METHYLPHENIDATE HYDROCHLORIDE,NDA202100,c2dc2109-44a6-4797-b04e-18761dd9d45a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202100-Methylphenidate-Clinpharm-1-PREA.pdf,
2012,QUILLIVANT XR,METHYLPHENIDATE HYDROCHLORIDE,NDA202100,c2dc2109-44a6-4797-b04e-18761dd9d45a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202100Orig1s000SumR.pdf,
2014,IVERMECTIN,IVERMECTIN,NDA206255,bd0bb2c2-3bc2-4672-9dc1-9ee9b5d70140,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206255Orig1s000TOC.cfm,
2014,IVERMECTIN,IVERMECTIN,NDA206255,bd0bb2c2-3bc2-4672-9dc1-9ee9b5d70140,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206255Orig1s000SumR.pdf,
2014,N/A,N/A,NDA205060,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205060Orig1EpanovaTOC.cfm,
1989,N/A,N/A,NDA019810,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/19810-S57_Prilosec.pdf,
1989,N/A,N/A,NDA019810,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/019810_S003_S058_PRILOSEC.pdf,
1989,N/A,N/A,NDA019810,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019810_S008_OMEPRAZOLE_AP.pdf,
1989,N/A,N/A,NDA019810,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/019810_S003_S058_PRILOSEC.pdf,
1989,N/A,N/A,NDA019810,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/019810s38s50s56.cfm,
1989,N/A,N/A,NDA019810,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/19810-S062_Prilosec.pdf,
1989,N/A,N/A,NDA019810,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/019810s38s50s56.cfm,
1989,N/A,N/A,NDA019810,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/019810ap.pdf,
1989,N/A,N/A,NDA019810,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/019810s38s50s56.cfm,
2017,N/A,N/A,NDA208945,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208945Orig1s000TOC.cfm,
2017,N/A,N/A,NDA208945,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/221_208945 ozenoxacin clinical prea.pdf,
2017,N/A,N/A,NDA208945,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/222_208945 ozenoxacin clinpharm prea.pdf,
2017,N/A,N/A,NDA208945,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/223_208945 ozenoxacin statistical prea.pdf,
2022,NORLIQVA,AMLODIPINE,NDA214439,c1730a51-4383-4c61-a9a1-7e1326bd0abe,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214439Orig1s000TOC.cfm,
2021,NULIBRY,FOSDENOPTERIN HYDROBROMIDE,NDA214018,736aeea3-f206-454d-95d0-fd30964e8aab,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214018Orig1s000TOC.cfm,
2024,TRYNGOLZA,OLEZARSEN SODIUM,NDA218614,0f51aa8e-8475-8cf9-e063-6394a90a6848,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/218614Orig1s000TOC.cfm,
2022,CIMERLI,RANIBIZUMAB-EQRN,BLA761165,e0e23118-1490-a554-e053-2995a90ab90c,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761165Orig1s000TOC.cfm,
2023,LODOCO,COLCHICINE TABLETS 0.5 MG,NDA215727,ff06d68f-d65f-d097-e053-6294a90a7e5f,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/215727Orig1s000TOC.cfm,
1997,N/A,N/A,NDA020683,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020683_alesse_toc.cfm,
1997,CARBATROL,CARBAMAZEPINE,NDA020712,bc03e499-5bac-4293-bff4-6864153a624d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020712_carbatrol_toc.cfm,
2010,TRELSTAR,TRIPTORELIN PAMOATE,NDA022437,b1b84d62-a369-a4b7-5c41-dd1f553a18f3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022437_trelstar_toc.cfm,
2010,TRELSTAR,TRIPTORELIN PAMOATE,NDA022437,b1b84d62-a369-a4b7-5c41-dd1f553a18f3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022437Orig1s000sumr.pdf,
1998,LAMIVUDINE,LAMIVUDINE,NDA021003,a5b963ec-b139-4e28-b447-b72c9e710c1f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/21003_Epivir.cfm,
1998,LAMIVUDINE,LAMIVUDINE,NDA021003,a5b963ec-b139-4e28-b447-b72c9e710c1f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-003SE1002_EpivirHBV.cfm,
2004,GONAL-F RFF REDI-JECT,FOLLITROPIN,BLA021684,b6d11c45-b502-478e-bb28-2ff596ea259c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021684s000_GonalTOC.cfm,
1983,INDERAL LA,PROPRANOLOL HYDROCHLORIDE,NDA018553,35d28979-36b1-4630-b85e-a44e0a443734,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018553_s012_INDERAL LA.pdf,
1983,INDERAL LA,PROPRANOLOL HYDROCHLORIDE,NDA018553,35d28979-36b1-4630-b85e-a44e0a443734,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018553_s006_INDERAL LA.pdf,
1983,INDERAL LA,PROPRANOLOL HYDROCHLORIDE,NDA018553,35d28979-36b1-4630-b85e-a44e0a443734,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018553_s015_INDERAL LA.pdf,
1983,INDERAL LA,PROPRANOLOL HYDROCHLORIDE,NDA018553,35d28979-36b1-4630-b85e-a44e0a443734,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018553_s013_INDERAL LA.pdf,
1983,INDERAL LA,PROPRANOLOL HYDROCHLORIDE,NDA018553,35d28979-36b1-4630-b85e-a44e0a443734,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018553_s005_INDERAL LA.pdf,
1983,N/A,N/A,NDA018647,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/18-647_corzide.pdf,
2013,N/A,N/A,NDA203568,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203568Orig1s000TOC.cfm,
2013,N/A,N/A,NDA203568,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203568Orig1s000SumR.pdf,
2002,HUMIRA,ADALIMUMAB,BLA125057,4977567e-3525-44ac-9ff5-f1e74b053950,http://www.accessdata.fda.gov/drugsatfda_docs/bla/2005/125057Orig1s045.pdf,
2002,HUMIRA,ADALIMUMAB,BLA125057,4977567e-3525-44ac-9ff5-f1e74b053950,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125057Orig1s322.pdf,
2002,HUMIRA,ADALIMUMAB,BLA125057,4977567e-3525-44ac-9ff5-f1e74b053950,http://www.accessdata.fda.gov/drugsatfda_docs/bla/2014/125057Orig1s381.pdf,
2002,HUMIRA,ADALIMUMAB,BLA125057,4977567e-3525-44ac-9ff5-f1e74b053950,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/125057Orig1s023.pdf,
2002,HUMIRA,ADALIMUMAB,BLA125057,4977567e-3525-44ac-9ff5-f1e74b053950,http://www.accessdata.fda.gov/drugsatfda_docs/bla/2010/125057Orig1s0213.pdf,
2002,HUMIRA,ADALIMUMAB,BLA125057,4977567e-3525-44ac-9ff5-f1e74b053950,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/0125057s114_Adalimumab (Humira)_Clinical_PREA.pdf,
2002,HUMIRA,ADALIMUMAB,BLA125057,4977567e-3525-44ac-9ff5-f1e74b053950,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/0125057s114_Adalimumab (Humira)_Clinpharm_PREA.pdf,
2002,HUMIRA,ADALIMUMAB,BLA125057,4977567e-3525-44ac-9ff5-f1e74b053950,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/0125057s114_Adalimumab (Humira)_Statistical_PREA.pdf,
2002,HUMIRA,ADALIMUMAB,BLA125057,4977567e-3525-44ac-9ff5-f1e74b053950,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125057Orig1s394SumR.pdf,
2002,HUMIRA,ADALIMUMAB,BLA125057,4977567e-3525-44ac-9ff5-f1e74b053950,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/125057s110TOC.cfm,
2002,HUMIRA,ADALIMUMAB,BLA125057,4977567e-3525-44ac-9ff5-f1e74b053950,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/125057s110_SumR.pdf,
2002,HUMIRA,ADALIMUMAB,BLA125057,4977567e-3525-44ac-9ff5-f1e74b053950,http://www.accessdata.fda.gov/drugsatfda_docs/bla/2005/125057Orig1s046.pdf,
2002,HUMIRA,ADALIMUMAB,BLA125057,4977567e-3525-44ac-9ff5-f1e74b053950,http://www.accessdata.fda.gov/drugsatfda_docs/bla/2007/125057_S0089.pdf,
2002,HUMIRA,ADALIMUMAB,BLA125057,4977567e-3525-44ac-9ff5-f1e74b053950,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/125057_toc.cfm,
2002,HUMIRA,ADALIMUMAB,BLA125057,4977567e-3525-44ac-9ff5-f1e74b053950,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/338_125057S408 adalimumab multidisciplinary prea.pdf,
2002,HUMIRA,ADALIMUMAB,BLA125057,4977567e-3525-44ac-9ff5-f1e74b053950,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125057Orig1s232.pdf,
2002,HUMIRA,ADALIMUMAB,BLA125057,4977567e-3525-44ac-9ff5-f1e74b053950,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/125057Orig1s356.pdf,
2002,HUMIRA,ADALIMUMAB,BLA125057,4977567e-3525-44ac-9ff5-f1e74b053950,http://www.accessdata.fda.gov/drugsatfda_docs/bla/2004/125057Orig1s016.pdf,
2002,HUMIRA,ADALIMUMAB,BLA125057,4977567e-3525-44ac-9ff5-f1e74b053950,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/125057Orig1s393.pdf,
2012,LINZESS,LINACLOTIDE,NDA202811,09beda19-56d6-4a56-afdc-9a77b70b2ef3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/202811Orig1s010.pdf,
2012,LINZESS,LINACLOTIDE,NDA202811,09beda19-56d6-4a56-afdc-9a77b70b2ef3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202811Orig1s000TOC.cfm,
2012,LINZESS,LINACLOTIDE,NDA202811,09beda19-56d6-4a56-afdc-9a77b70b2ef3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202811Orig1s000SumR.pdf,
2014,BELEODAQ,BELINOSTAT,NDA206256,2e8ef36b-71fa-4492-a16f-577d5f7d111d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206256Orig1s000SumR.pdf,
2014,BELEODAQ,BELINOSTAT,NDA206256,2e8ef36b-71fa-4492-a16f-577d5f7d111d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206256Orig1s000TOC.cfm,
2019,FULVESTRANT,FULVESTRANT,NDA210326,fabe9bd8-ac23-4df1-a89a-223d5cd38914,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210326Orig1s000TOC.cfm,
2016,DESCOVY,EMTRICITABINE AND TENOFOVIR ALAFENAMIDE,NDA208215,06f66e98-e6ee-4538-9506-6c1282cc14c1,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/187_208125s005 descovy clinpharm prea.pdf,
2016,DESCOVY,EMTRICITABINE AND TENOFOVIR ALAFENAMIDE,NDA208215,06f66e98-e6ee-4538-9506-6c1282cc14c1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208215Orig1_toc.cfm,
2016,DESCOVY,EMTRICITABINE AND TENOFOVIR ALAFENAMIDE,NDA208215,06f66e98-e6ee-4538-9506-6c1282cc14c1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208215Orig1s000SumR.pdf,
2016,DESCOVY,EMTRICITABINE AND TENOFOVIR ALAFENAMIDE,NDA208215,06f66e98-e6ee-4538-9506-6c1282cc14c1,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208215 emtricitabine and tenofovir alafenamide clinpharm  prea.pdf,
2016,DESCOVY,EMTRICITABINE AND TENOFOVIR ALAFENAMIDE,NDA208215,06f66e98-e6ee-4538-9506-6c1282cc14c1,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208215 emtricitabine and tenofovir alafenamide statistical prea.pdf,
2016,DESCOVY,EMTRICITABINE AND TENOFOVIR ALAFENAMIDE,NDA208215,06f66e98-e6ee-4538-9506-6c1282cc14c1,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/185_208215s005 descovy clinical prea.pdf,
2016,DESCOVY,EMTRICITABINE AND TENOFOVIR ALAFENAMIDE,NDA208215,06f66e98-e6ee-4538-9506-6c1282cc14c1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/208215Orig1s012.pdf,
2016,DESCOVY,EMTRICITABINE AND TENOFOVIR ALAFENAMIDE,NDA208215,06f66e98-e6ee-4538-9506-6c1282cc14c1,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/518_208215s012 emtricitabine and tenofovir alafenamide clinical prea.pdf,
2024,DANZITEN,NILOTINIB,NDA219293,d288d165-3505-49bb-9b2e-124490d65f49,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219293Orig1s000TOC.cfm,
2021,BESREMI,ROPEGINTERFERON ALFA-2B,BLA761166,9583405d-53a0-49dc-88eb-5e6384ebabcb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761166Orig1s000TOC.cfm,
1996,DURACLON,CLONIDINE HYDROCHLORIDE,NDA020615,8c126bb8-732a-4949-8754-2f50b5543638,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020615ap.pdf,
1997,TIAGABINE HYDROCHLORIDE,TIAGABINE HYDROCHLORIDE,NDA020646,953ef3cc-e3cb-480f-b9ea-256520fd62b8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020646_gabitril_toc.cfm,
2024,VOYDEYA,DANICOPAN,NDA218037,ab8d1cbd-a28b-4d49-82ab-5c7460719ac7,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/218037Orig1s000TOC.cfm,
2011,N/A,N/A,NDA022439,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022439_zutripro_toc.cfm,
2011,N/A,N/A,NDA022439,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022439Orig1s000SumR.pdf,
1998,N/A,N/A,NDA021004,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/21003_Epivir.cfm,
1998,N/A,N/A,NDA021004,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-003SE1002_EpivirHBV.cfm,
2006,EMSAM,SELEGILINE,NDA021336,b891bd9f-fdb8-4862-89c5-ecdd700398a3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21336_selegiline_Clinical_1_PREA.pdf,
2006,EMSAM,SELEGILINE,NDA021336,b891bd9f-fdb8-4862-89c5-ecdd700398a3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21336_selegiline_Clinical_2_PREA.pdf,
2006,EMSAM,SELEGILINE,NDA021336,b891bd9f-fdb8-4862-89c5-ecdd700398a3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21336_selegiline_Secondary_Clinical_1_PREA.pdf,
2006,EMSAM,SELEGILINE,NDA021336,b891bd9f-fdb8-4862-89c5-ecdd700398a3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21336_selegiline_Secondary_Clinical_2_PREA.pdf,
2006,EMSAM,SELEGILINE,NDA021336,b891bd9f-fdb8-4862-89c5-ecdd700398a3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021336s000_021708s000TOC.cfm,
2004,VYTORIN,EZETIMIBE AND SIMVASTATIN,NDA021687,89b860d2-de83-468e-b7e8-76aeec2edca2,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021687s023_Ezetimbe(Vytorin)_Clinical_PREA.pdf,
2004,VYTORIN,EZETIMIBE AND SIMVASTATIN,NDA021687,89b860d2-de83-468e-b7e8-76aeec2edca2,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021687s023_Ezetimbe(Vytorin)_Clinpharm_PREA.pdf,
2004,VYTORIN,EZETIMIBE AND SIMVASTATIN,NDA021687,89b860d2-de83-468e-b7e8-76aeec2edca2,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021687s023_021445s020_Ezetimbe(Vytorin)_Statistical_PREA.pdf,
2004,VYTORIN,EZETIMIBE AND SIMVASTATIN,NDA021687,89b860d2-de83-468e-b7e8-76aeec2edca2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-687_Vytorin.cfm,
2004,VYTORIN,EZETIMIBE AND SIMVASTATIN,NDA021687,89b860d2-de83-468e-b7e8-76aeec2edca2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021687Orig1s041.pdf,
2004,VYTORIN,EZETIMIBE AND SIMVASTATIN,NDA021687,89b860d2-de83-468e-b7e8-76aeec2edca2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/021687Orig1s057.pdf,
2007,SEROQUEL XR,QUETIAPINE,NDA022047,473a3ac4-67f4-4782-baa9-7f9bdd8761f4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022047s000TOC.cfm,
2007,SEROQUEL XR,QUETIAPINE,NDA022047,473a3ac4-67f4-4782-baa9-7f9bdd8761f4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022047Orig1s011.pdf,
2004,TYSABRI,NATALIZUMAB,BLA125104,c5fdde91-1989-4dd2-9129-4f3323ea2962,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/125104s000_Natalizumab.cfm,
2004,TYSABRI,NATALIZUMAB,BLA125104,c5fdde91-1989-4dd2-9129-4f3323ea2962,http://www.accessdata.fda.gov/drugsatfda_docs/bla/2008/125104Orig1s0033.pdf,
2004,TYSABRI,NATALIZUMAB,BLA125104,c5fdde91-1989-4dd2-9129-4f3323ea2962,http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125104Orig1s015SumR.pdf,
2012,MIFEPRISTONE,MIFEPRISTONE,NDA202107,63c068cd-9370-460f-829b-70e8c7ebe91e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107_korlym_toc.cfm,
2012,MIFEPRISTONE,MIFEPRISTONE,NDA202107,63c068cd-9370-460f-829b-70e8c7ebe91e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000SumR.pdf,
2015,SPIRIVA RESPIMAT,TIOTROPIUM BROMIDE INHALATION SPRAY,NDA207070,7b656b14-fcaa-2741-f6f0-e0be48971c02,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/207070_tiotropium bromide_Spiriva_Clinical_PREA.pdf,
2015,SPIRIVA RESPIMAT,TIOTROPIUM BROMIDE INHALATION SPRAY,NDA207070,7b656b14-fcaa-2741-f6f0-e0be48971c02,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/207070_tiotropium bromide_Spiriva_Clinpharm_PREA.pdf,
2015,SPIRIVA RESPIMAT,TIOTROPIUM BROMIDE INHALATION SPRAY,NDA207070,7b656b14-fcaa-2741-f6f0-e0be48971c02,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/207070_tiotropium bromide_Spiriva_stat_PREA.pdf,
2015,SPIRIVA RESPIMAT,TIOTROPIUM BROMIDE INHALATION SPRAY,NDA207070,7b656b14-fcaa-2741-f6f0-e0be48971c02,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207070Orig1s000TOC.cfm,
2015,SPIRIVA RESPIMAT,TIOTROPIUM BROMIDE INHALATION SPRAY,NDA207070,7b656b14-fcaa-2741-f6f0-e0be48971c02,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207070Orig1s000SumR.pdf,
2016,ZEMBRACE SYMTOUCH,SUMATRIPTAN SUCCINATE,NDA208223,6e5b104f-2b9e-416e-92fb-ef1bdaea867d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208223Orig1s000TOC.cfm,
1993,DOBUTAMINE HYDROCHLORIDE IN DEXTROSE,DOBUTAMINE HYDROCHLORIDE,NDA020255,6b17b98b-e06d-42ed-925f-69aa2699dead,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20255-s006_dobutamine.pdf,
2019,RECARBRIO,"IMIPENEM ANHYDROUS, CILASTATIN, AND RELEBACTAM ANHYDROUS",NDA212819,be32f468-738b-40df-a425-591e12f65159,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000TOC.cfm,
2022,STIMUFEND,PEGFLILGRASTIM-FPGK,BLA761173,b44bcb82-7e60-4dab-a658-115bdf5c053c,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761173Orig1s000TOC.cfm,
2012,N/A,N/A,NDA022453,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022453Orig1s000SumR.pdf,
2012,N/A,N/A,NDA022453,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022453_topotecan_toc.cfm,
1956,N/A,N/A,NDA010151,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/010151_S034_DILANTIN_AP.pdf,
1956,N/A,N/A,NDA010151,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/010151_S032_DILANTIN_AP.pdf,
1956,N/A,N/A,NDA010151,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/010151_S030_DILANTIN_AP.pdf,
1956,N/A,N/A,NDA010151,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/010151_S022_DILANTIN_AP.pdf,
1956,N/A,N/A,NDA010151,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/010151_S029_DILANTIN_AP.pdf,
1956,N/A,N/A,NDA010151,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/010151_S033_DILANTIN_AP.pdf,
2007,N/A,N/A,NDA022055,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22055_retapumulin_clinical_PREA.pdf,
2007,N/A,N/A,NDA022055,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22055_retapumulin_clinpharm_PREA.pdf,
2007,N/A,N/A,NDA022055,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022055s000TOC.cfm,
2013,BROMFENAC OPHTHALMIC SOLUTION,BROMFENAC SODIUM,NDA203168,246e2110-6a2d-4e22-8e37-72d80796b9af,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203168_prolensa_toc.cfm,
2013,BROMFENAC OPHTHALMIC SOLUTION,BROMFENAC SODIUM,NDA203168,246e2110-6a2d-4e22-8e37-72d80796b9af,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203168Orig1s000SumR.pdf,
2004,ERBITUX,CETUXIMAB,BLA125084,8bc6397e-4bd8-4d37-a007-a327e4da34d9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/0125084_s030_erbitux.pdf,
2004,ERBITUX,CETUXIMAB,BLA125084,8bc6397e-4bd8-4d37-a007-a327e4da34d9,http://www.accessdata.fda.gov/drugsatfda_docs/bla/2007/125084Orig1s103.pdf,
2004,ERBITUX,CETUXIMAB,BLA125084,8bc6397e-4bd8-4d37-a007-a327e4da34d9,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/125084Orig1s277,s280.pdf",
2004,ERBITUX,CETUXIMAB,BLA125084,8bc6397e-4bd8-4d37-a007-a327e4da34d9,http://www.accessdata.fda.gov/drugsatfda_docs/bla/2004/125084_erbitux_toc.cfm,
2004,ERBITUX,CETUXIMAB,BLA125084,8bc6397e-4bd8-4d37-a007-a327e4da34d9,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/125084Orig1s277,s280.pdf",
2018,YUTIQ,FLUOCINOLONE ACETONIDE,NDA210331,43ba66d9-653d-48b9-9914-b0a50b68b79a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210331Orig1s000TOC.cfm,
1995,N/A,N/A,NDA020489,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/020489Orig1s034.pdf,
1995,N/A,N/A,NDA020489,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020489_S007_ANDRODERM_AP.pdf,
1995,N/A,N/A,NDA020489,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20489-S003_ANDRODERM.PDF,
1995,N/A,N/A,NDA020489,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/020489Orig1s031.pdf,
2023,UZEDY,RISPERIDONE,NDA213586,734eb776-4be0-4808-834b-0d8b0f9e021e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/213586Orig1s000TOC.cfm,
2020,PHESGO,"PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF",BLA761170,27dd5e6b-72cd-458d-a015-cf4dab5800da,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761170Orig1s000TOC.cfm,
1998,INFASURF,CALFACTANT,BLA020521,315c128a-272d-4c57-bfbe-1a8b3402af08,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20521_Infasurf.cfm,
2023,XALKORI,CRIZOTINIB,NDA217581,2a51b0de-47d6-455e-a94c-d2c737b04ff7,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/217581Orig1s000tOC.cfm,
2023,XALKORI,CRIZOTINIB,NDA217581,2a51b0de-47d6-455e-a94c-d2c737b04ff7,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/217581Orig1s000tOC.cfm,
2016,SUSTOL,GRANISETRON,NDA022445,f7c7ffdd-8270-4030-bc1e-a1cb28a6de56,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/022445Orig1s000TOC.cfm,
2001,FROVA,FROVATRIPTAN SUCCINATE,NDA021006,c0703630-9ce8-4259-841e-71fd2019fa66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-006_Frova.cfm,
2006,N/A,N/A,NDA021338,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021338_toc.cfm,
2006,N/A,N/A,NDA021338,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/021338Orig1s005.pdf,
2005,N/A,N/A,NDA021689,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021689s000TOC.cfm,
2005,N/A,N/A,NDA021689,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21689_Esomeprazole_Clinical_Prea.pdf,
2005,N/A,N/A,NDA021689,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21689_Esomeprazole_Clinpharm_Prea.pdf,
2005,N/A,N/A,NDA021689,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/021689Orig1s014.pdf,
2007,FLONASE SENSIMIST ALLERGY RELIEF,FLUTICASONE FUROATE,NDA022051,893234b5-be82-4425-b850-2b884637b18e,http://www.accessdata.fda.gov/drugsatfda_docs/review/2018/022051Orig1s017.pdf,
2007,FLONASE SENSIMIST ALLERGY RELIEF,FLUTICASONE FUROATE,NDA022051,893234b5-be82-4425-b850-2b884637b18e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022051_veramyst_toc.cfm,
2004,AVASTIN,BEVACIZUMAB,BLA125085,939b5d1f-9fb2-4499-80ef-0607aa6b114e,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125085Orig1s301SumR.pdf,
2004,AVASTIN,BEVACIZUMAB,BLA125085,939b5d1f-9fb2-4499-80ef-0607aa6b114e,http://www.accessdata.fda.gov/drugsatfda_docs/bla/2006/125085_0074_avastin.pdf,
2004,AVASTIN,BEVACIZUMAB,BLA125085,939b5d1f-9fb2-4499-80ef-0607aa6b114e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/125085Orig1s332.pdf,
2004,AVASTIN,BEVACIZUMAB,BLA125085,939b5d1f-9fb2-4499-80ef-0607aa6b114e,http://www.accessdata.fda.gov/drugsatfda_docs/bla/2006/125085_0085_avastin.pdf,
2004,AVASTIN,BEVACIZUMAB,BLA125085,939b5d1f-9fb2-4499-80ef-0607aa6b114e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/STN-125085_Avastin.cfm,
2004,AVASTIN,BEVACIZUMAB,BLA125085,939b5d1f-9fb2-4499-80ef-0607aa6b114e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/125085_s091_avastin.pdf,
2004,AVASTIN,BEVACIZUMAB,BLA125085,939b5d1f-9fb2-4499-80ef-0607aa6b114e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/125085Orig1s319.pdf,
2004,AVASTIN,BEVACIZUMAB,BLA125085,939b5d1f-9fb2-4499-80ef-0607aa6b114e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/125085Orig1s331.pdf,
2019,LOTEMAX SM,LOTEPREDNOL ETABONATE,NDA208219,6f9477b5-699f-4d3b-b9a6-0cc238266237,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/208219Orig1s000TOC.cfm,
2025,EKTERLY,SEBETRALSTAT,NDA219301,1d145e2f-8e7e-2e90-e063-6294a90a4449,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219301Orig1s000TOC.cfm,
2020,DANYELZA,NAXITAMAB,BLA761171,29a80c6b-8bad-4650-8c7f-f18490c868ec,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761171Orig1s000TOC.cfm,
2023,COMBOGESIC IV,ACETAMINOPHEN AND IBUPROFEN INJECTION,NDA215320,be408a5a-48e4-43c0-9cb1-bbf830b54f5b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/215320Orig1s000TOC.cfm,
2022,OLPRUVA,SODIUM PHENYLBUTYRATE,NDA214860,89abc31c-43e8-4809-9eb7-172cb31a86f1,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/214860Orig1s000TOC.cfm,
2022,PYRUKYND,MITAPIVAT,NDA216196,4ccee896-e313-4c6c-9674-b4746ada0a90,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216196Orig1s000TOC.cfm,
2005,N/A,N/A,NDA021690,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021690s000TOC.cfm,
2007,N/A,N/A,NDA022052,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022052_zyflo_toc.cfm,
2004,KEPIVANCE,PALIFERMIN,BLA125103,426f6e64-2c20-4a61-6d65-7320426f6e64,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/125103s000_KepivanceTOC.cfm,
2004,KEPIVANCE,PALIFERMIN,BLA125103,426f6e64-2c20-4a61-6d65-7320426f6e64,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/125103 palifermin Kepivance clinical prea.pdf,
2004,KEPIVANCE,PALIFERMIN,BLA125103,426f6e64-2c20-4a61-6d65-7320426f6e64,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/125103 palifermin Kepivance_clinpharm prea.pdf,
2011,N/A,N/A,NDA200732,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/200732_zidovudine_toc.cfm,
2015,MEROPENEM AND SODIUM CHLORIDE,MEROPENEM AND SODIUM CHLORIDE,NDA202106,3b952a55-6ef7-45c8-be21-16eefe37ec2e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/202106Orig1s000TOC.cfm,
2015,MEROPENEM AND SODIUM CHLORIDE,MEROPENEM AND SODIUM CHLORIDE,NDA202106,3b952a55-6ef7-45c8-be21-16eefe37ec2e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/202106Orig1s000SumR.pdf,
2013,KUVAN,SAPROPTERIN DIHYDROCHLORIDE,NDA205065,af38711e-8873-4790-a92d-4d583e23fb89,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205065Orig1s000TOC.cfm,
2013,KUVAN,SAPROPTERIN DIHYDROCHLORIDE,NDA205065,af38711e-8873-4790-a92d-4d583e23fb89,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205065Orig1s000SumR.pdf,
2016,BONJESTA,DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE,NDA209661,dba60bb4-54ff-4e06-b8d2-acbbd3717666,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209661Orig1s000TOC.cfm,
2021,VUITY,PILOCARPINE HYDROCHLORIDE,NDA214028,8d806897-8a2a-4518-8c68-0ec3b778de50,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214028Orig1s000TOC.cfm,
1996,DIFFERIN,ADAPALENE,NDA020380,0739d631-171b-42a8-bd55-0022b8df2d8a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/020380s10_toc.cfm,
2020,EBANGA,ANSUVIMAB,BLA761172,de220c8f-ffcb-4522-a6a2-c7d6ce5de1b5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761172Orig1s000TOC.cfm,
2010,N/A,N/A,NDA022450,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022450_ofirmev_toc.cfm,
2010,N/A,N/A,NDA022450,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/66_22450 Acetaminophen clinpharm prea.pdf,
2010,N/A,N/A,NDA022450,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022450Orig1s000SumR.pdf,
2010,N/A,N/A,NDA022450,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22450-Acetaminophen-clinical-prea.pdf,
2010,N/A,N/A,NDA022450,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22450-Acetaminophen-clinpharm-prea.pdf,
2010,N/A,N/A,NDA022450,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22450-Acetaminophen_Statistical-prea.pdf,
2010,N/A,N/A,NDA022450,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22450_Acetaminophen_Clinical_Safety_PREA.pdf,
1998,SANDOSTATIN LAR DEPOT,OCTREOTIDE ACETATE,NDA021008,d0b7fe9e-7000-4b79-ba3b-291ce92c14f9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/021008.cfm,
1998,SANDOSTATIN LAR DEPOT,OCTREOTIDE ACETATE,NDA021008,d0b7fe9e-7000-4b79-ba3b-291ce92c14f9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/021008Orig1s028.pdf,
1998,SANDOSTATIN LAR DEPOT,OCTREOTIDE ACETATE,NDA021008,d0b7fe9e-7000-4b79-ba3b-291ce92c14f9,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/316_21008s018octreotide_Sandostatin-MedRev.pdf,
1998,SANDOSTATIN LAR DEPOT,OCTREOTIDE ACETATE,NDA021008,d0b7fe9e-7000-4b79-ba3b-291ce92c14f9,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/315_21008s018octreotide_Sandostatin-ClinPharmRev.pdf,
1998,SANDOSTATIN LAR DEPOT,OCTREOTIDE ACETATE,NDA021008,d0b7fe9e-7000-4b79-ba3b-291ce92c14f9,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/317_21008s018octreotide_Sandostatin-StatsRev.pdf,
2002,LEVOTHYROXINE SODIUM,LEVOTHYROXINE SODIUM,NDA021342,a8db0f7d-8863-9309-e053-2995a90a284a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021342_s004_Levo.pdf,
2002,LEVOTHYROXINE SODIUM,LEVOTHYROXINE SODIUM,NDA021342,a8db0f7d-8863-9309-e053-2995a90a284a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-342_Levothyroxine.cfm,
2002,LEVOTHYROXINE SODIUM,LEVOTHYROXINE SODIUM,NDA021342,a8db0f7d-8863-9309-e053-2995a90a284a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021342_s003_Levo.pdf,
2005,N/A,N/A,NDA021692,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021692s000_RalivaTOC.cfm,
1975,ROBINUL,ROBINUL,NDA017558,38f88829-a226-4810-866c-1b62c47e8aee,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/017558_S000_RobinulTOC.cfm,
2006,N/A,N/A,BLA125141,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/125141s000_MyozymeTOC.cfm,
2016,SYNDROS,DRONABINOL,NDA205525,a7801c70-995d-46a2-91ee-141ef427c6b5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000TOC.cfm,
2018,LOKELMA,SODIUM ZIRCONIUM CYCLOSILICATE,NDA207078,90bf8e28-748d-4e4b-a19f-9cf483370eff,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/207078Orig1s000TOC.cfm,
2022,KONVOMEP,OMEPRAZOLE AND SODIUM BICARBONATE,NDA213593,688ed6f1-d78a-4006-a682-57021cb38a3e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/213593Orig1s000TOC.cfm,
2022,BORTEZOMIB,BORTEZOMIB,NDA215331,c40e6a28-d577-43d4-bca6-bef28da1d580,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215331Orig1s000TOC.cfm,
2023,INPEFA,SOTAGLIFLOZIN,NDA216203,1a46614e-05f6-421a-b6f4-d6f8760d643a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216203Orig1s000TOC.cfm,
1999,N/A,N/A,NDA020746,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20746_Rhinocort.cfm,
2021,SKYTROFA,LONAPEGSOMATROPIN-TCGD,BLA761177,9229f871-bc61-4ddc-8122-d126d40e36ac,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761177Orig1s000TOC.cfm,
2000,TRILEPTAL,OXCARBAZEPINE,NDA021014,4c5c86c8-ab7f-4fcf-bc1b-5a0b1fd0691b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21-014_Trileptal.cfm,
2000,TRILEPTAL,OXCARBAZEPINE,NDA021014,4c5c86c8-ab7f-4fcf-bc1b-5a0b1fd0691b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021014s013_oxcarbazepine_Trileptal-MedRev.pdf,
2000,TRILEPTAL,OXCARBAZEPINE,NDA021014,4c5c86c8-ab7f-4fcf-bc1b-5a0b1fd0691b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021014s013_oxcarbazepine_Trileptal-ClinPharmRev.pdf,
2000,TRILEPTAL,OXCARBAZEPINE,NDA021014,4c5c86c8-ab7f-4fcf-bc1b-5a0b1fd0691b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021014s013_oxcarbazepine_Trileptal-StatsRev.pdf,
2000,TRILEPTAL,OXCARBAZEPINE,NDA021014,4c5c86c8-ab7f-4fcf-bc1b-5a0b1fd0691b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021014_s003_TrileptalTOC.cfm,
2003,RISPERDAL CONSTA,RISPERIDONE,NDA021346,bb34ee82-d2c2-43b8-ba21-2825c0954691,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/021346Orig1s058.pdf,
2003,RISPERDAL CONSTA,RISPERIDONE,NDA021346,bb34ee82-d2c2-43b8-ba21-2825c0954691,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/021346Orig1s064.pdf,
2003,RISPERDAL CONSTA,RISPERIDONE,NDA021346,bb34ee82-d2c2-43b8-ba21-2825c0954691,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/021346Orig1s056.pdf,
2003,RISPERDAL CONSTA,RISPERIDONE,NDA021346,bb34ee82-d2c2-43b8-ba21-2825c0954691,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021346Orig1s048.pdf,
2003,RISPERDAL CONSTA,RISPERIDONE,NDA021346,bb34ee82-d2c2-43b8-ba21-2825c0954691,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/021346Orig1s062.pdf,
2003,RISPERDAL CONSTA,RISPERIDONE,NDA021346,bb34ee82-d2c2-43b8-ba21-2825c0954691,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/021346Orig1s054.pdf,
2003,RISPERDAL CONSTA,RISPERIDONE,NDA021346,bb34ee82-d2c2-43b8-ba21-2825c0954691,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/021346Orig1s060.pdf,
2003,RISPERDAL CONSTA,RISPERIDONE,NDA021346,bb34ee82-d2c2-43b8-ba21-2825c0954691,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/021346Orig1s052.pdf,
2003,RISPERDAL CONSTA,RISPERIDONE,NDA021346,bb34ee82-d2c2-43b8-ba21-2825c0954691,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021346Orig1s050.pdf,
2003,RISPERDAL CONSTA,RISPERIDONE,NDA021346,bb34ee82-d2c2-43b8-ba21-2825c0954691,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/021346Orig1s059.pdf,
2003,RISPERDAL CONSTA,RISPERIDONE,NDA021346,bb34ee82-d2c2-43b8-ba21-2825c0954691,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021346Orig1s049.pdf,
2003,RISPERDAL CONSTA,RISPERIDONE,NDA021346,bb34ee82-d2c2-43b8-ba21-2825c0954691,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/021346Orig1s063.pdf,
2003,RISPERDAL CONSTA,RISPERIDONE,NDA021346,bb34ee82-d2c2-43b8-ba21-2825c0954691,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/021346Orig1s055.pdf,
2003,RISPERDAL CONSTA,RISPERIDONE,NDA021346,bb34ee82-d2c2-43b8-ba21-2825c0954691,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/021346Orig1s061.pdf,
2003,RISPERDAL CONSTA,RISPERIDONE,NDA021346,bb34ee82-d2c2-43b8-ba21-2825c0954691,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/021346Orig1s051.pdf,
2003,RISPERDAL CONSTA,RISPERIDONE,NDA021346,bb34ee82-d2c2-43b8-ba21-2825c0954691,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21346_RisperdalTOC.cfm,
2004,N/A,N/A,NDA021698,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021698s000TOC.cfm,
2007,TYKERB,LAPATINIB,NDA022059,eee37f88-ec6a-4c30-b8aa-e2c71f93088c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022059Orig1s017.pdf,
2007,TYKERB,LAPATINIB,NDA022059,eee37f88-ec6a-4c30-b8aa-e2c71f93088c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022059Orig1s007.pdf,
2007,TYKERB,LAPATINIB,NDA022059,eee37f88-ec6a-4c30-b8aa-e2c71f93088c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022059s000TOC.cfm,
2005,NAGLAZYME,GALSULFASE,BLA125117,59341250-deac-ed71-3823-a4f5d64dbd77,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/125117s000_NaglazyneTOC.cfm,
2015,FINACEA FOAM,AZELAIC ACID,NDA207071,9fabd24e-4c3b-49a0-aa5f-c8d75ae67572,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207071Orig1s000TOC.cfm,
2015,FINACEA FOAM,AZELAIC ACID,NDA207071,9fabd24e-4c3b-49a0-aa5f-c8d75ae67572,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207071Orig1s000SumR.pdf,
2016,KYLEENA,LEVONORGESTREL,NDA208224,2e07c155-21e1-4781-9633-ce8bddd47080,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208224Orig1s000TOC.cfm,
2017,N/A,N/A,NDA208603,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208603Orig1s000TOC.cfm,
2017,TRIPTODUR,TRIPTORELIN,NDA208956,f41380e7-b830-432d-a5f5-a872932f107e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208956Orig1s000TOC.cfm,
1991,N/A,N/A,NDA020156,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020156_S039_VIDEX.pdf,
1991,N/A,N/A,NDA020156,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020156_S007_VIDEX.pdf,
1991,N/A,N/A,NDA020156,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020154s032s033_020155s023s024_020156s024s025_Videx.cfm,
1991,N/A,N/A,NDA020156,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020154s040s041_020155s030s031_020156s031s032_Videx.cfm,
1991,N/A,N/A,NDA020156,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-154s028_20-155s020_20156s021_Videx.cfm,
1991,N/A,N/A,NDA020156,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020154s040s041_020155s030s031_020156s031s032_Videx.cfm,
1991,N/A,N/A,NDA020156,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020154s032s033_020155s023s024_020156s024s025_Videx.cfm,
1991,N/A,N/A,NDA020156,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020156_S016_VIDEX.pdf,
1991,N/A,N/A,NDA020156,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-154s029s030_20-155s021_20-156s022_Videx.cfm,
2025,ROMVIMZA,VIMSELTINIB,NDA219304,f73c7a62-9601-4df0-810f-100f515d79ea,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219304Orig1s000TOC.cfm,
2021,JEMPERLI,DOSTARLIMAB,BLA761174,095eab9f-545a-4f12-bfb7-19477fb901a5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761174Orig1s000TOC.cfm,
2011,DATSCAN,IOFLUPANE I-123,NDA022454,ef7804d7-c691-495b-8aaf-5bc54fd5d9f6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022454sOrig1s000SumR.pdf,
2011,DATSCAN,IOFLUPANE I-123,NDA022454,ef7804d7-c691-495b-8aaf-5bc54fd5d9f6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022454sOrig1s000TOC.cfm,
1999,ALOCRIL,NEDOCROMIL SODIUM,NDA021009,2fe8d7ad-2158-4169-94b0-719ad20242b7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/021009_Alocril.cfm,
2002,ELIGARD,LEUPROLIDE ACETATE,NDA021343,b78d1919-9dee-44fa-90f9-e0a26d32481d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-343_Eligard.cfm,
2002,ELIGARD,LEUPROLIDE ACETATE,NDA021343,b78d1919-9dee-44fa-90f9-e0a26d32481d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/021343Orig1s033.pdf,
2008,PRILOSEC,OMEPRAZOLE MAGNESIUM,NDA022056,b6761f84-53ac-4745-a8c8-1e5427d7e179,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22056 omeprazole clinical prea.pdf,
2008,PRILOSEC,OMEPRAZOLE MAGNESIUM,NDA022056,b6761f84-53ac-4745-a8c8-1e5427d7e179,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22056 omeprazole clinpharm prea.pdf,
2008,PRILOSEC,OMEPRAZOLE MAGNESIUM,NDA022056,b6761f84-53ac-4745-a8c8-1e5427d7e179,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022056_prilosec_toc.cfm,
2008,PRILOSEC,OMEPRAZOLE MAGNESIUM,NDA022056,b6761f84-53ac-4745-a8c8-1e5427d7e179,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22056s000_Omeprazole_Clinical_PREA.pdf,
2008,PRILOSEC,OMEPRAZOLE MAGNESIUM,NDA022056,b6761f84-53ac-4745-a8c8-1e5427d7e179,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22056s000_Omeprazole_Clinpharm_PREA.pdf,
2008,PRILOSEC,OMEPRAZOLE MAGNESIUM,NDA022056,b6761f84-53ac-4745-a8c8-1e5427d7e179,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22056s000_Omeprazole_Clinical_PREA.pdf,
2008,PRILOSEC,OMEPRAZOLE MAGNESIUM,NDA022056,b6761f84-53ac-4745-a8c8-1e5427d7e179,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22056s000_Omeprazole_Clinpharm_PREA.pdf,
2008,PRILOSEC,OMEPRAZOLE MAGNESIUM,NDA022056,b6761f84-53ac-4745-a8c8-1e5427d7e179,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22056s000_Omeprazole_Clinical_PREA.pdf,
2008,PRILOSEC,OMEPRAZOLE MAGNESIUM,NDA022056,b6761f84-53ac-4745-a8c8-1e5427d7e179,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022056s000SumR.pdf,
1980,REGLAN,METOCLOPRAMIDE HYDROCHLORIDE,NDA017854,de55c133-eb08-4a35-91a2-5dc093027397,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/18821-S018_Reglan.pdf,
1980,REGLAN,METOCLOPRAMIDE HYDROCHLORIDE,NDA017854,de55c133-eb08-4a35-91a2-5dc093027397,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/017854_s051_reglan_tablets.pdf,
2011,DOCETAXEL,DOCETAXEL,NDA201525,0e0f06bd-d190-45da-be8b-062e8de01970,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201525_docetaxel_toc.cfm,
2011,DOCETAXEL,DOCETAXEL,NDA201525,0e0f06bd-d190-45da-be8b-062e8de01970,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201525Orig1s000SumR.pdf,
2011,DOCETAXEL,DOCETAXEL,NDA201525,0e0f06bd-d190-45da-be8b-062e8de01970,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/201525Orig1s012.pdf,
2015,PATADAY ONCE DAILY RELIEF,OLOPATADINE HYDROCHLORIDE,NDA206276,6d07a5d6-265c-4735-97b3-8a2575b276cb,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/206276 olopatadine clinical bpca (2).pdf,
2015,PATADAY ONCE DAILY RELIEF,OLOPATADINE HYDROCHLORIDE,NDA206276,6d07a5d6-265c-4735-97b3-8a2575b276cb,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/206276 olopatadine clinpharm bpca.pdf,
2015,PATADAY ONCE DAILY RELIEF,OLOPATADINE HYDROCHLORIDE,NDA206276,6d07a5d6-265c-4735-97b3-8a2575b276cb,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/206276 olopatadine statistical bpca.pdf,
2015,PATADAY ONCE DAILY RELIEF,OLOPATADINE HYDROCHLORIDE,NDA206276,6d07a5d6-265c-4735-97b3-8a2575b276cb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206276Orig1s000TOC.cfm,
2015,PATADAY ONCE DAILY RELIEF,OLOPATADINE HYDROCHLORIDE,NDA206276,6d07a5d6-265c-4735-97b3-8a2575b276cb,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206276Orig1s005.pdf,
2015,PATADAY ONCE DAILY RELIEF,OLOPATADINE HYDROCHLORIDE,NDA206276,6d07a5d6-265c-4735-97b3-8a2575b276cb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206276Orig1s001.pdf,
2020,TABRECTA,CAPMATINIB,NDA213591,455892c3-d144-4ba8-9ab4-79cabff9876d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213591Orig1s000TOC.cfm,
2021,N/A,N/A,NDA214032,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214032Orig1s000TOC.cfm,
1994,N/A,N/A,NDA020121,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20548s018_fluticasone propionate_Flovent-ClinPharmRev-BPCA.pdf,
1994,N/A,N/A,NDA020121,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20548s018_DD summary review_BPCA.pdf,
1994,N/A,N/A,NDA020121,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20548s018_fluticasone propionate_Flovent-MedRev-BPCA.pdf,
1994,N/A,N/A,NDA020121,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20548s018_fluticasone propionate_Flovent-StatsRev-BPCA.pdf,
1994,N/A,N/A,NDA020121,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20548s018_TL Summary review_BPCA.pdf,
1994,N/A,N/A,NDA020121,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20121S009_Flonase.cfm,
1994,N/A,N/A,NDA020121,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20121.pdf,
2019,BRUKINSA,ZANUBRUTINIB,NDA213217,3e08fe23-d70e-424c-bc51-1222e320f902,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/213217Orig1s000TOC.cfm,
2019,BRUKINSA,ZANUBRUTINIB,NDA213217,3e08fe23-d70e-424c-bc51-1222e320f902,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/213217Orig1s007.pdf,
2019,BRUKINSA,ZANUBRUTINIB,NDA213217,3e08fe23-d70e-424c-bc51-1222e320f902,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/213217Orig1s004.pdf,
2021,DHIVY,CARBIDOPA LEVODOPA,NDA214869,39d79ade-8ee0-40ba-9fdd-13045b8ddbdf,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214869Orig1s000TOC.cfm,
2009,N/A,N/A,NDA022456,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022456_magnsium_hydroxide_omeprazole_sodium_bicarbonate_toc.cfm,
2009,N/A,N/A,NDA022456,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022456s000sumr.pdf,
2000,ROXICODONE,OXYCODONE HYDROCHLORIDE,NDA021011,5a8157d3-ba20-4abf-b0d4-6ad141b31d63,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-011_Roxicodone.cfm,
2002,FASLODEX,FULVESTRANT,NDA021344,83d7a440-e904-4e36-afb5-cb02b1c919f7,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21344s013_ fulvestrant CDTLclinical prea.pdf,
2002,FASLODEX,FULVESTRANT,NDA021344,83d7a440-e904-4e36-afb5-cb02b1c919f7,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21344s013_fulvestrant clinical prea.pdf,
2002,FASLODEX,FULVESTRANT,NDA021344,83d7a440-e904-4e36-afb5-cb02b1c919f7,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21344s013_fulvestrant clinpharm prea.pdf,
2002,FASLODEX,FULVESTRANT,NDA021344,83d7a440-e904-4e36-afb5-cb02b1c919f7,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21344s013_fulvestrant statistical prea.pdf,
2002,FASLODEX,FULVESTRANT,NDA021344,83d7a440-e904-4e36-afb5-cb02b1c919f7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/021344Orig1s026.pdf,
2002,FASLODEX,FULVESTRANT,NDA021344,83d7a440-e904-4e36-afb5-cb02b1c919f7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021344Orig1s020.pdf,
2002,FASLODEX,FULVESTRANT,NDA021344,83d7a440-e904-4e36-afb5-cb02b1c919f7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021344Orig1s012.pdf,
2002,FASLODEX,FULVESTRANT,NDA021344,83d7a440-e904-4e36-afb5-cb02b1c919f7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-344_FulvestrantFaslodex.cfm,
2002,FASLODEX,FULVESTRANT,NDA021344,83d7a440-e904-4e36-afb5-cb02b1c919f7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/021344Orig1s029.pdf,
2004,FENOFIBRATE,FENOFIBRATE,NDA021695,37b25526-0bd0-4459-a4be-f3a6893506f9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021695s000_AntaraTOC.cfm,
2007,ENDOMETRIN,PROGESTERONE,NDA022057,2ba50fa9-b349-40cb-9a4b-1af8faa4ec09,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022057_endometrin_toc.cfm,
2005,ORENCIA,ABATACEPT,BLA125118,0836c6ac-ee37-5640-2fed-a3185a0b16eb,http://www.accessdata.fda.gov/drugsatfda_docs/bla/2011/125118Orig1s107.pdf,
2005,ORENCIA,ABATACEPT,BLA125118,0836c6ac-ee37-5640-2fed-a3185a0b16eb,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/012510125118s045_Abatacept_Statistical_PREA.pdf,
2005,ORENCIA,ABATACEPT,BLA125118,0836c6ac-ee37-5640-2fed-a3185a0b16eb,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/101_125118 abatacept clinpharm-2 bpca.pdf,
2005,ORENCIA,ABATACEPT,BLA125118,0836c6ac-ee37-5640-2fed-a3185a0b16eb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/125118_s0000_OrenciaTOC.cfm,
2005,ORENCIA,ABATACEPT,BLA125118,0836c6ac-ee37-5640-2fed-a3185a0b16eb,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/99_125118 abatacept clinical bpca.pdf,
2005,ORENCIA,ABATACEPT,BLA125118,0836c6ac-ee37-5640-2fed-a3185a0b16eb,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/100_125118 abatacept clinpharm bpca.pdf,
2005,ORENCIA,ABATACEPT,BLA125118,0836c6ac-ee37-5640-2fed-a3185a0b16eb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125118Orig1s122.pdf,
2005,ORENCIA,ABATACEPT,BLA125118,0836c6ac-ee37-5640-2fed-a3185a0b16eb,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/125118Orig1s240.pdf,
2014,INVOKAMET,CANAGLIFLOZIN AND METFORMIN HYDROCHLORIDE,NDA204353,6868666b-c25e-40d1-9d1f-306bbe9390c1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204353Orig1s000SumR.pdf,
2014,INVOKAMET,CANAGLIFLOZIN AND METFORMIN HYDROCHLORIDE,NDA204353,6868666b-c25e-40d1-9d1f-306bbe9390c1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204353Orig1s000TOC.cfm,
2013,MIRVASO,BRIMONIDINE TARTRATE,NDA204708,f6a4353f-ae69-4214-901f-e5d42a6fbde7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204708Orig1s000TOC.cfm,
2013,MIRVASO,BRIMONIDINE TARTRATE,NDA204708,f6a4353f-ae69-4214-901f-e5d42a6fbde7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204708Orig1s000SumR.pdf,
1991,NOVOLIN 70/30,HUMAN INSULIN,BLA019991,508a2763-3cb7-4be5-9e53-544e84cd9b1f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019991ap.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2021,SOAANZ,TORSEMIDE,NDA213218,05eaa163-b6e9-438a-85f8-6a60e743d460,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/213218Orig1s000TOC.cfm,
1998,N/A,N/A,NDA020774,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774.cfm,
2023,CABTREO,CLINDAMYCIN PHOSPHATE/BENZOYL PEROXIDE/ADAPALENE,NDA216632,9468da0f-9978-4c58-8135-0274c3415084,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/216632Orig1s000TOC.cfm,
2012,ELELYSO,TALIGLUCERASE ALFA,BLA022458,fa3cbd5d-677c-4b19-9032-d9182cb69a83,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022458Orig1s000TOC.cfm,
2001,ARIXTRA,FONDAPARINUX SODIUM,NDA021345,d3b30c68-cf45-4b46-8ba6-72090f7ba01a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-345_Arixtra.cfm,
2005,N/A,N/A,NDA021697,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021697s000_VaprisolTOC.cfm,
2007,SUPPRELIN LA,HISTRELIN ACETATE,NDA022058,d8fb000e-3cc9-4803-b71d-2cc597661977,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022058_supprelin_la_toc.cfm,
2007,SUPPRELIN LA,HISTRELIN ACETATE,NDA022058,d8fb000e-3cc9-4803-b71d-2cc597661977,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022058s000_SumR.pdf,
2012,N/A,N/A,NDA203585,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000TOC.cfm,
2012,N/A,N/A,NDA203585,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000SumR.pdf,
2008,CIMZIA,CERTOLIZUMAB PEGOL,BLA125160,b4c2c9dc-a0bb-4d64-a667-a67ebe88392d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/125160s000_SumR.pdf,
2008,CIMZIA,CERTOLIZUMAB PEGOL,BLA125160,b4c2c9dc-a0bb-4d64-a667-a67ebe88392d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/125160s000TOC2.cfm,
2008,CIMZIA,CERTOLIZUMAB PEGOL,BLA125160,b4c2c9dc-a0bb-4d64-a667-a67ebe88392d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/125160Orig1s213.pdf,
2008,CIMZIA,CERTOLIZUMAB PEGOL,BLA125160,b4c2c9dc-a0bb-4d64-a667-a67ebe88392d,http://www.accessdata.fda.gov/drugsatfda_docs/bla/2009/125160Orig1s080.pdf,
2008,CIMZIA,CERTOLIZUMAB PEGOL,BLA125160,b4c2c9dc-a0bb-4d64-a667-a67ebe88392d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/125160Orig1s283.pdf,
2008,CIMZIA,CERTOLIZUMAB PEGOL,BLA125160,b4c2c9dc-a0bb-4d64-a667-a67ebe88392d,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/125160Orig1s237.pdf,
2008,CIMZIA,CERTOLIZUMAB PEGOL,BLA125160,b4c2c9dc-a0bb-4d64-a667-a67ebe88392d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125160Orig1s215.pdf,
2012,SODIUM CHLORIDE,SODIUM CHLORIDE,NDA202832,d1468c0f-dd4f-4d38-a84c-c1d110303965,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202832_sodiumc_toc.cfm,
2014,N/A,N/A,NDA206289,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206289Orig1s000TOC.cfm,
2014,N/A,N/A,NDA206289,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206289Orig1s000SumR.pdf,
2014,N/A,N/A,NDA206289,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/82_206289 atropine clinical prea.pdf,
2014,N/A,N/A,NDA206289,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/83_206289 atropine clinpharm prea.pdf,
2014,N/A,N/A,NDA206289,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/84_206289 atropine statistical prea.pdf,
2018,DIACOMIT,STIRIPENTOL,NDA206709,58304ba8-9779-4658-811e-94ffe08c3f16,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206709Orig1s000,207223Orig1s000TOC.cfm",
2017,BAXDELA,DELAFLOXACIN MEGLUMINE,NDA208610,fb77637a-88d9-4aea-958f-e270030ce30d,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000TOC.cfm",
1997,N/A,N/A,NDA020490,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-490s007_Alphagan.cfm,
2017,N/A,N/A,NDA210709,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/210709Orig1s000TOC.cfm,
2022,RYALTRIS,OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE,NDA211746,382eac74-a7ce-4f42-ac0a-b253308f335f,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/211746Orig1000TOC.cfm,
2019,NUBEQA,DAROLUTAMIDE,NDA212099,1a7cb212-56e4-4b9d-a73d-bfee7fe4735e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000TOC.cfm,
1995,NUTROPIN AQ NUSPIN 10,SOMATROPIN,BLA020522,139d2038-e6a9-4ab1-ab00-aa7d8aa8df5f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020522_s002ap.pdf,
1995,NUTROPIN AQ NUSPIN 10,SOMATROPIN,BLA020522,139d2038-e6a9-4ab1-ab00-aa7d8aa8df5f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-522s013_Somatropin.cfm,
1995,NUTROPIN AQ NUSPIN 10,SOMATROPIN,BLA020522,139d2038-e6a9-4ab1-ab00-aa7d8aa8df5f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20522S9.PDF,
1995,NUTROPIN AQ NUSPIN 10,SOMATROPIN,BLA020522,139d2038-e6a9-4ab1-ab00-aa7d8aa8df5f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020522_S011_NUTROPIN FOR INJ.pdf,
1995,NUTROPIN AQ NUSPIN 10,SOMATROPIN,BLA020522,139d2038-e6a9-4ab1-ab00-aa7d8aa8df5f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020522a_s004.pdf,
2021,EVKEEZA,EVINACUMAB,BLA761181,73412138-6d8f-4ea6-bb72-a740190470ff,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761181Orig1s000TOC.cfm,
1999,HUMALOG MIX50/50 KWIKPEN,INSULIN LISPRO,BLA021018,b34cd3ff-d0af-4852-b4ef-2a8b4a93aeae,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021018Orig1s034.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
1999,HUMALOG MIX50/50 KWIKPEN,INSULIN LISPRO,BLA021018,b34cd3ff-d0af-4852-b4ef-2a8b4a93aeae,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21017_Humalog.cfm,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2005,ANGELIQ,DROSPIRENONE AND ESTRADIOL,NDA021355,761834c2-6b61-4583-84c2-f1ca4a97c4f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021355s000TOC.cfm,
2007,IXEMPRA,IXABEPILONE,NDA022065,241f0b1e-8b95-470d-876f-bf1804daaf18,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22065_ixabepilone_statistical_BPCA.pdf,
2007,IXEMPRA,IXABEPILONE,NDA022065,241f0b1e-8b95-470d-876f-bf1804daaf18,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22065_ixabepilone_clinpharm_BPCA.pdf,
2007,IXEMPRA,IXABEPILONE,NDA022065,241f0b1e-8b95-470d-876f-bf1804daaf18,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22065_ixabepilone_clinical_BPCA.pdf,
2007,IXEMPRA,IXABEPILONE,NDA022065,241f0b1e-8b95-470d-876f-bf1804daaf18,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22065S006-Ixempra---Ixabepilone-Clinical-PREA.pdf,
2007,IXEMPRA,IXABEPILONE,NDA022065,241f0b1e-8b95-470d-876f-bf1804daaf18,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022065TOC.cfm,
1982,CORTIFOAM,HYDROCORTISONE ACETATE,NDA017351,0093b694-9fcb-46ae-b1ab-7d0fa204c6c8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/17-351s027_Cortifoam.cfm,
1982,CORTIFOAM,HYDROCORTISONE ACETATE,NDA017351,0093b694-9fcb-46ae-b1ab-7d0fa204c6c8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/017351_s030_CortifoamTOC.cfm,
1979,N/A,N/A,NDA017521,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/017521_s062_s063_DEXTROSE_INJ.pdf,
1979,N/A,N/A,NDA017521,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/017521_s062_s063_DEXTROSE_INJ.pdf,
2006,VECTIBIX,PANITUMUMAB,BLA125147,e0fa4bca-f245-4d92-ae29-b0c630a315c2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/125147s0000TOC.cfm,
2011,LOTEMAX,LOTEPREDNOL ETABONATE,NDA200738,902a3c6b-2625-44ec-a077-926e012b3176,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/200738_lotemax_toc.cfm,
2011,LOTEMAX,LOTEPREDNOL ETABONATE,NDA200738,902a3c6b-2625-44ec-a077-926e012b3176,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/200738Orig1s000SumR.pdf,
2015,DUOPA,CARBIDOPA AND LEVODOPA,NDA203952,7066d371-dc6a-0d6f-7bed-e5dd4ee912da,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/203952Orig1s000TOC.cfm,
1990,N/A,N/A,NDA019813,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/019813Orig1s044.pdf,
1990,N/A,N/A,NDA019813,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/019813_S036_DURAGESIC.pdf,
1990,N/A,N/A,NDA019813,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/019813_S026_DURAGESIC.pdf,
1990,N/A,N/A,NDA019813,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019813_S018_Duragesic.pdf,
1990,N/A,N/A,NDA019813,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/019813_S030_DURAGESIC.pdf,
1990,N/A,N/A,NDA019813,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/019813s036_fentanyl-Duragesic MedRev.pdf,
1990,N/A,N/A,NDA019813,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/019813s036_fentanyl-Duragesic-ClinPharmRev.pdf,
1990,N/A,N/A,NDA019813,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019813_ORIGINAL APPROVAL_PACKAGE.pdf,
1990,N/A,N/A,NDA019813,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019813_S020_Duragesic.pdf,
1990,N/A,N/A,NDA019813,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/019813_S039_DURAGESIC.pdf,
1990,N/A,N/A,NDA019813,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019813_S019_Duragesic.pdf,
1990,N/A,N/A,NDA019813,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/019813Orig1s033.pdf,
1990,N/A,N/A,NDA019813,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/019813_S025_DURAGESIC.pdf,
1990,N/A,N/A,NDA019813,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/019813_S023_DURAGESIC.pdf,
1990,N/A,N/A,NDA019813,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019813_S021_Duragesic.pdf,
1989,N/A,N/A,NDA019880,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/19880S009_Paraplatin.pdf,
2024,RALDESY TM,TRAZODONE HYDROCHLORIDE ORAL,NDA218637,34708cc1-b0b2-4fd0-b9f3-7f008b457fc9,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/218637Orig1s000TOC.cfm,
1998,N/A,N/A,NDA020713,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20713.cfm,
2010,N/A,N/A,NDA022460,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022460Orig1s000SumR.pdf,
2010,N/A,N/A,NDA022460,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022460s000_jalyn_toc.cfm,
2021,N/A,N/A,BLA761178,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761178Orig1s000TOC.cfm,
2000,TESTOSTERONE,TESTOSTERONE,NDA021015,68b2375d-0365-4797-bc3d-63531c9f42fd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021015_s008_AndrogelTOC.cfm,
2000,TESTOSTERONE,TESTOSTERONE,NDA021015,68b2375d-0365-4797-bc3d-63531c9f42fd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021015_s010_AndrogelTOC.cfm,
2000,TESTOSTERONE,TESTOSTERONE,NDA021015,68b2375d-0365-4797-bc3d-63531c9f42fd,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22227, 22228 testosterone clinical bpca.pdf",
2000,TESTOSTERONE,TESTOSTERONE,NDA021015,68b2375d-0365-4797-bc3d-63531c9f42fd,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22227, 22228 testosterone clinpharm bpca.pdf",
2000,TESTOSTERONE,TESTOSTERONE,NDA021015,68b2375d-0365-4797-bc3d-63531c9f42fd,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022227, 022228_Testoterone_ClinPharm.pdf",
2000,TESTOSTERONE,TESTOSTERONE,NDA021015,68b2375d-0365-4797-bc3d-63531c9f42fd,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22227, 22228 testosterone statistical bpca.pdf",
2000,TESTOSTERONE,TESTOSTERONE,NDA021015,68b2375d-0365-4797-bc3d-63531c9f42fd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-015_AndroGel.cfm,
2003,ZAVESCA,MIGLUSTAT,NDA021348,817892d1-ee12-4632-85fc-57ccdf16d7b8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-348_Zavesca.cfm,
2005,N/A,N/A,NDA021700,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021700s000TOC.cfm,
1962,N/A,N/A,NDA012945,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/012945Orig1s037.pdf,
1962,N/A,N/A,NDA012945,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/012945Orig1s038.pdf,
2006,ELAPRASE,IDURSULFASE,BLA125151,60cba843-5aab-4dd7-96dc-66648d413be3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/125151s0000_ElapraseTOC.cfm,
1995,ZOMACTON,SOMATROPIN,BLA019774,85ba081b-bee0-4a9a-aa0f-ae5b5e9a0886,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/019774_s009_TEV TROPIN.pdf,
2020,TRAMADOL HYDROCHLORIDE,TRAMADOL HYDROCHLORIDE,NDA214044,2804c640-9d47-4b40-b58b-da321b79cf39,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214044Orig1s000TOC.cfm,
1996,N/A,N/A,NDA020616,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020616S1_Kadian.pdf,
1996,N/A,N/A,NDA020616,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/020616_S017_KADIAN.pdf,
1996,N/A,N/A,NDA020616,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/020616_S021_KADIAN.pdf,
1996,N/A,N/A,NDA020647,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020647a_s01_s02_s03.pdf,
1996,N/A,N/A,NDA020685,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020685s022.pdf,
1996,N/A,N/A,NDA020685,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020685_S047_Crixivan.pdf,
1996,N/A,N/A,NDA020685,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020685_s005ap.pdf,
1996,N/A,N/A,NDA020685,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-685-S043.pdf,
1996,N/A,N/A,NDA020685,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20685s041.pdf,
1996,N/A,N/A,NDA020685,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020685_S054_Crixivan.pdf,
1996,N/A,N/A,NDA020685,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020685_S046_Crixivan.pdf,
1996,N/A,N/A,NDA020685,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020685_S060_Crixivan.pdf,
1996,N/A,N/A,NDA020685,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020685_S052_Crixivan.pdf,
1996,N/A,N/A,NDA020685,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020685_S044_Crixivan.pdf,
1996,N/A,N/A,NDA020685,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020685Orig1s000rev.pdf,
2021,RYLAZE,ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)-RYWN,BLA761179,857e53aa-1098-4dad-b654-0276cdd43e03,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761179Orig1s000TOC.cfm,
2002,RELPAX,ELETRIPTAN HYDROBROMIDE,NDA021016,85745375-fcb6-4edc-b6db-a77b4a5f3e8c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21016_Relpax.cfm,
2005,N/A,N/A,NDA021350,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021350s000TOC.cfm,
2006,PRISMASOL BGK2/0,"MAGNESIUM CHLORIDE, DEXTROSE ANHYDROUS, LACTIC ACID, SODIUM CHLORIDE, SODIUM BICARBONATE, AND POTASSIUM CHLORIDE",NDA021703,7f675fee-8940-4ece-bb0c-75ac79d8708c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021703s000TOC.cfm,
2017,MYDAYIS,"DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, AND AMPHETAMINE SULFATE",NDA022063,141a7970-3f06-44ea-9ab7-aeece2c085fc,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/149_22063 mixed salts clinical prea.pdf,
2017,MYDAYIS,"DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, AND AMPHETAMINE SULFATE",NDA022063,141a7970-3f06-44ea-9ab7-aeece2c085fc,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/150_22063 mixed salts clinpharm prea.pdf,
2017,MYDAYIS,"DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, AND AMPHETAMINE SULFATE",NDA022063,141a7970-3f06-44ea-9ab7-aeece2c085fc,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/151_22063 mixed salts statistical prea.pdf,
2017,MYDAYIS,"DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, AND AMPHETAMINE SULFATE",NDA022063,141a7970-3f06-44ea-9ab7-aeece2c085fc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/022063Orig1s000TOC.cfm,
1980,N/A,N/A,NDA050542,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50-542s016_50-754s001_Amoxil.cfm,
1980,N/A,N/A,NDA050542,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/050542s005s010s011.cfm,
1980,N/A,N/A,NDA050542,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-542s017_50-754s002_50-760s001_50-761s001_Amoxil.cfm,
1980,N/A,N/A,NDA050542,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/050542s005s010s011.cfm,
1980,N/A,N/A,NDA050542,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/050542s005s010s011.cfm,
1982,N/A,N/A,NDA018467,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018467-S13&S14_Hepatolite_toc.cfm,
1982,N/A,N/A,NDA018467,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018467-S13&S14_Hepatolite_toc.cfm,
2006,LUCENTIS,RANIBIZUMAB,BLA125156,de4e66cc-ca05-4dc9-8262-e00e9b41c36d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/125156Orig1s114.pdf,
2006,LUCENTIS,RANIBIZUMAB,BLA125156,de4e66cc-ca05-4dc9-8262-e00e9b41c36d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125156Orig1s106.pdf,
2006,LUCENTIS,RANIBIZUMAB,BLA125156,de4e66cc-ca05-4dc9-8262-e00e9b41c36d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125156Orig1s112.pdf,
2006,LUCENTIS,RANIBIZUMAB,BLA125156,de4e66cc-ca05-4dc9-8262-e00e9b41c36d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125156Orig1s110.pdf,
2006,LUCENTIS,RANIBIZUMAB,BLA125156,de4e66cc-ca05-4dc9-8262-e00e9b41c36d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/125156s0000_LucentisTOC.cfm,
2006,LUCENTIS,RANIBIZUMAB,BLA125156,de4e66cc-ca05-4dc9-8262-e00e9b41c36d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/125156Orig1s117.pdf,
2006,LUCENTIS,RANIBIZUMAB,BLA125156,de4e66cc-ca05-4dc9-8262-e00e9b41c36d,http://www.accessdata.fda.gov/drugsatfda_docs/bla/2010/125156Orig1s053.pdf,
2012,CYSTARAN,CYSTEAMINE HYDROCHLORIDE,NDA200740,b98ee838-ed23-42a9-93b5-72579e490fba,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/200740_cystaran_toc.cfm,
2012,CYSTARAN,CYSTEAMINE HYDROCHLORIDE,NDA200740,b98ee838-ed23-42a9-93b5-72579e490fba,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/200740Orig1s000SumR.pdf,
2010,HALAVEN,ERIBULIN MESYLATE,NDA201532,8fc8fe1d-59fe-4e43-a95c-e7aa13422cd6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/201532s000_halaven_TOC.cfm,
2010,HALAVEN,ERIBULIN MESYLATE,NDA201532,8fc8fe1d-59fe-4e43-a95c-e7aa13422cd6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/201532Orig1s000SumR.pdf,
1994,N/A,N/A,BLA019676,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/19676S13_nutropin.cfm,
1994,N/A,N/A,BLA019676,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/19-676s016_Nutropin.cfm,
2017,N/A,N/A,NDA208609,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208609Orig1s000TOC.cfm,
2021,TEMBEXA,BRINCIDOFOVIR,NDA214460,0784838e-00bd-4b14-9b7e-653b7fbb7eea,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214460Orig1s000, 214461Orig1s000TOC.cfm",
2019,GVOKE HYPOPEN 0.5 MG AUTO-INJECTOR,"GLUCAGON INJECTION, SOLUTION",NDA212097,92385737-dbad-98c5-e053-2995a90a2805,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212097Orig1s000TOC.cfm,
2019,GVOKE HYPOPEN 0.5 MG AUTO-INJECTOR,"GLUCAGON INJECTION, SOLUTION",NDA212097,92385737-dbad-98c5-e053-2995a90a2805,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/469_212097 glucagon clinical prea_0.pdf,
2019,GVOKE HYPOPEN 0.5 MG AUTO-INJECTOR,"GLUCAGON INJECTION, SOLUTION",NDA212097,92385737-dbad-98c5-e053-2995a90a2805,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/468_212097 glucagon CDTL prea.pdf,
2019,GVOKE HYPOPEN 0.5 MG AUTO-INJECTOR,"GLUCAGON INJECTION, SOLUTION",NDA212097,92385737-dbad-98c5-e053-2995a90a2805,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/466_212097 glucagon clinpharm prea.pdf,
2019,GVOKE HYPOPEN 0.5 MG AUTO-INJECTOR,"GLUCAGON INJECTION, SOLUTION",NDA212097,92385737-dbad-98c5-e053-2995a90a2805,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/467_212097 glucagon statistical prea.pdf,
2019,POTASSIUM PHOSPHATES,POTASSIUM PHOSPHATES,NDA212832,357c3020-ea6f-4401-a2e7-cebb82b03144,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212832Orig1s000TOC.cfm,
2023,ZEJULA,NIRAPARIB,NDA214876,b7f675e2-159c-490c-b6f4-3f16d9492b7d,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/214876Orig1s000TOC.cfm,
2023,ZEJULA,NIRAPARIB,NDA214876,b7f675e2-159c-490c-b6f4-3f16d9492b7d,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/214876Orig1s003Med,StatR.pdf",
1997,N/A,N/A,NDA020587,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020587_sclerosol_toc.cfm,
2010,GABLOFEN,BACLOFEN INJECTION,NDA022462,00d3e846-dd92-448d-9ab8-6a07be823cc1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022462Orig1s000TOC.cfm,
2010,GABLOFEN,BACLOFEN INJECTION,NDA022462,00d3e846-dd92-448d-9ab8-6a07be823cc1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022462Orig1s000SumR.pdf,
2010,GABLOFEN,BACLOFEN INJECTION,NDA022462,00d3e846-dd92-448d-9ab8-6a07be823cc1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022462Orig1s008.pdf,
2021,ADBRY,TRALOKINUMAB-LDRM,BLA761180,d8020b69-3001-44e2-9b5d-5f93d9aaf6e1,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761180Orig1s000TOC.cfm,
1999,HUMALOG MIX75/25,INSULIN LISPRO,BLA021017,c73da51a-1899-45ad-b6cf-9c52c36a25dd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21017_Humalog.cfm,
1999,HUMALOG MIX75/25,INSULIN LISPRO,BLA021017,c73da51a-1899-45ad-b6cf-9c52c36a25dd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021017_S002_Humalog Mix_APPROVAL PACKAGE.pdf,
2003,OXYTROL,OXYBUTYNIN,NDA021351,20dee37f-1412-44ed-9e8b-f4379ce23eb0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-351_Oxytrol.cfm,
2004,ALLEGRA-D ALLERGY AND CONGESTION,FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,NDA021704,1fb77d6a-fae2-40ae-8f8e-fa2dc66f4403,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021704s000_AllegraTOC.cfm,
2007,XYZAL,LEVOCETIRIZINE DIHYDROCHLORIDE,NDA022064,1673f7ff-0c7c-4403-86cf-c05eb1475222,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022064_xyzal_toc.cfm,
2007,XYZAL,LEVOCETIRIZINE DIHYDROCHLORIDE,NDA022064,1673f7ff-0c7c-4403-86cf-c05eb1475222,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022064s000_SumR.pdf,
2007,XYZAL,LEVOCETIRIZINE DIHYDROCHLORIDE,NDA022064,1673f7ff-0c7c-4403-86cf-c05eb1475222,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022064_Levocetirizine_Clinical_BPCA.pdf,
2007,XYZAL,LEVOCETIRIZINE DIHYDROCHLORIDE,NDA022064,1673f7ff-0c7c-4403-86cf-c05eb1475222,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022064_Levocetirizine_Clinpharm_BPCA.pdf,
1979,N/A,N/A,NDA018024,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/018024_S036_NUBAIN_INJECTION.pdf,
1979,N/A,N/A,NDA018024,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/018024_S040_NUBAIN.pdf,
2009,USTEKINUMAB,USTEKINUMAB,BLA125261,23b486eb-f48d-47d4-815e-1313d4ebfbfa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/125261s000TOC.cfm,
2009,USTEKINUMAB,USTEKINUMAB,BLA125261,23b486eb-f48d-47d4-815e-1313d4ebfbfa,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202_125261-ustekinumab-clinical-prea.pdf,
2009,USTEKINUMAB,USTEKINUMAB,BLA125261,23b486eb-f48d-47d4-815e-1313d4ebfbfa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/125261s000_SumR.pdf,
2009,USTEKINUMAB,USTEKINUMAB,BLA125261,23b486eb-f48d-47d4-815e-1313d4ebfbfa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125261Orig1s103.pdf,
2009,USTEKINUMAB,USTEKINUMAB,BLA125261,23b486eb-f48d-47d4-815e-1313d4ebfbfa,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/201_125261 ustekinumab CDTL clinical prea.pdf,
2009,USTEKINUMAB,USTEKINUMAB,BLA125261,23b486eb-f48d-47d4-815e-1313d4ebfbfa,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/203_125261 ustekinumab clinpharm prea.pdf,
2009,USTEKINUMAB,USTEKINUMAB,BLA125261,23b486eb-f48d-47d4-815e-1313d4ebfbfa,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/204_125261 ustekinumab statistical prea.pdf,
2009,USTEKINUMAB,USTEKINUMAB,BLA125261,23b486eb-f48d-47d4-815e-1313d4ebfbfa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125261Orig1s086.pdf,
2015,EMEND,APREPITANT,NDA207865,696f9e80-9cae-403b-de9e-078343ce4713,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207865Orig1s000TOC.cfm,
2015,EMEND,APREPITANT,NDA207865,696f9e80-9cae-403b-de9e-078343ce4713,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/207865 aprepitant clinical prea.pdf,
2015,EMEND,APREPITANT,NDA207865,696f9e80-9cae-403b-de9e-078343ce4713,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/207865 aprepitant clinpharm-467340.pdf,
2015,EMEND,APREPITANT,NDA207865,696f9e80-9cae-403b-de9e-078343ce4713,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/207865 aprepitant statistical prea.pdf,
2015,EMEND,APREPITANT,NDA207865,696f9e80-9cae-403b-de9e-078343ce4713,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021549Orig1s025 aprepitant clinpharm prea.pdf,
2015,EMEND,APREPITANT,NDA207865,696f9e80-9cae-403b-de9e-078343ce4713,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021549Orig1s025 aprepitant DD clinical prea.pdf,
2015,EMEND,APREPITANT,NDA207865,696f9e80-9cae-403b-de9e-078343ce4713,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021549Orig1s025 aprepitant clinical prea.pdf,
2015,EMEND,APREPITANT,NDA207865,696f9e80-9cae-403b-de9e-078343ce4713,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021549Orig1s025 aprepitant statisical prea.pdf,
2019,N/A,N/A,NDA212839,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212839Orig1s000TOC.cfm,
2020,DETECTNET,COPPER CU 64 DOTATATE,NDA213227,f898c8a7-beb7-4318-a8ea-6f058d69342b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213227Orig1s000TOC.cfm,
2021,KERENDIA,FINERENONE,NDA215341,fc726765-5d5a-4d6e-b037-b847bda9fb7c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000TOC.cfm,
2009,FOLOTYN,PRALATREXATE,NDA022468,9f3d9c4d-9386-4451-b712-0fbdc5478d8f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022468s000TOC.cfm,
2022,NEXOBRID,ANACAULASE-BCDB,BLA761192,1a2f23ad-78ef-43fa-9864-6bd77aac9e57,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761192Orig1s000TOC.cfm,
2008,N/A,N/A,NDA021711,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021711s000_SumR.pdf,
2008,N/A,N/A,NDA021711,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021711s000TOC.cfm,
2007,TASIGNA,NILOTINIB,NDA022068,6093952a-5248-45cb-ad17-33716a411146,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22068S027-nilotinib-clinical-bpca.pdf,
2007,TASIGNA,NILOTINIB,NDA022068,6093952a-5248-45cb-ad17-33716a411146,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/264_22068S027-nilotinib-clinpharm-bpca.pdf,
2007,TASIGNA,NILOTINIB,NDA022068,6093952a-5248-45cb-ad17-33716a411146,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/263_22068S027-nilotinib-statistical-bpca.pdf,
2007,TASIGNA,NILOTINIB,NDA022068,6093952a-5248-45cb-ad17-33716a411146,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022068s000_SumR.pdf,
2007,TASIGNA,NILOTINIB,NDA022068,6093952a-5248-45cb-ad17-33716a411146,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022068TOC.cfm,
1983,BUMEX,BUMETANIDE,NDA018225,32dfbea3-eb2b-4070-8605-57ce3e6d5a2f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/18-225s018s19_18-226s24s25_Bumex.cfm,
1983,BUMEX,BUMETANIDE,NDA018225,32dfbea3-eb2b-4070-8605-57ce3e6d5a2f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/18-225s018s19_18-226s24s25_Bumex.cfm,
2007,MIRCERA,METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA,BLA125164,22c56f2a-f73c-60e7-e054-00144ff88e88,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/288_125164s78methoxypolyethylene-glucol-epoetin-beta-clinical-prea.pdf,
2007,MIRCERA,METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA,BLA125164,22c56f2a-f73c-60e7-e054-00144ff88e88,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/287_125164S78-methoxypolyethylene-glucol-epoetin-beta-statistical-prea.pdf,
2007,MIRCERA,METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA,BLA125164,22c56f2a-f73c-60e7-e054-00144ff88e88,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/125164TOC.cfm,
2012,N/A,N/A,NDA202833,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/202833Orig1s005.pdf,
2012,N/A,N/A,NDA202833,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202833Orig1s000TOC.cfm,
2011,COMPLERA,"EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE",NDA202123,d637cfab-f1e8-4eb3-a1b3-f85ca3bec612,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202123 complera clinical prea.pdf,
2011,COMPLERA,"EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE",NDA202123,d637cfab-f1e8-4eb3-a1b3-f85ca3bec612,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202123 Complera clinpharm prea.pdf,
2011,COMPLERA,"EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE",NDA202123,d637cfab-f1e8-4eb3-a1b3-f85ca3bec612,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202123_compleratm_toc.cfm,
2011,COMPLERA,"EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE",NDA202123,d637cfab-f1e8-4eb3-a1b3-f85ca3bec612,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202123Orig1s000SumR.pdf,
2020,MYCAPSSA,OCTREOTIDE,NDA208232,58d80bc6-bdfb-4908-93e7-aace447c8d1a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/208232Orig1s000TOC.cfm,
2017,BAXDELA,DELAFLOXACIN MEGLUMINE,NDA208611,fb77637a-88d9-4aea-958f-e270030ce30d,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000TOC.cfm",
2021,TEMBEXA,BRINCIDOFOVIR,NDA214461,209aa94b-c613-4880-ad89-41be83d12c0a,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214460Orig1s000, 214461Orig1s000TOC.cfm",
2020,THYQUIDITY,LEVOTHYROXINE SODIUM,NDA214047,c17ec992-a122-4cd9-8469-d91255c32440,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214047Orig1s000TOC.cfm,
2020,FINTEPLA,FENFLURAMINE,NDA212102,e88f360e-33ad-4cd6-b2de-5ef885857c5d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212102Orig1s000TOC.cfm,
2024,BYNFEZIA PEN,OCTREOTIDE ACETATE,NDA213224,20ed4e79-ad4c-426f-859d-83790c00439b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/213224Orig1s000TOC.cfm,
2023,IVRA,MELPHALAN,NDA217110,310ae23f-9f48-206d-e063-6394a90a6ce2,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217110Orig1s000TOC.cfm,
1960,N/A,N/A,NDA011522,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/11-522S030_Adderall.cfm,
1960,N/A,N/A,NDA011522,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/11522S010_Adderall.pdf,
2022,TZIELD,TEPLIZUMAB-MZWV,BLA761183,e8a39a5f-139c-4510-9777-71cbb00138fa,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761183Orig1s000TOC.cfm,
2001,VIREAD,TENOFOVIR DISOPROXIL FUMARATE,NDA021356,33fd6418-fbdc-42ca-a50d-ce2a476a5418,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/388_21356S57 tenofovir statistical prea.pdf,
2001,VIREAD,TENOFOVIR DISOPROXIL FUMARATE,NDA021356,33fd6418-fbdc-42ca-a50d-ce2a476a5418,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/389_21356S57 tenofovir CDTL clinical prea.pdf,
2001,VIREAD,TENOFOVIR DISOPROXIL FUMARATE,NDA021356,33fd6418-fbdc-42ca-a50d-ce2a476a5418,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/390_21356S57 tenofovir clinpharm prea.pdf,
2001,VIREAD,TENOFOVIR DISOPROXIL FUMARATE,NDA021356,33fd6418-fbdc-42ca-a50d-ce2a476a5418,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21356_Tenofavir_Clinical_PREA.pdf,
2001,VIREAD,TENOFOVIR DISOPROXIL FUMARATE,NDA021356,33fd6418-fbdc-42ca-a50d-ce2a476a5418,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21356_Tenofavir_Clinpharm_PREA.pdf,
2001,VIREAD,TENOFOVIR DISOPROXIL FUMARATE,NDA021356,33fd6418-fbdc-42ca-a50d-ce2a476a5418,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21356_Tenofovir_Statistical_PREA.pdf,
2001,VIREAD,TENOFOVIR DISOPROXIL FUMARATE,NDA021356,33fd6418-fbdc-42ca-a50d-ce2a476a5418,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-356_Viread.cfm,
2007,N/A,N/A,NDA022066,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022066s000_SumR.pdf,
2007,N/A,N/A,NDA022066,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022066s000TOC.cfm,
2007,SOLIRIS,ECULIZUMAB,BLA125166,ebcd67fa-b4d1-4a22-b33d-ee8bf6b9c722,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/125166Orig1s431.pdf,
2007,SOLIRIS,ECULIZUMAB,BLA125166,ebcd67fa-b4d1-4a22-b33d-ee8bf6b9c722,http://www.accessdata.fda.gov/drugsatfda_docs/bla/2011/125166Orig1s172-2.pdf,
2007,SOLIRIS,ECULIZUMAB,BLA125166,ebcd67fa-b4d1-4a22-b33d-ee8bf6b9c722,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/125166s0000TOC.cfm,
2007,SOLIRIS,ECULIZUMAB,BLA125166,ebcd67fa-b4d1-4a22-b33d-ee8bf6b9c722,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/125166Orig1s422.pdf,
2018,BALCOLTRA,LEVONORGESTREL AND ETHINYL ESTRADIOL,NDA208612,752ab698-4b48-4614-8016-d1d33ee7c007,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208612Orig1s000TOC.cfm,
2023,REXTOVY,NALOXONE HYDROCHLORIDE,NDA208969,fe9735db-c57e-44a8-bffb-b87a84c2a6f3,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/208969Orig1s000TOC.cfm,
2022,CUVRIOR,TRIENTINE TETRAHYDROCHLORIDE,NDA215760,f73feeae-62ad-401e-b9f7-5cb269127750,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215760Orig1s000TOC.cfm,
2023,XDEMVY,LOTILANER OPHTHALMIC SOLUTION,NDA217603,ccd9e37c-654e-4e84-8c85-6523457df979,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217603Orig1s000TOC.cfm,
2009,VOTRIENT,PAZOPANIB HYDROCHLORIDE,NDA022465,eeaaaf38-fb86-4d9f-a19d-0f61daac2fd7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000TOC.cfm,
2009,VOTRIENT,PAZOPANIB HYDROCHLORIDE,NDA022465,eeaaaf38-fb86-4d9f-a19d-0f61daac2fd7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_SumR.pdf,
2023,NGENLA,SOMATROGON-GHLA,BLA761184,06dce529-b741-4a1b-8842-3ad77be6e308,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761184Orig1s000TOC.cfm,
2004,MULTIHANCE,GADOBENATE DIMEGLUMINE,NDA021357,59077a3e-5f03-4342-ae24-856267545631,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021357_Gadobendate_Clinical_PREA.pdf,
2004,MULTIHANCE,GADOBENATE DIMEGLUMINE,NDA021357,59077a3e-5f03-4342-ae24-856267545631,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021357_Gadobendate_Clinpharm_PREA.pdf,
2004,MULTIHANCE,GADOBENATE DIMEGLUMINE,NDA021357,59077a3e-5f03-4342-ae24-856267545631,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021357_Gadobendate_Statistical_PREA.pdf,
2004,MULTIHANCE,GADOBENATE DIMEGLUMINE,NDA021357,59077a3e-5f03-4342-ae24-856267545631,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021357_021358_Multihance.cfm,
2004,EQUETRO,CARBAMAZEPINE,NDA021710,be478f3c-40f6-47cc-8ab9-f420a9372b1c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021710s000_EquetroTOC.cfm,
2008,ARCALYST,RILONACEPT,BLA125249,ad965f38-dd22-4607-a673-2fb92f3b527a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/125249Orig1s049.pdf,
2008,ARCALYST,RILONACEPT,BLA125249,ad965f38-dd22-4607-a673-2fb92f3b527a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/125249s000TOC.cfm,
2012,FYCOMPA,PERAMPANEL,NDA202834,71cf3309-e182-473c-8b0b-280cabd0e122,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/337_202834S14 208277S2 perampanel CDTL clinical prea.pdf,
2012,FYCOMPA,PERAMPANEL,NDA202834,71cf3309-e182-473c-8b0b-280cabd0e122,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/335_202834S14 208277S2 perampanel clinical prea.pdf,
2012,FYCOMPA,PERAMPANEL,NDA202834,71cf3309-e182-473c-8b0b-280cabd0e122,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/336_202834S14 208277S2 perampanel clinpharm prea.pdf,
2012,FYCOMPA,PERAMPANEL,NDA202834,71cf3309-e182-473c-8b0b-280cabd0e122,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/158_202834S012 perampanel clinical prea.pdf,
2012,FYCOMPA,PERAMPANEL,NDA202834,71cf3309-e182-473c-8b0b-280cabd0e122,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/159_202834S012 perampanel clinpharm prea.pdf,
2012,FYCOMPA,PERAMPANEL,NDA202834,71cf3309-e182-473c-8b0b-280cabd0e122,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202834 perampanel statistical prea (2).pdf,
2012,FYCOMPA,PERAMPANEL,NDA202834,71cf3309-e182-473c-8b0b-280cabd0e122,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202834 perampanel Clinical 2 prea (1).pdf,
2012,FYCOMPA,PERAMPANEL,NDA202834,71cf3309-e182-473c-8b0b-280cabd0e122,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/N202-834S005-Perampanel-Clinical-PREA.pdf,
2012,FYCOMPA,PERAMPANEL,NDA202834,71cf3309-e182-473c-8b0b-280cabd0e122,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/N202-834S005-Perampanel-Clinical-2-PREA.pdf,
2012,FYCOMPA,PERAMPANEL,NDA202834,71cf3309-e182-473c-8b0b-280cabd0e122,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/N202-834S005-Perampanel-Statistical-PREA.pdf,
2012,FYCOMPA,PERAMPANEL,NDA202834,71cf3309-e182-473c-8b0b-280cabd0e122,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202834 perampanel statistical prea.pdf,
2012,FYCOMPA,PERAMPANEL,NDA202834,71cf3309-e182-473c-8b0b-280cabd0e122,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202834 perampanel clinpharm_prea.pdf,
2012,FYCOMPA,PERAMPANEL,NDA202834,71cf3309-e182-473c-8b0b-280cabd0e122,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202834 perampanel statistical prea.pdf,
2012,FYCOMPA,PERAMPANEL,NDA202834,71cf3309-e182-473c-8b0b-280cabd0e122,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202834Orig1s000TOC.cfm,
2018,N/A,N/A,NDA208614,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208614Orig1s000TOC.cfm,
1994,N/A,N/A,NDA020340,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020340s003_temovate_toc.cfm,
2024,PYRIDOSTIGMINE BROMIDE,PYRIDOSTIGMINE BROMIDE,NDA217604,52d6f195-165a-400b-a13b-489e94bcf0b0,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/217604Orig1s000TOC.cfm,
2010,ORABLOC,ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE,NDA022466,d18424f0-a691-11dd-ad8b-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022466_articaine_toc.cfm,
2010,ORABLOC,ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE,NDA022466,d18424f0-a691-11dd-ad8b-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022466Orig1s000SumR.pdf,
2008,N/A,N/A,NDA022067,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022067_flo-pred_toc.cfm,
2008,N/A,N/A,NDA022067,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022067s000sumr.pdf,
2012,N/A,N/A,NDA203188,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203188s000TOC.cfm,
2010,ACTEMRA,TOCILIZUMAB,BLA125276,2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/125276s022_toclizumab_ clinical_ prea.pdf,
2010,ACTEMRA,TOCILIZUMAB,BLA125276,2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/125276s022_ toclizumab_clinpharm_ prea.pdf,
2010,ACTEMRA,TOCILIZUMAB,BLA125276,2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/125276s022_ toclizumab_ statistical_ preaL.pdf,
2010,ACTEMRA,TOCILIZUMAB,BLA125276,2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125276s000TOC.cfm,
2010,ACTEMRA,TOCILIZUMAB,BLA125276,2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125276s000SumR.pdf,
2010,ACTEMRA,TOCILIZUMAB,BLA125276,2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/125276Orig1s131.pdf,
2010,ACTEMRA,TOCILIZUMAB,BLA125276,2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/284_125276S115 tocilizumab clinpharm prea.pdf,
2010,ACTEMRA,TOCILIZUMAB,BLA125276,2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/282_125276S115 tocilizumab clinical prea.pdf,
2010,ACTEMRA,TOCILIZUMAB,BLA125276,2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125276Orig1s064.pdf,
2010,ACTEMRA,TOCILIZUMAB,BLA125276,2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/125276Orig1s114TOC.cfm,
2010,ACTEMRA,TOCILIZUMAB,BLA125276,2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/125276Orig1s112.pdf,
2010,ACTEMRA,TOCILIZUMAB,BLA125276,2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,http://www.accessdata.fda.gov/drugsatfda_docs/bla/2012/125276Orig1s049TOC.cfm,
2002,N/A,N/A,NDA020776,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-776_Daypro.cfm,
2025,GOMEKLI,MIRDAMETINIB,NDA219389,4c41bf90-5fa7-4935-a95c-e047ea6bbf8e,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219379Orig1s000,219389Orig1s000TOC.cfm",
2022,N/A,N/A,NDA216660,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216660Orig1s000SumR.pdf,
2022,N/A,N/A,NDA216660,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216660Orig1s000TOC.cfm,
1997,NICOTROL,NICOTINE,NDA020714,62245d7d-b50d-48d9-9f03-071c61620ccf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020714_nicotrol_toc.cfm,
2010,ELLA,ULIPRISTAL ACETATE,NDA022474,2bf93d23-cddd-4613-9066-5b5fa090404b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22474 ella clinical prea.pdf,
2010,ELLA,ULIPRISTAL ACETATE,NDA022474,2bf93d23-cddd-4613-9066-5b5fa090404b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22474 ella clinpharm prea.pdf,
2010,ELLA,ULIPRISTAL ACETATE,NDA022474,2bf93d23-cddd-4613-9066-5b5fa090404b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22474 ella statistical prea.pdf,
2010,ELLA,ULIPRISTAL ACETATE,NDA022474,2bf93d23-cddd-4613-9066-5b5fa090404b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022474s000TOC.cfm,
2010,ELLA,ULIPRISTAL ACETATE,NDA022474,2bf93d23-cddd-4613-9066-5b5fa090404b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022474s000SumR.pdf,
2010,ELLA,ULIPRISTAL ACETATE,NDA022474,2bf93d23-cddd-4613-9066-5b5fa090404b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022474Orig1s007TOC.cfm,
2021,ZYNLONTA,LONCASTUXIMAB TESIRINE,BLA761196,af54af12-3edf-4301-8bc5-0446bc813c1d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761196Orig1s000TOC.cfm,
2000,N/A,N/A,NDA021027,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21027_Hectorol.cfm,
2000,N/A,N/A,NDA021027,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021027Orig1s015.pdf,
2004,XIFAXAN,RIFAXIMIN,NDA021361,c5e8e2fd-7087-4b78-9181-cc259c0be2f1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-361_Xifaxan.cfm,
2007,SOMATULINE DEPOT,LANREOTIDE ACETATE,NDA022074,6e4a41fd-a753-4362-87ee-8cc56ed3660d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022074s000TOC.cfm,
2007,SOMATULINE DEPOT,LANREOTIDE ACETATE,NDA022074,6e4a41fd-a753-4362-87ee-8cc56ed3660d,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/022074Orig1s017.pdf,
2007,SOMATULINE DEPOT,LANREOTIDE ACETATE,NDA022074,6e4a41fd-a753-4362-87ee-8cc56ed3660d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022074Orig1s004.pdf,
2007,SOMATULINE DEPOT,LANREOTIDE ACETATE,NDA022074,6e4a41fd-a753-4362-87ee-8cc56ed3660d,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/022074Orig1s011.pdf,
2007,SOMATULINE DEPOT,LANREOTIDE ACETATE,NDA022074,6e4a41fd-a753-4362-87ee-8cc56ed3660d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/22074Orig1s009.pdf,
2007,SOMATULINE DEPOT,LANREOTIDE ACETATE,NDA022074,6e4a41fd-a753-4362-87ee-8cc56ed3660d,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/022074Orig1s007.pdf,
2021,NEXVIAZYME,AVALGLUCOSIDASE ALFA-NGPT,BLA761194,80eb3c9c-01d3-44fe-90ef-81df101b954d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761194Orig1s000TOC.cfm,
1998,PRIFTIN,RIFAPENTINE,NDA021024,3a64fb70-b85e-43d9-8bcd-7e893f568ae1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21024S5_Priftin.cfm,
1998,PRIFTIN,RIFAPENTINE,NDA021024,3a64fb70-b85e-43d9-8bcd-7e893f568ae1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/21024.cfm,
1998,PRIFTIN,RIFAPENTINE,NDA021024,3a64fb70-b85e-43d9-8bcd-7e893f568ae1,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21024s011 rifapentine clinical prea.pdf,
1998,PRIFTIN,RIFAPENTINE,NDA021024,3a64fb70-b85e-43d9-8bcd-7e893f568ae1,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21024s011 rifapentine clinpharm prea.pdf,
1998,PRIFTIN,RIFAPENTINE,NDA021024,3a64fb70-b85e-43d9-8bcd-7e893f568ae1,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21024s011 rifapentine statistical prea.pdf,
1998,PRIFTIN,RIFAPENTINE,NDA021024,3a64fb70-b85e-43d9-8bcd-7e893f568ae1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021024Orig1s008.pdf,
2004,MULTIHANCE,GADOBENATE DIMEGLUMINE,NDA021358,f63abe56-46d9-4e32-afb1-f4e22370717d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021358s000_021357s000_MultiHance.cfm,
2007,TRETINOIN,TRETINOIN,NDA022070,c5ee36ac-2ffd-4cca-ad47-b1dae7ebdb3b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022070_atralin_toc.cfm,
1985,N/A,N/A,NDA018830,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018830Orig1s000rev.pdf,
2008,NPLATE,ROMIPLOSTIM,BLA125268,c45f9a58-37c1-4f76-8e36-97d38c577037,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/125268s000_sumR.pdf,
2008,NPLATE,ROMIPLOSTIM,BLA125268,c45f9a58-37c1-4f76-8e36-97d38c577037,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/125268_romiplostim_toc.cfm,
2008,NPLATE,ROMIPLOSTIM,BLA125268,c45f9a58-37c1-4f76-8e36-97d38c577037,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/125268Orig1s167.pdf,
2016,N/A,N/A,NDA206302,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206302Orig1ByvalsonTOC.cfm,
1990,CIPROFLOXACIN HYDROCHLORIDE,CIPROFLOXACIN HYDROCHLORIDE,NDA019992,ab52b14d-345b-47ff-a832-465caddd3801,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/102_19992-ciprofloxacin-clinical-bpca.pdf,
2016,XELJANZ XR,TOFACITINIB,NDA208246,cf74ba2f-afc5-4baa-8594-979c889a5831,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208246Orig1s000TOC.cfm,
2025,GOMEKLI,MIRDAMETINIB,NDA219379,4c41bf90-5fa7-4935-a95c-e047ea6bbf8e,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219379Orig1s000,219389Orig1s000TOC.cfm",
2025,GOMEKLI,MIRDAMETINIB,NDA219379,4c41bf90-5fa7-4935-a95c-e047ea6bbf8e,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219379Orig1s000,219389Orig1s000TOC.cfm",
2022,IHEEZO,CHLOROPROCAINE HYDROCHLORIDE OPHTHALMIC GEL,NDA216227,ea3b2d2c-8b33-d199-e053-2995a90a699c,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216227Orig1s000TOC.cfm,
2024,OPIPZA,ARIPIPRAZOLE,NDA216655,b47ede68-8942-4432-af7e-57afc14b2ba4,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/216655Orig1s000TOC.cfm,
2014,AFREZZA,INSULIN HUMAN,BLA022472,29f4637b-e204-425b-b89c-7238008d8c10,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022472Orig1s000SumR.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2014,AFREZZA,INSULIN HUMAN,BLA022472,29f4637b-e204-425b-b89c-7238008d8c10,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022472Orig1s000TOC.cfm,
1998,N/A,N/A,NDA020843,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020843_s000_PrometriumTOC.cfm,
2000,N/A,N/A,NDA021025,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/021025_S003_EXELON_AP.pdf,
2000,N/A,N/A,NDA021025,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021025_s008_exelon_capsules.pdf,
2000,N/A,N/A,NDA021025,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-025_Exelon.cfm,
2011,RECTIV,NITROGLYCERIN,NDA021359,603aa9ed-54c4-4a35-ade4-690fa44850e4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021359_rectiv_toc.cfm,
2011,RECTIV,NITROGLYCERIN,NDA021359,603aa9ed-54c4-4a35-ade4-690fa44850e4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021359Orig1s000SumR.pdf,
2004,N/A,N/A,NDA021713,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021713Orig1s014_s015_s017.pdf,
2004,N/A,N/A,NDA021713,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/021436s19s20s22,21713s14s15s017SUMR.pdf",
2004,N/A,N/A,NDA021713,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021713Orig1s014_s015_s017.pdf,
2004,N/A,N/A,NDA021713,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/021436s19s20s22,21713s14s15s017SUMR.pdf",
2004,N/A,N/A,NDA021713,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021436 aripiprazole clinical prea.pdf,
2004,N/A,N/A,NDA021713,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021713Orig1s014_s015_s017.pdf,
2004,N/A,N/A,NDA021713,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/021436s19s20s22,21713s14s15s017SUMR.pdf",
2004,N/A,N/A,NDA021713,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021713s000_AbilifyTOC2.cfm,
2007,N/A,N/A,NDA022071,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022071_Terbinafine_Clinical_PREA.pdf,
2007,N/A,N/A,NDA022071,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022071_Terbinafine_Clinpharm_PREA.pdf,
2007,N/A,N/A,NDA022071,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022071_Terbinafine_Statistical_PREA.pdf,
2007,N/A,N/A,NDA022071,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022071_lamisil_toc.cfm,
2013,N/A,N/A,NDA203595,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203595Orig1s000TOC.cfm,
2013,N/A,N/A,NDA203595,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203595Orig1s000SumR.pdf,
2009,DYSPORT,BOTULINUM TOXIN TYPE A,BLA125274,71313a04-1349-4c26-b840-a39e4a3ddaed,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/125274s001_dysport_toc.cfm,
2009,DYSPORT,BOTULINUM TOXIN TYPE A,BLA125274,71313a04-1349-4c26-b840-a39e4a3ddaed,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/125274Orig1s001SumR.pdf,
2009,DYSPORT,BOTULINUM TOXIN TYPE A,BLA125274,71313a04-1349-4c26-b840-a39e4a3ddaed,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/481_125274S115 abotulinumtoxin A statistical prea_0.pdf,
2009,DYSPORT,BOTULINUM TOXIN TYPE A,BLA125274,71313a04-1349-4c26-b840-a39e4a3ddaed,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/482_125274S115 abotulinumtoxin A 2clinical prea_0.pdf,
2009,DYSPORT,BOTULINUM TOXIN TYPE A,BLA125274,71313a04-1349-4c26-b840-a39e4a3ddaed,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/125274 abobotulinumtoxin CDTL clinical prea.pdf,
2009,DYSPORT,BOTULINUM TOXIN TYPE A,BLA125274,71313a04-1349-4c26-b840-a39e4a3ddaed,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/125274 abobotulinumtoxin clinical prea.pdf,
2009,DYSPORT,BOTULINUM TOXIN TYPE A,BLA125274,71313a04-1349-4c26-b840-a39e4a3ddaed,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/125274 abobotulinumtoxin statistical prea.pdf,
2009,DYSPORT,BOTULINUM TOXIN TYPE A,BLA125274,71313a04-1349-4c26-b840-a39e4a3ddaed,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/125274s000_SumR.pdf,
2009,DYSPORT,BOTULINUM TOXIN TYPE A,BLA125274,71313a04-1349-4c26-b840-a39e4a3ddaed,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/125274s000_dysport_toc.cfm,
2012,N/A,N/A,NDA202129,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202129 ciclesonide clinical prea.pdf,
2012,N/A,N/A,NDA202129,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202129 ciclesonide clinpharm prea.pdf,
2012,N/A,N/A,NDA202129,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202129 ciclesonide statistical prea.pdf,
2012,N/A,N/A,NDA202129,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202129Orig1s000SumR.pdf,
2012,N/A,N/A,NDA202129,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202129_zetonna_toc.cfm,
2018,QBREXZA,GLYCOPYRRONIUM,NDA210361,5b372650-e56e-47a5-93e2-c0c292017059,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210361Orig1s000TOC.cfm,
2023,CEFAZOLIN,CEFAZOLIN,NDA211413,4f3a9248-a354-4c77-bf5b-9eed38f00219,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/211413Orig1s000TOC.cfm,
2023,SUFLAVE,"POLYETHYLENE GLYCOL 3350, SODIUM SULFATE, POTASSIUM CHLORIDE, MAGNESIUM SULFATE, AND SODIUM CHLORIDE FOR ORAL SOLUTION",NDA215344,546cfc44-791c-4524-99a9-6a0af96c4ec8,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/215344Orig1s000TOC.cfm,
1998,FENTANYL CITRATE,FENTANYL CITRATE,NDA020747,78221eab-66fd-4cd8-9c81-af52eb83671c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020747_S019_ACTIQ.pdf,
1998,FENTANYL CITRATE,FENTANYL CITRATE,NDA020747,78221eab-66fd-4cd8-9c81-af52eb83671c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020747Orig1s003.pdf,
1998,FENTANYL CITRATE,FENTANYL CITRATE,NDA020747,78221eab-66fd-4cd8-9c81-af52eb83671c,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/020747Orig1s050.pdf,
1998,FENTANYL CITRATE,FENTANYL CITRATE,NDA020747,78221eab-66fd-4cd8-9c81-af52eb83671c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20747_Actiq.cfm,
2009,REVATIO,SILDENAFIL CITRATE,NDA022473,f158fe10-d5dc-4432-b2c9-fc665401291b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022473_revatio_toc.cfm,
2009,REVATIO,SILDENAFIL CITRATE,NDA022473,f158fe10-d5dc-4432-b2c9-fc665401291b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022473s000_SumR.pdf,
2021,VYVGART,EFGARTIGIMOD ALFA,BLA761195,8aefc8e3-26d6-4ff6-aab9-a7542927e084,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761195Orig1s000TOC.cfm,
2006,VUSION,"MICONAZOLE NITRATE, ZINC OXIDE, WHITE PETROLATUM",NDA021026,b44b452d-3630-4cb5-8ed1-1f8edac4690c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021026_vusion_toc.cfm,
2002,N/A,N/A,NDA021360,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021360_S006_SUSTIVA.pdf,
2002,N/A,N/A,NDA021360,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-360_EfavirenzSustiva.cfm,
2002,N/A,N/A,NDA021360,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021360_S014_SUSTIVA.pdf,
2010,LUMIZYME,ALGLUCOSIDASE ALFA,BLA125291,d6bfbc45-2d34-439e-8aad-59ee2d53d4df,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125291s000TOC.cfm,
2010,LUMIZYME,ALGLUCOSIDASE ALFA,BLA125291,d6bfbc45-2d34-439e-8aad-59ee2d53d4df,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125291s000SumR.pdf,
2010,LUMIZYME,ALGLUCOSIDASE ALFA,BLA125291,d6bfbc45-2d34-439e-8aad-59ee2d53d4df,http://www.accessdata.fda.gov/drugsatfda_docs/bla/2014/125291Orig1s136.pdf,
2018,PRIMATENE MIST,EPINEPHRINE INHALATION,NDA205920,95011f7e-51be-4851-80a6-a7e9c6cad82a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/205920Orig1s000TOC.cfm,
2014,FOSRENOL,LANTHANUM CARBONATE,NDA204734,f10776b2-2c25-4343-aabe-68f302e5cb54,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204734Orig1s000TOC.cfm,
2014,FOSRENOL,LANTHANUM CARBONATE,NDA204734,f10776b2-2c25-4343-aabe-68f302e5cb54,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204734Orig1s000SumR.pdf,
1987,N/A,N/A,NDA019527,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019462_S030 & 019527_S024 & 020752_S005_Pepcid RPD_AP.pdf,
1987,N/A,N/A,NDA019527,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/19462s27.pdf,
2016,N/A,N/A,NDA208624,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208624Orig1s000TOC.cfm,
2003,PYRIDOSTIGMINE BROMIDE,PYRIDOSTIGMINE BROMIDE,NDA020414,0b296555-c32f-42db-b5f3-ea981a3dd2f8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/020414Orig1s003.pdf,
2003,PYRIDOSTIGMINE BROMIDE,PYRIDOSTIGMINE BROMIDE,NDA020414,0b296555-c32f-42db-b5f3-ea981a3dd2f8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/20414_pyridostigmine.cfm,
2003,PYRIDOSTIGMINE BROMIDE,PYRIDOSTIGMINE BROMIDE,NDA020414,0b296555-c32f-42db-b5f3-ea981a3dd2f8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/020414Orig1s004.pdf,
2003,PYRIDOSTIGMINE BROMIDE,PYRIDOSTIGMINE BROMIDE,NDA020414,0b296555-c32f-42db-b5f3-ea981a3dd2f8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/020414Orig1s002.pdf,
1997,GALZIN,ZINC ACETATE,NDA020458,2c4fb943-4b2f-273d-e063-6394a90abb47,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020458ap.pdf,
2020,TAUVID,FLORTAUCIPIR F-18,NDA212123,b483abad-5230-462a-adfb-1a65160f01d0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212123Orig1s000TOC.cfm,
2021,BREXAFEMME,IBREXAFUNGERP,NDA214900,c33be3a1-c4fd-512c-e053-2995a90a63eb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000TOC.cfm,
2021,BYOOVIZ,RANIBIZUMAB-NUNA,BLA761202,e46db299-edd1-4457-89b2-c1e2e505f1b0,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761202Orig1s000TOC.cfm,
2000,N/A,N/A,NDA021037,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21037_Magnevist.pdf,
2003,FEMRING,ESTRADIOL ACETATE,NDA021367,7aaa97f9-a9d1-c815-e053-2991aa0afb9e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021367TOC.cfm,
2004,N/A,N/A,NDA021721,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021721Orig1s029s031.pdf,
2004,N/A,N/A,NDA021721,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021721Orig1s029s031.pdf,
2004,N/A,N/A,NDA021721,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/020634se5-047,020635se5-051,021721se5-015_SUMR.pdf",
2004,N/A,N/A,NDA021721,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/020634Orig1s061, 020635Orig1s067, 021721Orig1s028TOC.cfm",
2004,N/A,N/A,NDA021721,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/020634Orig1s061,%20020635Orig1s067,%20021721Orig1s028SumR.pdf",
2004,N/A,N/A,NDA021721,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021721s000TOC.cfm,
2007,LETAIRIS,AMBRISENTAN,NDA022081,725d4e73-6c83-477a-adc6-0ae4a133a844,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022081Orig1s017.pdf,
2007,LETAIRIS,AMBRISENTAN,NDA022081,725d4e73-6c83-477a-adc6-0ae4a133a844,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022081s000TOC.cfm,
2007,LETAIRIS,AMBRISENTAN,NDA022081,725d4e73-6c83-477a-adc6-0ae4a133a844,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022081Orig1s039.pdf,
1985,DRONABINOL,DRONABINOL,NDA018651,adb1801c-0fb5-4e16-b969-1db91230e0b9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/18651S011_Marinol.pdf,
1985,DRONABINOL,DRONABINOL,NDA018651,adb1801c-0fb5-4e16-b969-1db91230e0b9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018651Orig1s000rev.pdf,
2009,KALBITOR,ECALLANTIDE,BLA125277,f56aec67-c662-477c-b866-bfc23e8809cf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/125277s000TOC.cfm,
2009,KALBITOR,ECALLANTIDE,BLA125277,f56aec67-c662-477c-b866-bfc23e8809cf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/125277s000SumR.pdf,
2014,PARICALCITOL,PARICALCITOL,NDA205917,4db985c4-3ba2-4967-898b-35af77f150de,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205917Orig1s000TOC.cfm,
2014,N/A,N/A,NDA206307,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206307Orig1s000TOC.cfm,
2014,N/A,N/A,NDA206307,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206307Orig1s000SumR.pdf,
2014,N/A,N/A,NDA206307,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/206307 finafloxacin clinical bpca.pdf,
2014,N/A,N/A,NDA206307,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/206307 finafloxacin ClinPharm bpca.pdf,
2014,N/A,N/A,NDA206307,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/206307 finafloxacin Statistical bpca.pdf,
2019,QUZYTTIR,CETIRIZINE HYDROCHLORIDE,NDA211415,f33e859d-ebc9-4d4f-a57d-204c48760d20,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211415Orig1s000TOC.cfm,
1997,DIAZEPAM,DIAZEPAM,NDA020648,b1b2848b-b265-4f6f-9141-bf106dec0726,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020648_S002_DIASTAT_AP.pdf,
2021,SUSVIMO,RANIBIZUMAB,BLA761197,9c6d9e2a-9a77-4d11-b692-de87cfde3444,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761197Orig1s000TOC.cfm,
1999,TEMODAR,TEMOZOLOMIDE,NDA021029,046a9011-3911-4d3f-a15f-fbb56d5aad56,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21029_Temodar.cfm,
1999,TEMODAR,TEMOZOLOMIDE,NDA021029,046a9011-3911-4d3f-a15f-fbb56d5aad56,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/021029Orig1s036,037,038,022277Orig1s017,018,019TOC.cfm",
1999,TEMODAR,TEMOZOLOMIDE,NDA021029,046a9011-3911-4d3f-a15f-fbb56d5aad56,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021029s005_temozaolomide_Temodar-ClinicalRev.pdf,
1999,TEMODAR,TEMOZOLOMIDE,NDA021029,046a9011-3911-4d3f-a15f-fbb56d5aad56,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21029 temodar clinpharm bpca.pdf,
1999,TEMODAR,TEMOZOLOMIDE,NDA021029,046a9011-3911-4d3f-a15f-fbb56d5aad56,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21029 temodar clinical statistical bpca.pdf,
1999,TEMODAR,TEMOZOLOMIDE,NDA021029,046a9011-3911-4d3f-a15f-fbb56d5aad56,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/021029Orig1s036,037,038,022277Orig1s017,018,019TOC.cfm",
1999,TEMODAR,TEMOZOLOMIDE,NDA021029,046a9011-3911-4d3f-a15f-fbb56d5aad56,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/021029Orig1s036,037,038,022277Orig1s017,018,019TOC.cfm",
1999,TEMODAR,TEMOZOLOMIDE,NDA021029,046a9011-3911-4d3f-a15f-fbb56d5aad56,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21029-S004_TEMODAR_review.pdf,
2006,N/A,N/A,NDA021717,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021717_tradename_toc.cfm,
2019,NOURIANZ,ISTRADEFYLLINE,NDA022075,a7d008cb-b273-4049-a5d2-9c6902910d58,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022075Orig1s000TOC.cfm,
1989,DRAXIMAGE DTPA,KIT FOR THE PREPARATION OF TECHNETIUM TC 99M PENTETATE,NDA018511,becdab53-f7a7-7280-6930-21f3a61b99e7,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/232_18511S28 draximage clinical prea.pdf,
1989,DRAXIMAGE DTPA,KIT FOR THE PREPARATION OF TECHNETIUM TC 99M PENTETATE,NDA018511,becdab53-f7a7-7280-6930-21f3a61b99e7,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/231_18511S28 draximage statistical prea.pdf,
2011,NULOJIX,BELATACEPT,BLA125288,c16ac648-d5d2-9f7d-8637-e2328572754e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125288Orig1s000TOC.cfm,
2014,MERCAPTOPURINE,MERCAPTOPURINE,NDA205919,9c6fc66b-522f-499d-961a-cde6ca0ec2e5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205919Orig1s000TOC.cfm,
2013,N/A,N/A,NDA204369,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204369Orig1s000TOC.cfm,
2013,N/A,N/A,NDA204369,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204369Orig1s000SumR.pdf,
2017,GANCICLOVIR,GANCICLOVIR,NDA209347,26361de8-39b5-4266-90f6-2b307940135d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209347Orig1s000TOC.cfm,
2019,POTASSIUM PHOSPHATES,MONOBASIC POTASSIUM PHOSPHATE AND DIBASIC POTASSIUM PHOSPHATE,NDA212121,2c2078d1-9edc-4d0c-a72a-5491c28a5aac,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212121Orig1s000TOC.cfm,
2023,RYKINDO EXTENDED-RELEASE MICROSPHERES,RISPERIDONE,NDA212849,58534c96-96f5-4c2e-a061-92d4506aee91,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/212849Orig1s000TOC.cfm,
1996,RISPERIDONE,RISPERIDONE,NDA020588,701e1cd8-2868-4d29-85a9-a2212c88165f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20588.pdf,
1996,RISPERIDONE,RISPERIDONE,NDA020588,701e1cd8-2868-4d29-85a9-a2212c88165f,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020272Orig1s036,s041,020588Orig1s024,s028,s029,21444Orig1s008,s015.pdf",
1996,RISPERIDONE,RISPERIDONE,NDA020588,701e1cd8-2868-4d29-85a9-a2212c88165f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/020272_s046_risperdal_toc.cfm,
1996,RISPERIDONE,RISPERIDONE,NDA020588,701e1cd8-2868-4d29-85a9-a2212c88165f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020588_S021_RISPERDAL_TABLETS.pdf,
1996,RISPERIDONE,RISPERIDONE,NDA020588,701e1cd8-2868-4d29-85a9-a2212c88165f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/020272_s046_risperdal_toc.cfm,
1996,RISPERIDONE,RISPERIDONE,NDA020588,701e1cd8-2868-4d29-85a9-a2212c88165f,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020588s028.pdf020272Orig1s036,s041,020588Orig1s024,s028,s029,21444Orig1s008,s015.pdf",
1996,RISPERIDONE,RISPERIDONE,NDA020588,701e1cd8-2868-4d29-85a9-a2212c88165f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020588_s004_RISPERDAL TABLETS.pdf,
2010,ZYCLARA,IMIQUIMOD,NDA022483,28cd9b5b-680b-480f-b33d-9c5b52bbf03d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022483_zyclara_toc.cfm,
2010,ZYCLARA,IMIQUIMOD,NDA022483,28cd9b5b-680b-480f-b33d-9c5b52bbf03d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022483Orig1s000SumR.pdf,
2023,AVZIVI TNJN,BEVACIZUMAB,BLA761198,a3976cf9-9edb-4ca2-9375-9bcd2e32f5b4,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761198Orig1s000TOC.cfm,
1999,KEPPRA,LEVETIRACETAM,NDA021035,3ca9df05-a506-4ec8-a4fe-320f1219ab21,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021035s073_Levetiracetam_Medical_BPCA.pdf,
1999,KEPPRA,LEVETIRACETAM,NDA021035,3ca9df05-a506-4ec8-a4fe-320f1219ab21,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021035s073_Levetiracetam_Clinpharm_BPCA.pdf,
1999,KEPPRA,LEVETIRACETAM,NDA021035,3ca9df05-a506-4ec8-a4fe-320f1219ab21,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/021035Orig1s102.pdf,
1999,KEPPRA,LEVETIRACETAM,NDA021035,3ca9df05-a506-4ec8-a4fe-320f1219ab21,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21035_Keppra.cfm,
1999,KEPPRA,LEVETIRACETAM,NDA021035,3ca9df05-a506-4ec8-a4fe-320f1219ab21,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021035s040, 021505s007_levetiracetam_Keppra-MedRev.pdf",
1999,KEPPRA,LEVETIRACETAM,NDA021035,3ca9df05-a506-4ec8-a4fe-320f1219ab21,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021035s040, 021505s007_levetiracetam_Keppra-ClinPharmRev.pdf",
1999,KEPPRA,LEVETIRACETAM,NDA021035,3ca9df05-a506-4ec8-a4fe-320f1219ab21,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021035s040, 021505s007_levetiracetam_Keppra-StatRev.pdf",
2002,N/A,N/A,NDA021365,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021323_S007&021365_S001_LEXAPRO_TABS.pdf,
2002,N/A,N/A,NDA021365,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-365_Lexapro.cfm,
2002,N/A,N/A,NDA021365,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021323_S003&021365_S004_LEXAPRO_TABS.pdf,
2007,LOCOID,HYDROCORTISONE BUTYRATE,NDA022076,a147236d-be90-47cf-9d88-7ea14d3a8158,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022076_locoid_toc.cfm,
2009,SIMPONI,GOLIMUMAB,BLA125289,f86cb4a7-c358-4136-ae57-b32bda9bba00,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/125289s133 golimumab clinical prea.pdf,
2009,SIMPONI,GOLIMUMAB,BLA125289,f86cb4a7-c358-4136-ae57-b32bda9bba00,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/125289s133 golimumab clinpharm prea.pdf,
2009,SIMPONI,GOLIMUMAB,BLA125289,f86cb4a7-c358-4136-ae57-b32bda9bba00,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/125289s133 golimumab CDTL clinical prea.pdf,
2009,SIMPONI,GOLIMUMAB,BLA125289,f86cb4a7-c358-4136-ae57-b32bda9bba00,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/125289s133 golimumab statistical prea.pdf,
2009,SIMPONI,GOLIMUMAB,BLA125289,f86cb4a7-c358-4136-ae57-b32bda9bba00,http://www.accessdata.fda.gov/drugsatfda_docs/bla/2013/125289Orig1s103.pdf,
2009,SIMPONI,GOLIMUMAB,BLA125289,f86cb4a7-c358-4136-ae57-b32bda9bba00,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/125289s0000TOC.cfm,
2009,SIMPONI,GOLIMUMAB,BLA125289,f86cb4a7-c358-4136-ae57-b32bda9bba00,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/125289s000_SumR.pdf,
2009,SIMPONI,GOLIMUMAB,BLA125289,f86cb4a7-c358-4136-ae57-b32bda9bba00,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125289s124.pdf,
2012,N/A,N/A,NDA202497,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202497_marqibo_toc.cfm,
2012,N/A,N/A,NDA202497,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202497Orig1s000SumR.pdf,
2011,FLUOXETINE HCL,FLUOXETINE HCL,NDA202133,b47b291f-3340-0c2a-3585-0926b9c1a71f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202133_fluoxetine_toc.cfm,
2011,FLUOXETINE HCL,FLUOXETINE HCL,NDA202133,b47b291f-3340-0c2a-3585-0926b9c1a71f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202133Orig1s000SumR.pdf,
2013,XOFIGO,RADIUM RA 223 DICHLORIDE,NDA203971,a398400e-bd31-41a9-9696-4f7c06569ede,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203971Orig1s000TOC.cfm,
2013,XOFIGO,RADIUM RA 223 DICHLORIDE,NDA203971,a398400e-bd31-41a9-9696-4f7c06569ede,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203971Orig1s000SumR.pdf,
2015,VRAYLAR,CARIPRAZINE,NDA204370,4b5f7c65-aa2d-452a-b3db-bc85c06ff12f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig2s000TOC.cfm,
2013,VARITHENA,POLIDOCANOL,NDA205098,dfd6b4a0-b0dc-11e2-9e96-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205098Orig1s000TOC.cfm,
2013,VARITHENA,POLIDOCANOL,NDA205098,dfd6b4a0-b0dc-11e2-9e96-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205098Orig1s000SumR.pdf,
2018,EPIDIOLEX,CANNABIDIOL,NDA210365,8bf27097-4870-43fb-94f0-f3d0871d1eec,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000TOC.cfm,
2016,CIPROFLOXACIN AND FLUOCINOLONE ACETONIDE,CIPROFLOXACIN AND FLUOCINOLONE ACETONIDE,NDA208251,f7664db7-c1aa-4b40-8df8-9cc0b57825f6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208251Orig1s000TOC.cfm,
2016,CIPROFLOXACIN AND FLUOCINOLONE ACETONIDE,CIPROFLOXACIN AND FLUOCINOLONE ACETONIDE,NDA208251,f7664db7-c1aa-4b40-8df8-9cc0b57825f6,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208251 ciprofloxacin and fluocinolone acetonide clinical prea.pdf,
2016,CIPROFLOXACIN AND FLUOCINOLONE ACETONIDE,CIPROFLOXACIN AND FLUOCINOLONE ACETONIDE,NDA208251,f7664db7-c1aa-4b40-8df8-9cc0b57825f6,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208251 ciprofloxacin and fluocinolone acetonide clinpharm prea.pdf,
2016,CIPROFLOXACIN AND FLUOCINOLONE ACETONIDE,CIPROFLOXACIN AND FLUOCINOLONE ACETONIDE,NDA208251,f7664db7-c1aa-4b40-8df8-9cc0b57825f6,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208251 ciprofloxacin and fluocinolone acetonide statistical prea.pdf,
2018,GALAFOLD,MIGALASTAT HYDROCHLORIDE,NDA208623,66dbd928-0f1c-48b1-a832-54e4abd9f1db,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208623Orig1s000TOC.cfm,
1995,CORVERT,IBUTILIDE FUMARATE,NDA020491,2428969a-7431-4e94-9503-ad5c680e2ea4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20491s002_Corvert.pdf,
1995,CORVERT,IBUTILIDE FUMARATE,NDA020491,2428969a-7431-4e94-9503-ad5c680e2ea4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020491Orig1s000rev.pdf,
1995,CORVERT,IBUTILIDE FUMARATE,NDA020491,2428969a-7431-4e94-9503-ad5c680e2ea4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-491S003.pdf,
1995,CORVERT,IBUTILIDE FUMARATE,NDA020491,2428969a-7431-4e94-9503-ad5c680e2ea4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20491s001.cfm,
2020,BREZTRI,"BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE",NDA212122,715433dc-cb2b-43ea-b6df-c5b4177adc6c,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/212122Orig1s004.pdf,
2020,BREZTRI,"BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE",NDA212122,715433dc-cb2b-43ea-b6df-c5b4177adc6c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212122Orig1s000TOC.cfm,
2021,ZIMHI,NALOXONE HYDROCHLORIDE,NDA212854,523c0909-bff6-4010-988a-53de18b7cb3f,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/212854Orig1s000TOC.cfm,
2023,N/A,N/A,NDA215352,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215352Orig1s000TOC.cfm,
2021,INSULIN GLARGINE,INSULIN GLARGINE-YFGN,BLA761201,3ac85ebb-5594-59c8-77fd-df254329d151,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761201Orig1s000TOC.cfm,
1999,RELENZA,ZANAMIVIR,NDA021036,d7c3bcc3-0c0d-4068-fd80-88cf54a376ef,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021036Orig1s008.pdf,
1999,RELENZA,ZANAMIVIR,NDA021036,d7c3bcc3-0c0d-4068-fd80-88cf54a376ef,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21036.cfm,
1999,RELENZA,ZANAMIVIR,NDA021036,d7c3bcc3-0c0d-4068-fd80-88cf54a376ef,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-036-s001_Relenza.cfm,
2003,CRESTOR,ROSUVASTATIN,NDA021366,325a5d0e-9a72-4015-9fcd-1655fb504cee,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021366s024.pdf,
2003,CRESTOR,ROSUVASTATIN,NDA021366,325a5d0e-9a72-4015-9fcd-1655fb504cee,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021366s016_crestor_toc.cfm,
2003,CRESTOR,ROSUVASTATIN,NDA021366,325a5d0e-9a72-4015-9fcd-1655fb504cee,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021366s016SumR.pdf,
2003,CRESTOR,ROSUVASTATIN,NDA021366,325a5d0e-9a72-4015-9fcd-1655fb504cee,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021366s010.pdf,
2003,CRESTOR,ROSUVASTATIN,NDA021366,325a5d0e-9a72-4015-9fcd-1655fb504cee,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021366_Rosuvastatin_Clinical_BPCA.pdf,
2003,CRESTOR,ROSUVASTATIN,NDA021366,325a5d0e-9a72-4015-9fcd-1655fb504cee,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021366_Rosuvastatin_Cllinpharm_BPCA.pdf,
2003,CRESTOR,ROSUVASTATIN,NDA021366,325a5d0e-9a72-4015-9fcd-1655fb504cee,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021366_Rosuvastatin_Statistical_BPCA.pdf,
2003,CRESTOR,ROSUVASTATIN,NDA021366,325a5d0e-9a72-4015-9fcd-1655fb504cee,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-366_Crestor.cfm,
2004,N/A,N/A,NDA021720,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021720_s000_AriceptTOC.cfm,
2013,ZOLEDRONIC ACID,ZOLEDRONIC ACID,NDA203231,567578e6-cd2d-4339-b0f6-7a15444c0639,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203231Orig1s000TOC.cfm,
2011,YERVOY,IPILIMUMAB,BLA125377,2265ef30-253e-11df-8a39-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125377Orig1s000TOC.cfm,
2011,YERVOY,IPILIMUMAB,BLA125377,2265ef30-253e-11df-8a39-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125377Orig1s000SumR.pdf,
2011,YERVOY,IPILIMUMAB,BLA125377,2265ef30-253e-11df-8a39-0800200c9a66,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/125377Orig1s106.pdf,
2011,YERVOY,IPILIMUMAB,BLA125377,2265ef30-253e-11df-8a39-0800200c9a66,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/164_125377S087 ipilimumab clinical bpca.pdf,
2011,YERVOY,IPILIMUMAB,BLA125377,2265ef30-253e-11df-8a39-0800200c9a66,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/165_125377S087 ipilimumab clinpharm bpca.pdf,
2011,YERVOY,IPILIMUMAB,BLA125377,2265ef30-253e-11df-8a39-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/125377Orig1s110_125554Orig1s082.pdf,
2016,RUBY-FILL,RUBIDIUM RB 82,NDA202153,b3c0cc0c-2f4b-4e08-8a84-3cb77473c2e8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/202153Orig1s000TOC.cfm,
2012,TAFLUPROST OPHTHALMIC,TAFLUPROST,NDA202514,79fceaef-7d83-4f4b-8d5c-61a6c1ee6368,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202514s000TOC.cfm,
1953,DILANTIN-125,PHENYTOIN,NDA008762,f339f9e4-b289-4efe-82b9-46c57d1dc277,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/008762Orig1s039.pdf,
2016,N/A,N/A,NDA207916,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/207916_toc.cfm,
2017,SOLOSEC,SECNIDAZOLE,NDA209363,056485b6-8bba-4a21-ae00-cdb4e7ae4bfa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209363Orig1s000TOC.cfm,
1995,COZAAR,LOSARTAN POTASSIUM,NDA020386,9949448f-c3b9-44ee-94ed-c1aca8c90f39,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020386Orig1s000rev.pdf,
1995,COZAAR,LOSARTAN POTASSIUM,NDA020386,9949448f-c3b9-44ee-94ed-c1aca8c90f39,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-386s028_Cozaar.cfm,
1995,COZAAR,LOSARTAN POTASSIUM,NDA020386,9949448f-c3b9-44ee-94ed-c1aca8c90f39,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20386-s018_cozaar.pdf,
1995,COZAAR,LOSARTAN POTASSIUM,NDA020386,9949448f-c3b9-44ee-94ed-c1aca8c90f39,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/20-386s032_Cozaar.cfm,
1995,COZAAR,LOSARTAN POTASSIUM,NDA020386,9949448f-c3b9-44ee-94ed-c1aca8c90f39,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20386-s020_cozaar.pdf,
1995,COZAAR,LOSARTAN POTASSIUM,NDA020386,9949448f-c3b9-44ee-94ed-c1aca8c90f39,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020386ap.pdf,
1995,COZAAR,LOSARTAN POTASSIUM,NDA020386,9949448f-c3b9-44ee-94ed-c1aca8c90f39,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/20-386S019S029_Cozaar.cfm,
1995,COZAAR,LOSARTAN POTASSIUM,NDA020386,9949448f-c3b9-44ee-94ed-c1aca8c90f39,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/20-386S019S029_Cozaar.cfm,
1995,COZAAR,LOSARTAN POTASSIUM,NDA020386,9949448f-c3b9-44ee-94ed-c1aca8c90f39,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20386S017_Cozaar.pdf,
1995,COZAAR,LOSARTAN POTASSIUM,NDA020386,9949448f-c3b9-44ee-94ed-c1aca8c90f39,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20386s015_Cozaar.pdf,
1995,COZAAR,LOSARTAN POTASSIUM,NDA020386,9949448f-c3b9-44ee-94ed-c1aca8c90f39,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20386-s008_cozaar.pdf,
2024,XOLREMDI,MAVORIXAFOR,NDA218709,7f3a5ee3-ca73-4876-85a0-ed1e108a2237,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/218709Orig1s000TOC.cfm,
2022,ALYMSYS,BEVACIZUMAB-MALY,BLA761231,6b4040a2-a5c5-4ff0-ab45-935d7e49cf78,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761231Orig1s000TOC.cfm,
2004,TERCONAZOLE VAGINAL CREAM 0.8%,TERCONAZOLE,NDA021735,f59448bd-f730-46d2-a785-c2d6205579ff,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021735s000_TerconazoleTOC.cfm,
1973,N/A,N/A,NDA017386,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/017386Orig1s039.pdf,
1973,N/A,N/A,NDA017386,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/017386Orig1s040.pdf,
2012,RAXIBACUMAB,RAXIBACUMAB,BLA125349,f6927e91-bb46-47b3-ab66-f9d8a9d7b12a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125349Orig1s000SumR.pdf,
2012,RAXIBACUMAB,RAXIBACUMAB,BLA125349,f6927e91-bb46-47b3-ab66-f9d8a9d7b12a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125349Orig1s000TOC.cfm,
2012,AFINITOR DISPERZ,EVEROLIMUS,NDA203985,2150f73a-179b-4afc-b8ce-67c85cc72f04,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203985Orig1s000SumR.pdf,
2012,AFINITOR DISPERZ,EVEROLIMUS,NDA203985,2150f73a-179b-4afc-b8ce-67c85cc72f04,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/203985_Orig1s000MedR_PREA.pdf,
2012,AFINITOR DISPERZ,EVEROLIMUS,NDA203985,2150f73a-179b-4afc-b8ce-67c85cc72f04,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/203985_Everolimus_Clinpharm_BPCA.pdf,
2012,AFINITOR DISPERZ,EVEROLIMUS,NDA203985,2150f73a-179b-4afc-b8ce-67c85cc72f04,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/203985_Everolimus_Statistical_BPCA.pdf,
2012,AFINITOR DISPERZ,EVEROLIMUS,NDA203985,2150f73a-179b-4afc-b8ce-67c85cc72f04,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203985_afinitor_toc.cfm,
2013,VELPHORO,SUCROFERRIC OXYHYDROXIDE,NDA205109,237da26c-f38c-4faa-93ad-735e71c9d0c1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205109Orig1s000SumR.pdf,
2013,VELPHORO,SUCROFERRIC OXYHYDROXIDE,NDA205109,237da26c-f38c-4faa-93ad-735e71c9d0c1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205109Orig1s000TOC.cfm,
2019,EPINEPHRINE,EPINEPHRINE,NDA209359,ef18a92f-ba83-4bb0-808b-d09d736f6a81,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209359Orig1s000TOC.cfm,
2021,CYCLOPHOSPHAMIDE,CYCLOPHOSPHAMIDE,NDA210735,3c1eb470-0bba-457d-94e3-b9508f0d398a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/210735Orig1s000TOC.cfm,
2022,GLYCOPYRROLATE,GLYCOPYRROLATE,NDA214919,685aaf64-1a64-42f9-a96f-4764d650c26f,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214919Orig1s000TOC.cfm,
2010,LO LOESTRIN FE,"NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL AND FERROUS FUMARATE",NDA022501,c33072cf-625d-4b4a-981e-ec049c5d78aa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022501_lo_loestrin_fe_toc.cfm,
2010,LO LOESTRIN FE,"NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL AND FERROUS FUMARATE",NDA022501,c33072cf-625d-4b4a-981e-ec049c5d78aa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022501Orig1s000SumR.pdf,
2010,LO LOESTRIN FE,"NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL AND FERROUS FUMARATE",NDA022501,c33072cf-625d-4b4a-981e-ec049c5d78aa,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22501-Loestrin-Clinical-PREA.pdf,
2010,LO LOESTRIN FE,"NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL AND FERROUS FUMARATE",NDA022501,c33072cf-625d-4b4a-981e-ec049c5d78aa,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22501-Loestrin-Clinpharm-PREA.pdf,
2010,LO LOESTRIN FE,"NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL AND FERROUS FUMARATE",NDA022501,c33072cf-625d-4b4a-981e-ec049c5d78aa,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22501-Loestrin-Statisical-PREA.pdf,
2021,TEZSPIRE,TEZEPELUMAB-EKKO,BLA761224,60f0aa03-ad25-4d48-80ce-7fcfa76f325f,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761224Orig1s000TOC.cfm,
1999,N/A,N/A,NDA021045,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021045s11_planb.cfm,
1999,N/A,N/A,NDA021045,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21-045_PlanB.cfm,
2007,AZOR,AMLODIPINE BESYLATE AND OLMESARTAN MEDOXOMIL,NDA022100,c5535406-b63b-49aa-88b9-169aaf0ed08e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022100_azor_toc.cfm,
2004,N/A,N/A,NDA021732,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021732s000_VantasTOC.cfm,
2012,XELJANZ,TOFACITINIB,NDA203214,cf74ba2f-afc5-4baa-8594-979c889a5831,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/203214Orig1s013.pdf,
2012,XELJANZ,TOFACITINIB,NDA203214,cf74ba2f-afc5-4baa-8594-979c889a5831,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/203214Orig1s008.pdf,
2012,XELJANZ,TOFACITINIB,NDA203214,cf74ba2f-afc5-4baa-8594-979c889a5831,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203214Orig1s04.pdf,
2012,XELJANZ,TOFACITINIB,NDA203214,cf74ba2f-afc5-4baa-8594-979c889a5831,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203214Orig1s002.pdf,
2012,XELJANZ,TOFACITINIB,NDA203214,cf74ba2f-afc5-4baa-8594-979c889a5831,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/203214Orig1s018.pdf,
2012,XELJANZ,TOFACITINIB,NDA203214,cf74ba2f-afc5-4baa-8594-979c889a5831,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203214Orig1s000TOC.cfm,
2012,XELJANZ,TOFACITINIB,NDA203214,cf74ba2f-afc5-4baa-8594-979c889a5831,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203214Orig1s000SumR.pdf,
2010,XEOMIN,INCOBOTULINUMTOXINA,BLA125360,ccdc3aae-6e2d-4cd0-a51c-8375bfee9458,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125360s0000TOC.cfm,
2010,XEOMIN,INCOBOTULINUMTOXINA,BLA125360,ccdc3aae-6e2d-4cd0-a51c-8375bfee9458,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125360s000SumR.pdf,
1989,N/A,N/A,NDA019591,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/019591Orig1s027.pdf,
1989,N/A,N/A,NDA019591,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/019591Orig1s025.pdf,
1989,N/A,N/A,NDA019591,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/019591Orig1s014;s017.pdf,
1989,N/A,N/A,NDA019591,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/019591Orig1s023.pdf,
1989,N/A,N/A,NDA019591,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/019591Orig1s026;s028.pdf,
1989,N/A,N/A,NDA019591,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/019591Orig1s026;s028.pdf,
1989,N/A,N/A,NDA019591,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/019591Orig1s030.pdf,
1989,N/A,N/A,NDA019591,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/019591Orig1s022.pdf,
1989,N/A,N/A,NDA019591,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/019591Orig1s014;s017.pdf,
1989,N/A,N/A,NDA019591,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/019591Orig1s020.pdf,
2015,TUXARIN,CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE,NDA206323,a7cfab67-6087-4ab4-b7cd-4f9295413180,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206323Orig1s000TOC.cfm,
2016,ZEPATIER,ELBASVIR AND GRAZOPREVIR,NDA208261,164dc02a-9180-426a-b8b5-04ab39d2bbd4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208261Orig1s000TOC.cfm,
2016,ZEPATIER,ELBASVIR AND GRAZOPREVIR,NDA208261,164dc02a-9180-426a-b8b5-04ab39d2bbd4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208261Orig1s000SumR.pdf,
2017,GIAPREZA,ANGIOTENSIN II,NDA209360,c265d69a-3efe-4107-9a9e-e6fd3d531c48,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209360Orig1s000TOC.cfm,
1995,N/A,N/A,NDA020496,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020496s015_glimepiride_Amaryl_Clinical_BPCA.pdf,
1995,N/A,N/A,NDA020496,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020496s015_glimepiride_Amaryl-Statistical_BPCA.pdf,
1995,N/A,N/A,NDA020496,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020496S002.cfm,
1995,N/A,N/A,NDA020496,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020496Orig1s000rev.pdf,
1995,N/A,N/A,NDA020496,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20496-S005_Amaryl.pdf,
2020,ONGENTYS,OPICAPONE,NDA212489,a511a531-112e-43f8-a43f-5334b0efe979,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212489Orig1s000TOC.cfm,
1996,N/A,N/A,NDA020555,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20555S003_AxidAr.cfm,
1996,N/A,N/A,NDA020555,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20555S003_AxidAr.cfm,
2023,APHEXDA,MOTIXAFORTIDE,NDA217159,e704b2db-f119-40ba-9346-9229e3281c9e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217159Orig1s000TOC.cfm,
2010,DIFFERIN,ADAPALENE,NDA022502,78b3c1f9-0fc2-4075-6cf0-454a492e6ae3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022502 (adapalene)_Biostat Review PREA.pdf,
2010,DIFFERIN,ADAPALENE,NDA022502,78b3c1f9-0fc2-4075-6cf0-454a492e6ae3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022502 (adapalene)_Clinpharm Review PREA.pdf,
2010,DIFFERIN,ADAPALENE,NDA022502,78b3c1f9-0fc2-4075-6cf0-454a492e6ae3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022502 (adapalene)_Clinical Review 1_PREA_CORRECTED.pdf,
2010,DIFFERIN,ADAPALENE,NDA022502,78b3c1f9-0fc2-4075-6cf0-454a492e6ae3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022502_differin_toc.cfm,
2010,DIFFERIN,ADAPALENE,NDA022502,78b3c1f9-0fc2-4075-6cf0-454a492e6ae3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022502s000SumR.pdf,
2024,LETYBO,LETIBOTULINUMTOXINA-WLBG,BLA761225,910e5d0e-4d0b-4de8-8e2d-97879a044181,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761225Orig1s000TOC.cfm,
1999,N/A,N/A,NDA021046,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020822Orig1s038s040_021046Orig1s016s017Rev.pdf,
1999,N/A,N/A,NDA021046,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21-046_Celexa.pdf,
1999,N/A,N/A,NDA021046,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021046Orig1s019.pdf,
1999,N/A,N/A,NDA021046,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020822Orig1s038s040_021046Orig1s016s017Rev.pdf,
2002,VABRINTY,LEUPROLIDE ACETATE,NDA021379,008776cc-83f1-4f8c-819b-6471425da15f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021379_s002_ELIGARD.pdf,
2002,VABRINTY,LEUPROLIDE ACETATE,NDA021379,008776cc-83f1-4f8c-819b-6471425da15f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-379_Eligard.cfm,
2008,NEXIUM,ESOMEPRAZOLE MAGNESIUM,NDA022101,f4853677-1622-4037-688b-fdf533a11d96,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022101_nexium_toc.cfm,
2008,NEXIUM,ESOMEPRAZOLE MAGNESIUM,NDA022101,f4853677-1622-4037-688b-fdf533a11d96,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022101s000sumr.pdf,
2008,NEXIUM,ESOMEPRAZOLE MAGNESIUM,NDA022101,f4853677-1622-4037-688b-fdf533a11d96,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022101s000_Esmoprazole_Clinical_PREA.pdf,
2008,NEXIUM,ESOMEPRAZOLE MAGNESIUM,NDA022101,f4853677-1622-4037-688b-fdf533a11d96,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022101s000_Esmoprazole_Clinpharm_PREA.pdf,
2008,NEXIUM,ESOMEPRAZOLE MAGNESIUM,NDA022101,f4853677-1622-4037-688b-fdf533a11d96,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022101s000_Esomeprazole_Statistic_PREA.pdf,
1982,AMIDATE,ETOMIDATE,NDA018227,b7ed5bf8-ba75-44dc-8f81-96b4ad5766be,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/018227_s012_AmidateTOC.cfm,
2011,BENLYSTA,BELIMUMAB,BLA125370,2fa3c528-1777-4628-8a55-a69dae2381a3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125370Orig1s000TOC.cfm,
2011,BENLYSTA,BELIMUMAB,BLA125370,2fa3c528-1777-4628-8a55-a69dae2381a3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125370Orig1s000SumR.pdf,
2011,BENLYSTA,BELIMUMAB,BLA125370,2fa3c528-1777-4628-8a55-a69dae2381a3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/125370S64 belimumab unireview prea.pdf,
2011,N/A,N/A,NDA202513,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202513_anturol_toc.cfm,
2011,N/A,N/A,NDA202513,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202513Orig1s000SumR.pdf,
2015,N/A,N/A,NDA205934,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205934Orig1s000TOC.cfm,
1986,N/A,N/A,NDA019404,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019404Orig1s000rev.pdf,
1996,REMERON,MIRTAZAPINE,NDA020415,98ad1917-a094-44f5-a28f-a64a8cfcd887,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20-415s003_Remeron.cfm,
1996,REMERON,MIRTAZAPINE,NDA020415,98ad1917-a094-44f5-a28f-a64a8cfcd887,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020415Orig1s000rev.pdf,
2019,N/A,N/A,NDA210737,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210737Orig1s000, 210737Orig2s000TOC.cfm",
2019,N/A,N/A,NDA210737,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210737Orig1s000, 210737Orig2s000TOC.cfm",
2024,ONYDA XR,CLONIDINE HYDROCHLORIDE,NDA217645,4a15c850-9da5-4bdc-a34d-7f740a6149b7,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217645Orig1s000TOC.cfm,
2015,METAXALONE,METAXALONE,NDA022503,fc6de1a6-26aa-47ac-a5d2-bf127a6ca563,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022503Orig1s000TOC.cfm,
2015,METAXALONE,METAXALONE,NDA022503,fc6de1a6-26aa-47ac-a5d2-bf127a6ca563,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022503Orig1s000SumR.pdf,
2022,KIMMTRAK,TEBENTAFUSP,BLA761228,24a49f57-d2fc-4ffe-9eb1-fe0460c6b067,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761228Orig1s000TOC.cfm,
1999,N/A,N/A,BLA021047,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21-047_Repronex.cfm,
1999,N/A,N/A,BLA021047,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-047S001.pdf,
2007,N/A,N/A,NDA022102,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022102_calomist_toc.cfm,
2007,N/A,N/A,NDA022102,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022102s000_SumR.pdf,
1984,AUGMENTIN,AMOXICILLIN AND CLAVULANATE POTASSIUM,NDA050575,f55f61af-10f1-0e17-e053-2995a90adc43,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/050564s022_augmentin.pdf,
2014,MYALEPT,METRELEPTIN,BLA125390,d3b50bbd-140b-425c-b5ec-d4682aad62bc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125390Orig1s000TOC.cfm,
2014,MYALEPT,METRELEPTIN,BLA125390,d3b50bbd-140b-425c-b5ec-d4682aad62bc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125390Orig1s000SumR.pdf,
2018,N/A,N/A,NDA202158,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/202158Orig1s000TOC.cfm,
2012,ONFI,CLOBAZAM,NDA203993,de03bd69-2dca-459c-93b4-541fd3e9571c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203993_onfi_toc.cfm,
2012,ONFI,CLOBAZAM,NDA203993,de03bd69-2dca-459c-93b4-541fd3e9571c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203993Orig1s000SumR.pdf,
2014,TOPIRAMATE,TOPIRAMATE,NDA205122,691d276c-9cc1-4d39-828f-0f44d7ef6328,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205122Orig1s000SumR.pdf,
2014,TOPIRAMATE,TOPIRAMATE,NDA205122,691d276c-9cc1-4d39-828f-0f44d7ef6328,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205122Orig1s000TOC.cfm,
2015,MOXIFLOXACIN,MOXIFLOXACIN HYDROCHLORIDE,NDA205572,a4e28b09-714b-46e7-b4e6-0163cad78fc5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205572Orig1s000TOC.cfm,
2015,MOXIFLOXACIN,MOXIFLOXACIN HYDROCHLORIDE,NDA205572,a4e28b09-714b-46e7-b4e6-0163cad78fc5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205572Orig1s000SumR.pdf,
1992,IMITREX,SUMATRIPTAN,NDA020080,fee7d073-0b99-48f2-7985-0d8cf970894b,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020080_S030_IMITREX TABLETS, NASAL SPRAY INJ.pdf",
1992,IMITREX,SUMATRIPTAN,NDA020080,fee7d073-0b99-48f2-7985-0d8cf970894b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020080ap.pdf,
2015,CRESEMBA,ISAVUCONAZONIUM SULFATE,NDA207501,8f7f73b8-586a-4df0-935f-fecd4696c16c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000Lbl.pdf,
2015,CRESEMBA,ISAVUCONAZONIUM SULFATE,NDA207501,8f7f73b8-586a-4df0-935f-fecd4696c16c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000TOC.cfm,
2016,RELISTOR,METHYLNALTREXONE BROMIDE,NDA208271,c488fb7c-0a5b-487c-b452-996809d1cb99,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208271Orig1s000TOC.cfm,
2017,QVAR REDIHALER,BECLOMETHASONE DIPROPIONATE HFA,NDA207921,cada897a-264e-450d-ae00-36e7fe747080,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207921Orig1s000TOC.cfm,
2018,APADAZ,BENZHYDROCODONE AND ACETAMINOPHEN,NDA208653,0590d4e5-7107-4015-a6a8-deac14265aa2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208653Orig1s000TOC.cfm,
2024,FEMLYV,NORETHINDRONE ACETATE/ETHINYL ESTRADIOL,NDA218718,a3c99fc1-9b05-4f0a-ad00-5e3e206302c9,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/218718Orig1s000TOC.cfm,
2022,ERMEZA,LEVOTHYROXINE SODIUM,NDA215809,8ceeadb4-18be-46c7-9204-68b4edfbb96b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215809Orig1s000TOC.cfm,
2011,N/A,N/A,NDA022510,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022510_abstral_toc.cfm,
2011,N/A,N/A,NDA022510,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022510Orig1s000SumR.pdf,
1999,INOMAX,NITRIC OXIDE,NDA020845,762b51be-1893-4cd1-9511-e645fc420d3a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/020845Orig1s014.pdf,
1999,INOMAX,NITRIC OXIDE,NDA020845,762b51be-1893-4cd1-9511-e645fc420d3a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/020845Orig1s017.pdf,
1999,INOMAX,NITRIC OXIDE,NDA020845,762b51be-1893-4cd1-9511-e645fc420d3a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020845 nitric oxide clinical both_PREA.pdf,
1999,INOMAX,NITRIC OXIDE,NDA020845,762b51be-1893-4cd1-9511-e645fc420d3a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020845 nitric oxide clinpharm both_PREA.pdf,
1999,INOMAX,NITRIC OXIDE,NDA020845,762b51be-1893-4cd1-9511-e645fc420d3a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020845 nitric oxide statistical both_PREA.pdf,
1999,INOMAX,NITRIC OXIDE,NDA020845,762b51be-1893-4cd1-9511-e645fc420d3a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20845_INOmax.cfm,
2000,TARGRETIN,BEXAROTENE,NDA021056,d35b4697-3f3b-4aa1-b5d9-153993e83811,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-056_Targretin.cfm,
2008,N/A,N/A,NDA022107,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022107_tekturna_toc.cfm,
2008,N/A,N/A,NDA022107,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022107s000_SumR.pdf,
2007,BYSTOLIC,NEBIVOLOL HYDROCHLORIDE,NDA021742,8b8ad213-1dc8-454e-a524-075685c0e1a8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000TOC.cfm,
1986,AZACTAM,AZTREONAM,NDA050580,9a105eaf-ee77-4016-beeb-d425a5565db2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/050580Orig1s000rev.pdf,
1985,SYPRINE,TRIENTINE HYDROCHLORIDE,NDA019194,c34f77a7-996b-4470-b5df-d946a7fe5dbe,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/19194-S005_Syprine.pdf,
1985,SYPRINE,TRIENTINE HYDROCHLORIDE,NDA019194,c34f77a7-996b-4470-b5df-d946a7fe5dbe,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019194Orig1s000rev.pdf,
2011,EYLEA,AFLIBERCEPT,BLA125387,f96cfd69-da34-41ee-90a9-610a4655cd1c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125387Orig1s023.pdf,
2011,EYLEA,AFLIBERCEPT,BLA125387,f96cfd69-da34-41ee-90a9-610a4655cd1c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125387s0000TOC.cfm,
2011,EYLEA,AFLIBERCEPT,BLA125387,f96cfd69-da34-41ee-90a9-610a4655cd1c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125387Orig1s000SumR.pdf,
2011,EYLEA,AFLIBERCEPT,BLA125387,f96cfd69-da34-41ee-90a9-610a4655cd1c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125387Orig1s015.pdf,
2011,EYLEA,AFLIBERCEPT,BLA125387,f96cfd69-da34-41ee-90a9-610a4655cd1c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125387Orig1s048.pdf,
2011,EYLEA,AFLIBERCEPT,BLA125387,f96cfd69-da34-41ee-90a9-610a4655cd1c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/125387Orig1s060.pdf,
2011,EYLEA,AFLIBERCEPT,BLA125387,f96cfd69-da34-41ee-90a9-610a4655cd1c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125387Orig1s020.pdf,
2011,EYLEA,AFLIBERCEPT,BLA125387,f96cfd69-da34-41ee-90a9-610a4655cd1c,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/125387Orig1s061.pdf,
2011,EYLEA,AFLIBERCEPT,BLA125387,f96cfd69-da34-41ee-90a9-610a4655cd1c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/125387Orig1s053.pdf,
2012,N/A,N/A,NDA202155,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000TOC.cfm,
2012,N/A,N/A,NDA202155,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202155Orig1s002TOC.cfm,
2012,N/A,N/A,NDA202155,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/202155Orig1s013.pdf,
1984,ANTISEPTIC SKIN CLEANSER,CHLORHEXIDINE GLUCONATE 4%,NDA019125,1223185b-c94c-5a9a-e054-00144ff88e88,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/19-125S028.pdf,
2015,KYBELLA,DEOXYCHOLIC ACID,NDA206333,fe431ed4-ea6f-4e99-b4bc-ec25ae7b8553,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206333Orig1s000TOC.cfm,
2015,KYBELLA,DEOXYCHOLIC ACID,NDA206333,fe431ed4-ea6f-4e99-b4bc-ec25ae7b8553,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206333Orig1s000SumR.pdf,
2018,N/A,N/A,NDA210045,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210045Orig1s000TOC.cfm,
2017,TEPADINA,THIOTEPA,NDA208264,559e353c-2dc0-16ba-e054-00144ff8d46c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208264Orig1s000TOC.cfm,
2015,EPIDUO FORTE,ADAPALENE AND BENZOYL PEROXIDE,NDA207917,f4e5d381-098a-4c93-9ff0-002cae46daac,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207917Orig1s000TOC.cfm,
2015,EPIDUO FORTE,ADAPALENE AND BENZOYL PEROXIDE,NDA207917,f4e5d381-098a-4c93-9ff0-002cae46daac,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/207917 adapalene benzoyl clinical prea.pdf,
2015,EPIDUO FORTE,ADAPALENE AND BENZOYL PEROXIDE,NDA207917,f4e5d381-098a-4c93-9ff0-002cae46daac,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/207917 adapalene benzoyl clinpharm prea.pdf,
2015,EPIDUO FORTE,ADAPALENE AND BENZOYL PEROXIDE,NDA207917,f4e5d381-098a-4c93-9ff0-002cae46daac,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/207917 adapalene benzoyl statistical prea.pdf,
2024,N/A,N/A,NDA218710,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/218710Orig1s000TOC.cfm,
2010,N/A,N/A,NDA022504,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022504Orig1s005.pdf,
2010,N/A,N/A,NDA022504,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022504Orig1s000SumR.pdf,
2010,N/A,N/A,NDA022504,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022504_axiron_toc.cfm,
2024,TEVIMBRA,TISLELIZUMAB-JSGR,BLA761232,08ef1e3e-496f-4b0b-94ee-fbba3cc1985a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761232Orig1s000TOC.cfm,
2007,N/A,N/A,NDA022103,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022103s000TOC.cfm,
1970,FLUOROURACIL,FLUOROURACIL,NDA016831,744737c5-0d96-4214-82ab-6cff016b1ea0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/16831_s035_efudex.pdf,
1970,FLUOROURACIL,FLUOROURACIL,NDA016831,744737c5-0d96-4214-82ab-6cff016b1ea0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/16831_s031_efudex.pdf,
1970,FLUOROURACIL,FLUOROURACIL,NDA016831,744737c5-0d96-4214-82ab-6cff016b1ea0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/16831_s008_efudex.pdf,
1970,FLUOROURACIL,FLUOROURACIL,NDA016831,744737c5-0d96-4214-82ab-6cff016b1ea0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/16831_s011_efudex.pdf,
1970,FLUOROURACIL,FLUOROURACIL,NDA016831,744737c5-0d96-4214-82ab-6cff016b1ea0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/16831_s028_efudex.pdf,
1970,FLUOROURACIL,FLUOROURACIL,NDA016831,744737c5-0d96-4214-82ab-6cff016b1ea0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/16831_s030_efudex.pdf,
2011,ADCETRIS,BRENTUXIMAB VEDOTIN,BLA125388,3904f8dd-1aef-3490-e48f-bd55f32ed67f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125388_adcetris_toc.cfm,
2011,ADCETRIS,BRENTUXIMAB VEDOTIN,BLA125388,3904f8dd-1aef-3490-e48f-bd55f32ed67f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125388Orig1s000SumR.pdf,
2011,MORPHINE SULFATE,MORPHINE SULFATE,NDA202515,ee8057d1-ed12-4e18-9efa-d83504abf612,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202515_morphine_sulfate_toc.cfm,
2011,MORPHINE SULFATE,MORPHINE SULFATE,NDA202515,ee8057d1-ed12-4e18-9efa-d83504abf612,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202515Orig1s000SumR.pdf,
2014,ORBACTIV,ORITAVANCIN,NDA206334,ff09a726-9f9b-4e30-b509-396781293220,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206334Orig1s000TOC.cfm,
2014,ORBACTIV,ORITAVANCIN,NDA206334,ff09a726-9f9b-4e30-b509-396781293220,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206334Orig1s000SumR.pdf,
2012,SIRTURO,BEDAQUILINE FUMARATE,NDA204384,1534c9ae-4948-4cf4-9f66-222a99db6d0e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/204384Orig1s000TOC.cfm,
2012,SIRTURO,BEDAQUILINE FUMARATE,NDA204384,1534c9ae-4948-4cf4-9f66-222a99db6d0e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/204384Orig1s000SumR.pdf,
2018,EZALLOR SPRINKLE,ROSUVASTATIN,NDA208647,619add8c-3e39-4bb7-8828-450bd82c0404,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208647Orig1s000TOC.cfm,
2022,DAPTOMYCIN IN SODIUM CHLORIDE,DAPTOMYCIN IN SODIUM CHLORIDE,NDA213645,7ed4d986-2aa9-43cd-9a8a-fbd11cb5ecef,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/213645Orig1s000TOC.cfm,
2024,BEIZRAY,DOCETAXEL,NDA218711,8fb7d980-d6c7-468b-a9f0-adff16101a4b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/218711Orig1s000TOC.cfm,
2022,BLUDIGO,INDIGOTINDISULFONATE SODIUM,NDA216264,73f246c4-b127-452e-856f-134b56cb8870,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216264Orig1s000TOC.cfm,
2023,SYFOVRE,PEGCETACOPLAN,NDA217171,b4434e61-9ec9-4e0e-bd60-45aaa0a87e64,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217171Orig1s000TOC.cfm,
2010,EGRIFTA WR,TESAMORELIN,BLA022505,839334d3-8c1d-4c26-9036-2ab524a6ea75,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022505Orig1s000SumR.pdf,
2010,EGRIFTA WR,TESAMORELIN,BLA022505,839334d3-8c1d-4c26-9036-2ab524a6ea75,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022505Orig1s000TOC.cfm,
2022,OPDUALAG,NIVOLUMAB AND RELATLIMAB-RMBW,BLA761234,b22c9d83-3256-4e17-85f7-f331a504adc6,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761234Orig1s000TOC.cfm,
1999,N/A,N/A,NDA021052,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021052_S021_VIOXX.pdf,
1999,N/A,N/A,NDA021052,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-042s007_Vioxx.cfm,
1999,N/A,N/A,NDA021052,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021042_s017_021052_s011_VioxxTOC.cfm,
1999,N/A,N/A,NDA021052,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-042s007_Vioxx.cfm,
1999,N/A,N/A,NDA021052,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-042s007_Vioxx.cfm,
1999,N/A,N/A,NDA021052,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/021042_52_Vioxx.cfm,
1999,N/A,N/A,NDA021052,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021042_s020s021s022_021052_s014s015s016_VioxxTOC.cfm,
1999,N/A,N/A,NDA021052,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021042_s020s021s022_021052_s014s015s016_VioxxTOC.cfm,
1999,N/A,N/A,NDA021052,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-042s007_Vioxx.cfm,
1999,N/A,N/A,NDA021052,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-042s007_Vioxx.cfm,
1999,N/A,N/A,NDA021052,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021052_S010_VIOXX.pdf,
1999,N/A,N/A,NDA021052,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-042s007_Vioxx.cfm,
1999,N/A,N/A,NDA021052,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021052_S019_VIOXX.pdf,
1999,N/A,N/A,NDA021052,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021042_s024_021052_s017_VioxxtmTOC.cfm,
1999,N/A,N/A,NDA021052,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021042_s020s021s022_021052_s014s015s016_VioxxTOC.cfm,
2008,VENLAFAXINE HYDROCHLORIDE,VENLAFAXINE HYDROCHLORIDE,NDA022104,82872e90-4f86-49f7-9f38-39c0f75e4467,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022104s000_SumR.pdf,
2008,VENLAFAXINE HYDROCHLORIDE,VENLAFAXINE HYDROCHLORIDE,NDA022104,82872e90-4f86-49f7-9f38-39c0f75e4467,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022104_venlafaxine_hydrochloride_toc.cfm,
2005,RETISERT,FLUOCINOLONE ACETONIDE,NDA021737,1ab0f849-2a0d-47ce-ad05-768094da8cc9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021737s000TOC.cfm,
1985,N/A,N/A,NDA050578,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/050578Orig1s000rev.pdf,
1978,KIT FOR THE PREPARTION OF TECHNETIUM TC99M SULFUR COLLOID,TECHNETIUM TC 99M SULFUR COLLOID,NDA017858,eeaf70fd-46bd-4fec-ba9d-2366fdf07888,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/017858Orig1s035MedR.pdf,
2019,GENOSYL,NITRIC OXIDE,NDA202860,c9560c54-9e28-4039-a4e5-5000c41c6c85,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/202860Orig1s000TOC.cfm,
2015,CRESEMBA,ISAVUCONAZONIUM SULFATE,NDA207500,8f7f73b8-586a-4df0-935f-fecd4696c16c,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/207500Orig1s013.pdf,
2015,CRESEMBA,ISAVUCONAZONIUM SULFATE,NDA207500,8f7f73b8-586a-4df0-935f-fecd4696c16c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000TOC.cfm,
2015,CRESEMBA,ISAVUCONAZONIUM SULFATE,NDA207500,8f7f73b8-586a-4df0-935f-fecd4696c16c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000Lbl.pdf,
2015,NEXIUM 24HR,ESOMEPRAZOLE MAGNESIUM,NDA207920,61f67858-ba2f-449b-8b30-c15cdaf49222,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207920Orig1s002.pdf,
2015,NEXIUM 24HR,ESOMEPRAZOLE MAGNESIUM,NDA207920,61f67858-ba2f-449b-8b30-c15cdaf49222,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207920Orig1s000TOC.cfm,
2015,NEXIUM 24HR,ESOMEPRAZOLE MAGNESIUM,NDA207920,61f67858-ba2f-449b-8b30-c15cdaf49222,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207920Orig1s000SumR.pdf,
2023,ATORVALIQ,ATORVALIQ,NDA213260,41fca2d8-7f3f-45b9-8974-81b89accc211,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/213260Orig1s000TOC.cfm,
2023,SKYCLARYS,OMAVELOXOLONE,NDA216718,2709e870-df3d-f30f-e063-6394a90aeda1,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216718Orig1s000TOC.cfm,
2023,CYCLOPHOSPHAMIDE,"CYCLOPHOSPHAMIDE INJECTION, SOLUTION",NDA217651,34dbffee-80e0-49c3-90e8-95713a0b7fbe,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217651Orig1s000TOC.cfm,
2022,VABYSMO,FARICIMAB,BLA761235,04cc9ef7-c02a-4e92-a655-0062674e8487,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761235Orig1s000TOC.cfm,
1999,TARGRETIN,BEXAROTENE,NDA021055,1d056725-0576-4338-8089-6336e768ccdc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21055_Targretin.cfm,
2007,N/A,N/A,NDA022106,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022106TOC.cfm,
2007,N/A,N/A,NDA022106,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022106s000_SumR.pdf,
2007,N/A,N/A,NDA021738,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021738_extina_toc.cfm,
2012,N/A,N/A,BLA125422,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125422_jetrea_toc.cfm,
2012,N/A,N/A,BLA125422,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/6_125422 ocriplasmin clinical prea.pdf,
2012,N/A,N/A,BLA125422,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/5_125422 ocriplasmin clinpharm prea.pdf,
2012,N/A,N/A,BLA125422,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/4_125422 ocriplasmin statistical prea.pdf,
2014,MOVANTIK,NALOXEGOL OXALATE,NDA204760,300a6474-ebcd-4404-8040-48fdcfcc1635,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204760Orig1s000TOC.cfm,
2014,MOVANTIK,NALOXEGOL OXALATE,NDA204760,300a6474-ebcd-4404-8040-48fdcfcc1635,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204760Orig1s000SumR.pdf,
2016,FYCOMPA,PERAMPANEL,NDA208277,71cf3309-e182-473c-8b0b-280cabd0e122,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208277Orig1s000TOC.cfm,
2016,FYCOMPA,PERAMPANEL,NDA208277,71cf3309-e182-473c-8b0b-280cabd0e122,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208277%20perampanel%20clinical%20prea.pdf,
2016,FYCOMPA,PERAMPANEL,NDA208277,71cf3309-e182-473c-8b0b-280cabd0e122,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208277%20perampanel%20clinpharm%20MTL%20prea.pdf,
2016,FYCOMPA,PERAMPANEL,NDA208277,71cf3309-e182-473c-8b0b-280cabd0e122,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208277%20perampanel%20clinpharm%20MTL%20prea.pdf,
2015,N/A,N/A,NDA207923,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207923Orig1_toc.cfm,
2015,N/A,N/A,NDA207923,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207923Orig1s000SumR.pdf,
2016,SYNJARDY XR,"EMPAGLIFLOZIN, METFORMIN HYDROCHLORIDE",NDA208658,8006ba29-ee3a-f852-a9bb-c8ec9b41cf66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208658Orig1s000TOC.cfm,
2020,ORLADEYO,BEROTRALSTAT HYDROCHLORIDE,NDA214094,3527ece1-e7e0-40b1-b0c5-6baeb0deabeb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214094Orig1s000TOC.cfm,
2021,MICAFUNGIN,MICAFUNGIN,NDA212156,70b3f044-95ca-4503-b669-ed39972592b6,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212156Orig1s000TOC.cfm,
2020,CYCLOPHOSPHAMIDE,CYCLOPHOSPHAMIDE,NDA212501,a5818647-d840-e9d7-c7b8-6541b485e44e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212501Orig1s000TOC.cfm,
2010,N/A,N/A,NDA022516,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022516Orig1s000SumR.pdf,
2010,N/A,N/A,NDA022516,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022516_cymbalta_tocEDT.cfm,
2024,KISUNLA,DONANEMAB-AZBT,BLA761248,190352d4-ef62-4679-b4fa-e846e2766afa,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761248Orig1s000TOC.cfm,
1999,N/A,N/A,NDA021065,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21065_Femhrt.cfm,
2003,N/A,N/A,NDA021388,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-388_SterileTalc.cfm,
2007,ZINGO,LIDOCAINE HYDROCHLORIDE MONOHYDRATE,NDA022114,25368079-b2ac-4d31-e063-6394a90aa324,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022114_zingo_toc.cfm,
2012,N/A,N/A,NDA021746,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021746Orig1s000SumR.pdf,
2012,N/A,N/A,NDA021746,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021746Orig1s000TOC.cfm,
1978,HEPARIN SODIUM,HEPARIN SODIUM,NDA017651,d55b4a63-0c04-4874-b74f-9e9b9e8b008c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/017651_ORIGINAL APPROVAL_PACKAGE.pdf,
2011,N/A,N/A,BLA125399,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125399_adcetris_toc.cfm,
2011,N/A,N/A,BLA125399,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125399Orig1s000SumR.pdf,
2013,N/A,N/A,NDA205123,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000TOC.cfm,
2013,N/A,N/A,NDA205123,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000SumR.pdf,
2013,N/A,N/A,NDA205123,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205123Orig1s008.pdf,
2022,EPSOLAY,BENZOYL PEROXIDE,NDA214510,507e2cd7-6bcf-4606-bc62-694d64537701,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/214510Orig1s000TOC.cfm,
2024,MIPLYFFA,ARIMOCLOMOL CITRATE,NDA214927,5feffc0e-453d-47fa-91dd-38d4952309bc,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/214927Orig1s000TOC.cfm,
2010,VIMOVO,NAPROXEN AND ESOMEPRAZOLE MAGNESIUM,NDA022511,baa47781-7151-4c75-a9a2-d2eac0a7d55e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022511Orig1s000SumR.pdf,
2010,VIMOVO,NAPROXEN AND ESOMEPRAZOLE MAGNESIUM,NDA022511,baa47781-7151-4c75-a9a2-d2eac0a7d55e,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/152_22511 S19 naproxen-esomeprazole clinical prea.pdf,
2010,VIMOVO,NAPROXEN AND ESOMEPRAZOLE MAGNESIUM,NDA022511,baa47781-7151-4c75-a9a2-d2eac0a7d55e,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/153_22511 S19 naproxen-esomeprazole clinpharm prea.pdf,
2010,VIMOVO,NAPROXEN AND ESOMEPRAZOLE MAGNESIUM,NDA022511,baa47781-7151-4c75-a9a2-d2eac0a7d55e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022511Orig1s000TOC.cfm,
2022,BRIUMVI,UBLITUXIMAB,BLA761238,3a77cd8c-811b-407c-9140-d0c5c26435c2,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761238Orig1s000TOC.cfm,
1999,GANIRELIX ACETATE,GANIRELIX ACETATE,NDA021057,32fb74ff-993a-49fe-8943-e029372b863e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21057_Antagon.cfm,
2003,ERTACZO,SERTACONAZOLE NITRATE,NDA021385,821073f7-33f6-464d-baed-f66d97987d6d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-385_Ertaczo.cfm,
2008,APLENZIN,BUPROPION HYDROBROMIDE,NDA022108,6494d2d9-0ce4-4126-b1c7-49684395942b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022108s000TOC.cfm,
2008,APLENZIN,BUPROPION HYDROBROMIDE,NDA022108,6494d2d9-0ce4-4126-b1c7-49684395942b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022108s000_SumR.pdf,
2004,TARCEVA,ERLOTINIB HYDROCHLORIDE,NDA021743,57bccb29-1c47-4c64-ab6a-77960a91cc20,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-743_Tarceva.cfm,
2004,TARCEVA,ERLOTINIB HYDROCHLORIDE,NDA021743,57bccb29-1c47-4c64-ab6a-77960a91cc20,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21743 erlotinib clinical bpca.pdf,
2004,TARCEVA,ERLOTINIB HYDROCHLORIDE,NDA021743,57bccb29-1c47-4c64-ab6a-77960a91cc20,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21743 erlotinib clinpharm bpca.pdf,
2015,NEOSTIGMINE METHYLSULFATE,NEOSTIGMINE METHYLSULFATE,NDA203629,6448229c-e650-47ba-bb00-cba3604502c5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/203629Orig1s000SumR.pdf,
2015,NEOSTIGMINE METHYLSULFATE,NEOSTIGMINE METHYLSULFATE,NDA203629,6448229c-e650-47ba-bb00-cba3604502c5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/203629Orig1s000TOC.cfm,
2012,PERJETA,PERTUZUMAB,BLA125409,17f85d17-ab71-4f5b-9fe3-0b8c822f69ff,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/125409Orig1s109.pdf,
2012,PERJETA,PERTUZUMAB,BLA125409,17f85d17-ab71-4f5b-9fe3-0b8c822f69ff,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/125409Orig1s113.pdf,
2012,PERJETA,PERTUZUMAB,BLA125409,17f85d17-ab71-4f5b-9fe3-0b8c822f69ff,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125409Orig1s000TOC.cfm,
2012,PERJETA,PERTUZUMAB,BLA125409,17f85d17-ab71-4f5b-9fe3-0b8c822f69ff,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/125409Orig1s118.pdf,
2012,PERJETA,PERTUZUMAB,BLA125409,17f85d17-ab71-4f5b-9fe3-0b8c822f69ff,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125409_perjeta_toc.cfm,
2012,PERJETA,PERTUZUMAB,BLA125409,17f85d17-ab71-4f5b-9fe3-0b8c822f69ff,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125409Orig1s051SumR.pdf,
2018,N/A,N/A,NDA208276,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208276Orig1s000TOC.cfm,
2024,LUMISIGHT,PEGULICIANINE,NDA214511,7160e774-663a-43e4-ba4a-06cc57830e66,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/214511Orig1s000TOC.cfm,
2020,VILTEPSO,VILTOLARSEN,NDA212154,1ffff9a8-6d6a-4dcb-8493-1b6cc3a5d123,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212154Orig1s000TOC.cfm,
1997,VIRACEPT,NELFINAVIR MESYLATE,NDA020779,e72c2bc6-9462-4a2e-8e1d-b97592376cbd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020779_S036_VIRACEPT.pdf,
1997,VIRACEPT,NELFINAVIR MESYLATE,NDA020779,e72c2bc6-9462-4a2e-8e1d-b97592376cbd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020779_S042_VIRACEPT.pdf,
1997,VIRACEPT,NELFINAVIR MESYLATE,NDA020779,e72c2bc6-9462-4a2e-8e1d-b97592376cbd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020779_S026_VIRACEPT.pdf,
1997,VIRACEPT,NELFINAVIR MESYLATE,NDA020779,e72c2bc6-9462-4a2e-8e1d-b97592376cbd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20779S22_viracept.cfm,
1997,VIRACEPT,NELFINAVIR MESYLATE,NDA020779,e72c2bc6-9462-4a2e-8e1d-b97592376cbd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/1999/020779_S020_VIRACEPT.pdf,
1997,VIRACEPT,NELFINAVIR MESYLATE,NDA020779,e72c2bc6-9462-4a2e-8e1d-b97592376cbd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020779_S045_VIRACEPT.pdf,
1997,VIRACEPT,NELFINAVIR MESYLATE,NDA020779,e72c2bc6-9462-4a2e-8e1d-b97592376cbd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020779_S035_VIRACEPT.pdf,
1997,VIRACEPT,NELFINAVIR MESYLATE,NDA020779,e72c2bc6-9462-4a2e-8e1d-b97592376cbd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020779ap.pdf,
1997,VIRACEPT,NELFINAVIR MESYLATE,NDA020779,e72c2bc6-9462-4a2e-8e1d-b97592376cbd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20778S11_viracept.cfm,
2022,DOCIVYX,DOCETAXEL,NDA215813,4763744e-360e-4d37-be05-cce4114548cd,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215813Orig1s000TOC.cfm,
1997,N/A,N/A,NDA020716,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020716_vicoprofen_toc.cfm,
2010,PRADAXA,DABIGATRAN ETEXILATE MESYLATE,NDA022512,ba74e3cd-b06f-4145-b284-5fd6b84ff3c9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022512Orig1s011_replace.pdf,
2010,PRADAXA,DABIGATRAN ETEXILATE MESYLATE,NDA022512,ba74e3cd-b06f-4145-b284-5fd6b84ff3c9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022512Orig1s004.pdf,
2010,PRADAXA,DABIGATRAN ETEXILATE MESYLATE,NDA022512,ba74e3cd-b06f-4145-b284-5fd6b84ff3c9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022512Orig1s000TOC.cfm,
2010,PRADAXA,DABIGATRAN ETEXILATE MESYLATE,NDA022512,ba74e3cd-b06f-4145-b284-5fd6b84ff3c9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022512Orig1s000SumR.pdf,
2023,LOQTORZI,TORIPALIMAB-TPZI,BLA761240,82e7921a-1e84-4988-9799-0ad7d19b2a75,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761240Orig1s000TOC.cfm,
2004,PRIALT,ZICONOTIDE ACETATE,NDA021060,b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-060_Prialt.cfm,
2004,PRIALT,ZICONOTIDE ACETATE,NDA021060,b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021060_S001_PRIALT.pdf,
2002,N/A,N/A,NDA021386,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-386_Zometa.cfm,
2009,VIBATIV,TELAVANCIN HYDROCHLORIDE,NDA022110,5359b759-db7c-4672-9e8a-59c93869bd91,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022110s000TOC.cfm,
2009,VIBATIV,TELAVANCIN HYDROCHLORIDE,NDA022110,5359b759-db7c-4672-9e8a-59c93869bd91,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022110s000_SumR.pdf,
2005,N/A,N/A,NDA021744,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021744s000TOC.cfm,
2012,ZALTRAP,ZIV-AFLIBERCEPT,BLA125418,f6725df6-50ee-4b0a-b900-d02ba634395d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125418Orig1s000SumR.pdf,
2012,ZALTRAP,ZIV-AFLIBERCEPT,BLA125418,f6725df6-50ee-4b0a-b900-d02ba634395d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125418_zaltrap_toc.cfm,
1988,ZESTRIL,LISINOPRIL,NDA019777,838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019777-S11_ZestrilTablets_toc.cfm,
1988,ZESTRIL,LISINOPRIL,NDA019777,838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/19777-S9_Zestril.pdf,
1988,ZESTRIL,LISINOPRIL,NDA019777,838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/19-777S042S044_Zestril.cfm,
1988,ZESTRIL,LISINOPRIL,NDA019777,838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/19-777S042S044_Zestril.cfm,
1988,ZESTRIL,LISINOPRIL,NDA019777,838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/19777-S3_Zestril.pdf,
1988,ZESTRIL,LISINOPRIL,NDA019777,838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/19777-s034_zestril.pdf,
1988,ZESTRIL,LISINOPRIL,NDA019777,838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019777-S26_ZestrilTablets_toc.cfm,
1988,ZESTRIL,LISINOPRIL,NDA019777,838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/19777-S1_Zestril.pdf,
1988,ZESTRIL,LISINOPRIL,NDA019777,838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/19888-S12_Zestril.pdf,
1988,ZESTRIL,LISINOPRIL,NDA019777,838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019777ap.pdf,
1988,ZESTRIL,LISINOPRIL,NDA019777,838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019777-S24_ZestrilTablets_toc.cfm,
1988,ZESTRIL,LISINOPRIL,NDA019777,838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019777-S30_ZestrilTablets_toc.cfm,
1988,ZESTRIL,LISINOPRIL,NDA019777,838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019777-S12_Zestril_toc.cfm,
1988,ZESTRIL,LISINOPRIL,NDA019777,838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019777-S8_ZestrilTablets_toc.cfm,
1988,ZESTRIL,LISINOPRIL,NDA019777,838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/19777s037.pdf,
1988,ZESTRIL,LISINOPRIL,NDA019777,838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019777-S6_ZestrilTablets_toc.cfm,
1988,ZESTRIL,LISINOPRIL,NDA019777,838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/19777-s035_Zestril.pdf,
1988,ZESTRIL,LISINOPRIL,NDA019777,838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/19777-S4_Zestril.pdf,
1988,ZESTRIL,LISINOPRIL,NDA019777,838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019777-S27_ZestrilTablets_toc.cfm,
1988,ZESTRIL,LISINOPRIL,NDA019777,838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019777-S2_ZestrilTablets_toc.cfm,
1988,ZESTRIL,LISINOPRIL,NDA019777,838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/19777-s033_zestril.pdf,
1988,ZESTRIL,LISINOPRIL,NDA019777,838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019777-S17_ZestrilTablets_toc.cfm,
1988,ZESTRIL,LISINOPRIL,NDA019777,838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019777-S31_ZestrilTablets_toc.cfm,
1988,ZESTRIL,LISINOPRIL,NDA019777,838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019777-S15_ZestrilTablets_toc.cfm,
1988,ZESTRIL,LISINOPRIL,NDA019777,838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019777-S13_ZestrilTablets_toc.cfm,
1990,N/A,N/A,NDA019847,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/019847_S022_CIPRO.pdf,
1990,N/A,N/A,NDA019847,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019847_S012_CIPRO.pdf,
1990,N/A,N/A,NDA019847,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/019847_S029_CIPRO.pdf,
1990,N/A,N/A,NDA019847,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/019537s49_19847s27_19857s31_20780s13TOC.cfm,
1990,N/A,N/A,NDA019847,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/019847_S031_CIPRO.pdf,
1990,N/A,N/A,NDA019847,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/019847_S036_Cipro.pdf,
1990,N/A,N/A,NDA019847,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/019847_S028_CIPRO.pdf,
1990,N/A,N/A,NDA019847,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019847_S026_CIPRO.pdf,
1990,N/A,N/A,NDA019847,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/19-537S038_Cipro.cfm,
2025,N/A,N/A,NDA211448,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/211448Orig1s000TOC.cfm,
2020,CERIANNA,FLUOROESTRADIOL F 18,NDA212155,b2c2a2df-cf3e-4a29-a033-231ed5a94b58,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212155Orig1s000TOC.cfm,
2022,REZLIDHIA,OLUTASIDENIB,NDA215814,4a0c7c8b-b95f-455d-9600-b7351e4397fe,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215814Orig1s000TOC.cfm,
1996,COPAXONE,GLATIRAMER ACETATE,NDA020622,aa88f583-4f5f-433b-80b4-1f4c9fb28357,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020622Orig1s000rev.pdf,
1996,COPAXONE,GLATIRAMER ACETATE,NDA020622,aa88f583-4f5f-433b-80b4-1f4c9fb28357,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/020622Orig1s118.pdf,
1996,COPAXONE,GLATIRAMER ACETATE,NDA020622,aa88f583-4f5f-433b-80b4-1f4c9fb28357,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/020622Orig1s119.pdf,
1996,COPAXONE,GLATIRAMER ACETATE,NDA020622,aa88f583-4f5f-433b-80b4-1f4c9fb28357,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/020622Orig1s119.pdf,
1996,COPAXONE,GLATIRAMER ACETATE,NDA020622,aa88f583-4f5f-433b-80b4-1f4c9fb28357,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020622_S015_COPAXONE_INJECTION_AP.pdf,
1996,COPAXONE,GLATIRAMER ACETATE,NDA020622,aa88f583-4f5f-433b-80b4-1f4c9fb28357,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/020622Orig1s089.pdf,
1996,PATADAY TWICE A DAY RELIEF,OLOPATADINE HYDROCHLORIDE,NDA020688,b7a24375-25df-4405-aa7c-34c46af51194,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020688_S011_PATANOL.pdf,
1996,PATADAY TWICE A DAY RELIEF,OLOPATADINE HYDROCHLORIDE,NDA020688,b7a24375-25df-4405-aa7c-34c46af51194,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020688_S009_PATANOL.pdf,
1996,PATADAY TWICE A DAY RELIEF,OLOPATADINE HYDROCHLORIDE,NDA020688,b7a24375-25df-4405-aa7c-34c46af51194,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/020688Orig1s032.pdf,
1996,PATADAY TWICE A DAY RELIEF,OLOPATADINE HYDROCHLORIDE,NDA020688,b7a24375-25df-4405-aa7c-34c46af51194,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020688_S003_PATANOL.pdf,
1996,PATADAY TWICE A DAY RELIEF,OLOPATADINE HYDROCHLORIDE,NDA020688,b7a24375-25df-4405-aa7c-34c46af51194,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020688_S001_PATANOL.pdf,
1996,PATADAY TWICE A DAY RELIEF,OLOPATADINE HYDROCHLORIDE,NDA020688,b7a24375-25df-4405-aa7c-34c46af51194,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020688_S010_PATANOL.pdf,
1996,PATADAY TWICE A DAY RELIEF,OLOPATADINE HYDROCHLORIDE,NDA020688,b7a24375-25df-4405-aa7c-34c46af51194,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020688Orig1s000rev.pdf,
1996,PATADAY TWICE A DAY RELIEF,OLOPATADINE HYDROCHLORIDE,NDA020688,b7a24375-25df-4405-aa7c-34c46af51194,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020688_S008_PATANOL.pdf,
1996,PATADAY TWICE A DAY RELIEF,OLOPATADINE HYDROCHLORIDE,NDA020688,b7a24375-25df-4405-aa7c-34c46af51194,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020688_S006_PATANOL.pdf,
1996,PATADAY TWICE A DAY RELIEF,OLOPATADINE HYDROCHLORIDE,NDA020688,b7a24375-25df-4405-aa7c-34c46af51194,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020688_S004_PATANOL.pdf,
1996,PATADAY TWICE A DAY RELIEF,OLOPATADINE HYDROCHLORIDE,NDA020688,b7a24375-25df-4405-aa7c-34c46af51194,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020688_S002_PATANOL.pdf,
1996,PATADAY TWICE A DAY RELIEF,OLOPATADINE HYDROCHLORIDE,NDA020688,b7a24375-25df-4405-aa7c-34c46af51194,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020688_S013_PATANOL.pdf,
2024,TEZRULY,TERAZOSIN,NDA218139,69582e0c-6569-490c-8c14-999f3750336f,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/218139Orig1s000TOC.cfm,
2022,SPEVIGO,SPESOLIMAB-SBZO,BLA761244,41a481ee-3062-45d1-aed5-17e8b105634d,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761244Orig1s000TOC.cfm,
2001,DEFINITY,PERFLUTREN,NDA021064,8ab9c79c-1b5c-4e86-899c-cc74686f070a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/021064Orig1s024.pdf,
2001,DEFINITY,PERFLUTREN,NDA021064,8ab9c79c-1b5c-4e86-899c-cc74686f070a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-064_Definity.cfm,
2001,DEFINITY,PERFLUTREN,NDA021064,8ab9c79c-1b5c-4e86-899c-cc74686f070a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021064Orig1s011SumR.pdf,
2001,DEFINITY,PERFLUTREN,NDA021064,8ab9c79c-1b5c-4e86-899c-cc74686f070a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021064Orig1s011TOC.cfm,
2011,ADVIL ALLERGY AND CONGESTION RELIEF,"CHLORPHENIRAMINE MALEATE, IBUPROFEN, AND PHENYLEPHRINE HYDROCHLORIDE",NDA022113,a6cc97d8-252a-4527-a470-6d9e356342fd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022113_advil_toc.cfm,
2011,ADVIL ALLERGY AND CONGESTION RELIEF,"CHLORPHENIRAMINE MALEATE, IBUPROFEN, AND PHENYLEPHRINE HYDROCHLORIDE",NDA022113,a6cc97d8-252a-4527-a470-6d9e356342fd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022113Orig1s000SumR.pdf,
1988,N/A,N/A,NDA019201,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/19-201s018_Voltaren.cfm,
2014,VIMIZIM,ELOSULFASE ALFA,BLA125460,0caa2565-12b2-0ad0-1f9a-273e81c3d4cc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125460Orig1s000SumR.pdf,
2014,VIMIZIM,ELOSULFASE ALFA,BLA125460,0caa2565-12b2-0ad0-1f9a-273e81c3d4cc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125460Orig1s000TOC.cfm,
2011,N/A,N/A,NDA201655,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201655_opana_er_toc.cfm,
2011,N/A,N/A,NDA201655,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201655Orig1s000SumR.pdf,
2015,EVOTAZ,ATAZANAVIR AND COBICISTAT,NDA206353,83db29d7-5d85-49d6-8cb6-740473365cf8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206353Orig1s000TOC.cfm,
2015,EVOTAZ,ATAZANAVIR AND COBICISTAT,NDA206353,83db29d7-5d85-49d6-8cb6-740473365cf8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206353Orig1s000SumR.pdf,
2014,DECITABINE,DECITABINE,NDA205582,c155d6ba-9a16-406c-919e-65a149689ab9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205582Orig1s000SumR.pdf,
2014,DECITABINE,DECITABINE,NDA205582,c155d6ba-9a16-406c-919e-65a149689ab9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205582Orig1s000TOC.cfm,
2015,N/A,N/A,NDA207930,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207930Orig1s000TOC.cfm,
2018,PLENVU,"POLYETHYLENE GLYCOL 3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, ASCORBIC ACID, SODIUM ASCORBATE",NDA209381,79f930fa-5674-4f30-8ae8-9448d6243797,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209381Orig1s000TOC.cfm,
2020,HETLIOZ LQ,TASIMELTEON,NDA214517,ca4a9b63-708e-49e9-8f9b-010625443b90,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214517Orig1s000TOC.cfm,
1993,N/A,N/A,NDA020261,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020261_S004_LESCOL_AP.pdf,
1993,N/A,N/A,NDA020261,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020261_s002_Lescol Capsules.pdf,
1993,N/A,N/A,NDA020261,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020261_s029_LESCOL_CAPSULES.pdf,
1993,N/A,N/A,NDA020261,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020261_S019_LESCOL_CAPSULES.pdf,
1993,N/A,N/A,NDA020261,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020261_S033_LESCOL_CAPS_AP.pdf,
1993,N/A,N/A,NDA020261,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020261_S017_LESCOL_TABLETS.pdf,
1993,N/A,N/A,NDA020261,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020261_s031_LESCOL_CAPSULES.pdf,
1993,N/A,N/A,NDA020261,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020261_S016_LESCOL_TABLETS.pdf,
1993,N/A,N/A,NDA020261,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020261_S021_LESCOL_CAPSULES.pdf,
1993,N/A,N/A,NDA020261,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020261_S013_LESCOL.pdf,
1993,N/A,N/A,NDA020261,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020261_S009_LESCOL_CAPSULES.pdf,
1993,N/A,N/A,NDA020261,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020261_S011_LESCOL_CAPSULES.pdf,
1993,N/A,N/A,NDA020261,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020261_S007_LESCOL_CAPSULES.pdf,
1993,N/A,N/A,NDA020261,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/020261s046.pdf,
1993,N/A,N/A,NDA020261,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020261_S003_LESCOL_AP.pdf,
1993,N/A,N/A,NDA020261,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020261s036_fluvastatin_Lescol-MedRev_PREA.pdf,
1993,N/A,N/A,NDA020261,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020261s036_fluvastatin_Lescol-StatsRev_PREA.pdf,
1993,N/A,N/A,NDA020261,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-192_Lescol.cfm,
1993,N/A,N/A,NDA020261,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020261_s034_Lescol Capsules.pdf,
1993,N/A,N/A,NDA020261,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020261s018s022.cfm,
1993,N/A,N/A,NDA020261,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020261_s032_LESCOL_CAPSULES.pdf,
1993,N/A,N/A,NDA020261,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020261_S016_LESCOL_TABLETS.pdf,
1993,N/A,N/A,NDA020261,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020261s018s022.cfm,
1993,N/A,N/A,NDA020261,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020261_S014_LESCOL.pdf,
1993,N/A,N/A,NDA020261,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020261_S020_LESCOL_CAPSULES.pdf,
1993,N/A,N/A,NDA020261,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020261_S010_LESCOL.pdf,
2024,ALYFTREK,"VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR",NDA218730,7e635909-c6fd-4f0d-ae77-cdff03653a20,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/218730Orig1s000TOC.cfm,
2021,VOXZOGO 0.4MG,VOSORITIDE,NDA214938,228e8560-04a4-4bb1-a81f-29531a9e4d27,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/214938Orig1s002.pdf,
2021,VOXZOGO 0.4MG,VOSORITIDE,NDA214938,228e8560-04a4-4bb1-a81f-29531a9e4d27,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214938Orig1s000TOC.cfm,
2011,N/A,N/A,NDA022519,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022519_duexis_toc.cfm,
2011,N/A,N/A,NDA022519,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022519Orig1s000SumR.pdf,
2022,SKYRIZI,RISANKIZUMAB-RZAA,BLA761262,7148c8eb-b39e-e20a-6494-a6df82392858,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761262Orig1s000TOC.cfm,
2004,SPIRIVA HANDIHALER,TIOTROPIUM BROMIDE,NDA021395,820839ef-e53d-47e8-a3b9-d911ff92e6a9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-395_Spiriva.cfm,
2004,SPIRIVA HANDIHALER,TIOTROPIUM BROMIDE,NDA021395,820839ef-e53d-47e8-a3b9-d911ff92e6a9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021395Orig1s029.pdf,
2009,SAPHRIS,ASENAPINE MALEATE,NDA022117,5429f134-839f-4ffc-9944-55f51238def8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22117 asenapine clinical2 bpca.pdf,
2009,SAPHRIS,ASENAPINE MALEATE,NDA022117,5429f134-839f-4ffc-9944-55f51238def8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22117 asenapine clinpharm bpca.pdf,
2009,SAPHRIS,ASENAPINE MALEATE,NDA022117,5429f134-839f-4ffc-9944-55f51238def8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22117 asenapine statistical bpca.pdf,
2009,SAPHRIS,ASENAPINE MALEATE,NDA022117,5429f134-839f-4ffc-9944-55f51238def8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022117s000TOC.cfm,
2009,SAPHRIS,ASENAPINE MALEATE,NDA022117,5429f134-839f-4ffc-9944-55f51238def8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022117s000_SumR.pdf,
2009,SAPHRIS,ASENAPINE MALEATE,NDA022117,5429f134-839f-4ffc-9944-55f51238def8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22117 asenapine clinical bpca.pdf,
2009,SAPHRIS,ASENAPINE MALEATE,NDA022117,5429f134-839f-4ffc-9944-55f51238def8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22117 asenapine clinpharm bpca.pdf,
2009,SAPHRIS,ASENAPINE MALEATE,NDA022117,5429f134-839f-4ffc-9944-55f51238def8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22117 asenapine statistical bpca.pdf,
1985,CEFOTAN,CEFOTETAN,NDA050588,f1510f5e-d001-44e0-accb-27cf79fd4f9a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/050588Orig1s000rev.pdf,
1972,TRIDESILON CREAM,DESONIDE 0.05%,NDA017010,30d60cbc-fba8-7209-e054-00144ff8d46c,http://www.accessdata.fda.gov/drugsatfda_docs/review/2018/017010Orig1s000Approv.pdf,
2013,KADCYLA,ADO-TRASTUZUMAB EMTANSINE,BLA125427,23f3c1f4-0fc8-4804-a9e3-04cf25dd302e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125427Orig1s000TOC.cfm,
2013,KADCYLA,ADO-TRASTUZUMAB EMTANSINE,BLA125427,23f3c1f4-0fc8-4804-a9e3-04cf25dd302e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125427Orig1s000SumR.pdf,
2013,TROKENDI XR,TOPIRAMATE,NDA201635,2dc7957e-a3e5-46bb-aa66-f3250f872f5e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/201635Orig1s000TOC.cfm,
2013,TROKENDI XR,TOPIRAMATE,NDA201635,2dc7957e-a3e5-46bb-aa66-f3250f872f5e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/201635Orig1s000SumR.pdf,
1988,DERMOTIC,FLUOCINOLONE ACETONIDE,NDA019452,eb00f222-8105-4e05-90e8-bbd129784364,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/19452_Fluocinolone_Clinical_PREA.pdf,
1988,DERMOTIC,FLUOCINOLONE ACETONIDE,NDA019452,eb00f222-8105-4e05-90e8-bbd129784364,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/19452_Fluocinolone_Clinpharm_PREA.pdf,
1988,DERMOTIC,FLUOCINOLONE ACETONIDE,NDA019452,eb00f222-8105-4e05-90e8-bbd129784364,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/19452_Fluocinolone_Statistical_PREA.pdf,
1988,DERMOTIC,FLUOCINOLONE ACETONIDE,NDA019452,eb00f222-8105-4e05-90e8-bbd129784364,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/19-452S017_DermaSmoothe.cfm,
1988,DERMOTIC,FLUOCINOLONE ACETONIDE,NDA019452,eb00f222-8105-4e05-90e8-bbd129784364,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/19452S15_DermaSmooth.cfm,
2014,RYANODEX DANTROLENE SODIUM,DANTROLENE SODIUM,NDA205579,8f7b3ac0-604d-4c78-b545-5e0f8ea3d698,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205579Orig1s000TOC.cfm,
2014,RYANODEX DANTROLENE SODIUM,DANTROLENE SODIUM,NDA205579,8f7b3ac0-604d-4c78-b545-5e0f8ea3d698,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205579Orig1s000SumR.pdf,
2015,CEFAZOLIN,CEFAZOLIN SODIUM,NDA207131,d91a8d13-99a0-4d87-88dc-71cbd37922b4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207131Orig1s000TOC.cfm,
2015,CEFAZOLIN,CEFAZOLIN SODIUM,NDA207131,d91a8d13-99a0-4d87-88dc-71cbd37922b4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207131Orig1s000SumR.pdf,
2018,OLUMIANT,BARICITINIB,NDA207924,866e9f35-9035-4581-a4b1-75a621ab55cf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/207924Orig1s000TOC.cfm,
2020,TRALEMENT,TRACE ELEMENTS INJECTION 4,NDA209376,a49ffb90-f307-433e-a86e-aaea6d6a9982,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209376Orig1s000TOC.cfm,
2020,TRALEMENT,TRACE ELEMENTS INJECTION 4,NDA209376,a49ffb90-f307-433e-a86e-aaea6d6a9982,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/209376Orig1s002.pdf,
2021,TEPMETKO,TEPOTINIB HYDROCHLORIDE,NDA214096,80a0f1b9-071a-47f5-9e67-32d638a669dc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214096Orig1s000TOC.cfm,
2020,ELYXYB - CELECOXIB,CELECOXIB,NDA212157,c8a5de07-9f27-4a54-a885-8089f0307bd7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212157Orig1s000TOC.cfm,
2018,N/A,N/A,NDA022517,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/022517Orig1s000TOC.cfm,
2024,IDACIO,ADALIMUMAB-AACF,BLA761255,08dbaffe-9d05-43cf-b24b-b44ade8685fc,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761255Orig2s000TOC.cfm,
2024,IDACIO,ADALIMUMAB-AACF,BLA761255,08dbaffe-9d05-43cf-b24b-b44ade8685fc,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761255Orig1s000TOC.cfm,
1999,N/A,N/A,NDA021066,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/021066Orig1s001.pdf,
1999,N/A,N/A,NDA021066,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21-066_Zaditor.cfm,
2003,CARDIZEM LA,DILTIAZEM HYDROCHLORIDE,NDA021392,3e180dc7-c871-4efc-8755-cae882976c8d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-392_CardizemTOC.cfm,
2003,CARDIZEM LA,DILTIAZEM HYDROCHLORIDE,NDA021392,3e180dc7-c871-4efc-8755-cae882976c8d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021392_S002_CARDIZEM_LA_EXENTED_AP.pdf,
2009,LAMICTAL XR,LAMOTRIGINE,NDA022115,3e2c9a35-6a39-41d7-ad84-3c0bb8894b09,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022115s000TOC.cfm,
2009,LAMICTAL XR,LAMOTRIGINE,NDA022115,3e2c9a35-6a39-41d7-ad84-3c0bb8894b09,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022115_Lamotrigine_Clinical_BPCA.pdf,
2009,LAMICTAL XR,LAMOTRIGINE,NDA022115,3e2c9a35-6a39-41d7-ad84-3c0bb8894b09,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022115s000_Lamotrigine_Clinpharm_BPCA.pdf,
2009,LAMICTAL XR,LAMOTRIGINE,NDA022115,3e2c9a35-6a39-41d7-ad84-3c0bb8894b09,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022115_Lamotrigine_Statistical_BPCA.pdf,
2009,LAMICTAL XR,LAMOTRIGINE,NDA022115,3e2c9a35-6a39-41d7-ad84-3c0bb8894b09,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022115s000_SumR.pdf,
2009,LAMICTAL XR,LAMOTRIGINE,NDA022115,3e2c9a35-6a39-41d7-ad84-3c0bb8894b09,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/022115Orig1s006.pdf,
2009,LAMICTAL XR,LAMOTRIGINE,NDA022115,3e2c9a35-6a39-41d7-ad84-3c0bb8894b09,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22115s006_ lamotrigine_clinical_prea.pdf,
2009,LAMICTAL XR,LAMOTRIGINE,NDA022115,3e2c9a35-6a39-41d7-ad84-3c0bb8894b09,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22115s006_ lamotrigine_ clinpharm_ prea.pdf,
2009,LAMICTAL XR,LAMOTRIGINE,NDA022115,3e2c9a35-6a39-41d7-ad84-3c0bb8894b09,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22115s006_ lamotrigine_ statistical_ prea.pdf,
2011,COMBIVENT RESPIMAT,IPRATROPIUM BROMIDE AND ALBUTEROL,NDA021747,9832312e-0310-4ab6-8501-afa976fc7eb2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021747_combivent_toc.cfm,
2011,COMBIVENT RESPIMAT,IPRATROPIUM BROMIDE AND ALBUTEROL,NDA021747,9832312e-0310-4ab6-8501-afa976fc7eb2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021747Orig1s000SumR.pdf,
1959,MEDROXYPROGESTERONE ACETATE,MEDROXYPROGESTERONE ACETATE,NDA011839,2627eb11-06bf-4a45-9172-094468e3ca07,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/11839-S068_Provera.pdf,
2013,BUDESONIDE,BUDESONIDE,NDA203634,a12b2e99-c8b3-4d08-9af0-8c4a4376ebf1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203634_uceris_toc.cfm,
2013,BUDESONIDE,BUDESONIDE,NDA203634,a12b2e99-c8b3-4d08-9af0-8c4a4376ebf1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203634Orig1s000SumR.pdf,
2014,N/A,N/A,BLA125431,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125431Orig1s000TOC.cfm,
2014,N/A,N/A,BLA125431,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125431Orig1s000SumR.pdf,
2015,STIOLTO RESPIMAT,TIOTROPIUM BROMIDE AND OLODATEROL,NDA206756,01e15aee-40e0-23f3-537f-c96dd63e2cb1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206756Orig1s000TOC.cfm,
2015,N/A,N/A,NDA207925,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207925Orig1s000SumR.pdf,
2015,N/A,N/A,NDA207925,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207925Orig1s000TOC.cfm,
2019,ZINC SULFATE,ZINC SULFATE,NDA209377,4b528c88-07a0-4dce-84c6-ccd32555bbff,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209377Orig1s000TOC.cfm,
2021,WELIREG,BELZUTIFAN,NDA215383,13e15ee0-d679-4fa9-9430-e2e2170474da,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215383Orig1s000TOC.cfm,
2023,TRIKAFTA,"ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR",NDA217660,f354423a-85c2-41c3-a9db-0f3aee135d8d,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217660Orig1s000TOC.cfm,
2010,DULERA,MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE,NDA022518,8f399784-f257-4f31-b3dc-368bf2a1864d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22518 mometasone clinical prea.pdf,
2010,DULERA,MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE,NDA022518,8f399784-f257-4f31-b3dc-368bf2a1864d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022518_dulera_toc.cfm,
2010,DULERA,MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE,NDA022518,8f399784-f257-4f31-b3dc-368bf2a1864d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22518s000_mometasone_statistical_PREA.pdf,
2010,DULERA,MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE,NDA022518,8f399784-f257-4f31-b3dc-368bf2a1864d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22518s000_mometasone_clinpharm_PREA.pdf,
2010,DULERA,MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE,NDA022518,8f399784-f257-4f31-b3dc-368bf2a1864d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22518s000_mometasone_clinical_PREA.pdf,
2010,DULERA,MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE,NDA022518,8f399784-f257-4f31-b3dc-368bf2a1864d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22518s000_mometasone_statistical_PREA.pdf,
2010,DULERA,MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE,NDA022518,8f399784-f257-4f31-b3dc-368bf2a1864d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022518Orig1s000SumR.pdf,
2025,PENPULIMAB KCQX,PENPULIMAB,BLA761258,830004e8-31af-4cc6-ab16-e870cab1c5ca,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761258Orig1s000TOC.cfm,
2005,ASMANEX,MOMETASONE FUROATE,NDA021067,10b36fb2-6b0d-4f20-b197-3564d6f594b9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021067s000_AsmanexTOC.cfm,
2005,ASMANEX,MOMETASONE FUROATE,NDA021067,10b36fb2-6b0d-4f20-b197-3564d6f594b9,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021067s003_Mometasone_Clinical_PREA.pdf,
2005,ASMANEX,MOMETASONE FUROATE,NDA021067,10b36fb2-6b0d-4f20-b197-3564d6f594b9,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021067s003_Mometasone_Clinpharm_PREA.pdf,
2005,ASMANEX,MOMETASONE FUROATE,NDA021067,10b36fb2-6b0d-4f20-b197-3564d6f594b9,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021067s003_Mometasone_Statistical_PREA.pdf,
2005,ASMANEX,MOMETASONE FUROATE,NDA021067,10b36fb2-6b0d-4f20-b197-3564d6f594b9,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021067s003_Mometasone_Statistical2_PREA.pdf,
2005,ADVIL PM,"DIPHENHYDRAMINE HCL, IBUPROFEN",NDA021393,405afdb4-c157-1d88-f232-848063ba4714,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021393,021394_AdvilTOC.cfm",
2007,N/A,N/A,NDA022116,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022116_lexiva_toc.cfm,
2005,METFORMIN HYDROCHLORIDE,METFORMIN HYDROCHLORIDE,NDA021748,74d32a8a-c4c2-4dbb-b376-eea3f8fa64d7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021748s000_GlumetzaTOC.cfm,
1980,PITOCIN,OXYTOCIN,NDA018261,6e5a66fc-e507-497c-b5ce-44a8c95898ad,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/018261_s023_PITOCIN_LBL.pdf,
1980,PITOCIN,OXYTOCIN,NDA018261,6e5a66fc-e507-497c-b5ce-44a8c95898ad,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/018261_s021_PITOCIN_LBL.pdf,
1980,PITOCIN,OXYTOCIN,NDA018261,6e5a66fc-e507-497c-b5ce-44a8c95898ad,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/18261-s011_pitocin.pdf,
2013,SIMPONI ARIA,GOLIMUMAB,BLA125433,9e260a47-55af-4c92-8d88-a86ccc767fff,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125433review.pdf,
2013,SIMPONI ARIA,GOLIMUMAB,BLA125433,9e260a47-55af-4c92-8d88-a86ccc767fff,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125433Orig1s14.pdf,
2014,REYATAZ,ATAZANAVIR,NDA206352,165cff62-b284-4a27-a65d-9ec8a5bfcdd8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206352Orig1s000_021567Orig1s035TOC.cfm,
2014,REYATAZ,ATAZANAVIR,NDA206352,165cff62-b284-4a27-a65d-9ec8a5bfcdd8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206352Orig1s000_021567Orig1s035SumR.pdf,
1985,BETAXOLOL HYDROCHLORIDE,BETAXOLOL HYDROCHLORIDE,NDA019270,a73519d5-546c-4377-92ed-0d4be2685d60,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019270Orig1s000rev.pdf,
1986,N/A,N/A,NDA019353,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019353Orig1s000rev.pdf,
2018,BELRAPZO,BENDAMUSTINE HYDROCHLORIDE,NDA205580,9759a4ae-82ca-40cf-9c02-e1cadb21cbdc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/205580Orig1s000TOC.cfm,
2015,PHENYLEPHRINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE,NDA207926,cacbb3fd-1c03-4523-a1bf-0ccc4be102ef,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207926Orig1s000TOC.cfm,
2019,SELENIOUS ACID,SELENIOUS ACID,NDA209379,49324999-50e3-43ed-a8dd-156d6dbedd9f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209379Orig1s000TOC.cfm,
2019,VYNDAMAX,TAFAMIDIS,NDA212161,1b4121ee-a733-4456-a917-be2603477839,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211996Orig1s000, 212161Orig1s000TOC.cfm",
2021,VOCABRIA,CABOTEGRAVIR SODIUM,NDA212887,66d450fb-cca4-476c-b0c7-c0730e3e4cf3,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212887Orig1s000,212888Orig1s000TOC.cfm",
1995,HYZAAR,LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE,NDA020387,4116ccde-2e23-45f4-b12f-6337df877744,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20-387S010_Hyzaar.pdf,
1995,HYZAAR,LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE,NDA020387,4116ccde-2e23-45f4-b12f-6337df877744,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20-387S006_Hyzaar.pdf,
1995,HYZAAR,LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE,NDA020387,4116ccde-2e23-45f4-b12f-6337df877744,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020387_s037_hyzaar.pdf,
1995,HYZAAR,LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE,NDA020387,4116ccde-2e23-45f4-b12f-6337df877744,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/20-387S013S015S027Hyzaar.cfm,
1995,HYZAAR,LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE,NDA020387,4116ccde-2e23-45f4-b12f-6337df877744,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20386-s020_cozaar.pdf,
1995,HYZAAR,LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE,NDA020387,4116ccde-2e23-45f4-b12f-6337df877744,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/20-387S013S015S027Hyzaar.cfm,
1995,HYZAAR,LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE,NDA020387,4116ccde-2e23-45f4-b12f-6337df877744,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/20-387S013S015S027Hyzaar.cfm,
1995,HYZAAR,LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE,NDA020387,4116ccde-2e23-45f4-b12f-6337df877744,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20387s011_Hyzaar.pdf,
1995,HYZAAR,LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE,NDA020387,4116ccde-2e23-45f4-b12f-6337df877744,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020386ap.pdf,
1995,HYZAAR,LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE,NDA020387,4116ccde-2e23-45f4-b12f-6337df877744,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20-387S003_Hyzaar.pdf,
1995,HYZAAR,LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE,NDA020387,4116ccde-2e23-45f4-b12f-6337df877744,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20386-s018_cozaar.pdf,
1995,HYZAAR,LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE,NDA020387,4116ccde-2e23-45f4-b12f-6337df877744,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20387S012_Hyzaar.pdf,
1995,HYZAAR,LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE,NDA020387,4116ccde-2e23-45f4-b12f-6337df877744,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20-387S008_Hyzaar.pdf,
2023,PAXLOVID,NIRMATRELVIR AND RITONAVIR,NDA217188,8a99d6d6-fd9e-45bb-b1bf-48c7f761232a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217188Orig1s000TOC.cfm,
2022,XENPOZYME,OLIPUDASE ALFA-RPCP,BLA761261,01a910ee-a33e-4be3-ac41-322d64c34311,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761261Orig1s000TOC.cfm,
1998,CALCITRIOL,CALCITRIOL,NDA021068,66a69351-5b09-4368-a9fa-acf81b5ad882,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/021068.cfm,
2005,"ADVIL PM- DIPHENHYDRAMINE CITRATE AND IBUPROFEN TABLET, COATED",ADVIL PM,NDA021394,d1138e15-8ae4-7b49-e053-2995a90a9607,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021393,021394_AdvilTOC.cfm",
2004,PENTETATE CALCIUM TRISODIUM,PENTETATE CALCIUM TRISODIUM,NDA021749,bc563e90-10e5-475d-aa84-b0e3d582ae95,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-749_21-751_Pentetate.cfm,
1985,PRIMAXIN IV,IMIPENEM AND CILASTATIN SODIUM,NDA050587,f41d8abd-7792-4918-1b93-bd83ea01955e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/050587_S054_PRIMAXIN I.V..pdf,
1985,PRIMAXIN IV,IMIPENEM AND CILASTATIN SODIUM,NDA050587,f41d8abd-7792-4918-1b93-bd83ea01955e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/050587_S046_PRIMAXIN.pdf,
1985,PRIMAXIN IV,IMIPENEM AND CILASTATIN SODIUM,NDA050587,f41d8abd-7792-4918-1b93-bd83ea01955e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/050587_S052_PRIMAXIN I.V..pdf,
1985,PRIMAXIN IV,IMIPENEM AND CILASTATIN SODIUM,NDA050587,f41d8abd-7792-4918-1b93-bd83ea01955e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/050587_S059_PRIMAXIN.pdf,
1985,PRIMAXIN IV,IMIPENEM AND CILASTATIN SODIUM,NDA050587,f41d8abd-7792-4918-1b93-bd83ea01955e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/050587_S055_PRIMAXIN I.V.pdf,
1985,PRIMAXIN IV,IMIPENEM AND CILASTATIN SODIUM,NDA050587,f41d8abd-7792-4918-1b93-bd83ea01955e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/050587_S061_PRIMAXIN.pdf,
1985,PRIMAXIN IV,IMIPENEM AND CILASTATIN SODIUM,NDA050587,f41d8abd-7792-4918-1b93-bd83ea01955e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/050587_S039_PRIMAXIN.pdf,
1985,PRIMAXIN IV,IMIPENEM AND CILASTATIN SODIUM,NDA050587,f41d8abd-7792-4918-1b93-bd83ea01955e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/050587_S045_PRIMAXIN.pdf,
1985,PRIMAXIN IV,IMIPENEM AND CILASTATIN SODIUM,NDA050587,f41d8abd-7792-4918-1b93-bd83ea01955e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/050587_S041_PRIMAXIN.pdf,
1985,PRIMAXIN IV,IMIPENEM AND CILASTATIN SODIUM,NDA050587,f41d8abd-7792-4918-1b93-bd83ea01955e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/050587Orig1s000rev.pdf,
1985,PRIMAXIN IV,IMIPENEM AND CILASTATIN SODIUM,NDA050587,f41d8abd-7792-4918-1b93-bd83ea01955e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/050587_S058_PRIMAXIN.pdf,
2014,ENTYVIO,VEDOLIZUMAB,BLA125476,6e94621c-1a95-4af9-98d1-52b9e6f1949c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125476Orig1s000TOC.cfm,
2014,ENTYVIO,VEDOLIZUMAB,BLA125476,6e94621c-1a95-4af9-98d1-52b9e6f1949c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125476Orig1s000SumR.pdf,
2014,N/A,N/A,NDA204768,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204768Orig1s000SumR.pdf,
2014,N/A,N/A,NDA204768,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204768Orig1s000TOC.cfm,
2019,FOSAPREPITANT,FOSAPREPITANT,NDA210064,9dbd4c29-d894-4839-9b22-a2f65c8c8ad1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210064Orig1s000TOC.cfm,
2022,TADLIQ,TADALAFIL,NDA214522,7a909b25-3772-403e-a5fe-e4a040293fb7,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/214522Orig1s000TOC.cfm,
1997,EVISTA,RALOXIFENE HYDROCHLORIDE,NDA020815,fcaaa6dc-74e8-4fb8-800c-5574bf0f8de9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20815s2_Evista.pdf,
1997,EVISTA,RALOXIFENE HYDROCHLORIDE,NDA020815,fcaaa6dc-74e8-4fb8-800c-5574bf0f8de9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020815_evista_toc.cfm,
1997,EVISTA,RALOXIFENE HYDROCHLORIDE,NDA020815,fcaaa6dc-74e8-4fb8-800c-5574bf0f8de9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20815S3_Evista.cfm,
2023,N/A,N/A,NDA214952,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/214952Orig1s000TOC.cfm,
2023,LITFULO,RITLECITINIB,NDA215830,6b2f9446-fb23-4741-b73a-5a2f993733c3,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215830Orig1s000TOC.cfm,
2010,NAMENDA XR,MEMANTINE HYDROCHLORIDE,NDA022525,710f523f-0158-4639-8ce7-57598247d48c,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022525Orig1s000_Memantine_Clinical.pdf,
2010,NAMENDA XR,MEMANTINE HYDROCHLORIDE,NDA022525,710f523f-0158-4639-8ce7-57598247d48c,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022525Orig1s000_Memantine_Clinpharm.pdf,
2010,NAMENDA XR,MEMANTINE HYDROCHLORIDE,NDA022525,710f523f-0158-4639-8ce7-57598247d48c,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022525Orig1s000_Memantine_Statistical.pdf,
2010,NAMENDA XR,MEMANTINE HYDROCHLORIDE,NDA022525,710f523f-0158-4639-8ce7-57598247d48c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022525s000_namenda_xr_toc.cfm,
2010,NAMENDA XR,MEMANTINE HYDROCHLORIDE,NDA022525,710f523f-0158-4639-8ce7-57598247d48c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022525Orig1s000SumR.pdf,
2023,LEQEMBI,LECANEMAB,BLA761269,9d1ff786-e577-410a-a273-c4d7d0e4e975,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761269Orig1s001.pdf,
2023,LEQEMBI,LECANEMAB,BLA761269,9d1ff786-e577-410a-a273-c4d7d0e4e975,https://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2023/761269Orig1s000SumR.pdf,
2023,LEQEMBI,LECANEMAB,BLA761269,9d1ff786-e577-410a-a273-c4d7d0e4e975,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761269Orig1s000TOC.cfm,
1999,ACTOS,PIOGLITAZONE,NDA021073,d2ddc491-88a9-4063-9150-443b4fa4330c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/021073_S008_ACTOS TABLETS.pdf,
1999,ACTOS,PIOGLITAZONE,NDA021073,d2ddc491-88a9-4063-9150-443b4fa4330c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/021073_S006_ACTOS.pdf,
1999,ACTOS,PIOGLITAZONE,NDA021073,d2ddc491-88a9-4063-9150-443b4fa4330c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/021073_S004_ACTOS.pdf,
1999,ACTOS,PIOGLITAZONE,NDA021073,d2ddc491-88a9-4063-9150-443b4fa4330c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/021073_S002_ACTOS.pdf,
1999,ACTOS,PIOGLITAZONE,NDA021073,d2ddc491-88a9-4063-9150-443b4fa4330c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021073_s023_ACTOS TABS.pdf,
1999,ACTOS,PIOGLITAZONE,NDA021073,d2ddc491-88a9-4063-9150-443b4fa4330c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021073_S015_ACTOS_TABLETS.pdf,
1999,ACTOS,PIOGLITAZONE,NDA021073,d2ddc491-88a9-4063-9150-443b4fa4330c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021073_S013_ACTOS_TABLETS.pdf,
1999,ACTOS,PIOGLITAZONE,NDA021073,d2ddc491-88a9-4063-9150-443b4fa4330c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/021073_S007_ACTOS.pdf,
1999,ACTOS,PIOGLITAZONE,NDA021073,d2ddc491-88a9-4063-9150-443b4fa4330c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/021073_S005_ACTOS.pdf,
1999,ACTOS,PIOGLITAZONE,NDA021073,d2ddc491-88a9-4063-9150-443b4fa4330c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/021073_S003_ACTOS.pdf,
1999,ACTOS,PIOGLITAZONE,NDA021073,d2ddc491-88a9-4063-9150-443b4fa4330c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/021073_S001_ACTOS.pdf,
1999,ACTOS,PIOGLITAZONE,NDA021073,d2ddc491-88a9-4063-9150-443b4fa4330c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021073_s024_ACTOS TABS.pdf,
1999,ACTOS,PIOGLITAZONE,NDA021073,d2ddc491-88a9-4063-9150-443b4fa4330c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021073_S016_ACTOS.pdf,
1999,ACTOS,PIOGLITAZONE,NDA021073,d2ddc491-88a9-4063-9150-443b4fa4330c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/021073_S014_ACTOS.pdf,
1999,ACTOS,PIOGLITAZONE,NDA021073,d2ddc491-88a9-4063-9150-443b4fa4330c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/021073A_Actos.cfm,
1999,ACTOS,PIOGLITAZONE,NDA021073,d2ddc491-88a9-4063-9150-443b4fa4330c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021073_S020_ACTOS TABLETS_AP.pdf,
1999,ACTOS,PIOGLITAZONE,NDA021073,d2ddc491-88a9-4063-9150-443b4fa4330c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/021073_S012_ACTOS TABLETS.pdf,
1999,ACTOS,PIOGLITAZONE,NDA021073,d2ddc491-88a9-4063-9150-443b4fa4330c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021073_S010_Actos Tablets_APPROVAL PACKAGE.pdf,
2007,BRIMONIDINE TARTRATE AND TIMOLOL MALEATE,"BRIMONIDINE TARTRATE, TIMOLOL MALEATE",NDA021398,8b13bd5a-b65f-4e39-83f1-8d3abe97d4c0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021398s000TOC.cfm,
2007,BRIMONIDINE TARTRATE AND TIMOLOL MALEATE,"BRIMONIDINE TARTRATE, TIMOLOL MALEATE",NDA021398,8b13bd5a-b65f-4e39-83f1-8d3abe97d4c0,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021398s000_Brimonidine-timolol_clinical_PREA.pdf,
2007,BRIMONIDINE TARTRATE AND TIMOLOL MALEATE,"BRIMONIDINE TARTRATE, TIMOLOL MALEATE",NDA021398,8b13bd5a-b65f-4e39-83f1-8d3abe97d4c0,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021398s000_Brimonidine-timolol_clinpharm_PREA.pdf,
2007,BRIMONIDINE TARTRATE AND TIMOLOL MALEATE,"BRIMONIDINE TARTRATE, TIMOLOL MALEATE",NDA021398,8b13bd5a-b65f-4e39-83f1-8d3abe97d4c0,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021398s000_Brimonidine-timolol_statistical_PREA.pdf,
2007,BRIMONIDINE TARTRATE AND TIMOLOL MALEATE,"BRIMONIDINE TARTRATE, TIMOLOL MALEATE",NDA021398,8b13bd5a-b65f-4e39-83f1-8d3abe97d4c0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021398s000_SumR.pdf,
1979,LITHOBID,LITHIUM CARBONATE,NDA018027,f7f5b69a-c2a1-4586-a189-1475d41387c0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/018027_s055_lithobid_LBL.pdf,
2014,TRULICITY,DULAGLUTIDE,BLA125469,463050bd-2b1c-40f5-b3c3-0a04bb433309,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125469Orig1s000SumR.pdf,
2014,TRULICITY,DULAGLUTIDE,BLA125469,463050bd-2b1c-40f5-b3c3-0a04bb433309,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125469Orig1s000TOC.cfm,
2017,N/A,N/A,NDA201656,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2017/201656Orig1s000SumR.pdf,
2017,N/A,N/A,NDA201656,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/201656Orig1s000TOC.cfm,
2014,N/A,N/A,NDA205583,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205583Orig1s000SumR.pdf,
2014,N/A,N/A,NDA205583,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205583Orig1s000TOC.cfm,
2015,N/A,N/A,NDA207931,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207931Orig1s000TOC.cfm,
2022,TPOXX,TECOVIRIMAT MONOHYDRATE,NDA214518,fce826ab-4d6a-4139-a2ee-a304a913a253,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214518Orig1s000TOC.cfm,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020164_S057_LOVENOX INJECION_AP.pdf,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20164S10_lovenox.cfm,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020164_S055_Lovenox_Approval_Package.pdf,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020164_S039_LOVENOX_INJECTION.pdf,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020164_S040&045&046_LOVENOX INJ.pdf,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020164_S051_LOVENOX INJ.pdf,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020164_S043_LOVENOX_INJECTION.pdf,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020164_S004_LOVENOX_INJECTION.pdf,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020164_S041_LOVENOX_INJECTION.pdf,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020164_S019_LOVENOX.pdf,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020164_S023_LOVENOX_INJECTION.pdf,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20164S15_Lovenox.cfm,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020164_S021_LOVENOX.pdf,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020164_S013_LOVENOX_INJECTION.pdf,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020164_S058_LOVENOX INJECTION_AP.pdf,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020164_S011_LOVENOX.pdf,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020164_S056_LOVENOX INJ.pdf,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020164_S009_LOVENOX INJ.pdf,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020164_S040&045&046_LOVENOX INJ.pdf,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020164_S038_LOVENOX_INJECTION.pdf,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020164_S044_LOVENOX INJ.pdf,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020164_S005_LOVENOX INJ.pdf,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020164_S050_LOVENOX INJ.pdf,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020164_S042_LOVENOX_INJECTION.pdf,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020164_S026_LOVENOX.pdf,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020164_S040&045&046_LOVENOX INJ.pdf,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020164_S032_LOVENOX_INJECTION.pdf,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020164_S024_LOVENOX.pdf,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020164_S030_LOVENOX_INJECTION.pdf,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020164_S022_LOVENOX.pdf,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022138_020164_lovenox_enoxaparin_sodium_toc.cfm,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20-164_review.pdf,
1993,ENOXAPARIN SODIUM,ENOXAPARIN SODIUM,NDA020164,20635579-c92d-4f6c-a332-1096d51002f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020164_S012_LOVENOX_INJECTION.pdf,
2021,CABENUVA,CABOTEGRAVIR AND RILPIVIRINE,NDA212888,1698baf3-f895-4c42-a1b1-e9ee3f20da36,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212887Orig1s000,212888Orig1s000TOC.cfm",
2011,DALIRESP,ROFLUMILAST,NDA022522,c9a1d0a8-581f-4f91-a2b8-f419192d0ebf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022522Orig1s000TOC.cfm,
2011,DALIRESP,ROFLUMILAST,NDA022522,c9a1d0a8-581f-4f91-a2b8-f419192d0ebf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022522Orig1s000SumR.pdf,
2022,LUNSUMIO,MOSUNETUZUMAB,BLA761263,2ef0cf38-101c-4681-98fe-c05dc9ead443,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761263Orig1s000TOC.cfm,
1943,HYCODAN,HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE,NDA005213,901d4115-f71a-4681-bd0e-c9b691151b78,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/005213Orig1s023.pdf,
2007,N/A,N/A,NDA022118,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022118_fenofibrate_toc.cfm,
2004,PENTETATE ZINC TRISODIUM,PENTETATE ZINC TRISODIUM,NDA021751,366e7ca9-4fd3-4688-bd83-1f369885e0fc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-751_21-749_Pentetate.cfm,
1979,N/A,N/A,NDA017862,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/017862Orig1s063.pdf,
1979,N/A,N/A,NDA017862,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/017862Orig1s061.pdf,
1979,N/A,N/A,NDA017862,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/18821-S018_Reglan.pdf,
1983,N/A,N/A,NDA018986,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/1983-018986ap.pdf,
2012,LOTEMAX,LOTEPREDNOL ETABONATE,NDA202872,9a666065-d467-42b8-8ecd-0ec1de9986d5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/307_202872S002-loteprednol-etabonate-DD-clinical-prea.pdf,
2012,LOTEMAX,LOTEPREDNOL ETABONATE,NDA202872,9a666065-d467-42b8-8ecd-0ec1de9986d5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/308_202872S002-loteprednol-etabonate-clinical-prea.pdf,
2012,LOTEMAX,LOTEPREDNOL ETABONATE,NDA202872,9a666065-d467-42b8-8ecd-0ec1de9986d5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/309_202872S002-loteprednol-etabonate-statistical-prea.pdf,
2012,LOTEMAX,LOTEPREDNOL ETABONATE,NDA202872,9a666065-d467-42b8-8ecd-0ec1de9986d5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202872Orig1s000SumR.pdf,
2012,LOTEMAX,LOTEPREDNOL ETABONATE,NDA202872,9a666065-d467-42b8-8ecd-0ec1de9986d5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202872_lotemax_toc.cfm,
2016,ORFADIN,NITISINONE,NDA206356,00307f42-748d-4227-8c6f-ed5f0a89ae0a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206356Orig1_toc.cfm,
2016,ORFADIN,NITISINONE,NDA206356,00307f42-748d-4227-8c6f-ed5f0a89ae0a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206356Orig1s000SumR.pdf,
2014,VOGELXO,TESTOSTERONE,NDA204399,2dd150f6-cdfd-4d51-8888-12b288f26262,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204399Orig1s000SumRedt.pdf,
2014,VOGELXO,TESTOSTERONE,NDA204399,2dd150f6-cdfd-4d51-8888-12b288f26262,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204399Orig1s000TOC.cfm,
2019,N/A,N/A,NDA210063,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210063Orig1s000TOC.cfm,
2018,3M SOLUPREP S,CHLORHEXIDINE GLUCONATE AND ISOPROPYL ALCOHOL,NDA208288,084aa305-5863-441a-a94d-36bc1b05195a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208288Orig1s000TOC.cfm,
2015,BELBUCA,BUPRENORPHINE HYDROCHLORIDE,NDA207932,bc2b7a3d-72cf-497c-95b0-ba2b71f63c64,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207932Orig1s000TOC.cfm,
2020,OXLUMO,LUMASIRAN,NDA214103,16985a31-f5e4-4557-9266-fc78d4bc5055,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214103Orig1s000TOC.cfm,
2023,DEFENCATH,TAUROLIDINE AND HEPARIN,NDA214520,13b3a61e-5a4b-4afb-8fa1-d76ebdb344d6,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/214520Orig1s000TOC.cfm,
1999,ACCURETIC,QUINAPRIL AND HYDROCHLOROTHIAZIDE,NDA020125,80e9d61d-9674-4ac4-b84c-79a875d408dd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20125_Accuretic.cfm,
2022,N/A,N/A,NDA216285,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216285Orig1s000TOC.cfm,
2010,PANCREAZE,"PANCRELIPASE LIPASE, PANCRELIPASE AMYLASE, AND PANCRELIPASE PROTEASE",BLA022523,e8f5d2fe-728d-42af-99a6-83dddc6539c5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/N22523S004-Pancrelipase-Clinical-PREA.pdf,
2010,PANCREAZE,"PANCRELIPASE LIPASE, PANCRELIPASE AMYLASE, AND PANCRELIPASE PROTEASE",BLA022523,e8f5d2fe-728d-42af-99a6-83dddc6539c5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022523_pancreaze_toc.cfm,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2010,PANCREAZE,"PANCRELIPASE LIPASE, PANCRELIPASE AMYLASE, AND PANCRELIPASE PROTEASE",BLA022523,e8f5d2fe-728d-42af-99a6-83dddc6539c5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22523 pancrelipase clinical prea.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2010,PANCREAZE,"PANCRELIPASE LIPASE, PANCRELIPASE AMYLASE, AND PANCRELIPASE PROTEASE",BLA022523,e8f5d2fe-728d-42af-99a6-83dddc6539c5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022523_pancreaze_statistical_PREA.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2010,PANCREAZE,"PANCRELIPASE LIPASE, PANCRELIPASE AMYLASE, AND PANCRELIPASE PROTEASE",BLA022523,e8f5d2fe-728d-42af-99a6-83dddc6539c5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022523_Pancreaze_Clinical_PREA_Pediatric-Review.pdf,
2010,PANCREAZE,"PANCRELIPASE LIPASE, PANCRELIPASE AMYLASE, AND PANCRELIPASE PROTEASE",BLA022523,e8f5d2fe-728d-42af-99a6-83dddc6539c5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022523_Pancreaze_ClinPharm_PREA_Pediatric_Review.pdf,
2010,PANCREAZE,"PANCRELIPASE LIPASE, PANCRELIPASE AMYLASE, AND PANCRELIPASE PROTEASE",BLA022523,e8f5d2fe-728d-42af-99a6-83dddc6539c5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022523_Pancreaze_Statistical_PREA_Pediatric_Review.pdf,
2010,PANCREAZE,"PANCRELIPASE LIPASE, PANCRELIPASE AMYLASE, AND PANCRELIPASE PROTEASE",BLA022523,e8f5d2fe-728d-42af-99a6-83dddc6539c5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022523Orig1s000SumR.pdf,
2022,VEGZELMA,BEVACIZUMAB-ADCD,BLA761268,4cdcccda-7b9a-49d0-ac50-f4605a3c0ebe,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761268Orig1s000TOC.cfm,
2007,AMMONIA N 13,NH3N13,NDA022119,c857724f-b172-4844-ad42-6fa4c42b0405,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022119Orig1s001.pdf,
2007,AMMONIA N 13,NH3N13,NDA022119,c857724f-b172-4844-ad42-6fa4c42b0405,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/22119s000TOC.cfm,
2004,TRUVADA,EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE,NDA021752,54e82b13-a037-49ed-b4b3-030b37c0ecdd,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21752 emtricitabine tenofovir disproxil fumarate clinical prea.pdf,
2004,TRUVADA,EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE,NDA021752,54e82b13-a037-49ed-b4b3-030b37c0ecdd,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21752 emtricitabine tenofovir disproxil fumarate clinpharm prea.pdf,
2004,TRUVADA,EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE,NDA021752,54e82b13-a037-49ed-b4b3-030b37c0ecdd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021752s000_TruvadaTOC.cfm,
2004,TRUVADA,EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE,NDA021752,54e82b13-a037-49ed-b4b3-030b37c0ecdd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021752_S002_TRUVADA.pdf,
2004,TRUVADA,EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE,NDA021752,54e82b13-a037-49ed-b4b3-030b37c0ecdd,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/21752Orig1s060.pdf,
2004,TRUVADA,EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE,NDA021752,54e82b13-a037-49ed-b4b3-030b37c0ecdd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021752Orig1s030SumR.pdf,
2004,TRUVADA,EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE,NDA021752,54e82b13-a037-49ed-b4b3-030b37c0ecdd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021752_truvada_toc.cfm,
2013,ACTEMRA,TOCILIZUMAB,BLA125472,2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/125472Orig1s044.pdf,
2013,ACTEMRA,TOCILIZUMAB,BLA125472,2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125472Orig1s018.pdf,
2013,ACTEMRA,TOCILIZUMAB,BLA125472,2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125472Orig1s000TOC.cfm,
2013,ACTEMRA,TOCILIZUMAB,BLA125472,2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125472Orig1s000SumR.pdf,
2014,N/A,N/A,NDA201657,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/201657Orig1s000TOC.cfm,
2015,ACETAMINOPHEN,ACETAMINOPHEN,NDA204767,a0cece43-256e-4adc-92f8-11a0f473bb83,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204767Orig1s000TOC.cfm,
2016,AKOVAZ,EPHEDRINE SULFATE,NDA208289,e92f3eda-33eb-4b34-9e8b-db8d32a5dbd9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208289Orig1s000SumR.pdf,
2016,AKOVAZ,EPHEDRINE SULFATE,NDA208289,e92f3eda-33eb-4b34-9e8b-db8d32a5dbd9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208289Orig1s000TOC.cfm,
2016,AKOVAZ,EPHEDRINE SULFATE,NDA208289,e92f3eda-33eb-4b34-9e8b-db8d32a5dbd9,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/208289Orig1s006.pdf,
2017,NIPRIDE RTU,SODIUM NITROPRUSSIDE,NDA209387,5acf0836-93ff-4064-b888-3f560e8a558d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209387Orig1s000TOC.cfm,
2022,IGALMI,DEXMEDETOMIDINE,NDA215390,99476e8c-2527-4cb0-9d67-9f9cd91343c6,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215390Orig1s000TOC.cfm,
2022,IGALMI,DEXMEDETOMIDINE,NDA215390,99476e8c-2527-4cb0-9d67-9f9cd91343c6,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215390Orig1s000TOC.cfm,
2010,N/A,N/A,NDA022524,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022524_zuplenz_toc.cfm,
2010,N/A,N/A,NDA022524,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022524Orig1s000SumR.pdf,
1999,N/A,N/A,NDA021071,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021071_S004_AVANDIA.pdf,
1999,N/A,N/A,NDA021071,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021071s015_rosiglitazone_Avandia-MedRev.pdf,
1999,N/A,N/A,NDA021071,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21071s015-Rosiglitazone-Statisitical-BPCA.pdf,
1999,N/A,N/A,NDA021071,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/021071Orig1s048.pdf,
1999,N/A,N/A,NDA021071,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-071S001_Avandia.cfm,
1999,N/A,N/A,NDA021071,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21071_Avandia.cfm,
1999,N/A,N/A,NDA021071,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021071_s014_Avandia Tabs.pdf,
2007,VOLTAREN ARTHRITIS PAIN,DICLOFENAC SODIUM,NDA022122,30a94282-0892-442a-aa10-6525cbd4fe88,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/Voltaren_022122.cfm,
2007,VOLTAREN ARTHRITIS PAIN,DICLOFENAC SODIUM,NDA022122,30a94282-0892-442a-aa10-6525cbd4fe88,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022122_SumR.pdf,
2007,VOLTAREN ARTHRITIS PAIN,DICLOFENAC SODIUM,NDA022122,30a94282-0892-442a-aa10-6525cbd4fe88,http://www.accessdata.fda.gov/drugsatfda_docs/review/2018/022122Orig1s011.pdf,
2007,ADAPALENE,ADAPALENE,NDA021753,9a0d9a0d-a9f3-4eb9-be76-166ef182d13a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021753TOC.cfm,
1987,N/A,N/A,NDA050591,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50591S022_Bactroban.pdf,
2014,PLEGRIDY PEN,PEGINTERFERON BETA-1A,BLA125499,08f0ea03-4e6d-195d-aef4-886e32befa95,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125499Orig1s000TOC.cfm,
2014,PLEGRIDY PEN,PEGINTERFERON BETA-1A,BLA125499,08f0ea03-4e6d-195d-aef4-886e32befa95,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125499Orig1s000SumR.pdf,
2015,N/A,N/A,NDA204016,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204016Orig1s000TOC.cfm,
1995,CASODEX,BICALUTAMIDE,NDA020498,dfee4fe7-8478-4a3e-925d-00be3cd0ab67,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020498Orig1s000rev.pdf,
1995,CASODEX,BICALUTAMIDE,NDA020498,dfee4fe7-8478-4a3e-925d-00be3cd0ab67,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022310s000_Bicalutamide_ClinPharm_BPCA.pdf,
1995,CASODEX,BICALUTAMIDE,NDA020498,dfee4fe7-8478-4a3e-925d-00be3cd0ab67,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022310s000_Bicalutamide_Clinical_BPCA.pdf,
1995,CASODEX,BICALUTAMIDE,NDA020498,dfee4fe7-8478-4a3e-925d-00be3cd0ab67,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022310s000_Bicalutamide_Statistical_.pdf,
2018,XERAVA,ERAVACYCLINE,NDA211109,a4b188d4-f467-470c-ad7b-25ffbdd8862a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000TOC.cfm,
2019,IBSRELA,TENAPANOR HYDROCHLORIDE,NDA211801,2102da5f-a1a0-4ac7-a1f6-38698cf7273a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211801Orig1s003.pdf,
2019,IBSRELA,TENAPANOR HYDROCHLORIDE,NDA211801,2102da5f-a1a0-4ac7-a1f6-38698cf7273a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211801Orig1s000TOC.cfm,
2020,UPNEEQ,OXYMETAZOLINE HYDROCHLORIDE OPHTHALMIC,NDA212520,cf6c9a1f-2367-46d2-99c3-c7d67ec6f519,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212520Orig1s000TOC.cfm,
1995,PREMPRO,CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE,NDA020527,fd0c0836-5d23-2183-da81-9dc7f4287052,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020527_s024_prempro.pdf,
1995,PREMPRO,CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE,NDA020527,fd0c0836-5d23-2183-da81-9dc7f4287052,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20527se2006_prempro.cfm,
1995,PREMPRO,CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE,NDA020527,fd0c0836-5d23-2183-da81-9dc7f4287052,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20527S004_Prempro.pdf,
1995,PREMPRO,CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE,NDA020527,fd0c0836-5d23-2183-da81-9dc7f4287052,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020527s017_prempro_toc.cfm,
1995,PREMPRO,CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE,NDA020527,fd0c0836-5d23-2183-da81-9dc7f4287052,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020527_s031_prempro.pdf,
1995,PREMPRO,CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE,NDA020527,fd0c0836-5d23-2183-da81-9dc7f4287052,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20527S013_Prempro.pdf,
1995,PREMPRO,CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE,NDA020527,fd0c0836-5d23-2183-da81-9dc7f4287052,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/020527Orig1s046.pdf,
1995,PREMPRO,CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE,NDA020527,fd0c0836-5d23-2183-da81-9dc7f4287052,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020527_s026_prempro.pdf,
1995,FOSAMAX,ALENDRONATE SODIUM,NDA020560,14e931fd-2c5f-4d90-b7db-5980706f4a56,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020560S13_Fosamax.cfm,
1995,FOSAMAX,ALENDRONATE SODIUM,NDA020560,14e931fd-2c5f-4d90-b7db-5980706f4a56,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020560_s036_FOSAMAX_TABLETS.pdf,
1995,FOSAMAX,ALENDRONATE SODIUM,NDA020560,14e931fd-2c5f-4d90-b7db-5980706f4a56,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020560_s028_FOSAMAX TABS.pdf,
1995,FOSAMAX,ALENDRONATE SODIUM,NDA020560,14e931fd-2c5f-4d90-b7db-5980706f4a56,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020560_S042 & 021575_S003_FOSAMAX_TABS_ORAL_SOLUTION_AP.pdf,
1995,FOSAMAX,ALENDRONATE SODIUM,NDA020560,14e931fd-2c5f-4d90-b7db-5980706f4a56,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20560ap_s03_s06.pdf,
1995,FOSAMAX,ALENDRONATE SODIUM,NDA020560,14e931fd-2c5f-4d90-b7db-5980706f4a56,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20560S18_fosamax.cfm,
1995,FOSAMAX,ALENDRONATE SODIUM,NDA020560,14e931fd-2c5f-4d90-b7db-5980706f4a56,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020560_s032_FOSAMAX_TABLETS.pdf,
1995,FOSAMAX,ALENDRONATE SODIUM,NDA020560,14e931fd-2c5f-4d90-b7db-5980706f4a56,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020560_S016_FOSAMAX.pdf,
1995,FOSAMAX,ALENDRONATE SODIUM,NDA020560,14e931fd-2c5f-4d90-b7db-5980706f4a56,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020560_S014_FOSAMAX TABLETS.pdf,
1995,FOSAMAX,ALENDRONATE SODIUM,NDA020560,14e931fd-2c5f-4d90-b7db-5980706f4a56,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020560_alendronate - Fosamax NDA Medical Rev.pdf,
1995,FOSAMAX,ALENDRONATE SODIUM,NDA020560,14e931fd-2c5f-4d90-b7db-5980706f4a56,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020560_alendronate - Fosamax NDA Clin Pharm Rev.pdf,
1995,FOSAMAX,ALENDRONATE SODIUM,NDA020560,14e931fd-2c5f-4d90-b7db-5980706f4a56,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020560_alendronate - Fosamax NDA Stat Rev.pdf,
1995,FOSAMAX,ALENDRONATE SODIUM,NDA020560,14e931fd-2c5f-4d90-b7db-5980706f4a56,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020560Orig1s000rev.pdf,
1995,FOSAMAX,ALENDRONATE SODIUM,NDA020560,14e931fd-2c5f-4d90-b7db-5980706f4a56,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020560_S020_FOSAMAX.pdf,
1995,FOSAMAX,ALENDRONATE SODIUM,NDA020560,14e931fd-2c5f-4d90-b7db-5980706f4a56,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020560S12_Fosamax.cfm,
1995,FOSAMAX,ALENDRONATE SODIUM,NDA020560,14e931fd-2c5f-4d90-b7db-5980706f4a56,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020560_s037_FOSAMAX TABS.pdf,
1995,FOSAMAX,ALENDRONATE SODIUM,NDA020560,14e931fd-2c5f-4d90-b7db-5980706f4a56,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20560ap_s03_s06.pdf,
1995,FOSAMAX,ALENDRONATE SODIUM,NDA020560,14e931fd-2c5f-4d90-b7db-5980706f4a56,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020560_S029_FOSAMAX.pdf,
1995,FOSAMAX,ALENDRONATE SODIUM,NDA020560,14e931fd-2c5f-4d90-b7db-5980706f4a56,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020560_s041_FOSAMAX TABS.pdf,
1995,FOSAMAX,ALENDRONATE SODIUM,NDA020560,14e931fd-2c5f-4d90-b7db-5980706f4a56,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020560_S019_FOSAMAX_TABLETS.pdf,
1995,FOSAMAX,ALENDRONATE SODIUM,NDA020560,14e931fd-2c5f-4d90-b7db-5980706f4a56,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020560_s033_FOSAMAX TABS.pdf,
1995,FOSAMAX,ALENDRONATE SODIUM,NDA020560,14e931fd-2c5f-4d90-b7db-5980706f4a56,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020560_s031_FOSAMAX_TABLETS.pdf,
1995,FOSAMAX,ALENDRONATE SODIUM,NDA020560,14e931fd-2c5f-4d90-b7db-5980706f4a56,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20560S15_fosamax.cfm,
2024,CLOBETASOL PROPIONATE,CLOBETASOL PROPIONATE,NDA218158,7687c980-7006-4222-80b9-c32773772d3e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/218158Orig1s000TOC.cfm,
2011,DOCETAXEL,DOCETAXEL,NDA022534,c85b2c62-3c33-4cbc-8b79-d5e17851a1b4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022534_docefrez_toc.cfm,
2011,DOCETAXEL,DOCETAXEL,NDA022534,c85b2c62-3c33-4cbc-8b79-d5e17851a1b4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022534Orig1s000SumR.pdf,
2023,LAMZEDE,VELMANASE ALFA-TYCV,BLA761278,36d50a08-60bd-40eb-807c-778d69bf2d2e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761278Orig1s000TOC.cfm,
2000,MALARONE,ATOVAQUONE AND PROGUANIL HYDROCHLORIDE,NDA021078,fc22e8d8-3bfb-4f70-a599-dd81262a4887,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021078_s004_MalaroneTOC.cfm,
2000,MALARONE,ATOVAQUONE AND PROGUANIL HYDROCHLORIDE,NDA021078,fc22e8d8-3bfb-4f70-a599-dd81262a4887,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021078_s005_MalaroneTOC.cfm,
2000,MALARONE,ATOVAQUONE AND PROGUANIL HYDROCHLORIDE,NDA021078,fc22e8d8-3bfb-4f70-a599-dd81262a4887,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/021078_malarone.cfm,
2000,MALARONE,ATOVAQUONE AND PROGUANIL HYDROCHLORIDE,NDA021078,fc22e8d8-3bfb-4f70-a599-dd81262a4887,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021078_s003_MalaroneTOC.cfm,
2000,MALARONE,ATOVAQUONE AND PROGUANIL HYDROCHLORIDE,NDA021078,fc22e8d8-3bfb-4f70-a599-dd81262a4887,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021078_s001_MalaroneTOC.cfm,
2005,N/A,N/A,NDA021406,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021406s000TOC.cfm,
2010,LASTACAFT,ALCAFTADINE,NDA022134,17d37e8d-7825-424b-b6ca-0a85d0bf4694,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22134_alcaftadine_clinical_PREA.pdf,
2010,LASTACAFT,ALCAFTADINE,NDA022134,17d37e8d-7825-424b-b6ca-0a85d0bf4694,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22134_alcaftaine_clinpharm_PREA.pdf,
2010,LASTACAFT,ALCAFTADINE,NDA022134,17d37e8d-7825-424b-b6ca-0a85d0bf4694,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22134_alcaftadine_statistical_PREA.pdf,
2010,LASTACAFT,ALCAFTADINE,NDA022134,17d37e8d-7825-424b-b6ca-0a85d0bf4694,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022134s000TOC.cfm,
2010,LASTACAFT,ALCAFTADINE,NDA022134,17d37e8d-7825-424b-b6ca-0a85d0bf4694,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022134s000SumR.pdf,
2005,FOSAMAX PLUS D,ALENDRONATE SODIUM AND CHOLECALCIFEROL,NDA021762,10307e7e-9a84-4aa1-8c5c-4b209cffe4d1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021762s000_FosamaxTOC.cfm,
1960,KENALOG-10,TRIAMCINOLONE ACETONIDE,NDA012041,ec04ecbb-2896-3feb-85fd-a64aba93b289,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/012041Orig1s038.pdf,
2014,CYRAMZA,RAMUCIRUMAB,BLA125477,c6080942-dee6-423e-b688-1272c2ae90d4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125477Orig1s000TOC.cfm,
2014,CYRAMZA,RAMUCIRUMAB,BLA125477,c6080942-dee6-423e-b688-1272c2ae90d4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125477Orig1s000SumR.pdf,
2013,N/A,N/A,NDA202880,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202880Orig1s003SumR.pdf,
2013,N/A,N/A,NDA202880,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202880Orig1s000TOC.cfm,
2013,N/A,N/A,NDA202880,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202880Orig1s000SumR.pdf,
2016,BEVESPI AEROSPHERE,GLYCOPYRROLATE AND FORMOTEROL FUMARATE,NDA208294,ae02436e-9528-490e-a844-0c0f6f2843f9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208294Orig1s000TOC.cfm,
2020,GIMOTI,METOCLOPRAMIDE HYDROCHLORIDE,NDA209388,95269b1f-779c-4ca0-9f86-e74e677f9900,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/209388Orig1s000TOC.cfm,
1997,CIPRO,CIPROFLOXACIN,NDA020780,888dc7f9-ad9c-4c00-8d50-8ddfd9bd27c0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020780_S014_CIPRO.pdf,
1997,CIPRO,CIPROFLOXACIN,NDA020780,888dc7f9-ad9c-4c00-8d50-8ddfd9bd27c0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020780_S020_CIPRO.pdf,
1997,CIPRO,CIPROFLOXACIN,NDA020780,888dc7f9-ad9c-4c00-8d50-8ddfd9bd27c0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020780_S012_CIPRO.pdf,
1997,CIPRO,CIPROFLOXACIN,NDA020780,888dc7f9-ad9c-4c00-8d50-8ddfd9bd27c0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020780_S003_Cipro.pdf,
1997,CIPRO,CIPROFLOXACIN,NDA020780,888dc7f9-ad9c-4c00-8d50-8ddfd9bd27c0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020780_S001_Cipro.pdf,
1997,CIPRO,CIPROFLOXACIN,NDA020780,888dc7f9-ad9c-4c00-8d50-8ddfd9bd27c0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020780_S017_CIPRO.pdf,
1997,CIPRO,CIPROFLOXACIN,NDA020780,888dc7f9-ad9c-4c00-8d50-8ddfd9bd27c0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/19-537S038_Cipro.cfm,
1997,CIPRO,CIPROFLOXACIN,NDA020780,888dc7f9-ad9c-4c00-8d50-8ddfd9bd27c0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020780_S015_CIPRO.pdf,
1997,CIPRO,CIPROFLOXACIN,NDA020780,888dc7f9-ad9c-4c00-8d50-8ddfd9bd27c0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/019537s49_19847s27_19857s31_20780s13TOC.cfm,
1997,CIPRO,CIPROFLOXACIN,NDA020780,888dc7f9-ad9c-4c00-8d50-8ddfd9bd27c0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020780_S011_CIPRO.pdf,
1997,CIPRO,CIPROFLOXACIN,NDA020780,888dc7f9-ad9c-4c00-8d50-8ddfd9bd27c0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020780_S002_CIPRO.pdf,
1997,CIPRO,CIPROFLOXACIN,NDA020780,888dc7f9-ad9c-4c00-8d50-8ddfd9bd27c0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020780_S018_CIPRO.pdf,
2021,LANREOTIDE ACETATE,LANREOTIDE ACETATE,NDA215395,11da176a-99bc-4ada-8b3f-6bd2b37a6313,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215395Orig1s000TOC.cfm,
1998,MODAFINIL,MODAFINIL,NDA020717,9f3b0bd2-72a3-411f-aeec-b533373f1a97,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020717_S001_PROVIGIL_TABS_AP.pdf,
1998,MODAFINIL,MODAFINIL,NDA020717,9f3b0bd2-72a3-411f-aeec-b533373f1a97,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020717A_Provigil.cfm,
1998,MODAFINIL,MODAFINIL,NDA020717,9f3b0bd2-72a3-411f-aeec-b533373f1a97,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020717s21_modafinil_Provigil-MedRev.pdf,
1998,MODAFINIL,MODAFINIL,NDA020717,9f3b0bd2-72a3-411f-aeec-b533373f1a97,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020717s21_modafinil_Provigil-ClinPharmRev.pdf,
1998,MODAFINIL,MODAFINIL,NDA020717,9f3b0bd2-72a3-411f-aeec-b533373f1a97,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020717s021_modafinil_Provigil-statistical review.pdf,
1998,MODAFINIL,MODAFINIL,NDA020717,9f3b0bd2-72a3-411f-aeec-b533373f1a97,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020717_S006_PROVIGIL_TABS.pdf,
1998,MODAFINIL,MODAFINIL,NDA020717,9f3b0bd2-72a3-411f-aeec-b533373f1a97,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020717_S004_PROVIGIL_TABS_AP.pdf,
1998,MODAFINIL,MODAFINIL,NDA020717,9f3b0bd2-72a3-411f-aeec-b533373f1a97,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020717_S002_PROVIGIL_TABS_AP.pdf,
1998,MODAFINIL,MODAFINIL,NDA020717,9f3b0bd2-72a3-411f-aeec-b533373f1a97,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020717_S009_PROVIGIL_TABS.pdf,
1998,MODAFINIL,MODAFINIL,NDA020717,9f3b0bd2-72a3-411f-aeec-b533373f1a97,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020717_S003_PROVIGIL_TABS_AP.pdf,
2015,ADDYI,FLIBANSERIN,NDA022526,3819daf3-e935-2c53-c527-e1d57922f394,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/22526Orig1s009.pdf,
2015,ADDYI,FLIBANSERIN,NDA022526,3819daf3-e935-2c53-c527-e1d57922f394,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/22526Orig1s008.pdf,
2015,ADDYI,FLIBANSERIN,NDA022526,3819daf3-e935-2c53-c527-e1d57922f394,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000TOC.cfm,
2015,ADDYI,FLIBANSERIN,NDA022526,3819daf3-e935-2c53-c527-e1d57922f394,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000SumRedt.pdf,
2022,N/A,N/A,BLA761270,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761270Orig1s000TOC.cfm,
2001,3M AVAGARD,CHLORHEXIDINE GLUCONATE AND ALCOHOL,NDA021074,8bf8fe8e-76cb-4eda-a18d-1687050285ae,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-074_Avagard.cfm,
2007,SEVELAMER CARBONATE,SEVELAMER CARBONATE,NDA022127,3abc32fe-1bfc-4759-8f7c-36095e221b06,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022127s000TOC.cfm,
2007,SEVELAMER CARBONATE,SEVELAMER CARBONATE,NDA022127,3abc32fe-1bfc-4759-8f7c-36095e221b06,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022127s000_SumR.pdf,
2007,SEVELAMER CARBONATE,SEVELAMER CARBONATE,NDA022127,3abc32fe-1bfc-4759-8f7c-36095e221b06,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22127 sevelamer clinical prea.pdf,
2007,SEVELAMER CARBONATE,SEVELAMER CARBONATE,NDA022127,3abc32fe-1bfc-4759-8f7c-36095e221b06,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/38_22127 sevelamer clinpharm prea.pdf,
2007,SEVELAMER CARBONATE,SEVELAMER CARBONATE,NDA022127,3abc32fe-1bfc-4759-8f7c-36095e221b06,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/39_22127 sevelamer statistical prea.pdf,
2004,N/A,N/A,NDA021756,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-756_Macugen.cfm,
2014,SIGNIFOR LAR,PASIREOTIDE,NDA203255,a0aad470-3f38-af97-e053-2995a90a383a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203255Orig1s000TOC.cfm,
2014,SIGNIFOR LAR,PASIREOTIDE,NDA203255,a0aad470-3f38-af97-e053-2995a90a383a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203255Orig1s000SumR.pdf,
2013,GAZYVA,OBINUTUZUMAB,BLA125486,df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125486Orig1s000TOC.cfm,
2013,GAZYVA,OBINUTUZUMAB,BLA125486,df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda,http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125486Orig1s000SumR.pdf,
2012,N/A,N/A,NDA202535,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202535_prepopik_toc.cfm,
2012,N/A,N/A,NDA202535,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202535Orig1s000SumR.pdf,
2012,N/A,N/A,NDA202535,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/461_209589S5 citric acid-magnesium oxide-sodium CDTL clinical prea.pdf,
2014,N/A,N/A,NDA206769,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206769Orig1s000SumR.pdf,
2014,N/A,N/A,NDA206769,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206769Orig1s000TOC.cfm,
2017,XADAGO,SAFINAMIDE MESYLATE,NDA207145,c4d65f28-983f-42b4-bb23-023ae0fe81b2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000TOC.cfm,
1989,N/A,N/A,NDA019778,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20507-s001_Teczem.pdf,
1989,N/A,N/A,NDA019778,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/19778s028.cfm,
1989,N/A,N/A,NDA019778,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/19778-S-034_Prinzide_review.pdf,
2017,XHANCE,FLUTICASONE PROPIONATE,NDA209022,c79bbb9f-e483-4093-8c92-ea978e7bf278,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209022Orig1s000_revTOC.cfm,
2019,DRIZALMA SPRINKLE,DULOXETINE,NDA212516,b41423b8-dfec-4d79-ba3c-e43a87803d85,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212516Orig1s000TOC.cfm,
2019,CONJUPRI,LEVAMLODIPINE,NDA212895,c3cca66e-348a-43e8-8f96-e995104dae3d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212895Orig1s000TOC.cfm,
2019,CONJUPRI,LEVAMLODIPINE,NDA212895,c3cca66e-348a-43e8-8f96-e995104dae3d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/520_212895 levamlodipine clinical prea.pdf,
2019,CONJUPRI,LEVAMLODIPINE,NDA212895,c3cca66e-348a-43e8-8f96-e995104dae3d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/521_212895 levamlodipine clinpharm prea_0.pdf,
2022,PLUVICTO,LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN,NDA215833,fb973a8d-7fea-4a7a-963f-2a8e67a46e55,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215833Orig1s000TOC.cfm,
1997,N/A,N/A,NDA020623,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020623_anzemet_toc.cfm,
1996,ARICEPT,DONEPEZIL HYDROCHLORIDE,NDA020690,98e451e1-e4d7-4439-a675-c5457ba20975,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020690Orig1s000rev.pdf,
1996,ARICEPT,DONEPEZIL HYDROCHLORIDE,NDA020690,98e451e1-e4d7-4439-a675-c5457ba20975,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020690_s011_aricept.pdf,
2025,BRINSUPRI,BRENSOCATIB,NDA217673,b56986ae-e7db-421e-b622-a7f41e321f3d,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/217673Orig1s000TOC.cfm,
2010,GILENYA,FINGOLIMOD HCL,NDA022527,cc9e1c8c-0e2b-44e2-878b-27057f786be9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022527Orig1s000sumr.pdf,
2010,GILENYA,FINGOLIMOD HCL,NDA022527,cc9e1c8c-0e2b-44e2-878b-27057f786be9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022527Orig1s000TOC.cfm,
2010,GILENYA,FINGOLIMOD HCL,NDA022527,cc9e1c8c-0e2b-44e2-878b-27057f786be9,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/275_22527S024-fingolimod-CDTL-clinical-both.pdf,
2010,GILENYA,FINGOLIMOD HCL,NDA022527,cc9e1c8c-0e2b-44e2-878b-27057f786be9,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/276_22527S024-fingolimod-clinical-both.pdf,
2010,GILENYA,FINGOLIMOD HCL,NDA022527,cc9e1c8c-0e2b-44e2-878b-27057f786be9,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/277_22527S024-fingolimod-clinpharm-both.pdf,
2010,GILENYA,FINGOLIMOD HCL,NDA022527,cc9e1c8c-0e2b-44e2-878b-27057f786be9,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/278_22527s024-fingolimod-statistical-both.pdf,
2024,N/A,N/A,BLA761274,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761274Orig1s000TOC.cfm,
1999,N/A,N/A,NDA021076,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21-076_Aleve.cfm,
2003,N/A,N/A,NDA021400,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra.cfm,
2007,SELZENTRY,MARAVIROC,NDA022128,46f30ac5-c96b-429e-976d-8c5ee1c0761b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022128_selzentry_toc.cfm,
2007,SELZENTRY,MARAVIROC,NDA022128,46f30ac5-c96b-429e-976d-8c5ee1c0761b,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208984Orig1s000,022128Orig1s017TOC.cfm",
2005,VANOS,FLUOCINONIDE,NDA021758,95cb19a0-4b71-4c66-92bd-901cfd223301,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021758s000TOC.cfm,
2014,SYLVANT,SILTUXIMAB,BLA125496,8d663642-f52e-49c0-a023-2da083fdfc0b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125496Orig1s000TOC.cfm,
2014,SYLVANT,SILTUXIMAB,BLA125496,8d663642-f52e-49c0-a023-2da083fdfc0b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125496Orig1s000SumR.pdf,
1986,HUMATROPE,SOMATROPIN,BLA019640,a774e1ae-3997-49ee-8b0e-99a2b315d409,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019640_s020_HUMATROPE 5.pdf,
1986,HUMATROPE,SOMATROPIN,BLA019640,a774e1ae-3997-49ee-8b0e-99a2b315d409,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019640ap.pdf,
1986,HUMATROPE,SOMATROPIN,BLA019640,a774e1ae-3997-49ee-8b0e-99a2b315d409,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/019640_S033_HUMATROPE_AP.pdf,
1986,HUMATROPE,SOMATROPIN,BLA019640,a774e1ae-3997-49ee-8b0e-99a2b315d409,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019640ap.pdf,
1986,HUMATROPE,SOMATROPIN,BLA019640,a774e1ae-3997-49ee-8b0e-99a2b315d409,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/019640_S032_HUMATROPE_AP.pdf,
1986,HUMATROPE,SOMATROPIN,BLA019640,a774e1ae-3997-49ee-8b0e-99a2b315d409,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/019640_s022_HUMATROPE.pdf,
2016,SOLIQUA 100/33,INSULIN GLARGINE AND LIXISENATIDE,BLA208673,4bba538b-cf7c-4310-ae8f-cb711ed21bcc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208673Orig1s000SumR.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2016,SOLIQUA 100/33,INSULIN GLARGINE AND LIXISENATIDE,BLA208673,4bba538b-cf7c-4310-ae8f-cb711ed21bcc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208673Orig1_toc.cfm,
1996,ZYPREXA,OLANZAPINE,NDA020592,d5051fbc-846b-4946-82df-341fb1216341,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020592_s034_Zyprexa Tabs.pdf,
1996,ZYPREXA,OLANZAPINE,NDA020592,d5051fbc-846b-4946-82df-341fb1216341,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/020592_s40s41_zyprexa_toc.cfm,
1996,ZYPREXA,OLANZAPINE,NDA020592,d5051fbc-846b-4946-82df-341fb1216341,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020592s040_olanzapine_Zyprexa_MedR_PREA.pdf,
1996,ZYPREXA,OLANZAPINE,NDA020592,d5051fbc-846b-4946-82df-341fb1216341,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020592s040_olanzapine_Zyprexa_MedR(2)_PREA.pdf,
1996,ZYPREXA,OLANZAPINE,NDA020592,d5051fbc-846b-4946-82df-341fb1216341,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020592s040_olanzapine_Zyprexa_ClinPharm_PREA.pdf,
1996,ZYPREXA,OLANZAPINE,NDA020592,d5051fbc-846b-4946-82df-341fb1216341,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020592s040_olanzapine_Zyprexa_ClinPharm(2)_PREA.pdf,
1996,ZYPREXA,OLANZAPINE,NDA020592,d5051fbc-846b-4946-82df-341fb1216341,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020592s040_olanzapine_Zyprexa_StatR_PREA.pdf,
1996,ZYPREXA,OLANZAPINE,NDA020592,d5051fbc-846b-4946-82df-341fb1216341,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020592_S018_ZYPREXA_AP.pdf,
1996,ZYPREXA,OLANZAPINE,NDA020592,d5051fbc-846b-4946-82df-341fb1216341,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020592_S006_ZUPREXA_ORAL_TABS_AP.pdf,
1996,ZYPREXA,OLANZAPINE,NDA020592,d5051fbc-846b-4946-82df-341fb1216341,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/020592Orig1s049.pdf,
1996,ZYPREXA,OLANZAPINE,NDA020592,d5051fbc-846b-4946-82df-341fb1216341,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/020592Orig1s055.pdf,
1996,ZYPREXA,OLANZAPINE,NDA020592,d5051fbc-846b-4946-82df-341fb1216341,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/Zyprexa_20592s39_toc.cfm,
1996,ZYPREXA,OLANZAPINE,NDA020592,d5051fbc-846b-4946-82df-341fb1216341,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/020592Orig1s053.pdf,
1996,ZYPREXA,OLANZAPINE,NDA020592,d5051fbc-846b-4946-82df-341fb1216341,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020592Orig1s035.pdf,
1996,ZYPREXA,OLANZAPINE,NDA020592,d5051fbc-846b-4946-82df-341fb1216341,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/020592_s40s41_zyprexa_toc.cfm,
1996,ZYPREXA,OLANZAPINE,NDA020592,d5051fbc-846b-4946-82df-341fb1216341,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020592_s019_Zyprexa.pdf,
1996,ZYPREXA,OLANZAPINE,NDA020592,d5051fbc-846b-4946-82df-341fb1216341,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020592_Original_Approval_Pkg .pdf,
1996,ZYPREXA,OLANZAPINE,NDA020592,d5051fbc-846b-4946-82df-341fb1216341,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-592S011_review.pdf,
1996,N/A,N/A,NDA020655,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-665s008_Alora.cfm,
2010,DROSPIRENONE/ETHINYL ESTRADIOL/LEVOMEFOLATE CALCIUM AND LEVOMEFOLATE CALCIUM,DROSPIRENONE/ETHINYL ESTRADIOL/LEVOMEFOLATE CALCIUM AND LEVOMEFOLATE CALCIUM,NDA022532,58cd12d3-39b1-4375-b7e0-09ba2378a52b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022532Orig1s004.pdf,
2010,DROSPIRENONE/ETHINYL ESTRADIOL/LEVOMEFOLATE CALCIUM AND LEVOMEFOLATE CALCIUM,DROSPIRENONE/ETHINYL ESTRADIOL/LEVOMEFOLATE CALCIUM AND LEVOMEFOLATE CALCIUM,NDA022532,58cd12d3-39b1-4375-b7e0-09ba2378a52b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022532Orig1s000SumR.pdf,
2010,DROSPIRENONE/ETHINYL ESTRADIOL/LEVOMEFOLATE CALCIUM AND LEVOMEFOLATE CALCIUM,DROSPIRENONE/ETHINYL ESTRADIOL/LEVOMEFOLATE CALCIUM AND LEVOMEFOLATE CALCIUM,NDA022532,58cd12d3-39b1-4375-b7e0-09ba2378a52b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22532 beyaz clinical prea.pdf,
2010,DROSPIRENONE/ETHINYL ESTRADIOL/LEVOMEFOLATE CALCIUM AND LEVOMEFOLATE CALCIUM,DROSPIRENONE/ETHINYL ESTRADIOL/LEVOMEFOLATE CALCIUM AND LEVOMEFOLATE CALCIUM,NDA022532,58cd12d3-39b1-4375-b7e0-09ba2378a52b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22532 beyaz clinpharm prea.pdf,
2010,DROSPIRENONE/ETHINYL ESTRADIOL/LEVOMEFOLATE CALCIUM AND LEVOMEFOLATE CALCIUM,DROSPIRENONE/ETHINYL ESTRADIOL/LEVOMEFOLATE CALCIUM AND LEVOMEFOLATE CALCIUM,NDA022532,58cd12d3-39b1-4375-b7e0-09ba2378a52b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22532 beyaz statistical prea.pdf,
2010,DROSPIRENONE/ETHINYL ESTRADIOL/LEVOMEFOLATE CALCIUM AND LEVOMEFOLATE CALCIUM,DROSPIRENONE/ETHINYL ESTRADIOL/LEVOMEFOLATE CALCIUM AND LEVOMEFOLATE CALCIUM,NDA022532,58cd12d3-39b1-4375-b7e0-09ba2378a52b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022532_beyaz_toc.cfm,
2010,DROSPIRENONE/ETHINYL ESTRADIOL/LEVOMEFOLATE CALCIUM AND LEVOMEFOLATE CALCIUM,DROSPIRENONE/ETHINYL ESTRADIOL/LEVOMEFOLATE CALCIUM AND LEVOMEFOLATE CALCIUM,NDA022532,58cd12d3-39b1-4375-b7e0-09ba2378a52b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022532Orig1s001.pdf,
2024,TYENNE,TOCILIZUMAB-AAZG,BLA761275,e400bbe6-43c5-4de6-82b9-cb44ce3cd906,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761275Orig1s000TOC.cfm,
2000,ADVAIR DISKUS,FLUTICASONE PROPIONATE AND SALMETEROL,NDA021077,4eeb5f6a-593f-4a9e-9692-adefa2caf8fc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021077_s019_ADVAIR DISKUS.pdf,
2000,ADVAIR DISKUS,FLUTICASONE PROPIONATE AND SALMETEROL,NDA021077,4eeb5f6a-593f-4a9e-9692-adefa2caf8fc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021077Orig1s017.pdf,
2000,ADVAIR DISKUS,FLUTICASONE PROPIONATE AND SALMETEROL,NDA021077,4eeb5f6a-593f-4a9e-9692-adefa2caf8fc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21077_AdvairDiskus.cfm,
2000,ADVAIR DISKUS,FLUTICASONE PROPIONATE AND SALMETEROL,NDA021077,4eeb5f6a-593f-4a9e-9692-adefa2caf8fc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/021077Orig1s056.pdf,
2000,ADVAIR DISKUS,FLUTICASONE PROPIONATE AND SALMETEROL,NDA021077,4eeb5f6a-593f-4a9e-9692-adefa2caf8fc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/021077Orig1s052.pdf,
2000,ADVAIR DISKUS,FLUTICASONE PROPIONATE AND SALMETEROL,NDA021077,4eeb5f6a-593f-4a9e-9692-adefa2caf8fc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021077Orig1s050.pdf,
2000,ADVAIR DISKUS,FLUTICASONE PROPIONATE AND SALMETEROL,NDA021077,4eeb5f6a-593f-4a9e-9692-adefa2caf8fc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021077Orig1S003.pdf,
2000,ADVAIR DISKUS,FLUTICASONE PROPIONATE AND SALMETEROL,NDA021077,4eeb5f6a-593f-4a9e-9692-adefa2caf8fc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/021077Orig1s057.pdf,
2000,ADVAIR DISKUS,FLUTICASONE PROPIONATE AND SALMETEROL,NDA021077,4eeb5f6a-593f-4a9e-9692-adefa2caf8fc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/021077Orig1s051.pdf,
2000,ADVAIR DISKUS,FLUTICASONE PROPIONATE AND SALMETEROL,NDA021077,4eeb5f6a-593f-4a9e-9692-adefa2caf8fc,http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/021077se2-029_SUMR.pdf,
2002,SYNTHROID,LEVOTHYROXINE SODIUM,NDA021402,1e11ad30-1041-4520-10b0-8f9d30d30fcc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-402_Synthroid.cfm,
2009,N/A,N/A,NDA022129,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022129_Benzyl Alcohol_Clinical_PREA.pdf,
2009,N/A,N/A,NDA022129,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022129_Benzyl Alcohol_ClinPharm_PREA.pdf,
2009,N/A,N/A,NDA022129,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022129s000_Benzyl Alcohol_Statistical_Prea.pdf,
2009,N/A,N/A,NDA022129,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022129s000TOC.cfm,
2009,N/A,N/A,NDA022129,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022129s000_SumR.pdf,
2005,OXALIPLATIN,OXALIPLATIN,NDA021759,70269278-fe61-4800-a064-32cb6845cc28,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021759s000TOC.cfm,
2015,STRENSIQ,ASFOTASE ALFA,BLA125513,3387574f-5eaa-4501-a71d-4cbfbd563031,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125513Orig1s000SumR.pdf,
2015,STRENSIQ,ASFOTASE ALFA,BLA125513,3387574f-5eaa-4501-a71d-4cbfbd563031,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125513Orig1s000TOC.cfm,
2013,MESALAMINE,MESALAMINE,NDA204412,370bd908-55af-4dfc-8837-913bf73babbd,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/204412s003 mesalamine clinical prea.pdf,
2013,MESALAMINE,MESALAMINE,NDA204412,370bd908-55af-4dfc-8837-913bf73babbd,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/204412s003 mesalamine clinpharm prea.pdf,
2013,MESALAMINE,MESALAMINE,NDA204412,370bd908-55af-4dfc-8837-913bf73babbd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204412_delzicol_toc.cfm,
2013,MESALAMINE,MESALAMINE,NDA204412,370bd908-55af-4dfc-8837-913bf73babbd,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/204412 mesalamine clinical prea.pdf,
2013,MESALAMINE,MESALAMINE,NDA204412,370bd908-55af-4dfc-8837-913bf73babbd,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/204412 mesalamine clinpharm prea.pdf,
2013,MESALAMINE,MESALAMINE,NDA204412,370bd908-55af-4dfc-8837-913bf73babbd,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/204412 mesalamine statistical prea.pdf,
2013,MESALAMINE,MESALAMINE,NDA204412,370bd908-55af-4dfc-8837-913bf73babbd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204412Orig1s006.pdf,
1991,NICOTINE TRANSDERMAL SYSTEM,NICOTINE,NDA020165,cd9aa56c-ac88-4f9b-9ff9-a9720af6c1a7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020165_S020_NICODERM CQ.pdf,
1997,N/A,N/A,NDA020231,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020231_total_toc.cfm,
2021,FOTIVDA,TIVOZANIB,NDA212904,de77155c-ecf2-4f15-9758-21d271449d83,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000TOC.cfm,
2022,IMJUDO,TREMELIMUMAB,BLA761289,6690679c-be2f-4588-a2e4-89fff74dd6be,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761289Orig1s000TOC.cfm,
1999,SIROLIMUS,SIROLIMUS,NDA021083,384cb547-55a4-47fc-a0a6-054c18a51b84,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/sirolimus_Rapamune-MedRev-21083s019.pdf,
1999,SIROLIMUS,SIROLIMUS,NDA021083,384cb547-55a4-47fc-a0a6-054c18a51b84,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/sirolimus_Rapamune clinical pharmacology review 21083s019.pdf,
1999,SIROLIMUS,SIROLIMUS,NDA021083,384cb547-55a4-47fc-a0a6-054c18a51b84,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/sirolimus_Rapamune-StatsRev-21083s019.pdf,
1999,SIROLIMUS,SIROLIMUS,NDA021083,384cb547-55a4-47fc-a0a6-054c18a51b84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021083_S006_RAPAMUNE.pdf,
1999,SIROLIMUS,SIROLIMUS,NDA021083,384cb547-55a4-47fc-a0a6-054c18a51b84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21083A.cfm,
2004,N/A,N/A,BLA021765,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021765s000TOC.cfm,
2015,COSENTYX,SECUKINUMAB,BLA125504,77c4b13e-7df3-42d4-81db-3d0cddb7f67a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125504Orig1s000TOC.cfm,
2015,COSENTYX,SECUKINUMAB,BLA125504,77c4b13e-7df3-42d4-81db-3d0cddb7f67a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125504Orig1s000SumR.pdf,
2015,COSENTYX,SECUKINUMAB,BLA125504,77c4b13e-7df3-42d4-81db-3d0cddb7f67a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/125504Orig1s002.pdf,
2015,COSENTYX,SECUKINUMAB,BLA125504,77c4b13e-7df3-42d4-81db-3d0cddb7f67a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/125504Orig1s073.pdf,
2015,COSENTYX,SECUKINUMAB,BLA125504,77c4b13e-7df3-42d4-81db-3d0cddb7f67a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/125504Orig1s001.pdf,
2015,COSENTYX,SECUKINUMAB,BLA125504,77c4b13e-7df3-42d4-81db-3d0cddb7f67a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/125504Orig1s063.pdf,
2020,TWIRLA,LEVONORGESTREL/ETHINYL ESTRADIOL,NDA204017,bcaf8db0-1750-425d-b008-255b5e7a9cc6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/204017Orig1s000TOC.cfm,
2017,MAVYRET,GLECAPREVIR AND PIBRENTASVIR,NDA209394,7bf99777-0401-9095-8645-16c6e907fcc0,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209394_toc.cfm,
2017,MAVYRET,GLECAPREVIR AND PIBRENTASVIR,NDA209394,7bf99777-0401-9095-8645-16c6e907fcc0,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209394Orig1s000SumR.pdf,
2017,MAVYRET,GLECAPREVIR AND PIBRENTASVIR,NDA209394,7bf99777-0401-9095-8645-16c6e907fcc0,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/209394S6 mavyret CDTL clinical addendum prea.pdf,
2017,MAVYRET,GLECAPREVIR AND PIBRENTASVIR,NDA209394,7bf99777-0401-9095-8645-16c6e907fcc0,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/209394S6 mavyret clinpharm prea.pdf,
2017,MAVYRET,GLECAPREVIR AND PIBRENTASVIR,NDA209394,7bf99777-0401-9095-8645-16c6e907fcc0,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/209394S6 mavyret statistical prea.pdf,
2022,SOTYKTU,DEUCRAVACITINIB,NDA214958,ff4d7258-5068-4cdf-9692-8cae04c3198e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214958Orig1s000TOC.cfm,
2024,RAPIBLYK,LANDIOLOL,NDA217202,27e7f20f-78a4-f1a9-e063-6394a90ae465,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217202Orig1s000TOC.cfm,
2014,ESBRIET,PIRFENIDONE,NDA022535,2e8c3537-36d7-4de5-9b5c-7a624b9a9e6e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000toc.cfm,
2014,ESBRIET,PIRFENIDONE,NDA022535,2e8c3537-36d7-4de5-9b5c-7a624b9a9e6e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000SumR.pdf,
2023,OMVOH,MIRIKIZUMAB-MRKZ,BLA761279,472cbe04-263e-433d-9a0f-58c1b50b715a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761279Orig1s000TOC.cfm,
1999,N/A,N/A,NDA021079,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21079_Alamast.pdf,
2007,N/A,N/A,NDA022137,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022137_fludarabine_toc.cfm,
2007,N/A,N/A,NDA022137,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/022137Orig1s015MultidisciplineR.pdf,
1985,N/A,N/A,NDA050597,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/050597Orig1s000rev.pdf,
2016,ANTHIM,OBILTOXAXIMAB,BLA125509,39ad8799-00a4-4fc8-9852-c0536350c474,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125509Orig1s000TOC.cfm,
2016,ANTHIM,OBILTOXAXIMAB,BLA125509,39ad8799-00a4-4fc8-9852-c0536350c474,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125509Orig1s000SumR.pdf,
2016,ANTHIM,OBILTOXAXIMAB,BLA125509,39ad8799-00a4-4fc8-9852-c0536350c474,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/125509_obiltoxaximab_clinical_PREA.pdf,
2016,ANTHIM,OBILTOXAXIMAB,BLA125509,39ad8799-00a4-4fc8-9852-c0536350c474,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/125509_obiltoxaximab_clinpharm_PREA.pdf,
2016,ANTHIM,OBILTOXAXIMAB,BLA125509,39ad8799-00a4-4fc8-9852-c0536350c474,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/125509_obiltoxaximab_StatR_PREA.pdf,
2014,NOXAFIL,POSACONAZOLE,NDA205596,b073b082-7b57-4423-8c06-4fd4263d6f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205596Orig1s000SumR.pdf,
2014,NOXAFIL,POSACONAZOLE,NDA205596,b073b082-7b57-4423-8c06-4fd4263d6f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205596Orig1s000TOC.cfm,
2019,PIQRAY,ALPELISIB,NDA212526,b20b4e18-7a4b-4500-a08f-06c6dab0ee5b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212526Orig1s000TOC.cfm,
1994,N/A,N/A,NDA020388,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-388s008_Navelbine.cfm,
1994,N/A,N/A,NDA020388,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020388_S014_NAVELBINE_INJECTION_AP.pdf,
1994,N/A,N/A,NDA020388,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/1997/020388_S003_NAVELBINE INJECTION_AP.pdf,
2023,SITAGLIPTIN AND METFORMIN HYDROCHLORIDE,SITAGLIPTIN AND METFORMIN HYDROCHLORIDE,NDA216743,e07abcb1-1f0c-4cad-8405-8eedba4b8ff8,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/216743Orig1s000TOC.cfm,
2023,OGSIVEO,NIROGACESTAT,NDA217677,f172e6ff-3190-41b0-b95a-58a7ef9e9e1e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217677Orig1s000TOC.cfm,
2024,RETEVMO,SELPERCATINIB,NDA218160,7fa848ba-a59c-4144-9f52-64d090f4d828,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/218160Orig1s000TOC.cfm,
2023,WEZLANA,USTEKINUMAB-AUUB,BLA761285,a6c23978-09f0-4796-88f7-d0ce7e3ed04e,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761285Orig1s000,761331Orig1s000TOC.cfm",
2000,INSULIN GLARGINE SOLOSTAR,INSULIN GLARGINE,BLA021081,406883ea-7f97-4eff-8d43-0bab004654f1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021081_s017_Lantus.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2000,INSULIN GLARGINE SOLOSTAR,INSULIN GLARGINE,BLA021081,406883ea-7f97-4eff-8d43-0bab004654f1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/021081Orig1s062.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2000,INSULIN GLARGINE SOLOSTAR,INSULIN GLARGINE,BLA021081,406883ea-7f97-4eff-8d43-0bab004654f1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021081Orig1s034.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2000,INSULIN GLARGINE SOLOSTAR,INSULIN GLARGINE,BLA021081,406883ea-7f97-4eff-8d43-0bab004654f1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21081_Lantus.cfm,
2000,INSULIN GLARGINE SOLOSTAR,INSULIN GLARGINE,BLA021081,406883ea-7f97-4eff-8d43-0bab004654f1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021081Orig1s024.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2002,SINGULAIR,MONTELUKAST SODIUM,NDA021409,482dcc92-b47f-4ea6-854a-f5ac2aea7842,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-409_Singulair.cfm,
2002,SINGULAIR,MONTELUKAST SODIUM,NDA021409,482dcc92-b47f-4ea6-854a-f5ac2aea7842,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021409_S007_SINGULAIR_TABLETS_AP.pdf,
2002,SINGULAIR,MONTELUKAST SODIUM,NDA021409,482dcc92-b47f-4ea6-854a-f5ac2aea7842,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020829_S023 & 020830_S026 & 021409_S005_SINGULAR_AP.pdf,
2006,BRIMONIDINE TARTRATE,BRIMONIDINE TARTRATE,NDA021764,b1e7ebd4-d0d2-40a5-aa11-5f68bc5972bd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021764s000TOC.cfm,
2015,NATPARA (PARATHYROID HORMONE),PARATHYROID HORMONE,BLA125511,d11fba31-0a6c-11e3-8ffd-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125511Orig1s000SumR.pdf,
2015,NATPARA (PARATHYROID HORMONE),PARATHYROID HORMONE,BLA125511,d11fba31-0a6c-11e3-8ffd-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125511Orig1s000TOC.cfm,
2013,OPSUMIT,MACITENTAN,NDA204410,1e484a50-55db-4b85-8c57-6cd1b0353abd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204410Orig1s000TOC.cfm,
2013,OPSUMIT,MACITENTAN,NDA204410,1e484a50-55db-4b85-8c57-6cd1b0353abd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204410Orig1s000SumR.pdf,
2017,MACRILEN,MACIMORELIN ACETATE,NDA205598,6034c9b8-5a36-4961-a5dd-11ebf7bdab78,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/205598Orig1s000TOC.cfm,
2019,TURALIO,PEXIDARTINIB HYDROCHLORIDE,NDA211810,7b0ec4bf-b2ac-49ee-96af-7740ad3f2e16,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211810Orig1s000TOC.cfm,
1992,N/A,N/A,NDA020262,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020262s036,037,038_Taxol.pdf",
1992,N/A,N/A,NDA020262,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020262s036,037,038_Taxol.pdf",
1992,N/A,N/A,NDA020262,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020262s026s027s028.cfm,
1992,N/A,N/A,NDA020262,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020262s026s027s028.cfm,
1992,N/A,N/A,NDA020262,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20262s024.cfm,
1992,N/A,N/A,NDA020262,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20262S031_Taxol.pdf,
1992,N/A,N/A,NDA020262,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20262S031_Taxol.pdf,
1992,N/A,N/A,NDA020262,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020262s036,037,038_Taxol.pdf",
1992,N/A,N/A,NDA020262,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020262s026s027s028.cfm,
1992,N/A,N/A,NDA020262,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20262S031_Taxol.pdf,
1992,N/A,N/A,NDA020262,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20262S031_Taxol.pdf,
1992,N/A,N/A,NDA020262,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/020262Orig1s048.pdf,
1994,MAGNESIUM SULFATE IN WATER,MAGNESIUM SULFATE IN WATER,NDA020309,22ca78b4-f5a3-4144-cf89-5f633acf1e6d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020309_original_approval.pdf,
2022,N/A,N/A,NDA215401,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215401Orig1s000TOC.cfm,
2010,INDOMETHACIN,INDOMETHACIN,NDA022536,30e38747-c553-4e2d-bc23-634e1dd90b8d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022536s000SumR.pdf,
2010,INDOMETHACIN,INDOMETHACIN,NDA022536,30e38747-c553-4e2d-bc23-634e1dd90b8d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022536_indomethacin_toc.cfm,
2023,RYSTIGGO,ROZANOLIXIZUMAB,BLA761286,3c0eb8c2-c042-4954-b451-3baa77f5e6d1,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761286Orig1s000TOC.cfm,
2002,N/A,N/A,NDA021410,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021071_s014_Avandia%20Tabs.pdf,
2002,N/A,N/A,NDA021410,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021410_avandamet.cfm,
1974,N/A,N/A,NDA017531,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/017531_S010_TIGAN_CAPSULE_AP.pdf,
2016,TALTZ,IXEKIZUMAB,BLA125521,ac96658a-d7dc-4c7c-8928-2adcdf4318b2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125521Orig1s000TOC.cfm,
2016,TALTZ,IXEKIZUMAB,BLA125521,ac96658a-d7dc-4c7c-8928-2adcdf4318b2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125521Orig1s000SumR.pdf,
2018,ELEPSIA XR 1000 MG,LEVETIRACETAM,NDA204417,cac83d47-88a2-4447-a0c0-90b44ffda0ac,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/204417Orig1s000TOC.cfm,
1990,SYNAREL,NAFARELIN ACETATE,NDA019886,d0aa57cb-d2f4-46d7-af43-7c8b06aa81a6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/019886S013%20.cfm,
1999,N/A,N/A,NDA020781,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20781_Zofran.pdf,
1999,N/A,N/A,NDA020781,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020781_S001_ZOFRAN.pdf,
1999,N/A,N/A,NDA020781,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/020781Orig1s017Rev.pdf,
2022,AZMIRO,TESTOSTERONE CYPIONATE,NDA216318,235b5625-570d-3fba-e063-6394a90aa2d1,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216318Orig1s000TOC.cfm,
2023,LIKMEZ,METRONIDAZOLE ORAL,NDA216755,23927a8b-1641-4104-aa85-d7b7bf4ebb9d,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/216755Orig1s000TOC.cfm,
2023,IZERVAY,AVACINCAPTAD PEGOL,NDA217225,1642fe6a-dc26-4d20-ae6e-654af744e3bd,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217225Orig1s000TOC.cfm,
1998,N/A,N/A,NDA020718,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-718_Integrilin.cfm,
1998,N/A,N/A,NDA020718,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20718S002_Integrilin.cfm,
1998,N/A,N/A,NDA020718,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-718_Integrilin.cfm,
1998,N/A,N/A,NDA020718,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20718_Integrilin.cfm,
2010,N/A,N/A,NDA022545,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022545Origs000SumR.pdf,
2010,N/A,N/A,NDA022545,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022545_tekamlo_toc.cfm,
2024,UNLOXCYT,COSIBELIMAB,BLA761297,83345764-75b8-42d7-bf46-3061136cad5d,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761297Orig1s000TOC.cfm,
2000,ZYPREXA ZYDIS,OLANZAPINE,NDA021086,d5051fbc-846b-4946-82df-341fb1216341,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-086_ZyprexaZydis.cfm,
2003,N/A,N/A,NDA021416,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-416_Rythmol.cfm,
2005,ZOLPIDEM TARTRATE,ZOLPIDEM TARTRATE,NDA021774,68d4314d-1973-481e-806a-da9f5b4baeb0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021774Orig1s003.pdf,
2005,ZOLPIDEM TARTRATE,ZOLPIDEM TARTRATE,NDA021774,68d4314d-1973-481e-806a-da9f5b4baeb0,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/019908Orig1s032,s034,021774Orig1s013,s015review.pdf",
2005,ZOLPIDEM TARTRATE,ZOLPIDEM TARTRATE,NDA021774,68d4314d-1973-481e-806a-da9f5b4baeb0,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/019908Orig1s032,s034,021774Orig1s013,s015review.pdf",
2005,ZOLPIDEM TARTRATE,ZOLPIDEM TARTRATE,NDA021774,68d4314d-1973-481e-806a-da9f5b4baeb0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021774s000_AmbienTOC.cfm,
1986,UNASYN,AMPICILLIN SODIUM AND SULBACTAM SODIUM,NDA050608,155c7ec0-5862-404f-b1d0-f278f8a8bbda,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/050608ap.pdf,
1986,UNASYN,AMPICILLIN SODIUM AND SULBACTAM SODIUM,NDA050608,155c7ec0-5862-404f-b1d0-f278f8a8bbda,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/050608Orig1s000rev.pdf,
2011,LEVETIRACETAM,LEVETIRACETAM,NDA202543,62f3d1c8-ca5b-4760-9fc9-41e4fb4cc926,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202543_levetiracetam_toc.cfm,
2011,LEVETIRACETAM,LEVETIRACETAM,NDA202543,62f3d1c8-ca5b-4760-9fc9-41e4fb4cc926,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202543Orig1s000SumR.pdf,
2016,ACZONE,DAPSONE,NDA207154,22058b7d-a578-4eaa-a476-ac982337f02a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/471_207154s4 dapsone clinical prea.pdf,
2016,ACZONE,DAPSONE,NDA207154,22058b7d-a578-4eaa-a476-ac982337f02a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/470_207154s4 dapsone clinpharm prea.pdf,
2016,ACZONE,DAPSONE,NDA207154,22058b7d-a578-4eaa-a476-ac982337f02a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/207154Orig1s000TOC.cfm,
2016,ACZONE,DAPSONE,NDA207154,22058b7d-a578-4eaa-a476-ac982337f02a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/117_207154 dapsone clinical prea.pdf,
2016,ACZONE,DAPSONE,NDA207154,22058b7d-a578-4eaa-a476-ac982337f02a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/118_207154 dapsone clinpharm prea.pdf,
2016,ACZONE,DAPSONE,NDA207154,22058b7d-a578-4eaa-a476-ac982337f02a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/119_207154 dapsone statistical prea.pdf,
2017,BERKLEY AND JENSEN OMEPRAZOLE,OMEPRAZOLE,NDA209400,1729c60d-3475-45cd-b192-f88438403d1a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209400Orig1s000TOC.cfm,
2020,XTANDI,ENZALUTAMIDE,NDA213674,b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213674Orig1s000TOC.cfm,
2023,YCANTH,CANTHARIDIN,NDA212905,7c9bdeaa-9822-4c69-a719-ea4a8643f59c,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/212905Orig1s000TOC.cfm,
2022,TASCENSO ODT,FINGOLIMOD LAURYL SULFATE,NDA214962,bf8e7f89-ea09-43c7-a7eb-e44724350721,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214962Orig2s000TOC.cfm,
2024,ENSACOVE,ENSARTINIB,NDA218171,1e1b2f79-678a-472a-b924-66909c8a4b2e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/218171Orig1s000TOC.cfm,
2022,TECVAYLI,TECLISTAMAB,BLA761291,54e0f974-ccee-44ea-9254-40e9883cee1e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761291Orig1s000TOC.cfm,
2002,STRATTERA,ATOMOXETINE HYDROCHLORIDE,NDA021411,309de576-c318-404a-bc15-660c2b1876fb,http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/021411se1-005_SUMR.pdf,
2002,STRATTERA,ATOMOXETINE HYDROCHLORIDE,NDA021411,309de576-c318-404a-bc15-660c2b1876fb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-411_Strattera.cfm,
2002,STRATTERA,ATOMOXETINE HYDROCHLORIDE,NDA021411,309de576-c318-404a-bc15-660c2b1876fb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021411_S001_STRATTERA_CAPSULES_AP.pdf,
2018,CIMDUO,LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE,NDA022141,a300f04d-118f-4136-aaf3-ddfd00197f86,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/022141Orig1s000TOC.cfm,
2018,CIMDUO,LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE,NDA022141,a300f04d-118f-4136-aaf3-ddfd00197f86,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/253_22141-lamivudine-and-tenofovir-clinical-prea.pdf,
2018,CIMDUO,LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE,NDA022141,a300f04d-118f-4136-aaf3-ddfd00197f86,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/254_22141-lamivudine-and-tenofovir-clinpharm-prea.pdf,
2014,KEYTRUDA,PEMBROLIZUMAB,BLA125514,9333c79b-d487-4538-a9f0-71b91a02b287,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s59-64,69,76-83SumR.pdf",
2014,KEYTRUDA,PEMBROLIZUMAB,BLA125514,9333c79b-d487-4538-a9f0-71b91a02b287,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125514Orig1s000SumR.pdf,
2014,KEYTRUDA,PEMBROLIZUMAB,BLA125514,9333c79b-d487-4538-a9f0-71b91a02b287,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125514Orig1s000TOC.cfm,
2014,KEYTRUDA,PEMBROLIZUMAB,BLA125514,9333c79b-d487-4538-a9f0-71b91a02b287,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s59-64,69,76-83SumR.pdf",
2014,KEYTRUDA,PEMBROLIZUMAB,BLA125514,9333c79b-d487-4538-a9f0-71b91a02b287,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/125514Orig1s056.pdf,
2014,KEYTRUDA,PEMBROLIZUMAB,BLA125514,9333c79b-d487-4538-a9f0-71b91a02b287,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s59-64,69,76-83SumR.pdf",
2014,KEYTRUDA,PEMBROLIZUMAB,BLA125514,9333c79b-d487-4538-a9f0-71b91a02b287,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s59-64,69,76-83SumR.pdf",
2014,KEYTRUDA,PEMBROLIZUMAB,BLA125514,9333c79b-d487-4538-a9f0-71b91a02b287,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/125514Orig1s052.pdf,
2014,KEYTRUDA,PEMBROLIZUMAB,BLA125514,9333c79b-d487-4538-a9f0-71b91a02b287,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/125514Orig1s097.pdf,
2014,KEYTRUDA,PEMBROLIZUMAB,BLA125514,9333c79b-d487-4538-a9f0-71b91a02b287,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/125514Orig1s034.pdf,
2014,KEYTRUDA,PEMBROLIZUMAB,BLA125514,9333c79b-d487-4538-a9f0-71b91a02b287,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/125514Orig1s024TOC.cfm,
2014,KEYTRUDA,PEMBROLIZUMAB,BLA125514,9333c79b-d487-4538-a9f0-71b91a02b287,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s59-64,69,76-83SumR.pdf",
2014,KEYTRUDA,PEMBROLIZUMAB,BLA125514,9333c79b-d487-4538-a9f0-71b91a02b287,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s59-64,69,76-83SumR.pdf",
2014,KEYTRUDA,PEMBROLIZUMAB,BLA125514,9333c79b-d487-4538-a9f0-71b91a02b287,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s59-64,69,76-83SumR.pdf",
2014,KEYTRUDA,PEMBROLIZUMAB,BLA125514,9333c79b-d487-4538-a9f0-71b91a02b287,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/125514Orig1s014.pdf,
2014,KEYTRUDA,PEMBROLIZUMAB,BLA125514,9333c79b-d487-4538-a9f0-71b91a02b287,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s59-64,69,76-83SumR.pdf",
2014,KEYTRUDA,PEMBROLIZUMAB,BLA125514,9333c79b-d487-4538-a9f0-71b91a02b287,"http://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s59-64,69,76-83SumR.pdf",
2014,KEYTRUDA,PEMBROLIZUMAB,BLA125514,9333c79b-d487-4538-a9f0-71b91a02b287,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/125514Orig1s065.pdf,
2014,KEYTRUDA,PEMBROLIZUMAB,BLA125514,9333c79b-d487-4538-a9f0-71b91a02b287,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s59-64,69,76-83SumR.pdf",
2014,KEYTRUDA,PEMBROLIZUMAB,BLA125514,9333c79b-d487-4538-a9f0-71b91a02b287,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/125514Orig1s055.pdf,
2014,KEYTRUDA,PEMBROLIZUMAB,BLA125514,9333c79b-d487-4538-a9f0-71b91a02b287,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/125514Orig1s047.pdf,
2014,KEYTRUDA,PEMBROLIZUMAB,BLA125514,9333c79b-d487-4538-a9f0-71b91a02b287,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s59-64,69,76-83SumR.pdf",
2014,KEYTRUDA,PEMBROLIZUMAB,BLA125514,9333c79b-d487-4538-a9f0-71b91a02b287,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/125514Orig1s045.pdf,
2014,KEYTRUDA,PEMBROLIZUMAB,BLA125514,9333c79b-d487-4538-a9f0-71b91a02b287,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/125514Orig1s096.pdf,
2014,KEYTRUDA,PEMBROLIZUMAB,BLA125514,9333c79b-d487-4538-a9f0-71b91a02b287,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s59-64,69,76-83SumR.pdf",
2014,KEYTRUDA,PEMBROLIZUMAB,BLA125514,9333c79b-d487-4538-a9f0-71b91a02b287,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/125514Orig1s092.pdf,
2014,KEYTRUDA,PEMBROLIZUMAB,BLA125514,9333c79b-d487-4538-a9f0-71b91a02b287,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s59-64,69,76-83SumR.pdf",
2014,KEYTRUDA,PEMBROLIZUMAB,BLA125514,9333c79b-d487-4538-a9f0-71b91a02b287,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/125514Orig1s009.pdf,
2014,KEYTRUDA,PEMBROLIZUMAB,BLA125514,9333c79b-d487-4538-a9f0-71b91a02b287,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s59-64,69,76-83SumR.pdf",
2011,JAKAFI,RUXOLITINIB,NDA202192,f1c82580-87ae-11e0-bc84-0002a5d5c51b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202192Orig1s000SumR.pdf,
2011,JAKAFI,RUXOLITINIB,NDA202192,f1c82580-87ae-11e0-bc84-0002a5d5c51b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/202192Orig1s000.pdf,
2011,JAKAFI,RUXOLITINIB,NDA202192,f1c82580-87ae-11e0-bc84-0002a5d5c51b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/243_202192S15-ruxolitinib-clinical-bpca.pdf,
2011,JAKAFI,RUXOLITINIB,NDA202192,f1c82580-87ae-11e0-bc84-0002a5d5c51b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/242_202192S15-ruxolitinib-clinpharm-bpca.pdf,
2011,JAKAFI,RUXOLITINIB,NDA202192,f1c82580-87ae-11e0-bc84-0002a5d5c51b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/243_202192S15-ruxolitinib-clinical-bpca.pdf,
2011,JAKAFI,RUXOLITINIB,NDA202192,f1c82580-87ae-11e0-bc84-0002a5d5c51b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/242_202192S15-ruxolitinib-clinpharm-bpca.pdf,
2016,EVOMELA,MELPHALAN,NDA207155,69f55869-dc11-408e-8fc7-47634269a52c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/207155Orig1s000_Orig2s000TOC.cfm,
2016,EVOMELA,MELPHALAN,NDA207155,69f55869-dc11-408e-8fc7-47634269a52c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/207155Orig1s000_Orig2s000TOC.cfm,
2015,ARISTADA,ARIPIPRAZOLE LAUROXIL,NDA207533,17a8d11b-73b0-4833-a0b4-cf1ef85edefb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207533Orig1s000TOC.cfm,
2015,ARISTADA,ARIPIPRAZOLE LAUROXIL,NDA207533,17a8d11b-73b0-4833-a0b4-cf1ef85edefb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207533Orig1s000SumR.pdf,
2015,INVEGA HAFYERA,PALIPERIDONE PALMITATE,NDA207946,6cd61892-d2cb-434d-83ed-5c1b2c4e7a0b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207946Orig1s000SumR.pdf,
2015,INVEGA HAFYERA,PALIPERIDONE PALMITATE,NDA207946,6cd61892-d2cb-434d-83ed-5c1b2c4e7a0b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207946Orig1s000TOC.cfm,
2017,VYXEOS,(DAUNORUBICIN AND CYTARABINE) LIPOSOME,NDA209401,7ea701ce-e7d3-4349-a9c2-642a501d45c8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209401Orig1s000TOC.cfm,
2020,ONUREG,AZACITIDINE,NDA214120,0e95e33f-8aba-4f19-b332-2416580d358b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214120Orig1s000TOC.cfm,
2019,CYSTEINE HYDROCHLORIDE,CYSTEINE HYDROCHLORIDE,NDA212535,cbf70fc3-14b3-4c17-8de8-acba1e12ac95,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212535Orig1s000TOC.cfm,
2021,VERKAZIA,CYCLOSPORINE,NDA214965,c795cd2f-89da-78e3-e053-2a95a90a9422,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214965Orig1s000TOC.cfm,
2022,LOCAMETZ,KIT FOR THE PREPARATION OF GALLIUM GA 68 GOZETOTIDE,NDA215841,1ea62b65-8138-4a88-8a33-4060ececa42f,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215841Orig1s000TOC.cfm,
2024,VIGAFYDE,VIGABATRIN,NDA217684,8d3d6316-33ab-41e8-9485-4495c218be56,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/217684Orig1s000TOC.cfm,
2012,VIOKACE,PANCRELIPASE,BLA022542,58bdb8de-582d-44e6-9b72-8d5a42fdf501,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/022542Orig1s007.pdf,
2012,VIOKACE,PANCRELIPASE,BLA022542,58bdb8de-582d-44e6-9b72-8d5a42fdf501,https://www.accessdata.fda.gov/drusgsatfda_docs/nda/2024/022542Orig1s010.pdf,
2012,VIOKACE,PANCRELIPASE,BLA022542,58bdb8de-582d-44e6-9b72-8d5a42fdf501,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022542_viokace_toc.cfm,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2012,VIOKACE,PANCRELIPASE,BLA022542,58bdb8de-582d-44e6-9b72-8d5a42fdf501,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022542Orig1s000SumR.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2012,VIOKACE,PANCRELIPASE,BLA022542,58bdb8de-582d-44e6-9b72-8d5a42fdf501,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/022542Orig1s008.pdf,
2012,VIOKACE,PANCRELIPASE,BLA022542,58bdb8de-582d-44e6-9b72-8d5a42fdf501,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/022542Orig1s006.pdf,
2018,SYMFI,"EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE",NDA022142,81a55dd9-78a8-49c3-88ab-8f5bffafa359,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/022142Orig1s000TOC.cfm,
2018,SYMFI,"EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE",NDA022142,81a55dd9-78a8-49c3-88ab-8f5bffafa359,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/259_22142-symfi-clinpharm-prea.pdf,
2005,ALPHAGAN P,BRIMONIDINE TARTRATE,NDA021770,264c4494-c225-486f-888a-caaf36be46b3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021770s000TOC.cfm,
1987,N/A,N/A,NDA050605,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50605S032_Ceftin.pdf,
1984,TENORETIC,ATENOLOL AND CHLORTHALIDONE,NDA018760,992e66b7-525a-4bf8-bce7-6b29cb120378,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/18240-s025_Tenormin.pdf,
1984,TENORETIC,ATENOLOL AND CHLORTHALIDONE,NDA018760,992e66b7-525a-4bf8-bce7-6b29cb120378,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/18240-s026_tenormin.pdf,
2015,UNITUXIN,DINUTUXIMAB,BLA125516,d66bdf0d-9d65-45de-ae5b-a58617c27492,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125516Orig1s000TOC.cfm,
2015,UNITUXIN,DINUTUXIMAB,BLA125516,d66bdf0d-9d65-45de-ae5b-a58617c27492,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125516Orig1s000SumR.pdf,
2013,DOTAREM,GADOTERATE MEGLUMINE,NDA204781,e2c4a5ac-2df2-4cf4-a2d3-6fbe2d898ebc,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/174_204781S1-gadoterate-clinpharm-prea.pdf,
2013,DOTAREM,GADOTERATE MEGLUMINE,NDA204781,e2c4a5ac-2df2-4cf4-a2d3-6fbe2d898ebc,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/173_204781S1-gadoterate-clinical-prea.pdf,
2013,DOTAREM,GADOTERATE MEGLUMINE,NDA204781,e2c4a5ac-2df2-4cf4-a2d3-6fbe2d898ebc,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/175_204781S1-gadoterate-statistical-prea.pdf,
2013,DOTAREM,GADOTERATE MEGLUMINE,NDA204781,e2c4a5ac-2df2-4cf4-a2d3-6fbe2d898ebc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204781Orig1s000TOC.cfm,
2013,DOTAREM,GADOTERATE MEGLUMINE,NDA204781,e2c4a5ac-2df2-4cf4-a2d3-6fbe2d898ebc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204781Orig1s000SumR.pdf,
2013,DOTAREM,GADOTERATE MEGLUMINE,NDA204781,e2c4a5ac-2df2-4cf4-a2d3-6fbe2d898ebc,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/204781 gadoterate meglumine Dotarem ClinPharm prea.pdf,
2013,DOTAREM,GADOTERATE MEGLUMINE,NDA204781,e2c4a5ac-2df2-4cf4-a2d3-6fbe2d898ebc,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/204781 gadoterate meglumine Dotarem Clinical prea.pdf,
2013,DOTAREM,GADOTERATE MEGLUMINE,NDA204781,e2c4a5ac-2df2-4cf4-a2d3-6fbe2d898ebc,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/204781 gadoterate meglumine Dotarem Statistical prea.pdf,
2018,KAPSPARGO,METOPROLOL SUCCINATE,NDA210428,9cfa55b4-15c6-40f7-b6e5-41096ee51bfc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210428Orig1s000TOC.cfm,
2018,KAPSPARGO,METOPROLOL SUCCINATE,NDA210428,9cfa55b4-15c6-40f7-b6e5-41096ee51bfc,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/413_210428 metoprolol succinate CDTL clinical prea.pdf,
2018,KAPSPARGO,METOPROLOL SUCCINATE,NDA210428,9cfa55b4-15c6-40f7-b6e5-41096ee51bfc,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/414_210428 metoprolol succinate Clinpharm prea.pdf,
2017,N/A,N/A,NDA207534,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207534Orig1s0000TOC.cfm,
2015,UPTRAVI,SELEXIPAG,NDA207947,a7a23b87-f892-4e2c-8e2e-ebf841220f90,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000TOC.cfm,
2015,UPTRAVI,SELEXIPAG,NDA207947,a7a23b87-f892-4e2c-8e2e-ebf841220f90,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000SumR.pdf,
1991,NOVOLIN N,HUMAN INSULIN,BLA019959,82f1445c-b2c6-445a-82cf-ba8825fac776,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019959ap.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2020,N/A,N/A,NDA214121,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214121Orig1s000TOC.cfm,
2019,BIORPHEN,PHENYLEPHRINE HYDROCHLORIDE,NDA212909,bf7daa65-2a6c-4d59-a6f3-3af70edcc7e2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212909Orig1s000TOC.cfm,
1998,BRINZOLAMIDE,BRINZOLAMIDE,NDA020816,ed6dbc25-47d7-42db-9787-5814d71f45ce,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021114s002_levobetaxolol_Betaxon MedRev.pdf,
1998,BRINZOLAMIDE,BRINZOLAMIDE,NDA020816,ed6dbc25-47d7-42db-9787-5814d71f45ce,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020816_azopt.cfm,
2023,RIVFLOZA,NEDOSIRAN,NDA215842,ace9d4bc-4d20-4beb-9e9d-888690424833,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215842Orig1s000TOC.cfm,
2011,GRALISE,GABAPENTIN,NDA022544,466273b1-c9fc-3930-c94b-aa11394d5140,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/022544Orig1s027.pdf,
2011,GRALISE,GABAPENTIN,NDA022544,466273b1-c9fc-3930-c94b-aa11394d5140,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022544Orig1s000SumR.pdf,
2011,GRALISE,GABAPENTIN,NDA022544,466273b1-c9fc-3930-c94b-aa11394d5140,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022544_gralise_toc.cfm,
1999,N/A,N/A,NDA021085,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21-085_Avelox.cfm,
1999,N/A,N/A,NDA021085,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/13_21085 moxifloxacin clinical prea.pdf,
1999,N/A,N/A,NDA021085,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/14_21085 moxifloxacin clinpharm prea.pdf,
1999,N/A,N/A,NDA021085,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/12_21085 moxifloxacin statistical prea.pdf,
1999,N/A,N/A,NDA021085,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021085_S022_Avelox_Tablets.pdf,
1999,N/A,N/A,NDA021085,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-085S10_Avelox.cfm,
2004,N/A,N/A,NDA021415,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021415s000_MetvixiaTOC.cfm,
2007,ISENTRESS,RALTEGRAVIR,NDA022145,89a5ec53-d956-4329-8004-0f40f51c88a3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022145Orig1s004.pdf,
2007,ISENTRESS,RALTEGRAVIR,NDA022145,89a5ec53-d956-4329-8004-0f40f51c88a3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/Raltegravir-N22-145S022-Clinical-PREA.pdf,
2007,ISENTRESS,RALTEGRAVIR,NDA022145,89a5ec53-d956-4329-8004-0f40f51c88a3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/Raltegravir-N22-145S022-Clinpharm-PREA.pdf,
2007,ISENTRESS,RALTEGRAVIR,NDA022145,89a5ec53-d956-4329-8004-0f40f51c88a3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022145_Isentress.cfm,
2007,ISENTRESS,RALTEGRAVIR,NDA022145,89a5ec53-d956-4329-8004-0f40f51c88a3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022145_SumR.pdf,
2007,ISENTRESS,RALTEGRAVIR,NDA022145,89a5ec53-d956-4329-8004-0f40f51c88a3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/127_22145S036 raltegravir CDTL clinical prea.pdf,
2007,ISENTRESS,RALTEGRAVIR,NDA022145,89a5ec53-d956-4329-8004-0f40f51c88a3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/128_22145S036 raltegravir clinpharm prea.pdf,
2007,ISENTRESS,RALTEGRAVIR,NDA022145,89a5ec53-d956-4329-8004-0f40f51c88a3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/129_22145S036 raltegravir statistical prea.pdf,
2007,ISENTRESS,RALTEGRAVIR,NDA022145,89a5ec53-d956-4329-8004-0f40f51c88a3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022145 raltegravir_Isentress_clinical prea.pdf,
2005,BYETTA,EXENATIDE,NDA021773,53d03c03-ebf7-418d-88a8-533eabd2ee4f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021773_ByettaTOC.cfm,
1965,CELESTONE SOLUSPAN,BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE,NDA014602,bf78d1be-42d7-4837-92a5-49113a79278f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/014602Orig1s056.pdf,
2016,INFLECTRA,INFLIXIMAB-DYYB,BLA125544,37eaca10-d812-48bc-8b8e-b836bfa9968f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/125544 StatReview.pdf,
2016,INFLECTRA,INFLIXIMAB-DYYB,BLA125544,37eaca10-d812-48bc-8b8e-b836bfa9968f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/125544 Clinical Review-05 04 2015.pdf,
2016,INFLECTRA,INFLIXIMAB-DYYB,BLA125544,37eaca10-d812-48bc-8b8e-b836bfa9968f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125544Orig1s000TOC.cfm,
2013,ECOZA,ECONAZOLE NITRATE,NDA205175,0bb5fa27-32ed-ed13-e063-6394a90a1577,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205175_ECONAZOLE_NITRATE_STATISTICAL_BPCA.pdf,
2013,ECOZA,ECONAZOLE NITRATE,NDA205175,0bb5fa27-32ed-ed13-e063-6394a90a1577,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205175_ECONAZOLE_NITRATE_CLINICAL_BPCA.pdf,
2013,ECOZA,ECONAZOLE NITRATE,NDA205175,0bb5fa27-32ed-ed13-e063-6394a90a1577,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205175_ECONAZOLE_NITRATE_CLINPHARM_BPCA.pdf,
2013,ECOZA,ECONAZOLE NITRATE,NDA205175,0bb5fa27-32ed-ed13-e063-6394a90a1577,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205175Orig1s000TOC.cfm,
2013,ECOZA,ECONAZOLE NITRATE,NDA205175,0bb5fa27-32ed-ed13-e063-6394a90a1577,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205175Orig1s000SumR.pdf,
2015,YONDELIS,TRABECTEDIN,NDA207953,472bd78e-be17-4b9d-90f4-9482c3aec9ff,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207953Orig1s000SumR.pdf,
2015,YONDELIS,TRABECTEDIN,NDA207953,472bd78e-be17-4b9d-90f4-9482c3aec9ff,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/297_207953S4-trabectedin-clinpharm-bpca.pdf,
2015,YONDELIS,TRABECTEDIN,NDA207953,472bd78e-be17-4b9d-90f4-9482c3aec9ff,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207953Orig1s000TOC.cfm,
2015,YONDELIS,TRABECTEDIN,NDA207953,472bd78e-be17-4b9d-90f4-9482c3aec9ff,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/298_207953S4-trabectedin-clinical-bpca.pdf,
2021,FYARRO,SIROLIMUS,NDA213312,0f9bb784-53e2-46f9-a65d-1c6c2a230eaf,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/213312Orig1s000TOC.cfm,
2025,ARBLI,LOSARTAN POTASSIUM,NDA218772,afd2d1ba-e7af-4e4e-8b7e-a9f72612fc97,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/218772Orig1s000TOC.cfm,
1996,N/A,N/A,NDA020528,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020528Orig1s000rev.pdf,
1996,N/A,N/A,NDA020528,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020528_s001ap.pdf,
2024,EBGLYSS,LEBRIKIZUMAB-LBKZ,BLA761306,7a774ea2-acde-4aaa-9a8f-ccba5a5b1d5f,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761306Orig1s000TOC.cfm,
2007,CHILDRENS ZYRTEC,CETIRIZINE HYDROCHLORIDE,NDA022155,9d8e78ea-af98-4f7c-8db5-044b49582f80,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022155s000TOC.cfm,
2004,N/A,N/A,NDA021779,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021779Orig1s009.pdf,
2004,N/A,N/A,NDA021779,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-779_Ventavis.cfm,
1986,N/A,N/A,NDA050611,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-207s054s55_50-297s018_50-611s018_Erthromycin.cfm,
2021,REPATHA,EVOLOCUMAB,BLA125522,cd61e902-166d-4aa6-9f3c-a18c1008d07e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125522Orig1s004.pdf,
2021,REPATHA,EVOLOCUMAB,BLA125522,cd61e902-166d-4aa6-9f3c-a18c1008d07e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/125522Orig2s000TOC.cfm,
2021,REPATHA,EVOLOCUMAB,BLA125522,cd61e902-166d-4aa6-9f3c-a18c1008d07e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125522Orig1s001.pdf,
2021,REPATHA,EVOLOCUMAB,BLA125522,cd61e902-166d-4aa6-9f3c-a18c1008d07e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125522Orig1s000SumR.pdf,
2021,REPATHA,EVOLOCUMAB,BLA125522,cd61e902-166d-4aa6-9f3c-a18c1008d07e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125522Orig1s000TOC.cfm,
1991,LOTENSIN,BENAZEPRIL HYDROCHLORIDE,NDA019851,2abb091b-a53e-46b0-9b84-e5ee8f2bdd8e,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/019851s028_benazepril_Lotensin_MedReview.pdf,
1991,LOTENSIN,BENAZEPRIL HYDROCHLORIDE,NDA019851,2abb091b-a53e-46b0-9b84-e5ee8f2bdd8e,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/019851s028_benazepril_Lotensin_ClinPharmReview.pdf,
1991,LOTENSIN,BENAZEPRIL HYDROCHLORIDE,NDA019851,2abb091b-a53e-46b0-9b84-e5ee8f2bdd8e,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/019851s028_benazepril_Lotensin_StatReview.pdf,
2017,EMFLAZA,DEFLAZACORT,NDA208684,31b347d2-f156-4055-9d8f-7cf0df420296,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208684,208685Orig1s000TOC.cfm",
1997,N/A,N/A,NDA020624,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020624_anzemet_toc.cfm,
1997,N/A,N/A,NDA020624,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020624_S009_ANZEMET.pdf,
1997,N/A,N/A,NDA020624,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020624_S008_AMZEMET_AP.pdf,
1997,SEREVENT DISKUS,SALMETEROL XINAFOATE,NDA020692,12d9728e-6b5c-4aee-bfb0-745e542ed2e4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020692s000_SereventTOC.cfm,
1997,SEREVENT DISKUS,SALMETEROL XINAFOATE,NDA020692,12d9728e-6b5c-4aee-bfb0-745e542ed2e4,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20692S1,2_Serevent.cfm",
1997,SEREVENT DISKUS,SALMETEROL XINAFOATE,NDA020692,12d9728e-6b5c-4aee-bfb0-745e542ed2e4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020692_s024_SEREVENT DISKUS.pdf,
1997,SEREVENT DISKUS,SALMETEROL XINAFOATE,NDA020692,12d9728e-6b5c-4aee-bfb0-745e542ed2e4,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20692S1,2_Serevent.cfm",
2024,TRYVIO,APROCITENTAN,NDA217686,dfe7a2ee-612c-4aba-834a-d68e6b59a0a6,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217686Orig1s000TOC.cfm,
2024,PAVBLU,AFLIBERCEPT-AYYH,BLA761298,c61062f3-80ec-4a20-8c28-46e468592a06,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761298Orig1s000TOC.cfm,
1999,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021087,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/021087_S009_021246s004TamifluTOC.cfm,
1999,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021087,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/021087_S007_TamifluTOC.cfm,
1999,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021087,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/021087_s005s006_021246s001_TamifluTOC.cfm,
1999,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021087,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21087_Tamiflu.cfm,
1999,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021087,ee3c9555-60f2-4f82-a760-11983c86e97b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021087SLR016_oseltamivir_Tamiflu-MedRev.pdf,
1999,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021087,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021087_S011_TamilfluTOC.cfm,
1999,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021087,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/021087_S003_TamifluTOC.cfm,
1999,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021087,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021087Orig1s056.pdf,
1999,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021087,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021087Orig1s048.pdf,
1999,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021087,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2012/021087Orig1s062021246Orig1s045SumR.pdf,
1999,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021087,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021246Orig1s045_021087Orig1s062_tamiflu_toc.cfm,
1999,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021087,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/021087_S001_TamifluTOC.cfm,
1999,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021087,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021087Orig1s040.pdf,
1999,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021087,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021087_S016_021246s010TamifluTOC.cfm,
1999,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021087,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021087Orig1s030.pdf,
1999,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021087,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/021087_S008_021246s003_TamifluTOC.cfm,
1999,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021087,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/021087_s005s006_021246s001_TamifluTOC.cfm,
1999,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021087,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021087_S012_TamifluTOC.cfm,
1999,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021087,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/021087_S004_TamifluTOC.cfm,
1999,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021087,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021087_S010_021246s007_TamifluTOC.cfm,
1999,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021087,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021087Orig1s049.pdf,
1999,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021087,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-087SE1-002_review.pdf,
2011,FIRAZYR,ICATIBANT ACETATE,NDA022150,ed6657ca-ab68-477a-9968-e12dc928b540,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022150_firazyr_toc.cfm,
2008,N/A,N/A,NDA021775,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/021775s000_SUMR.pdf,
2008,N/A,N/A,NDA021775,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021775_ENTEREGTOC.cfm,
2015,NUCALA,MEPOLIZUMAB,BLA125526,fefb887c-e4ac-431e-8893-e9d1a5a63fea,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/125256 mepolizumab clinical prea.pdf,
2015,NUCALA,MEPOLIZUMAB,BLA125526,fefb887c-e4ac-431e-8893-e9d1a5a63fea,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/125526 mepolizumab clinpharm prea.pdf,
2015,NUCALA,MEPOLIZUMAB,BLA125526,fefb887c-e4ac-431e-8893-e9d1a5a63fea,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/125526 mepolizumab statistical prea.pdf,
2015,NUCALA,MEPOLIZUMAB,BLA125526,fefb887c-e4ac-431e-8893-e9d1a5a63fea,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125526Orig1s000TOC.cfm,
2015,NUCALA,MEPOLIZUMAB,BLA125526,fefb887c-e4ac-431e-8893-e9d1a5a63fea,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125526Orig1s000SumR.pdf,
2013,POMALYST,POMALIDOMIDE,NDA204026,2b25ef01-5c9e-11e1-b86c-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204026Orig1s000TOC.cfm,
2013,POMALYST,POMALIDOMIDE,NDA204026,2b25ef01-5c9e-11e1-b86c-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204026Orig1s000SumR.pdf,
2018,N/A,N/A,NDA208313,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208313Orig1s000TOC.cfm,
2021,N/A,N/A,NDA207949,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/207949Orig1s000TOC.cfm,
2022,TRIUMEQ PD,"ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE",NDA215413,2997739a-aa91-42aa-a206-a70e2db7b84f,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215413Orig1s000TOC.cfm,
1996,N/A,N/A,NDA020593,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020593_S006_DEPACON.pdf,
1997,N/A,N/A,NDA020657,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-966S001_Sporanox.cfm,
1997,N/A,N/A,NDA020657,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-966S001_Sporanox.cfm,
2010,ZYMAXID,GATIFLOXACIN,NDA022548,1160b16c-929a-4e85-9c0b-1d8c96a7678b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/022548Orig1s002.pdf,
2010,ZYMAXID,GATIFLOXACIN,NDA022548,1160b16c-929a-4e85-9c0b-1d8c96a7678b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022548s000_zymaxid_toc.cfm,
2010,ZYMAXID,GATIFLOXACIN,NDA022548,1160b16c-929a-4e85-9c0b-1d8c96a7678b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022548_Gatifloxacin_Clinical_PREA.pdf,
2010,ZYMAXID,GATIFLOXACIN,NDA022548,1160b16c-929a-4e85-9c0b-1d8c96a7678b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022548_Gatifloxacin_Clinpharm_PREA.pdf,
2010,ZYMAXID,GATIFLOXACIN,NDA022548,1160b16c-929a-4e85-9c0b-1d8c96a7678b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22548_Gatifloxacin_Statistical_PREA.pdf,
2010,ZYMAXID,GATIFLOXACIN,NDA022548,1160b16c-929a-4e85-9c0b-1d8c96a7678b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022548s000_zymaxid_toc.cfm,
2024,ADALIMUMAB-RYVK,ADALIMUMAB-RYVK,BLA761299,dce1590f-9e47-4c4d-9437-cfb18b779a75,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761299Orig1s000TOC.cfm,
2000,N/A,N/A,NDA021088,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/02-1088_Vidaur.cfm,
2002,METHYLIN,METHYLPHENIDATE HYDROCHLORIDE,NDA021419,9e3c22d9-71d9-46a7-b315-8021c94c4bec,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-419_Methylin.cfm,
2008,N/A,N/A,NDA022152,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022152s000_SumR.pdf,
2008,N/A,N/A,NDA022152,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022152_stavzor_toc.cfm,
2007,CYCLOBENZAPRINE HYDROCHLORIDE,CYCLOBENZAPRINE HYDROCHLORIDE,NDA021777,dd546a0e-e5be-4232-8ad8-fcd7d5f9a903,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021777s000TOC.cfm,
2011,PREZISTA,DARUNAVIR,NDA202895,814301f9-c990-46a5-b481-2879a521a16f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202895-Darunavir-Clinpharm-BPCA.pdf,
2011,PREZISTA,DARUNAVIR,NDA202895,814301f9-c990-46a5-b481-2879a521a16f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202895-Darunavir-Clinical-BPCA.pdf,
2011,PREZISTA,DARUNAVIR,NDA202895,814301f9-c990-46a5-b481-2879a521a16f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202895_prezista_toc.cfm,
2011,PREZISTA,DARUNAVIR,NDA202895,814301f9-c990-46a5-b481-2879a521a16f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202895Orig1s000SumR.pdf,
2015,N/A,N/A,BLA125527,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125527Orig1s000TOC.cfm,
2013,TOBI PODHALER,TOBRAMYCIN,NDA201688,c4b5bb1f-e158-4ac1-9c35-e98a416c743a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/201688Orig1s000TOC.cfm,
2013,TOBI PODHALER,TOBRAMYCIN,NDA201688,c4b5bb1f-e158-4ac1-9c35-e98a416c743a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/201688Orig1s000SumR.pdf,
1988,N/A,N/A,NDA019596,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019596a_s08_s09_022896_Magnevist.pdf,
1988,N/A,N/A,NDA019596,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019596a_s08_s09_022896_Magnevist.pdf,
2013,TAYTULLA,"NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, AND FERROUS FUMARATE",NDA204426,2fa8e8dc-f7b0-429a-b554-0e3c4291c92c,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/204426 ee ne clinical prea.pdf,
2013,TAYTULLA,"NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, AND FERROUS FUMARATE",NDA204426,2fa8e8dc-f7b0-429a-b554-0e3c4291c92c,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/204426 ee ne clinpharm prea.pdf,
2013,TAYTULLA,"NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, AND FERROUS FUMARATE",NDA204426,2fa8e8dc-f7b0-429a-b554-0e3c4291c92c,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/204426 ee ne statistical prea.pdf,
2013,TAYTULLA,"NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, AND FERROUS FUMARATE",NDA204426,2fa8e8dc-f7b0-429a-b554-0e3c4291c92c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204426_minastrin_toc.cfm,
2013,TAYTULLA,"NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, AND FERROUS FUMARATE",NDA204426,2fa8e8dc-f7b0-429a-b554-0e3c4291c92c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204426Orig1s000SumR.pdf,
2014,BUDESONIDE,BUDESONIDE,NDA205613,b2cf85c5-3ae0-4f91-9f3a-1d6771e14a73,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205613Orig1s000TOC.cfm,
2014,BUDESONIDE,BUDESONIDE,NDA205613,b2cf85c5-3ae0-4f91-9f3a-1d6771e14a73,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205613Orig1s000SumR.pdf,
2016,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA208686,c7934b45-eb6b-44c1-bd2c-ef0fa10850c1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208686Orig1s000TOC.cfm,
2020,TYBLUME,LEVONORGESTREL AND ETHINYL ESTRADIOL,NDA209405,b2482d51-d606-4aaa-8af4-19e4fe2f8872,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209405Orig1s000TOC.cfm,
2020,DOJOLVI,TRIHEPTANOIN,NDA213687,4cfeb8bd-143e-4dd7-bc34-b0bcda02460d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213687Orig1s000TOC.cfm,
2024,N/A,N/A,NDA218771,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/218771Orig1s000TOC.cfm,
2025,AVMAPKI FAKZYNJA CO-PACK,AVUTOMETINIB POTASSIUM AND DEFACTINIB HYDROCHLORIDE,NDA219616,65889527-1406-45df-8a85-e2690dcf427d,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219616Orig1s000TOC.cfm,
1996,INSULIN LISPRO,INSULIN LISPRO,BLA020563,97d5e596-aae1-42c9-ae89-c3780959c467,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020563_S009_Humalog_APPROVAL PACKAGE.pdf,
1996,INSULIN LISPRO,INSULIN LISPRO,BLA020563,97d5e596-aae1-42c9-ae89-c3780959c467,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020563Orig1s000rev.pdf,
1996,INSULIN LISPRO,INSULIN LISPRO,BLA020563,97d5e596-aae1-42c9-ae89-c3780959c467,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020563a_s003_071697.pdf,
2012,N/A,N/A,NDA022549,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022549_adasuve_toc.cfm,
2012,N/A,N/A,NDA022549,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022549Orig1s000SumR.pdf,
2012,N/A,N/A,NDA022549,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022549Orig1s000SumR.pdf,
2023,VYVGART HYTRULO,EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT),BLA761304,7104d9e5-9910-47f5-9a93-741ac50f43b6,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761304Orig1s000TOC.cfm,
2000,N/A,N/A,NDA021090,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-090_Cyclessa.cfm,
2009,N/A,N/A,NDA022154,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022154s000_SumR.pdf,
2009,N/A,N/A,NDA022154,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022154_tyzeka_toc.cfm,
2005,N/A,N/A,NDA021778,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021778s000TOC.cfm,
2013,RAVICTI,GLYCEROL PHENYLBUTYRATE,NDA203284,900e7dc0-9afe-4f50-80de-90567bb78519,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203284Orig1s000TOC.cfm,
1987,PROZAC,FLUOXETINE HYDROCHLORIDE,NDA018936,c88f33ed-6dfb-4c5e-bc01-d8e36dd97299,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/018936Orig1s093.pdf,
1987,PROZAC,FLUOXETINE HYDROCHLORIDE,NDA018936,c88f33ed-6dfb-4c5e-bc01-d8e36dd97299,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/018936_S060,S062,S063_ProzacTOC.cfm",
1987,PROZAC,FLUOXETINE HYDROCHLORIDE,NDA018936,c88f33ed-6dfb-4c5e-bc01-d8e36dd97299,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/018936Orig1s111.pdf,
1987,PROZAC,FLUOXETINE HYDROCHLORIDE,NDA018936,c88f33ed-6dfb-4c5e-bc01-d8e36dd97299,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018936_S033_PROZAC.pdf,
1987,PROZAC,FLUOXETINE HYDROCHLORIDE,NDA018936,c88f33ed-6dfb-4c5e-bc01-d8e36dd97299,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/018936Orig1s078.pdf,
1987,PROZAC,FLUOXETINE HYDROCHLORIDE,NDA018936,c88f33ed-6dfb-4c5e-bc01-d8e36dd97299,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/18936s064_Prozac.cfm,
1987,PROZAC,FLUOXETINE HYDROCHLORIDE,NDA018936,c88f33ed-6dfb-4c5e-bc01-d8e36dd97299,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/018936_S060,S062,S063_ProzacTOC.cfm",
1987,PROZAC,FLUOXETINE HYDROCHLORIDE,NDA018936,c88f33ed-6dfb-4c5e-bc01-d8e36dd97299,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/18-936s054_Prozac.cfm,
1987,PROZAC,FLUOXETINE HYDROCHLORIDE,NDA018936,c88f33ed-6dfb-4c5e-bc01-d8e36dd97299,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/018936_S060,S062,S063_ProzacTOC.cfm",
1987,PROZAC,FLUOXETINE HYDROCHLORIDE,NDA018936,c88f33ed-6dfb-4c5e-bc01-d8e36dd97299,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/18-936S052_20-101S024_Prozac.cfm,
1987,PROZAC,FLUOXETINE HYDROCHLORIDE,NDA018936,c88f33ed-6dfb-4c5e-bc01-d8e36dd97299,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/018936Orig1s097.pdf,
1987,PROZAC,FLUOXETINE HYDROCHLORIDE,NDA018936,c88f33ed-6dfb-4c5e-bc01-d8e36dd97299,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/18936S036_ProzacPulvules.pdf,
2013,KIT FOR THE PREPARATION OF LYMPHOSEEK (TECHNETIUM TC 99M TILMANOCEPT),TILMANOCEPT,NDA202207,72f31b09-4d7b-475c-b37a-9daf2ad80240,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202207Orig1s000TOC.cfm,
2013,KIT FOR THE PREPARATION OF LYMPHOSEEK (TECHNETIUM TC 99M TILMANOCEPT),TILMANOCEPT,NDA202207,72f31b09-4d7b-475c-b37a-9daf2ad80240,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202207Orig1s000SumR.pdf,
2013,N/A,N/A,NDA203667,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203667_norethindrone_toc.cfm,
2013,N/A,N/A,NDA203667,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203667Orig1s000SumR.pdf,
2015,LEVETIRACETAM,LEVETIRACETAM,NDA207958,dd175fa3-1d7a-4542-affd-988ac5bba1db,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207958Orig1s000TOC.cfm,
2016,CABOMETYX,CABOZANTINIB,NDA208692,3850cce2-6137-42e5-a792-d318c4a4b3b5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208692Orig1s000TOC.cfm,
1996,N/A,N/A,NDA020130,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20130-s003_Estrostep.pdf,
2024,VORANIGO,VORASIDENIB,NDA218784,31405fee-55b7-4857-987e-2724ee76be84,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/218784Orig1s000TOC.cfm,
2010,ATELVIA,RISEDRONATE SODIUM,NDA022560,c8b9ab88-1a26-46c3-80ec-4eaa45202021,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022560Orig1s000TOC.cfm,
2010,ATELVIA,RISEDRONATE SODIUM,NDA022560,c8b9ab88-1a26-46c3-80ec-4eaa45202021,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022560Orig1s000SumR.pdf,
2023,N/A,N/A,BLA761313,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2024/761313Orig1s000SumR.pdf,
2004,CYMBALTA,DULOXETINE HYDROCHLORIDE,NDA021427,2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021427Orig1s015_s017.pdf,
2004,CYMBALTA,DULOXETINE HYDROCHLORIDE,NDA021427,2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021427Orig1s039.pdf,
2004,CYMBALTA,DULOXETINE HYDROCHLORIDE,NDA021427,2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21427 duloxetine clinical prea.pdf,
2004,CYMBALTA,DULOXETINE HYDROCHLORIDE,NDA021427,2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21427 duloxetine statistical bpca.pdf,
2004,CYMBALTA,DULOXETINE HYDROCHLORIDE,NDA021427,2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021427_s000_Cymbalta.cfm,
2004,CYMBALTA,DULOXETINE HYDROCHLORIDE,NDA021427,2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21427 duloxetine clinical prea.pdf,
2004,CYMBALTA,DULOXETINE HYDROCHLORIDE,NDA021427,2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/050795s010 doxycycline statistical prea.pdf,
2004,CYMBALTA,DULOXETINE HYDROCHLORIDE,NDA021427,2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21427 duloxetine clinical bpca.pdf,
2004,CYMBALTA,DULOXETINE HYDROCHLORIDE,NDA021427,2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21427 duloxetine clinpharm bpca.pdf,
2004,CYMBALTA,DULOXETINE HYDROCHLORIDE,NDA021427,2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021427Orig1s015_s017.pdf,
2008,ORAVERSE,PHENTOLAMINE MESYLATE,NDA022159,4025cf98-ea87-4531-b0fc-6283c84f63f3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/N22-159S011-Phentolamine-mesylate-Clinical-PREA.pdf,
2008,ORAVERSE,PHENTOLAMINE MESYLATE,NDA022159,4025cf98-ea87-4531-b0fc-6283c84f63f3,http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/022159s000_SUMR.pdf,
2008,ORAVERSE,PHENTOLAMINE MESYLATE,NDA022159,4025cf98-ea87-4531-b0fc-6283c84f63f3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22159 phentolamine statistical prea.pdf,
2008,ORAVERSE,PHENTOLAMINE MESYLATE,NDA022159,4025cf98-ea87-4531-b0fc-6283c84f63f3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22159 phentolamine clinical prea.pdf,
2008,ORAVERSE,PHENTOLAMINE MESYLATE,NDA022159,4025cf98-ea87-4531-b0fc-6283c84f63f3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022159_Phentolamine_Clinpharm_PREA.pdf,
2008,ORAVERSE,PHENTOLAMINE MESYLATE,NDA022159,4025cf98-ea87-4531-b0fc-6283c84f63f3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022159_oraverse_toc.cfm,
2004,N/A,N/A,NDA021785,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021785_S002_FORTOVASE.pdf,
2004,N/A,N/A,NDA021785,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021785s000_InviraseTOC.cfm,
2018,RETACRIT,EPOETIN ALFA-EPBX,BLA125545,e6e4dd0c-25ca-40b2-ba6b-6138a68621fe,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/125545Orig1s000TOC.cfm,
2010,PILOCARPINE HYDROCHLORIDE,PILOCARPINE HYDROCHLORIDE,NDA200890,53fa0b7a-f982-48a7-92c4-6f098683c1ed,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200890_carpine_toc.cfm,
2010,PILOCARPINE HYDROCHLORIDE,PILOCARPINE HYDROCHLORIDE,NDA200890,53fa0b7a-f982-48a7-92c4-6f098683c1ed,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200890s000SumR.pdf,
2010,PILOCARPINE HYDROCHLORIDE,PILOCARPINE HYDROCHLORIDE,NDA200890,53fa0b7a-f982-48a7-92c4-6f098683c1ed,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/200890_pilocarpine_clinical_PREA.pdf,
2010,PILOCARPINE HYDROCHLORIDE,PILOCARPINE HYDROCHLORIDE,NDA200890,53fa0b7a-f982-48a7-92c4-6f098683c1ed,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/200890_pilocarpine_clinpharm_PREA.pdf,
2010,PILOCARPINE HYDROCHLORIDE,PILOCARPINE HYDROCHLORIDE,NDA200890,53fa0b7a-f982-48a7-92c4-6f098683c1ed,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/200890_pilocarpine_statistical_PREA.pdf,
2014,N/A,N/A,NDA204427,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/310_204427S6-tavaborole-multireview-both.pdf,
2014,N/A,N/A,NDA204427,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000TOC.cfm,
2014,N/A,N/A,NDA204427,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000SumR.pdf,
2013,TIVICAY,DOLUTEGRAVIR SODIUM,NDA204790,63df5af3-b8ac-4e76-9830-2dbb340af922,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204790Orig1s000TOC.cfm,
2013,TIVICAY,DOLUTEGRAVIR SODIUM,NDA204790,63df5af3-b8ac-4e76-9830-2dbb340af922,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/204790_dolutegravir_Tivicay_Clinical Rev_PREA.pdf,
2013,TIVICAY,DOLUTEGRAVIR SODIUM,NDA204790,63df5af3-b8ac-4e76-9830-2dbb340af922,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/204790 dolutegravir clinical prea.pdf,
2013,TIVICAY,DOLUTEGRAVIR SODIUM,NDA204790,63df5af3-b8ac-4e76-9830-2dbb340af922,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/204790_dolutegravir_Tivicay_Stat Rev_PREA.pdf,
2013,TIVICAY,DOLUTEGRAVIR SODIUM,NDA204790,63df5af3-b8ac-4e76-9830-2dbb340af922,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204790Orig1S000SumR.pdf,
2013,TIVICAY,DOLUTEGRAVIR SODIUM,NDA204790,63df5af3-b8ac-4e76-9830-2dbb340af922,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/204790 dolutegravir clinical CDTL prea.pdf,
2013,TIVICAY,DOLUTEGRAVIR SODIUM,NDA204790,63df5af3-b8ac-4e76-9830-2dbb340af922,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/204790 dolutegravir clinpharm prea.pdf,
2013,TIVICAY,DOLUTEGRAVIR SODIUM,NDA204790,63df5af3-b8ac-4e76-9830-2dbb340af922,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/204790 dolutegravir_Tivicay_ClinPharm_PREA.pdf,
2019,GIVLAARI,GIVOSIRAN SODIUM,NDA212194,167e663c-11e1-497b-a3fc-951d65d58eaa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212194Orig1s000TOC.cfm,
2023,COLUMVI,GLOFITAMAB,BLA761309,3516e753-f064-4d30-9bd5-e3f2e143f75d,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761309Orig1s000TOC.cfm,
2000,CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE,CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE,NDA021093,bd8d318d-167a-4b26-935d-265dde3193de,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-093_AtacandHCT.cfm,
2002,N/A,N/A,NDA021425,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021425_ultravist.cfm,
2008,CLEVIPREX,CLEVIDIPINE,NDA022156,a6826aa3-fabb-4ff1-a7a3-cd4c34e3a330,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022156s000_SumR.pdf,
2008,CLEVIPREX,CLEVIDIPINE,NDA022156,a6826aa3-fabb-4ff1-a7a3-cd4c34e3a330,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022156_cleviprex_toc.cfm,
2006,N/A,N/A,NDA021780,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021780_nitromist_toc.cfm,
2015,PORTRAZZA,NECITUMUMAB,BLA125547,89bcf553-669a-40b0-a9d7-67a5c1d2f591,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125547Orig1s000TOC.cfm,
2015,PORTRAZZA,NECITUMUMAB,BLA125547,89bcf553-669a-40b0-a9d7-67a5c1d2f591,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125547Orig1s000SumR.pdf,
2021,RECORLEV,LEVOKETOCONAZOLE,NDA214133,d4c5fead-bc4a-fb02-e053-2a95a90ae4fc,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214133Orig1s000TOC.cfm,
2020,ZILXI,MINOCYCLINE,NDA213690,116f9ade-1bdc-4162-98d8-d3a0c592f419,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213690Orig1s000TOC.cfm,
2021,CAMCEVI,LEUPROLIDE,NDA211488,d7a8761a-d953-413a-e053-2a95a90a60ee,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211488Orig1s000TOC.cfm,
1993,LUPRON DEPOT-PED,LEUPROLIDE ACETATE,NDA020263,e99f47d2-da10-3127-ecb3-e5d942ae6e81,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020263_S006_Lupron Depot_APPROVAL PACKAGE.pdf,
1993,LUPRON DEPOT-PED,LEUPROLIDE ACETATE,NDA020263,e99f47d2-da10-3127-ecb3-e5d942ae6e81,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020263_S028_Lupron Depot Ped_APPROVAL PACKAGE.pdf,
1993,LUPRON DEPOT-PED,LEUPROLIDE ACETATE,NDA020263,e99f47d2-da10-3127-ecb3-e5d942ae6e81,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/020263Orig1s042.pdf,
1993,LUPRON DEPOT-PED,LEUPROLIDE ACETATE,NDA020263,e99f47d2-da10-3127-ecb3-e5d942ae6e81,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020263_S003_Lupron Depot_APPROVAL PACKAGE.pdf,
1993,LUPRON DEPOT-PED,LEUPROLIDE ACETATE,NDA020263,e99f47d2-da10-3127-ecb3-e5d942ae6e81,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020263_S012_Lupron Depot_APPROVAL_PACKAGE.pdf,
1997,NIZORAL,KETOCONAZOLE,NDA020310,63840ff7-d447-4f4e-a05b-1fbed2da8a25,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20310_Nizoral.cfm,
1996,VISIPAQUE,IODIXANOL,NDA020351,e9d87b8c-7695-4c0f-8e81-000dedb5f66d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/169_20351S44 iodixanol CDTL clinical prea.pdf,
1996,VISIPAQUE,IODIXANOL,NDA020351,e9d87b8c-7695-4c0f-8e81-000dedb5f66d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/170_20351S44 iodixanol clinical prea.pdf,
1996,VISIPAQUE,IODIXANOL,NDA020351,e9d87b8c-7695-4c0f-8e81-000dedb5f66d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/172_20351S44 iohexol statistical prea.pdf,
1996,VISIPAQUE,IODIXANOL,NDA020351,e9d87b8c-7695-4c0f-8e81-000dedb5f66d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/171_20351S44 iodixanol clinpharm prea.pdf,
1996,VISIPAQUE,IODIXANOL,NDA020351,e9d87b8c-7695-4c0f-8e81-000dedb5f66d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/020351Orig1s044.pdf,
2021,XARELTO,RIVAROXABAN,NDA215859,10db92f9-2300-4a80-836b-673e1ae91610,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215859Orig1s000TOC.cfm,
2010,CYSVIEW,HEXAMINOLEVULINATE HYDROCHLORIDE,NDA022555,5aeed40d-6841-4adf-8940-f51d439fdfa3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022555_cysview_toc.cfm,
2010,CYSVIEW,HEXAMINOLEVULINATE HYDROCHLORIDE,NDA022555,5aeed40d-6841-4adf-8940-f51d439fdfa3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022555Orig1s000SumR.pdf,
2022,ELAHERE,MIRVETUXIMAB SORAVTANSINE,BLA761310,00c424b5-6ccd-48ab-9e88-1986451120e2,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761310Orig1s000TOC.cfm,
2000,N/A,N/A,NDA021097,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21097_Visicol.cfm,
2000,N/A,N/A,NDA021097,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021097Orig1s014.pdf,
2006,OMNITROPE,SOMATROPIN,BLA021426,58d84ffa-4056-4e36-ad67-7bd4aef444a5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021426s000TOC.cfm,
2006,OMNITROPE,SOMATROPIN,BLA021426,58d84ffa-4056-4e36-ad67-7bd4aef444a5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021426Orig1s008.pdf,
2006,OMNITROPE,SOMATROPIN,BLA021426,58d84ffa-4056-4e36-ad67-7bd4aef444a5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021426Orig1s004.pdf,
2006,OMNITROPE,SOMATROPIN,BLA021426,58d84ffa-4056-4e36-ad67-7bd4aef444a5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021426Orig1s002.pdf,
2006,OMNITROPE,SOMATROPIN,BLA021426,58d84ffa-4056-4e36-ad67-7bd4aef444a5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021426Orig1s007.pdf,
2015,ZARXIO,FILGRASTIM-SNDZ,BLA125553,c0d1c22b-566b-4776-bdbf-00f96dad0cae,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125553Orig1s000SumR.pdf,
2015,ZARXIO,FILGRASTIM-SNDZ,BLA125553,c0d1c22b-566b-4776-bdbf-00f96dad0cae,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/125553 filgrastim-sndz clinical prea.pdf,
2015,ZARXIO,FILGRASTIM-SNDZ,BLA125553,c0d1c22b-566b-4776-bdbf-00f96dad0cae,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/125553 filgrastim-sndz statistical prea.pdf,
2015,ZARXIO,FILGRASTIM-SNDZ,BLA125553,c0d1c22b-566b-4776-bdbf-00f96dad0cae,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/125553 filgrastim-sndz clinpharm DD prea.pdf,
2015,ZARXIO,FILGRASTIM-SNDZ,BLA125553,c0d1c22b-566b-4776-bdbf-00f96dad0cae,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/125553 filgrastim-sndz clinical TL prea.pdf,
2015,ZARXIO,FILGRASTIM-SNDZ,BLA125553,c0d1c22b-566b-4776-bdbf-00f96dad0cae,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/125553 filgrastim-sndz clinpharm prea.pdf,
2015,ZARXIO,FILGRASTIM-SNDZ,BLA125553,c0d1c22b-566b-4776-bdbf-00f96dad0cae,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125553Orig1s000TOC.cfm,
1986,N/A,N/A,NDA019032,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019032Orig1s000rev.pdf,
1986,N/A,N/A,NDA019032,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/19-032s16s17_Tenex.cfm,
1986,N/A,N/A,NDA019032,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/19-032s16s17_Tenex.cfm,
1986,N/A,N/A,NDA019081,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/019081_s036&s039_ESTRADERM.pdf,
1986,N/A,N/A,NDA019081,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/019081_s036&s039_ESTRADERM.pdf,
2014,N/A,N/A,NDA204031,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204031Orig1s000TOC.cfm,
2018,N/A,N/A,NDA209410,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209410Orig1s000TOC.cfm,
2020,N/A,N/A,NDA213691,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213691Orig1s000TOC.cfm,
2022,QUVIVIQ,DARIDOREXANT,NDA214985,3a2d1503-b816-40c9-9fac-7e03c5a3bcef,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214985Orig1s000TOC.cfm,
2013,CARBINOXAMINE MALEATE EXTENDED-RELEASE ORAL SUSPENSION,CARBINOXAMINE MALEATE,NDA022556,199f46e5-6288-5627-e063-6294a90ae086,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022556 carbinoxamine clinical prea.pdf,
2013,CARBINOXAMINE MALEATE EXTENDED-RELEASE ORAL SUSPENSION,CARBINOXAMINE MALEATE,NDA022556,199f46e5-6288-5627-e063-6294a90ae086,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022556 carbinoxamine clinpharm prea.pdf,
2013,CARBINOXAMINE MALEATE EXTENDED-RELEASE ORAL SUSPENSION,CARBINOXAMINE MALEATE,NDA022556,199f46e5-6288-5627-e063-6294a90ae086,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022556Orig1s000TOC.cfm,
2013,CARBINOXAMINE MALEATE EXTENDED-RELEASE ORAL SUSPENSION,CARBINOXAMINE MALEATE,NDA022556,199f46e5-6288-5627-e063-6294a90ae086,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022556Orig1s000SumR.pdf,
2024,LYMPHIR,DENILEUKIN DIFTITOX-CXDL,BLA761312,ac3613d7-4304-40e7-a3f5-adb8a8adca5d,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761312Orig1s000TOC.cfm,
2001,YASMIN,DROSPIRENONE AND ETHINYL ESTRADIOL,NDA021098,d7ea6a60-5a56-4f81-b206-9b27b7e58875,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-098_Yasmin.cfm,
2001,YASMIN,DROSPIRENONE AND ETHINYL ESTRADIOL,NDA021098,d7ea6a60-5a56-4f81-b206-9b27b7e58875,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021098Orig1s022.pdf,
2008,N/A,N/A,NDA022157,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022157_xyzal_toc.cfm,
2008,N/A,N/A,NDA022157,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022157s000SumR.pdf,
2008,N/A,N/A,NDA022157,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022157_Levocitirizine_Clinical_PREA.pdf,
2008,N/A,N/A,NDA022157,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022157_Levocitirizine_Clinpharm_PREA.pdf,
2005,ROZEREM,RAMELTEON,NDA021782,9de82310-70e8-47b9-b1fc-6c6848b99455,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_RozeremTOC.cfm,
1982,ACYCLOVIR,ACYCLOVIR,NDA018604,b360a808-a24d-4f3c-89a7-9941422d17d6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/018604S014.pdf,
2015,KANUMA,SEBELIPASE ALFA,BLA125561,83a77b9d-42f0-4645-8420-786285da7326,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125561Orig1s000TOC.cfm,
2018,ORILISSA,ELAGOLIX,NDA210450,a86757b3-09c5-fd3b-1223-244e94f50a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210450Orig1s000TOC.cfm,
2025,SEPHIENCE,SEPIAPTERIN,NDA219666,9fabfee2-9488-4d03-b203-8fa50f9a7f55,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219666Orig1s000TOC.cfm,
2022,CITALOPRAM,CITALOPRAM,NDA215428,2f815b0c-6da7-cb61-e89c-7de628092d0d,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215428Orig1s000TOC.cfm,
2024,OJEMDA,TOVORAFENIB,NDA217700,ea3a9631-3a66-6a7c-e053-2995a90ae2ad,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217700Orig1s000, 218033Orig1s000TOC.cfm",
2010,ADVIL SINUS CONGESTION AND PAIN,"IBUPROFEN, PHENYLEPHRINE HYDROCHLORIDE",NDA022565,b1e29c19-fe03-4d2b-b966-0adf4eb4b4cf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022565s000SumR.pdf,
2010,ADVIL SINUS CONGESTION AND PAIN,"IBUPROFEN, PHENYLEPHRINE HYDROCHLORIDE",NDA022565,b1e29c19-fe03-4d2b-b966-0adf4eb4b4cf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022565s000TOC.cfm,
2023,EPKINLY,EPCORITAMAB-BYSP,BLA761324,d7836711-b677-412d-bf2d-0f7c8444103a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761324Orig1s000TOC.cfm,
2003,SOMAVERT,PEGVISOMANT,BLA021106,3cbb485b-6df1-49ce-8747-592b395b1988,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021106_somavert.cfm,
2004,FLUTICASONE PROPIONATE HFA,FLUTICASONE PROPIONATE,NDA021433,99249b31-bf0a-464f-8335-845279350dbe,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21433-Fluticasone-Clinpharm-PREA.pdf,
2004,FLUTICASONE PROPIONATE HFA,FLUTICASONE PROPIONATE,NDA021433,99249b31-bf0a-464f-8335-845279350dbe,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021433s000_FloventHFATOC.cfm,
2005,N/A,N/A,NDA021793,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021793s000TOC.cfm,
2005,N/A,N/A,NDA021793,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021793_s004a_reglan tablets.pdf,
2014,OPDIVO,NIVOLUMAB,BLA125554,f570b9c4-6846-4de2-abfa-4d0a4ae4e394,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125554Orig1s003.pdf,
2014,OPDIVO,NIVOLUMAB,BLA125554,f570b9c4-6846-4de2-abfa-4d0a4ae4e394,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/125554Orig1s034.pdf,
2014,OPDIVO,NIVOLUMAB,BLA125554,f570b9c4-6846-4de2-abfa-4d0a4ae4e394,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/125554Orig1s091.pdf,
2014,OPDIVO,NIVOLUMAB,BLA125554,f570b9c4-6846-4de2-abfa-4d0a4ae4e394,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/125554Orig1s022.pdf,
2014,OPDIVO,NIVOLUMAB,BLA125554,f570b9c4-6846-4de2-abfa-4d0a4ae4e394,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/125554Orig1s081.pdf,
2014,OPDIVO,NIVOLUMAB,BLA125554,f570b9c4-6846-4de2-abfa-4d0a4ae4e394,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125554Orig1s000TOC.cfm,
2014,OPDIVO,NIVOLUMAB,BLA125554,f570b9c4-6846-4de2-abfa-4d0a4ae4e394,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125554Orig1s000SumR.pdf,
2014,OPDIVO,NIVOLUMAB,BLA125554,f570b9c4-6846-4de2-abfa-4d0a4ae4e394,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/125554Orig1s065.pdf,
2014,OPDIVO,NIVOLUMAB,BLA125554,f570b9c4-6846-4de2-abfa-4d0a4ae4e394,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/125554Orig1s049.pdf,
2014,OPDIVO,NIVOLUMAB,BLA125554,f570b9c4-6846-4de2-abfa-4d0a4ae4e394,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/125554Orig1s061.pdf,
2014,OPDIVO,NIVOLUMAB,BLA125554,f570b9c4-6846-4de2-abfa-4d0a4ae4e394,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/125554Orig1s051.pdf,
2014,OPDIVO,NIVOLUMAB,BLA125554,f570b9c4-6846-4de2-abfa-4d0a4ae4e394,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125554Orig1s004.pdf,
2014,OPDIVO,NIVOLUMAB,BLA125554,f570b9c4-6846-4de2-abfa-4d0a4ae4e394,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/125554Orig1s041.pdf,
2014,OPDIVO,NIVOLUMAB,BLA125554,f570b9c4-6846-4de2-abfa-4d0a4ae4e394,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/125377Orig1s110_125554Orig1s082.pdf,
2014,OPDIVO,NIVOLUMAB,BLA125554,f570b9c4-6846-4de2-abfa-4d0a4ae4e394,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/125554Orig1s066.pdf,
2014,OPDIVO,NIVOLUMAB,BLA125554,f570b9c4-6846-4de2-abfa-4d0a4ae4e394,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/125554Orig1s080.pdf,
2014,OPDIVO,NIVOLUMAB,BLA125554,f570b9c4-6846-4de2-abfa-4d0a4ae4e394,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/125554Orig1s064.pdf,
2014,OPDIVO,NIVOLUMAB,BLA125554,f570b9c4-6846-4de2-abfa-4d0a4ae4e394,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/424_125554S70 nivolumab DD prea.pdf,
2014,OPDIVO,NIVOLUMAB,BLA125554,f570b9c4-6846-4de2-abfa-4d0a4ae4e394,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/425_125554S70 nivolumab clinical prea.pdf,
2014,OPDIVO,NIVOLUMAB,BLA125554,f570b9c4-6846-4de2-abfa-4d0a4ae4e394,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/426_125554S70 nivolumab clinpharm prea.pdf,
2014,OPDIVO,NIVOLUMAB,BLA125554,f570b9c4-6846-4de2-abfa-4d0a4ae4e394,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/125554Orig1s048.pdf,
2014,OPDIVO,NIVOLUMAB,BLA125554,f570b9c4-6846-4de2-abfa-4d0a4ae4e394,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/125554Orig1s062.pdf,
2014,OPDIVO,NIVOLUMAB,BLA125554,f570b9c4-6846-4de2-abfa-4d0a4ae4e394,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/125554Orig1s052.pdf,
2014,OPDIVO,NIVOLUMAB,BLA125554,f570b9c4-6846-4de2-abfa-4d0a4ae4e394,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/125554Orig1s050.pdf,
2014,FLUTICASONE FUROATE ELLIPTA,FLUTICASONE FUROATE,NDA205625,d3e797fc-2636-49a0-b89e-5246b18ee440,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205625Orig1s000TOC.cfm,
2014,FLUTICASONE FUROATE ELLIPTA,FLUTICASONE FUROATE,NDA205625,d3e797fc-2636-49a0-b89e-5246b18ee440,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205625Orig1s000SumR.pdf,
2014,FLUTICASONE FUROATE ELLIPTA,FLUTICASONE FUROATE,NDA205625,d3e797fc-2636-49a0-b89e-5246b18ee440,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205625 fluticasone clinpharm prea.pdf,
2014,FLUTICASONE FUROATE ELLIPTA,FLUTICASONE FUROATE,NDA205625,d3e797fc-2636-49a0-b89e-5246b18ee440,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205625 fluticasone statistical prea.pdf,
2014,FLUTICASONE FUROATE ELLIPTA,FLUTICASONE FUROATE,NDA205625,d3e797fc-2636-49a0-b89e-5246b18ee440,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205625 fluticasone clinical prea.pdf,
2020,PULMOTECH MAA,KIT FOR THE PREPARATION OF TECHNETIUM TC 99M ALBUMIN AGGREGATED,BLA210089,a8b7adf0-2c6b-4acd-96d3-a099306951a0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210089Orig1s000TOC.cfm,
2017,PARSABIV,ETELCALCETIDE,NDA208325,cd270093-c6a8-4596-a4ab-e6aa0a2c8a0c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208325Orig1s000TOC.cfm,
2015,QUILLICHEW ER,METHYLPHENIDATE HYDROCHLORIDE,NDA207960,defc1205-8e90-4b1e-b862-05e4c35c7364,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/207960 methyphenidate clinical CDTL prea.pdf,
2015,QUILLICHEW ER,METHYLPHENIDATE HYDROCHLORIDE,NDA207960,defc1205-8e90-4b1e-b862-05e4c35c7364,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/207960 methylphenidate clinical prea.pdf,
2015,QUILLICHEW ER,METHYLPHENIDATE HYDROCHLORIDE,NDA207960,defc1205-8e90-4b1e-b862-05e4c35c7364,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/207960 methyphenidate clinpharm prea.pdf,
2015,QUILLICHEW ER,METHYLPHENIDATE HYDROCHLORIDE,NDA207960,defc1205-8e90-4b1e-b862-05e4c35c7364,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/207960 methylphenidate statistical prea.pdf,
2015,QUILLICHEW ER,METHYLPHENIDATE HYDROCHLORIDE,NDA207960,defc1205-8e90-4b1e-b862-05e4c35c7364,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207960Orig1s000TOC.cfm,
2017,ZERVIATE,CETIRIZINE,NDA208694,6fc5ef4e-4aea-4c34-8d51-0c07ab9aad59,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/136_208694 cetirizine clinical resub both.pdf,
2017,ZERVIATE,CETIRIZINE,NDA208694,6fc5ef4e-4aea-4c34-8d51-0c07ab9aad59,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/135_208694 cetirizine clinical both.pdf,
2017,ZERVIATE,CETIRIZINE,NDA208694,6fc5ef4e-4aea-4c34-8d51-0c07ab9aad59,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/137_208694 cetirizine clinpharm both.pdf,
2017,ZERVIATE,CETIRIZINE,NDA208694,6fc5ef4e-4aea-4c34-8d51-0c07ab9aad59,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/138_208694 cetirizine statistical both.pdf,
2017,ZERVIATE,CETIRIZINE,NDA208694,6fc5ef4e-4aea-4c34-8d51-0c07ab9aad59,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208694Orig1s000TOC.cfm,
2017,ZERVIATE,CETIRIZINE,NDA208694,6fc5ef4e-4aea-4c34-8d51-0c07ab9aad59,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208694Orig1s000TOC.cfm,
2021,LYVISPAH,BACLOFEN,NDA215422,f8992a56-9010-4c4b-84d5-ddcc3e2c3317,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215422Orig1s000TOC.cfm,
2022,MOUNJARO,TIRZEPATIDE,NDA215866,d2d7da5d-ad07-4228-955f-cf7e355c8cc0,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000TOC.cfm,
2022,MOUNJARO,TIRZEPATIDE,NDA215866,d2d7da5d-ad07-4228-955f-cf7e355c8cc0,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/215866Orig1s002.pdf,
2023,ALVAIZ,ELTROMBOPAG,NDA216774,ed51e463-7a03-4858-bbd2-882ce4753d5a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/216774Orig1s000TOC.cfm,
2019,MAVENCLAD,CLADRIBINE,NDA022561,9c75e30a-a410-40f1-b653-04d532bd9144,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022561Orig1s000TOC.cfm,
2024,ALHEMO,CONCIZUMAB,BLA761315,156f6404-1f6f-417f-bcf8-f07a27a82cc1,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761315Orig1s000TOC.cfm,
2002,PREVACID SOLUTAB,LANSOPRAZOLE,NDA021428,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21428_20406s052_21281s007_PrevacidTOC.cfm,
2002,PREVACID SOLUTAB,LANSOPRAZOLE,NDA021428,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021428_S004_PREVACID DELAYED RELEASE CAPS.pdf,
2009,OXALIPLATIN,OXALIPLATIN,NDA022160,9e51cc79-620c-48d7-b267-78e43c1ef6e4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022160_oxaliplatin_toc.cfm,
2009,OXALIPLATIN,OXALIPLATIN,NDA022160,9e51cc79-620c-48d7-b267-78e43c1ef6e4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022160s000SumR.pdf,
1988,TOBRADEX,TOBRAMYCIN AND DEXAMETHASONE,NDA050616,7f310e0e-0d3b-493d-b6c4-238493a2a9b9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/50-616S009.pdf,
1988,TOBRADEX,TOBRAMYCIN AND DEXAMETHASONE,NDA050616,7f310e0e-0d3b-493d-b6c4-238493a2a9b9,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/050616Orig1s015.pdf,
1988,TOBRADEX,TOBRAMYCIN AND DEXAMETHASONE,NDA050616,7f310e0e-0d3b-493d-b6c4-238493a2a9b9,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/050616Orig1s007.pdf,
1988,TOBRADEX,TOBRAMYCIN AND DEXAMETHASONE,NDA050616,7f310e0e-0d3b-493d-b6c4-238493a2a9b9,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/050616Orig1s005.pdf,
1988,TOBRADEX,TOBRAMYCIN AND DEXAMETHASONE,NDA050616,7f310e0e-0d3b-493d-b6c4-238493a2a9b9,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/050616Orig1s011.pdf,
1988,TOBRADEX,TOBRAMYCIN AND DEXAMETHASONE,NDA050616,7f310e0e-0d3b-493d-b6c4-238493a2a9b9,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/050616Orig1s003pdf,
1988,TOBRADEX,TOBRAMYCIN AND DEXAMETHASONE,NDA050616,7f310e0e-0d3b-493d-b6c4-238493a2a9b9,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/050616Orig1s001.pdf,
1988,TOBRADEX,TOBRAMYCIN AND DEXAMETHASONE,NDA050616,7f310e0e-0d3b-493d-b6c4-238493a2a9b9,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/050616Orig1s018.pdf,
1988,TOBRADEX,TOBRAMYCIN AND DEXAMETHASONE,NDA050616,7f310e0e-0d3b-493d-b6c4-238493a2a9b9,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/050616Orig1s008.pdf,
1988,TOBRADEX,TOBRAMYCIN AND DEXAMETHASONE,NDA050616,7f310e0e-0d3b-493d-b6c4-238493a2a9b9,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/050616Orig1s006.pdf,
1988,TOBRADEX,TOBRAMYCIN AND DEXAMETHASONE,NDA050616,7f310e0e-0d3b-493d-b6c4-238493a2a9b9,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/050616Orig1s010.pdf,
1988,TOBRADEX,TOBRAMYCIN AND DEXAMETHASONE,NDA050616,7f310e0e-0d3b-493d-b6c4-238493a2a9b9,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/050616Orig1s002.pdf,
2014,BLINCYTO,BLINATUMOMAB,BLA125557,38b482a8-960b-4591-9857-5031ecb830aa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125557Orig1s005TOC.cfm,
2014,BLINCYTO,BLINATUMOMAB,BLA125557,38b482a8-960b-4591-9857-5031ecb830aa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/125557Orig1s013.pdf,
2014,BLINCYTO,BLINATUMOMAB,BLA125557,38b482a8-960b-4591-9857-5031ecb830aa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125557Orig1s000TOC.cfm,
2014,BLINCYTO,BLINATUMOMAB,BLA125557,38b482a8-960b-4591-9857-5031ecb830aa,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/353_125557 blinatumomab clinical bpca.pdf,
2014,BLINCYTO,BLINATUMOMAB,BLA125557,38b482a8-960b-4591-9857-5031ecb830aa,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/352_125557 blinatumomab clinpharm bpca.pdf,
2014,BLINCYTO,BLINATUMOMAB,BLA125557,38b482a8-960b-4591-9857-5031ecb830aa,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/354_125557 blinatumomab statistical bpca.pdf,
2014,BLINCYTO,BLINATUMOMAB,BLA125557,38b482a8-960b-4591-9857-5031ecb830aa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/125557Orig1s007.pdf,
2011,DIFICID,FIDAXOMICIN,NDA201699,dd966338-c820-4270-b704-09ef75fa3ceb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201699Orig1s000TOC.cfm,
2011,DIFICID,FIDAXOMICIN,NDA201699,dd966338-c820-4270-b704-09ef75fa3ceb,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/524_213138 fidaxomicin unireview bpca.pdf,
2011,DIFICID,FIDAXOMICIN,NDA201699,dd966338-c820-4270-b704-09ef75fa3ceb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201699Orig1s000SumR.pdf,
2014,LUMASON,SULFUR HEXAFLUORIDE,NDA203684,7c679424-c3f7-ed02-892f-20ca0d775089,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203684Orig1s000TOC.cfm,
2014,LUMASON,SULFUR HEXAFLUORIDE,NDA203684,7c679424-c3f7-ed02-892f-20ca0d775089,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/203684 sulfur hexafluoride clinical prea.pdf,
2014,LUMASON,SULFUR HEXAFLUORIDE,NDA203684,7c679424-c3f7-ed02-892f-20ca0d775089,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/203684 sulfur hexafluoride clinpharm prea.pdf,
2014,LUMASON,SULFUR HEXAFLUORIDE,NDA203684,7c679424-c3f7-ed02-892f-20ca0d775089,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/203684 sulfur hexafluoride statistical prea.pdf,
2014,LUMASON,SULFUR HEXAFLUORIDE,NDA203684,7c679424-c3f7-ed02-892f-20ca0d775089,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/59_203684 sulfur hexafluoride CDTL clinical prea.pdf,
2014,LUMASON,SULFUR HEXAFLUORIDE,NDA203684,7c679424-c3f7-ed02-892f-20ca0d775089,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203684Orig1s000SumR.pdf,
2014,LUMASON,SULFUR HEXAFLUORIDE,NDA203684,7c679424-c3f7-ed02-892f-20ca0d775089,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/496_203684S5 lumason clinical prea.pdf,
2014,LUMASON,SULFUR HEXAFLUORIDE,NDA203684,7c679424-c3f7-ed02-892f-20ca0d775089,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/495_203684S5 lumason clinpharm prea_0.pdf,
2018,N/A,N/A,NDA205626,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/205626Orig1s000TOC.cfm,
1993,PENTASA,MESALAMINE,NDA020049,e39d9a3d-5d3a-4bb6-aab1-fdbb2a598606,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020049a_052292_biopharmrev.pdf,
1993,PENTASA,MESALAMINE,NDA020049,e39d9a3d-5d3a-4bb6-aab1-fdbb2a598606,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/020049Orig1s027.pdf,
1993,PENTASA,MESALAMINE,NDA020049,e39d9a3d-5d3a-4bb6-aab1-fdbb2a598606,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20046S006_Pentasa.cfm,
1993,PENTASA,MESALAMINE,NDA020049,e39d9a3d-5d3a-4bb6-aab1-fdbb2a598606,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020049_S015_PENTASA.pdf,
1998,DIOVAN HCT,VALSARTAN AND HYDROCHLOROTHIAZIDE,NDA020818,d76a0419-05ee-437e-884c-65807aea9569,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020818_diovan_toc.cfm,
1998,DIOVAN HCT,VALSARTAN AND HYDROCHLOROTHIAZIDE,NDA020818,d76a0419-05ee-437e-884c-65807aea9569,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/20-818s016_Diovan.cfm,
2021,N/A,N/A,NDA215423,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215423Orig1s000TOC.cfm,
2022,N/A,N/A,NDA215868,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215868Orig1s000TOC.cfm,
2010,CARBAGLU,CARGLUMIC ACID,NDA022562,10175e73-5172-4dde-a508-8a88b7afc0a1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022562s000TOC.cfm,
1998,PROSOL,"VALINE, LYSINE, HISTIDINE, ISOLEUCINE, LEUCINE, PHENYLALANINE, THREONINE, METHIONINE, TRYPTOPHAN, ALANINE, GLYCINE, ARGININE, PROLINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID AND TYROSINE",NDA020849,cc2ace81-5881-43f1-ba94-41b674adc2fc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020849_s000_Prosol.cfm,
2008,LEXISCAN,REGADENOSON,NDA022161,057289f4-2e18-4c1e-bed4-6c1858e2ef16,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022161s000_LexiscanTOC.cfm,
2005,METRONIDAZOLE,METRONIDAZOLE,NDA021789,7c35a751-58ca-4186-91a0-7c11d49144c4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021789Orig1s004.pdf,
2005,METRONIDAZOLE,METRONIDAZOLE,NDA021789,7c35a751-58ca-4186-91a0-7c11d49144c4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021789s000_MetrogelTOC.cfm,
1952,ACTHAR,REPOSITORY CORTICOTROPIN,NDA008372,7b48ddec-e815-45f4-9ca0-5c0daaf56f30,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/008372Orig1s045.pdf,
2015,PRALUENT,ALIROCUMAB,BLA125559,7bcfbac2-e8ac-4569-8edc-bcde3b1fd172,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125559Orig1s000TOC.cfm,
2015,PRALUENT,ALIROCUMAB,BLA125559,7bcfbac2-e8ac-4569-8edc-bcde3b1fd172,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/125559Orig1s014TOC.cfm,
2013,OXYTROL FOR WOMEN,OXYBUTYNIN,NDA202211,8cdc5b4d-ff8d-4010-97d7-313422a0b868,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202211_oxytrol_toc.cfm,
2013,OXYTROL FOR WOMEN,OXYBUTYNIN,NDA202211,8cdc5b4d-ff8d-4010-97d7-313422a0b868,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202211Orig1s000SumR.pdf,
2016,PARICALCITOL,PARICALCITOL,NDA207174,2b7c7587-2042-0d9c-e054-00144ff88e88,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/207174Orig1s000TOC.cfm,
2016,PARICALCITOL,PARICALCITOL,NDA207174,2b7c7587-2042-0d9c-e054-00144ff88e88,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/207174Orig1s000SumR.pdf,
2018,ZTLIDO,LIDOCAINE,NDA207962,a1b17507-4560-490d-a388-74e7fd7eaa5e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/207962Orig1s000TOC.cfm,
1993,OCUFLOX,OFLOXACIN,NDA019921,7aab4449-3dda-4e2c-8e40-b3244a548bf5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/019921s018_ofloxacin_Ocuflox_MedR2.pdf,
1993,OCUFLOX,OFLOXACIN,NDA019921,7aab4449-3dda-4e2c-8e40-b3244a548bf5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/19981S018 ocuflox clinical bpca_rev1rev2kc_redone 6.23.15_Redacted.pdf,
1993,OCUFLOX,OFLOXACIN,NDA019921,7aab4449-3dda-4e2c-8e40-b3244a548bf5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/019921_S008_Ocuflox_Approval_Package.pdf,
2021,NEXTSTELLIS,DROSPIRENONE AND ESTETROL,NDA214154,c5270073-d083-4109-ae4b-156986175e0a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214154Orig1s000TOC.cfm,
2022,NEPHROSCAN,SUCCIMER,NDA214993,ddd90c4a-5792-49c9-837f-710d1a604742,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/214993Orig1s000TOC.cfm,
2023,N/A,N/A,NDA215870,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215870Orig1s000TOC.cfm,
2024,ZITUVIMET XR,SITAGLIPTIN AND METFORMIN HYDROCHLORIDE,NDA216778,2f635b36-e86a-4e53-8eaf-589917b5f342,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/216778Orig1s000TOC.cfm,
2023,ZORYVE,ROFLUMILAST,NDA217242,f9e0b4a9-a227-4947-b00c-41fb18d16589,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217242Orig1s000TOC.cfm,
1999,EXEMESTANE,EXEMESTANE,NDA020753,69abd0ff-b200-4d1a-b14a-80e980a8e781,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-753_Aromasin.cfm,
2010,CALCIPOTRIENE,CALCIPOTRIENE,NDA022563,26756ac7-a80c-49db-97bb-351f76ad8a71,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/487_22563S7 calcipotriene clinical prea.pdf,
2010,CALCIPOTRIENE,CALCIPOTRIENE,NDA022563,26756ac7-a80c-49db-97bb-351f76ad8a71,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563_sorilux_toc.cfm,
2010,CALCIPOTRIENE,CALCIPOTRIENE,NDA022563,26756ac7-a80c-49db-97bb-351f76ad8a71,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000SumR.pdf,
2010,CALCIPOTRIENE,CALCIPOTRIENE,NDA022563,26756ac7-a80c-49db-97bb-351f76ad8a71,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22563S6 calcipotriene multidisciplinary prea.pdf,
2010,CALCIPOTRIENE,CALCIPOTRIENE,NDA022563,26756ac7-a80c-49db-97bb-351f76ad8a71,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/488_22563S7 calcipotriene clinpharm prea_0.pdf,
2023,N/A,N/A,BLA761322,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761322Orig1s000TOC.cfm,
2004,N/A,N/A,NDA021431,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-431_Campral.cfm,
2009,DICLOFENAC POTASSIUM,DICLOFENAC POTASSIUM,NDA022165,9dd418b2-4b0e-498c-b453-f580c69ddc6d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022165s000SumR.pdf,
2009,DICLOFENAC POTASSIUM,DICLOFENAC POTASSIUM,NDA022165,9dd418b2-4b0e-498c-b453-f580c69ddc6d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022165s000TOC.cfm,
2006,N/A,N/A,NDA021790,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021790s000_DacogenTOC.cfm,
2006,N/A,N/A,NDA021790,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021790_decitabine_clinical_bpca.pdf,
2006,N/A,N/A,NDA021790,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021790_decitabine_clinpharm_bpca.pdf,
2016,N/A,N/A,NDA204442,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/204442Orig1s000TOC.cfm,
1986,N/A,N/A,NDA019500,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019500Orig1s000rev.pdf,
2014,N/A,N/A,NDA205637,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205637Orig1s000TOC.cfm,
2014,N/A,N/A,NDA205637,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205637Orig1s000SumR.pdf,
2018,LUTATHERA,LUTETIUM LU 177 DOTATATE,NDA208700,72d1a024-00b7-418a-b36e-b2cb48f2ab55,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208700Orig1s000TOC.cfm,
2018,KRINTAFEL,TAFENOQUINE SUCCINATE,NDA210795,5cf989d5-36f5-4561-a30b-9fcb9deb6b6a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210795Orig1s000TOC.cfm,
2022,VIVIMUSTA,BENDAMUSTINE HYDROCHLORIDE,NDA212209,4df6548f-c4ad-4eb2-a54f-19766a3d90ca,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/212209Orig1s000TOC.cfm,
2025,SYMBRAVO,"MELOXICAM, RIZATRIPTAN",NDA215431,dcf1ecd1-08a0-8e47-e053-2a95a90abdc7,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/215431Orig1s000TOC.cfm,
2024,BKEMV,ECULIZUMAB-AEEB,BLA761333,002f9748-b0e8-4b6e-a38b-56930a839491,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761333Orig1s000TOC.cfm,
2002,TRI-LUMA,"FLUOCINOLONE ACETONIDE, HYDROQUINONE, AND TRETINOIN",NDA021112,a35fa709-5eb5-4429-b38f-f1e0019bf0ee,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-112_Tri-Luma.cfm,
2002,EPLERENONE,EPLERENONE,NDA021437,4286699b-2320-4d3d-831c-32085f36fb67,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-437s002_Inspra.cfm,
2002,EPLERENONE,EPLERENONE,NDA021437,4286699b-2320-4d3d-831c-32085f36fb67,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021437S005_Eplerenone_Statistical_BPCA.pdf,
2002,EPLERENONE,EPLERENONE,NDA021437,4286699b-2320-4d3d-831c-32085f36fb67,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021437S005_Eplerenone_Clinpharm_BPCA.pdf,
2002,EPLERENONE,EPLERENONE,NDA021437,4286699b-2320-4d3d-831c-32085f36fb67,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021437S005_Eplerenone_Clinical_BPCA.pdf,
2002,EPLERENONE,EPLERENONE,NDA021437,4286699b-2320-4d3d-831c-32085f36fb67,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-437_Inspra.cfm,
2009,FERAHEME,FERUMOXYTOL,NDA022180,32b0e320-a739-11dc-a704-0002a5d5c51b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022180s000TOC.cfm,
2009,FERAHEME,FERUMOXYTOL,NDA022180,32b0e320-a739-11dc-a704-0002a5d5c51b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022180s000_SumR.pdf,
2005,BARACLUDE,ENTECAVIR,NDA021798,046e61c9-9298-4b2e-b76e-b26b81fecd20,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_21798_BaracludeTOC.cfm,
2013,INVOKANA,CANAGLIFLOZIN,NDA204042,b9057d3b-b104-4f09-8a61-c61ef9d4a3f3,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/204042Orig1s027.pdf,
2013,INVOKANA,CANAGLIFLOZIN,NDA204042,b9057d3b-b104-4f09-8a61-c61ef9d4a3f3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204042Orig1s013.pdf,
2013,INVOKANA,CANAGLIFLOZIN,NDA204042,b9057d3b-b104-4f09-8a61-c61ef9d4a3f3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/204042Orig1s026.pdf,
2013,INVOKANA,CANAGLIFLOZIN,NDA204042,b9057d3b-b104-4f09-8a61-c61ef9d4a3f3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/204042Orig1s032TOC.cfm,
2013,INVOKANA,CANAGLIFLOZIN,NDA204042,b9057d3b-b104-4f09-8a61-c61ef9d4a3f3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000TOC.cfm,
2013,INVOKANA,CANAGLIFLOZIN,NDA204042,b9057d3b-b104-4f09-8a61-c61ef9d4a3f3,http://www.accessdata.fda.gov/drugsatfda_docs/NDA/2013/204042Orig1s000SumR.pdf,
1989,ZOLADEX,GOSERELIN,NDA019726,294b168b-6e5f-4db9-bf70-d599271458b3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/19726-s022_zoladax.pdf,
1989,ZOLADEX,GOSERELIN,NDA019726,294b168b-6e5f-4db9-bf70-d599271458b3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/19726S018_Zoladex.cfm,
1989,ZOLADEX,GOSERELIN,NDA019726,294b168b-6e5f-4db9-bf70-d599271458b3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/19726-s024_Zoladax.cfm,
1989,ZOLADEX,GOSERELIN,NDA019726,294b168b-6e5f-4db9-bf70-d599271458b3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/19726-s022_zoladax.pdf,
1998,PROMETRIUM,PROGESTERONE,NDA019781,1cf237ff-c4f8-4faa-a7aa-77599c856889,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/19781.cfm,
2016,PALONOSETRON HYDROCHLORIDE,PALONOSETRON HYDROCHLORIDE,NDA207963,bb20ba9b-aa8c-4b24-8124-aff0cb6c956b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/207963Orig1_toc.cfm,
2016,PALONOSETRON HYDROCHLORIDE,PALONOSETRON HYDROCHLORIDE,NDA207963,bb20ba9b-aa8c-4b24-8124-aff0cb6c956b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/207963Orig1s000SumR.pdf,
2022,CAMZYOS,MAVACAMTEN,NDA214998,669c936b-3ee6-4e36-8a22-79dd11b1255b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214998Orig1s000TOC.cfm,
2022,N/A,N/A,NDA215429,N/A,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215152Orig1s000,215153Orig1s000TOC.cfm",
2022,N/A,N/A,NDA215429,N/A,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215152Orig1s000,215153Orig1s000TOC.cfm",
1995,EPIVIR,LAMIVUDINE,NDA020596,89226149-47fa-4f7d-bb1f-1aa7034486b8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20977 abacavir clinical prea.pdf,
1995,EPIVIR,LAMIVUDINE,NDA020596,89226149-47fa-4f7d-bb1f-1aa7034486b8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20977 abacavir clinpharm prea.pdf,
1995,EPIVIR,LAMIVUDINE,NDA020596,89226149-47fa-4f7d-bb1f-1aa7034486b8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20977 abacavir statistical prea.pdf,
1995,EPIVIR,LAMIVUDINE,NDA020596,89226149-47fa-4f7d-bb1f-1aa7034486b8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020596_S010_Epivir.pdf,
1995,EPIVIR,LAMIVUDINE,NDA020596,89226149-47fa-4f7d-bb1f-1aa7034486b8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020596_S019_Epivir.pdf,
1995,EPIVIR,LAMIVUDINE,NDA020596,89226149-47fa-4f7d-bb1f-1aa7034486b8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020596_S025_Epivir.pdf,
1995,EPIVIR,LAMIVUDINE,NDA020596,89226149-47fa-4f7d-bb1f-1aa7034486b8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020596_S021_Epivir.pdf,
1995,EPIVIR,LAMIVUDINE,NDA020596,89226149-47fa-4f7d-bb1f-1aa7034486b8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-564s012_20-596s013_Epivir.cfm,
1995,EPIVIR,LAMIVUDINE,NDA020596,89226149-47fa-4f7d-bb1f-1aa7034486b8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020596_S007_Epivir.pdf,
1997,N/A,N/A,NDA020658,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020658Orig1s013.pdf,
1997,N/A,N/A,NDA020658,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020658_requip_toc.cfm,
1997,N/A,N/A,NDA020658,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020658_s012_RequipTOC.cfm,
2011,VIIBRYD,VILAZODONE HYDROCHLORIDE,NDA022567,4c55ccfb-c4cf-11df-851a-0800200c9a66,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202_125261-ustekinumab-clinical-prea.pdf,
2011,VIIBRYD,VILAZODONE HYDROCHLORIDE,NDA022567,4c55ccfb-c4cf-11df-851a-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000TOC.cfm,
2011,VIIBRYD,VILAZODONE HYDROCHLORIDE,NDA022567,4c55ccfb-c4cf-11df-851a-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000SumR.pdf,
2025,MERILOG,INSULIN ASPART-SZJJ,BLA761325,eee07a52-1102-4d48-9782-26061db175ad,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761325Orig1s000TOC.cfm,
2000,LOTRONEX,ALOSETRON HYDROCHLORIDE,NDA021107,35cbb9d5-639b-207a-e054-00144ff88e88,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021107_S005_LOTRONEX_TABLETS.pdf,
2000,LOTRONEX,ALOSETRON HYDROCHLORIDE,NDA021107,35cbb9d5-639b-207a-e054-00144ff88e88,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/021107_S001_LOTRONEX_TABLET.pdf,
2000,LOTRONEX,ALOSETRON HYDROCHLORIDE,NDA021107,35cbb9d5-639b-207a-e054-00144ff88e88,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21107a_Lotronex.cfm,
2000,LOTRONEX,ALOSETRON HYDROCHLORIDE,NDA021107,35cbb9d5-639b-207a-e054-00144ff88e88,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/021107Orig1s026.pdf,
2000,LOTRONEX,ALOSETRON HYDROCHLORIDE,NDA021107,35cbb9d5-639b-207a-e054-00144ff88e88,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021107_S006_LOTRONEX_TABLETS.pdf,
2000,LOTRONEX,ALOSETRON HYDROCHLORIDE,NDA021107,35cbb9d5-639b-207a-e054-00144ff88e88,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/021107_S002_LOTRONEX_TABLET.pdf,
2003,XANAX XR,ALPRAZOLAM,NDA021434,c8990714-c2f5-4b0c-9f1c-91d77156d962,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-434_Xanax.cfm,
2003,XANAX XR,ALPRAZOLAM,NDA021434,c8990714-c2f5-4b0c-9f1c-91d77156d962,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021434_S001_Xanax_APPROVAL PACKAGE.pdf,
2009,ZYPREXA RELPREVV,OLANZAPINE PAMOATE,NDA022173,f9a73185-88de-4d7b-b3c0-bbf231483241,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022173s000SumR.pdf,
2009,ZYPREXA RELPREVV,OLANZAPINE PAMOATE,NDA022173,f9a73185-88de-4d7b-b3c0-bbf231483241,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022173_zyprexa_relprevv_toc.cfm,
2005,DAPSONE,DAPSONE,NDA021794,8dbe1a41-6d9d-414f-aa9c-09bd95857e2a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021794s000TOC.cfm,
2012,AUVI-Q,EPINEPHRINE,NDA201739,6180fb40-7fca-4602-b3da-ce62b8cd2470,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/201739_auviQ_toc.cfm,
2012,AUVI-Q,EPINEPHRINE,NDA201739,6180fb40-7fca-4602-b3da-ce62b8cd2470,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205_201739 epinephrine mulitdiciplinary prea.pdf,
2012,AUVI-Q,EPINEPHRINE,NDA201739,6180fb40-7fca-4602-b3da-ce62b8cd2470,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/201739Orig1s004pkg.pdf,
1988,N/A,N/A,NDA019599,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/32_19599%20naftifine%20clinical%20prea.pdf,
1988,N/A,N/A,NDA019599,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/33_19599 naftifine clinpharm prea.pdf,
1988,N/A,N/A,NDA019599,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/34_19599 naftifine statistical prea.pdf,
1988,N/A,N/A,NDA019599,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/019599Orig1s011.pdf,
1988,N/A,N/A,NDA019599,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019599Orig1s007.pdf,
1987,N/A,N/A,NDA019643,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/19643S062_Mevacor.pdf,
1987,N/A,N/A,NDA019643,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/19643S062_Mevacor.pdf,
1987,N/A,N/A,NDA019643,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019643a_s050.pdf,
1987,N/A,N/A,NDA019643,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/019643s085.pdf,
1987,N/A,N/A,NDA019643,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/019643_S073_MEVACOR_TABLETS_AP.pdf,
1987,N/A,N/A,NDA019643,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/19643S55_Mevacor.cfm,
1987,N/A,N/A,NDA019643,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019643a_s051_s053.pdf,
1987,N/A,N/A,NDA019643,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019643a_s051_s053.pdf,
1987,N/A,N/A,NDA019643,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019643_S017_MEVACOR_TABLETS_AP.pdf,
2018,JYNARQUE,TOLVAPTAN,NDA204441,3febc0a1-9e5a-4ce0-843d-210f21d862c4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/204441Orig1s000TOC.cfm,
1986,N/A,N/A,NDA019462,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019462_S030 & 019527_S024 & 020752_S005_Pepcid RPD_AP.pdf,
1986,N/A,N/A,NDA019462,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019462Orig1s000rev.pdf,
1986,N/A,N/A,NDA019462,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/19462s27.pdf,
2015,PROAIR DIGIHALER,ALBUTEROL SULFATE,NDA205636,667ce3ec-5217-4b10-b712-f3e54fbbf087,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205636S004 albuterol sulfate clinical prea.pdf,
2015,PROAIR DIGIHALER,ALBUTEROL SULFATE,NDA205636,667ce3ec-5217-4b10-b712-f3e54fbbf087,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205636s004 albuterol sulfate clinpharm prea.pdf,
2015,PROAIR DIGIHALER,ALBUTEROL SULFATE,NDA205636,667ce3ec-5217-4b10-b712-f3e54fbbf087,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205636s004 albuterol sulfate statistical prea.pdf,
2015,PROAIR DIGIHALER,ALBUTEROL SULFATE,NDA205636,667ce3ec-5217-4b10-b712-f3e54fbbf087,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205636Orig1s000SumR.pdf,
2015,PROAIR DIGIHALER,ALBUTEROL SULFATE,NDA205636,667ce3ec-5217-4b10-b712-f3e54fbbf087,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205636 albuterol sulfate clinical prea.pdf,
2015,PROAIR DIGIHALER,ALBUTEROL SULFATE,NDA205636,667ce3ec-5217-4b10-b712-f3e54fbbf087,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205636 albuterol sulfate clinpharm prea.pdf,
2015,PROAIR DIGIHALER,ALBUTEROL SULFATE,NDA205636,667ce3ec-5217-4b10-b712-f3e54fbbf087,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205636 albuterol sulfate statistical prea.pdf,
2015,PROAIR DIGIHALER,ALBUTEROL SULFATE,NDA205636,667ce3ec-5217-4b10-b712-f3e54fbbf087,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205636Orig1s000TOC.cfm,
2018,READYPREP CHG,CHLORHEXIDINE GLUCONATE 2%,NDA207964,458cf999-5e3d-4d4d-82d5-02118c331893,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/207964Orig1s000TOC.cfm,
1995,MEPRON,ATOVAQUONE,NDA020500,b426b6bf-f07e-4580-97ae-dfca1ddf5b8f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020500S005.cfm,
2018,NUPLAZID,PIMAVANSERIN TARTRATE,NDA210793,1e6bea44-57d6-4bac-9328-46e1ee59f83b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210793Orig1s000TOC.cfm,
2022,N/A,N/A,NDA215000,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215000Orig1s000TOC.cfm,
2004,EPIVIR,LAMIVUDINE,NDA020564,89226149-47fa-4f7d-bb1f-1aa7034486b8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020564_S024_Epivir.pdf,
2004,EPIVIR,LAMIVUDINE,NDA020564,89226149-47fa-4f7d-bb1f-1aa7034486b8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020564_S007_Epivir.pdf,
2004,EPIVIR,LAMIVUDINE,NDA020564,89226149-47fa-4f7d-bb1f-1aa7034486b8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020564_S020_Epivir.pdf,
2004,EPIVIR,LAMIVUDINE,NDA020564,89226149-47fa-4f7d-bb1f-1aa7034486b8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-564s012_20-596s013_Epivir.cfm,
2004,EPIVIR,LAMIVUDINE,NDA020564,89226149-47fa-4f7d-bb1f-1aa7034486b8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20977 abacavir clinical prea.pdf,
2004,EPIVIR,LAMIVUDINE,NDA020564,89226149-47fa-4f7d-bb1f-1aa7034486b8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20977 abacavir clinpharm prea.pdf,
2004,EPIVIR,LAMIVUDINE,NDA020564,89226149-47fa-4f7d-bb1f-1aa7034486b8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20977 abacavir statistical prea.pdf,
2004,EPIVIR,LAMIVUDINE,NDA020564,89226149-47fa-4f7d-bb1f-1aa7034486b8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020564_S017_Epivir.pdf,
2004,EPIVIR,LAMIVUDINE,NDA020564,89226149-47fa-4f7d-bb1f-1aa7034486b8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020564Orig1s000rev.pdf,
2023,ADRENALIN (EPINEPHRINE IN SODIUM CHLORIDE),EPINEPHRINE IN SODIUM CHLORIDE,NDA215875,61b0e2a2-71ed-43d6-b1a7-36d2dae651b5,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215875Orig1s000TOC.cfm,
2010,ARICEPT,DONEPEZIL HYDROCHLORIDE,NDA022568,98e451e1-e4d7-4439-a675-c5457ba20975,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568_aricept_toc.cfm,
2010,ARICEPT,DONEPEZIL HYDROCHLORIDE,NDA022568,98e451e1-e4d7-4439-a675-c5457ba20975,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000SumR.pdf,
2023,BEYFORTUS,NIRSEVIMAB,BLA761328,2f08fa60-f674-432d-801b-1f9514bd9b39,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761328Orig1s000TOC.cfm,
2000,RENOVA,TRETINOIN,NDA021108,9f0a0e8d-1051-48a4-80c5-1bd260dd9c36,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-108_Renova.cfm,
2012,PERTZYE,PANCRELIPASE,BLA022175,481eec00-9abf-11dd-b71c-0002a5d5c51b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022175_pertzye_toc.cfm,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2012,PERTZYE,PANCRELIPASE,BLA022175,481eec00-9abf-11dd-b71c-0002a5d5c51b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022175 pancrelipase_clinpharm_prea.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2012,PERTZYE,PANCRELIPASE,BLA022175,481eec00-9abf-11dd-b71c-0002a5d5c51b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022175 pancrelipase_clinical_prea.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2012,PERTZYE,PANCRELIPASE,BLA022175,481eec00-9abf-11dd-b71c-0002a5d5c51b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/Pancrelipase-Clinical-Prea.pdf,
2012,PERTZYE,PANCRELIPASE,BLA022175,481eec00-9abf-11dd-b71c-0002a5d5c51b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/Pancrelipase-22-175-Clinpharm-PREA.pdf,
2012,PERTZYE,PANCRELIPASE,BLA022175,481eec00-9abf-11dd-b71c-0002a5d5c51b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/Pancrelipase-22-175-Statistical-PREA.pdf,
2012,PERTZYE,PANCRELIPASE,BLA022175,481eec00-9abf-11dd-b71c-0002a5d5c51b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022175Orig1s000SumR.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2012,PERTZYE,PANCRELIPASE,BLA022175,481eec00-9abf-11dd-b71c-0002a5d5c51b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/31_22175 pancrelipase clinical prea.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2008,N/A,N/A,NDA021795,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021795_desmopressin_acetate.cfm,
2008,N/A,N/A,NDA021795,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021795_Desmopressin_Clinical_PREA.pdf,
2008,N/A,N/A,NDA021795,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021795_Desmopressin_Clinpharm_BPCA.pdf,
2008,N/A,N/A,NDA021795,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021795s000_SumR.pdf,
1962,N/A,N/A,NDA012209,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/12209-S038_Fluorouracil.pdf,
1996,NASACORT ALLERGY 24HR,TRIAMCINOLONE ACETONIDE,NDA020468,4bff57a5-cce0-401c-a0fe-23c65c1b7ddc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020468_s001_NASACORT AQ.pdf,
1996,NASACORT ALLERGY 24HR,TRIAMCINOLONE ACETONIDE,NDA020468,4bff57a5-cce0-401c-a0fe-23c65c1b7ddc,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020468s024_Triamcinolone_Clinical_PREA.pdf,
1996,NASACORT ALLERGY 24HR,TRIAMCINOLONE ACETONIDE,NDA020468,4bff57a5-cce0-401c-a0fe-23c65c1b7ddc,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020468s024_Triamcinolone_Clinpharm_PREA.pdf,
1996,NASACORT ALLERGY 24HR,TRIAMCINOLONE ACETONIDE,NDA020468,4bff57a5-cce0-401c-a0fe-23c65c1b7ddc,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020468s024_Triamcinolone_Statistical_PREA.pdf,
2020,ZEPZELCA,LURBINECTEDIN,NDA213702,632bb50c-3bcb-4c85-9056-fc33410550ae,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000TOC.cfm,
2022,AUVELITY,"DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE",NDA215430,dcefda7c-9a68-278e-e053-2995a90aec79,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/215430Orig1s000TOC.cfm,
2023,PACLITAXEL,PACLITAXEL,NDA216338,15dd51ed-29e8-468b-b6d1-21b1f84d6f2e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/216338Orig1s000TOC.cfm,
2023,TRUQAP,CAPIVASERTIB,NDA218197,d698c106-2322-401e-b738-cbd83c843ecf,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/218197Orig1s000TOC.cfm,
2011,N/A,N/A,NDA022569,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022569Orig1s000TOC.cfm,
2011,N/A,N/A,NDA022569,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022569Orig1s000SumR.pdf,
2023,WEZLANA,USTEKINUMAB-AUUB,BLA761331,a6c23978-09f0-4796-88f7-d0ce7e3ed04e,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761285Orig1s000,761331Orig1s000TOC.cfm",
2000,RAPAMUNE,SIROLIMUS,NDA021110,3275b824-3f82-4151-2ab2-0036a9ba0acc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021083_S006_RAPAMUNE.pdf,
2000,RAPAMUNE,SIROLIMUS,NDA021110,3275b824-3f82-4151-2ab2-0036a9ba0acc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21110_Rapamune.cfm,
2002,ABILIFY,ARIPIPRAZOLE,NDA021436,c040bd1d-45b7-49f2-93ea-aed7220b30ac,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021436Orig1s002.pdf,
2002,ABILIFY,ARIPIPRAZOLE,NDA021436,c040bd1d-45b7-49f2-93ea-aed7220b30ac,http://www.accessdata.fda.gov/drugsatfda_docs/NDA/2008/021436Orig1s019_s020_s022.pdf,
2002,ABILIFY,ARIPIPRAZOLE,NDA021436,c040bd1d-45b7-49f2-93ea-aed7220b30ac,"http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/021436s19s20s22,21713s14s15s017SUMR.pdf",
2002,ABILIFY,ARIPIPRAZOLE,NDA021436,c040bd1d-45b7-49f2-93ea-aed7220b30ac,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21436-29-Abilify-Clinical-PREA.pdf,
2002,ABILIFY,ARIPIPRAZOLE,NDA021436,c040bd1d-45b7-49f2-93ea-aed7220b30ac,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21436-29-Abilify-Statistical-PREA.pdf,
2002,ABILIFY,ARIPIPRAZOLE,NDA021436,c040bd1d-45b7-49f2-93ea-aed7220b30ac,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021436Orig1s027.pdf,
2002,ABILIFY,ARIPIPRAZOLE,NDA021436,c040bd1d-45b7-49f2-93ea-aed7220b30ac,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/021436Orig1s041.pdf,
2002,ABILIFY,ARIPIPRAZOLE,NDA021436,c040bd1d-45b7-49f2-93ea-aed7220b30ac,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-436_Abilify.cfm,
2002,ABILIFY,ARIPIPRAZOLE,NDA021436,c040bd1d-45b7-49f2-93ea-aed7220b30ac,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021436s017_aripiprazole_Abilify-StatsRev.pdf,
2002,ABILIFY,ARIPIPRAZOLE,NDA021436,c040bd1d-45b7-49f2-93ea-aed7220b30ac,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021436s017_aripiprazole_Abilify-MedRev.pdf,
2002,ABILIFY,ARIPIPRAZOLE,NDA021436,c040bd1d-45b7-49f2-93ea-aed7220b30ac,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021436s017_aripiprazole_Abilify-ClinPharmRev.pdf,
2002,ABILIFY,ARIPIPRAZOLE,NDA021436,c040bd1d-45b7-49f2-93ea-aed7220b30ac,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021436Orig1s019_s020_s022.pdf,
2002,ABILIFY,ARIPIPRAZOLE,NDA021436,c040bd1d-45b7-49f2-93ea-aed7220b30ac,"http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/021436s19s20s22,21713s14s15s017SUMR.pdf",
2002,ABILIFY,ARIPIPRAZOLE,NDA021436,c040bd1d-45b7-49f2-93ea-aed7220b30ac,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021436Orig1s007.pdf,
2002,ABILIFY,ARIPIPRAZOLE,NDA021436,c040bd1d-45b7-49f2-93ea-aed7220b30ac,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021436Orig1s017.pdf,
2002,ABILIFY,ARIPIPRAZOLE,NDA021436,c040bd1d-45b7-49f2-93ea-aed7220b30ac,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021436S017_Aripiprazole_Clinical_BPCA.pdf,
2002,ABILIFY,ARIPIPRAZOLE,NDA021436,c040bd1d-45b7-49f2-93ea-aed7220b30ac,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021436S017_Aripiprazole_Clinpharm_BPCA.pdf,
2002,ABILIFY,ARIPIPRAZOLE,NDA021436,c040bd1d-45b7-49f2-93ea-aed7220b30ac,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21436s017-Aripiprazole-Statistical-BPCA.pdf,
2002,ABILIFY,ARIPIPRAZOLE,NDA021436,c040bd1d-45b7-49f2-93ea-aed7220b30ac,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021436_S001_ABILIFY_TABLETS.pdf,
2002,ABILIFY,ARIPIPRAZOLE,NDA021436,c040bd1d-45b7-49f2-93ea-aed7220b30ac,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/021436Orig1s038.pdf,
2002,ABILIFY,ARIPIPRAZOLE,NDA021436,c040bd1d-45b7-49f2-93ea-aed7220b30ac,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021436 aripiprazole statistical prea.pdf,
2002,ABILIFY,ARIPIPRAZOLE,NDA021436,c040bd1d-45b7-49f2-93ea-aed7220b30ac,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021436 aripiprazole clinical prea.pdf,
2002,ABILIFY,ARIPIPRAZOLE,NDA021436,c040bd1d-45b7-49f2-93ea-aed7220b30ac,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/021436Orig1s040.pdf,
2002,ABILIFY,ARIPIPRAZOLE,NDA021436,c040bd1d-45b7-49f2-93ea-aed7220b30ac,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021436s018TOC.cfm,
2002,ABILIFY,ARIPIPRAZOLE,NDA021436,c040bd1d-45b7-49f2-93ea-aed7220b30ac,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021436s018_SumR.pdf,
2002,ABILIFY,ARIPIPRAZOLE,NDA021436,c040bd1d-45b7-49f2-93ea-aed7220b30ac,http://www.accessdata.fda.gov/drugsatfda_docs/NDA/2008/021436Orig1s019_s020_s022.pdf,
2002,ABILIFY,ARIPIPRAZOLE,NDA021436,c040bd1d-45b7-49f2-93ea-aed7220b30ac,"http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/021436s19s20s22,21713s14s15s017SUMR.pdf",
2002,ABILIFY,ARIPIPRAZOLE,NDA021436,c040bd1d-45b7-49f2-93ea-aed7220b30ac,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021436_S004_ABILIFY_TABLETS.pdf,
2005,BARACLUDE,ENTECAVIR,NDA021797,046e61c9-9298-4b2e-b76e-b26b81fecd20,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21797 entecavir clinical bpca.pdf,
2005,BARACLUDE,ENTECAVIR,NDA021797,046e61c9-9298-4b2e-b76e-b26b81fecd20,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21797 entecavir clinpharm bpca.pdf,
2005,BARACLUDE,ENTECAVIR,NDA021797,046e61c9-9298-4b2e-b76e-b26b81fecd20,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21797 entecavir statistical bpca.pdf,
2005,BARACLUDE,ENTECAVIR,NDA021797,046e61c9-9298-4b2e-b76e-b26b81fecd20,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_21798_BaracludeTOC.cfm,
1950,N/A,N/A,NDA007337,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/007337-S24_Percodan_toc.cfm,
2014,CONTRAVE EXTENDED-RELEASE,NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE,NDA200063,485ff360-32c8-11df-928b-0002a5d5c51b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/200063Orig1s000TOC.cfm,
2014,CONTRAVE EXTENDED-RELEASE,NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE,NDA200063,485ff360-32c8-11df-928b-0002a5d5c51b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/200063Orig1s000SumR.pdf,
2014,POTASSIUM CHLORIDE,POTASSIUM CHLORIDE,NDA206814,14cd12ee-a4a3-465a-9550-58c9ef0e4f21,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206814Orig1s000TOC.cfm,
2014,POTASSIUM CHLORIDE,POTASSIUM CHLORIDE,NDA206814,14cd12ee-a4a3-465a-9550-58c9ef0e4f21,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206814Orig1s000SumR.pdf,
2016,EPCLUSA,VELPATASVIR AND SOFOSBUVIR,NDA208341,7f30631a-ee3b-4cfe-866b-964df3f0a44f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208341Orig1s000TOC.cfm,
2023,AKEEGA,NIRAPARIB TOSYLATE MONOHYDRATE AND ABIRATERONE ACETATE,NDA216793,8245a990-3268-4613-b5c5-9537858a1eb9,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/216793Orig1s000TOC.cfm,
2010,SAFYRAL,DROSPIRENONE/ETHINYL ESTRADIOL/LEVOMEFOLATE CALCIUM AND LEVOMEFOLATE CALCIUM,NDA022574,97563516-306a-4e17-9690-edbda49ecd83,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022574Orig1s004.pdf,
2010,SAFYRAL,DROSPIRENONE/ETHINYL ESTRADIOL/LEVOMEFOLATE CALCIUM AND LEVOMEFOLATE CALCIUM,NDA022574,97563516-306a-4e17-9690-edbda49ecd83,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022574Orig1s001.pdf,
2010,SAFYRAL,DROSPIRENONE/ETHINYL ESTRADIOL/LEVOMEFOLATE CALCIUM AND LEVOMEFOLATE CALCIUM,NDA022574,97563516-306a-4e17-9690-edbda49ecd83,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022574_safyral_toc.cfm,
2010,SAFYRAL,DROSPIRENONE/ETHINYL ESTRADIOL/LEVOMEFOLATE CALCIUM AND LEVOMEFOLATE CALCIUM,NDA022574,97563516-306a-4e17-9690-edbda49ecd83,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022574Orig1s000SumR.pdf,
2010,SAFYRAL,DROSPIRENONE/ETHINYL ESTRADIOL/LEVOMEFOLATE CALCIUM AND LEVOMEFOLATE CALCIUM,NDA022574,97563516-306a-4e17-9690-edbda49ecd83,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022574 safyral clinical _PREA.pdf,
2010,SAFYRAL,DROSPIRENONE/ETHINYL ESTRADIOL/LEVOMEFOLATE CALCIUM AND LEVOMEFOLATE CALCIUM,NDA022574,97563516-306a-4e17-9690-edbda49ecd83,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022574 safyral clinpharm_ PREA.pdf,
2010,SAFYRAL,DROSPIRENONE/ETHINYL ESTRADIOL/LEVOMEFOLATE CALCIUM AND LEVOMEFOLATE CALCIUM,NDA022574,97563516-306a-4e17-9690-edbda49ecd83,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022574 safyral statistical _PREA_CORRECTED.pdf,
2023,VEOPOZ,POZELIMAB,BLA761339,a8d6f10e-9430-450a-a3dd-b538f9b2a308,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761339Orig1s000TOC.cfm,
2002,LEVOTHYROXINE SODIUM,LEVOTHYROXINE SODIUM,NDA021116,4ddcaec1-a58f-340b-9bc1-bbe048b8c885,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/021116Orig1s012.pdf,
2002,LEVOTHYROXINE SODIUM,LEVOTHYROXINE SODIUM,NDA021116,4ddcaec1-a58f-340b-9bc1-bbe048b8c885,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-116_Thyro-Tabs.cfm,
2002,ADVIL ALLERGY SINUS,"CHLORPHENIRAMINE MALEATE, IBUPROFEN, PSEUDOEPHEDRINE HCL",NDA021441,ecd6ea11-8b34-01b4-cbd9-901ba7a8f6e2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-441_Advil.cfm,
2008,TACLONEX,CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE,NDA022185,757c914f-dd8d-43cc-a973-212d591af4af,http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/022185s000_SUMR.pdf,
2008,TACLONEX,CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE,NDA022185,757c914f-dd8d-43cc-a973-212d591af4af,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022185_taclonex_scalp_toc.cfm,
2008,TACLONEX,CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE,NDA022185,757c914f-dd8d-43cc-a973-212d591af4af,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22185 talconex clinical prea.pdf,
2008,TACLONEX,CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE,NDA022185,757c914f-dd8d-43cc-a973-212d591af4af,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22185 talconex clinpharm prea.pdf,
2008,TACLONEX,CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE,NDA022185,757c914f-dd8d-43cc-a973-212d591af4af,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22185 talconex statistics prea.pdf,
2005,VANDAZOLE,METRONIDAZOLE,NDA021806,27d71471-8f89-4a1e-8c55-020a58961454,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021806s000TOC.cfm,
2011,N/A,N/A,NDA201743,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201743_argatroban_toc.cfm,
2011,N/A,N/A,NDA201743,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201743Orig1s000SumR.pdf,
2021,N/A,N/A,NDA204803,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/204803Orig1s000TOC.cfm,
2014,ASMANEX HFA,MOMETASONE FUROATE,NDA205641,0c6d63da-41bc-4894-bead-198e66c848ac,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205641 mometasone clinical prea.pdf,
2014,ASMANEX HFA,MOMETASONE FUROATE,NDA205641,0c6d63da-41bc-4894-bead-198e66c848ac,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205641Orig1s000TOC.cfm,
2014,ASMANEX HFA,MOMETASONE FUROATE,NDA205641,0c6d63da-41bc-4894-bead-198e66c848ac,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205641Orig1s000SumR.pdf,
2014,ASMANEX HFA,MOMETASONE FUROATE,NDA205641,0c6d63da-41bc-4894-bead-198e66c848ac,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205641 mometasone clinical prea.pdf,
2014,ASMANEX HFA,MOMETASONE FUROATE,NDA205641,0c6d63da-41bc-4894-bead-198e66c848ac,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205641 mometasone clinpharm prea.pdf,
2014,ASMANEX HFA,MOMETASONE FUROATE,NDA205641,0c6d63da-41bc-4894-bead-198e66c848ac,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205641 mometasone statistical prea.pdf,
2014,ASMANEX HFA,MOMETASONE FUROATE,NDA205641,0c6d63da-41bc-4894-bead-198e66c848ac,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205641Mometasone-clinical-prea.pdf,
2017,VABOMERE,MEROPENEM-VABORBACTAM,NDA209776,e237fd0f-3050-42a3-b43e-b6fb4824e93d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209776Orig1s000TOC.cfm,
2018,SYMTUZA,"DARUNAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE",NDA210455,85a17d00-6b7c-41ea-a6b3-5ad924820dab,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210455Orig1s000TOC.cfm,
2018,SYMTUZA,"DARUNAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE",NDA210455,85a17d00-6b7c-41ea-a6b3-5ad924820dab,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/210455S9 darunavir-cobicistat-emtricitabine-tenofovir alafenamide clinical prea.pdf,
2018,SYMTUZA,"DARUNAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE",NDA210455,85a17d00-6b7c-41ea-a6b3-5ad924820dab,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/210455S9 darunavir-cobicistat-emtricitabine-tenofovir alafenamide clinical prea.pdf,
2018,SYMTUZA,"DARUNAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE",NDA210455,85a17d00-6b7c-41ea-a6b3-5ad924820dab,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/528_210455S9 darunavir-cobicistat-emtricitabine-tenofovir alafenamide clinpharm prea.pdf,
2018,SYMTUZA,"DARUNAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE",NDA210455,85a17d00-6b7c-41ea-a6b3-5ad924820dab,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/529_210455S9 darunavir-cobicistat-emtricitabine-tenofovir alafenamide clinical prea.pdf,
2015,GENVOYA,"ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE",NDA207561,34784acf-15ed-4715-b504-eb30430518e9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207561Orig1s000SumR.pdf,
2015,GENVOYA,"ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE",NDA207561,34784acf-15ed-4715-b504-eb30430518e9,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/207561_Genvoya_clinical_prea.pdf,
2015,GENVOYA,"ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE",NDA207561,34784acf-15ed-4715-b504-eb30430518e9,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/207561_Genvoya_clinpharm_prea.pdf,
2015,GENVOYA,"ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE",NDA207561,34784acf-15ed-4715-b504-eb30430518e9,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/207561_Genvoya_statistical_prea.pdf,
2015,GENVOYA,"ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE",NDA207561,34784acf-15ed-4715-b504-eb30430518e9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207561Orig1s000TOC.cfm,
2015,GENVOYA,"ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE",NDA207561,34784acf-15ed-4715-b504-eb30430518e9,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/184_207561S14 genvoya clinical prea.pdf,
2015,GENVOYA,"ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE",NDA207561,34784acf-15ed-4715-b504-eb30430518e9,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/186_207561S14 genvoya clinpharm prea.pdf,
1995,N/A,N/A,NDA020312,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20-312_Moexipril_Univasc.pdf,
1995,N/A,N/A,NDA020312,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020312Orig1s000rev.pdf,
1996,NAPROXEN SODIUM,NAPROXEN SODIUM,NDA020353,7c22a2d6-821c-4f83-aead-e756aed930e5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020353s001_naprelan_toc.cfm,
2022,KRAZATI,ADAGRASIB,NDA216340,0b8bf078-34c2-4f45-9012-38a8ac082b01,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000TOC.cfm,
2022,KRAZATI,ADAGRASIB,NDA216340,0b8bf078-34c2-4f45-9012-38a8ac082b01,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/216340Orig1s005.pdf,
2010,CUVPOSA,GLYCOPYRROLATE,NDA022571,d200bd44-9856-4104-a29e-a4cca3db6737,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022571Orig1s000SumR.pdf,
2010,CUVPOSA,GLYCOPYRROLATE,NDA022571,d200bd44-9856-4104-a29e-a4cca3db6737,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022571s000_cuvposa_toc.cfm,
2023,ZYNYZ,RETIFANLIMAB-DLWR,BLA761334,109648d0-d30a-42fc-8273-39cb1540a751,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761334Orig1s000TOC.cfm,
2002,N/A,N/A,NDA021113,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-113_Pamidronate.cfm,
2003,INNOPRAN XL,PROPRANOLOL HYDROCHLORIDE,NDA021438,cd5601b3-4d87-4c3b-acac-b476e787609d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-438_Innopran.cfm,
2010,N/A,N/A,NDA200045,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200045s000_amturnide_toc.cfm,
2010,N/A,N/A,NDA200045,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200045Orig1s000SumR.pdf,
2017,ROXYBOND,OXYCODONE HYDROCHLORIDE,NDA209777,72398542-8e0a-47b2-afeb-9ca5a1f15083,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209777Orig1s000TOC.cfm,
2017,JADENU,DEFERASIROX,NDA207968,fee89140-fff1-4443-9f42-24ac004fcda1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207968Orig1s000TOC.cfm,
2017,JADENU,DEFERASIROX,NDA207968,fee89140-fff1-4443-9f42-24ac004fcda1,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207968Orig1s000SumR.pdf,
2019,SCENESSE,AFAMELANOTIDE,NDA210797,94f53286-11dd-7fbb-e053-2a95a90a7c48,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210797Orig1s000TOC.cfm,
1993,N/A,N/A,NDA020264,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020264Orig1s000.pdf,
2022,PEDMARK,SODIUM THIOSULFATE,NDA212937,f98c7076-2a7b-4fd7-ab90-eed5e9137bae,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/212937Orig1s000TOC.cfm,
2012,MITOSOL,MITOMYCIN,NDA022572,244002c6-c61d-43fe-9326-072797113979,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022572_mitosol_toc.cfm,
2012,MITOSOL,MITOMYCIN,NDA022572,244002c6-c61d-43fe-9326-072797113979,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022572Orig1s000SumR.pdf,
2024,ANKTIVA,NOGAPENDEKIN ALFA INBAKICEPT-PMLN,BLA761336,eae31db8-3e7a-d9e0-708d-74419d1b50ff,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761336Orig1s000TOC.cfm,
2007,KUVAN,SAPROPTERIN DIHYDROCHLORIDE,NDA022181,af38711e-8873-4790-a92d-4d583e23fb89,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022181TOC.cfm,
2007,KUVAN,SAPROPTERIN DIHYDROCHLORIDE,NDA022181,af38711e-8873-4790-a92d-4d583e23fb89,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022181s000_SumR.pdf,
2007,KUVAN,SAPROPTERIN DIHYDROCHLORIDE,NDA022181,af38711e-8873-4790-a92d-4d583e23fb89,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22181s013 sapropterin clinical bpca.pdf,
2007,KUVAN,SAPROPTERIN DIHYDROCHLORIDE,NDA022181,af38711e-8873-4790-a92d-4d583e23fb89,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22181s013 sapropterin clinpharm bpca.pdf,
2005,N/A,N/A,NDA021799,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021799s000TOC.cfm,
2015,ENVARSUS XR,TACROLIMUS,NDA206406,de2315b0-6344-43ac-9aea-3e3b68d828e7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206406Orig1_toc.cfm,
2013,TRINTELLIX,VORTIOXETINE,NDA204447,1a5b68e2-14d0-419d-9ec6-1ca97145e838,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/204447Orig1s017.pdf,
2013,TRINTELLIX,VORTIOXETINE,NDA204447,1a5b68e2-14d0-419d-9ec6-1ca97145e838,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204447Orig1s000TOC.cfm,
2013,TRINTELLIX,VORTIOXETINE,NDA204447,1a5b68e2-14d0-419d-9ec6-1ca97145e838,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204447Orig1s000SumR.pdf,
2013,TRINTELLIX,VORTIOXETINE,NDA204447,1a5b68e2-14d0-419d-9ec6-1ca97145e838,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/204447Orig1s020.pdf,
2013,TRINTELLIX,VORTIOXETINE,NDA204447,1a5b68e2-14d0-419d-9ec6-1ca97145e838,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/204447Orig1s009.pdf,
2016,TIGECYCLINE,TIGECYCLINE,NDA205645,acf5dbe5-ca75-4300-816f-b3f4625f6e7d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205645Orig1s000TOC.cfm,
2024,N/A,N/A,NDA207970,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/207970Orig1s000TOC.cfm,
2020,LABETALOL HYDROCHLORIDE,LABETALOL HYDROCHLORIDE,NDA213330,1c9d496d-cace-4283-82bb-6dcd3828b73e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213330Orig1s000TOC.cfm,
2024,CRENESSITY,CRINECERFONT,NDA218808,fd3a6fbd-9137-428a-ba46-df6606f07d28,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/218808Orig1s000,218820Orig1s000TOC.cfm",
2025,WAYRILZ,RILZABRUTINIB,NDA219685,95ffd367-9b0c-4f75-8487-5d8f3c0a5ad0,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219685Orig1s000TOC.cfm,
2010,LAYOLIS FE,"NORETHINDRONE, ETHINYL ESTRADIOL, AND FERROUS FUMARATE",NDA022573,c0db84ca-b8d4-4ed2-b2f6-19347283146e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022573_norethindrone_ethinyl_toc.cfm,
2010,LAYOLIS FE,"NORETHINDRONE, ETHINYL ESTRADIOL, AND FERROUS FUMARATE",NDA022573,c0db84ca-b8d4-4ed2-b2f6-19347283146e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022573Orig1s000SumR.pdf,
2010,LAYOLIS FE,"NORETHINDRONE, ETHINYL ESTRADIOL, AND FERROUS FUMARATE",NDA022573,c0db84ca-b8d4-4ed2-b2f6-19347283146e,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22573-Norethindrone-Clinical-EE-PREA.pdf,
2010,LAYOLIS FE,"NORETHINDRONE, ETHINYL ESTRADIOL, AND FERROUS FUMARATE",NDA022573,c0db84ca-b8d4-4ed2-b2f6-19347283146e,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22573-Norethindrone-EE-Clinpharm-PREA.pdf,
2010,LAYOLIS FE,"NORETHINDRONE, ETHINYL ESTRADIOL, AND FERROUS FUMARATE",NDA022573,c0db84ca-b8d4-4ed2-b2f6-19347283146e,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22573-Norethindrone-EE-Statistical-PREA.pdf,
2010,LUMIGAN,BIMATOPROST,NDA022184,a5e67c75-db88-4372-bb07-c8dd15c97631,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022184Orig1s000SumR.pdf,
2010,LUMIGAN,BIMATOPROST,NDA022184,a5e67c75-db88-4372-bb07-c8dd15c97631,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022184_lumigan_toc.cfm,
2005,FOCALIN XR,DEXMETHYLPHENIDATE HYDROCHLORIDE,NDA021802,9cf76f62-48aa-4065-94fd-6fc910391ab5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21802_ focalin_ clinical_ prea.pdf,
2005,FOCALIN XR,DEXMETHYLPHENIDATE HYDROCHLORIDE,NDA021802,9cf76f62-48aa-4065-94fd-6fc910391ab5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21802_ focalin_ clinpharm_ prea.pdf,
2005,FOCALIN XR,DEXMETHYLPHENIDATE HYDROCHLORIDE,NDA021802,9cf76f62-48aa-4065-94fd-6fc910391ab5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21802_ focalin_ statistical_ prea .pdf,
2005,FOCALIN XR,DEXMETHYLPHENIDATE HYDROCHLORIDE,NDA021802,9cf76f62-48aa-4065-94fd-6fc910391ab5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021802s000TOC.cfm,
2015,RYTARY,CARBIDOPA AND LEVODOPA,NDA203312,4647e9b8-2861-4e4c-af5e-9d07979d7999,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/203312Orig1s000TOC.cfm,
2015,RYTARY,CARBIDOPA AND LEVODOPA,NDA203312,4647e9b8-2861-4e4c-af5e-9d07979d7999,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/203312Orig1s000SumR.pdf,
2013,VAZALORE,ASPIRIN,NDA203697,c6d08008-2ac1-ab6e-e053-2a95a90a8aa2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203697Orig1s000SumR.pdf,
2013,VAZALORE,ASPIRIN,NDA203697,c6d08008-2ac1-ab6e-e053-2a95a90a8aa2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203697_aspirin_toc.cfm,
2022,SOVUNA,HYDROXYCHLOROQUINE SULFATE,NDA214581,dd441154-b196-4d4c-bc56-2e37f345ef8d,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214581Orig1s000TOC.cfm,
2021,LUPKYNIS,VOCLOSPORIN,NDA213716,9f489295-1156-52c7-5fd0-5c4c52f9b813,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000TOC.cfm,
2018,COPIKTRA,DUVELISIB,NDA211155,e3c5ac56-e1f6-473a-bc73-687836534780,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000TOC.cfm,
2018,COPIKTRA,DUVELISIB,NDA211155,e3c5ac56-e1f6-473a-bc73-687836534780,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000TOC.cfm,
2020,INQOVI,CEDAZURIDINE AND DECITABINE,NDA212576,91a0f80b-f865-4d06-a40d-4d148d99ee71,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212576Orig1s000TOC.cfm,
2024,CRENESSITY,CRINECERFONT,NDA218820,fd3a6fbd-9137-428a-ba46-df6606f07d28,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/218808Orig1s000,218820Orig1s000TOC.cfm",
2022,RADICAVA ORS,EDARAVONE,NDA215446,0ce2c1c4-2a40-485c-b7cb-96a9b85d9d11,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215446Orig1s000TOC.cfm,
1996,LATANOPROST,LATANOPROST,NDA020597,463ecfde-5acb-4983-969d-0c0021bfbf48,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020597Orig1s013Approv.pdf,
1996,LATANOPROST,LATANOPROST,NDA020597,463ecfde-5acb-4983-969d-0c0021bfbf48,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020597Orig1s011Approv.pdf,
1996,LATANOPROST,LATANOPROST,NDA020597,463ecfde-5acb-4983-969d-0c0021bfbf48,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020597Orig1s026Approv.pdf,
1996,LATANOPROST,LATANOPROST,NDA020597,463ecfde-5acb-4983-969d-0c0021bfbf48,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020597Orig1s000rev.pdf,
1996,LATANOPROST,LATANOPROST,NDA020597,463ecfde-5acb-4983-969d-0c0021bfbf48,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020597Orig1s005Approv.pdf,
1997,SUMATRIPTAN,SUMATRIPTAN,NDA020626,f63e616b-ae0c-432b-badc-8c45023aa725,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020626_s002_IMITREX_NASAL_SPRAY.pdf,
1997,SUMATRIPTAN,SUMATRIPTAN,NDA020626,f63e616b-ae0c-432b-badc-8c45023aa725,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020626_imitrex_toc.cfm,
1997,SUMATRIPTAN,SUMATRIPTAN,NDA020626,f63e616b-ae0c-432b-badc-8c45023aa725,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020626_S007_IMITREX TABLETS, NASAL SPRAY INJECTION.pdf",
1997,SUMATRIPTAN,SUMATRIPTAN,NDA020626,f63e616b-ae0c-432b-badc-8c45023aa725,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020626_s001_IMITREX_NASAL_SPRAY.pdf,
1997,SUMATRIPTAN,SUMATRIPTAN,NDA020626,f63e616b-ae0c-432b-badc-8c45023aa725,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020626Orig1s004_sumatriptan_Imitrex-MedRev-BPCA.pdf,
1997,SUMATRIPTAN,SUMATRIPTAN,NDA020626,f63e616b-ae0c-432b-badc-8c45023aa725,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020626Orig1s004_sumatriptan_Imitrex-ClinPharmRev_BPCA.pdf,
1997,SUMATRIPTAN,SUMATRIPTAN,NDA020626,f63e616b-ae0c-432b-badc-8c45023aa725,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020626Orig1s004_sumatriptan_Imitrex-StatsRev-BPCA.pdf,
1996,N/A,N/A,NDA020659,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020659_S034_NORVIR.pdf,
1996,N/A,N/A,NDA020659,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20659s034_ritonavir_Norvir-MedRev.pdf,
1996,N/A,N/A,NDA020659,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20659s034_ritonavir_Norvir-ClinPharmRev.pdf,
1996,N/A,N/A,NDA020659,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020659Orig1s000rev.pdf,
1996,N/A,N/A,NDA020659,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020659_S033_NORVIR.pdf,
1996,N/A,N/A,NDA020659,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020659s013_020680s011_Norvir.cfm,
2023,RIVIVE,NALOXONE HYDROCHLORIDE,NDA217722,1c4f1b9d-1c70-4666-a90e-2f5d2c670d4d,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217722Orig1s000TOC.cfm,
2012,PHENTERMINE AND TOPIRAMATE,PHENTERMINE AND TOPIRAMATE,NDA022580,876bd763-13fa-481e-b579-c2fc44dbf3c2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000_qsymia_toc.cfm,
2012,PHENTERMINE AND TOPIRAMATE,PHENTERMINE AND TOPIRAMATE,NDA022580,876bd763-13fa-481e-b579-c2fc44dbf3c2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000SumR.pdf,
2012,PHENTERMINE AND TOPIRAMATE,PHENTERMINE AND TOPIRAMATE,NDA022580,876bd763-13fa-481e-b579-c2fc44dbf3c2,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/022580Orig1s020.pdf,
2024,SELARSDI,USTEKINUMAB-AEKN,BLA761343,87f75b59-e48b-47c7-a4c0-5fe5965660e7,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761343Orig1s000TOC.cfm,
2000,METHYLPHENIDATE HYDROCHLORIDE,METHYLPHENIDATE HYDROCHLORIDE,NDA021121,dad446b7-b26c-44f2-9e30-4cbd10d8b23c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-121_Concerta.cfm,
2000,METHYLPHENIDATE HYDROCHLORIDE,METHYLPHENIDATE HYDROCHLORIDE,NDA021121,dad446b7-b26c-44f2-9e30-4cbd10d8b23c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021121s017.pdf,
2000,METHYLPHENIDATE HYDROCHLORIDE,METHYLPHENIDATE HYDROCHLORIDE,NDA021121,dad446b7-b26c-44f2-9e30-4cbd10d8b23c,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021121s008_methylphenidate_Concerta-MedRev.pdf,
2000,METHYLPHENIDATE HYDROCHLORIDE,METHYLPHENIDATE HYDROCHLORIDE,NDA021121,dad446b7-b26c-44f2-9e30-4cbd10d8b23c,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021121s008_methylphenidate_Concerta-ClinPharmRev.pdf,
2000,METHYLPHENIDATE HYDROCHLORIDE,METHYLPHENIDATE HYDROCHLORIDE,NDA021121,dad446b7-b26c-44f2-9e30-4cbd10d8b23c,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021121s008_methylphenidate_Concerta-StatsRev.pdf,
2000,METHYLPHENIDATE HYDROCHLORIDE,METHYLPHENIDATE HYDROCHLORIDE,NDA021121,dad446b7-b26c-44f2-9e30-4cbd10d8b23c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021121_S004_CONCERTA_AP.pdf,
2000,METHYLPHENIDATE HYDROCHLORIDE,METHYLPHENIDATE HYDROCHLORIDE,NDA021121,dad446b7-b26c-44f2-9e30-4cbd10d8b23c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/021121Orig1s037.pdf,
2004,LYRICA,PREGABALIN,NDA021446,60185c88-ecfd-46f9-adb9-b97c6b00a553,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021446_LyricaTOC.cfm,
2004,LYRICA,PREGABALIN,NDA021446,60185c88-ecfd-46f9-adb9-b97c6b00a553,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021446Orig1s028_lyrica_toc.cfm,
2004,LYRICA,PREGABALIN,NDA021446,60185c88-ecfd-46f9-adb9-b97c6b00a553,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021446Orig1s028SumR.pdf,
2004,LYRICA,PREGABALIN,NDA021446,60185c88-ecfd-46f9-adb9-b97c6b00a553,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/56_21446 22488 pregabalin clinical prea.pdf,
2004,LYRICA,PREGABALIN,NDA021446,60185c88-ecfd-46f9-adb9-b97c6b00a553,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/57_21446 22488 pregabalin clinpharm prea.pdf,
2004,LYRICA,PREGABALIN,NDA021446,60185c88-ecfd-46f9-adb9-b97c6b00a553,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/58_21446 22488 pregabalin statistical prea.pdf,
2006,ELESTRIN,ESTRADIOL,NDA021813,eff2dea1-f117-11e3-ac10-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021813_elestrin_toc.cfm,
2006,ELESTRIN,ESTRADIOL,NDA021813,eff2dea1-f117-11e3-ac10-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021813s000_SumR.pdf,
1976,KINEVAC,SINCALIDE,NDA017697,1408aabb-6982-48e5-ae9f-504ec43b0003,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/017697Orig1s014.pdf,
1976,KINEVAC,SINCALIDE,NDA017697,1408aabb-6982-48e5-ae9f-504ec43b0003,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/017697Orig1s012.pdf,
1976,KINEVAC,SINCALIDE,NDA017697,1408aabb-6982-48e5-ae9f-504ec43b0003,http://www.accessdata.fda.gov/drugsatfda_docs/review/2018/017697Orig1s027.pdf,
1976,KINEVAC,SINCALIDE,NDA017697,1408aabb-6982-48e5-ae9f-504ec43b0003,http://www.accessdata.fda.gov/drugsatfda_docs/review/2018/017697Orig1s031.pdf,
1976,KINEVAC,SINCALIDE,NDA017697,1408aabb-6982-48e5-ae9f-504ec43b0003,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/017697Orig1s015.pdf,
1976,KINEVAC,SINCALIDE,NDA017697,1408aabb-6982-48e5-ae9f-504ec43b0003,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/017697Orig1s013.pdf,
1992,N/A,N/A,NDA020051,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020051S003ap.pdf,
2017,N/A,N/A,NDA207975,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207975Orig1s000TOC.cfm,
1992,TOPROL XL,METOPROLOL SUCCINATE,NDA019962,496ddfaa-7c9c-4888-b747-a210249b367a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/19-962-S-002_Toprol_XL.pdf,
1992,TOPROL XL,METOPROLOL SUCCINATE,NDA019962,496ddfaa-7c9c-4888-b747-a210249b367a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/019962s033_metoprolol_ToprolXL-MedRev.pdf,
1992,TOPROL XL,METOPROLOL SUCCINATE,NDA019962,496ddfaa-7c9c-4888-b747-a210249b367a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/019962s033_metoprolol_ToprolXL-ClinPharmRev.pdf,
1992,TOPROL XL,METOPROLOL SUCCINATE,NDA019962,496ddfaa-7c9c-4888-b747-a210249b367a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/N-19-962S013_Toprol.cfm,
1992,TOPROL XL,METOPROLOL SUCCINATE,NDA019962,496ddfaa-7c9c-4888-b747-a210249b367a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/19-962-S-003_Toprol_XL.pdf,
1992,TOPROL XL,METOPROLOL SUCCINATE,NDA019962,496ddfaa-7c9c-4888-b747-a210249b367a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/19-962-S-001_Toprol_XL.pdf,
1992,TOPROL XL,METOPROLOL SUCCINATE,NDA019962,496ddfaa-7c9c-4888-b747-a210249b367a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/19-962S022.pdf,
1992,TOPROL XL,METOPROLOL SUCCINATE,NDA019962,496ddfaa-7c9c-4888-b747-a210249b367a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/19-962-S-004_Toprol_XL.pdf,
1998,ZEMPLAR,PARICALCITOL,NDA020819,7259652f-81bc-4ad1-bba5-d01f9fac1b80,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020819s014_paricalcitol_MedRev_BPCA.pdf,
1998,ZEMPLAR,PARICALCITOL,NDA020819,7259652f-81bc-4ad1-bba5-d01f9fac1b80,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020819s014_paricalcitol_StatsRev_BPCA.pdf,
1998,ZEMPLAR,PARICALCITOL,NDA020819,7259652f-81bc-4ad1-bba5-d01f9fac1b80,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/27_21606 paricalcitol CDTL clinical prea.pdf,
1998,ZEMPLAR,PARICALCITOL,NDA020819,7259652f-81bc-4ad1-bba5-d01f9fac1b80,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/29_21606 paricalcitol clinpharm prea.pdf,
1998,ZEMPLAR,PARICALCITOL,NDA020819,7259652f-81bc-4ad1-bba5-d01f9fac1b80,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20819_Zemplar.cfm,
2022,N/A,N/A,NDA215441,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215441Orig1s000TOC.cfm,
2023,AUGTYRO,REPOTRECTINIB,NDA218213,fb526827-40ba-4462-94cf-179ae3b0cb8a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/218213Orig1s000TOC.cfm,
2023,AUGTYRO,REPOTRECTINIB,NDA218213,fb526827-40ba-4462-94cf-179ae3b0cb8a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/218213Orig1s001.pdf,
2010,VPRIV,VELAGLUCERASE ALFA,BLA022575,ca02f7a4-ae4f-43c1-a06a-259fe4fcf9cf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022575s000TOC.cfm,
1998,MICARDIS,TELMISARTAN,NDA020850,cfb9309f-e0df-4a55-9542-0e869fce05fb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20850_Micardis.cfm,
2000,CALCIUM CHLORIDE,CALCIUM CHLORIDE,NDA021117,c4c65e48-85f8-4dcf-6281-06e40959cc79,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/021117_CalciumChloride.cfm,
2004,N/A,N/A,NDA021443,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021443s000_EnjuviaTOC.cfm,
2008,AK-FLUOR,FLUORESCEIN,NDA022186,73511e79-c050-4dc0-aa2f-a79ed320b5b0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022186_akfluor_toc.cfm,
2008,AK-FLUOR,FLUORESCEIN,NDA022186,73511e79-c050-4dc0-aa2f-a79ed320b5b0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022186s000_SumR.pdf,
2005,SOLTAMOX,TAMOXIFEN CITRATE,NDA021807,1e6ff055-590c-41e6-9530-1fdf04cdbd02,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021807s000TOC.cfm,
1975,KLONOPIN,CLONAZEPAM,NDA017533,cfa0d79a-843c-4b88-95a1-e9511d649ca1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/017533_S037_KLONOPIN_TABS_AP.pdf,
1975,KLONOPIN,CLONAZEPAM,NDA017533,cfa0d79a-843c-4b88-95a1-e9511d649ca1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/017533_S031_KLONOPIN_TABS_AP.pdf,
2011,XALKORI,CRIZOTINIB,NDA202570,2a51b0de-47d6-455e-a94c-d2c737b04ff7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202570Orig1s000SumR.pdf,
2011,XALKORI,CRIZOTINIB,NDA202570,2a51b0de-47d6-455e-a94c-d2c737b04ff7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202570Orig1s000TOC.cfm,
2013,N/A,N/A,NDA205208,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205208Orig1s000TOC.cfm,
2013,N/A,N/A,NDA205208,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205208Orig1s000SumR.pdf,
1997,N/A,N/A,NDA019922,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019922_toc.cfm,
2020,WAKIX,PITOLISANT HYDROCHLORIDE,NDA211150,8daa5562-824e-476c-9652-26ceef3d4b0e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211150Orig2s000TOC.cfm,
2020,WAKIX,PITOLISANT HYDROCHLORIDE,NDA211150,8daa5562-824e-476c-9652-26ceef3d4b0e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211150Orig1s000TOC.cfm,
2023,QALSODY,TOFERSEN,NDA215887,81356b45-1cb7-4eef-88ea-e44cc18b47c5,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215887Orig1s000TOC.cfm,
2012,VIREAD,TENOFOVIR DISOPROXIL FUMARATE,NDA022577,33fd6418-fbdc-42ca-a50d-ce2a476a5418,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022577Orig1s000SumR.pdf,
2012,VIREAD,TENOFOVIR DISOPROXIL FUMARATE,NDA022577,33fd6418-fbdc-42ca-a50d-ce2a476a5418,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22577s000, 21356s38_ tenofovir_clinpharm_ bpca.pdf",
2012,VIREAD,TENOFOVIR DISOPROXIL FUMARATE,NDA022577,33fd6418-fbdc-42ca-a50d-ce2a476a5418,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22577s000, 21356s38_tenofovir_clinical_bpca.pdf",
2012,VIREAD,TENOFOVIR DISOPROXIL FUMARATE,NDA022577,33fd6418-fbdc-42ca-a50d-ce2a476a5418,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22577s000_ tenofovir_ statistical_ bpca.pdf,
2012,VIREAD,TENOFOVIR DISOPROXIL FUMARATE,NDA022577,33fd6418-fbdc-42ca-a50d-ce2a476a5418,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022577_viread_toc.cfm,
2024,EPYSQLI,ECULIZUMAB-AAGH,BLA761340,1fa1aa80-1c59-44d4-9841-b6c52882651b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761340Orig1s000TOC.cfm,
2000,VISUDYNE,VERTEPORFIN FOR INJECTION,NDA021119,2f0a34ce-3c57-4ac8-b28e-512be807272f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-119s004_Visudyne.cfm,
2000,VISUDYNE,VERTEPORFIN FOR INJECTION,NDA021119,2f0a34ce-3c57-4ac8-b28e-512be807272f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-119_Visudyne.cfm,
2000,VISUDYNE,VERTEPORFIN FOR INJECTION,NDA021119,2f0a34ce-3c57-4ac8-b28e-512be807272f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-119s003_Visudyne.cfm,
2000,VISUDYNE,VERTEPORFIN FOR INJECTION,NDA021119,2f0a34ce-3c57-4ac8-b28e-512be807272f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-119S001_Visudyne.cfm,
2003,RISPERDAL M-TAB,RISPERIDONE,NDA021444,7e117c7e-02fc-4343-92a1-230061dfc5e0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/020272_s046_risperdal_toc.cfm,
2003,RISPERDAL M-TAB,RISPERIDONE,NDA021444,7e117c7e-02fc-4343-92a1-230061dfc5e0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021444_risperdal.cfm,
2003,RISPERDAL M-TAB,RISPERIDONE,NDA021444,7e117c7e-02fc-4343-92a1-230061dfc5e0,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020272Orig1s036,s041,020588Orig1s024,s028,s029,21444Orig1s008,s015.pdf",
2003,RISPERDAL M-TAB,RISPERIDONE,NDA021444,7e117c7e-02fc-4343-92a1-230061dfc5e0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021444_S004_RISPERDAL_TABLETS.pdf,
2003,RISPERDAL M-TAB,RISPERIDONE,NDA021444,7e117c7e-02fc-4343-92a1-230061dfc5e0,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020272Orig1s036,s041,020588Orig1s024,s028,s029,21444Orig1s008,s015.pdf",
2003,RISPERDAL M-TAB,RISPERIDONE,NDA021444,7e117c7e-02fc-4343-92a1-230061dfc5e0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/020272_s046_risperdal_toc.cfm,
2008,ETRAVIRINE,ETRAVIRINE,NDA022187,50ca19cb-0f43-4d7b-8c9e-8b3aaded0546,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022187TOC.cfm,
2008,ETRAVIRINE,ETRAVIRINE,NDA022187,50ca19cb-0f43-4d7b-8c9e-8b3aaded0546,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022187s000_SumR.pdf,
2008,ETRAVIRINE,ETRAVIRINE,NDA022187,50ca19cb-0f43-4d7b-8c9e-8b3aaded0546,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22187_etravirine_clinical_prea.pdf,
2008,ETRAVIRINE,ETRAVIRINE,NDA022187,50ca19cb-0f43-4d7b-8c9e-8b3aaded0546,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22187_etravirine_clinpharm_prea.pdf,
2008,ETRAVIRINE,ETRAVIRINE,NDA022187,50ca19cb-0f43-4d7b-8c9e-8b3aaded0546,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/300_22187S24-etravirine-CDTL-clinical-addendum-bpca.pdf,
2008,ETRAVIRINE,ETRAVIRINE,NDA022187,50ca19cb-0f43-4d7b-8c9e-8b3aaded0546,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/299_22187S24-etravirine-clinpharm-bpca.pdf,
2008,N/A,N/A,BLA021810,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021810_novolog_mix_toc.cfm,
2008,N/A,N/A,BLA021810,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021810S000_SumR.pdf,
1989,N/A,N/A,NDA050632,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/50632s010.cfm,
1982,DELSYM,DEXTROMETHORPHAN,NDA018658,e3e1d126-76c2-4776-8ce0-449625b7e6ba,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/018658_S017_DELSYM_AP.pdf,
2012,N/A,N/A,NDA203696,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203696_lupaneta_toc.cfm,
2012,N/A,N/A,NDA203696,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203696Orig1s000SumR.pdf,
2014,DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE,NDA205649,eaf135b6-e378-4f62-a1e7-db45e23668c7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205649Orig1s000TOC.cfm,
2014,DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE,NDA205649,eaf135b6-e378-4f62-a1e7-db45e23668c7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205649Orig1s000SumR.pdf,
1996,N/A,N/A,NDA019821,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/019821_S002&S006_SORIATANE_AP.pdf,
1996,N/A,N/A,NDA019821,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/019821_S002&S006_SORIATANE_AP.pdf,
1996,N/A,N/A,NDA019821,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/19821-S001_Soritane.pdf,
1989,ZESTORETIC,LISINOPRIL AND HYDROCHLOROTHIAZIDE,NDA019888,0d3a966f-f937-05a8-a90f-5aa52ebbd613,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019888s020_zestoretic_toc.cfm,
1989,ZESTORETIC,LISINOPRIL AND HYDROCHLOROTHIAZIDE,NDA019888,0d3a966f-f937-05a8-a90f-5aa52ebbd613,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/19888-S12_Zestril.pdf,
2022,VIVJOA,OTESECONAZOLE,NDA215888,e21d5008-800e-4417-927f-14340341865f,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215888Orig1s000TOC.cfm,
2010,ZYRTEC ALLERGY,CETIRIZINE HYDROCHLORIDE,NDA022578,6a962a1c-c197-492b-bfa6-e0c28eda1533,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022578Orig1s000SumR.pdf,
2010,ZYRTEC ALLERGY,CETIRIZINE HYDROCHLORIDE,NDA022578,6a962a1c-c197-492b-bfa6-e0c28eda1533,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022578s000_zyrtec_allergy_toc.cfm,
2023,TALVEY,TALQUETAMAB,BLA761342,9001355e-003d-4d4e-b4ce-337e0fd14952,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761342Orig1s000TOC.cfm,
2002,ZETIA,EZETIMIBE,NDA021445,174e45e0-45bb-48b7-9e60-8f6cfc1d22bb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021445_S001_S003_S004_ZETIA_TABLETS.pdf,
2002,ZETIA,EZETIMIBE,NDA021445,174e45e0-45bb-48b7-9e60-8f6cfc1d22bb,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/021445Orig1s042.pdf,
2002,ZETIA,EZETIMIBE,NDA021445,174e45e0-45bb-48b7-9e60-8f6cfc1d22bb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021445_S001_S003_S004_ZETIA_TABLETS.pdf,
2002,ZETIA,EZETIMIBE,NDA021445,174e45e0-45bb-48b7-9e60-8f6cfc1d22bb,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021445_Ezetimibe_Clinical_BPCA_rev2_cd_SPONSOR_REVISED_7-16-08.pdf,
2002,ZETIA,EZETIMIBE,NDA021445,174e45e0-45bb-48b7-9e60-8f6cfc1d22bb,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021445_Ezetimibe_Clinpharm_BPCA.pdf,
2002,ZETIA,EZETIMIBE,NDA021445,174e45e0-45bb-48b7-9e60-8f6cfc1d22bb,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021445_Ezetimibe_Statistical_BPCA.pdf,
2002,ZETIA,EZETIMIBE,NDA021445,174e45e0-45bb-48b7-9e60-8f6cfc1d22bb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21445_Zetia.cfm,
2002,ZETIA,EZETIMIBE,NDA021445,174e45e0-45bb-48b7-9e60-8f6cfc1d22bb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021445_S001_S003_S004_ZETIA_TABLETS.pdf,
2009,FANAPT,ILOPERIDONE,NDA022192,33f60b40-3fca-11de-8f56-0002a5d5c51b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022192s000TOC.cfm,
2009,FANAPT,ILOPERIDONE,NDA022192,33f60b40-3fca-11de-8f56-0002a5d5c51b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022192s000TOC.cfm,
2006,WOMENS ROGAINE UNSCENTED,MINOXIDIL,NDA021812,4d328537-b7f5-43cc-9837-c5a0c6c390f8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021812s000TOC.cfm,
1946,N/A,N/A,NDA006035,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/006035Orig1S078.pdf,
1986,CYKLOKAPRON,TRANEXAMIC ACID,NDA019281,6e89a7d9-4da4-42aa-b7f8-c602c24eefe5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/19281-S008_Cyklokapron.pdf,
1986,TIMOPTIC IN OCUDOSE,TIMOLOL MALEATE,NDA019463,c1293d51-b633-486c-8e13-fcf60063faeb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/019463_s026_TimopticTOC.cfm,
1986,TIMOPTIC IN OCUDOSE,TIMOLOL MALEATE,NDA019463,c1293d51-b633-486c-8e13-fcf60063faeb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/19-463S019.pdf,
2018,TIGLUTIK,RILUZOLE,NDA209080,75d68f19-4208-109e-e053-2991aa0ac857,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209080Orig1s000TOC.cfm,
1995,N/A,N/A,NDA020313,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020313_S023_MIACALCIN_AP.pdf,
2025,IBTROZI,TALETRECTINIB,NDA219713,51ac8e52-3269-4102-8dc8-dba22d82128c,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219713Orig1s000TOC.cfm,
2025,BLUJEPA,GEPOTIDACIN,NDA218230,80b57cfe-7819-4d95-a57d-014af42f118d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/218230Orig1s000TOC.cfm,
2024,TECENTRIQ HYBREZA,ATEZOLIZUMAB AND HYALURONIDASE-TQJS,BLA761347,a617b089-ce66-464b-987b-b45d029b4d6f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761347Orig1s000TOC.cfm,
2000,N/A,N/A,NDA021128,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-128_ChildrensMotrin.cfm,
2003,ORAQIX,LIDOCAINE AND PRILOCAINE,NDA021451,b501d239-923b-48b2-82ed-6c5c253a67e2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021451s000_OraqixTOC.cfm,
2015,N/A,N/A,BLA203313,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/44_203313 insulin degludec-insulin aspart clinpharm prea.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2015,N/A,N/A,BLA203313,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/46_203313_203314 insulin degludec-insulin aspart clinical prea.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2015,N/A,N/A,BLA203313,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/203313_203314_insulin degludec and insulin degludec-insulin aspart stat prea.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2015,N/A,N/A,BLA203313,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/203313_203314-Insulin-degludec-insulin-aspart-clinical-prea.pdf,
2015,N/A,N/A,BLA203313,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/203313-203314-insulin-degludec-and-insulin-degludec-insulin-aspart-statistical-prea.pdf,
2015,N/A,N/A,BLA203313,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/203313-203314-insulin-degludec-and-insulin-degludec-insulin-aspart-statistical-prea.pdf,
2015,N/A,N/A,BLA203313,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/203313-insulin-degludec-insulin-aspart-clinpharm-prea.pdf,
2015,N/A,N/A,BLA203313,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/203313and203314Orig1s000TOC.cfm,
2011,LEVOTHYROXINE SODIUM,LEVOTHYROXINE SODIUM ANHYDROUS,NDA202231,f88f44d8-2f18-4155-9d78-6323d19fbafe,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202231Orig1s000Sum.pdf,
2011,LEVOTHYROXINE SODIUM,LEVOTHYROXINE SODIUM ANHYDROUS,NDA202231,f88f44d8-2f18-4155-9d78-6323d19fbafe,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202231_levothyroxine_toc.cfm,
2018,PROGRAF,TACROLIMUS,NDA210115,7f667de1-9dfa-4bd6-8ba0-15ee2d78873b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/050708Orig1s053; 050709Orig1s045; 210115Orig1s005.pdf,
2018,PROGRAF,TACROLIMUS,NDA210115,7f667de1-9dfa-4bd6-8ba0-15ee2d78873b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210115Orig1s000TOC.cfm,
1989,PROCARDIA XL,NIFEDIPINE,NDA019684,8ebcb33c-f43b-4b36-9f94-9774b2a59e06,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/19787-S013_Norvasc.pdf,
2016,ODEFSEY,"EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR ALAFENAMIDE",NDA208351,ea3b9ec8-e04a-412c-8b3f-e5cbc7e641d5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208351Orig1s000TOC.cfm,
2016,ODEFSEY,"EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR ALAFENAMIDE",NDA208351,ea3b9ec8-e04a-412c-8b3f-e5cbc7e641d5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208351 emtricitabine rilpivirine tenofovir clinical prea.pdf,
2016,ODEFSEY,"EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR ALAFENAMIDE",NDA208351,ea3b9ec8-e04a-412c-8b3f-e5cbc7e641d5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208351 emtricitabine rilpivirine tenofovir CDTL clinical prea.pdf,
2016,ODEFSEY,"EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR ALAFENAMIDE",NDA208351,ea3b9ec8-e04a-412c-8b3f-e5cbc7e641d5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208351 emtricitabine rilpivirine and tenofovir alafenamide clinpharm prea.pdf,
2015,LONSURF,TRIFLURIDINE AND TIPIRACIL,NDA207981,f5beed22-d71d-4c0d-8dca-2c7317d65d85,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/207981Orig1s009.pdf,
2015,LONSURF,TRIFLURIDINE AND TIPIRACIL,NDA207981,f5beed22-d71d-4c0d-8dca-2c7317d65d85,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000TOC.cfm,
2015,LONSURF,TRIFLURIDINE AND TIPIRACIL,NDA207981,f5beed22-d71d-4c0d-8dca-2c7317d65d85,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000SumR.pdf,
2015,LONSURF,TRIFLURIDINE AND TIPIRACIL,NDA207981,f5beed22-d71d-4c0d-8dca-2c7317d65d85,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/207981Orig1s012.pdf,
2021,EPCLUSA,VELPATASVIR AND SOFOSBUVIR,NDA214187,7f30631a-ee3b-4cfe-866b-964df3f0a44f,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214187Orig1s000TOC.cfm,
1996,ALBUTEROL SULFATE,ALBUTEROL SULFATE,NDA020503,37c9f560-75d2-44b0-e063-6394a90a4377,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20503-S004_Proventil.pdf,
1996,ALBUTEROL SULFATE,ALBUTEROL SULFATE,NDA020503,37c9f560-75d2-44b0-e063-6394a90a4377,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/020503Orig1s047.pdf,
1996,ALBUTEROL SULFATE,ALBUTEROL SULFATE,NDA020503,37c9f560-75d2-44b0-e063-6394a90a4377,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20503-S011_Proventil.pdf,
2018,PIFELTRO,DORAVIRINE,NDA210806,76ce1f00-28c0-4314-bd2c-d473fe3d0970,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210806Orig1s000,210807Orig1s000TOC.cfm",
2019,THIOLA EC,TIOPRONIN,NDA211843,20298a52-a194-a161-8632-d84b6f26e23c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211843Orig1s000TOC.cfm,
2011,N/A,N/A,NDA022581,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022581Orig1s000SumR.pdf,
2011,N/A,N/A,NDA022581,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022581_phoslyra_toc.cfm,
2024,IMDELLTRA (AMG757),TARLATAMAB-DLLE,BLA761344,1e7b6163-5d83-42ea-82c9-cf7620cdc782,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761344Orig1s000TOC.cfm,
2001,N/A,N/A,NDA021123,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21123_Ultracet.cfm,
2002,ZANAFLEX,TIZANIDINE HYDROCHLORIDE,NDA021447,043d9e51-bfa2-4add-9058-5ece332f7e99,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-447_Zanaflex.cfm,
2008,MORPHINE SULFATE,MORPHINE SULFATE,NDA022195,ca359246-4674-4b32-b8b2-673d32b7112f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022195_022207_morphine_toc.cfm,
2008,MORPHINE SULFATE,MORPHINE SULFATE,NDA022195,ca359246-4674-4b32-b8b2-673d32b7112f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022195s000_022207s000_SumR.pdf,
2005,APTIVUS,TIPRANAVIR,NDA021814,08982e49-d2eb-4b25-b01a-1be52fd669ef,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021814_Tipranavir_Clinical_BPCA.pdf,
2005,APTIVUS,TIPRANAVIR,NDA021814,08982e49-d2eb-4b25-b01a-1be52fd669ef,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021814_Tipranavir_Clinpharm_BPCA.pdf,
2005,APTIVUS,TIPRANAVIR,NDA021814,08982e49-d2eb-4b25-b01a-1be52fd669ef,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021814_Tipranavir_Statistical_BPCA.pdf,
2005,APTIVUS,TIPRANAVIR,NDA021814,08982e49-d2eb-4b25-b01a-1be52fd669ef,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21814_000_AptivusTOC.cfm,
2005,APTIVUS,TIPRANAVIR,NDA021814,08982e49-d2eb-4b25-b01a-1be52fd669ef,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021814s005, 022292_aptivus_toc.cfm",
2005,APTIVUS,TIPRANAVIR,NDA021814,08982e49-d2eb-4b25-b01a-1be52fd669ef,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021814s005,%2022-292s000sumr.pdf",
2015,TRESIBA,INSULIN DEGLUDEC,BLA203314,456c5e87-3dfd-46fa-8ac0-c6128d4c97c6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/203313and203314Orig1s000TOC.cfm,
2015,TRESIBA,INSULIN DEGLUDEC,BLA203314,456c5e87-3dfd-46fa-8ac0-c6128d4c97c6,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/203314-Insulin-degludec-CDTL-clinical-prea.pdf,
2015,TRESIBA,INSULIN DEGLUDEC,BLA203314,456c5e87-3dfd-46fa-8ac0-c6128d4c97c6,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/46_203313_203314 insulin degludec-insulin aspart clinical prea.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2015,TRESIBA,INSULIN DEGLUDEC,BLA203314,456c5e87-3dfd-46fa-8ac0-c6128d4c97c6,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/47_203314 insulin degludec CDTL clinical prea.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2015,TRESIBA,INSULIN DEGLUDEC,BLA203314,456c5e87-3dfd-46fa-8ac0-c6128d4c97c6,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/203313_203314_insulin degludec and insulin degludec-insulin aspart stat prea.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2015,TRESIBA,INSULIN DEGLUDEC,BLA203314,456c5e87-3dfd-46fa-8ac0-c6128d4c97c6,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/203314-Insulin-degludec-clinpharm-prea.pdf,
2015,TRESIBA,INSULIN DEGLUDEC,BLA203314,456c5e87-3dfd-46fa-8ac0-c6128d4c97c6,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/203313-203314-insulin-degludec-and-insulin-degludec-insulin-aspart-statistical-prea.pdf,
2015,TRESIBA,INSULIN DEGLUDEC,BLA203314,456c5e87-3dfd-46fa-8ac0-c6128d4c97c6,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/203314-Insulin-degludec-insulin-aspart-clinical-prea.pdf,
2015,TRESIBA,INSULIN DEGLUDEC,BLA203314,456c5e87-3dfd-46fa-8ac0-c6128d4c97c6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/203314Orig1s008.pdf,
2013,RIVELSA,LEVONORGESTREL/ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL,NDA204061,822e56c6-562f-4299-bf4f-eaee0c0f2b7a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204061Orig1s000SumR.pdf,
2013,RIVELSA,LEVONORGESTREL/ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL,NDA204061,822e56c6-562f-4299-bf4f-eaee0c0f2b7a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/204061 levo ee clinpharm prea.pdf,
2013,RIVELSA,LEVONORGESTREL/ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL,NDA204061,822e56c6-562f-4299-bf4f-eaee0c0f2b7a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/204061 levo ee statistical prea.pdf,
2013,RIVELSA,LEVONORGESTREL/ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL,NDA204061,822e56c6-562f-4299-bf4f-eaee0c0f2b7a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/204061 levo ee clinpharm prea.pdf,
2013,RIVELSA,LEVONORGESTREL/ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL,NDA204061,822e56c6-562f-4299-bf4f-eaee0c0f2b7a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204061_quartette_toc.cfm,
2020,PHEXXI,"LACTIC ACID, L-, CITRIC ACID MONOHYDRATE, AND POTASSIUM BITARTRATE",NDA208352,173ff411-7227-47b0-94dc-844e1ebaf14e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/208352Orig1s000TOC.cfm,
2019,EGATEN,TRICLABENDAZOLE,NDA208711,5552884e-10ea-450c-9658-d3d4f33c946e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000TOC.cfm,
2018,DELSTRIGO,"DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE",NDA210807,cd1e9f84-607a-46d3-b01e-2736018d67b6,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210806Orig1s000,210807Orig1s000TOC.cfm",
2021,MIDAZOLAM IN SODIUM CHLORIDE,MIDAZOLAM,NDA211844,f051776f-94c5-4e34-80ed-f45b9c36881e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211844Orig1s000TOC.cfm,
2023,ELREXFIO,ELRANATAMAB-BCMM,BLA761345,aa044060-5b4b-4692-bf0f-9a50e140b10e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761345Orig1s000TOC.cfm,
2000,N/A,N/A,NDA021124,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-124_TerbinafineLamisil.cfm,
2002,N/A,N/A,NDA021449,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021449S011_Adefovir_Clinical_Review_BPCA.pdf,
2002,N/A,N/A,NDA021449,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021449S011_Adefovir_Clinpharm_Review_BPCA.pdf,
2002,N/A,N/A,NDA021449,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021449S011_Adefovir_Statistical_Review_BPCA.pdf,
2002,N/A,N/A,NDA021449,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-449_Hepsera.cfm,
2008,N/A,N/A,NDA022196,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022196s000TOC.cfm,
2008,N/A,N/A,NDA022196,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022196s000_SumR.pdf,
2007,RECLAST,ZOLEDRONIC ACID,NDA021817,3c79ff9c-a6f4-405d-b19c-7e473a61dedc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021817Orig1s012.pdf,
2007,RECLAST,ZOLEDRONIC ACID,NDA021817,3c79ff9c-a6f4-405d-b19c-7e473a61dedc,http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/021817se1-001_SUMR.pdf,
2007,RECLAST,ZOLEDRONIC ACID,NDA021817,3c79ff9c-a6f4-405d-b19c-7e473a61dedc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021817TOC.cfm,
2012,DYMISTA,AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE,NDA202236,4c557ec4-c4cf-11df-851a-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202236_dymista_toc.cfm,
2012,DYMISTA,AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE,NDA202236,4c557ec4-c4cf-11df-851a-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202236Orig1s000SumR.pdf,
2012,DYMISTA,AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE,NDA202236,4c557ec4-c4cf-11df-851a-0800200c9a66,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202236Orig1s000MedR.pdf,
2012,DYMISTA,AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE,NDA202236,4c557ec4-c4cf-11df-851a-0800200c9a66,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202236-Azelastine-and-Fluticasone-Clinpharm-PREA.pdf,
2012,DYMISTA,AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE,NDA202236,4c557ec4-c4cf-11df-851a-0800200c9a66,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202236-Azelastine-and-Fluticasone-Statistical-PREA.pdf,
2012,DYMISTA,AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE,NDA202236,4c557ec4-c4cf-11df-851a-0800200c9a66,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202236 azelastine-fluticasone clinical bpca.pdf,
2012,DYMISTA,AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE,NDA202236,4c557ec4-c4cf-11df-851a-0800200c9a66,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202236 azelastine-fluticasone statistical bpca.pdf,
1988,WOMENS ROGAINE UNSCENTED,MINOXIDIL,NDA019501,8bf0000c-95f3-4a4d-830b-f5ac1539823d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/019501s025.pdf,
2014,ZERBAXA,CEFTOLOZANE AND TAZOBACTAM,NDA206829,70ac1d90-eff3-4f0b-9f46-5846c571b32f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206829Orig1s000SumR.pdf,
2014,ZERBAXA,CEFTOLOZANE AND TAZOBACTAM,NDA206829,70ac1d90-eff3-4f0b-9f46-5846c571b32f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206829Orig1s000TOC.cfm,
2014,ZERBAXA,CEFTOLOZANE AND TAZOBACTAM,NDA206829,70ac1d90-eff3-4f0b-9f46-5846c571b32f,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/206829Orig1s008.pdf,
2022,VONJO,PACRITINIB,NDA208712,4b5ab444-0e1a-4984-99db-76ad11a298ee,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/208712Orig1s000TOC.cfm,
2018,TIGECYCLINE,TIGECYCLINE,NDA211158,8450bd15-2b06-4fc7-b302-9021312e3f0d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211158Orig1s000TOC.cfm,
2021,EMPAVELI,PEGCETACOPLAN,NDA215014,c23d89e9-b00b-4520-e053-2995a90a95af,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215014Orig1s000TOC.cfm,
2023,BOSULIF,BOSUTINIB,NDA217729,adc84ad5-a04d-4fee-9ba8-91f7abd928e3,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217729Orig1s000TOC.cfm,
2024,HERCESSI,TRASTUZUMAB-STRF,BLA761346,285d2142-5bfa-401c-9246-7de21c4451af,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761346Orig1s000TOC.cfm,
2000,N/A,N/A,NDA021127,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21127_Optivar.cfm,
2003,ZOMIG,ZOLMITRIPTAN,NDA021450,2438c223-605b-4885-afc3-a6794f190f89,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21450 zolmitriptan clinical prea.pdf,
2003,ZOMIG,ZOLMITRIPTAN,NDA021450,2438c223-605b-4885-afc3-a6794f190f89,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21450 zolmitriptan statistical prea.pdf,
2003,ZOMIG,ZOLMITRIPTAN,NDA021450,2438c223-605b-4885-afc3-a6794f190f89,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021450s005_Zolmitriptan_Clinical_PREA.pdf,
2003,ZOMIG,ZOLMITRIPTAN,NDA021450,2438c223-605b-4885-afc3-a6794f190f89,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021450s005_Zolmitriptan_Clinpharm.pdf,
2003,ZOMIG,ZOLMITRIPTAN,NDA021450,2438c223-605b-4885-afc3-a6794f190f89,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21450s005_Zolmitriptan_Statistical.pdf,
2003,ZOMIG,ZOLMITRIPTAN,NDA021450,2438c223-605b-4885-afc3-a6794f190f89,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-450_Zomig.cfm,
2008,SANCUSO,GRANISETRON,NDA022198,7379369a-03df-4ec3-8f2e-66645cc736d8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022198_sancuso_toc.cfm,
2014,MITIGARE,COLCHICINE,NDA204820,cb5f9d85-6b81-49f8-bcd6-17b7bfbc10f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204820Orig1s000TOC.cfm,
2014,MITIGARE,COLCHICINE,NDA204820,cb5f9d85-6b81-49f8-bcd6-17b7bfbc10f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204820Orig1s000SumR.pdf,
2022,N/A,N/A,NDA211530,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/211530Orig1s000TOC.cfm,
2022,ZTALMY,GANAXOLONE,NDA215904,d91612c4-b03a-4be4-a1ee-6a13e3b83d4e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215904Orig1s000TOC.cfm,
2008,N/A,N/A,NDA022203,N/A,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22203s010, 011 azelastine clinical prea.pdf",
2008,N/A,N/A,NDA022203,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022203s000SUMR.cfm,
2008,N/A,N/A,NDA022203,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022203s000TOC.cfm,
2008,N/A,N/A,NDA022203,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022203 azelastine clinical prea.pdf,
2008,N/A,N/A,NDA022203,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022203 azelastine Astepro statistical prea.pdf,
2008,N/A,N/A,NDA022203,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022203 azelastine clinpharm prea.pdf,
2002,MESNEX,MESNA,NDA020855,4a51ffdb-f59f-4e02-b3c4-f3457ab7b514,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020855_mesnex.cfm,
2000,ZYVOX,LINEZOLID,NDA021131,122faa9e-c71a-4597-9552-5fb330b7d8b9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21130_Zyvox.cfm,
2000,ZYVOX,LINEZOLID,NDA021131,122faa9e-c71a-4597-9552-5fb330b7d8b9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021131Orig1s012.pdf,
2000,ZYVOX,LINEZOLID,NDA021131,122faa9e-c71a-4597-9552-5fb330b7d8b9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-130s003_21131s003_21132s003_ZyvoxTOC.cfm,
2003,N/A,N/A,NDA021455,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021455Orig1s007.pdf,
2003,N/A,N/A,NDA021455,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva.cfm,
2005,N/A,N/A,NDA021823,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021823orig1s000.pdf,
1964,N/A,N/A,NDA014691,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/NDA/2001/14-691S20_Alkeran.cfm,
1978,TECHNETIUM TC 99M MEDRONATE,TECHNETIUM TC 99M MEDRONATE,NDA018035,3c91d0d8-6cc5-834c-bda0-aa83a873b9fb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/18-035_Technescan%20MDP.pdf,
2013,TECFIDERA,DIMETHYL FUMARATE,NDA204063,665d7e74-036c-5f68-5b67-ab84b9b49151,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204063Orig1s010.pdf,
2013,TECFIDERA,DIMETHYL FUMARATE,NDA204063,665d7e74-036c-5f68-5b67-ab84b9b49151,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204063Orig1s000TOC.cfm,
2013,TECFIDERA,DIMETHYL FUMARATE,NDA204063,665d7e74-036c-5f68-5b67-ab84b9b49151,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204063Orig1s000SumR.pdf,
2015,N/A,N/A,NDA207986,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207986Orig1s000TOC.cfm,
2015,N/A,N/A,NDA207986,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207986Orig1s000SumR.pdf,
2015,N/A,N/A,NDA207986,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/207986 ciprofloxacin clinical prea.pdf,
2015,N/A,N/A,NDA207986,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/207986 ciprofloxacin clinpharm prea.pdf,
2015,N/A,N/A,NDA207986,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/207986 ciprofloxacin statistical_prea.pdf,
2017,VERZENIO,ABEMACICLIB,NDA208716,be4bc0de-0fdc-4d46-8d25-be43c79e6a06,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208716Orig1s000TOC.cfm,
2019,AKLIEF,TRIFAROTENE,NDA211527,62d910db-85a6-4696-b69b-4bd2f3080cfc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000TOC.cfm,
2019,AKLIEF,TRIFAROTENE,NDA211527,62d910db-85a6-4696-b69b-4bd2f3080cfc,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/474_211527 trifarotene unireview PREA.pdf,
1996,TEGRETOL XR,CARBAMAZEPINE,NDA020234,8d409411-aa9f-4f3a-a52c-fbcb0c3ec053,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020234_complete_Approval_pkg.pdf,
1996,TEGRETOL XR,CARBAMAZEPINE,NDA020234,8d409411-aa9f-4f3a-a52c-fbcb0c3ec053,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020234_S017_TEGRETOL_AP.pdf,
1996,JUNIOR STRENGTH ADVIL,IBUPROFEN,NDA020267,5ed0d404-c54d-b05f-578a-d2730e8a78ee,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020267Orig1s009.pdf,
2020,RUKOBIA,FOSTEMSAVIR TROMETHAMINE,NDA212950,a21006b7-6d6f-4f06-81b4-17978756452b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000TOC.cfm,
2024,ERZOFRI EXTENDED-RELEASE,PALIPERIDONE PALMITATE,NDA216352,492bf9dd-868e-421a-92db-8cca8973aac1,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/216352Orig1s000TOC.cfm,
2023,COSENTYX,SECUKINUMAB,BLA761349,77c4b13e-7df3-42d4-81db-3d0cddb7f67a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761349Orig1s000TOC.cfm,
2000,NEURONTIN,GABAPENTIN,NDA021129,ee9ad9ed-6d9f-4ee1-9d7f-cfad438df388,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-216_20-235S15_20-882S2_21-129S5_Neurontin.cfm,
2000,NEURONTIN,GABAPENTIN,NDA021129,ee9ad9ed-6d9f-4ee1-9d7f-cfad438df388,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-129_Neurontin.cfm,
2012,N/A,N/A,NDA022200,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022200Orig1s000TOC.cfm,
2012,N/A,N/A,NDA022200,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022200Orig1s000SumRedt.pdf,
2012,N/A,N/A,NDA022200,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022200Orig1s008.pdf,
2014,NUVESSA,METRONIDAZOLE,NDA205223,3b6ff39d-f84b-43b3-9b07-c0521c6d7968,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205223Orig1s000TOC.cfm,
2014,NUVESSA,METRONIDAZOLE,NDA205223,3b6ff39d-f84b-43b3-9b07-c0521c6d7968,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205223S2-metronidazole-clinical-prea.pdf,
2014,NUVESSA,METRONIDAZOLE,NDA205223,3b6ff39d-f84b-43b3-9b07-c0521c6d7968,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205223S2-metronidazole-clinpharm-prea.pdf,
2014,NUVESSA,METRONIDAZOLE,NDA205223,3b6ff39d-f84b-43b3-9b07-c0521c6d7968,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205223S2-metronidazole-statistical-prea.pdf,
2014,NUVESSA,METRONIDAZOLE,NDA205223,3b6ff39d-f84b-43b3-9b07-c0521c6d7968,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205223Orig1s000SumR.pdf,
2017,ABILIFY MYCITE,ARIPIPRAZOLE,NDA207202,e8787c3f-5e41-42d1-8091-44b56346620f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207202Orig1s000TOC.cfm,
2018,DEHYDRATED ALCOHOL,ALCOHOL,NDA207987,636d6421-cadf-42b3-a431-ba40c06e36d2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/207987Orig1s000TOC.cfm,
2020,GAVRETO,PRALSETINIB,NDA213721,59984249-e3ff-4f97-8d7a-c1a905d604a8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213721Orig1s000TOC.cfm,
1995,IMITREX,SUMATRIPTAN,NDA020132,584abe73-8290-4484-ff8e-5890831c095e,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020132_S014_IMITREX TABLETS, NASAL SPRAY INJ.pdf",
1995,IMITREX,SUMATRIPTAN,NDA020132,584abe73-8290-4484-ff8e-5890831c095e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020132_s015_ImitrexTOC.cfm,
1993,N/A,N/A,BLA020168,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020168_S016&020656_S005_NUTROPIN FOR INJ.pdf,
2021,DARTISLA ODT,GLYCOPYRROLATE ORALLY DISINTEGRATING TABLETS,NDA215019,52daf47e-7ba3-4105-be7f-27001a87e16e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215019Orig1s000TOC.cfm,
2022,"NALOXONE HYDROCHLORIDE INJECTION, USP, AUTO-INJECTOR",NALOXONE HYDROCHLORIDE,NDA215457,b5463553-b775-47a3-8d10-31e01ca1ec72,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215457Orig1s000TOC.cfm,
2023,AUSTEDO XR,DEUTETRABENAZINE,NDA216354,7ea3c60a-45c7-44cc-afc2-d87fa53993c0,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/216354Orig1s000TOC.cfm,
2024,N/A,N/A,BLA761350,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761350Orig1s000TOC.cfm,
2008,FIRMAGON,DEGARELIX,NDA022201,ab11dd8a-0fd9-4013-89ab-e114557c7e4b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022201s000_TOC.cfm,
2008,FIRMAGON,DEGARELIX,NDA022201,ab11dd8a-0fd9-4013-89ab-e114557c7e4b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022201s000_SumR.pdf,
2005,TYGACIL,TIGECYCLINE,NDA021821,fd826e47-1b77-4ffd-bb22-fda3379903b0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021821Orig1s026.pdf,
2005,TYGACIL,TIGECYCLINE,NDA021821,fd826e47-1b77-4ffd-bb22-fda3379903b0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21-821_Tygacil.cfm,
2005,TYGACIL,TIGECYCLINE,NDA021821,fd826e47-1b77-4ffd-bb22-fda3379903b0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021821Orig1s031.pdf,
2013,ADEMPAS,RIOCIGUAT,NDA204819,7b57509a-3d5d-41d4-8fed-1471e26372a3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204819Orig1s000SumR.pdf,
2013,ADEMPAS,RIOCIGUAT,NDA204819,7b57509a-3d5d-41d4-8fed-1471e26372a3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204819Orig1s000TOC.cfm,
2015,N/A,N/A,NDA207988,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207988Orig1s000TOC.cfm,
2015,N/A,N/A,NDA207988,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207988Orig1s000SumR.pdf,
2019,FETROJA,CEFIDEROCOL SULFATE TOSYLATE,NDA209445,75c0c785-38e0-4049-a6fb-b77581f5b35c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209445Orig1s000TOC.cfm,
2019,FETROJA,CEFIDEROCOL SULFATE TOSYLATE,NDA209445,75c0c785-38e0-4049-a6fb-b77581f5b35c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209445Orig1s002.pdf,
2009,ZIPSOR,DICLOFENAC POTASSIUM,NDA022202,c982eca0-fc41-11e1-a9c8-0002a5d5c51b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022202_zipsor_toc.cfm,
2009,ZIPSOR,DICLOFENAC POTASSIUM,NDA022202,c982eca0-fc41-11e1-a9c8-0002a5d5c51b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022202s000sumr.pdf,
2024,BIZENGRI,ZENOCUTUZUMAB,BLA761352,2a33e782-fc75-4dba-b77c-a44536ac13a5,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761352Orig1s000TOC.cfm,
2000,ZYVOX,LINEZOLID,NDA021130,6e70e63b-bfd5-478d-a8ee-8ba22c9efabd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021130Orig1s012.pdf,
2000,ZYVOX,LINEZOLID,NDA021130,6e70e63b-bfd5-478d-a8ee-8ba22c9efabd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21130_Zyvox.cfm,
2000,ZYVOX,LINEZOLID,NDA021130,6e70e63b-bfd5-478d-a8ee-8ba22c9efabd,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21130 linezolid clinical bpca.pdf,
2000,ZYVOX,LINEZOLID,NDA021130,6e70e63b-bfd5-478d-a8ee-8ba22c9efabd,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21130 linezolid clinpharm bpca.pdf,
2000,ZYVOX,LINEZOLID,NDA021130,6e70e63b-bfd5-478d-a8ee-8ba22c9efabd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-130s003_21131s003_21132s003_ZyvoxTOC.cfm,
2002,TESTIM,TESTOSTERONE,NDA021454,9f2aae1f-898d-4955-be31-678e0cf85395,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-454_Testim.cfm,
2013,OTREXUP,METHOTREXATE,NDA204824,7dcd02d7-1ce0-43fc-8f25-2f0bb0caba2f,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204824Orig2s000TOC.cfm,
2013,OTREXUP,METHOTREXATE,NDA204824,7dcd02d7-1ce0-43fc-8f25-2f0bb0caba2f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204824Orig1s000TOC.cfm,Orig1
2017,XYZAL ALLERGY 24HR,LEVOCETIRIZINE DIHYDROCHLORIDE,NDA209089,8be45c2a-1eca-4a00-81b9-f7babdbdcd41,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209089Orig1s000_209090Orig1s000TOC.cfm,
2019,TETRACAINE HYDROCHLORIDE,TETRACAINE HYDROCHLORIDE,NDA210821,807dae5d-f34a-4f3d-9f54-dd350b056a92,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210821Orig1s000TOC.cfm,
2008,MORPHINE SULFATE,MORPHINE SULFATE,NDA022207,3c847554-3b4b-4d24-a145-2ef7e9b83699,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022195_022207_morphine_toc.cfm,
2008,MORPHINE SULFATE,MORPHINE SULFATE,NDA022207,3c847554-3b4b-4d24-a145-2ef7e9b83699,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022195s000_022207s000_SumR.pdf,
2024,N/A,N/A,BLA761359,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761359Orig1s000TOC.cfm,
2002,N/A,N/A,NDA021136,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021136_S006_SECRETFLO_INJ.pdf,
2002,N/A,N/A,NDA021136,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021136_S001_SECRETFLO_INJ.pdf,
2002,N/A,N/A,NDA021136,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-136_21-209_SecreFlo.cfm,
2004,ALIMTA,PEMETREXED DISODIUM,NDA021462,f5a860f3-37ec-429c-ae04-9c88d7c55c08,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-462_Alimta.cfm,
2004,ALIMTA,PEMETREXED DISODIUM,NDA021462,f5a860f3-37ec-429c-ae04-9c88d7c55c08,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21462 pemetrexed clinical bpca.pdf,
2004,ALIMTA,PEMETREXED DISODIUM,NDA021462,f5a860f3-37ec-429c-ae04-9c88d7c55c08,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21462 pemetrexed clinpharm bpca.pdf,
2004,ALIMTA,PEMETREXED DISODIUM,NDA021462,f5a860f3-37ec-429c-ae04-9c88d7c55c08,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21462 pemetrexed statistical bpca.pdf,
2004,ALIMTA,PEMETREXED DISODIUM,NDA021462,f5a860f3-37ec-429c-ae04-9c88d7c55c08,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021462s015.pdf,
2016,PHOTREXA CROSS-LINKING KIT,RIBOFLAVIN 5-PHOSPHATE OPHTHALMIC,NDA203324,f82cfe92-1a24-11e3-8ffd-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/203324Orig1s000SumR.pdf,
2016,PHOTREXA CROSS-LINKING KIT,RIBOFLAVIN 5-PHOSPHATE OPHTHALMIC,NDA203324,f82cfe92-1a24-11e3-8ffd-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/203324Orig1s000TOC.cfm,
2016,PHOTREXA CROSS-LINKING KIT,RIBOFLAVIN 5-PHOSPHATE OPHTHALMIC,NDA203324,f82cfe92-1a24-11e3-8ffd-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/203324Orig2s000SumR.pdf,
2016,PHOTREXA CROSS-LINKING KIT,RIBOFLAVIN 5-PHOSPHATE OPHTHALMIC,NDA203324,f82cfe92-1a24-11e3-8ffd-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/203324Orig2s000TOC.cfm,
2014,RAPIVAB,PERAMIVIR,NDA206426,fe04f6cd-e71c-4bd4-abac-97720bba2a0d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/188_206426S4 peramivir CDTL statistical prea.pdf,
2014,RAPIVAB,PERAMIVIR,NDA206426,fe04f6cd-e71c-4bd4-abac-97720bba2a0d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/189_206426S4 peramivir clinpharm prea.pdf,
2014,RAPIVAB,PERAMIVIR,NDA206426,fe04f6cd-e71c-4bd4-abac-97720bba2a0d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/188_206426S4 peramivir CDTL statistical prea.pdf,
2014,RAPIVAB,PERAMIVIR,NDA206426,fe04f6cd-e71c-4bd4-abac-97720bba2a0d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206426Orig1s000TOC.cfm,
2014,RAPIVAB,PERAMIVIR,NDA206426,fe04f6cd-e71c-4bd4-abac-97720bba2a0d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206426Orig1s000SumR.pdf,
2021,COSELA,TRILACICLIB,NDA214200,4b06922c-498d-4871-a037-84a44e6a6b6c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214200Orig1s000TOC.cfm,
1998,THALOMID,THALIDOMIDE,NDA020785,2eda833b-1357-4ed4-a093-194524fcb061,http://www.accessdata.fda.gov/drugsatfda_docs/label/2001/20785s12s14lbl.pdf,
1998,THALOMID,THALIDOMIDE,NDA020785,2eda833b-1357-4ed4-a093-194524fcb061,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020785s000_ThalidomideTOC.cfm,
1998,THALOMID,THALIDOMIDE,NDA020785,2eda833b-1357-4ed4-a093-194524fcb061,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020785_S020_THALOMID.pdf,
1998,THALOMID,THALIDOMIDE,NDA020785,2eda833b-1357-4ed4-a093-194524fcb061,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020785_S021_THALOMID.pdf,
1998,CELEXA,CITALOPRAM,NDA020822,4259d9b1-de34-43a4-85a8-41dd214e9177,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020822_s019_CelexaTOC.cfm,
1998,CELEXA,CITALOPRAM,NDA020822,4259d9b1-de34-43a4-85a8-41dd214e9177,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020822Orig1s038s040_021046Orig1s016s017Rev.pdf,
1998,CELEXA,CITALOPRAM,NDA020822,4259d9b1-de34-43a4-85a8-41dd214e9177,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/020822Orig1s042.pdf,
1998,CELEXA,CITALOPRAM,NDA020822,4259d9b1-de34-43a4-85a8-41dd214e9177,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020822Orig1s038s040_021046Orig1s016s017Rev.pdf,
1998,CELEXA,CITALOPRAM,NDA020822,4259d9b1-de34-43a4-85a8-41dd214e9177,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020822s016, 021046s002_citalopram_Celexa-MedRev.pdf",
1998,CELEXA,CITALOPRAM,NDA020822,4259d9b1-de34-43a4-85a8-41dd214e9177,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020822s016, 021046s002_citalopram_Celexa-ClinPharmRev.pdf",
1998,CELEXA,CITALOPRAM,NDA020822,4259d9b1-de34-43a4-85a8-41dd214e9177,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020822a.cfm,
2021,SODIUM PHENYLACETATE AND SODIUM BENZOATE,SODIUM PHENYLACETATE AND SODIUM BENZOATE,NDA215025,ab40b62b-9f8d-4394-92d5-09d9f1941eaa,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215025Orig1s000TOC.cfm,
2009,N/A,N/A,NDA022204,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022204s000_gelnique_toc.cfm,
2009,N/A,N/A,NDA022204,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022204s000SumR.pdf,
2023,TOFIDENCE,TOCILIZUMAB,BLA761354,00529b23-850a-42b9-a152-125a95b5242c,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761354Orig1s000TOC.cfm,
2000,LINEZOLID,LINEZOLID,NDA021132,83a84897-ccca-42a1-ab1a-bbf1d43a982b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021132Orig1s012.pdf,
2000,LINEZOLID,LINEZOLID,NDA021132,83a84897-ccca-42a1-ab1a-bbf1d43a982b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21130_Zyvox.cfm,
2000,LINEZOLID,LINEZOLID,NDA021132,83a84897-ccca-42a1-ab1a-bbf1d43a982b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-130s003_21131s003_21132s003_ZyvoxTOC.cfm,
2011,FERRIPROX,DEFERIPRONE,NDA021825,946718ff-df43-1baa-74d1-e5bcfbe8ad86,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021825Orig1s000SumR.pdf,
2011,FERRIPROX,DEFERIPRONE,NDA021825,946718ff-df43-1baa-74d1-e5bcfbe8ad86,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021825Orig1s000TOC.cfm,
2011,N/A,N/A,NDA202245,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202245_codeine_toc.cfm,
2011,N/A,N/A,NDA202245,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202245Orig1s000SumR.pdf,
2014,N/A,N/A,NDA204822,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204822Orig1s000TOC.cfm,
2014,N/A,N/A,NDA204822,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204822Orig1s000SumR.pdf,
2015,N/A,N/A,NDA206843,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206843Orig1s000TOC.cfm,
2015,N/A,N/A,NDA206843,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2016/206843Orig1s001, s003SumR.pdf",
2015,N/A,N/A,NDA206843,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206843Orig1s001,s003TOC.cfm",
2015,N/A,N/A,NDA206843,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2016/206843Orig1s001, s003SumR.pdf",
2015,N/A,N/A,NDA206843,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206843Orig1s001,s003TOC.cfm",
2019,VUMERITY,DIROXIMEL FUMARATE,NDA211855,2d74414f-6b83-4ea2-9a95-3cecabbce774,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211855Orig1s000TOC.cfm,
2020,VASOPRESSIN,VASOPRESSIN,NDA212593,0ab267f4-9ec9-44fd-8521-f975074667d9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212593Orig1s000TOC.cfm,
2022,N/A,"MIDAZOLAM INJECTION, 10 MG",NDA216359,d7362b4d-68a3-99a0-e053-2995a90a4f60,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216359Orig1s000TOC.cfm,
1997,N/A,N/A,NDA020723,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020723Orig1s001.pdf,
1997,N/A,N/A,NDA020723,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020723_S016_ALDARA_CREAM.pdf,
1997,N/A,N/A,NDA020723,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020723s020_imiquimod_Aldara-MedRev.pdf,
1997,N/A,N/A,NDA020723,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020723s020_imiquimod_Aldara-StatsRev.pdf,
2012,N/A,N/A,NDA022205,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022205_giazo_toc.cfm,
2012,N/A,N/A,NDA022205,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022205Orig1s000SumR.pdf,
2023,EYLEA HD,AFLIBERCEPT,BLA761355,86d8848b-111b-4da9-8957-7cccef1b8f66,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761355Orig1s000TOC.cfm,
2000,NITROSTAT,NITROGLYCERIN,NDA021134,79ba021e-183c-4b4d-822e-4ff5ef54ca61,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21134_Nitrostat.cfm,
2004,ALBUTEROL SULFATE HFA,ALBUTEROL SULFATE,NDA021457,7bb5b6dd-9105-4ee7-b205-ed79cf4b371b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021457s000TOC.cfm,
2007,NEUPRO,ROTIGOTINE,NDA021829,939e28c5-f3a9-42c0-9a2d-8d471d82a6e0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021829Orig1s001s002.pdf,
2007,NEUPRO,ROTIGOTINE,NDA021829,939e28c5-f3a9-42c0-9a2d-8d471d82a6e0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021829Orig1s001s002.pdf,
2007,NEUPRO,ROTIGOTINE,NDA021829,939e28c5-f3a9-42c0-9a2d-8d471d82a6e0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021829s000TOC.cfm,
1989,LUPRON DEPOT,LEUPROLIDE ACETATE,NDA019732,cbc8f94e-7330-4465-05ad-16d64493a5dd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019732_S009_Lupron Depot_APPROVAL PACKAGE.pdf,
1989,LUPRON DEPOT,LEUPROLIDE ACETATE,NDA019732,cbc8f94e-7330-4465-05ad-16d64493a5dd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019732_S007_Lupron Depot_APPROVAL PACKAGE.pdf,
1989,LUPRON DEPOT,LEUPROLIDE ACETATE,NDA019732,cbc8f94e-7330-4465-05ad-16d64493a5dd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/019732_S016_Lupron Depot_APPROVAL PACKAGE.pdf,
1989,LUPRON DEPOT,LEUPROLIDE ACETATE,NDA019732,cbc8f94e-7330-4465-05ad-16d64493a5dd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/019732s012_lupron.cfm,
1989,LUPRON DEPOT,LEUPROLIDE ACETATE,NDA019732,cbc8f94e-7330-4465-05ad-16d64493a5dd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/019732_S029_Lupron Depot_APPROVAL PACKAGE.pdf,
1989,LUPRON DEPOT,LEUPROLIDE ACETATE,NDA019732,cbc8f94e-7330-4465-05ad-16d64493a5dd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/019732_S027_Lupron Depot_APPROVAL PACKAGE.pdf,
1990,CARDIOLITE,TETRAKIS(2-METHOXYISOBUTYLISOCYANIDE)COPPER(I) TETRAFLUOROBORATE,NDA019785,49662def-2fb9-47b2-8467-ca56f6006167,http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/019785se5-018_SumR.pdf,
2016,N/A,N/A,NDA208723,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208723Orig1s000TOC.cfm,
2017,NITYR,NITISINONE,NDA209449,00fd1905-27e4-420e-8dc5-a69e4ddc1526,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209449Orig1s000TOC.cfm,
2017,NITYR,NITISINONE,NDA209449,00fd1905-27e4-420e-8dc5-a69e4ddc1526,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/176_209449 Nitisinone clinical prea.pdf,
2017,NITYR,NITISINONE,NDA209449,00fd1905-27e4-420e-8dc5-a69e4ddc1526,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/177_209449 Nitisinone clinpharm prea.pdf,
2018,TEGSEDI,INOTERSEN,NDA211172,8513207e-b55f-417b-9473-af785146a543,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211172Orig1s000TOC.cfm,
2019,N/A,N/A,NDA212595,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212595Orig1s000TOC.cfm,
2019,N/A,N/A,NDA212595,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/457_212595 metformin CDTL prea_1.pdf,
2019,N/A,N/A,NDA212595,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/456_212595 metformin clinpharm prea.pdf,
2024,IQIRVO,ELAFIBRANOR,NDA218860,d78aa14f-6ec1-4b1d-a4ae-e48658137a25,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/218860Orig1s000TOC.cfm,
1995,N/A,N/A,NDA020599,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/020599Orig1s013.pdf,
1995,N/A,N/A,NDA020599,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/020599Orig1s011,s012.pdf",
1995,N/A,N/A,NDA020599,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020599Orig1s008.pdf,
1995,N/A,N/A,NDA020599,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020599Orig1s002.pdf,
1995,N/A,N/A,NDA020599,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/020599Orig1s011,s012.pdf",
1995,N/A,N/A,NDA020599,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020599Orig1s000rev.pdf,
1995,N/A,N/A,NDA020599,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020599Orig1s005.pdf,
1995,N/A,N/A,NDA020599,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020599Orig1s003.pdf,
2008,RAPAFLO,SILODOSIN,NDA022206,da0314f6-b1d6-44ee-8b1e-f763dbb8613f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000TOC.cfm,
2008,RAPAFLO,SILODOSIN,NDA022206,da0314f6-b1d6-44ee-8b1e-f763dbb8613f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_SumR.pdf,
2023,ZYMFENTRA,INFLIXIMAB-DYYB,BLA761358,93a193ab-9f96-4da6-aa7c-31212e81879a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761358Orig1s000TOC.cfm,
2000,VENOFER,IRON SUCROSE,NDA021135,f1ab1a22-2b99-4d27-8b5a-9c3bcd5e3040,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021135_S008_VENOFER.pdf,
2000,VENOFER,IRON SUCROSE,NDA021135,f1ab1a22-2b99-4d27-8b5a-9c3bcd5e3040,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21135_Venofer.cfm,
2000,VENOFER,IRON SUCROSE,NDA021135,f1ab1a22-2b99-4d27-8b5a-9c3bcd5e3040,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21135 iron sucrose clinical prea.pdf,
2000,VENOFER,IRON SUCROSE,NDA021135,f1ab1a22-2b99-4d27-8b5a-9c3bcd5e3040,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21135 iron sucrose clinpharm prea.pdf,
2000,VENOFER,IRON SUCROSE,NDA021135,f1ab1a22-2b99-4d27-8b5a-9c3bcd5e3040,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21135 iron sucrose statistical prea.pdf,
2002,N/A,N/A,NDA021460,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021460_metaglip.cfm,
2008,N/A,N/A,NDA021830,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021830s006 mesalamine clinical prea.pdf,
2008,N/A,N/A,NDA021830,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021830s006 mesalamine statistical prea.pdf,
2008,N/A,N/A,NDA021830,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/19651Origs024_ mesalamine clinpharm PREA.pdf,
2008,N/A,N/A,NDA021830,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021830TOC.cfm,
2008,N/A,N/A,NDA021830,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/021830s000_SUMR.pdf,
2023,BRIXADI,BUPRENORPHINE,NDA210136,5d8a8fd0-8619-422a-a664-d1d2e8970f48,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/210136Orig1s000TOC.cfm,
2017,N/A,N/A,NDA208374,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208374Orig1s000TOC.cfm,
1993,NEURONTIN,GABAPENTIN,NDA020235,ee9ad9ed-6d9f-4ee1-9d7f-cfad438df388,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-216_20-235S15_20-882S2_21-129S5_Neurontin.cfm,
1993,NEURONTIN,GABAPENTIN,NDA020235,ee9ad9ed-6d9f-4ee1-9d7f-cfad438df388,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020235S011.pdf,
2023,JOENJA,LENIOLISIB,NDA217759,eefbcef8-2130-4654-8f29-b58077e08212,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217759Orig1s000TOC.cfm,
2008,DIFLUPREDNATE OPHTHALMIC,DIFLUPREDNATE OPHTHALMIC,NDA022212,0f60b857-7898-4a9e-935c-a9ddf0eb9194,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/022212Orig1s015.pdf,
2008,DIFLUPREDNATE OPHTHALMIC,DIFLUPREDNATE OPHTHALMIC,NDA022212,0f60b857-7898-4a9e-935c-a9ddf0eb9194,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022212s000_SumR.pdf,
2008,DIFLUPREDNATE OPHTHALMIC,DIFLUPREDNATE OPHTHALMIC,NDA022212,0f60b857-7898-4a9e-935c-a9ddf0eb9194,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022212s000TOC.cfm,
2008,DIFLUPREDNATE OPHTHALMIC,DIFLUPREDNATE OPHTHALMIC,NDA022212,0f60b857-7898-4a9e-935c-a9ddf0eb9194,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22212 difluprednate clinical bpca.pdf,
2008,DIFLUPREDNATE OPHTHALMIC,DIFLUPREDNATE OPHTHALMIC,NDA022212,0f60b857-7898-4a9e-935c-a9ddf0eb9194,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22212 defluprednate clinpharm bpca.pdf,
2008,DIFLUPREDNATE OPHTHALMIC,DIFLUPREDNATE OPHTHALMIC,NDA022212,0f60b857-7898-4a9e-935c-a9ddf0eb9194,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22212 difluprednate statistical bpca.pdf,
2024,VYLOY,ZOLBETUXIMAB,BLA761365,e7695a21-abb6-47ac-93f8-0ece5a9c4409,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761365Orig1s000TOC.cfm,
2000,N/A,N/A,NDA021142,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-142_Olux.cfm,
1979,N/A,N/A,NDA016792,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/16792S015.pdf,
1979,N/A,N/A,NDA016792,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/16792S020.pdf,
1979,N/A,N/A,NDA016792,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/16792S015.pdf,
1979,N/A,N/A,NDA016792,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/16792S015.pdf,
2013,N/A,N/A,NDA200153,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/200153_liptruzet_toc.cfm,
2013,N/A,N/A,NDA200153,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/200153Orig1s000SumR.pdf,
2013,BLOXIVERZ,NEOSTIGMINE METHYLSULFATE,NDA204078,1fb5c812-1e63-4bd9-a68e-7f9dc5e7a33a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204078Orig1s000TOC.cfm,
2013,BLOXIVERZ,NEOSTIGMINE METHYLSULFATE,NDA204078,1fb5c812-1e63-4bd9-a68e-7f9dc5e7a33a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204078Orig1s000SumR.pdf,
2013,BLOXIVERZ,NEOSTIGMINE METHYLSULFATE,NDA204078,1fb5c812-1e63-4bd9-a68e-7f9dc5e7a33a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/204078 neostigmine methylsulfate Bloxiverz clinical prea.pdf,
2013,BLOXIVERZ,NEOSTIGMINE METHYLSULFATE,NDA204078,1fb5c812-1e63-4bd9-a68e-7f9dc5e7a33a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/204078-Neostigmine-Methylsulfate-Clinpharm-PREA.pdf,
2018,BIJUVA,ESTRADIOL AND PROGESTERONE,NDA210132,59eadb88-c9f3-4871-b176-7ddd98faf9bc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210132Orig1s000TOC.cfm,
2017,CHILDRENS XYZAL ALLERGY,LEVOCETIRIZINE DIHYDROCHLORIDE,NDA209090,a33f2704-d350-428b-b467-91f4775ce17f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209089Orig1s000_209090Orig1s000TOC.cfm,
1996,CLARITIN-D 24 HOUR,LORATADINE AND PSEUDOEPHEDRINE SULFATE,NDA020470,f046a807-ab8c-0620-e053-2a95a90a9d3c,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/019670_s013,20470s10,18506s018_Claritin-DTOC.cfml",
1996,CLARITIN-D 24 HOUR,LORATADINE AND PSEUDOEPHEDRINE SULFATE,NDA020470,f046a807-ab8c-0620-e053-2a95a90a9d3c,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/1998/019670_s012,19658s14,20470s7,20641s3,20704s4_ClaritinDTOC.cfml",
1996,CLARITIN-D 24 HOUR,LORATADINE AND PSEUDOEPHEDRINE SULFATE,NDA020470,f046a807-ab8c-0620-e053-2a95a90a9d3c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20470-S005_Claritin.pdf,
1996,CLARITIN-D 24 HOUR,LORATADINE AND PSEUDOEPHEDRINE SULFATE,NDA020470,f046a807-ab8c-0620-e053-2a95a90a9d3c,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/1998/019670_s008,19658s10,20470s3,20641s120704s3_Claritin-DTOC.cfml",
1996,CLARITIN-D 24 HOUR,LORATADINE AND PSEUDOEPHEDRINE SULFATE,NDA020470,f046a807-ab8c-0620-e053-2a95a90a9d3c,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/19670s18,20470s16,19658s18,20704s8,20641s9_Claritin.cfm",
2009,ZENPEP,"PANCRELIPASE LIPASE, PANCRELIPASE PROTEASE, PANCRELIPASE AMYLASE",BLA022210,7f16f2d4-8df6-4bd7-ac10-56994fa257b0,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022210_Pancrelapse_Clinical_PREA.pdf,
2009,ZENPEP,"PANCRELIPASE LIPASE, PANCRELIPASE PROTEASE, PANCRELIPASE AMYLASE",BLA022210,7f16f2d4-8df6-4bd7-ac10-56994fa257b0,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022210s006 Zenpep clinical prea.pdf,
2009,ZENPEP,"PANCRELIPASE LIPASE, PANCRELIPASE PROTEASE, PANCRELIPASE AMYLASE",BLA022210,7f16f2d4-8df6-4bd7-ac10-56994fa257b0,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022210s006 Zenpep clinical prea.pdf,
2009,ZENPEP,"PANCRELIPASE LIPASE, PANCRELIPASE PROTEASE, PANCRELIPASE AMYLASE",BLA022210,7f16f2d4-8df6-4bd7-ac10-56994fa257b0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022210s000sumr.pdf,.
2009,ZENPEP,"PANCRELIPASE LIPASE, PANCRELIPASE PROTEASE, PANCRELIPASE AMYLASE",BLA022210,7f16f2d4-8df6-4bd7-ac10-56994fa257b0,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022210_Pancrelapse_Statistical_PREA.pdf,
2009,ZENPEP,"PANCRELIPASE LIPASE, PANCRELIPASE PROTEASE, PANCRELIPASE AMYLASE",BLA022210,7f16f2d4-8df6-4bd7-ac10-56994fa257b0,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022210_Pancrelipase_Clinpharm_PREA.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2009,ZENPEP,"PANCRELIPASE LIPASE, PANCRELIPASE PROTEASE, PANCRELIPASE AMYLASE",BLA022210,7f16f2d4-8df6-4bd7-ac10-56994fa257b0,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22210 Zenpep clinical prea.pdf,
2009,ZENPEP,"PANCRELIPASE LIPASE, PANCRELIPASE PROTEASE, PANCRELIPASE AMYLASE",BLA022210,7f16f2d4-8df6-4bd7-ac10-56994fa257b0,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22210s006 Zenpep clinical prea.pdf,
2009,ZENPEP,"PANCRELIPASE LIPASE, PANCRELIPASE PROTEASE, PANCRELIPASE AMYLASE",BLA022210,7f16f2d4-8df6-4bd7-ac10-56994fa257b0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022210_zenpep_toc.cfm,
2024,WYOST,DENOSUMAB,BLA761362,69e4890d-5dd9-42a5-aa41-ce50635eaed7,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761362Orig1s000TOC.cfm,
2003,N/A,N/A,NDA021137,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-137_Levolet.cfm,
2010,N/A,N/A,NDA021463,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021463_fortesta_toc.cfm,
2010,N/A,N/A,NDA021463,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021463Orig1s000SumR.pdf,
2005,CLOBEX,CLOBETASOL PROPIONATE,NDA021835,aaba92a9-65fb-4150-aec0-9d9f721ca5a5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021835s000TOC.cfm,
1990,N/A,N/A,NDA050649,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50-444S036_Minocin.cfm,
2017,RYDAPT,RYDAPT,NDA207997,11fa3fc9-6776-49a6-b1c1-653f627c3e58,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000TOC.cfm,
2017,QTERN,DAPAGLIFLOZIN AND SAXAGLIPTIN,NDA209091,423c489c-085b-4320-b892-7868ebd6dc6b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209091Orig1s000TOC.cfm,
2009,SABRIL,VIGABATRIN,NDA020427,a5d389d2-d0e1-4395-a2a2-b552808e7f98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/020427s000TOC.cfm,
2009,SABRIL,VIGABATRIN,NDA020427,a5d389d2-d0e1-4395-a2a2-b552808e7f98,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020427s011,s012_VIGABATRIN_CLINICAL_BPCA.pdf",
2009,SABRIL,VIGABATRIN,NDA020427,a5d389d2-d0e1-4395-a2a2-b552808e7f98,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020427s011,s012_VIGABATRIN_CLINPHARM_BPCA.pdf",
2009,SABRIL,VIGABATRIN,NDA020427,a5d389d2-d0e1-4395-a2a2-b552808e7f98,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020427s011,s012_VIGABATRIN_STATISTICAL_BPCA.pdf",
2022,SEZABY,PHENOBARBITAL SODIUM,NDA215910,8c7d0402-4977-4c25-bc4b-11db91339e9a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215910Orig1s000TOC.cfm,
2009,ZIRGAN,GANCICLOVIR,NDA022211,ea25e7ac-7a93-4ec8-975b-2cec197e1c27,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022211_zirgan_toc.cfm,
2009,ZIRGAN,GANCICLOVIR,NDA022211,ea25e7ac-7a93-4ec8-975b-2cec197e1c27,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022211s000_SumR.pdf,
2024,WINREVAIR,SOTATERCEPT-CSRK,BLA761363,21693ee2-cd23-4137-ac67-066bb3a4a9b7,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761363Orig1s000TOC.cfm,
2000,IMODIUM MULTI-SYMPTOM RELIEF,LOPERAMIDE HYDROCHLORIDE AND DIMETHICONE,NDA021140,ecb91e47-2b0c-47c8-9256-4623d8bc825e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021140_S003_IMODIUM_ADVANCED_CAPLETS.pdf,
2000,IMODIUM MULTI-SYMPTOM RELIEF,LOPERAMIDE HYDROCHLORIDE AND DIMETHICONE,NDA021140,ecb91e47-2b0c-47c8-9256-4623d8bc825e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-140_Imodium.cfm,
2000,IMODIUM MULTI-SYMPTOM RELIEF,LOPERAMIDE HYDROCHLORIDE AND DIMETHICONE,NDA021140,ecb91e47-2b0c-47c8-9256-4623d8bc825e,"http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/020606se8-014, 021140se8-011_SUMR.pdf",
2019,BAQSIMI,GLUCAGON,NDA210134,f1f5df9b-872f-44e5-a18f-f0b68e7e9254,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210134Orig1s000TOC.cfm,
2019,BAQSIMI,GLUCAGON,NDA210134,f1f5df9b-872f-44e5-a18f-f0b68e7e9254,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/477_210134 glucagon clinical prea.pdf,
2019,BAQSIMI,GLUCAGON,NDA210134,f1f5df9b-872f-44e5-a18f-f0b68e7e9254,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/478_210134 glucagon CDTL prea_0.pdf,
2019,BAQSIMI,GLUCAGON,NDA210134,f1f5df9b-872f-44e5-a18f-f0b68e7e9254,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/480_210134 glucagon clinpharm prea.pdf,
2019,BAQSIMI,GLUCAGON,NDA210134,f1f5df9b-872f-44e5-a18f-f0b68e7e9254,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/479_210134 glucagon statistical prea_0.pdf,
2016,OCALIVA,OBETICHOLIC ACID,NDA207999,cdfbe0cd-eb15-45a1-ac17-531bcda21aec,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/207999Orig1s000TOC.cfm,
2016,OCALIVA,OBETICHOLIC ACID,NDA207999,cdfbe0cd-eb15-45a1-ac17-531bcda21aec,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/207999Orig1s000SumR.pdf,
2017,KISQALI,RIBOCICLIB,NDA209092,aaeaef94-f3f5-4367-8ea2-b181d7be2da8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209092Orig1s001.pdf,
2017,KISQALI,RIBOCICLIB,NDA209092,aaeaef94-f3f5-4367-8ea2-b181d7be2da8,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/209092s018,209935s027MultidisciplineR.pdf",
2017,KISQALI,RIBOCICLIB,NDA209092,aaeaef94-f3f5-4367-8ea2-b181d7be2da8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209092Orig1s000TOC.cfm,
2018,SYMDEKO,TEZACAFTOR AND IVACAFTOR,NDA210491,302ae804-37db-44fd-ac2f-3dbdeda9aa4b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210491Orig1s000TOC.cfm,
1995,NISOLDIPINE,NISOLDIPINE,NDA020356,8a5fb6a2-9fae-4872-8c5c-0f1ba03a57cb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020356Orig1s000rev.pdf,
1995,NISOLDIPINE,NISOLDIPINE,NDA020356,8a5fb6a2-9fae-4872-8c5c-0f1ba03a57cb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/020356Orig1s019.pdf,
1995,NISOLDIPINE,NISOLDIPINE,NDA020356,8a5fb6a2-9fae-4872-8c5c-0f1ba03a57cb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20356-s007_sular.pdf,
1995,NISOLDIPINE,NISOLDIPINE,NDA020356,8a5fb6a2-9fae-4872-8c5c-0f1ba03a57cb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20356-s007_sular.pdf,
1995,N/A,N/A,NDA020394,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20394-S001_Atrovent.pdf,
1995,N/A,N/A,NDA020394,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020394 Orig1s004.pdf,
2022,BENDAMUSTINE HYDROCHLORIDE,BENDAMUSTINE HYDROCHLORIDE,NDA215033,085dd54c-4212-d879-afef-ee52732a48c0,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215033Orig1s000TOC.cfm,
2023,TECHNETIUM TC 99M MERTIATIDE,TECHNETIUM TC 99M MERTIATIDE,NDA216820,d497f2a2-8e8d-4372-ba09-f8e6b22d2cf8,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216820Orig1s000TOC.cfm,
2024,IMULDOSA,USTEKINUMAB-SRLF,BLA761364,2539a6cf-0fe5-1565-e063-6294a90a3618,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761364Orig1s000TOC.cfm,
1975,N/A,N/A,NDA017612,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/18-782S023.pdf,
2013,NYMALIZE,NIMODIPINE,NDA203340,e660fa26-b5c4-4d6d-8887-9e22b6666a10,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203340Orig1s000TOC.cfm,
2013,NYMALIZE,NIMODIPINE,NDA203340,e660fa26-b5c4-4d6d-8887-9e22b6666a10,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203340Orig1s000SumR.pdf,
2013,NYMALIZE,NIMODIPINE,NDA203340,e660fa26-b5c4-4d6d-8887-9e22b6666a10,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/203340Orig1s011.pdf,
2017,N/A,N/A,NDA208383,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000TOC.cfm,
2017,TRULANCE IMMEDIATE RELEASE,PLECANATIDE,NDA208745,fe2895bf-71a6-493a-b0ca-e06b2dfefc82,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208745Orig1s000TOC.cfm,
2022,PEMETREXED,PEMETREXED,NDA214218,3ae68628-7ab0-4491-b3ae-6a8330b719c8,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/214218Orig1s000TOC.cfm,
2020,KOSELUGO,SELUMETINIB,NDA213756,7d042c61-f28f-4ab5-ab10-d7558c0d49ff,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213756Orig1s000TOC.cfm,
1997,ALLEGRA-D ALLERGY AND CONGESTION,FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,NDA020786,b32e172a-abf5-4c17-aa39-19e517952b91,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020786_allegra-d_toc.cfm,
1997,ALLEGRA-D ALLERGY AND CONGESTION,FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,NDA020786,b32e172a-abf5-4c17-aa39-19e517952b91,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020786_s009_ALLEGRA D.pdf,
1997,ALLEGRA-D ALLERGY AND CONGESTION,FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,NDA020786,b32e172a-abf5-4c17-aa39-19e517952b91,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020786_s005_ALLEGRA D.pdf,
1997,ALLEGRA-D ALLERGY AND CONGESTION,FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,NDA020786,b32e172a-abf5-4c17-aa39-19e517952b91,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020786_s003_ALLEGRA TABS.pdf,
1997,ALLEGRA-D ALLERGY AND CONGESTION,FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,NDA020786,b32e172a-abf5-4c17-aa39-19e517952b91,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020786_s001_ALLEGRA TABS.pdf,
1997,ALLEGRA-D ALLERGY AND CONGESTION,FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,NDA020786,b32e172a-abf5-4c17-aa39-19e517952b91,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020786_s006_ALLEGRA CAPSULES.pdf,
1997,ALLEGRA-D ALLERGY AND CONGESTION,FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,NDA020786,b32e172a-abf5-4c17-aa39-19e517952b91,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020786_s004_ALLEGRA CAPSULES.pdf,
1997,ALLEGRA-D ALLERGY AND CONGESTION,FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,NDA020786,b32e172a-abf5-4c17-aa39-19e517952b91,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020786_s002_ALLEGRA D.pdf,
1997,ALLEGRA-D ALLERGY AND CONGESTION,FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,NDA020786,b32e172a-abf5-4c17-aa39-19e517952b91,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020786_S012_ALLEGRA D.pdf,
2000,N/A,N/A,NDA020823,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020823_016_exelon.pdf,
2000,N/A,N/A,NDA020823,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020823_S003_EXELON_AP.pdf,
2000,N/A,N/A,NDA020823,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20823_Exelon.cfm,
2022,VIJOICE,ALPELISIB,NDA215039,638069a4-aee0-46c9-9e21-54ad449c163c,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215039Orig1s000TOC.cfm,
2023,ZILBRYSQ,ZILUCOPLAN,NDA216834,9f1d53d6-e495-4a3a-8bb9-680a15d25034,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216834Orig1s000TOC.cfm,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-757s017_Avapro.PDF,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/20-757s031_Avapro.PDF,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/20-757s023_Avapro_P1.PDF,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20757-s015_avapro.pdf,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-757s021_Avapro.cfm,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-757s013_Avapro.pdf,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-757s011_Avapro.PDF,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-757s008_Avapro.PDF,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20-757s004_Avapro.PDF,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20-757s002_Avapro.PDF,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/20-757s028_Avapro_P2.PDF,Review Part 2
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/20-757s026_Avapro.PDF,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-757s018_Avapro_P1.pdf,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/20-757s032_Avapro.PDF,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020757_020758_toc.cfm,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020757s034_irbesartan_Avapro-StatsRev.pdf,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020757s034_irbesartan_Avapro-MedRev.pdf,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020757s034_irbesartan_Avapro-ClinPharmRev.pdf,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/20-757s024_Avapro_P1.PDF,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20757-s016_avapro.pdf,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/20-757s030_Avapro.PDF,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-757s022_Avapro.PDF,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-757S014_Avapro.pdf,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-757s020_Avapro.PDF,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-757s012_Avapro.PDF,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-757s009_Avapro.PDF,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-757s007_Avapro.PDF,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020757_s039_avapro.pdf,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20-757s005_Avapro.PDF,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20-757s001_Avapro.PDF,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/20-757s027_Avapro.PDF,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-757s019_Avapro.PDF,
1997,AVAPRO,IRBESARTAN,NDA020757,7885b2a8-be4e-48ab-8113-4e6ab791eb98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/20-757s033_Avapro.PDF,
2000,N/A,N/A,NDA021145,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/021145_S005_VANIQA CREAM.pdf,
2000,N/A,N/A,NDA021145,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/021145_S003_VANIQA CREAM.pdf,
2000,N/A,N/A,NDA021145,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/021145_S001_VANIQA CREAM.pdf,
2000,N/A,N/A,NDA021145,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21145_Vaniga.cfm,
2000,N/A,N/A,NDA021145,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/021145_S002_VANIQA CREAM.pdf,
2002,N/A,N/A,NDA021472,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-472_Ibuprofen.cfm,
2006,N/A,N/A,NDA021844,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021844_desonate_toc.cfm,
2016,N/A,N/A,NDA206030,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206030Orig1s000TOC.cfm,
2014,VASOSTRICT,VASOPRESSIN,NDA204485,b97e5c3e-ca28-4ffa-80af-6c5bdbadaf10,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/204485Orig1s004.pdf,
2014,VASOSTRICT,VASOPRESSIN,NDA204485,b97e5c3e-ca28-4ffa-80af-6c5bdbadaf10,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/204485Orig1s020.pdf,
2014,VASOSTRICT,VASOPRESSIN,NDA204485,b97e5c3e-ca28-4ffa-80af-6c5bdbadaf10,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204485Orig1s000TOC.cfm,
2014,VASOSTRICT,VASOPRESSIN,NDA204485,b97e5c3e-ca28-4ffa-80af-6c5bdbadaf10,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204485Orig1s000SumR.pdf,
2014,VASOSTRICT,VASOPRESSIN,NDA204485,b97e5c3e-ca28-4ffa-80af-6c5bdbadaf10,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/2044850Orig1s003.pdf,
2014,VASOSTRICT,VASOPRESSIN,NDA204485,b97e5c3e-ca28-4ffa-80af-6c5bdbadaf10,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/204485Orig1s013.pdf,
2014,HETLIOZ,TASIMELTEON,NDA205677,ca4a9b63-708e-49e9-8f9b-010625443b90,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000TOC.cfm,
2014,HETLIOZ,TASIMELTEON,NDA205677,ca4a9b63-708e-49e9-8f9b-010625443b90,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000SumR.pdf,
2018,DEXTENZA,DEXAMETHASONE,NDA208742,7514e6b8-c33f-4fbf-8810-ef520e1eb4bd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208742Orig1s000TOC.cfm,
2020,PEMAZYRE,PEMIGATINIB,NDA213736,9e1f2222-1d89-4e63-989c-ccebe2ab1eb4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213736Orig1s000TOC.cfm,
2018,AKYNZEO,FOSNETUPITANT AND PALONOSETRON,NDA210493,8e47618e-af46-4d82-94e8-1507c042252d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210493Orig1s000ApprovTOC.cfm,
1996,NILANDRON,NILUTAMIDE,NDA020169,5ccf0e9a-8935-4c8c-b883-b4967281eb4a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020169Orig1s000rev.pdf,
2025,ANDEMBRY,GARADACIMAB,BLA761367,07b0b671-db81-49f0-a402-0c0219db7fa2,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761367Orig1s000TOC.cfm,
2004,FOSRENOL,LANTHANUM CARBONATE,NDA021468,f10776b2-2c25-4343-aabe-68f302e5cb54,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021468_s004_fosrenol.pdf,
2004,FOSRENOL,LANTHANUM CARBONATE,NDA021468,f10776b2-2c25-4343-aabe-68f302e5cb54,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-468_Fosrenol.cfm,
2004,FOSRENOL,LANTHANUM CARBONATE,NDA021468,f10776b2-2c25-4343-aabe-68f302e5cb54,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021468_s005_fosrenol.pdf,
2005,INCRELEX,MECASERMIN,BLA021839,a8b27a1b-a611-4f91-ad22-76d4b390c3ae,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021839_IncrelexTOC.cfm,
1977,N/A,N/A,NDA017821,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/017821_S045_FLEXERIL.pdf,
2012,ADVIL,IBUPROFEN SODIUM,NDA201803,5be198b8-396e-4b44-8819-e2e3b5d2ad0e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/201803Orig1s000SumR.pdf,
2012,ADVIL,IBUPROFEN SODIUM,NDA201803,5be198b8-396e-4b44-8819-e2e3b5d2ad0e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/201803_advil_toc.cfm,
2017,STEGLATRO,ERTUGLIFLOZIN,NDA209803,e6f3e718-bb99-48f1-ab94-b9f0af05fed6,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209803,209805,209806Orig1s000TOC.cfm",
2017,ZYPITAMAG,PITAVASTATIN MAGNESIUM,NDA208379,c8c50e03-5cb8-43f4-bdef-8edd12f1945f,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208379_toc.cfm,
2017,ZYPITAMAG,PITAVASTATIN MAGNESIUM,NDA208379,c8c50e03-5cb8-43f4-bdef-8edd12f1945f,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208379Orig1s000SumR.pdf,
2017,TYMLOS,ABALOPARATIDE,NDA208743,712143d9-e21e-4013-bb3b-3426a21060a8,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208743Orig1s000TOC.cfm,
2017,TYMLOS,ABALOPARATIDE,NDA208743,712143d9-e21e-4013-bb3b-3426a21060a8,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208743Orig1s000SumR.pdf,
2017,PANTOPRAZOLE SODIUM,PANTOPRAZOLE SODIUM,NDA209463,c857dc41-7b47-4f26-a9f5-d76eb82b44ee,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209463Orig1s000TOC.cfm,
2025,N/A,N/A,NDA219839,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219839Orig1s000TOC.cfm,
2009,N/A,N/A,NDA022217,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022217_valturna_toc.cfm,
2009,N/A,N/A,NDA022217,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022217s000sumr.pdf,
2024,HYMPAVZI,MARSTACIMAB-HNCQ,BLA761369,a2cc631e-13a6-40c2-acf9-065ccedfb90a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761369Orig1s000TOC.cfm,
2000,CLOTRIMAZOLE,CLOTRIMAZOLE,NDA021143,474f5446-f9e3-4422-a9da-c7e23aaa0941,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole3.cfm,
2002,AZELAIC ACID GEL,AZELAIC ACID,NDA021470,66178511-5c1a-4ecd-bc98-2ceb54e710ac,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-470_Finacea.cfm,
2006,CAMRESE,LEVONORGESTREL / ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL,NDA021840,0e198d28-4986-4b93-833f-17c7ed4ce13e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021840s000TOC.cfm,
1991,N/A,N/A,NDA050662,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/050662s013_biaxin.pdf,
1991,N/A,N/A,NDA050662,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-662S028_Biaxin.cfm,
1991,N/A,N/A,NDA050662,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50-662s030s031_Biaxin.cfm,
1991,N/A,N/A,NDA050662,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-662S029_Biaxin.cfm,
1991,N/A,N/A,NDA050662,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50-662s030s031_Biaxin.cfm,
2014,NAMZARIC,MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE,NDA206439,90fedc32-19e5-480c-afc6-f35a5cf4b9aa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206439Orig1s000TOC.cfm,
2014,NAMZARIC,MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE,NDA206439,90fedc32-19e5-480c-afc6-f35a5cf4b9aa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206439Orig1s000SumR.pdf,
2017,STEGLUJAN,ERTUGLIFLOZIN AND SITAGLIPTIN,NDA209805,c2c553d8-5a9d-4366-bf53-8bdb5a876d19,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209803,209805,209806Orig1s000TOC.cfm",
2018,DIACOMIT,STIRIPENTOL,NDA207223,58304ba8-9779-4658-811e-94ffe08c3f16,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206709Orig1s000,207223Orig1s000TOC.cfm",
2015,ENSTILAR,CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE,NDA207589,d1193df2-d53f-4342-bd9d-d9cba7c89709,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207589Orig1s000TOC.cfm,
2015,ENSTILAR,CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE,NDA207589,d1193df2-d53f-4342-bd9d-d9cba7c89709,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207589Orig1s000SumR.pdf,
2015,ENSTILAR,CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE,NDA207589,d1193df2-d53f-4342-bd9d-d9cba7c89709,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/458_207589S5 calcipotriene and betamethasone clinical bpca.pdf,
2018,N/A,N/A,NDA208744,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208744Orig1s000TOC.cfm,
2018,BRAFTOVI,ENCORAFENIB,NDA210496,235dfc38-0f0b-4037-b501-7a9f4294740c,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/210496Orig1s017MultidisciplineR.pdf,
2018,BRAFTOVI,ENCORAFENIB,NDA210496,235dfc38-0f0b-4037-b501-7a9f4294740c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210496Orig1s000TOC.cfm,
2019,GA-68-DOTATOC,EDOTREOTIDE GALLIUM GA-68,NDA210828,c4d185c3-d520-462d-ba50-4f4ee485ace3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210828Orig1s000TOC.cfm,
2025,E-Z-DISK,BARIUM SULFATE,NDA219840,c759668b-5cf1-b237-00c8-a5e4733b6f4c,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219840Orig1s000TOC.cfm,
2024,VASOPRESSIN IN 0.9% SODIUM CHLORIDE,VASOPRESSIN,NDA217766,bf4b0b63-0055-40d8-b331-7f9f1ea3214c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/217766Orig1s000TOC.cfm,
2014,AVEED,TESTOSTERONE UNDECANOATE,NDA022219,f80f025b-17d8-40af-8739-20ce07902045,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/022219Orig1s009.pdf,
2014,AVEED,TESTOSTERONE UNDECANOATE,NDA022219,f80f025b-17d8-40af-8739-20ce07902045,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022219Orig1AveedTOC.cfm,
2014,AVEED,TESTOSTERONE UNDECANOATE,NDA022219,f80f025b-17d8-40af-8739-20ce07902045,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022219Orig1s005.pdf,
2014,AVEED,TESTOSTERONE UNDECANOATE,NDA022219,f80f025b-17d8-40af-8739-20ce07902045,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022219Orig1s001.pdf,
1997,COMBIVIR,LAMIVUDINE AND ZIDOVUDINE,NDA020857,16da660b-9981-4d24-a14a-94c7744fce4f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020857_S010_Combivar.pdf,
1997,COMBIVIR,LAMIVUDINE AND ZIDOVUDINE,NDA020857,16da660b-9981-4d24-a14a-94c7744fce4f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-857s008_Combivir.cfm,
1997,COMBIVIR,LAMIVUDINE AND ZIDOVUDINE,NDA020857,16da660b-9981-4d24-a14a-94c7744fce4f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020857_S011_Epivir.pdf,
1997,COMBIVIR,LAMIVUDINE AND ZIDOVUDINE,NDA020857,16da660b-9981-4d24-a14a-94c7744fce4f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020857_S009_Combivar.pdf,
2004,N/A,N/A,NDA021144,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-144_Ketek.cfm,
2004,N/A,N/A,NDA021144,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021144Orig1s012Approv.pdf,
2006,N/A,N/A,NDA021471,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021471s000TOC.cfm,
2005,ACTOPLUS MET,PIOGLITAZONE AND METFORMIN HYDROCHLORIDE,NDA021842,42e49120-6f3f-11db-9fe1-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021842s000TOC.cfm,
2012,TOBRAMYCIN INHALATION,TOBRAMYCIN INHALATION,NDA201820,b5b51665-c427-42b9-bd6e-6e3c06f650e1,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/201820 tobramycin clinpharm prea.pdf,
2012,TOBRAMYCIN INHALATION,TOBRAMYCIN INHALATION,NDA201820,b5b51665-c427-42b9-bd6e-6e3c06f650e1,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/201820 tobramycin clinical prea.pdf,
2012,TOBRAMYCIN INHALATION,TOBRAMYCIN INHALATION,NDA201820,b5b51665-c427-42b9-bd6e-6e3c06f650e1,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/201820 tobramycin statistical prea.pdf,
2012,TOBRAMYCIN INHALATION,TOBRAMYCIN INHALATION,NDA201820,b5b51665-c427-42b9-bd6e-6e3c06f650e1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/201820_bethkis_toc.cfm,
2012,TOBRAMYCIN INHALATION,TOBRAMYCIN INHALATION,NDA201820,b5b51665-c427-42b9-bd6e-6e3c06f650e1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/201820Orig1s000SumR.pdf,
2013,ASTAGRAF XL,TACROLIMUS EXTENDED-RELEASE CAPSULES,NDA204096,550a5cd4-fbf2-4c09-b577-6bde8fcbdf6e,http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204096Orig1s000SumR.pdf,
2013,ASTAGRAF XL,TACROLIMUS EXTENDED-RELEASE CAPSULES,NDA204096,550a5cd4-fbf2-4c09-b577-6bde8fcbdf6e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204096Orig1s000OTOC.cfm,
2016,RAYALDEE,CALCIFEDIOL,NDA208010,6a95effd-32a5-46b6-a30e-7f4f9bf8cc77,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208010Orig1_toc.cfm,
2016,RAYALDEE,CALCIFEDIOL,NDA208010,6a95effd-32a5-46b6-a30e-7f4f9bf8cc77,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208010Orig1s000SumR.pdf,
2017,FIASP,INSULIN ASPART INJECTION,BLA208751,834e7efc-393f-4c55-9125-628562a8a5cf,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/513_208751S10-11 insulin aspartate CDTL prea.pdf,
2017,FIASP,INSULIN ASPART INJECTION,BLA208751,834e7efc-393f-4c55-9125-628562a8a5cf,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/514_208751S10-11 insulin aspartate clinical prea_0.pdf,
2017,FIASP,INSULIN ASPART INJECTION,BLA208751,834e7efc-393f-4c55-9125-628562a8a5cf,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/515_208751S10-11 insulin aspartate clinpharm prea_0.pdf,
2017,FIASP,INSULIN ASPART INJECTION,BLA208751,834e7efc-393f-4c55-9125-628562a8a5cf,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/516_208751S10-11 insulin aspartate statistical prea_0.pdf,
2017,FIASP,INSULIN ASPART INJECTION,BLA208751,834e7efc-393f-4c55-9125-628562a8a5cf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208751Orig1s000TOC.cfm,
1996,N/A,N/A,NDA020471,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020471Orig1s000rev.pdf,
1996,N/A,N/A,NDA020471,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020471_s009_Zyflo_Filmtab.pdf,
1996,N/A,N/A,NDA020471,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020471_s007_Zyflo Filmtabs.pdf,
2022,NOREPINEPHRINE,NOREPINEPHRINE BITARTRATE,NDA214628,759807dd-61a8-4f6f-8bf5-f6ee773c81bc,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214628Orig1s000TOC.cfm,
2021,BYLVAY,ODEVIXIBAT,NDA215498,0935cd31-3251-4a0a-ac23-25ca4be12be9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215498Orig1s000TOC.cfm,
2022,CALQUENCE,ACALABRUTINIB,NDA216387,b1409184-3267-4d8c-8f17-4e01f69828b1,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216387Orig1Orig2s000TOC.cfm,
2022,CALQUENCE,ACALABRUTINIB,NDA216387,b1409184-3267-4d8c-8f17-4e01f69828b1,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216387Orig1Orig2s000TOC.cfm,
2023,FABHALTA,IPTACOPAN,NDA218276,a76b5845-6e21-4d3b-ad07-cd8df1b60bee,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/218276Orig1s000TOC.cfm,
2015,BRIDION,SUGAMMADEX,NDA022225,5171d883-fe8f-482c-97ab-40b00975b64a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000TOC.cfm,
2015,BRIDION,SUGAMMADEX,NDA022225,5171d883-fe8f-482c-97ab-40b00975b64a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000SumR.pdf,
2024,AHZANTIVE,AFLIBERCEPT-MRBB,BLA761378,289e4b90-f741-c0f6-e063-6394a90a2068,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761378Orig1s000TOC.cfm,
2001,ZYRTEC-D,CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,NDA021150,f1ecf9ba-1c03-7fb7-e053-2a95a90a875a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021150s007TOC.cfm,
2001,ZYRTEC-D,CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,NDA021150,f1ecf9ba-1c03-7fb7-e053-2a95a90a875a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-150_Zyrtec-D.cfm,
2002,ACYCLOVIR,ACYCLOVIR,NDA021478,103f29b8-2c13-4917-a446-59d3246d48d1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021478_S003_Zovirax_APPROVAL_PACKAGE.pdf,
2002,ACYCLOVIR,ACYCLOVIR,NDA021478,103f29b8-2c13-4917-a446-59d3246d48d1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-478_Zovirax.cfm,
2002,ACYCLOVIR,ACYCLOVIR,NDA021478,103f29b8-2c13-4917-a446-59d3246d48d1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/21478Orig1s008.pdf,
1982,HEPARIN SODIUM IN SODIUM CHLORIDE,HEPARIN SODIUM,NDA018609,0d929726-76c3-48fc-b4e7-fd06409f9fb3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/018609_s035_Heparin_Sodium.pdf,
1982,HEPARIN SODIUM IN SODIUM CHLORIDE,HEPARIN SODIUM,NDA018609,0d929726-76c3-48fc-b4e7-fd06409f9fb3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/018609_s033_Haparin_Sodium.pdf,
2012,BOSULIF,BOSUTINIB,NDA203341,adc84ad5-a04d-4fee-9ba8-91f7abd928e3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203341_bosulif_toc.cfm,
2012,BOSULIF,BOSUTINIB,NDA203341,adc84ad5-a04d-4fee-9ba8-91f7abd928e3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022090s000_SumR.pdf,
2011,N/A,N/A,NDA202258,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202258Orig1s000TOC.cfm,
2011,N/A,N/A,NDA202258,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202258Orig1s000SumR.pdf,
2017,SEGLUROMET,ERTUGLIFLOZIN AND METFORMIN HYDROCHLORIDE,NDA209806,a6aeb99a-ce49-4125-90ce-642df3f1ebad,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209803,209805,209806Orig1s000TOC.cfm",
2018,MEKTOVI,BINIMETINIB,NDA210498,6c3408ac-d401-4925-8a03-26591afbc240,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210498Orig1s000TOC.cfm,
2020,ORGOVYX,RELUGOLIX,NDA214621,077a92f6-9f1b-479a-87c7-c92b5db6aa9c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000TOC.cfm,
2024,N/A,N/A,NDA215040,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/215040Orig1s000TOC.cfm,
2024,REZENOPY,NALOXONE HYDROCHLORIDE,NDA215487,3c3e1795-eea4-4b88-bcca-88658194a0b3,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/215487Orig1s000TOC.cfm,
1998,TASMAR,TOLCAPONE,NDA020697,a0e47a9d-78e7-4523-983a-aa259f221736,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20697_Tasmar.cfm,
2009,CREON,PANCRELIPASE,BLA020725,073201aa-556d-4a70-918e-84e9616fd88d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/Creon-Clinical-Review.pdf,
2009,CREON,PANCRELIPASE,BLA020725,073201aa-556d-4a70-918e-84e9616fd88d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/Creon-Pharmacology-Review.pdf,
2009,CREON,PANCRELIPASE,BLA020725,073201aa-556d-4a70-918e-84e9616fd88d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/Creon-Statisitical-Review.pdf,
2009,CREON,PANCRELIPASE,BLA020725,073201aa-556d-4a70-918e-84e9616fd88d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/020725s000SumR.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2009,CREON,PANCRELIPASE,BLA020725,073201aa-556d-4a70-918e-84e9616fd88d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/020725_creon_toc.cfm,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2009,CREON,PANCRELIPASE,BLA020725,073201aa-556d-4a70-918e-84e9616fd88d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20725 Creon clinical prea.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2009,CREON,PANCRELIPASE,BLA020725,073201aa-556d-4a70-918e-84e9616fd88d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20725s011 Creon clinical prea.pdf,
2008,AKTEN,LIDOCAINE HYDROCHLORIDE ANHYDROUS,NDA022221,70ff9fb7-d323-4fe6-b1b1-6033e05f0749,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022221_akten_toc.cfm,
2008,AKTEN,LIDOCAINE HYDROCHLORIDE ANHYDROUS,NDA022221,70ff9fb7-d323-4fe6-b1b1-6033e05f0749,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022221s000_SumR.pdf,
2008,AKTEN,LIDOCAINE HYDROCHLORIDE ANHYDROUS,NDA022221,70ff9fb7-d323-4fe6-b1b1-6033e05f0749,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022221s000_Lidocaine_Clinical_PREA.pdf,
2008,AKTEN,LIDOCAINE HYDROCHLORIDE ANHYDROUS,NDA022221,70ff9fb7-d323-4fe6-b1b1-6033e05f0749,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022221s000_Lidocaine_Clinpharm_PREA.pdf,
2008,AKTEN,LIDOCAINE HYDROCHLORIDE ANHYDROUS,NDA022221,70ff9fb7-d323-4fe6-b1b1-6033e05f0749,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022221s000_Lidocaine_Statistical_PREA.pdf,
2024,USTEKINUMAB-TTWE,USTEKINUMAB-TTWE,BLA761373,2b34392a-ecf6-41bd-8706-d4e9f0b25da8,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761373Orig1s000,761425Orig1s000TOC.cfm",
2024,USTEKINUMAB-TTWE,USTEKINUMAB-TTWE,BLA761373,2b34392a-ecf6-41bd-8706-d4e9f0b25da8,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761373Orig1Orig2s001,761425Orig1Orig2s001CrossR.pdf",
2001,ATROPINE SULFATE,ATROPINE SULFATE,NDA021146,ad8916e7-206e-409e-2582-30d072845dd4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-146_Atropine.cfm,
2002,N/A,N/A,NDA021473,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021473_S009_CIPRO.pdf,
2002,N/A,N/A,NDA021473,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021473_S007_CIPRO.pdf,
2002,N/A,N/A,NDA021473,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021473_S005_CIPRO.pdf,
2002,N/A,N/A,NDA021473,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-473_Cipro.cfm,
2002,N/A,N/A,NDA021473,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021473_S006_CIPRO.pdf,
2002,N/A,N/A,NDA021473,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021473_S013_CIPRO.pdf,
2005,REVATIO,SILDENAFIL CITRATE,NDA021845,f158fe10-d5dc-4432-b2c9-fc665401291b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/021845Orig1s025.pdf,
2005,REVATIO,SILDENAFIL CITRATE,NDA021845,f158fe10-d5dc-4432-b2c9-fc665401291b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021845s000_RevatioTOC.cfm,
2015,N/A,N/A,NDA206038,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/0206038Orig1s000TOC.cfm,
2015,N/A,N/A,NDA206038,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/0206038Orig1s000SumR.pdf,
2017,DAPTOMYCIN,DAPTOMYCIN,NDA208385,548f3559-0531-4c95-9e1d-81f81a3801f1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208385Orig1s000TOC.cfm,
2022,N/A,N/A,NDA208746,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/208746Orig1s000TOC.cfm,
2018,SYMPAZAN,CLOBAZAM,NDA210833,5e3d8fcb-aa7d-4822-88fc-4f06264c3242,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210833Orig1s000TOC.cfm,
2021,N/A,N/A,NDA214622,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214622Orig1s000TOC.cfm,
1995,N/A,N/A,NDA020628,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020628_S023_FORTOVASE.pdf,
1995,N/A,N/A,NDA020628,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020628_S015_Invirase.pdf,
1995,N/A,N/A,NDA020628,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20628ap_s007.pdf,
1995,N/A,N/A,NDA020628,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020628Orig1s000rev.pdf,
1995,N/A,N/A,NDA020628,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020628 saquinavir clinical prea.pdf,
1995,N/A,N/A,NDA020628,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020628 saquinavir clinpharm prea.pdf,
1995,N/A,N/A,NDA020628,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020628 saquinavir statistical prea.pdf,
1995,N/A,N/A,NDA020628,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-628s016_Invirase.cfm,
1995,N/A,N/A,NDA020628,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020628_S020_INVIRASE.pdf,
1996,CABERGOLINE,CABERGOLINE,NDA020664,e497366b-a124-4d7f-bd45-a883c392d4bb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020664_toc.cfm,
2000,NORDITROPIN,SOMATROPIN,BLA021148,1058e17c-9261-459c-a3e6-fae38d196c14,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-148_Norditropin.cfm,
2003,N/A,N/A,NDA021475,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021475s000_MethylinTOC.cfm,
2015,ARGATROBAN,ARGATROBAN,NDA201811,e1cf0ad0-0b23-497e-9deb-3de3bf48be44,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/201811Orig1s000TOC.cfm,
2015,ARGATROBAN,ARGATROBAN,NDA201811,e1cf0ad0-0b23-497e-9deb-3de3bf48be44,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/201811Orig1s000SumR.pdf,
1992,CARDENE IV,NICARDIPINE HYDROCHLORIDE,NDA019734,f12cea0d-b7cd-41d8-b551-2c74cc7f5f4e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/019734Orig1s014.pdf,
1992,CARDENE IV,NICARDIPINE HYDROCHLORIDE,NDA019734,f12cea0d-b7cd-41d8-b551-2c74cc7f5f4e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/019734Orig1s013.pdf,
2020,AYVAKIT,AVAPRITINIB,NDA212608,645c887c-8cd4-4623-8da9-ac223d71a8b9,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/212608Orig1s013.pdf,
2020,AYVAKIT,AVAPRITINIB,NDA212608,645c887c-8cd4-4623-8da9-ac223d71a8b9,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/212608Orig1s006.pdf,
2020,AYVAKIT,AVAPRITINIB,NDA212608,645c887c-8cd4-4623-8da9-ac223d71a8b9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212608Orig1s000TOC.cfm,
2025,N/A,N/A,NDA219847,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219847Orig1s000TOC.cfm,
1996,CAMPTOSAR,IRINOTECAN HYDROCHLORIDE,NDA020571,e518dfc6-7e93-4fee-a66c-51e1ab71c056,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020571Orig1s000rev.pdf,
1996,CAMPTOSAR,IRINOTECAN HYDROCHLORIDE,NDA020571,e518dfc6-7e93-4fee-a66c-51e1ab71c056,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020571s008.cfm,
1996,CAMPTOSAR,IRINOTECAN HYDROCHLORIDE,NDA020571,e518dfc6-7e93-4fee-a66c-51e1ab71c056,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020571_S006_CAPTOSAR_AP.pdf,
1996,CAMPTOSAR,IRINOTECAN HYDROCHLORIDE,NDA020571,e518dfc6-7e93-4fee-a66c-51e1ab71c056,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020571s021_irinotecan_Campostar- MedRev-2_BPCA.pdf,
1996,CAMPTOSAR,IRINOTECAN HYDROCHLORIDE,NDA020571,e518dfc6-7e93-4fee-a66c-51e1ab71c056,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020571s021_irinotecan_Campostar- ClinPharmRev-2_BPCA.pdf,
1996,CAMPTOSAR,IRINOTECAN HYDROCHLORIDE,NDA020571,e518dfc6-7e93-4fee-a66c-51e1ab71c056,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/20-571s021_Camptosar.cfm,
1996,CAMPTOSAR,IRINOTECAN HYDROCHLORIDE,NDA020571,e518dfc6-7e93-4fee-a66c-51e1ab71c056,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20571-S009_Camptosar.cfm,
1996,CAMPTOSAR,IRINOTECAN HYDROCHLORIDE,NDA020571,e518dfc6-7e93-4fee-a66c-51e1ab71c056,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020571_S007_CAPTOSAR_AP.pdf,
1997,TAZORAC,TAZAROTENE,NDA020600,4e4e4b81-420e-4492-8a74-80b692a80057,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020600_tazorac_toc.cfm,
2023,ZAVZPRET,ZAVEGEPANT,NDA216386,9c4a7aec-daef-4961-ba77-92f4b58be780,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216386Orig1s000TOC.cfm,
2024,ZEVTERA,CEFTOBIPROLE MEDOCARIL SODIUM,NDA218275,2bd685df-7dc6-78a6-e063-6294a90a580b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/218275Orig1s000TOC.cfm,
2008,FENOFIBRIC ACID,FENOFIBRIC ACID,NDA022224,369b3e55-2c05-d879-fe7e-91296c529ae9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022224_trilipix_toc.cfm,
2008,FENOFIBRIC ACID,FENOFIBRIC ACID,NDA022224,369b3e55-2c05-d879-fe7e-91296c529ae9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022224s000_SumR.pdf,
2000,OVIDREL,CHORIOGONADOTROPIN ALFA,BLA021149,a683e58a-63ea-44b8-a326-1a99a537bcf2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-149_Ovidrel.cfm,
2004,LUNESTA,ESZOPICLONE,NDA021476,3821f4b7-a3c8-4920-ba80-18aa96532c09,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021476_Lunesta.cfm,
2004,LUNESTA,ESZOPICLONE,NDA021476,3821f4b7-a3c8-4920-ba80-18aa96532c09,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21476 eszopiclone clinical bpca.pdf,
2004,LUNESTA,ESZOPICLONE,NDA021476,3821f4b7-a3c8-4920-ba80-18aa96532c09,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21476 eszopiclone clinpharm bpca.pdf,
2006,OMEPRAZOLE AND SODIUM BICARBONATE,"OMEPRAZOLE, SODIUM BICARBONATE",NDA021849,c26b6893-8264-4d4a-ac7e-1ddda933451e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021849TOC.cfm,
2006,OMEPRAZOLE AND SODIUM BICARBONATE,"OMEPRAZOLE, SODIUM BICARBONATE",NDA021849,c26b6893-8264-4d4a-ac7e-1ddda933451e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021849Orig1s002.pdf,
1985,CARNITOR,LEVOCARNITINE,NDA018948,d2133bc3-9c15-48bd-8b16-b8995a6a14cd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018948a_s016_071492.pdf,
1985,CARNITOR,LEVOCARNITINE,NDA018948,d2133bc3-9c15-48bd-8b16-b8995a6a14cd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018948Orig1s000rev.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018998_S025_VASOTEC.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018998_S017_VASOTEC.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018998_S023_VASOTEC.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018998_Vasotec.cfm,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018998_S015_ VASOTEC_AP.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018998_S006_Vasotec_APPROVAL PACKAGE.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018998_S021_VASOTEC.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018998_S013_VASOTEC.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/18-998s058_Vasotec.cfm,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018998_S011_VASOTEC.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/018998_S064_Vasotec_APPROVAL PACKAGE.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/018998_S062_Vasotec_APPROVAL_PACKAGE.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018998_S046_VASOTEC_AP.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018998_s038_vasotec.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/1997/018998_S052_VASOTEC_AP.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018998_s044_vasotec.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/018998_S050_VASOTEC_AP.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018998_S042_VASOTEC_AP.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/018998_S034_VASOTEC_AP.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018998_s040_vasotec.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018998_S018_VASOTEC_AP.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018998_S009_Vasotec_APPROVAL PACKAGE.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018998_S024_VASOTEC.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018998_S016_VASOTEC.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018998_S022_VASOTEC.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018998_S005_Vasotec_APPROVAL PACKAGE.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018998_S020_VASOTEC_AP.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/18-998S059_Vasotec.cfm,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20507-s001_Teczem.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/018998_S061_Vasotec_APPROVAL PACKAGE.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018998_s039_vasotec.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019309_s021ap.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018998_S045_VASOTEC_AP.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/018998_S051_VASOTEC_AP.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018998_s043_vasotec.pdf,
1985,ENALAPRIL MALEATE,ENALAPRIL MALEATE,NDA018998,ebd2a62d-a704-4f8a-a104-749a5296502f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018998_S041_VASOTEC_AP.pdf,
2018,NUZYRA,OMADACYCLINE,NDA209816,51591524-4703-44c6-8bde-dce3e6a463d1,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209816Orig1s000,209817Orig1s000TOC.cfm",
2015,N/A,N/A,NDA207233,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207233Orig1s000TOC.cfm,
2017,N/A,N/A,NDA208399,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000TOC.cfm,
2021,TARPEYO,BUDESONIDE,NDA215935,938cada4-d6bf-4252-836f-dd40f9eadb4d,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215935Orig1s000TOC.cfm,
2008,N/A,N/A,NDA022233,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022233_aloxi_toc.cfm,
2008,N/A,N/A,NDA022233,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022233s000Sumr.pdf,
2006,N/A,N/A,NDA021483,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021483s000TOC.cfm,
2015,BASAGLAR TEMPO PEN,INSULIN GLARGINE,BLA205692,0ad21db3-2b1c-4ed9-a687-bdd6a74d0aae,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205692Orig1s000TOC.cfm,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2015,BASAGLAR TEMPO PEN,INSULIN GLARGINE,BLA205692,0ad21db3-2b1c-4ed9-a687-bdd6a74d0aae,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205692Orig1s000TOC.cfm,
2015,BASAGLAR TEMPO PEN,INSULIN GLARGINE,BLA205692,0ad21db3-2b1c-4ed9-a687-bdd6a74d0aae,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205692Orig1s000SumR.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
1995,AZELEX,AZELAIC ACID,NDA020428,ebdfcaf7-b5d6-47e1-be87-ccaba4b97e75,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020428Orig1s000rev.pdf,
1995,AZELEX,AZELAIC ACID,NDA020428,ebdfcaf7-b5d6-47e1-be87-ccaba4b97e75,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/20428S1S7_Azelex.pdf,
1995,AZELEX,AZELAIC ACID,NDA020428,ebdfcaf7-b5d6-47e1-be87-ccaba4b97e75,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/20428S1S7_Azelex.pdf,
2018,TIBSOVO,IVOSIDENIB,NDA211192,65d254c0-67ad-42c4-b972-ad463b755b2d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211192Orig1s000TOC.cfm,
1996,TOPAMAX,TOPIRAMATE,NDA020505,21628112-0c47-11df-95b3-498d55d89593,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-505s002_20-844s010_Topamax.cfm,
1996,TOPAMAX,TOPIRAMATE,NDA020505,21628112-0c47-11df-95b3-498d55d89593,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020505Orig1s018.pdf,
1996,TOPAMAX,TOPIRAMATE,NDA020505,21628112-0c47-11df-95b3-498d55d89593,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020505 topiramate clinical prea.pdf,
1996,TOPAMAX,TOPIRAMATE,NDA020505,21628112-0c47-11df-95b3-498d55d89593,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020505 topiramate statistical prea.pdf,
1996,TOPAMAX,TOPIRAMATE,NDA020505,21628112-0c47-11df-95b3-498d55d89593,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020505s000_Topamax.cfm,
1996,TOPAMAX,TOPIRAMATE,NDA020505,21628112-0c47-11df-95b3-498d55d89593,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20505se5-037-20844se5-031_Toprimate_Clinical_BPCA.pdf,
1996,TOPAMAX,TOPIRAMATE,NDA020505,21628112-0c47-11df-95b3-498d55d89593,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20505se5-037_20844se5-031_Toprimate_Clinpharm_BPCA.pdf,
1996,TOPAMAX,TOPIRAMATE,NDA020505,21628112-0c47-11df-95b3-498d55d89593,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20505S3_Topamax.cfm,
1996,TOPAMAX,TOPIRAMATE,NDA020505,21628112-0c47-11df-95b3-498d55d89593,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20505S1_Topamax.cfm,
2021,APRETUDE,CABOTEGRAVIR,NDA215499,4338428e-43d4-4e02-ac9d-bd98e738a7da,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215499Orig1s000TOC.cfm,
2025,OTULFI,USTEKINUMAB-AAUZ,BLA761379,853130e5-7406-4fd6-8138-ff2179195927,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761379Orig2s000TOC.cfm,
2025,OTULFI,USTEKINUMAB-AAUZ,BLA761379,853130e5-7406-4fd6-8138-ff2179195927,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761379Orig1s000TOC.cfm,
2000,N/A,N/A,NDA021151,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/021151_s000_BetapaceAFTOC.cfm,
2006,ZELAPAR,SELEGILINE HYDROCHLORIDE,NDA021479,380d7717-2a79-42f3-a712-efe5e7696ba0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021479_zelapar_toc.cfm,
2006,CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE,CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE,NDA021852,d9493e66-251c-426c-90a8-1bf1e526ab85,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21852s015_ calcipotriene betamethasone clinical prea.pdf,
2006,CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE,CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE,NDA021852,d9493e66-251c-426c-90a8-1bf1e526ab85,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21852s015_ calcipotriene betamethasone clinpharm prea.pdf,
2006,CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE,CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE,NDA021852,d9493e66-251c-426c-90a8-1bf1e526ab85,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021852TOC.cfm,
1991,N/A,N/A,NDA050670,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/050670ap.pdf,
1991,N/A,N/A,NDA050670,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-670S015_Zithromax.cfm,
1980,N/A,N/A,NDA018238,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018238_s013_MICROK.pdf,
1980,N/A,N/A,NDA018238,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018238_s011_MICRO-K.pdf,
2023,COMBOGESIC,ACETAMINOPHEN AND IBUPROFEN,NDA209471,b32651c4-7fa0-415b-91eb-854aa1c28f2a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/209471Orig1s000TOC.cfm,
2021,ZEGALOGUE,DASIGLUCAGON,NDA214231,14704879-872c-4967-8779-04a3bbdfb4e6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214231Orig1s000TOC.cfm,
1995,N/A,N/A,NDA020357,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020357_S020_GLUCOPHAGE_AP.pdf,
1995,N/A,N/A,NDA020357,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020357s010.cfm,
1995,N/A,N/A,NDA020357,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20357s19_glucophage.cfm,
1995,N/A,N/A,NDA020357,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20357S17.PDF,
1995,N/A,N/A,NDA020357,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf,
1995,N/A,N/A,NDA020357,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020357a_s006.pdf,
1996,ZANAFLEX,TIZANIDINE HYDROCHLORIDE,NDA020397,043d9e51-bfa2-4add-9058-5ece332f7e99,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020397_S004_ZANAFLEX TABLETS_AP.pdf,
1996,ZANAFLEX,TIZANIDINE HYDROCHLORIDE,NDA020397,043d9e51-bfa2-4add-9058-5ece332f7e99,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020397Orig1s000rev.pdf,
2023,IWILFIN,EFLORNITHINE HYDROCHLORIDE,NDA215500,6716d8cc-66e6-4cee-935c-ccb85ed984f5,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/215500Orig1s000TOC.cfm,
2024,RYTELO,IMETELSTAT SODIUM,NDA217779,b0fab7ca-e578-43c5-9df6-bdaff4182257,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217779Orig1s000TOC.cfm,
2005,N/A,N/A,NDA021152,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21152 fluticasone clinical prea.pdf,
2005,N/A,N/A,NDA021152,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21152_cutivate_clinpharm_prea.pdf,
2005,N/A,N/A,NDA021152,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21152_cutivate_statistical_prea.pdf,
2005,N/A,N/A,NDA021152,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021152s000TOC.cfm,
2003,FUZEON,ENFUVIRTIDE,NDA021481,6935e846-d5a1-49e5-89a2-f8ebe4d5590d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021481_fuzeon_review.cfm,
1993,VANCOMYCIN HYDROCHLORIDE,VANCOMYCIN HYDROCHLORIDE,NDA050671,99e523d8-9bde-43cb-8434-497015e5dcbd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/050671s002_vancocin.pdf,
1993,VANCOMYCIN HYDROCHLORIDE,VANCOMYCIN HYDROCHLORIDE,NDA050671,99e523d8-9bde-43cb-8434-497015e5dcbd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/050671s002_vancocin.pdf,
2016,VERMOX,MEBENDAZOLE,NDA208398,a720c424-517a-461b-8e13-6c37caf8aa3f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208398Orig1_toc.cfm,
2016,VERMOX,MEBENDAZOLE,NDA208398,a720c424-517a-461b-8e13-6c37caf8aa3f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208398Orig1s000SumR.pdf,
2020,PEMFEXY,PEMETREXED,NDA209472,2308f4e8-21c8-49c1-a5b8-deb8610bac6a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209472Orig1s000TOC.cfm,
1993,RISPERDAL,RISPERIDONE,NDA020272,7e117c7e-02fc-4343-92a1-230061dfc5e0,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020272Orig1s036,s041,020588Orig1s024,s028,s029,21444Orig1s008,s015.pdf",
1993,RISPERDAL,RISPERIDONE,NDA020272,7e117c7e-02fc-4343-92a1-230061dfc5e0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020272_S004_RISPERDAL TABLETS.pdf,
1993,RISPERDAL,RISPERIDONE,NDA020272,7e117c7e-02fc-4343-92a1-230061dfc5e0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020272_s026&s027_Risperdal_MEDR_.pdf,
1993,RISPERDAL,RISPERIDONE,NDA020272,7e117c7e-02fc-4343-92a1-230061dfc5e0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020272_safety_review.pdf,
1993,RISPERDAL,RISPERIDONE,NDA020272,7e117c7e-02fc-4343-92a1-230061dfc5e0,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20272 risperidone clinicalDD prea_clinical 5.pdf,
1993,RISPERDAL,RISPERIDONE,NDA020272,7e117c7e-02fc-4343-92a1-230061dfc5e0,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20272 risperidone clinical CDTL prea_clinical 4.pdf,
1993,RISPERDAL,RISPERIDONE,NDA020272,7e117c7e-02fc-4343-92a1-230061dfc5e0,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20272 risperidone clinical-1 prea.pdf,
1993,RISPERDAL,RISPERIDONE,NDA020272,7e117c7e-02fc-4343-92a1-230061dfc5e0,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20272 risperidone clinical2 prea.pdf,
1993,RISPERDAL,RISPERIDONE,NDA020272,7e117c7e-02fc-4343-92a1-230061dfc5e0,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20272 risperidone statistical prea.pdf,
1993,RISPERDAL,RISPERIDONE,NDA020272,7e117c7e-02fc-4343-92a1-230061dfc5e0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/020272_s046_risperdal_toc.cfm,
1993,RISPERDAL,RISPERIDONE,NDA020272,7e117c7e-02fc-4343-92a1-230061dfc5e0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020272_s008_RISPERDALE TABLETS.pdf,
1993,RISPERDAL,RISPERIDONE,NDA020272,7e117c7e-02fc-4343-92a1-230061dfc5e0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020272_S004_RISPERDAL TABLETS.pdf,
1993,RISPERDAL,RISPERIDONE,NDA020272,7e117c7e-02fc-4343-92a1-230061dfc5e0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020272_s026&s027_Risperdal_MEDR_.pdf,
1993,RISPERDAL,RISPERIDONE,NDA020272,7e117c7e-02fc-4343-92a1-230061dfc5e0,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020272Orig1s036,s041,020588Orig1s024,s028,s029,21444Orig1s008,s015.pdf",
1993,RISPERDAL,RISPERIDONE,NDA020272,7e117c7e-02fc-4343-92a1-230061dfc5e0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020272_S033_RISPERDAL_TABLETS.pdf,
1993,RISPERDAL,RISPERIDONE,NDA020272,7e117c7e-02fc-4343-92a1-230061dfc5e0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/020272_s046_risperdal_toc.cfm,
1993,RISPERDAL,RISPERIDONE,NDA020272,7e117c7e-02fc-4343-92a1-230061dfc5e0,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020272s046_risperidone_Risperdal-MedRev.pdf,
1993,RISPERDAL,RISPERIDONE,NDA020272,7e117c7e-02fc-4343-92a1-230061dfc5e0,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020272s046_risperidone_Risperdal-ClinPharmRev.pdf,
1993,RISPERDAL,RISPERIDONE,NDA020272,7e117c7e-02fc-4343-92a1-230061dfc5e0,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020272s046_Risperidone Risperdal-ClinPharm2.pdf,
1993,RISPERDAL,RISPERIDONE,NDA020272,7e117c7e-02fc-4343-92a1-230061dfc5e0,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020272s046_Risperidone Risperdal-Stat Review.pdf,
1993,RISPERDAL,RISPERIDONE,NDA020272,7e117c7e-02fc-4343-92a1-230061dfc5e0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20588.pdf,
2021,LYBALVI,OLANZAPINE AND SAMIDORPHAN L-MALATE,NDA213378,32ffddd1-4e2b-45d9-9b36-bb730167ec80,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213378Orig1Orig2s000TOC.cfm,
2021,LYBALVI,OLANZAPINE AND SAMIDORPHAN L-MALATE,NDA213378,32ffddd1-4e2b-45d9-9b36-bb730167ec80,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213378Orig1Orig2s000TOC.cfm,
2025,MODEYSO,DORDAVIPRONE,NDA219876,ad45b43e-fdef-47ad-9c34-055b41bdc576,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219876Orig1s000TOC.cfm,
2022,TERLIVAZ,TERLIPRESSIN,NDA022231,3a35b86c-f451-4fac-8499-43019e4da354,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/022231Orig1s000TOC.cfm,
2001,NEXIUM,ESOMEPRAZOLE MAGNESIUM,NDA021153,f4853677-1622-4037-688b-fdf533a11d96,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21154_Nexium.cfm,
2001,NEXIUM,ESOMEPRAZOLE MAGNESIUM,NDA021153,f4853677-1622-4037-688b-fdf533a11d96,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021153Orig1s047.pdf,
2001,NEXIUM,ESOMEPRAZOLE MAGNESIUM,NDA021153,f4853677-1622-4037-688b-fdf533a11d96,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021153Orig1s045.pdf,
2001,NEXIUM,ESOMEPRAZOLE MAGNESIUM,NDA021153,f4853677-1622-4037-688b-fdf533a11d96,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-153S005_review.pdf,
2001,NEXIUM,ESOMEPRAZOLE MAGNESIUM,NDA021153,f4853677-1622-4037-688b-fdf533a11d96,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021153_S015_NEXIUM_DELAYED_RELEASE.pdf,
2001,NEXIUM,ESOMEPRAZOLE MAGNESIUM,NDA021153,f4853677-1622-4037-688b-fdf533a11d96,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/021153Orig1s048.pdf,
2001,NEXIUM,ESOMEPRAZOLE MAGNESIUM,NDA021153,f4853677-1622-4037-688b-fdf533a11d96,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021153Orig1s008.pdf,
1994,N/A,N/A,NDA050672,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50605S032_Ceftin.pdf,
1984,NICORETTE ORIGINAL,NICOTINE POLACRILEX,NDA018612,673fd19f-69b3-4f73-b9b4-18b5f4cbf69c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/018612Orig1s050.pdf,
1984,NICORETTE ORIGINAL,NICOTINE POLACRILEX,NDA018612,673fd19f-69b3-4f73-b9b4-18b5f4cbf69c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/018612_S034_NICORETTE_GUM_AP.pdf,
1984,NICORETTE ORIGINAL,NICOTINE POLACRILEX,NDA018612,673fd19f-69b3-4f73-b9b4-18b5f4cbf69c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/018612s022_020066s004_Nicorette.cfm,
1984,NICORETTE ORIGINAL,NICOTINE POLACRILEX,NDA018612,673fd19f-69b3-4f73-b9b4-18b5f4cbf69c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/18-612s025_Nicorette.cfm,
1985,RIDAURA,AURANOFIN,NDA018689,43ba3de1-ab2e-06f6-e054-00144ff8d46c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018689Orig1s000rev.pdf,
2012,COMETRIQ,CABOZANTINIB,NDA203756,1a0c3bea-c87b-4d25-bb44-5f0174da6b34,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/203756Orig1s008.pdf,
2012,COMETRIQ,CABOZANTINIB,NDA203756,1a0c3bea-c87b-4d25-bb44-5f0174da6b34,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203756Orig1s000TOC.cfm,
2012,COMETRIQ,CABOZANTINIB,NDA203756,1a0c3bea-c87b-4d25-bb44-5f0174da6b34,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203756Orig1s000SumR.pdf,
2013,CLINOLIPID,OLIVE OIL AND SOYBEAN OIL,NDA204508,ae98eb03-c0e7-49d1-b024-77968e3d9d6e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204508Orig1s000TOC.cfm,
2013,CLINOLIPID,OLIVE OIL AND SOYBEAN OIL,NDA204508,ae98eb03-c0e7-49d1-b024-77968e3d9d6e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204508Orig1s000SumR.pdf,
2017,SUBLOCADE,BUPRENORPHINE,NDA209819,6189fb21-9432-45f8-8481-0bfaf3ccde95,http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2017/209819Orig1s000SumR.pdf,
2017,SUBLOCADE,BUPRENORPHINE,NDA209819,6189fb21-9432-45f8-8481-0bfaf3ccde95,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209819Orig1s000TOC.cfm,
2019,TRIKAFTA,"ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR",NDA212273,f354423a-85c2-41c3-a9db-0f3aee135d8d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000TOC.cfm,
2022,AMVUTTRA,VUTRISIRAN,NDA215515,8db0facb-81b6-4006-9239-27dc6409c5d3,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215515Orig1s000TOC.cfm,
1997,FEMARA,LETROZOLE,NDA020726,82b77d74-085f-45ac-a7dd-1f5c038bf406,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020726_femara_toc.cfm,
1997,FEMARA,LETROZOLE,NDA020726,82b77d74-085f-45ac-a7dd-1f5c038bf406,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-726S006_Femara.cfm,
2024,NEMLUVIO,NEMOLIZUMAB-ILTO,BLA761390,e9229ef1-ac60-4c24-afb6-009d3c781687,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761390Orig1s000TOC.cfm,
2001,N/A,N/A,NDA021160,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/021160_Phoslo.cfm,
2003,MEMANTINE HYDROCHLORIDE,MEMANTINE HYDROCHLORIDE,NDA021487,72973b46-f307-4a9e-8fb1-ad2cbccfd736,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-487_Namenda.cfm,
2005,HYLENEX RECOMBINANT,HYALURONIDASE,BLA021859,3023cc56-ed4b-4e87-b3a1-81b20943f658,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021859_s000_HylenexTOC.cfm,
1996,N/A,N/A,NDA050679,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50679S007_Maxipine.cfm,
1996,N/A,N/A,NDA050679,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/050679Orig1s000rev.pdf,
1996,N/A,N/A,NDA050679,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/050679s002.cfm,
2012,JANUMET XR,SITAGLIPTIN AND METFORMIN HYDROCHLORIDE,NDA202270,64beb3d2-3aeb-4cd5-ba11-dacf6c9a5b50,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202270_janumet_xr_toc.cfm,
2012,JANUMET XR,SITAGLIPTIN AND METFORMIN HYDROCHLORIDE,NDA202270,64beb3d2-3aeb-4cd5-ba11-dacf6c9a5b50,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202270Orig1s000SumR.pdf,
2012,ESTRADIOL,ESTRADIOL,NDA203752,bf185599-2138-4083-9c52-2b95dce09ae0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203752_minivelle_toc.cfm,
2012,ESTRADIOL,ESTRADIOL,NDA203752,bf185599-2138-4083-9c52-2b95dce09ae0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203752Orig1s000SumR.pdf,
2018,NUZYRA,OMADACYCLINE,NDA209817,51591524-4703-44c6-8bde-dce3e6a463d1,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209816Orig1s000,209817Orig1s000TOC.cfm",
2017,XATMEP,METHOTREXATE,NDA208400,aec9984e-34c5-481b-b6bf-9bb5caf1daf8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208400Orig1Orig2s000TOC.cfm,
2017,XATMEP,METHOTREXATE,NDA208400,aec9984e-34c5-481b-b6bf-9bb5caf1daf8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208400Orig1Orig2s000TOC.cfm,
2015,POTASSIUM CHLORIDE,POTASSIUM CHLORIDE,NDA208019,23d818e7-c076-40de-8dc1-0b51ba4be96a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208019Orig1s000SumR.pdf,
2015,POTASSIUM CHLORIDE,POTASSIUM CHLORIDE,NDA208019,23d818e7-c076-40de-8dc1-0b51ba4be96a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208019Orig1s000TOC.cfm,
2022,PACLITAXEL PROTEIN BOUND PARTICLES ALBUMIN BOUND,PACLITAXEL,NDA211875,f06d1bb3-83f1-4d84-8004-4c6681ad8a5a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/211875Orig1s000TOC.cfm,
2020,TRIJARDY XR,"EMPAGLIFLOZIN, LINAGLIPTIN, METFORMIN HYDROCHLORIDE",NDA212614,71873567-9594-452a-bb92-34a129adecac,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212614Orig1s000TOC.cfm,
2011,DOCETAXEL,DOCETAXEL,NDA022234,6b9999bb-869e-4d25-838c-23c3ab280044,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022234_docetaxel_toc.cfm,
2011,DOCETAXEL,DOCETAXEL,NDA022234,6b9999bb-869e-4d25-838c-23c3ab280044,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022234Orig1s000SumR.pdf,
2025,EMRELIS,TELISOTUZUMAB VEDOTIN,BLA761384,bc04f980-3957-4e35-ab81-8ec2ffe87215,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761384Orig1s000TOC.cfm,
1999,N/A,N/A,NDA021156,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21156-S007_Celebrex.cfm,
2005,ANTI-DIARRHEAL,LOPERAMIDE HYDROCHLORIDE,NDA021855,35a938af-decf-5b5d-e063-6294a90a9ab0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021855s000TOC.cfm,
1992,N/A,N/A,NDA050674,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/050674s012.cfm,
2010,JEVTANA,CABAZITAXEL,NDA201023,de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/130_201023 cabazitaxel clinical bpca.pdf,
2010,JEVTANA,CABAZITAXEL,NDA201023,de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/201023s000SumR.pdf,
2010,JEVTANA,CABAZITAXEL,NDA201023,de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/201023s000TOC.cfm,
2016,QBRELIS,LISINOPRIL,NDA208401,9f6e4e57-a489-4b36-b093-b93865d3717c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208401Orig1s000_toc.cfm,
2017,ASCOR,ASCORBIC ACID,NDA209112,388aad52-fc01-4784-9791-1dbc80c69306,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/209112Orig1s009.pdf,
2017,ASCOR,ASCORBIC ACID,NDA209112,388aad52-fc01-4784-9791-1dbc80c69306,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209112Orig1s000TOC.cfm,
2017,ASCOR,ASCORBIC ACID,NDA209112,388aad52-fc01-4784-9791-1dbc80c69306,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/209112Orig1s008.pdf,
2017,ASCOR,ASCORBIC ACID,NDA209112,388aad52-fc01-4784-9791-1dbc80c69306,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/209112Orig1s008.pdf,
2019,SECUADO,ASENAPINE,NDA212268,685eaf44-5944-4f38-afba-0a4fc0b3462b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212268Orig1s000TOC.cfm,
2023,FILSPARI,SPARSENTAN,NDA216403,d7354af1-f304-f4d9-e053-2995a90ab219,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216403Orig1s000TOC.cfm,
1999,N/A,N/A,NDA020859,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20859_Sonata.cfm,
2003,N/A,N/A,NDA021158,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive.cfm,
2003,"CARBIDOPA, LEVODOPA, AND ENTACAPONE","CARBIDOPA, LEVODOPA, AND ENTACAPONE",NDA021485,9c16c0e0-3b97-486b-b7d5-579f5853e2c5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-485_Stalevo.cfm,
2009,ULORIC,FEBUXOSTAT,NDA021856,54de10ef-fe5f-4930-b91d-6bbb04c664bd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021856s000TOC.cfm,
2009,ULORIC,FEBUXOSTAT,NDA021856,54de10ef-fe5f-4930-b91d-6bbb04c664bd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021856s000_SumR.pdf,
1992,N/A,N/A,NDA050675,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/050674s012.cfm,
1992,N/A,N/A,NDA050675,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/50675S14_Vantin.cfm,
1986,N/A,N/A,NDA018731,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/18-731S043_review.pdf,
1986,N/A,N/A,NDA018731,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018731Orig1s000rev.pdf,
2013,ABILIFY MAINTENA,ARIPIPRAZOLE,NDA202971,ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202971Orig1s003TOC.cfm,
2013,ABILIFY MAINTENA,ARIPIPRAZOLE,NDA202971,ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202971Orig1s000SumR.pdf,
2013,ABILIFY MAINTENA,ARIPIPRAZOLE,NDA202971,ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202971s000TOC.cfm,
2010,TRIBENZOR,OLMESARTAN MEDOXOMIL / AMLODIPINE BESYLATE / HYDROCHLOROTHIAZIDE,NDA200175,2f56d0bc-236b-41a0-9fc0-21cdfea8d890,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200175_tribenzor_toc.cfm,
2010,TRIBENZOR,OLMESARTAN MEDOXOMIL / AMLODIPINE BESYLATE / HYDROCHLOROTHIAZIDE,NDA200175,2f56d0bc-236b-41a0-9fc0-21cdfea8d890,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200175Orig1s000SumR.pdf,
2015,ODOMZO,SONIDEGIB,NDA205266,028312dc-d155-4fd5-8abd-6bb9f011d3cc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000TOC.cfm,
2016,ESMOLOL HYDROCHLORIDE IN WATER,ESMOLOL HYDROCHLORIDE,NDA205703,60b10020-f802-4fef-a487-0f11eca246c5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205703Orig1s000TOC.cfm,
2016,ESMOLOL HYDROCHLORIDE IN WATER,ESMOLOL HYDROCHLORIDE,NDA205703,60b10020-f802-4fef-a487-0f11eca246c5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205703Orig1s000SumR.pdf,
1991,N/A,N/A,NDA020007,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020007_s030_Zofran_Injection.pdf,
1991,N/A,N/A,NDA020007,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20-007s022_Zofran.cfm,
1991,N/A,N/A,NDA020007,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020007_s037_Zofran Inj.pdf,
1991,N/A,N/A,NDA020007,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020007s35_ondansetron_Zofran-MedRev.pdf,
1991,N/A,N/A,NDA020007,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020007s35_ondansetron_Zofran-StatsRev.pdf,
1991,N/A,N/A,NDA020007,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020007s35_ondansetron_Zofran-ClinPharmRev.pdf,
1991,N/A,N/A,NDA020007,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/20007Orig1s041.pdf,
2017,SPIRONOLACTONE,SPIRONOLACTONE,NDA209478,522bd365-ddcc-48f4-8a98-66dc4c3bb314,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209478Orig1s000TOC.cfm,
2020,FERRIPROX,DEFERIPRONE,NDA212269,946718ff-df43-1baa-74d1-e5bcfbe8ad86,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212269Orig1s000TOC.cfm,
2020,ORIAHNN,ELAGOLIX AND ESTRADIOL AND NORETHISTERONE,NDA213388,99f6eee7-7e52-6999-7eb8-488d06dd1710,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213388Orig1s000TOC.cfm,
1997,PROPECIA,FINASTERIDE,NDA020788,6f904709-65aa-44ce-b144-b4c8a0416e36,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020788_propecia_toc.cfm,
1997,PROPECIA,FINASTERIDE,NDA020788,6f904709-65aa-44ce-b144-b4c8a0416e36,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020788Orig1s017.pdf,
1997,PROPECIA,FINASTERIDE,NDA020788,6f904709-65aa-44ce-b144-b4c8a0416e36,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/020788Orig1s023.pdf,
1997,PROPECIA,FINASTERIDE,NDA020788,6f904709-65aa-44ce-b144-b4c8a0416e36,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/020788Orig1s021.pdf,
1997,PROPECIA,FINASTERIDE,NDA020788,6f904709-65aa-44ce-b144-b4c8a0416e36,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020788Orig1s018.pdf,
1997,PROPECIA,FINASTERIDE,NDA020788,6f904709-65aa-44ce-b144-b4c8a0416e36,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/020788Orig1s020.pdf,
2001,GEODON,ZIPRASIDONE,NDA020825,a2b4cc65-6a6d-49c4-adfc-a4458562a167,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/020825Orig1s034.pdf,
2001,GEODON,ZIPRASIDONE,NDA020825,a2b4cc65-6a6d-49c4-adfc-a4458562a167,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-825_Geodan.cfm,
2001,GEODON,ZIPRASIDONE,NDA020825,a2b4cc65-6a6d-49c4-adfc-a4458562a167,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020825_Ziprasidone_Clinical_PREA.pdf,
2001,GEODON,ZIPRASIDONE,NDA020825,a2b4cc65-6a6d-49c4-adfc-a4458562a167,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020825_Ziprasidone_Clinpharm_PREA.pdf,
2001,GEODON,ZIPRASIDONE,NDA020825,a2b4cc65-6a6d-49c4-adfc-a4458562a167,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020825_Ziprasidone_Statistical_PREA.pdf,
2001,GEODON,ZIPRASIDONE,NDA020825,a2b4cc65-6a6d-49c4-adfc-a4458562a167,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/020825_s021_GEODON.pdf,
2024,REZDIFFRA,RESMETIROM,NDA217785,e67ea09f-a840-439c-86c8-f98585f978b2,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217785Orig1s000TOC.cfm,
1997,AVALIDE,IRBESARTAN AND HYDROCHLOROTHIAZIDE,NDA020758,0d91895e-c869-4b33-9b83-d55c1ad6317e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20758-s016_avalide.pdf,
1997,AVALIDE,IRBESARTAN AND HYDROCHLOROTHIAZIDE,NDA020758,0d91895e-c869-4b33-9b83-d55c1ad6317e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/20-758s030_Avalide.pdf,
1997,AVALIDE,IRBESARTAN AND HYDROCHLOROTHIAZIDE,NDA020758,0d91895e-c869-4b33-9b83-d55c1ad6317e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020757_020758_toc.cfm,
1997,AVALIDE,IRBESARTAN AND HYDROCHLOROTHIAZIDE,NDA020758,0d91895e-c869-4b33-9b83-d55c1ad6317e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/20-757s030_Avapro.PDF,
1997,AVALIDE,IRBESARTAN AND HYDROCHLOROTHIAZIDE,NDA020758,0d91895e-c869-4b33-9b83-d55c1ad6317e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/20-758s031_Avalide.pdf,
1997,AVALIDE,IRBESARTAN AND HYDROCHLOROTHIAZIDE,NDA020758,0d91895e-c869-4b33-9b83-d55c1ad6317e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/20-757s024_Avapro_P1.PDF,
1997,AVALIDE,IRBESARTAN AND HYDROCHLOROTHIAZIDE,NDA020758,0d91895e-c869-4b33-9b83-d55c1ad6317e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/20-757s029_Avapro_P1.PDF,
1997,AVALIDE,IRBESARTAN AND HYDROCHLOROTHIAZIDE,NDA020758,0d91895e-c869-4b33-9b83-d55c1ad6317e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20758S003.cfm,
2009,N/A,N/A,NDA022239,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022239s000Sumr.pdf,
2009,N/A,N/A,NDA022239,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022239_sumavel_dosepro_toc.cfm,
2024,PIASKY,CROVALIMAB,BLA761388,2597efc2-a97b-487c-b500-a67fd282a73b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761388Orig1s000TOC.cfm,
2003,N/A,N/A,NDA021159,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21159_Loprox.cfm,
2006,N/A,N/A,NDA021858,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000TOC.cfm,
1985,FOAMING HAND WASH,CHLORHEXIDINE GLUCONATE,NDA019422,9b926809-65e9-4e5b-e053-2995a90add10,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/019422_S032_ChlorhexidineTOC.cfm,
2015,FERRIPROX,DEFERIPRONE,NDA208030,f057cf4d-b06f-4fbd-aa2e-68c5e4d8a846,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208030Orig1s000TOC.cfm,
2015,FERRIPROX,DEFERIPRONE,NDA208030,f057cf4d-b06f-4fbd-aa2e-68c5e4d8a846,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208030Orig1s000SumR.pdf,
2021,LEVOTHYROXINE SODIUM,LEVOTHYROXINE SODIUM,NDA214253,6279390b-ee61-4ef9-ac15-25537ca783c1,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214253Orig1s000TOC.cfm,
2018,XOFLUZA,BALOXAVIR MARBOXIL,NDA210854,e49e1a61-1b7c-4be5-ac84-af6240b511e7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210854Orig1s001.pdf,
2018,XOFLUZA,BALOXAVIR MARBOXIL,NDA210854,e49e1a61-1b7c-4be5-ac84-af6240b511e7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210854Orig1s000TOC.cfm,
2018,XOFLUZA,BALOXAVIR MARBOXIL,NDA210854,e49e1a61-1b7c-4be5-ac84-af6240b511e7,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214410Orig1s000, 210854Orig1s004, s010TOC.cfm",
2018,XOFLUZA,BALOXAVIR MARBOXIL,NDA210854,e49e1a61-1b7c-4be5-ac84-af6240b511e7,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214410Orig1s000, 210854Orig1s004, s010TOC.cfm",
2018,N/A,N/A,NDA211210,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211210Orig1s000TOC.cfm,
2023,OJJAARA,MOMELOTINIB,NDA216873,4a672fd1-eb7b-4aa9-9b23-845e4b5dc400,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216873Orig1s000TOC.cfm,
2010,AMPYRA,DALFAMPRIDINE,NDA022250,974fb2af-7012-4989-b330-e44a31c9c3e5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250s000TOC.cfm,
2001,CLARINEX,DESLORATADINE,NDA021165,c671342e-69a2-4ca5-abc2-8166ed4240d4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21165s001_Clarinex.cfm,
2001,CLARINEX,DESLORATADINE,NDA021165,c671342e-69a2-4ca5-abc2-8166ed4240d4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex.cfm,
2002,N/A,N/A,NDA021492,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-492_Eloxatin.cfm,
2002,N/A,N/A,NDA021492,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021492s008_oxaliplatin_Eloxatin-MedRev.pdf,
2002,N/A,N/A,NDA021492,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021492s008_oxaliplatin_Eloxatin-ClinPharmRev.pdf,
2002,N/A,N/A,NDA021492,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021492s008_oxaliplatin_Eloxatin-StatsRev.pdf,
2002,N/A,N/A,NDA021492,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021492_s002_EloxatinTOC.cfm,
2007,N/A,N/A,NDA021864,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021864_lybrel_toc.cfm,
1982,N/A,N/A,NDA018662,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/018662_S057_ACCUTANE_AP.pdf,
1982,N/A,N/A,NDA018662,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/018662_S055_ACCUTANE_AP.pdf,
1982,N/A,N/A,NDA018662,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/018662_S053_ACCUTANE_AP.pdf,
1982,N/A,N/A,NDA018662,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/018662_S056_ACCUTANE_AP.pdf,
1982,N/A,N/A,NDA018662,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/018662_S048_ACCUTANE_AP.pdf,
1982,N/A,N/A,NDA018662,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/018662_S054_ACCUTANE_AP.pdf,
1982,N/A,N/A,NDA018662,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/018662_S038_ACCUTANE_AP.pdf,
1982,N/A,N/A,NDA018662,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/018662_S052_ACCUTANE_AP.pdf,
1982,N/A,N/A,NDA018662,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/018662_S042_ACCUTANE_AP.pdf,
2010,N/A,N/A,NDA200179,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179_staxyn_toc.cfm,
2012,STENDRA,AVANAFIL,NDA202276,fa7d93e3-b69b-4e02-8146-89760cd8e9d6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202276Orig1s000TOC.cfm,
2012,MYRBETRIQ,MIRABEGRON,NDA202611,ba9e9e15-e666-4c56-9271-2e24739cfa2d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000TOC.cfm,
2013,MEKINIST,TRAMETINIB,NDA204114,0002ad27-779d-42ab-83b5-bc65453412a1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204114Orig1s000TOC.cfm,
2013,MEKINIST,TRAMETINIB,NDA204114,0002ad27-779d-42ab-83b5-bc65453412a1,http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204114Orig1s000SumR.pdf,
1990,N/A,N/A,NDA019857,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/19-537S038_Cipro.cfm,
1990,N/A,N/A,NDA019857,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/019857_S041_Cipro.pdf,
1990,N/A,N/A,NDA019857,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/019857_S033_CIPRO.pdf,
1990,N/A,N/A,NDA019857,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/019537s49_19847s27_19857s31_20780s13TOC.cfm,
1990,N/A,N/A,NDA019857,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019857_S013_CIPRO.pdf,
1990,N/A,N/A,NDA019857,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/019857_S036_CIPRO.pdf,
1990,N/A,N/A,NDA019857,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019857_S028_CIPRO.pdf,
1990,N/A,N/A,NDA019857,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/019857_S034_CIPRO.pdf,
1992,NORVASC,AMLODIPINE BESYLATE,NDA019787,7367289c-b0b0-466a-83e2-558e2985c29f,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019787-S8_Norvasc 2.5 mg, 5.0 mg, & 10.0 mg Tablets_toc.cfm",
1992,NORVASC,AMLODIPINE BESYLATE,NDA019787,7367289c-b0b0-466a-83e2-558e2985c29f,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019787-S6_Norvasc 2.5 mg, 5.0 mg, & 10.0 mg Tablets_toc.cfm",
1992,NORVASC,AMLODIPINE BESYLATE,NDA019787,7367289c-b0b0-466a-83e2-558e2985c29f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019787-S4_Norvasc Tablets_toc.cfm,
1992,NORVASC,AMLODIPINE BESYLATE,NDA019787,7367289c-b0b0-466a-83e2-558e2985c29f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/19787-s018_Norvasc.pdf,
1992,NORVASC,AMLODIPINE BESYLATE,NDA019787,7367289c-b0b0-466a-83e2-558e2985c29f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019787-S2_Norvasc Tablets_toc.cfm,
1992,NORVASC,AMLODIPINE BESYLATE,NDA019787,7367289c-b0b0-466a-83e2-558e2985c29f,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/019787-S16_Norvasc 2.5 mg, 5.0 mg, & 10.0 mg Tablets_toc.cfm",
1992,NORVASC,AMLODIPINE BESYLATE,NDA019787,7367289c-b0b0-466a-83e2-558e2985c29f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/019787_S30_NorvascTOC.cfm,
1992,NORVASC,AMLODIPINE BESYLATE,NDA019787,7367289c-b0b0-466a-83e2-558e2985c29f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/19787s022_Norvasc.pdf,
1992,NORVASC,AMLODIPINE BESYLATE,NDA019787,7367289c-b0b0-466a-83e2-558e2985c29f,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019787-S14_Norvasc 2.5 mg, 5.0 mg, & 10.0 mg Tablets_toc.cfm",
1992,NORVASC,AMLODIPINE BESYLATE,NDA019787,7367289c-b0b0-466a-83e2-558e2985c29f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/19787-s017_norvase.pdf,
1992,NORVASC,AMLODIPINE BESYLATE,NDA019787,7367289c-b0b0-466a-83e2-558e2985c29f,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/019787-S12_Norvasc 2.5 mg, 5.0 mg, & 10.0 mg Tablets_toc.cfm",
1992,NORVASC,AMLODIPINE BESYLATE,NDA019787,7367289c-b0b0-466a-83e2-558e2985c29f,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/019787-S10_Norvasc 2.5 mg, 5.0 mg, & 10.0 mg Tablets_toc.cfm",
1992,NORVASC,AMLODIPINE BESYLATE,NDA019787,7367289c-b0b0-466a-83e2-558e2985c29f,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019787-S9_Norvasc 2.5 mg, 5.0 mg, & 10.0 mg Tablets_toc.cfm",
1992,NORVASC,AMLODIPINE BESYLATE,NDA019787,7367289c-b0b0-466a-83e2-558e2985c29f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/19-787s007_Amlodipine.cfm,
1992,NORVASC,AMLODIPINE BESYLATE,NDA019787,7367289c-b0b0-466a-83e2-558e2985c29f,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019787-S5_Norvasc 2.5 mg, 5.0 mg, & 10.0 mg Tablets_toc.cfm",
1992,NORVASC,AMLODIPINE BESYLATE,NDA019787,7367289c-b0b0-466a-83e2-558e2985c29f,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/019787-S19_Norvasc 2.5 mg, 5.0 mg, & 10.0 mg Tablets_toc.cfm",
1992,NORVASC,AMLODIPINE BESYLATE,NDA019787,7367289c-b0b0-466a-83e2-558e2985c29f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019787-S3_Norvasc_toc.cfm,
1992,NORVASC,AMLODIPINE BESYLATE,NDA019787,7367289c-b0b0-466a-83e2-558e2985c29f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/19787-s017_norvase.pdf,
1992,NORVASC,AMLODIPINE BESYLATE,NDA019787,7367289c-b0b0-466a-83e2-558e2985c29f,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019787-S15_Norvasc 2.5 mg, 5.0 mg, & 10.0 mg Tablets_toc.cfm",
1992,NORVASC,AMLODIPINE BESYLATE,NDA019787,7367289c-b0b0-466a-83e2-558e2985c29f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/19787s021_norvasc.pdf,
1992,NORVASC,AMLODIPINE BESYLATE,NDA019787,7367289c-b0b0-466a-83e2-558e2985c29f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/19787-S013_Norvasc.pdf,
1992,NORVASC,AMLODIPINE BESYLATE,NDA019787,7367289c-b0b0-466a-83e2-558e2985c29f,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/019787-S11_Norvasc 2.5 mg, 5.0 mg, & 10.0 mg Tablets_toc.cfm",
2016,EQUATE LANSOPRAZOLE,LANSOPRAZOLE,NDA208025,89b91d5f-008c-4e9d-83e0-23b673b9c469,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208025Orig1s000TOC.cfm,
2018,VANCOMYCIN HYDROCHLORIDE,VANCOMYCIN HYDROCHLORIDE,NDA209481,caf22ccb-df75-45ea-a1d0-ccb2d37272fb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209481Orig1s000TOC.cfm,
1996,DENAVIR,PENCICLOVIR,NDA020629,61229829-55a0-4d6f-a423-4b48a2b4d8e5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020629Orig1s000rev.pdf,
1996,N/A,N/A,NDA020665,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-283s001_Diovan.cfm,
1996,N/A,N/A,NDA020665,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020665s004_diovan_toc.cfm,
1996,N/A,N/A,NDA020665,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020665_s000.pdf,
2009,N/A,N/A,NDA022246,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022246_metozolv_odt_toc.cfm,
2009,N/A,N/A,NDA022246,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022246s000_SumR.pdf,
2000,MICARDIS HCT,TELMISARTAN AND HYDROCHLOROTHIAZIDE,NDA021162,b078dae2-664d-4144-847a-3b9d9b557402,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-162_Micards.cfm,
2003,ELIGARD,LEUPROLIDE ACETATE,NDA021488,b78d1919-9dee-44fa-90f9-e0a26d32481d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021488_eligard.cfm,
2006,N/A,N/A,NDA021860,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021860_sarafem_toc.cfm,
1992,CLINDAMYCIN PHOSPHATE,CLINDAMYCIN PHOSPHATE,NDA050680,b52bdaf7-3b54-4165-9ab0-9dfa08170e47,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/050680S002.cfm,
1990,N/A,N/A,NDA019735,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/019735_S053_floxin.pdf,
1990,N/A,N/A,NDA019735,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019735_S019_Floxin.pdf,
1990,N/A,N/A,NDA019735,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019735_s007_FloxinTOC.cfm,
1990,N/A,N/A,NDA019735,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019735_S023_FLOXIN.pdf,
1990,N/A,N/A,NDA019735,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019735_s001_FloxinTOC.cfm,
1990,N/A,N/A,NDA019735,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/019735_S052_Floxin.pdf,
1990,N/A,N/A,NDA019735,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019735_s008_FloxinTOC.cfm,
1990,N/A,N/A,NDA019735,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019735_S018_Floxin.pdf,
1990,N/A,N/A,NDA019735,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019735_s016_FloxinTOC.cfm,
1990,N/A,N/A,NDA019735,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019735_S022_FLOXIN.pdf,
1990,N/A,N/A,NDA019735,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019735_s004_FloxinTOC.cfm,
2015,NARCAN,NALOXONE HYDROCHLORIDE NASAL,NDA208411,a0ebc83d-2892-40de-bc0a-775ce90b30db,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/208411Orig1s006TOC.cfm,
2015,NARCAN,NALOXONE HYDROCHLORIDE NASAL,NDA208411,a0ebc83d-2892-40de-bc0a-775ce90b30db,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208411Orig1s000TOC.cfm,
2015,NARCAN,NALOXONE HYDROCHLORIDE NASAL,NDA208411,a0ebc83d-2892-40de-bc0a-775ce90b30db,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208411 naloxone DD clinical prea.pdf,
2015,NARCAN,NALOXONE HYDROCHLORIDE NASAL,NDA208411,a0ebc83d-2892-40de-bc0a-775ce90b30db,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208411 naloxone clinpharm prea.pdf,
2015,NARCAN,NALOXONE HYDROCHLORIDE NASAL,NDA208411,a0ebc83d-2892-40de-bc0a-775ce90b30db,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208411 naloxone CDTL clinical prea.pdf,
2015,NARCAN,NALOXONE HYDROCHLORIDE NASAL,NDA208411,a0ebc83d-2892-40de-bc0a-775ce90b30db,http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2017/208411s001SumR.pdf,
2016,JENTADUETO XR,LINAGLIPTIN AND METFORMIN HYDROCHLORIDE,NDA208026,3d02a4d4-d312-80b4-05c4-691b8f0aa7aa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208026Orig1s000TOC.cfm,
2016,JENTADUETO XR,LINAGLIPTIN AND METFORMIN HYDROCHLORIDE,NDA208026,3d02a4d4-d312-80b4-05c4-691b8f0aa7aa,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208026Orig1s000SumR.pdf,
2016,RUBRACA,RUCAPARIB,NDA209115,a6d46c03-bb1d-417b-b8e5-3bffe352fe29,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209115Orig1s000TOC.cfm,
2017,TRELEGY ELLIPTA,"FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE",NDA209482,b5a81d5a-4648-4c7a-951d-33c014a63c7e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209482Orig1s000TOC.cfm,
2022,SINCALIDE,SINCALIDE,NDA210850,4149af34-7b3d-4200-9609-ea856b1d6aab,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/210850Orig1s000TOC.cfm,
2019,ARAZLO,TAZAROTENE,NDA211882,d941ff25-c221-4a55-8012-0dcf3bbcbbd1,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/508_211882 tazarotene multidisciplinary prea.pdf,
2019,ARAZLO,TAZAROTENE,NDA211882,d941ff25-c221-4a55-8012-0dcf3bbcbbd1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211882Orig1s000TOC.cfm,
1996,N/A,N/A,NDA020601,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-603s002_Ibuprofen.cfm,
2013,DUAVEE,CONJUGATED ESTROGENS/BAZEDOXIFENE,NDA022247,e1b75458-2e5b-46b9-92c6-fa6daba3770f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022247_duavee_toc.cfm,
2000,ADULT INFUVITE MULTIPLE VITAMINS,"ASCORBIC ACID, VITAMIN A PALMITATE, CHOLECALCIFEROL, THIAMINE HYDROCHLORIDE, RIBOFLAVIN-5 PHOSPHATE SODIUM, PYRIDOXINE HYDROCHLORIDE, NIACINAMIDE, DEXPANTHENOL, ALPHA-TOCOPHEROL ACETATE, VITAMIN K1, FOLIC ACID, BIOTIN, CYANOCOBALAMIN",NDA021163,4c8d32a4-3334-434b-a828-979d087a6ed9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-163_Multi-12.cfm,
2003,PROHANCE,GADOTERIDOL,NDA021489,e8b76200-c0aa-491b-aad7-e22d2f68496f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021489s000_ProhanceTOC.cfm,
2008,OLOPATADINE HYDROCHLORIDE,OLOPATADINE HYDROCHLORIDE,NDA021861,6393e997-7080-4ce6-8a34-2f80b48f5a3a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021861s000TOC.cfm,
2008,OLOPATADINE HYDROCHLORIDE,OLOPATADINE HYDROCHLORIDE,NDA021861,6393e997-7080-4ce6-8a34-2f80b48f5a3a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021861_Olopatadine_Clinical_PREA.pdf,
2008,OLOPATADINE HYDROCHLORIDE,OLOPATADINE HYDROCHLORIDE,NDA021861,6393e997-7080-4ce6-8a34-2f80b48f5a3a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21861 patanase clinical both.pdf,
2008,OLOPATADINE HYDROCHLORIDE,OLOPATADINE HYDROCHLORIDE,NDA021861,6393e997-7080-4ce6-8a34-2f80b48f5a3a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021861_Olopatadine_Clinpharm_PREA.pdf,
2008,OLOPATADINE HYDROCHLORIDE,OLOPATADINE HYDROCHLORIDE,NDA021861,6393e997-7080-4ce6-8a34-2f80b48f5a3a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021861_Olopatadine_Statistical_PREA.pdf,
2008,OLOPATADINE HYDROCHLORIDE,OLOPATADINE HYDROCHLORIDE,NDA021861,6393e997-7080-4ce6-8a34-2f80b48f5a3a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21861 patanase clinpharm both.pdf,
2008,OLOPATADINE HYDROCHLORIDE,OLOPATADINE HYDROCHLORIDE,NDA021861,6393e997-7080-4ce6-8a34-2f80b48f5a3a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21861 patanase statistical both.pdf,
2013,N/A,N/A,NDA202278,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202278Orig1s000TOC.cfm,
2013,N/A,N/A,NDA202278,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202278Orig1s000SumR.pdf,
2017,IMPOYZ,CLOBETASOL PROPIONATE,NDA209483,40173654-334e-4618-847b-6a1e030cd2fd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209483Orig1s000TOC.cfm,
1996,ESTRING,ESTRADIOL,NDA020472,110b9865-5a07-4d45-b560-e89947f12600,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020472_s004_ESTRING 2 MG.pdf,
1996,ESTRING,ESTRADIOL,NDA020472,110b9865-5a07-4d45-b560-e89947f12600,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020472_s003_ESTRING 2 MG.pdf,
1996,ESTRING,ESTRADIOL,NDA020472,110b9865-5a07-4d45-b560-e89947f12600,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020472_s001_ESTRING 2 MG.pdf,
2023,FRINDOVYX,CYCLOPHOSPHAMIDE,NDA210852,5ad8ea65-4c98-487a-9c8d-df778765ec5e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/210852Orig1s000TOC.cfm,
2019,EXEM FOAM,AIR POLYMER-TYPE A INTRAUTERINE FOAM,NDA212279,b8cb3e4d-ed22-4e88-abca-508c794b4b91,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212279Orig1s000TOC.cfm,
2021,AZSTARYS,SERDEXMETHYLPHENIDATE AND DEXMETHYLPHENIDATE,NDA212994,00b5e716-5564-4bbd-acaf-df2bc45a5663,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212994Orig1s000TOC.cfm,
1996,NAROPIN,ROPIVACAINE HYDROCHLORIDE,NDA020533,dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020533Orig1s000rev.pdf,
1996,NAROPIN,ROPIVACAINE HYDROCHLORIDE,NDA020533,dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-533s002_Naropin.cfm,
2008,TREANDA,BENDAMUSTINE HYDROCHLORIDE,NDA022249,39d53698-57fa-7c99-fc5b-f52a55684826,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/22249s000_SumR.pdf,
2008,TREANDA,BENDAMUSTINE HYDROCHLORIDE,NDA022249,39d53698-57fa-7c99-fc5b-f52a55684826,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/treanda_022249_TOC.cfm,
2008,TREANDA,BENDAMUSTINE HYDROCHLORIDE,NDA022249,39d53698-57fa-7c99-fc5b-f52a55684826,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022249Orig1s012_bendamustine clinical_bpca.pdf,
2008,TREANDA,BENDAMUSTINE HYDROCHLORIDE,NDA022249,39d53698-57fa-7c99-fc5b-f52a55684826,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022249Orig1s012_bendamustine clinpharm_bpca.pdf,
2008,TREANDA,BENDAMUSTINE HYDROCHLORIDE,NDA022249,39d53698-57fa-7c99-fc5b-f52a55684826,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022249Orig1s001.pdf,
2008,TREANDA,BENDAMUSTINE HYDROCHLORIDE,NDA022249,39d53698-57fa-7c99-fc5b-f52a55684826,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022249Orig1s019.pdf,
2008,TREANDA,BENDAMUSTINE HYDROCHLORIDE,NDA022249,39d53698-57fa-7c99-fc5b-f52a55684826,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022249Orig1s015.pdf,
2008,TREANDA,BENDAMUSTINE HYDROCHLORIDE,NDA022249,39d53698-57fa-7c99-fc5b-f52a55684826,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022249Orig1s021.pdf,
2025,DATROWAY,DATOPOTAMAB DERUXTECAN,BLA761394,2950227c-6230-4ca4-a135-46e44d9424a0,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761394Orig1s000TOC.cfm,
2023,EXXUA,GEPIRONE,NDA021164,28b360dc-6337-4cae-a5bb-79f974b5a3b2,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/021164Orig1s000TOC.cfm,
2003,N/A,N/A,NDA021490,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-490_NorethinOvcon.cfm,
2005,NEVANAC,NEPAFENAC,NDA021862,11b9a0cf-2a70-17ef-e063-6394a90a5d9e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021862s000_NevanacTOC.cfm,
2014,AKYNZEO,NETUPITANT AND PALONOSETRON,NDA205718,8e47618e-af46-4d82-94e8-1507c042252d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205718Orig1s000TOC.cfm,
2014,AKYNZEO,NETUPITANT AND PALONOSETRON,NDA205718,8e47618e-af46-4d82-94e8-1507c042252d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205718Orig1s000SumR.pdf,
2017,CALCIUM GLUCONATE,CALCIUM GLUCONATE,NDA208418,7f5101e0-abf9-4fcf-8986-c799e3333434,http://www.accessdata.fda.gov/drugsatfda_docs/review/2018/208418Orig1s001.pdf,
2017,CALCIUM GLUCONATE,CALCIUM GLUCONATE,NDA208418,7f5101e0-abf9-4fcf-8986-c799e3333434,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/141_208418 calcium gluconate clinical prea.pdf,
2017,CALCIUM GLUCONATE,CALCIUM GLUCONATE,NDA208418,7f5101e0-abf9-4fcf-8986-c799e3333434,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/140_208418 calcium gluconate CDTL clinical prea.pdf,
2017,CALCIUM GLUCONATE,CALCIUM GLUCONATE,NDA208418,7f5101e0-abf9-4fcf-8986-c799e3333434,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/142_208418 calcium gluconate clinpharm prea.pdf,
2017,CALCIUM GLUCONATE,CALCIUM GLUCONATE,NDA208418,7f5101e0-abf9-4fcf-8986-c799e3333434,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208418Orig1s000TOC.cfm,
1993,N/A,N/A,NDA020136,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020136ap_s08_s09.pdf,
2019,BIVALIRUDIN,BIVALIRUDIN,NDA211215,c727199d-f4cd-4658-8fdf-568590beface,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211215Orig1s000TOC.cfm,
2008,VIMPAT,LACOSAMIDE,NDA022253,9e79b42c-38a3-4b2c-a196-a5a1948250e2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_SumR.pdf,
2008,VIMPAT,LACOSAMIDE,NDA022253,9e79b42c-38a3-4b2c-a196-a5a1948250e2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000TOC.cfm,
2008,VIMPAT,LACOSAMIDE,NDA022253,9e79b42c-38a3-4b2c-a196-a5a1948250e2,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/250_22253S39-lacosamide-CDTL-clinical-prea.pdf,
2008,VIMPAT,LACOSAMIDE,NDA022253,9e79b42c-38a3-4b2c-a196-a5a1948250e2,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/251_22253S39-lacosamide-clinical-prea.pdf,
2008,VIMPAT,LACOSAMIDE,NDA022253,9e79b42c-38a3-4b2c-a196-a5a1948250e2,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/252_22253S39-lacosamide-clinpharm-prea.pdf,
2024,YESINTEK,USTEKINUMAB,BLA761406,12a75613-ee33-d30a-215b-2a51cfa19b00,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761406Orig1Orig2s000TOC.cfm,
2024,YESINTEK,USTEKINUMAB,BLA761406,12a75613-ee33-d30a-215b-2a51cfa19b00,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761406Orig1Orig2s000TOC.cfm,
2000,DEPAKOTE ER,DIVALPROEX SODIUM,NDA021168,0dc024ce-efc8-4690-7cb5-639c728fccac,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021168_S007_DepakoteTOC.cfm,
2000,DEPAKOTE ER,DIVALPROEX SODIUM,NDA021168,0dc024ce-efc8-4690-7cb5-639c728fccac,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021168_Divalproex_Clinical(DPP)_BPCA.pdf,
2000,DEPAKOTE ER,DIVALPROEX SODIUM,NDA021168,0dc024ce-efc8-4690-7cb5-639c728fccac,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021168_Divalproex_Clinical(DNP2)_BPCA.pdf,
2000,DEPAKOTE ER,DIVALPROEX SODIUM,NDA021168,0dc024ce-efc8-4690-7cb5-639c728fccac,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021168_Divalproex_Clinpharm_BPCA.pdf,
2000,DEPAKOTE ER,DIVALPROEX SODIUM,NDA021168,0dc024ce-efc8-4690-7cb5-639c728fccac,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-168_Depakote.cfm,
2000,DEPAKOTE ER,DIVALPROEX SODIUM,NDA021168,0dc024ce-efc8-4690-7cb5-639c728fccac,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021168_S004_DepakoteTOC.cfm,
2006,N/A,N/A,NDA021871,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021871TOC.cfm,
1969,N/A,N/A,NDA016466,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/016466Orig1s032.pdf,
1969,N/A,N/A,NDA016466,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/016466Orig1s045.pdf,
2023,HEPZATO KIT,"MELPHALAN HYDROCHLORIDE INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",NDA201848,4f83c8f7-4cc0-4219-88d5-7cfddce91198,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/201848Orig1s000TOC.cfm,
2015,LINEZOLID,LINEZOLID,NDA206473,c401f1a8-cc37-461b-bfef-f2e156629bf8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206473Orig1s000TOC.cfm,
2017,ALUNBRIG,BRIGATINIB,NDA208772,0fe9ff20-d402-41f3-bc1e-7002ea7007db,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208772Orig1s000TOC.cfm,
2021,DYANAVEL XR,AMPHETAMINE,NDA210526,ae304b29-0b40-40ec-ad0d-76b742d4a9b9,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/210526Orig1s000TOC.cfm,
2024,REVUFORJ,REVUMENIB,NDA218944,6eb3cdbc-0e74-477d-82d6-3bb172d3f63f,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/218944Orig1s000TOC.cfm,
2004,ESTROGEL,ESTRADIOL,NDA021166,762ac371-bb8b-47e7-b48f-e80d452c9dd4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21166_EstrogelTOC.cfm,
2003,N/A,N/A,NDA021493,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021493_Gatifloxacin_Clinical_BPCA.pdf,
2003,N/A,N/A,NDA021493,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021493_Gatifloxacin_Clinpharm_BPCA.pdf,
2003,N/A,N/A,NDA021493,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021493_Gatifloxacin_Statistical_BPCA.pdf,
2003,N/A,N/A,NDA021493,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/103_21493 gatifloxacin clinical bpca.pdf,
2003,N/A,N/A,NDA021493,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021493_Zymar.cfm,
2006,N/A,N/A,NDA021866,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021866Orig1s006_s007_s009.pdf,
2006,N/A,N/A,NDA021866,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/021729s6s7s9,21866s6s7s9SUMR.pdf",
2006,N/A,N/A,NDA021866,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021866TOC.cfm,
2006,N/A,N/A,NDA021866,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021866s000_SumR.pdf,
2006,N/A,N/A,NDA021866,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021866Orig1s006_s007_s009.pdf,
2006,N/A,N/A,NDA021866,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/021729s6s7s9,21866s6s7s9SUMR.pdf",
2006,N/A,N/A,NDA021866,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/021729s6s7s9,21866s6s7s9SUMR.pdf",
2006,N/A,N/A,NDA021866,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021866Orig1s006_s007_s009.pdf,
2006,N/A,N/A,NDA021866,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021436 aripiprazole clinical prea.pdf,
1993,N/A,N/A,NDA050684,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/050684_S045_050750_s012_ZosynTOC.cfm,
2015,GLUCAGON,GLUCAGON,NDA201849,8c8acad6-44cc-43aa-966b-027e053be8f5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/201849Orig1s000TOC.cfm,
2015,ENTRESTO,SACUBITRIL AND VALSARTAN,NDA207620,000dc81d-ab91-450c-8eae-8eb74e72296f,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/218591Orig1s000,207620Orig1s025TOC.cfm",
2015,ENTRESTO,SACUBITRIL AND VALSARTAN,NDA207620,000dc81d-ab91-450c-8eae-8eb74e72296f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207620Orig1s000SumR.pdf,
2015,ENTRESTO,SACUBITRIL AND VALSARTAN,NDA207620,000dc81d-ab91-450c-8eae-8eb74e72296f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207620Orig1s000TOC.cfm,
2015,ENTRESTO,SACUBITRIL AND VALSARTAN,NDA207620,000dc81d-ab91-450c-8eae-8eb74e72296f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/510_207620S13 sacubitril-valsartan clinical bpca.pdf,
2015,ENTRESTO,SACUBITRIL AND VALSARTAN,NDA207620,000dc81d-ab91-450c-8eae-8eb74e72296f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/511_207620S13 sacubitril-valsartan clinpharm bpca_0.pdf,
2015,ENTRESTO,SACUBITRIL AND VALSARTAN,NDA207620,000dc81d-ab91-450c-8eae-8eb74e72296f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/512_207620S13 sacubitril-valsartan statistical bpca.pdf,
2015,ENTRESTO,SACUBITRIL AND VALSARTAN,NDA207620,000dc81d-ab91-450c-8eae-8eb74e72296f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/207620Orig1s018.pdf,
2016,N/A,N/A,NDA208032,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208032Orig1s000TOC.cfm,
2016,N/A,N/A,NDA208032,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208032 tetracaine and oxymetazoline clinical prea.pdf,
2016,N/A,N/A,NDA208032,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208032 tetracaine and oxymetazoline clinpharm prea.pdf,
2016,N/A,N/A,NDA208032,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208032 tetracaine and oxymetazoline statistical prea.pdf,
2020,IMCIVREE,SETMELANOTIDE,NDA213793,70c3ccf7-4df0-4c75-ba07-fede9970c8d9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000TOC.cfm,
1993,CALCIPOTRIENE,CALCIPOTRIENE,NDA020273,fe7cd92a-f066-4c4a-80c8-e3f929ad4181,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020273_s008_DOVONEX.pdf,
1993,CALCIPOTRIENE,CALCIPOTRIENE,NDA020273,fe7cd92a-f066-4c4a-80c8-e3f929ad4181,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20273S004_Dovonex.pdf,
1996,WELLBUTRIN SR,BUPROPION HYDROCHLORIDE,NDA020358,cbc8c074-f080-4489-a5ae-207b5fadeba3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020358Orig1s025.pdf,
1996,WELLBUTRIN SR,BUPROPION HYDROCHLORIDE,NDA020358,cbc8c074-f080-4489-a5ae-207b5fadeba3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020358Orig1s020_s021_s022.pdf,
1996,WELLBUTRIN SR,BUPROPION HYDROCHLORIDE,NDA020358,cbc8c074-f080-4489-a5ae-207b5fadeba3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020358a_s001_s003.pdf,
1996,WELLBUTRIN SR,BUPROPION HYDROCHLORIDE,NDA020358,cbc8c074-f080-4489-a5ae-207b5fadeba3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020358a_s001_s003.pdf,
1996,WELLBUTRIN SR,BUPROPION HYDROCHLORIDE,NDA020358,cbc8c074-f080-4489-a5ae-207b5fadeba3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/020358Orig1s054.pdf,
1996,WELLBUTRIN SR,BUPROPION HYDROCHLORIDE,NDA020358,cbc8c074-f080-4489-a5ae-207b5fadeba3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020358Orig1s040.pdf,
1996,WELLBUTRIN SR,BUPROPION HYDROCHLORIDE,NDA020358,cbc8c074-f080-4489-a5ae-207b5fadeba3,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/018644s027s028,020358s031s032,021515s006s007_WellbutrinTOC.cfm",
1996,WELLBUTRIN SR,BUPROPION HYDROCHLORIDE,NDA020358,cbc8c074-f080-4489-a5ae-207b5fadeba3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020358Orig1s020_s021_s022.pdf,
1996,WELLBUTRIN SR,BUPROPION HYDROCHLORIDE,NDA020358,cbc8c074-f080-4489-a5ae-207b5fadeba3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020358Orig1s020_s021_s022.pdf,
1996,WELLBUTRIN SR,BUPROPION HYDROCHLORIDE,NDA020358,cbc8c074-f080-4489-a5ae-207b5fadeba3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/020358Orig1s053.pdf,
1996,WELLBUTRIN SR,BUPROPION HYDROCHLORIDE,NDA020358,cbc8c074-f080-4489-a5ae-207b5fadeba3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020358_S027_WELLBUTRIN_TABS_AP.pdf,
1996,WELLBUTRIN SR,BUPROPION HYDROCHLORIDE,NDA020358,cbc8c074-f080-4489-a5ae-207b5fadeba3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-358S019_Bupropion.pdf,
2023,FILSUVEZ,BIRCH TRITERPENES,NDA215064,da793f2d-0a3d-4792-8c22-982f9f8cdd97,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/215064Orig1s000TOC.cfm,
2009,LAMICTAL ODT,LAMOTRIGINE,NDA022251,d7e3572d-56fe-4727-2bb4-013ccca22678,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022251_lamictal_odt_lamotrigine.cfm,
2009,LAMICTAL ODT,LAMOTRIGINE,NDA022251,d7e3572d-56fe-4727-2bb4-013ccca22678,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022251s000_SumR.pdf,
2009,LAMICTAL ODT,LAMOTRIGINE,NDA022251,d7e3572d-56fe-4727-2bb4-013ccca22678,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22251 lamotrigine clinical prea.pdf,
2009,LAMICTAL ODT,LAMOTRIGINE,NDA022251,d7e3572d-56fe-4727-2bb4-013ccca22678,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22251 lamotrigine clinpharm prea.pdf,
2009,LAMICTAL ODT,LAMOTRIGINE,NDA022251,d7e3572d-56fe-4727-2bb4-013ccca22678,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22251 lamotrigine statistical prea.pdf,
2025,LYNOZYFIC,LINVOSELTAMAB-GCPT,BLA761400,e9fd0739-1b3f-4b8b-824a-1f0a902384d3,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761400Orig1s000TOC.cfm,
1995,N/A,N/A,NDA050685,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/050685Orig1s000rev.pdf,
2016,N/A,N/A,NDA207621,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/207621Orig1toc.cfm,
2016,N/A,N/A,NDA207621,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/207621Orig1s000SumR.pdf,
2016,VARIBAR THIN LIQUID,BARIUM SULFATE,NDA208036,59493c83-3941-cc84-cc37-a8696ae42873,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208036Orig1s000TOC.cfm,
2016,VARIBAR THIN LIQUID,BARIUM SULFATE,NDA208036,59493c83-3941-cc84-cc37-a8696ae42873,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208036 barium sulfate clinical prea.pdf,
2016,VARIBAR THIN LIQUID,BARIUM SULFATE,NDA208036,59493c83-3941-cc84-cc37-a8696ae42873,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208036-barium-sulfate-statistical-prea.pdf,
2018,DSUVIA,SUFENTANIL,NDA209128,8b580f3d-e3b5-4086-b093-87a980631147,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209128Orig1s000TOC.cfm,
1994,SALAGEN,PILOCARPINE HYDROCHLORIDE,NDA020237,62eda83d-d043-4c7e-8fcf-75d05efbf35b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020237_S012_SALAGEN_AP.pdf,
1994,SALAGEN,PILOCARPINE HYDROCHLORIDE,NDA020237,62eda83d-d043-4c7e-8fcf-75d05efbf35b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20237s007_Salagen.cfm,
2020,N/A,N/A,NDA213400,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213400Orig1s000TOC.cfm,
2020,ATROPINE SULFATE,ATROPINE SULFATE,NDA214652,d5e07279-48ca-4f83-9633-299e65a7f821,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214652Orig1s000TOC.cfm,
2010,NATAZIA,ESTRADIOL VALERATE AND ESTRADIOL VALERATE/DIENOGEST,NDA022252,02c91fba-9c47-43ef-ac78-e82369798834,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022252_Orig-1TOC.cfm,
2010,NATAZIA,ESTRADIOL VALERATE AND ESTRADIOL VALERATE/DIENOGEST,NDA022252,02c91fba-9c47-43ef-ac78-e82369798834,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022252_Orig-1_SumR.pdf,
2010,NATAZIA,ESTRADIOL VALERATE AND ESTRADIOL VALERATE/DIENOGEST,NDA022252,02c91fba-9c47-43ef-ac78-e82369798834,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22252 Natazia clinical prea.pdf,
2010,NATAZIA,ESTRADIOL VALERATE AND ESTRADIOL VALERATE/DIENOGEST,NDA022252,02c91fba-9c47-43ef-ac78-e82369798834,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22252 Natazia clinpharm prea.pdf,
2010,NATAZIA,ESTRADIOL VALERATE AND ESTRADIOL VALERATE/DIENOGEST,NDA022252,02c91fba-9c47-43ef-ac78-e82369798834,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22252-Natazia-Statistical-PREA.pdf,
2005,FLUDEOXYGLUCOSE F18,FLUDEOXYGLUCOSE F18,NDA021870,dfd91498-4bfc-4d45-a9a3-cee6153ae573,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021870s000TOC.cfm,
2012,AUBAGIO,TERIFLUNOMIDE,NDA202992,4650d12c-b9c8-4525-b07f-a2d773eca155,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202992Orig1s000SumR.pdf,
2012,AUBAGIO,TERIFLUNOMIDE,NDA202992,4650d12c-b9c8-4525-b07f-a2d773eca155,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202992Orig1s000TOC.cfm,
2015,GLYXAMBI,EMPAGLIFLOZIN AND LINAGLIPTIN,NDA206073,ddbab689-f76c-488c-9613-4168d41dd730,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/206073Orig1s017.pdf,
2015,GLYXAMBI,EMPAGLIFLOZIN AND LINAGLIPTIN,NDA206073,ddbab689-f76c-488c-9613-4168d41dd730,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/206073Orig1s021.pdf,
2015,GLYXAMBI,EMPAGLIFLOZIN AND LINAGLIPTIN,NDA206073,ddbab689-f76c-488c-9613-4168d41dd730,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206073Orig1s000TOC.cfm,
2015,GLYXAMBI,EMPAGLIFLOZIN AND LINAGLIPTIN,NDA206073,ddbab689-f76c-488c-9613-4168d41dd730,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206073Orig1s000SumR.pdf,
2016,EXONDYS 51,ETEPLIRSEN,NDA206488,33bff678-7829-479e-9110-b8e33a0bc0aa,http://www.accessdata.fda.gov/drugsatfda_docs/review/2018/206488Orig1s006.pdf,
2016,EXONDYS 51,ETEPLIRSEN,NDA206488,33bff678-7829-479e-9110-b8e33a0bc0aa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206488_summary review_Redacted.pdf,
2016,EXONDYS 51,ETEPLIRSEN,NDA206488,33bff678-7829-479e-9110-b8e33a0bc0aa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206488_TOC.cfm,
2019,TALICIA,"OMEPRAZOLE MAGNESIUM, AMOXICILLIN AND RIFABUTIN",NDA213004,68c4e9dc-dbcf-4151-b6f7-5e4b9922b76f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/213004Orig1s000TOC.cfm,
2022,PEMETREXED,PEMETREXED DISODIUM,NDA214657,7ac04ab7-7f8c-46ce-ab56-a7a08cd02ab3,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214657Orig1s000TOC.cfm,
1996,ULTIVA,REMIFENTANIL HYDROCHLORIDE,NDA020630,4dbcb8f9-1987-4b66-bd2f-d251fda0be10,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020630Orig1s000rev.pdf,
1996,ALBENDAZOLE,ALBENDAZOLE,NDA020666,06b5eefc-0b95-4862-b9b6-770063f2adf0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020666Orig1s000rev.pdf,
1997,EFFEXOR XR,VENLAFAXINE HYDROCHLORIDE,NDA020699,c848a5d8-ba94-4c84-80e3-0bf35fb8e32e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020699_s039_EFFEXOR XR_EXTENDED_RELEASE_CAPS.pdf,
1997,EFFEXOR XR,VENLAFAXINE HYDROCHLORIDE,NDA020699,c848a5d8-ba94-4c84-80e3-0bf35fb8e32e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020699_s045_EFFEXOR_XR_EXTENDED_RELEASE_CAPS.pdf,
1997,EFFEXOR XR,VENLAFAXINE HYDROCHLORIDE,NDA020699,c848a5d8-ba94-4c84-80e3-0bf35fb8e32e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020699_S029_EFFEXOR_AP.pdf,
1997,EFFEXOR XR,VENLAFAXINE HYDROCHLORIDE,NDA020699,c848a5d8-ba94-4c84-80e3-0bf35fb8e32e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020699_S043_EFFEXOR_AP.pdf,
1997,EFFEXOR XR,VENLAFAXINE HYDROCHLORIDE,NDA020699,c848a5d8-ba94-4c84-80e3-0bf35fb8e32e,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020151s16s19s20s21s22s23s25,020699s14s18s21s23s26s27s34TOC.cfm",
1997,EFFEXOR XR,VENLAFAXINE HYDROCHLORIDE,NDA020699,c848a5d8-ba94-4c84-80e3-0bf35fb8e32e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020699_S041_EFFEXOR_TABLETS.pdf,
1997,EFFEXOR XR,VENLAFAXINE HYDROCHLORIDE,NDA020699,c848a5d8-ba94-4c84-80e3-0bf35fb8e32e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020699_S025_EFFEXOR_XR.pdf,
1997,EFFEXOR XR,VENLAFAXINE HYDROCHLORIDE,NDA020699,c848a5d8-ba94-4c84-80e3-0bf35fb8e32e,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020151s16s19s20s21s22s23s25,020699s14s18s21s23s26s27s34TOC.cfm",
1997,EFFEXOR XR,VENLAFAXINE HYDROCHLORIDE,NDA020699,c848a5d8-ba94-4c84-80e3-0bf35fb8e32e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020699_effexorxr_toc.cfm,
1997,EFFEXOR XR,VENLAFAXINE HYDROCHLORIDE,NDA020699,c848a5d8-ba94-4c84-80e3-0bf35fb8e32e,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020151s017s018,020699s015s016EffexorTOC.cfm",
1997,EFFEXOR XR,VENLAFAXINE HYDROCHLORIDE,NDA020699,c848a5d8-ba94-4c84-80e3-0bf35fb8e32e,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020151s16s19s20s21s22s23s25,020699s14s18s21s23s26s27s34TOC.cfm",
1997,EFFEXOR XR,VENLAFAXINE HYDROCHLORIDE,NDA020699,c848a5d8-ba94-4c84-80e3-0bf35fb8e32e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020699_s013_EFFEXOR_XR.pdf,
1997,EFFEXOR XR,VENLAFAXINE HYDROCHLORIDE,NDA020699,c848a5d8-ba94-4c84-80e3-0bf35fb8e32e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020699_S048_EFFEXOR_TABLETS.pdf,
1997,EFFEXOR XR,VENLAFAXINE HYDROCHLORIDE,NDA020699,c848a5d8-ba94-4c84-80e3-0bf35fb8e32e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020699_S038_EFFEXOR_AP.pdf,
1997,EFFEXOR XR,VENLAFAXINE HYDROCHLORIDE,NDA020699,c848a5d8-ba94-4c84-80e3-0bf35fb8e32e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020699_S052_EFFEXOR_TABLETS.pdf,
1997,EFFEXOR XR,VENLAFAXINE HYDROCHLORIDE,NDA020699,c848a5d8-ba94-4c84-80e3-0bf35fb8e32e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020699_S028_EFFEXOR.pdf,
1997,EFFEXOR XR,VENLAFAXINE HYDROCHLORIDE,NDA020699,c848a5d8-ba94-4c84-80e3-0bf35fb8e32e,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020151s16s19s20s21s22s23s25,020699s14s18s21s23s26s27s34TOC.cfm",
1997,EFFEXOR XR,VENLAFAXINE HYDROCHLORIDE,NDA020699,c848a5d8-ba94-4c84-80e3-0bf35fb8e32e,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020151s16s19s20s21s22s23s25,020699s14s18s21s23s26s27s34TOC.cfm",
1997,EFFEXOR XR,VENLAFAXINE HYDROCHLORIDE,NDA020699,c848a5d8-ba94-4c84-80e3-0bf35fb8e32e,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020151s16s19s20s21s22s23s25,020699s14s18s21s23s26s27s34TOC.cfm",
1997,EFFEXOR XR,VENLAFAXINE HYDROCHLORIDE,NDA020699,c848a5d8-ba94-4c84-80e3-0bf35fb8e32e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020699_S032_EFFEXOR_AP.pdf,
1997,EFFEXOR XR,VENLAFAXINE HYDROCHLORIDE,NDA020699,c848a5d8-ba94-4c84-80e3-0bf35fb8e32e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020699_s024_EFFEXOR XR_EXTENDED_RELEASE_CAPS.pdf,
1997,EFFEXOR XR,VENLAFAXINE HYDROCHLORIDE,NDA020699,c848a5d8-ba94-4c84-80e3-0bf35fb8e32e,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020151s017s018,020699s015s016EffexorTOC.cfm",
1997,EFFEXOR XR,VENLAFAXINE HYDROCHLORIDE,NDA020699,c848a5d8-ba94-4c84-80e3-0bf35fb8e32e,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020151s16s19s20s21s22s23s25,020699s14s18s21s23s26s27s34TOC.cfm",
1997,EFFEXOR XR,VENLAFAXINE HYDROCHLORIDE,NDA020699,c848a5d8-ba94-4c84-80e3-0bf35fb8e32e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020699_s005_EFFEXOR XR_EXTENDED_RELEASE_CAPS.pdf,
1997,EFFEXOR XR,VENLAFAXINE HYDROCHLORIDE,NDA020699,c848a5d8-ba94-4c84-80e3-0bf35fb8e32e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020699_S012_EFFEXOR_XR.pdf,
1997,EFFEXOR XR,VENLAFAXINE HYDROCHLORIDE,NDA020699,c848a5d8-ba94-4c84-80e3-0bf35fb8e32e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020699_S010_EFFEXOR.pdf,
2009,VALCYTE,VALGANCICLOVIR HYDROCHLORIDE,NDA022257,4c517a39-2ded-4c5a-8d56-276853414b31,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022257_021304s007_valcyte_valganciclovir hydrochloride_toc.cfm,
2009,VALCYTE,VALGANCICLOVIR HYDROCHLORIDE,NDA022257,4c517a39-2ded-4c5a-8d56-276853414b31,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21304 valganciclovir clinical prea.pdf,
2009,VALCYTE,VALGANCICLOVIR HYDROCHLORIDE,NDA022257,4c517a39-2ded-4c5a-8d56-276853414b31,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21304 valganciclovir clinpharm prea.pdf,
2009,VALCYTE,VALGANCICLOVIR HYDROCHLORIDE,NDA022257,4c517a39-2ded-4c5a-8d56-276853414b31,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022257Original-1_021304s007sumr.pdf,
2024,N/A,N/A,BLA761417,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761417Orig1s000TOC.cfm,
2002,ATNAA ATROPINE AND PRALIDOXIME CHLORIDE AUTO-INJECTOR,ATROPINE AND PRALIDOXIME CHLORIDE,NDA021175,596c7a8f-27cd-4de2-9491-476f43570b8b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21175_Atnaa.cfm,
2003,EMTRIVA,EMTRICITABINE,NDA021500,d6599395-3944-44f9-97f2-e0424c6b6a1f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021500_emtriva_toc.cfm,
2013,DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE,DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE,NDA021876,76d10d65-0279-4e86-8104-cade4343f839,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021876Orig1s000SumR.pdf,
2013,DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE,DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE,NDA021876,76d10d65-0279-4e86-8104-cade4343f839,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021876Orig1s000TOC.cfm,
2011,N/A,N/A,NDA200199,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/200199_topotecan_toc.cfm,
2011,N/A,N/A,NDA200199,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/200199Orig1s000SumR.pdf,
2013,PAROXETINE,PAROXETINE,NDA204516,1383d713-79b9-45bd-bd06-65707f28bc99,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204516Orig1s000TOC.cfm,
2013,PAROXETINE,PAROXETINE,NDA204516,1383d713-79b9-45bd-bd06-65707f28bc99,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204516Orig1s000SumR.pdf,
1995,N/A,N/A,NDA020059,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-059S007_Adenoscan.pdf,
2020,PEMETREXED,PEMETREXED,NDA208419,8b660f68-b770-4e0a-b2f9-25e663deecc3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/208419Orig1s000TOC.cfm,
2023,SITAGLIPTIN,SITAGLIPTIN,NDA211566,e5ac97e8-3a0b-4750-8e3f-337412570746,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/211566Orig1s000TOC.cfm,
2008,VIMPAT,LACOSAMIDE,NDA022254,9e79b42c-38a3-4b2c-a196-a5a1948250e2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000TOC.cfm,
2008,VIMPAT,LACOSAMIDE,NDA022254,9e79b42c-38a3-4b2c-a196-a5a1948250e2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_SumR.pdf,
2001,N/A,N/A,NDA021169,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-169_Reminyl.cfm,
2006,KEPPRA,LEVETIRACETAM,NDA021872,c6d5784d-abf9-45fe-ac5a-d5c53bd50f7e,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021872 levetiracetam clinical prea.pdf,
2006,KEPPRA,LEVETIRACETAM,NDA021872,c6d5784d-abf9-45fe-ac5a-d5c53bd50f7e,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021872_Levetiracetam_ Clinpharm_prea.pdf,
2006,KEPPRA,LEVETIRACETAM,NDA021872,c6d5784d-abf9-45fe-ac5a-d5c53bd50f7e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021872s000TOC.cfm,
2006,KEPPRA,LEVETIRACETAM,NDA021872,c6d5784d-abf9-45fe-ac5a-d5c53bd50f7e,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21872_Levetiracetam_ Clinpharm_prea.pdf,
2006,KEPPRA,LEVETIRACETAM,NDA021872,c6d5784d-abf9-45fe-ac5a-d5c53bd50f7e,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21872 levetiracetam clinical prea.pdf,
1996,SODIUM SULFACETAMIDE,SODIUM SULFACETAMIDE,NDA019931,6fa7399b-4ced-492d-b6f6-cf155764087a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/019931ap.pdf,
1990,N/A,N/A,NDA019967,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/019967_S004_ULTRAVATE CREAM.pdf,
2018,VITRAKVI,LAROTRECTINIB,NDA210861,9525f887-a055-4e33-8e92-898d42828cd1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210861Orig1s000_21171Orig1s000TOC.cfm,
1998,MONISTAT 3 3 DAY,MICONAZOLE NITRATE,NDA020827,f38c7e1d-2439-4b3b-8be8-60b2d8e61ce5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20827_Monistat3.cfm,
2024,SOFDRA,SOFPIRONIUM BROMIDE,NDA217347,78f86f4f-658c-468b-bd54-49182ddcc7ac,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217347Orig1s000TOC.cfm,
2010,VIMPAT,LACOSAMIDE,NDA022255,9e79b42c-38a3-4b2c-a196-a5a1948250e2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022255_vimpat_toc.cfm,
2010,VIMPAT,LACOSAMIDE,NDA022255,9e79b42c-38a3-4b2c-a196-a5a1948250e2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022255Orig1s000SumR.pdf,
2024,NIKTIMVO,AXATILIMAB-CSFR,BLA761411,bb6dba23-e7a6-4765-a1e6-b9e277ce0381,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761411Orig1s000TOC.cfm,
2004,N/A,N/A,NDA021497,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-497_21-498s001_Alinia.cfm,
1982,N/A,N/A,NDA018613,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/18613s009s010_ovide.pdf,
1982,N/A,N/A,NDA018613,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/18613s009s010_ovide.pdf,
2018,ARISTADA INITIO,ARIPIPRAZOLE LAUROXIL,NDA209830,b18fdfd9-31cd-4a2f-9f1c-ebc70d7a9403,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209830Orig1s000TOC.cfm,
2018,MOTEGRITY,PRUCALOPRIDE,NDA210166,bca1e4c6-4b2b-4876-8ab3-654629c4ff1b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210166Orig1s000TOC.cfm,
2021,MYRBETRIQ,MIRABEGRON,NDA213801,ba9e9e15-e666-4c56-9271-2e24739cfa2d,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/213801Orig1s000TOC.cfm,
2020,N/A,N/A,NDA210864,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/210864Orig1s000TOC.cfm,
2020,EMERPHED,EPHEDRINE SULFATE,NDA213407,e1323592-dc57-4c9d-b84d-442648a7b114,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213407Orig1s000TOC.cfm,
2000,ZONEGRAN,ZONISAMIDE,NDA020789,d12de43e-3ac3-4335-bc85-70d7366a91eb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020789_Zonegran.cfm,
2005,BIDIL,HYDRALAZINE HYDROCHLORIDE AND ISOSORBIDE DINITRATE,NDA020727,e1e63cd5-d1e4-4af5-bad5-1ad41ea46b00,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020727_s000_BidilTOC.cfm,
2009,SAVELLA,MILNACIPRAN HYDROCHLORIDE,NDA022256,16a4a314-f97e-4e91-95e9-576a3773d284,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022256Orig1s010.pdf,
2009,SAVELLA,MILNACIPRAN HYDROCHLORIDE,NDA022256,16a4a314-f97e-4e91-95e9-576a3773d284,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022256s000TOC.cfm,
2009,SAVELLA,MILNACIPRAN HYDROCHLORIDE,NDA022256,16a4a314-f97e-4e91-95e9-576a3773d284,http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2009/022256s000SumR.pdf,
2024,ZIIHERA,ZANIDATAMAB-HRII,BLA761416,ae5d9425-fae5-4541-a158-150998343348,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761416Orig1s000TOC.cfm,
2001,INSULIN ASPART PROTAMINE AND INSULIN ASPART MIX 70/30,INSULIN ASPART,BLA021172,fc94baa4-3606-48bc-a781-9617ab6960ef,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21172_Novolog.cfm,
2002,N/A,N/A,NDA021498,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021818s000_021498s003TOC.cfm,
2002,N/A,N/A,NDA021498,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-497_21-498s001_Alinia.cfm,
2002,N/A,N/A,NDA021498,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-498_Alinia.cfm,
2007,NUVIGIL,ARMODAFINIL,NDA021875,d878aed0-ddbf-8fa1-abf7-d3e480260845,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875_nuvigil_toc.cfm,
1947,N/A,N/A,NDA006134,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/006134_s028_dolophine_hydrochloride.pdf,Approval Package
1994,AZITHROMYCIN,AZITHROMYCIN,NDA050693,d470695c-c0d7-4361-8783-45f58a932ac4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-670S015_Zithromax.cfm,
1980,LORAZEPAM,LORAZEPAM,NDA018140,b79b38ee-c29d-4099-964f-000031f47f5a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/018140_S027_ATIVAN_INJECTION_AP.pdf,
1980,LORAZEPAM,LORAZEPAM,NDA018140,b79b38ee-c29d-4099-964f-000031f47f5a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/018140ap_s003.pdf,
1981,TENORMIN,ATENOLOL,NDA018240,746db603-a6e1-4dc3-c2d8-92314419098c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/18240-s025_Tenormin.pdf,
1981,TENORMIN,ATENOLOL,NDA018240,746db603-a6e1-4dc3-c2d8-92314419098c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/18240-s026_tenormin.pdf,
1987,N/A,N/A,NDA019297,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019297_S000_ORIGINAL_APPROVAL_PKG.pdf,
1987,N/A,N/A,NDA019297,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/019297_s014ap.pdf,
1987,N/A,N/A,NDA019297,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/19297-S021_Novantrone.pdf,
2021,UPTRAVI,SELEXIPAG,NDA214275,a7a23b87-f892-4e2c-8e2e-ebf841220f90,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214275Orig1s000TOC.cfm,
2019,N/A,N/A,NDA210872,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210872Orig1s000TOC.cfm,
2018,KHAPZORY,LEVOLEUCOVORIN,NDA211226,344f65ac-9f04-49d7-b7c3-4ba19bd7b429,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211226Orig1s000TOC.cfm,
1994,N/A,N/A,NDA020323,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-323S021_Vivelle.cfm,
1994,N/A,N/A,NDA020323,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-167_20-323S23_Vivelle.cfm,
1998,N/A,N/A,NDA020400,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20400.cfm,
2021,LIVMARLI,MARALIXIBAT CHLORIDE,NDA214662,64000394-1ef6-4e76-8ba8-11f25ba1b167,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214662Orig1s000TOC.cfm,
2022,SUNLENCA,LENACAPAVIR SODIUM,NDA215974,e5652804-29c4-40d7-aeb2-0142ed2a7b5b,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215973,215974Orig1s000TOC.cfm",
2001,N/A,N/A,NDA021180,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021180_s001_ORTHO EVRA.pdf,
2001,N/A,N/A,NDA021180,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021180_s008_ORTHO EVRA.pdf,
2001,N/A,N/A,NDA021180,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021180_s004_OrthoTOC.cfm,
2001,N/A,N/A,NDA021180,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021180_s002_ORTHO EVRA.pdf,
2001,N/A,N/A,NDA021180,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/021-180_ORTHO.cfm,
2001,N/A,N/A,NDA021180,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21180_S005_OrthoEvraTOC.cfm,
2001,N/A,N/A,NDA021180,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021180_s003_OrthoTOC.cfm,
2005,REVLIMID,LENALIDOMIDE,NDA021880,5fa97bf5-28a2-48f1-8955-f56012d296be,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021880s000_RevlimidTOC.cfm,
2000,N/A,N/A,NDA074973,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/74973_Primsol.pdf,
2012,MYTESI,CROFELEMER,NDA202292,45584fba-8081-4cd1-a21e-3ea8237f62ff,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202292Orig1s000TOC.cfm,
2012,MYTESI,CROFELEMER,NDA202292,45584fba-8081-4cd1-a21e-3ea8237f62ff,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202292Orig1s000SumR.pdf,
1992,N/A,N/A,NDA019651,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/asacol_19651s5.cfm,
2018,N/A,N/A,NDA208042,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208042Orig1s000TOC.cfm,
2017,ESBRIET,PIRFENIDONE,NDA208780,2e8c3537-36d7-4de5-9b5c-7a624b9a9e6e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208780Orig1s000TOC.cfm,
2022,ZONISADE,ZONISAMIDE,NDA214273,ac16fa15-32e9-4f92-8bc6-d8d41ae002c6,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/214273Orig1s000TOC.cfm,
2018,MOXIDECTIN,MOXIDECTIN,NDA210867,6eb02ae9-9065-176f-e053-2991aa0ac891,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210867Orig1s000TOC.cfm,
1996,BUPHENYL,SODIUM PHENYLBUTYRATE,NDA020573,463a36fa-3eb2-4326-8bd0-c8c7a11bca3a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020573Orig1s000rev.pdf,
1996,N/A,N/A,NDA020602,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-603s002_Ibuprofen.cfm,
2015,TOLAK,FLUOROURACIL,NDA022259,59de2709-00b8-4f0a-867c-f0dfeb947192,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022259Orig1s000TOC.cfm,
2015,TOLAK,FLUOROURACIL,NDA022259,59de2709-00b8-4f0a-867c-f0dfeb947192,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022259Orig1s000SumR.pdf,
2000,WELCHOL,COLESEVELAM HYDROCHLORIDE,NDA021176,89cbd0a3-2d1b-41db-8c97-35ec67b7b09f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-141_Welchol.cfm,
2000,WELCHOL,COLESEVELAM HYDROCHLORIDE,NDA021176,89cbd0a3-2d1b-41db-8c97-35ec67b7b09f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021176_Colesevelam_Clinical_BPCA.pdf,
2000,WELCHOL,COLESEVELAM HYDROCHLORIDE,NDA021176,89cbd0a3-2d1b-41db-8c97-35ec67b7b09f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021176_Colesevelam_Statistical_BPCA.pdf,
2006,N/A,N/A,NDA021501,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021501_capital_soleil_toc.cfm,
2005,ARRANON,NELARABINE,NDA021877,0f9051de-5c4d-4c0f-8c19-e15214498cca,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021877_s000_ArranonTOC.cfm,
2014,FARXIGA,DAPAGLIFLOZIN,NDA202293,72ad22ae-efe6-4cd6-a302-98aaee423d69,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/202293Orig1s020.pdf,
2014,FARXIGA,DAPAGLIFLOZIN,NDA202293,72ad22ae-efe6-4cd6-a302-98aaee423d69,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000TOC.cfm,
2014,FARXIGA,DAPAGLIFLOZIN,NDA202293,72ad22ae-efe6-4cd6-a302-98aaee423d69,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000SumR.pdf,
2014,FARXIGA,DAPAGLIFLOZIN,NDA202293,72ad22ae-efe6-4cd6-a302-98aaee423d69,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/202293Orig1s026.pdf,
2014,FARXIGA,DAPAGLIFLOZIN,NDA202293,72ad22ae-efe6-4cd6-a302-98aaee423d69,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/202293Orig1s018.pdf,
2014,FARXIGA,DAPAGLIFLOZIN,NDA202293,72ad22ae-efe6-4cd6-a302-98aaee423d69,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/202293Orig1s024TOC.cfm,
2016,N/A,N/A,NDA208424,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208424Orig1toc.cfm,
2018,LORBRENA,LORLATINIB,NDA210868,2b34d62d-e02a-4af3-bc0d-1571dd4ee76d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210868Orig1s000TOC.cfm,
2020,GEMTESA,VIBEGRON,NDA213006,25f21d25-14f8-4fda-91f6-7aa8b68aa1c8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000TOC.cfm,
2020,TUKYSA,TUCATINIB,NDA213411,f27eb1b9-b7fc-424e-988f-84dd7bb195a3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213411Orig1s000TOC.cfm,
2008,VELETRI,EPOPROSTENOL,NDA022260,df502787-46ec-4dd1-a2c0-be90f6d95a5d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022260Orig1s005.pdf,
2008,VELETRI,EPOPROSTENOL,NDA022260,df502787-46ec-4dd1-a2c0-be90f6d95a5d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022260s000_SumR.pdf,
2008,VELETRI,EPOPROSTENOL,NDA022260,df502787-46ec-4dd1-a2c0-be90f6d95a5d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022260_epoprostenol_toc.cfm,
2000,N/A,N/A,NDA021178,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-178S004_Glucovance.cfm,
2000,N/A,N/A,NDA021178,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-178_Glucovance.cfm,
2000,N/A,N/A,NDA021178,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021178s007_glyburide-metformin_Glucovance-MedRev.pdf,
2000,N/A,N/A,NDA021178,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021178s007_glyburide-metformin_Glucovance-StatsRev.pdf,
2006,N/A,N/A,NDA021502,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021502s000_AntheliosTOC.cfm,
2006,N/A,N/A,NDA021502,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021502s001lbl.pdf,
1987,N/A,N/A,NDA019555,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/19-555S008_Diprosone.cfm,
1987,N/A,N/A,NDA019555,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/19-555S008_Diprosone.cfm,
2019,ZYKADIA,CERITINIB,NDA211225,fff5d805-4ffd-4e8e-8e63-6f129697563e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211225Orig1s000TOC.cfm,
2022,SUNLENCA,LENACAPAVIR SODIUM,NDA215973,e5652804-29c4-40d7-aeb2-0142ed2a7b5b,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215973,215974Orig1s000TOC.cfm",
2023,ZEPBOUND,TIRZEPATIDE,NDA217806,487cd7e7-434c-4925-99fa-aa80b1cc776b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217806Orig1s000TOC.cfm,
2024,POTASSIUM PHOSPHATES,POTASSIUM PHOSPHATES IN SODIUM CHLORIDE,NDA218343,dce22c93-aa48-48a9-ac8b-716400d33c9e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/218343Orig1s000TOC.cfm,
2008,CAMRESE LO,LEVONORGESTREL/ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL,NDA022262,4a48e24c-9280-47fe-b200-9b79a7f6bd96,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022262_loseasonique_toc.cfm,
2008,CAMRESE LO,LEVONORGESTREL/ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL,NDA022262,4a48e24c-9280-47fe-b200-9b79a7f6bd96,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022262s000_SumR.pdf,
2025,USTEKINUMAB-TTWE,USTEKINUMAB-TTWE,BLA761425,2b34392a-ecf6-41bd-8706-d4e9f0b25da8,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761373Orig1Orig2s001,761425Orig1Orig2s001CrossR.pdf",
2025,USTEKINUMAB-TTWE,USTEKINUMAB-TTWE,BLA761425,2b34392a-ecf6-41bd-8706-d4e9f0b25da8,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761373Orig1s000,761425Orig1s000TOC.cfm",
2000,SEVELAMER HYDROCHLORIDE,SEVELAMER HYDROCHLORIDE,NDA021179,5a76bd76-a6cc-46f1-bb58-660566eaec06,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-179_Renagel.cfm,
2003,VIRACEPT,NELFINAVIR MESYLATE,NDA021503,e72c2bc6-9462-4a2e-8e1d-b97592376cbd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021503s000_ViraceptTOC.cfm,
2003,VIRACEPT,NELFINAVIR MESYLATE,NDA021503,e72c2bc6-9462-4a2e-8e1d-b97592376cbd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021503_S006_VIRACEPT.pdf,
2003,VIRACEPT,NELFINAVIR MESYLATE,NDA021503,e72c2bc6-9462-4a2e-8e1d-b97592376cbd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021503_S001_VIRACEPT.pdf,
2010,NUEDEXTA,DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE,NDA021879,c8cce784-8c5f-415b-8068-76e5d481d159,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/021879Orig1s007.pdf,
2010,NUEDEXTA,DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE,NDA021879,c8cce784-8c5f-415b-8068-76e5d481d159,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021879Orig1s000TOC.cfm,
2010,NUEDEXTA,DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE,NDA021879,c8cce784-8c5f-415b-8068-76e5d481d159,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021879Orig1s000SumR.pdf,
1984,N/A,N/A,NDA017473,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/017473Orig1s046.pdf,
2010,XIAFLEX,COLLAGENASE CLOSTRIDIUM HISTOLYTICUM,BLA125338,805cecd0-fd1f-11dd-87af-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125338s000TOC.cfm,
2010,XIAFLEX,COLLAGENASE CLOSTRIDIUM HISTOLYTICUM,BLA125338,805cecd0-fd1f-11dd-87af-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125338s000SumR.pdf,
2014,SAXENDA,LIRAGLUTIDE,NDA206321,3946d389-0926-4f77-a708-0acb8153b143,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/206321Orig1s004.pdf,
2014,SAXENDA,LIRAGLUTIDE,NDA206321,3946d389-0926-4f77-a708-0acb8153b143,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206321Orig1s000TOC.cfm,
2014,SOTYLIZE,SOTALOL HYDROCHLORIDE,NDA205108,1f33f900-0777-4a92-a7f7-00cf3d57d95c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205108Orig1s000TOC.cfm,
1989,BETOPTIC S,BETAXOLOL HYDROCHLORIDE,NDA019845,905ba189-456c-4aa4-8231-39a971374ad8,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/019845s020, 020963s010_betaxolol-MedRev.pdf",
1989,BETOPTIC S,BETAXOLOL HYDROCHLORIDE,NDA019845,905ba189-456c-4aa4-8231-39a971374ad8,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/019845s020, 020963s010_betaxolol-MedRev2.pdf",
1997,EDEX,ALPROSTADIL,NDA020649,e8b8ec8d-1318-43e4-a182-446e9f9579de,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020649_edex_toc.cfm,
2000,N/A,N/A,NDA020687,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/020687Orig1s020TOC.cfm,
2000,N/A,N/A,NDA020687,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20687_mifepristone.cfm,
2000,N/A,N/A,NDA020687,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2023/020687Orig1s025SumR.pdf,
2000,N/A,N/A,NDA020687,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/020687Orig1s025.pdf,
2000,N/A,N/A,NDA020687,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/020687Orig1s026.pdf,
2023,ORSERDU,ELACESTRANT,NDA217639,aa66ae5c-2bd2-4444-8178-b55651e054ef,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217639Orig1s000TOC.cfm,
2021,N/A,N/A,BLA761223,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761223Orig1s000TOC.cfm,
2004,N/A,N/A,NDA021044,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021044s000_PalladoneTOC.cfm,
2004,VABRINTY,LEUPROLIDE ACETATE,NDA021731,008776cc-83f1-4f8c-819b-6471425da15f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021731s000_EligardTOC.cfm,
1986,MIACALCIN,CALCITONIN SALMON,NDA017808,89cd4f46-b88a-4c10-b25c-47352280dc4e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/017808a_s014.pdf,
2010,PROLIA,DENOSUMAB,BLA125320,49e5afe9-a0c7-40c4-af9f-f287a80c5c88,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125320Orig1s006.pdf,
2010,PROLIA,DENOSUMAB,BLA125320,49e5afe9-a0c7-40c4-af9f-f287a80c5c88,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125320Orig1s094.pdf,
2010,PROLIA,DENOSUMAB,BLA125320,49e5afe9-a0c7-40c4-af9f-f287a80c5c88,http://www.accessdata.fda.gov/drugsatfda_docs/review/2018/125320Orig1s007.pdf,
2010,PROLIA,DENOSUMAB,BLA125320,49e5afe9-a0c7-40c4-af9f-f287a80c5c88,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125320Orig1s005.pdf,
2010,PROLIA,DENOSUMAB,BLA125320,49e5afe9-a0c7-40c4-af9f-f287a80c5c88,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125320s0000TOC.cfm,
2010,PROLIA,DENOSUMAB,BLA125320,49e5afe9-a0c7-40c4-af9f-f287a80c5c88,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125320s000SumR.pdf,
2011,GEMCITABINE,GEMCITABINE,NDA200795,dc02a23b-3ff9-4441-aa91-8e9e629a7315,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/200795_gemcitabine_toc.cfm,
2011,GEMCITABINE,GEMCITABINE,NDA200795,dc02a23b-3ff9-4441-aa91-8e9e629a7315,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/200795Orig1s000SumR.pdf,
2015,N/A,N/A,NDA206317,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206317Orig1s000TOC.cfm,
2015,N/A,N/A,NDA206317,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206317Orig1s000SumR.pdf,
2013,IMBRUVICA,IBRUTINIB,NDA205552,0dfd0279-ff17-4ea9-89be-9803c71bab44,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/205552Orig1S001.pdf,
2013,IMBRUVICA,IBRUTINIB,NDA205552,0dfd0279-ff17-4ea9-89be-9803c71bab44,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205552Orig1s000SumR.pdf,
2013,IMBRUVICA,IBRUTINIB,NDA205552,0dfd0279-ff17-4ea9-89be-9803c71bab44,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/205552Orig1s002.pdf,
2013,IMBRUVICA,IBRUTINIB,NDA205552,0dfd0279-ff17-4ea9-89be-9803c71bab44,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205552Orig2s000TOC.cfm,
2013,IMBRUVICA,IBRUTINIB,NDA205552,0dfd0279-ff17-4ea9-89be-9803c71bab44,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205552Orig2s000SumR.pdf,
2013,IMBRUVICA,IBRUTINIB,NDA205552,0dfd0279-ff17-4ea9-89be-9803c71bab44,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205552s001.pdf,
2013,IMBRUVICA,IBRUTINIB,NDA205552,0dfd0279-ff17-4ea9-89be-9803c71bab44,http://www.accessdata.fda.gov/drugsatfda_docs/review/2018/205552Orig1s017SumR.pdf,
2013,IMBRUVICA,IBRUTINIB,NDA205552,0dfd0279-ff17-4ea9-89be-9803c71bab44,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/205552Origs1s017.pdf,
2019,UBRELVY,UBROGEPANT,NDA211765,fd9f9458-fd96-4688-be3f-f77b3d1af6ab,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000TOC.cfm,
2023,CYCLOPHOSPHAMIDE,CYCLOPHOSPHAMIDE,NDA217150,cf2f4b95-0327-499a-a5a3-51b1bdef68c5,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217150Orig1s000TOC.cfm,
2011,EXPAREL,BUPIVACAINE,NDA022496,bb5a9e59-0f51-11df-8a39-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022496Orig1s000TOC.cfm,
2011,EXPAREL,BUPIVACAINE,NDA022496,bb5a9e59-0f51-11df-8a39-0800200c9a66,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/22496Orig1s037.pdf,
1998,TOPAMAX,TOPIRAMATE,NDA020844,21628112-0c47-11df-95b3-498d55d89593,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020844s000_Topamax.cfm,
1998,TOPAMAX,TOPIRAMATE,NDA020844,21628112-0c47-11df-95b3-498d55d89593,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20844S1_Topamax.cfm,
1998,TOPAMAX,TOPIRAMATE,NDA020844,21628112-0c47-11df-95b3-498d55d89593,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20844S4_Topamax.cfm,
1998,TOPAMAX,TOPIRAMATE,NDA020844,21628112-0c47-11df-95b3-498d55d89593,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-505s002_20-844s010_Topamax.cfm,
1999,N/A,N/A,NDA021041,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21-041_DepoCyt.cfm,
2003,PALONOSETRON HYDROCHLORIDE,PALONOSETRON HYDROCHLORIDE,NDA021372,37e7ef89-fd77-44e0-9271-ae91f8822603,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021372 palonsetron clinical 18 bpca.pdf,
2003,PALONOSETRON HYDROCHLORIDE,PALONOSETRON HYDROCHLORIDE,NDA021372,37e7ef89-fd77-44e0-9271-ae91f8822603,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021372s008s010TOC.cfm,
2003,PALONOSETRON HYDROCHLORIDE,PALONOSETRON HYDROCHLORIDE,NDA021372,37e7ef89-fd77-44e0-9271-ae91f8822603,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021372s008s010_SumR.pdf,
2003,PALONOSETRON HYDROCHLORIDE,PALONOSETRON HYDROCHLORIDE,NDA021372,37e7ef89-fd77-44e0-9271-ae91f8822603,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-372_Alox.cfm,
2003,PALONOSETRON HYDROCHLORIDE,PALONOSETRON HYDROCHLORIDE,NDA021372,37e7ef89-fd77-44e0-9271-ae91f8822603,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021372s008s010TOC.cfm,
2003,PALONOSETRON HYDROCHLORIDE,PALONOSETRON HYDROCHLORIDE,NDA021372,37e7ef89-fd77-44e0-9271-ae91f8822603,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021372s008s010_SumR.pdf,
2003,PALONOSETRON HYDROCHLORIDE,PALONOSETRON HYDROCHLORIDE,NDA021372,37e7ef89-fd77-44e0-9271-ae91f8822603,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021372 palonsetron clinical bpca.pdf,
2003,PALONOSETRON HYDROCHLORIDE,PALONOSETRON HYDROCHLORIDE,NDA021372,37e7ef89-fd77-44e0-9271-ae91f8822603,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021372 palonsetron clinpharm bpca.pdf,
2003,PALONOSETRON HYDROCHLORIDE,PALONOSETRON HYDROCHLORIDE,NDA021372,37e7ef89-fd77-44e0-9271-ae91f8822603,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021372 palonsetron statistical prea.pdf,
2007,TORISEL,TEMSIROLIMUS,NDA022088,95b7dc92-2180-42f1-8699-3c28f609e674,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022088s000TOC.cfm,
2007,TORISEL,TEMSIROLIMUS,NDA022088,95b7dc92-2180-42f1-8699-3c28f609e674,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022088_temsirolimus_clinical_bpca.pdf,
2007,TORISEL,TEMSIROLIMUS,NDA022088,95b7dc92-2180-42f1-8699-3c28f609e674,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022088_temsirolimus_clinpharm_bpca.pdf,
2014,NORTHERA,DROXIDOPA,NDA203202,2179f02c-48d7-48eb-8007-5ae43d8d16bc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203202Orig1s000TOC.cfm,
2009,ARZERRA,OFATUMUMAB,BLA125326,77785ce3-e8df-4ca1-8f8e-6c418c6a17de,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/125326Orig1s070.pdf,
2009,ARZERRA,OFATUMUMAB,BLA125326,77785ce3-e8df-4ca1-8f8e-6c418c6a17de,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/125326s000TOC.cfm,
2009,ARZERRA,OFATUMUMAB,BLA125326,77785ce3-e8df-4ca1-8f8e-6c418c6a17de,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/125326s000_SumR.pdf,
2011,EDARBI,AZILSARTAN KAMEDOXOMIL,NDA200796,52b27c75-9f5a-4816-bafd-dace9d7d2063,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/200796sOrig1s000_Edarbi_TOC.cfm,
2017,STERITALC 2G,TALC,NDA205555,c94e51d9-beef-4b06-e053-2a95a90a754a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/205555Orig1s000TOC.cfm,
2020,OLINVYK,OLICERIDINE,NDA210730,ce167984-8b9d-40b7-84ce-d0f33fff1eaa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000TOC.cfm,
2019,PRETOMANID,PRETOMANID,NDA212862,f1906fc9-cb3c-4e13-8a4a-da76100c1bf3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212862Orig1s000TOC.cfm,
2020,RETEVMO,SELPERCATINIB,NDA213246,7fa848ba-a59c-4144-9f52-64d090f4d828,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213246Orig1s000TOC.cfm,
1998,INFANTS ADVIL,IBUPROFEN,NDA020812,db5ed801-7a7e-3c83-0172-77f914daaa5a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020812Orig1s011.pdf,
1998,INFANTS ADVIL,IBUPROFEN,NDA020812,db5ed801-7a7e-3c83-0172-77f914daaa5a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020812Orig1s007.pdf,
1998,INFANTS ADVIL,IBUPROFEN,NDA020812,db5ed801-7a7e-3c83-0172-77f914daaa5a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020812_PediatricTOC.cfm,
2000,DIFFERIN,ADAPALENE,NDA020748,ab4b2120-57fc-6c61-b239-37c21789c065,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020748_differin.cfm,
2011,BUPROPION HYDROCHLORIDE,BUPROPION HYDROCHLORIDE,NDA022497,2e3f36e9-1cb7-4987-92c9-2d9fc519c694,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022497_forfivo_xl_toc.cfm,
2011,BUPROPION HYDROCHLORIDE,BUPROPION HYDROCHLORIDE,NDA022497,2e3f36e9-1cb7-4987-92c9-2d9fc519c694,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022497Orig1s000SumR.pdf,
2021,YUSIMRY,ADALIMUMAB-AQVH,BLA761216,cd0e7af2-7704-49ce-bde9-f645294b6788,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761216Orig1s000TOC.cfm,
1999,N/A,N/A,NDA021042,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021042_s017_021052_s011_VioxxTOC.cfm,
1999,N/A,N/A,NDA021042,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021042_s023_VioxxtmTOC.cfm,
1999,N/A,N/A,NDA021042,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-042s007_Vioxx.cfm,
1999,N/A,N/A,NDA021042,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021042_S015_VIOXX.pdf,
1999,N/A,N/A,NDA021042,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021042_s020s021s022_021052_s014s015s016_VioxxTOC.cfm,
1999,N/A,N/A,NDA021042,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-042s007_Vioxx.cfm,
1999,N/A,N/A,NDA021042,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-042s007_Vioxx.cfm,
1999,N/A,N/A,NDA021042,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/021042_52_Vioxx.cfm,
1999,N/A,N/A,NDA021042,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/rofecoxib DD.pdf,
1999,N/A,N/A,NDA021042,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/rofecoxib dd 2.pdf,
1999,N/A,N/A,NDA021042,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/rofecoxib CDTL.pdf,
1999,N/A,N/A,NDA021042,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/rofecoxib_Vioxx-ClinPharmRev-21042s026_21052s019.pdf,
1999,N/A,N/A,NDA021042,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/rofecoxib clinpharm (2).pdf,
1999,N/A,N/A,NDA021042,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/rofecoxib_Vioxx-StatsRev-21042s026_21052s019.pdf,
1999,N/A,N/A,NDA021042,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/021042_S011_VIOXX.pdf,
1999,N/A,N/A,NDA021042,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/021042_S001_VIOXX.pdf,
1999,N/A,N/A,NDA021042,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021042_S028_VIOXX.pdf,
1999,N/A,N/A,NDA021042,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/rofecoxib_Vioxx-MedRev-21042s026_21052s019.pdf,
1999,N/A,N/A,NDA021042,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021042_S026_VIOXX.pdf,
1999,N/A,N/A,NDA021042,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021042_s024_021052_s017_VioxxtmTOC.cfm,
1999,N/A,N/A,NDA021042,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021042_S016_VIOXX.pdf,
1999,N/A,N/A,NDA021042,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021042_s020s021s022_021052_s014s015s016_VioxxTOC.cfm,
1999,N/A,N/A,NDA021042,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-042s007_Vioxx.cfm,
1999,N/A,N/A,NDA021042,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-042s007_Vioxx.cfm,
1999,N/A,N/A,NDA021042,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021042_s020s021s022_021052_s014s015s016_VioxxTOC.cfm,
1999,N/A,N/A,NDA021042,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-042s007_Vioxx.cfm,
1999,N/A,N/A,NDA021042,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/021042_S004_VIOXX.pdf,
1999,N/A,N/A,NDA021042,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-042s007_Vioxx.cfm,
1999,N/A,N/A,NDA021042,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/021042_S002_VIOXX.pdf,
2002,N/A,N/A,NDA021373,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-373_Ibuprofen%20Childrens%20Advil.cfm,
2006,N/A,N/A,NDA021729,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021729Orig1s006_s007_s009.pdf,
2006,N/A,N/A,NDA021729,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/021729s6s7s9,21866s6s7s9SUMR.pdf",
2006,N/A,N/A,NDA021729,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021729s000TOC.cfm,
2006,N/A,N/A,NDA021729,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021436 aripiprazole clinical prea.pdf,
2006,N/A,N/A,NDA021729,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021729Orig1s006_s007_s009.pdf,
2006,N/A,N/A,NDA021729,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/021729s6s7s9,21866s6s7s9SUMR.pdf",
2006,N/A,N/A,NDA021729,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021729Orig1s006_s007_s009.pdf,
2006,N/A,N/A,NDA021729,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/021729s6s7s9,21866s6s7s9SUMR.pdf",
2008,EOVIST,GADOXETATE DISODIUM,NDA022090,6218b1e1-cbc3-4c14-bec7-528ac163a561,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022090s000TOC.cfm,
2008,EOVIST,GADOXETATE DISODIUM,NDA022090,6218b1e1-cbc3-4c14-bec7-528ac163a561,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022090 gadoxetate clinical prea.pdf,
2008,EOVIST,GADOXETATE DISODIUM,NDA022090,6218b1e1-cbc3-4c14-bec7-528ac163a561,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022090 gadoxetate clinpharm prea.pdf,
2008,EOVIST,GADOXETATE DISODIUM,NDA022090,6218b1e1-cbc3-4c14-bec7-528ac163a561,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022090s000_SumR.pdf,
1984,PARAGARD T 380A,COPPER,NDA018680,3c420b53-c95e-46af-aebd-73741be58391,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018680_original_approval.pdf,
2012,VORAXAZE,GLUCARPIDASE,BLA125327,acaef5a6-b740-40e3-8ffe-74a75c74745c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125327Orig1s000TOC.cfm,
2014,DOXYCYCLINE HYCLATE,DOXYCYCLINE HYCLATE,NDA205931,fad03768-f1d2-459f-965e-0ec29f189f1f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205931Orig1s000TOC.cfm,
1996,N/A,N/A,NDA019815,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/19-815s005_Midodrine.cfm,
1996,N/A,N/A,NDA019815,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019815Orig1s000rev.pdf,
2019,ROCKLATAN,"NETARSUDIL AND LATANOPROST OPHTHALMIC SOLUTION, 0.02%/0.005%",NDA208259,b1d71f41-be06-4a08-94d4-e352198f09c2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/208259Orig1s000TOC.cfm,
1997,N/A,N/A,NDA020778,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020778_S010_VIRACEPT.pdf,
1997,N/A,N/A,NDA020778,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/nelfinavir_Viracept-MedRev-20778.pdf,
1997,N/A,N/A,NDA020778,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/nelfinavir_Viracept-ClinPharmRev-20778.pdf,
1997,N/A,N/A,NDA020778,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020778ap.pdf,
1997,N/A,N/A,NDA020778,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020778_S015_VIRACEPT.pdf,
1997,N/A,N/A,NDA020778,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020778_S022_VIRACEPT.pdf,
1997,N/A,N/A,NDA020778,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020778_S012_VIRACEPT.pdf,
2021,KORSUVA,DIFELIKEFALIN,NDA214916,0c7b81f2-0fd3-47cb-8b0f-185e07f19c87,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000TOC.cfm,
2023,FOCINVEZ,FOSAPREPITANT DIMEGLUMINE,NDA216686,18a60093-cec8-1b8c-e063-6394a90a8902,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216686Orig1s000TOC.cfm,
2000,TRELSTAR,TRIPTORELIN PAMOATE,NDA020715,b1b84d62-a369-a4b7-5c41-dd1f553a18f3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-715_Trelstar.cfm,
2023,ADALIMUMAB,ADALIMUMAB-AATY,BLA761219,c44365e9-d470-4e35-978d-8565a9e3471e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761219Orig1s000TOC.cfm,
2002,ADVIL COLD AND SINUS,"IBUPROFEN, PSEUDOEPHEDRINE HYDROCHLORIDE",NDA021374,0da9ed22-bfb4-d61b-110b-0c7760332a98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-374_Ibuprofen.cfm,
2005,XOPENEX HFA,LEVALBUTEROL TARTRATE,NDA021730,70a35706-d7a8-4a48-98c6-1cab1c42fe8d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21730 levalbuterol clinpharm prea.pdf,
2005,XOPENEX HFA,LEVALBUTEROL TARTRATE,NDA021730,70a35706-d7a8-4a48-98c6-1cab1c42fe8d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21730 levalbuterol clinical prea.pdf,
2005,XOPENEX HFA,LEVALBUTEROL TARTRATE,NDA021730,70a35706-d7a8-4a48-98c6-1cab1c42fe8d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21730 levalbuterol statistical prea.pdf,
2005,XOPENEX HFA,LEVALBUTEROL TARTRATE,NDA021730,70a35706-d7a8-4a48-98c6-1cab1c42fe8d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021730s000TOC.cfm,
2015,VARUBI,ROLAPITANT,NDA206500,a52896cd-4a98-49b8-82db-bf1985a64d97,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206500Orig1s000TOC.cfm,
2015,VARUBI,ROLAPITANT,NDA206500,a52896cd-4a98-49b8-82db-bf1985a64d97,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206500Orig1s000SumR.pdf,
1991,DILTIAZEM HCL CD,DILTIAZEM HYDROCHLORIDE,NDA020062,5e39be50-ea17-4077-a2dc-668267049f6a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/020062Orig1s042.pdf,
1991,DILTIAZEM HCL CD,DILTIAZEM HYDROCHLORIDE,NDA020062,5e39be50-ea17-4077-a2dc-668267049f6a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20062-s027_cardizem.pdf,
2020,GALLIUM GA-68 PSMA-11,GALLIUM GA-68 GOZETOTIDE,NDA212643,b6253a7b-0f73-36be-e053-2a95a90a9015,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212643Orig1s000TOC.cfm,
2020,WYNZORA,CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE,NDA213422,36c5c818-0d40-445e-a3c0-0f46723a25e2,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213422Orig1s000TOC.cfm,
2017,MVASI,BEVACIZUMAB-AWWB,BLA761028,0a562b4e-67ce-4bab-852c-d9ee71e55fb8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761028Orig1s000TOC.cfm,
2025,TRYPTYR,ACOLTREMON,NDA217370,2b7715a1-035c-4002-b582-5238efee5d58,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/217370Orig1s000TOC.cfm,
2009,COARTEM,ARTEMETHER AND LUMEFANTRINE,NDA022268,7866ec19-dfac-47d4-a53f-511a12643cbf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000TOC.cfm,
2009,COARTEM,ARTEMETHER AND LUMEFANTRINE,NDA022268,7866ec19-dfac-47d4-a53f-511a12643cbf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_SumR.pdf,
1999,N/A,N/A,NDA020862,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020862_Hectorol.cfm,
2001,NUVARING,ETONOGESTREL AND ETHINYL ESTRADIOL,NDA021187,19ef66d1-913f-49a8-a0a5-59b4e20322f5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021187Orig1s021s022TOC.cfm,
2001,NUVARING,ETONOGESTREL AND ETHINYL ESTRADIOL,NDA021187,19ef66d1-913f-49a8-a0a5-59b4e20322f5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021187Orig1s021s022SumR.pdf,
2001,NUVARING,ETONOGESTREL AND ETHINYL ESTRADIOL,NDA021187,19ef66d1-913f-49a8-a0a5-59b4e20322f5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-187_NuvaRing.cfm,
2001,NUVARING,ETONOGESTREL AND ETHINYL ESTRADIOL,NDA021187,19ef66d1-913f-49a8-a0a5-59b4e20322f5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/021187Orig1s034.pdf,
2001,NUVARING,ETONOGESTREL AND ETHINYL ESTRADIOL,NDA021187,19ef66d1-913f-49a8-a0a5-59b4e20322f5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021187Orig1s021s022TOC.cfm,
2001,NUVARING,ETONOGESTREL AND ETHINYL ESTRADIOL,NDA021187,19ef66d1-913f-49a8-a0a5-59b4e20322f5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021187Orig1s021s022SumR.pdf,
2014,N/A,N/A,NDA021883,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/021883Orig1s003.pdf,
2014,N/A,N/A,NDA021883,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/021883Orig1s000TOC.cfm,
2014,N/A,N/A,NDA021883,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/021883Orig1s000SumR.pdf,
1994,PROGRAF,TACROLIMUS,NDA050708,7f667de1-9dfa-4bd6-8ba0-15ee2d78873b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/050708_prograf_toc.cfm,
1994,PROGRAF,TACROLIMUS,NDA050708,7f667de1-9dfa-4bd6-8ba0-15ee2d78873b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/050708Orig1s053; 050709Orig1s045; 210115Orig1s005.pdf,
1994,PROGRAF,TACROLIMUS,NDA050708,7f667de1-9dfa-4bd6-8ba0-15ee2d78873b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/050708Orig1s027_StatR.pdf,
1985,N/A,N/A,NDA019219,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019219Orig1s000rev.pdf,
2015,AVYCAZ,"CEFTAZIDIME, AVIBACTAM",NDA206494,d9c2803f-dc9c-4b19-b4a3-8303bc8c15fd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206494Orig1s000TOC.cfm,
2015,AVYCAZ,"CEFTAZIDIME, AVIBACTAM",NDA206494,d9c2803f-dc9c-4b19-b4a3-8303bc8c15fd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206494Orig1s000SumR.pdf,
2015,AVYCAZ,"CEFTAZIDIME, AVIBACTAM",NDA206494,d9c2803f-dc9c-4b19-b4a3-8303bc8c15fd,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/400_206494S5_avibactam_ceftazidine_unireview_prea.pdf,
2019,CAPLYTA,LUMATEPERONE,NDA209500,db730b06-6351-47fd-8183-e61e61bbead5,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/209500Orig1s006_Redacted.pdf,
2019,CAPLYTA,LUMATEPERONE,NDA209500,db730b06-6351-47fd-8183-e61e61bbead5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209500Orig1s000TOC.cfm,
2019,CAPLYTA,LUMATEPERONE,NDA209500,db730b06-6351-47fd-8183-e61e61bbead5,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/209500Orig1s005_Redacted.pdf,
2019,N/A,N/A,NDA210874,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210874Orig1s000TOC.cfm,
2018,N/A,N/A,NDA211580,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211580Orig1s000TOC.cfm,
2019,N/A,N/A,NDA212640,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212640Orig1s000TOC.cfm,
2009,INVEGA SUSTENNA,PALIPERIDONE PALMITATE,NDA022264,1af14e42-951d-414d-8564-5d5fce138554,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022264_invega_sustenna_toc.cfm,
2009,INVEGA SUSTENNA,PALIPERIDONE PALMITATE,NDA022264,1af14e42-951d-414d-8564-5d5fce138554,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022264s000sumr.pdf,
2009,INVEGA SUSTENNA,PALIPERIDONE PALMITATE,NDA022264,1af14e42-951d-414d-8564-5d5fce138554,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/022264Orig1s015.pdf,
2000,N/A,N/A,NDA021183,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021183_S001_VIDEX_AP.pdf,
2000,N/A,N/A,NDA021183,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021183s020_Didansine (Videx EC)_Clinical_PREA.pdf,
2000,N/A,N/A,NDA021183,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021183s020_Didansine (Videx EC)_Clinpharm_PREA.pdf,
2000,N/A,N/A,NDA021183,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-183_Videx.cfm,
2000,N/A,N/A,NDA021183,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-183s002_Videx.cfm,
2003,KEPPRA,LEVETIRACETAM,NDA021505,3ca9df05-a506-4ec8-a4fe-320f1219ab21,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/0221505_s000_Keppra.cfm,
1973,OPILL,NORGESTREL,NDA017031,69dfa2ac-6a7e-4587-929c-9acabd97973b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/017031Orig1s041SumR.pdf,
1985,OMNIPAQUE,IOHEXOL,NDA018956,eee15ebe-d349-4497-acef-6abe7a8247fb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/18956a_s043_061595.pdf,
1985,OMNIPAQUE,IOHEXOL,NDA018956,eee15ebe-d349-4497-acef-6abe7a8247fb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018956-S28_Omnipaque_toc.cfm,
2017,LYRICA CR,PREGABALIN,NDA209501,2d832165-3d98-497c-84b0-2d9ae3f838f9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209501Orig1s000TOC.cfm,
2020,N/A,N/A,NDA210875,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210875Orig1s000TOC.cfm,
1995,TAGAMET,CIMETIDINE,NDA020238,c8ba8815-9d99-439f-b397-3869f729d9f4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020238_s013_TAGAMET HB.pdf,
2020,BYFAVO,REMIMAZOLAM BESYLATE,NDA212295,4e1838f2-b999-41a7-a761-d94f09aa531f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212295Orig1s000TOC.cfm,
2016,AMJEVITA,ADALIMUMAB-ATTO,BLA761024,d7862491-2634-4402-b001-dcc1abf8dd58,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761024_toc.cfm,
2016,AMJEVITA,ADALIMUMAB-ATTO,BLA761024,d7862491-2634-4402-b001-dcc1abf8dd58,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22_761024 adalimumab-atto DPARP CDTL clinical prea.pdf,
2016,AMJEVITA,ADALIMUMAB-ATTO,BLA761024,d7862491-2634-4402-b001-dcc1abf8dd58,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/23_761024 adalimumab-atto gi clinical prea.pdf,
2016,AMJEVITA,ADALIMUMAB-ATTO,BLA761024,d7862491-2634-4402-b001-dcc1abf8dd58,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21_761024 adalimumab-atto Clinical prea.pdf,
2016,AMJEVITA,ADALIMUMAB-ATTO,BLA761024,d7862491-2634-4402-b001-dcc1abf8dd58,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20_761024 adalimumab-atto clinical DD prea.pdf,
2016,AMJEVITA,ADALIMUMAB-ATTO,BLA761024,d7862491-2634-4402-b001-dcc1abf8dd58,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/19_761024 adalimumab atto DPARP clinpharm prea.pdf,
2016,AMJEVITA,ADALIMUMAB-ATTO,BLA761024,d7862491-2634-4402-b001-dcc1abf8dd58,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/19_761024 adalimumab atto DPARP clinpharm prea.pdf,
2016,AMJEVITA,ADALIMUMAB-ATTO,BLA761024,d7862491-2634-4402-b001-dcc1abf8dd58,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/26_761024 adalimumab-atto statistical prea.pdf,
2016,AMJEVITA,ADALIMUMAB-ATTO,BLA761024,d7862491-2634-4402-b001-dcc1abf8dd58,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/24_761024 adalimumab-atto statistical 2 prea.pdf,
2016,AMJEVITA,ADALIMUMAB-ATTO,BLA761024,d7862491-2634-4402-b001-dcc1abf8dd58,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/25_761024 adalimumab-atto statistical 3 prea.pdf,
2016,AMJEVITA,ADALIMUMAB-ATTO,BLA761024,d7862491-2634-4402-b001-dcc1abf8dd58,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/Amgen-Clinical-Pharmacology-Review.pdf,
2021,LUMAKRAS,SOTORASIB,NDA214665,c80a362c-7ac3-4894-a076-0691e68ef8c1,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/214665Orig1s009.pdf,
2021,LUMAKRAS,SOTORASIB,NDA214665,c80a362c-7ac3-4894-a076-0691e68ef8c1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000TOC.cfm,
2023,HYDROMORPHONE HYDROCHLORIDE,HYDROMORPHONE HYDROCHLORIDE,NDA217812,c729424e-e483-4bf8-b86c-ce56636dcffa,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217812Orig1s000TOC.cfm,
2024,RINVOQ,UPADACITINIB,NDA218347,2966aec7-2ef0-923c-d8ff-fe1a957bf095,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/218347Orig1s000TOC.cfm,
2009,N/A,N/A,NDA022266,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022266_onsolis_toc.cfm,
2009,N/A,N/A,NDA022266,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022266s000_SumR_P1.pdf,
2025,IMAAVY,NIPOCALIMAB,BLA761430,8886274c-f2b2-48af-85c1-2f90bfe304b8,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761430Orig1s000TOC.cfm,
2006,MOVIPREP,"POLYETHYLENE GLYCOL 3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, ASCORBIC ACID, SODIUM ASCORBATE",NDA021881,8ff46193-2a3b-4de0-9572-775dda8cd8b2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021881_moviprep_toc.cfm,
1979,TRANSDERM SCOP,SCOPOLAMINE,NDA017874,b877a694-a1d0-4280-937a-a06820b12a88,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/017874_S018 & S027_SCOPOLAMINE_AP.pdf,
1979,TRANSDERM SCOP,SCOPOLAMINE,NDA017874,b877a694-a1d0-4280-937a-a06820b12a88,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/017874_S018 & S027_SCOPOLAMINE_AP.pdf,
2013,DESOXIMETASONE,DESOXIMETASONE,NDA204141,b046ab97-ba1a-4be6-a238-09670b38b397,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204141Orig1s000SumR.pdf,
2013,DESOXIMETASONE,DESOXIMETASONE,NDA204141,b046ab97-ba1a-4be6-a238-09670b38b397,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204141_topicort_toc.cfm,
2015,VELTASSA,PATIROMER,NDA205739,bf002984-d6c9-46df-aecb-a07733f763c1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205739Orig1s000TOC.cfm,
2018,N/A,N/A,NDA209844,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209844Orig1s000TOC.cfm,
2020,ESOMEPRAZOLE,ESOMEPRAZOLE,NDA214278,3922a971-b371-4159-8c34-369798809965,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214278Orig1s000TOC.cfm,
2020,GALLIUM GA-68 PSMA-11,GALLIUM GA-68 GOZETOTIDE,NDA212642,7744bafb-755e-29a2-e053-2991aa0a86a9,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212642Orig1s000TOC.cfm,
2021,AMONDYS 45,CASIMERSEN,NDA213026,e9e5fd44-eeda-4580-bba1-a734828bbcc3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213026Orig1s000TOC.cfm,
2015,PRAXBIND,IDARUCIZUMAB,BLA761025,c7400f8a-dcf4-a6df-6d07-983081b1bf34,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/0761025Orig1000TOC.cfm,
2023,ZURZUVAE,ZURANOLONE,NDA217369,f18e53b0-d0bb-422d-8de7-ab64b7292b29,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217369Orig2s000TOC.cfm,
2025,ENFLONSIA,CLESROVIMAB,BLA761432,c9004a92-40e8-4cdb-b22d-d07929f8fc3b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761432Orig1s000TOC.cfm,
2000,TAZORAC,TAZAROTENE,NDA021184,021744d1-a6d7-4ad6-99c2-7187c24e64c6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-184S001_Tazorac.cfm,
2000,TAZORAC,TAZAROTENE,NDA021184,021744d1-a6d7-4ad6-99c2-7187c24e64c6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-184s002_Avage.cfm,
2000,TAZORAC,TAZAROTENE,NDA021184,021744d1-a6d7-4ad6-99c2-7187c24e64c6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-184_Tazorac.cfm,
2005,MYCAMINE,MICAFUNGIN SODIUM,NDA021506,a064c4a7-25ec-4a2c-afc2-703491a4a38b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021506s015 micafungin Mycamine clinical bpca.pdf,
2005,MYCAMINE,MICAFUNGIN SODIUM,NDA021506,a064c4a7-25ec-4a2c-afc2-703491a4a38b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021506s015 micafungin Mycamine clinpharm bpca.pdf,
2005,MYCAMINE,MICAFUNGIN SODIUM,NDA021506,a064c4a7-25ec-4a2c-afc2-703491a4a38b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021506s015 micafungin Mycamine statistical bpca.pdf,
2005,MYCAMINE,MICAFUNGIN SODIUM,NDA021506,a064c4a7-25ec-4a2c-afc2-703491a4a38b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21-506_Mycamine.cfm,
2005,EXJADE,DEFERASIROX,NDA021882,3495a70c-870c-4968-940e-8baea152cf85,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021882_s000_ExjadeTOC.cfm,
2005,EXJADE,DEFERASIROX,NDA021882,3495a70c-870c-4968-940e-8baea152cf85,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21882 deferasirox clinical prea.pdf,
2005,EXJADE,DEFERASIROX,NDA021882,3495a70c-870c-4968-940e-8baea152cf85,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21882 deferasirox clinpharm prea.pdf,
2005,EXJADE,DEFERASIROX,NDA021882,3495a70c-870c-4968-940e-8baea152cf85,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21882 deferasirox statistical prea.pdf,
1996,N/A,N/A,NDA050706,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/050706Orig1s034.pdf,
1996,N/A,N/A,NDA050706,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/050706_S018_MERREM.pdf,
1989,N/A,N/A,NDA019653,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/019653_s018_ORTHO CYCLEN.pdf,
1989,N/A,N/A,NDA019653,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019653_s032_ORTHOCYCLEN.pdf,
1989,N/A,N/A,NDA019653,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/019653_s024_ORTHO CYCLEN.pdf,
1989,N/A,N/A,NDA019653,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/019653_s016_ORTHO CYCLEN.pdf,
1989,N/A,N/A,NDA019653,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/019653_s030_ORTHO CYCLEN.pdf,
1989,N/A,N/A,NDA019653,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/019653_s022_ORTHO CYCLEN.pdf,
1989,N/A,N/A,NDA019653,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/019653_s020_ORTHOCYCLEN.pdf,
1989,N/A,N/A,NDA019653,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/019653_s035_ORTHOCYCLEN.pdf,
1989,N/A,N/A,NDA019653,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/019653_s027_ORTHO CYCLEN.pdf,
1989,N/A,N/A,NDA019653,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019653_s033_ORTHOCYCLEN.pdf,
1989,N/A,N/A,NDA019653,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/019653_s017_ORTHOCYCLEN.pdf,
1989,N/A,N/A,NDA019653,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019653_s031_ORTHO CYCLEN.pdf,
1989,N/A,N/A,NDA019653,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/019653_s023_ORTHOCYCLEN.pdf,
1989,N/A,N/A,NDA019653,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/019653_s021_ORTHOCYCLEN.pdf,
2013,N/A,N/A,NDA203791,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203791Orig1s000TOC.cfm,
2013,N/A,N/A,NDA203791,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203791Orig1s000SumR.pdf,
1954,PURIFIED CORTROPHIN GEL,REPOSITORY CORTICOTROPIN,NDA008975,f27544ee-a0e2-4d84-b193-1c9efdf9e34c,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/008975Orig1s008.pdf,
2016,AXUMIN,FLUCICLOVINE F-18,NDA208054,389a502e-a7d5-43dd-b6bf-f022ff23f3b9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208054Orig1s000TOC.cfm,
2016,AXUMIN,FLUCICLOVINE F-18,NDA208054,389a502e-a7d5-43dd-b6bf-f022ff23f3b9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208054Orig1s000SumR.pdf,
2017,CLOROTEKAL,CHLOROPROCAINE HYDROCHLORIDE,NDA208791,90f7a095-f6db-456b-951f-9aee54c5dbc0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208791Orig1s000TOC.cfm,
2020,BARHEMSYS,AMISULPRIDE,NDA209510,ab23bc6e-b6a8-165f-e053-2a95a90ab144,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000TOC.cfm,
2020,DURYSTA,BIMATOPROST,NDA211911,3f59da84-0bcc-4c84-b3e2-e215681ef341,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/211911Orig1s000TOC.cfm,
2021,N/A,N/A,NDA213426,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/213426Orig1s000TOC.cfm,
2016,CINQAIR,RESLIZUMAB,BLA761033,053b9158-2a5b-48b9-bf47-5fa78a35ec33,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761033Orig1s000SumR.pdf,
2016,CINQAIR,RESLIZUMAB,BLA761033,053b9158-2a5b-48b9-bf47-5fa78a35ec33,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/761033 reslizumab clinical prea.pdf,
2016,CINQAIR,RESLIZUMAB,BLA761033,053b9158-2a5b-48b9-bf47-5fa78a35ec33,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/761033 reslizumab clinpharm prea.pdf,
2016,CINQAIR,RESLIZUMAB,BLA761033,053b9158-2a5b-48b9-bf47-5fa78a35ec33,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/761033 reslizumab statistical prea.pdf,
2016,CINQAIR,RESLIZUMAB,BLA761033,053b9158-2a5b-48b9-bf47-5fa78a35ec33,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761033Orig1s000TOC.cfm,
1996,INFANTS MOTRIN,IBUPROFEN,NDA020603,c2302bfe-b367-4867-b803-29f066a42dc7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-603s002_Ibuprofen.cfm,
1996,INFANTS MOTRIN,IBUPROFEN,NDA020603,c2302bfe-b367-4867-b803-29f066a42dc7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-603S3_InfantsMotrin.pdf,
1996,INFANTS MOTRIN,IBUPROFEN,NDA020603,c2302bfe-b367-4867-b803-29f066a42dc7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20-603s001_Ibuprofen.cfm,
2009,SAMSCA,TOLVAPTAN,NDA022275,5526617c-c7b9-4556-886d-729bbabbc566,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022275s000TOC.cfm,
2009,SAMSCA,TOLVAPTAN,NDA022275,5526617c-c7b9-4556-886d-729bbabbc566,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022275s000_SumR.pdf,
2002,SODIUM OXYBATE,SODIUM OXYBATE,NDA021196,a6c17f6f-46bc-4852-a825-07f49cc08495,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-196_Xyrem.cfm,
2002,SODIUM OXYBATE,SODIUM OXYBATE,NDA021196,a6c17f6f-46bc-4852-a825-07f49cc08495,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/021196Orig1s030.pdf,
2002,SODIUM OXYBATE,SODIUM OXYBATE,NDA021196,a6c17f6f-46bc-4852-a825-07f49cc08495,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021196s005.pdf,
2002,SODIUM OXYBATE,SODIUM OXYBATE,NDA021196,a6c17f6f-46bc-4852-a825-07f49cc08495,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/021196Orig1s019.pdf,
2002,SODIUM OXYBATE,SODIUM OXYBATE,NDA021196,a6c17f6f-46bc-4852-a825-07f49cc08495,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021196Orig1s013.pdf,
2006,METHYLPHENIDATE TRANSDERMAL SYSTEM,METHYLPHENIDATE,NDA021514,7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/021514Orig1s017.pdf,
2006,METHYLPHENIDATE TRANSDERMAL SYSTEM,METHYLPHENIDATE,NDA021514,7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/021514Orig1s023.pdf,
2006,METHYLPHENIDATE TRANSDERMAL SYSTEM,METHYLPHENIDATE,NDA021514,7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21514_Methylphenidate_Clinical_PREA.pdf,
2006,METHYLPHENIDATE TRANSDERMAL SYSTEM,METHYLPHENIDATE,NDA021514,7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21514_Methylphenidate_Clinpharm_PREA.pdf,
2006,METHYLPHENIDATE TRANSDERMAL SYSTEM,METHYLPHENIDATE,NDA021514,7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21514_Methylphenidate_Statistical_PREA.pdf,
2006,METHYLPHENIDATE TRANSDERMAL SYSTEM,METHYLPHENIDATE,NDA021514,7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21514_Methylphenidate_ClinicalMTL_PREA.pdf,
2006,METHYLPHENIDATE TRANSDERMAL SYSTEM,METHYLPHENIDATE,NDA021514,7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021514_daytrana_toc.cfm,
2006,CLARITIN CHEWABLE GRAPE AND BUBBLEGUM,LORATADINE,NDA021891,0371368b-dca6-af2f-e063-6394a90a0ac0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021891s000TOC.cfm,
1990,LUPRON DEPOT,LEUPROLIDE ACETATE,NDA020011,00c486b0-bd7b-4898-834d-8c656e5e73cb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-011S021_Lupron.cfm,
1990,LUPRON DEPOT,LEUPROLIDE ACETATE,NDA020011,00c486b0-bd7b-4898-834d-8c656e5e73cb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20011-s014_Lupron.cfm,
2017,NERLYNX,NERATINIB,NDA208051,d1e41dcf-e82a-47c2-a0ad-6c6eef621834,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208051Orig1s000TOC.cfm,
2019,SUNOSI,SOLRIAMFETOL,NDA211230,362f206b-73e7-4009-8c34-5a9df55679ab,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000TOC.cfm,
2019,SUNOSI,SOLRIAMFETOL,NDA211230,362f206b-73e7-4009-8c34-5a9df55679ab,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000TOC.cfm,
2023,SOHONOS,PALOVAROTENE,NDA215559,67dce406-7cc4-4d66-92de-ad18b6df0625,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215559Orig1s000TOC.cfm,
2013,ALOGLIPTIN,ALOGLIPTIN,NDA022271,b25f155a-1259-47c2-aa3b-7c1356e4c7f6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000SumR.pdf,
2013,ALOGLIPTIN,ALOGLIPTIN,NDA022271,b25f155a-1259-47c2-aa3b-7c1356e4c7f6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000TOC.cfm,
2002,N/A,N/A,NDA021511,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21511 ribavirin clinical prea-Dawn.pdf,
2002,N/A,N/A,NDA021511,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21511 ribavirin clinpharm prea.pdf,
2002,N/A,N/A,NDA021511,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21511 ribavirin clinical prea-Dawn (1).pdf,
2002,N/A,N/A,NDA021511,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-511_Copegus.cfm,
1965,ERYTHROMYCIN ETHYLSUCCINATE,ERYTHROMYCIN ETHYLSUCCINATE,NDA050207,f4a3fffd-ce02-450f-bbcc-d425374e3e32,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-207s054s055_Erythromycin.cfm,
1965,ERYTHROMYCIN ETHYLSUCCINATE,ERYTHROMYCIN ETHYLSUCCINATE,NDA050207,f4a3fffd-ce02-450f-bbcc-d425374e3e32,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-207s054s055_Erythromycin.cfm,
1994,PROGRAF,TACROLIMUS,NDA050709,7f667de1-9dfa-4bd6-8ba0-15ee2d78873b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/050709Orig1s021_StatR.pdf,
1994,PROGRAF,TACROLIMUS,NDA050709,7f667de1-9dfa-4bd6-8ba0-15ee2d78873b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/050709_prograf_toc.cfm,
1994,PROGRAF,TACROLIMUS,NDA050709,7f667de1-9dfa-4bd6-8ba0-15ee2d78873b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/050708Orig1s053; 050709Orig1s045; 210115Orig1s005.pdf,
1984,MARCAINE SPINAL,BUPIVACAINE HYDROCHLORIDE IN DEXTROSE,NDA018692,9679cc05-2f8a-4e88-53b5-6e9122c8b8c0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018692Orig1s000.pdf,
2012,ERIVEDGE,VISMODEGIB,NDA203388,eb368bb6-80e3-4df9-8a85-91df0a2ada6a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203388Orig1s000TOC.cfm,
2014,N/A,N/A,NDA204886,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204886Orig1s000TOC.cfm,
2014,N/A,N/A,NDA204886,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204886Orig1s000SumR.pdf,
2015,ALECENSA,ALECTINIB HYDROCHLORIDE,NDA208434,42c49deb-713b-427a-9670-08af08adcffb,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/208434Orig1s015MultidisciplineR.pdf,
2015,ALECENSA,ALECTINIB HYDROCHLORIDE,NDA208434,42c49deb-713b-427a-9670-08af08adcffb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208434Orig1s000TOC.cfm,
2015,ALECENSA,ALECTINIB HYDROCHLORIDE,NDA208434,42c49deb-713b-427a-9670-08af08adcffb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208434Orig1s000SumR.pdf,
2016,N/A,N/A,BLA761029,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761029Orig1s000TOC.cfm,
2016,N/A,N/A,BLA761029,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761029Orig1s000SumR.pdf,
2023,PREVDUO,NEOSTIGMINE METHYLSULFATE AND GLYCOPYRROLATE,NDA216903,dd8ad38f-247b-4948-a13c-8f3a4921b4f1,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216903Orig1s000TOC.cfm,
1997,N/A,N/A,NDA020729,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020729_S010_UNIRETIC.pdf,
2010,OXYCONTIN,OXYCODONE HYDROCHLORIDE,NDA022272,bfdfe235-d717-4855-a3c8-a13d26dadede,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022272s000SumR.pdf,
2010,OXYCONTIN,OXYCODONE HYDROCHLORIDE,NDA022272,bfdfe235-d717-4855-a3c8-a13d26dadede,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22272 oxycodone clinical bpca.pdf,
2010,OXYCONTIN,OXYCODONE HYDROCHLORIDE,NDA022272,bfdfe235-d717-4855-a3c8-a13d26dadede,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22272  oxycodone clinpharm bpca.pdf,
2010,OXYCONTIN,OXYCODONE HYDROCHLORIDE,NDA022272,bfdfe235-d717-4855-a3c8-a13d26dadede,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22272 oxycodone statistical bpca.pdf,
2010,OXYCONTIN,OXYCODONE HYDROCHLORIDE,NDA022272,bfdfe235-d717-4855-a3c8-a13d26dadede,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022272s000TOC.cfm,
2010,OXYCONTIN,OXYCODONE HYDROCHLORIDE,NDA022272,bfdfe235-d717-4855-a3c8-a13d26dadede,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022272Orig1s027TOC.cfm,
2010,OXYCONTIN,OXYCODONE HYDROCHLORIDE,NDA022272,bfdfe235-d717-4855-a3c8-a13d26dadede,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022272Orig1s014TOC.cfm,
1995,ZITHROMAX,AZITHROMYCIN DIHYDRATE,NDA050710,db52b91e-79f7-4cc1-9564-f2eee8e31c45,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50-710S011_50-711S009_Zithromax.cfm,
2013,PROCYSBI,CYSTEAMINE BITARTRATE,NDA203389,d3a3ec28-f746-463a-bb92-3bc8826db09e,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/224_203389S20 cysteamine clinical bpca.pdf,
2013,PROCYSBI,CYSTEAMINE BITARTRATE,NDA203389,d3a3ec28-f746-463a-bb92-3bc8826db09e,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/230_203389S20 cysteamine clinpharm bpca.pdf,
2013,PROCYSBI,CYSTEAMINE BITARTRATE,NDA203389,d3a3ec28-f746-463a-bb92-3bc8826db09e,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/229_203389S20 cysteamine statistical bpca.pdf,
2013,PROCYSBI,CYSTEAMINE BITARTRATE,NDA203389,d3a3ec28-f746-463a-bb92-3bc8826db09e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203389Orig1s000TOC.cfm,
2013,PROCYSBI,CYSTEAMINE BITARTRATE,NDA203389,d3a3ec28-f746-463a-bb92-3bc8826db09e,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/203389 cysteamine clinical bpca.pdf,
2013,PROCYSBI,CYSTEAMINE BITARTRATE,NDA203389,d3a3ec28-f746-463a-bb92-3bc8826db09e,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/203389 cysteamine clinpharm bpca.pdf,
2013,PROCYSBI,CYSTEAMINE BITARTRATE,NDA203389,d3a3ec28-f746-463a-bb92-3bc8826db09e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203389Orig1s000SumR.pdf,
2013,DESVENLAFAXINE,DESVENLAFAXINE,NDA204150,91cf39c9-4d26-480a-a3a3-a3d8d4c4d222,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204150_desvenlafaxine_toc.cfm,
2013,DESVENLAFAXINE,DESVENLAFAXINE,NDA204150,91cf39c9-4d26-480a-a3a3-a3d8d4c4d222,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204150Orig1s000SumR.pdf,
2015,JADENU,DEFERASIROX,NDA206910,fee89140-fff1-4443-9f42-24ac004fcda1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206910Orig1s000TOC.cfm,
1989,N/A,N/A,NDA019860,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/019860_S020_IMODIUM_CHEWABLE_TABLETS.pdf,
2019,TOSYMRA,SUMATRIPTAN,NDA210884,015a5cf9-f246-48bc-b91e-cd730a53d8aa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210884Orig1s000TOC.cfm,
2020,N/A,N/A,NDA213036,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213036Orig1s000TOC.cfm,
2017,SILIQ,BRODALUMAB,BLA761032,1a550c33-456a-4833-814e-8591aea7c688,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761032Orig1s000TOC.cfm,
1997,N/A,N/A,NDA020667,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020667.cfm,
1997,N/A,N/A,NDA020667,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/review/2018/020667Orig1s000_LBL.pdf,
1997,N/A,N/A,NDA020667,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020667_S008_MirapexTOC.cfm,
2000,LESCOL XL,FLUVASTATIN SODIUM,NDA021192,726ea2db-f1b0-4b73-a515-02157db88a42,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021192_s003_LESCOL_CAPSULES.pdf,
2000,LESCOL XL,FLUVASTATIN SODIUM,NDA021192,726ea2db-f1b0-4b73-a515-02157db88a42,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-192_Lescol.cfm,
2000,LESCOL XL,FLUVASTATIN SODIUM,NDA021192,726ea2db-f1b0-4b73-a515-02157db88a42,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021192s019.pdf,
2000,LESCOL XL,FLUVASTATIN SODIUM,NDA021192,726ea2db-f1b0-4b73-a515-02157db88a42,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021192_s004_LESCOL_CAPSULES.pdf,
2004,N/A,N/A,NDA021513,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex.cfm,
2007,ALLI,ORLISTAT,NDA021887,a2d3bd73-f3af-4ea5-a57c-66b0004cfe4f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021887s000TOC.cfm,
1996,ZITHROMAX,AZITHROMYCIN DIHYDRATE,NDA050711,db52b91e-79f7-4cc1-9564-f2eee8e31c45,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50-710S011_50-711S009_Zithromax.cfm,
1996,ZITHROMAX,AZITHROMYCIN DIHYDRATE,NDA050711,db52b91e-79f7-4cc1-9564-f2eee8e31c45,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/050711_Original_ap_pkg.PDF,
1961,GLYCOPYRROLATE,GLYCOPYRROLATE,NDA012827,58c4cb1f-59b8-4be9-a222-2264ca077d93,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/012827_s015_Robinul - Robinul_Forte_Tabs.pdf,
1961,GLYCOPYRROLATE,GLYCOPYRROLATE,NDA012827,58c4cb1f-59b8-4be9-a222-2264ca077d93,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/012827_s009_s010_s011_Robinul & Robinul Forte_Tablets.pdf,
1961,GLYCOPYRROLATE,GLYCOPYRROLATE,NDA012827,58c4cb1f-59b8-4be9-a222-2264ca077d93,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/012827_s009_s010_s011_Robinul%20&%20Robinul%20Forte_Tablets.pdf,
1961,GLYCOPYRROLATE,GLYCOPYRROLATE,NDA012827,58c4cb1f-59b8-4be9-a222-2264ca077d93,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/012827_s032&s033_Robinul & Robinul Forte Tablets.pdf,
1961,GLYCOPYRROLATE,GLYCOPYRROLATE,NDA012827,58c4cb1f-59b8-4be9-a222-2264ca077d93,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/012827_s024&s025_Robinul_Robinul_Forte_Tabs.pdf,
1961,GLYCOPYRROLATE,GLYCOPYRROLATE,NDA012827,58c4cb1f-59b8-4be9-a222-2264ca077d93,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/012827_s014_Robinul_Forte_Tabs.pdf,
1961,GLYCOPYRROLATE,GLYCOPYRROLATE,NDA012827,58c4cb1f-59b8-4be9-a222-2264ca077d93,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/012827_s009_s010_s011_Robinul%20&%20Robinul%20Forte_Tablets.pdf,
1961,GLYCOPYRROLATE,GLYCOPYRROLATE,NDA012827,58c4cb1f-59b8-4be9-a222-2264ca077d93,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/012827_s035_Robinul Forte Tablets.pdf,
1961,GLYCOPYRROLATE,GLYCOPYRROLATE,NDA012827,58c4cb1f-59b8-4be9-a222-2264ca077d93,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/012827_s032&s033_Robinul & Robinul Forte Tablets.pdf,
1961,GLYCOPYRROLATE,GLYCOPYRROLATE,NDA012827,58c4cb1f-59b8-4be9-a222-2264ca077d93,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/012827_s024&s025_Robinul_Robinul_Forte_Tabs.pdf,
1961,GLYCOPYRROLATE,GLYCOPYRROLATE,NDA012827,58c4cb1f-59b8-4be9-a222-2264ca077d93,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/012827_s017_Robinul-Robinul_Forte_Tabs.pdf,
1978,TIMOPTIC,TIMOLOL MALEATE,NDA018086,45ac65b3-19f7-4f33-aebf-cadd3daa4bf1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/018086_s060_TimopticTOC.cfm,
1978,TIMOPTIC,TIMOLOL MALEATE,NDA018086,45ac65b3-19f7-4f33-aebf-cadd3daa4bf1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/18-086S052.pdf,
1978,TIMOPTIC,TIMOLOL MALEATE,NDA018086,45ac65b3-19f7-4f33-aebf-cadd3daa4bf1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/18-086S047.pdf,
1986,VASERETIC,ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE,NDA019221,bf3007e2-8fcc-48de-8fd5-55e95033d62f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/18-998s058_Vasotec.cfm,
1986,VASERETIC,ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE,NDA019221,bf3007e2-8fcc-48de-8fd5-55e95033d62f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/19221s024.pdf,
1986,VASERETIC,ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE,NDA019221,bf3007e2-8fcc-48de-8fd5-55e95033d62f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20507-s001_Teczem.pdf,
1986,VASERETIC,ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE,NDA019221,bf3007e2-8fcc-48de-8fd5-55e95033d62f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019221_s023ap.pdf,
2012,N/A,N/A,NDA201922,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/201922_ximino_toc.cfm,
2012,N/A,N/A,NDA201922,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/201922Orig1s000SumR.pdf,
2015,CHOLBAM,CHOLIC ACID,NDA205750,e5b67402-8550-4604-97a0-c7b149fbf753,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205750Orig1s000TOC.cfm,
2017,ARMONAIR DIGIHALER,FLUTICASONE PROPIONATE,NDA208798,5cea205f-e6d4-45e8-bfcc-a12a6907d5bb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208798Orig1s000TOC.cfm,
2017,ARMONAIR DIGIHALER,FLUTICASONE PROPIONATE,NDA208798,5cea205f-e6d4-45e8-bfcc-a12a6907d5bb,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208798 ArmonAir Clinical prea.pdf,
2017,ARMONAIR DIGIHALER,FLUTICASONE PROPIONATE,NDA208798,5cea205f-e6d4-45e8-bfcc-a12a6907d5bb,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208798 ArmonAir Clinpharm prea.pdf,
2017,ARMONAIR DIGIHALER,FLUTICASONE PROPIONATE,NDA208798,5cea205f-e6d4-45e8-bfcc-a12a6907d5bb,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208798 ArmonAir statistical prea.pdf,
2019,N/A,N/A,NDA210895,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210895Orig1s000TOC.cfm,
2019,N/A,N/A,NDA210895,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/422_210895 colesevelam clinpharm prea.pdf,
2019,N/A,N/A,NDA210895,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/210895 colesevelam clinical prea.pdf,
2019,N/A,N/A,NDA210895,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/210895_colesevelam CDTL prea.pdf,
1995,GENOTROPIN,SOMATROPIN,BLA020280,ffebf88b-d257-4542-9808-74d9b7167765,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020280_s049_genotropin_medr.pdf,
1995,GENOTROPIN,SOMATROPIN,BLA020280,ffebf88b-d257-4542-9808-74d9b7167765,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-280S031_Genotropin.cfm,
1995,GENOTROPIN,SOMATROPIN,BLA020280,ffebf88b-d257-4542-9808-74d9b7167765,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020280s008.pdf,
1995,GENOTROPIN,SOMATROPIN,BLA020280,ffebf88b-d257-4542-9808-74d9b7167765,http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/020280se1-060_SUMR.pdf,
1994,N/A,N/A,NDA020363,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-363S-019_review.pdf,
1994,N/A,N/A,NDA020363,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020363_Famciclovir_Clinpharm_BPCA.pdf,
1994,N/A,N/A,NDA020363,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020363_Famciclovir_Clinical_BPCA.pdf,
2017,KEVZARA,SARILUMAB,BLA761037,827bc01c-d379-4266-a18c-c7f904b76af3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761037Orig1s000TOC.cfm,
2023,WAINUA,EPLONTERSEN,NDA217388,d7dcb847-71dd-4fff-82d0-d43a465fc096,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217388Orig1s000TOC.cfm,
2009,N/A,N/A,NDA022278,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022278_membraneblue_toc.cfm,
1998,MAXALT,RIZATRIPTAN BENZOATE,NDA020864,007b4644-e0e7-4863-9ae3-fe09676b3f5f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20864S-007.pdf,
1998,MAXALT,RIZATRIPTAN BENZOATE,NDA020864,007b4644-e0e7-4863-9ae3-fe09676b3f5f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20864S-005.pdf,
1998,MAXALT,RIZATRIPTAN BENZOATE,NDA020864,007b4644-e0e7-4863-9ae3-fe09676b3f5f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20864-20865.cfm,
1998,MAXALT,RIZATRIPTAN BENZOATE,NDA020864,007b4644-e0e7-4863-9ae3-fe09676b3f5f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20864---20865-Rizatriptan-Clinical-BPCA.pdf,
1998,MAXALT,RIZATRIPTAN BENZOATE,NDA020864,007b4644-e0e7-4863-9ae3-fe09676b3f5f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20864-and-20865-Rizatriptan-Clinical-1-BPCA.pdf,
1998,MAXALT,RIZATRIPTAN BENZOATE,NDA020864,007b4644-e0e7-4863-9ae3-fe09676b3f5f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20864-and-20865-Rizatriptan-Clinpharm-BPCA.pdf,
1998,MAXALT,RIZATRIPTAN BENZOATE,NDA020864,007b4644-e0e7-4863-9ae3-fe09676b3f5f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20864-and-20865-Rizatriptan-CTDL-Addendum-BPCA.pdf,
1998,MAXALT,RIZATRIPTAN BENZOATE,NDA020864,007b4644-e0e7-4863-9ae3-fe09676b3f5f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20864-and-20865-Rizatriptan-CTDL-Clinical-BPCA.pdf,
1998,MAXALT,RIZATRIPTAN BENZOATE,NDA020864,007b4644-e0e7-4863-9ae3-fe09676b3f5f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20864-and-20865-Rizatriptan-DD-Memo-BPCA.pdf,
1998,MAXALT,RIZATRIPTAN BENZOATE,NDA020864,007b4644-e0e7-4863-9ae3-fe09676b3f5f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20864-and-20865-Rizatriptan-Statistical-BPCA.pdf,
1998,MAXALT,RIZATRIPTAN BENZOATE,NDA020864,007b4644-e0e7-4863-9ae3-fe09676b3f5f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20864-and-20865-Rizatriptan-Statistical-2-BPCA.pdf,
1998,MAXALT,RIZATRIPTAN BENZOATE,NDA020864,007b4644-e0e7-4863-9ae3-fe09676b3f5f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020864_s008_MAXALT_TABLETS.pdf,
1998,MAXALT,RIZATRIPTAN BENZOATE,NDA020864,007b4644-e0e7-4863-9ae3-fe09676b3f5f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-864S004_review.pdf,
1998,MAXALT,RIZATRIPTAN BENZOATE,NDA020864,007b4644-e0e7-4863-9ae3-fe09676b3f5f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-864S004_review.pdf,
2010,ASCLERA,POLIDOCANOL,NDA021201,bb1f342b-5352-4059-a0b2-e60fd652fd28,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021201s000TOC.cfm,
2010,ASCLERA,POLIDOCANOL,NDA021201,bb1f342b-5352-4059-a0b2-e60fd652fd28,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021201s000_Sumr.pdf,
2007,FLUVOXAMINE MALEATE,FLUVOXAMINE MALEATE,NDA021519,7ecd83ec-88f5-4f85-9cc2-9068375d8820,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021519_luvox_toc.cfm,
2007,FLUVOXAMINE MALEATE,FLUVOXAMINE MALEATE,NDA021519,7ecd83ec-88f5-4f85-9cc2-9068375d8820,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021519s000_SumR.pdf,
1995,DOXORUBICIN HYDROCHLORIDE LIPOSOME,DOXORUBICIN HYDROCHLORIDE LIPOSOME,NDA050718,cf25a018-e795-49e4-8533-a581f8366dd9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/050718Orig1s019.pdf,
1995,DOXORUBICIN HYDROCHLORIDE LIPOSOME,DOXORUBICIN HYDROCHLORIDE LIPOSOME,NDA050718,cf25a018-e795-49e4-8533-a581f8366dd9,http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/050718se7-033_SUMR.pdf,
1995,DOXORUBICIN HYDROCHLORIDE LIPOSOME,DOXORUBICIN HYDROCHLORIDE LIPOSOME,NDA050718,cf25a018-e795-49e4-8533-a581f8366dd9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/050718Orig1s046.pdf,
1995,DOXORUBICIN HYDROCHLORIDE LIPOSOME,DOXORUBICIN HYDROCHLORIDE LIPOSOME,NDA050718,cf25a018-e795-49e4-8533-a581f8366dd9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/050718Orig1s006.pdf,
1995,DOXORUBICIN HYDROCHLORIDE LIPOSOME,DOXORUBICIN HYDROCHLORIDE LIPOSOME,NDA050718,cf25a018-e795-49e4-8533-a581f8366dd9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/050718Orig1s050.pdf,
2011,N/A,N/A,NDA201917,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201917Orig1s000TOC.cfm,
2011,N/A,N/A,NDA201917,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201917Orig1s000SumR.pdf,
1987,DOPAMINE HYDROCHLORIDE AND DEXTROSE,DOPAMINE HYDROCHLORIDE,NDA019615,cb97d4a0-89ed-407c-a763-209386b6f75c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/19615S012_Dopamine.pdf,
2015,N/A,N/A,NDA206510,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206510Orig1s000SumR.pdf,
2015,N/A,N/A,NDA206510,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/N206510-Lamivudine-and-Raltegravir-Clinical-PREA.pdf,
2015,N/A,N/A,NDA206510,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/N206510-Lamivudine-and-Raltegravir-Clinpharm-PREA.pdf,
2015,N/A,N/A,NDA206510,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206510Orig1s000TOC.cfm,
2013,LUZU,LULICONAZOLE,NDA204153,a7016010-ce43-4c09-8d21-aeb697ffed31,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/241_204153S4-luliconazole-CDTL-clinical-prea.pdf,
2013,LUZU,LULICONAZOLE,NDA204153,a7016010-ce43-4c09-8d21-aeb697ffed31,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/240_204153S4-luliconazole-clinical-prea.pdf,
2013,LUZU,LULICONAZOLE,NDA204153,a7016010-ce43-4c09-8d21-aeb697ffed31,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/239_204153S4-luliconazole-clinpharm-prea.pdf,
2013,LUZU,LULICONAZOLE,NDA204153,a7016010-ce43-4c09-8d21-aeb697ffed31,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/238_204153S4-luliconazole-statistical-prea.pdf,
2013,LUZU,LULICONAZOLE,NDA204153,a7016010-ce43-4c09-8d21-aeb697ffed31,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/237_204153S5-luliconazole-CDTL-clinical-prea.pdf,
2013,LUZU,LULICONAZOLE,NDA204153,a7016010-ce43-4c09-8d21-aeb697ffed31,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/236_204153S5-luliconazole-clinical-prea.pdf,
2013,LUZU,LULICONAZOLE,NDA204153,a7016010-ce43-4c09-8d21-aeb697ffed31,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/235_204153S5-luliconazole-clinpharm-prea.pdf,
2013,LUZU,LULICONAZOLE,NDA204153,a7016010-ce43-4c09-8d21-aeb697ffed31,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204153Orig1s000TOC.cfm,
2013,LUZU,LULICONAZOLE,NDA204153,a7016010-ce43-4c09-8d21-aeb697ffed31,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204153Orig1s000SumR.pdf,
2015,HUMALOG TEMPO PEN,INSULIN LISPRO,BLA205747,c8ecbd7a-0e22-4fc7-a503-faa58c1b6f3f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205747Orig1s000TOC.cfm,
2016,SMOFLIPID,SMOFLIPID,NDA207648,e0e9d917-ff6f-488e-a6a8-0ad59dd17d80,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/207648Orig1s000TOC.cfm,
2017,XERMELO,TELOTRISTAT ETHYL,NDA208794,f9108ac3-ca6e-4faf-9d04-953abb64d072,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208794Orig1s000TOC.cfm,
2020,N/A,N/A,NDA209511,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/209511Orig1s000TOC.cfm,
2016,TECENTRIQ,ATEZOLIZUMAB,BLA761034,6fa682c9-a312-4932-9831-f286908660ee,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761034Orig1s000TOC.cfm,
2016,TECENTRIQ,ATEZOLIZUMAB,BLA761034,6fa682c9-a312-4932-9831-f286908660ee,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761034Orig1s000SumR.pdf,
2016,TECENTRIQ,ATEZOLIZUMAB,BLA761034,6fa682c9-a312-4932-9831-f286908660ee,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761034Orig1s019.pdf,
2021,EPRONTIA,TOPIRAMATE,NDA214679,37c8a54c-a803-d22f-e063-6294a90a8f5d,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214679Orig1s000TOC.cfm,
1996,VIVELLE-DOT,ESTRADIOL,NDA020538,5ccb77f9-d47b-4381-ad5c-5b92524e1c4a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20538S6.cfm,
1996,VIVELLE-DOT,ESTRADIOL,NDA020538,5ccb77f9-d47b-4381-ad5c-5b92524e1c4a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020538_s015_VivelleTOC.cfm,
2022,ZORYVE,ROFLUMILAST,NDA215985,ec1bb0d1-f38a-4080-831a-68791d1d1fdb,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215985Orig1s000TOC.cfm,
2008,NICARDIPINE HYDROCHLORIDE,NICARDIPINE HYDROCHLORIDE,NDA022276,55bd6dcc-1f12-4378-8e9e-1ceed26818f5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/022276Orig1s008.pdf,
2008,NICARDIPINE HYDROCHLORIDE,NICARDIPINE HYDROCHLORIDE,NDA022276,55bd6dcc-1f12-4378-8e9e-1ceed26818f5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022276s000_SumR.pdf,
2008,NICARDIPINE HYDROCHLORIDE,NICARDIPINE HYDROCHLORIDE,NDA022276,55bd6dcc-1f12-4378-8e9e-1ceed26818f5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022276s000TOC.cfm,
2025,N/A,N/A,BLA761464,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761464Orig1s000TOC.cfm,
2000,CETROTIDE,CETRORELIX ACETATE,NDA021197,aca7768e-28a7-4027-b1d8-e66247665f79,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-197_Cetrotide.cfm,
2003,WELLBUTRIN XL,BUPROPION HYDROCHLORIDE,NDA021515,a435da9d-f6e8-4ddc-897d-8cd2bf777b21,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021515_Wellbutrin.cfm,
2003,WELLBUTRIN XL,BUPROPION HYDROCHLORIDE,NDA021515,a435da9d-f6e8-4ddc-897d-8cd2bf777b21,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/018644s027s028,020358s031s032,021515s006s007_WellbutrinTOC.cfm",
2006,N/A,N/A,NDA021892,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021892_osmoprep_toc.cfm,
2006,N/A,N/A,NDA021892,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021892Orig1s003.pdf,
2014,N/A,N/A,NDA206088,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206088Orig1s000TOC.cfm,
2014,N/A,N/A,NDA206088,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206088Orig1s000SumR.pdf,
2012,N/A,N/A,NDA203794,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203794s005s006lbl.pdf#page=34,
2012,N/A,N/A,NDA203794,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203794_nucynta_toc.cfm,
2012,N/A,N/A,NDA203794,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203794Orig1s000SumR.pdf,
2012,N/A,N/A,NDA203794,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203794s005s006lbl.pdf#page=34,
2017,NORVIR,RITONAVIR,NDA209512,2849298e-de6e-47bb-8194-56e075b33fc3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209512Orig1s000TOC.cfm,
2016,BROMSITE 0.075%,BROMFENAC,NDA206911,144a5072-341b-4591-8705-773b63044bcc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206911Orig1s000TOC.cfm,
2017,N/A,N/A,NDA208437,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208437Orig1s000TOC.cfm,
2016,N/A,N/A,NDA208056,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208056Orig1s000TOC.cfm,
1997,RETIN-A MICRO,TRETINOIN,NDA020475,08ab7e0c-1437-455f-815c-98904d96a289,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/020475Org1s021.pdf,
1997,RETIN-A MICRO,TRETINOIN,NDA020475,08ab7e0c-1437-455f-815c-98904d96a289,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020475ap.pdf,
1995,TRETINOIN,TRETINOIN,NDA020438,1e29818c-1937-4e39-957a-4017fa9c6bdc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20438-S001_VESANOID_review.pdf,
2019,ABSORICA LD,ISOTRETINOIN,NDA211913,3ef0cff8-19c1-4441-b780-fca6c7ee1615,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211913Orig1s000TOC.cfm,
2022,ADLARITY,DONEPEZIL HYDROCHLORIDE,NDA212304,1cb44c65-00e8-4b5c-99c2-ad15173115a0,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/212304Orig1s000TOC.cfm,
2015,EMPLICITI,ELOTUZUMAB,BLA761035,80686b7e-f6f4-4154-b5c0-c846425e2d91,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/761035Orig1s000TOC.cfm,
2015,EMPLICITI,ELOTUZUMAB,BLA761035,80686b7e-f6f4-4154-b5c0-c846425e2d91,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/761035Orig1s000SumR.pdf,
2023,QLOSI,PILOCARPINE HYDROCHLORIDE,NDA217836,4ee2a840-1203-473a-aa42-316a3ddf2fbe,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217836Orig1s000TOC.cfm,
2009,TEMODAR,TEMOZOLOMIDE,NDA022277,046a9011-3911-4d3f-a15f-fbb56d5aad56,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022277s000_SumR.pdf,
2009,TEMODAR,TEMOZOLOMIDE,NDA022277,046a9011-3911-4d3f-a15f-fbb56d5aad56,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022277_temodar_toc.cfm,
2009,TEMODAR,TEMOZOLOMIDE,NDA022277,046a9011-3911-4d3f-a15f-fbb56d5aad56,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/021029Orig1s036,037,038,022277Orig1s017,018,019TOC.cfm",
2009,TEMODAR,TEMOZOLOMIDE,NDA022277,046a9011-3911-4d3f-a15f-fbb56d5aad56,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/021029Orig1s036,037,038,022277Orig1s017,018,019TOC.cfm",
2009,TEMODAR,TEMOZOLOMIDE,NDA022277,046a9011-3911-4d3f-a15f-fbb56d5aad56,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/021029Orig1s036,037,038,022277Orig1s017,018,019TOC.cfm",
2025,KEYTRUDA QLEX,PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH,BLA761467,097d166f-b73b-41d3-9b37-7653cd2a0c41,"The following file has been added to Drugs@FDA:  https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761467Orig1,Orig2s000TOC.cfm",
2025,KEYTRUDA QLEX,PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH,BLA761467,097d166f-b73b-41d3-9b37-7653cd2a0c41,"The following file has been added to Drugs@FDA:  https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761467Orig1,Orig2s000TOC.cfm",
2000,N/A,N/A,NDA021199,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-199_Quixin.cfm,
2004,ISTALOL,TIMOLOL MALEATE,NDA021516,258bbc8d-00ee-45b0-ac35-6f16c4e8d45f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021516s000_IstalolTOC.cfm,
2008,XENAZINE,TETRABENAZINE,NDA021894,ac768bab-8afa-4446-bc7f-caeeffec0cda,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021894s000TOC.cfm,
2008,XENAZINE,TETRABENAZINE,NDA021894,ac768bab-8afa-4446-bc7f-caeeffec0cda,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021894s000_SumR.pdf,
2020,N/A,N/A,NDA201110,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/201110Orig1s000TOC.cfm,
2019,JATENZO,TESTOSTERONE UNDECANOATE,NDA206089,ed7b5d41-7475-4c10-99b9-b62b3434ae60,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/206089Orig1s000TOC.cfm,
2019,XPOVIO,SELINEXOR,NDA212306,f6dd2682-75a6-4863-90a8-a3197f6f78a8,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212306Orig1s000TOC.cfm,
1995,PEPCID AC MAXIMUM STRENGTH,FAMOTIDINE,NDA020325,2854047f-c5c4-43c3-8ef2-5c0a84a307f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020325s015TOC.cfm,
1995,DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE,DILTIAZEM HYDROCHLORIDE,NDA020401,862d65cb-a732-4786-b569-bad2eaafddfd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20401-s019_tiazac.pdf,
1995,DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE,DILTIAZEM HYDROCHLORIDE,NDA020401,862d65cb-a732-4786-b569-bad2eaafddfd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020401ap.pdf,
1995,DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE,DILTIAZEM HYDROCHLORIDE,NDA020401,862d65cb-a732-4786-b569-bad2eaafddfd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20-401S013_Tiazac.pdf,
2024,LAZCLUZE,LAZERTINIB,NDA219008,c417f9ee-2027-4ed5-92ad-3c19266de16c,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/219008Orig1s000TOC.cfm,
2015,DARZALEX,DARATUMUMAB,BLA761036,a4d0efe9-5e54-467e-9eb4-56fa7d53b60b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/761036Orig1s000TOC.cfm,
2015,DARZALEX,DARATUMUMAB,BLA761036,a4d0efe9-5e54-467e-9eb4-56fa7d53b60b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/761036Orig1s000SumR.pdf,
2022,OMLONTI,OMIDENEPAG ISOPROPYL,NDA215092,4258e437-7e92-4b09-baf1-01cb158cfc05,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215092Orig1s000TOC.cfm,
1999,N/A,N/A,NDA020863,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm,
2002,N/A,N/A,NDA021200,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/021200Orig1s015MultidisciplineR.pdf,
2002,N/A,N/A,NDA021200,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-200_Zelnorm.cfm,
2004,VESICARE,SOLIFENACIN SUCCINATE,NDA021518,9acee910-cdb2-4052-b8b3-c26aff1c8716,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/167_209529 solifenacin clinpharm bpca.pdf,
2004,VESICARE,SOLIFENACIN SUCCINATE,NDA021518,9acee910-cdb2-4052-b8b3-c26aff1c8716,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/555_209529 solifenacin succinate clinpharm prea.pdf,
2004,VESICARE,SOLIFENACIN SUCCINATE,NDA021518,9acee910-cdb2-4052-b8b3-c26aff1c8716,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VesiCare.cfm,
2004,VESICARE,SOLIFENACIN SUCCINATE,NDA021518,9acee910-cdb2-4052-b8b3-c26aff1c8716,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/166_209529 solifenacin clinical bpca.pdf,
2004,VESICARE,SOLIFENACIN SUCCINATE,NDA021518,9acee910-cdb2-4052-b8b3-c26aff1c8716,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/167_209529 solifenacin clinpharm bpca.pdf,
2004,VESICARE,SOLIFENACIN SUCCINATE,NDA021518,9acee910-cdb2-4052-b8b3-c26aff1c8716,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/168_209529 solifenacin statistical bpca.pdf,
2005,EMTRIVA,EMTRICITABINE,NDA021896,d6599395-3944-44f9-97f2-e0424c6b6a1f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021896s000_emtricitabine_Emtriva-MedRev (2005).pdf,
2005,EMTRIVA,EMTRICITABINE,NDA021896,d6599395-3944-44f9-97f2-e0424c6b6a1f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021896s000_emtricitabine_Emtriva-ClinPharmRev (2005).pdf,
2005,EMTRIVA,EMTRICITABINE,NDA021896,d6599395-3944-44f9-97f2-e0424c6b6a1f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021896s000_emtricitabine_Emtriva-StatsRev (2005).pdf,
2005,EMTRIVA,EMTRICITABINE,NDA021896,d6599395-3944-44f9-97f2-e0424c6b6a1f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021896s000TOC.cfm,
1996,N/A,N/A,NDA050717,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/050717Orig1s000rev.pdf,
2019,VYLEESI,BREMELANOTIDE,NDA210557,8c9607a2-5b57-4a59-b159-cf196deebdd9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000TOC.cfm,
2019,RYBELSUS,ORAL SEMAGLUTIDE,NDA213051,27f15fac-7d98-4114-a2ec-92494a91da98,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/213051Orig1s000TOC.cfm,
2021,TRUDHESA,DIHYDROERGOTAMINE MESYLATE,NDA213436,b81397b0-910d-4eb4-8fee-a9a3c9d94d63,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/213436Orig1s000TOC.cfm,
2024,EDURANT PED,RILPIVIRINE HYDROCHLORIDE,NDA219016,03880372-2c68-45c6-a53a-f420c49541d6,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219016Orig1s000TOC.cfm,
1998,SINGULAIR,MONTELUKAST SODIUM,NDA020829,482dcc92-b47f-4ea6-854a-f5ac2aea7842,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020829_S026_SINGULAIR_TABLETS_AP.pdf,
1998,SINGULAIR,MONTELUKAST SODIUM,NDA020829,482dcc92-b47f-4ea6-854a-f5ac2aea7842,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020829s000_SingulairTOC.cfm,
1998,SINGULAIR,MONTELUKAST SODIUM,NDA020829,482dcc92-b47f-4ea6-854a-f5ac2aea7842,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021409 montelukast clinical prea.pdf,
1998,SINGULAIR,MONTELUKAST SODIUM,NDA020829,482dcc92-b47f-4ea6-854a-f5ac2aea7842,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021409 montelukast clinpharm prea.pdf,
1998,SINGULAIR,MONTELUKAST SODIUM,NDA020829,482dcc92-b47f-4ea6-854a-f5ac2aea7842,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021409 montelukast statistical prea.pdf,
1998,SINGULAIR,MONTELUKAST SODIUM,NDA020829,482dcc92-b47f-4ea6-854a-f5ac2aea7842,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/020829Orig1s073.pdf,
1998,SINGULAIR,MONTELUKAST SODIUM,NDA020829,482dcc92-b47f-4ea6-854a-f5ac2aea7842,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20830-s001_singulair.pdf,
1998,SINGULAIR,MONTELUKAST SODIUM,NDA020829,482dcc92-b47f-4ea6-854a-f5ac2aea7842,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020829s033_020830s035_021409s012Approv.pdf,
1998,SINGULAIR,MONTELUKAST SODIUM,NDA020829,482dcc92-b47f-4ea6-854a-f5ac2aea7842,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020829_S025_SINGULAIR_TABLETS_AP.pdf,
1998,SINGULAIR,MONTELUKAST SODIUM,NDA020829,482dcc92-b47f-4ea6-854a-f5ac2aea7842,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020829_S023 & 020830_S026 & 021409_S005_SINGULAR_AP.pdf,
1997,N/A,N/A,NDA020762,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020762_S007_NASONEX_AQUEOUS_NASAL_SPRAY.pdf,
1997,N/A,N/A,NDA020762,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020762_S014_NASONEX_AP.pdf,
1997,N/A,N/A,NDA020762,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20762-S001_Nasonex.pdf,
1997,N/A,N/A,NDA020762,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/020762Orig1s049.pdf,
1997,N/A,N/A,NDA020762,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/020762Orig1s051.pdf,
1997,N/A,N/A,NDA020762,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020762Orig1s023_FINAL_corrected.pdf,
1997,N/A,N/A,NDA020762,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020762_s000.pdf,
1997,N/A,N/A,NDA020762,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020762_mometasone_Clinical_PREA.pdf,
1997,N/A,N/A,NDA020762,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020762_mometasone_Statistical_PREA.pdf,
1997,N/A,N/A,NDA020762,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20762 nasonex clinical prea.pdf,
1997,N/A,N/A,NDA020762,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20762 nasonex clinpharm prea.pdf,
1997,N/A,N/A,NDA020762,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20762 nasonex statistical prea.pdf,
1997,N/A,N/A,NDA020762,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/020762Orig1s050.pdf,
2013,N/A,N/A,NDA022283,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022283Orig1s000TOC.cfm,
2013,N/A,N/A,NDA022283,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022283Orig1s000SumR.pdf,
1997,N/A,N/A,NDA020868,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020868a.pdf,
2000,N/A,N/A,NDA021204,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-204_Stsrlix.cfm,
2000,N/A,N/A,NDA021204,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021204_S006_STARLIX_TABS_AP.pdf,
2003,N/A,N/A,NDA021525,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020415s012_021525_PhotofrinTOC.cfm,
2005,KALETRA,LOPINAVIR AND RITONAVIR,NDA021906,8290add3-4449-4e58-6c97-8fe1eec972e3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021906s000TOC.cfm,
1997,CELLCEPT,MYCOPHENOLATE MOFETIL,NDA050723,37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-722S007_CellCept.cfm,
1997,CELLCEPT,MYCOPHENOLATE MOFETIL,NDA050723,37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-722S005_CellCept.cfm,
1997,CELLCEPT,MYCOPHENOLATE MOFETIL,NDA050723,37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-722s004_50-723s003_50-758s003_50-759s004_CellCept.cfm,
1978,N/A,N/A,NDA017948,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/017948s045,018926s012lbl.pdf",
2014,ILUVIEN,FLUOCINOLONE ACETONIDE,NDA201923,4400e471-7402-11df-93f2-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/201923Orig1s000TOC.cfm,
2017,FLUTICASONE PROPIONATE AND SALMETEROL,FLUTICASONE PROPIONATE AND SALMETEROL,NDA208799,43a27267-2f2b-410d-9c30-9cb95f35d9a1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208799Orig1s000TOC.cfm,
2017,FLUTICASONE PROPIONATE AND SALMETEROL,FLUTICASONE PROPIONATE AND SALMETEROL,NDA208799,43a27267-2f2b-410d-9c30-9cb95f35d9a1,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208799 AirDuo clinical prea.pdf,
2017,FLUTICASONE PROPIONATE AND SALMETEROL,FLUTICASONE PROPIONATE AND SALMETEROL,NDA208799,43a27267-2f2b-410d-9c30-9cb95f35d9a1,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208799 AirDuo Clinpharm prea.pdf,
2017,FLUTICASONE PROPIONATE AND SALMETEROL,FLUTICASONE PROPIONATE AND SALMETEROL,NDA208799,43a27267-2f2b-410d-9c30-9cb95f35d9a1,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208799 AirDuo statistical prea.pdf,
1993,N/A,N/A,NDA020239,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20239_ granisetron_ clinical_ prea.pdf,
1993,N/A,N/A,NDA020239,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20239_ granisetron_ clinpharm_ prea.pdf,
1993,N/A,N/A,NDA020239,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20239_ granisetron_ statistical_ prea.pdf,
1993,N/A,N/A,NDA020239,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020239_s007_KYTRIL INJ.pdf,
1993,N/A,N/A,NDA020239,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020239_s017_KYTRIL.pdf,
1993,N/A,N/A,NDA020239,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020239_s015_KYTRIL INJECTION.pdf,
1993,N/A,N/A,NDA020239,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020239_s018_Kytril Inj.pdf,
1993,N/A,N/A,NDA020239,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020239_s016_KYTRIL.pdf,
2020,WINLEVI,CLASCOTERONE,NDA213433,1673a84b-7f5c-47ab-a99c-1e3db21a6a09,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213433Orig1s000TOC.cfm,
2016,N/A,N/A,BLA761038,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761038Orig1s000TOC.cfm,
2016,N/A,N/A,BLA761038,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761038Orig1s001.pdf,
2024,OHTUVAYRE,ENSIFENTRINE,NDA217389,e6433c98-41a0-4f99-8f7f-d0e9db6e3f40,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217389Orig1s000TOC.cfm,
2015,N/A,N/A,NDA022279,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022279Orig1s000TOC.cfm,
2015,N/A,N/A,NDA022279,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022279Orig1s000SumR.pdf,
2006,VIVITROL,NALTREXONE,NDA021897,cd11c435-b0f0-4bb9-ae78-60f101f3703f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021897_toc_Vivitrol.cfm,
2012,COSOPT PF,DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE,NDA202667,535fc801-8c3f-4974-a120-3eff1d5a5062,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202667_cosoptpf_toc.cfm,
2012,COSOPT PF,DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE,NDA202667,535fc801-8c3f-4974-a120-3eff1d5a5062,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202667Orig1s000SumR.pdf,
2014,N/A,N/A,NDA205755,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000TOC.cfm,
2014,N/A,N/A,NDA205755,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000SumR.pdf,
2018,SEYSARA,SARECYCLINE HYDROCHLORIDE,NDA209521,b200957c-3004-4988-be97-9fd619a83649,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209521Orig1s000TOC.cfm,
2008,N/A,N/A,NDA020140,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/020140_levoleucovorin_toc.cfm,
2008,N/A,N/A,NDA020140,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/020140s000SumR.pdf,
2018,UDENYCA,PEGFILGRASTIM-CBQV,BLA761039,a8c290ee-b699-4395-a596-1453d4a4b4eb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761039Orig1s000TOC.cfm,
2018,UDENYCA,PEGFILGRASTIM-CBQV,BLA761039,a8c290ee-b699-4395-a596-1453d4a4b4eb,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/345_761039 pegflilgrastim-cbqv clinical prea.pdf,
2018,UDENYCA,PEGFILGRASTIM-CBQV,BLA761039,a8c290ee-b699-4395-a596-1453d4a4b4eb,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/343_761039 pegflilgrastim-cbqv DD clinical prea.pdf,
2018,UDENYCA,PEGFILGRASTIM-CBQV,BLA761039,a8c290ee-b699-4395-a596-1453d4a4b4eb,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/344_761039 pegflilgrastim-cbqv CDTL clinical prea.pdf,
2009,ZEGERID OTC,"OMEPRAZOLE, SODIUM BICARBONATE",NDA022281,1d764fc5-8eae-4fc9-a2e9-3f1954a3ac05,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022281s000TOC.cfm,
1998,MAXALT-MLT,RIZATRIPTAN BENZOATE,NDA020865,007b4644-e0e7-4863-9ae3-fe09676b3f5f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020865_s009_MAXALT_TABLETS.pdf,
1998,MAXALT-MLT,RIZATRIPTAN BENZOATE,NDA020865,007b4644-e0e7-4863-9ae3-fe09676b3f5f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20865S-007.pdf,
1998,MAXALT-MLT,RIZATRIPTAN BENZOATE,NDA020865,007b4644-e0e7-4863-9ae3-fe09676b3f5f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20865S-005.pdf,
1998,MAXALT-MLT,RIZATRIPTAN BENZOATE,NDA020865,007b4644-e0e7-4863-9ae3-fe09676b3f5f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20865S-006.pdf,
1998,MAXALT-MLT,RIZATRIPTAN BENZOATE,NDA020865,007b4644-e0e7-4863-9ae3-fe09676b3f5f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-864S004_review.pdf,
1998,MAXALT-MLT,RIZATRIPTAN BENZOATE,NDA020865,007b4644-e0e7-4863-9ae3-fe09676b3f5f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-865S002_review.pdf,
1998,MAXALT-MLT,RIZATRIPTAN BENZOATE,NDA020865,007b4644-e0e7-4863-9ae3-fe09676b3f5f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20864-20865.cfm,
2000,N/A,N/A,NDA021202,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-202_Glucophage.cfm,
2003,SYMBYAX,OLANZAPINE AND FLUOXETINE HYDROCHLORIDE,NDA021520,6b28c424-0b7e-4b75-b090-f116b113554e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21520_SymbyaxTOC.cfm,
2003,SYMBYAX,OLANZAPINE AND FLUOXETINE HYDROCHLORIDE,NDA021520,6b28c424-0b7e-4b75-b090-f116b113554e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021520Orig1s012.pdf,
2003,SYMBYAX,OLANZAPINE AND FLUOXETINE HYDROCHLORIDE,NDA021520,6b28c424-0b7e-4b75-b090-f116b113554e,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21520s039 Symbyax clinical prea.pdf,
2003,SYMBYAX,OLANZAPINE AND FLUOXETINE HYDROCHLORIDE,NDA021520,6b28c424-0b7e-4b75-b090-f116b113554e,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21520s039 Symbyax Clinpharm prea.pdf,
2003,SYMBYAX,OLANZAPINE AND FLUOXETINE HYDROCHLORIDE,NDA021520,6b28c424-0b7e-4b75-b090-f116b113554e,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21520s039 Symbyax Statistical PREA.pdf,
2006,VEREGEN,SINECATECHINS,NDA021902,f0fc1e21-e3cf-4bce-860c-307f670b192e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021902s000TOC.cfm,
1996,AMOXICILLIN AND CLAVULANATE POTASSIUM,AMOXICILLIN AND CLAVULANATE POTASSIUM,NDA050720,c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/050720s008_Augmentin.cfm,
1996,AMOXICILLIN AND CLAVULANATE POTASSIUM,AMOXICILLIN AND CLAVULANATE POTASSIUM,NDA050720,c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/050720s006_Augmentin.cfm,
1996,AMOXICILLIN AND CLAVULANATE POTASSIUM,AMOXICILLIN AND CLAVULANATE POTASSIUM,NDA050720,c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/050720s004_Augmentin.cfm,
1996,AMOXICILLIN AND CLAVULANATE POTASSIUM,AMOXICILLIN AND CLAVULANATE POTASSIUM,NDA050720,c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/050720s016_Augmentin.cfm,
1996,AMOXICILLIN AND CLAVULANATE POTASSIUM,AMOXICILLIN AND CLAVULANATE POTASSIUM,NDA050720,c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/050720s012_Augmentin.cfm,
1996,AMOXICILLIN AND CLAVULANATE POTASSIUM,AMOXICILLIN AND CLAVULANATE POTASSIUM,NDA050720,c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/050720s009_Augmentin.cfm,
1996,AMOXICILLIN AND CLAVULANATE POTASSIUM,AMOXICILLIN AND CLAVULANATE POTASSIUM,NDA050720,c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/050720s007_Augmentin.cfm,
1996,AMOXICILLIN AND CLAVULANATE POTASSIUM,AMOXICILLIN AND CLAVULANATE POTASSIUM,NDA050720,c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/050720s005_Augmentin.cfm,
1996,AMOXICILLIN AND CLAVULANATE POTASSIUM,AMOXICILLIN AND CLAVULANATE POTASSIUM,NDA050720,c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/050720s017_Augmentin.cfm,
1996,AMOXICILLIN AND CLAVULANATE POTASSIUM,AMOXICILLIN AND CLAVULANATE POTASSIUM,NDA050720,c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/050720s001_Augmentin.cfm,
1996,AMOXICILLIN AND CLAVULANATE POTASSIUM,AMOXICILLIN AND CLAVULANATE POTASSIUM,NDA050720,c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/050720s015_Augmentin.cfm,
1996,AMOXICILLIN AND CLAVULANATE POTASSIUM,AMOXICILLIN AND CLAVULANATE POTASSIUM,NDA050720,c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/050720s013_Augmentin.cfm,
1996,AMOXICILLIN AND CLAVULANATE POTASSIUM,AMOXICILLIN AND CLAVULANATE POTASSIUM,NDA050720,c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/050720s011_Augmentin.cfm,
2016,N/A,N/A,NDA209862,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209862Orig1s000TOC.cfm,
2015,TAGRISSO,OSIMERTINIB,NDA208065,5e81b4a7-b971-45e1-9c31-29cea8c87ce7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208065Orig1s000SumR.pdf,
2015,TAGRISSO,OSIMERTINIB,NDA208065,5e81b4a7-b971-45e1-9c31-29cea8c87ce7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208065Orig1s000TOC.cfm,
1992,N/A,N/A,NDA020098,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20098S009_Mivacron.cfm,
2019,SPRAVATO,ESKETAMINE HYDROCHLORIDE,NDA211243,d81a6a79-a74a-44b7-822c-0dfa3036eaed,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/211243Orig1s006.pdf,
2019,SPRAVATO,ESKETAMINE HYDROCHLORIDE,NDA211243,d81a6a79-a74a-44b7-822c-0dfa3036eaed,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/211243Orig1s004.pdf,
2019,SPRAVATO,ESKETAMINE HYDROCHLORIDE,NDA211243,d81a6a79-a74a-44b7-822c-0dfa3036eaed,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211243Orig1s000TOC.cfm,
2024,EMROSI,MINOCYCLINE HYDROCHLORIDE EXTENDED-RELEASE,NDA219015,0899eb25-8807-037c-f66c-141a2696b1c0,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219015Orig1s000TOC.cfm,
2017,BESPONSA,INOTUZUMAB OZOGAMICIN,BLA761040,cc7014b1-c775-411d-b374-8113248b4077,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761040Orig1s000TOC.cfm,
2009,CYCLOSET,BROMOCRIPTINE MESYLATE,NDA020866,e42ba916-16b9-4d1c-8d09-9d2fbb1b6c20,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/020866_cycloset_toc.cfm,
2009,CYCLOSET,BROMOCRIPTINE MESYLATE,NDA020866,e42ba916-16b9-4d1c-8d09-9d2fbb1b6c20,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/020866Orig1s000SumR.pdf,
2001,N/A,N/A,NDA021203,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-203_Tricor.cfm,
2005,PREVANTICS SWAB,CHLORHEXIDINE GLUCONATE AND ISOPROPYL ALCOHOL,NDA021524,ff999b50-0b6b-404e-b4f1-c6694fe47a9b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021524s000TOC.cfm,
2006,NEOPROFEN,IBUPROFEN LYSINE,NDA021903,6f5ede6f-b0b7-4fc8-969e-652f60ead047,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21-903s000TOC.cfm,
1995,CELLCEPT,MYCOPHENOLATE MOFETIL,NDA050722,37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-722s006_CellCept.cfm,
1995,CELLCEPT,MYCOPHENOLATE MOFETIL,NDA050722,37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-722s004_50-723s003_50-758s003_50-759s004_CellCept.cfm,
1995,CELLCEPT,MYCOPHENOLATE MOFETIL,NDA050722,37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/50-722s009_CellCept.cfm,
1995,CELLCEPT,MYCOPHENOLATE MOFETIL,NDA050722,37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/050722Orig1s000rev.pdf,
1995,CELLCEPT,MYCOPHENOLATE MOFETIL,NDA050722,37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-722S007_CellCept.cfm,
1995,CELLCEPT,MYCOPHENOLATE MOFETIL,NDA050722,37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-722S005_CellCept.cfm,
2013,KAZANO,ALOGLIPTIN AND METFORMIN HYDROCHLORIDE,NDA203414,83cb7914-a683-47bb-a713-f2bc6a596bd2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203414Orig1s000TOC.cfm,
2013,KAZANO,ALOGLIPTIN AND METFORMIN HYDROCHLORIDE,NDA203414,83cb7914-a683-47bb-a713-f2bc6a596bd2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203414Orig1s000SumR.pdf,
2018,N/A,"ATROPINE INJECTION, 2 MG",NDA212319,4a4fa6e8-0e0a-0e76-e054-00144ff8d46c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/212319Orig1s000TOC.cfm,
2016,USTEKINUMAB,USTEKINUMAB,BLA761044,23b486eb-f48d-47d4-815e-1313d4ebfbfa,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761044Orig1s003.pdf,
2016,USTEKINUMAB,USTEKINUMAB,BLA761044,23b486eb-f48d-47d4-815e-1313d4ebfbfa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761044Orig1s000TOC.cfm,
2024,INGREZZA SPRINKLE,VALBENAZINE,NDA218390,4c970164-cafb-421f-9eb5-c226ef0a3417,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/218390Orig1s000TOC.cfm,
2008,ADREVIEW,IOBENGUANE I-123,NDA022290,c89d3ecc-4f4c-4566-8808-79152344194d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022290s000TOC.cfm,
2008,ADREVIEW,IOBENGUANE I-123,NDA022290,c89d3ecc-4f4c-4566-8808-79152344194d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022290s000_SumR.pdf,
2000,BIVALIRUDIN,BIVALIRUDIN,NDA020873,19a4afc5-151d-4d3c-bfef-48aa8797d695,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020873_Bivalirudin_Clinical_BPCA.pdf,
2000,BIVALIRUDIN,BIVALIRUDIN,NDA020873,19a4afc5-151d-4d3c-bfef-48aa8797d695,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020873_Bivalirudin_Clinpharm_BPCA.pdf,
2000,BIVALIRUDIN,BIVALIRUDIN,NDA020873,19a4afc5-151d-4d3c-bfef-48aa8797d695,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20873_Angiomax.cfm,
2006,NEXPLANON,ETONOGESTREL,NDA021529,487f8a62-e142-457c-97cc-2e398fde7594,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/021529Orig1s001.pdf,
2006,NEXPLANON,ETONOGESTREL,NDA021529,487f8a62-e142-457c-97cc-2e398fde7594,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/021529Orig1s008.pdf,
2006,NEXPLANON,ETONOGESTREL,NDA021529,487f8a62-e142-457c-97cc-2e398fde7594,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/021529Orig1s011.pdf,
2006,NEXPLANON,ETONOGESTREL,NDA021529,487f8a62-e142-457c-97cc-2e398fde7594,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/021529Orig1s004.pdf,
2006,NEXPLANON,ETONOGESTREL,NDA021529,487f8a62-e142-457c-97cc-2e398fde7594,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021529_implanon_toc.cfm,
2006,NEXPLANON,ETONOGESTREL,NDA021529,487f8a62-e142-457c-97cc-2e398fde7594,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/021529Orig1s018.pdf,
2006,NEXPLANON,ETONOGESTREL,NDA021529,487f8a62-e142-457c-97cc-2e398fde7594,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021529Orig1s007.pdf,
2008,BANZEL,RUFINAMIDE,NDA021911,0a3fa925-1abd-458a-bd57-4ae780a1ef2d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021911s000_TOC.cfm,
2008,BANZEL,RUFINAMIDE,NDA021911,0a3fa925-1abd-458a-bd57-4ae780a1ef2d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021911s000_SumR.pdf,
1975,N/A,N/A,NDA017577,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/017577_s032&s033_DITROPAN TABS.pdf,
1975,N/A,N/A,NDA017577,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/017577_s032&s033_DITROPAN TABS.pdf,
2011,N/A,N/A,NDA201152,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201152Orig1s000SumR.pdf,
2011,N/A,N/A,NDA201152,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/Nevirapine-201152-Clinpharm-PREA.pdf,
2011,N/A,N/A,NDA201152,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/Nevirapine-201152-Statistical-PREA.pdf,
2011,N/A,N/A,NDA201152,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/Nevirapine-201152-Clinical-PREA.pdf,
2011,N/A,N/A,NDA201152,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201152Orig1s000TOC.cfm,
2013,VALCHLOR,MECHLORETHAMINE HYDROCHLORIDE,NDA202317,6a52e4c2-6a9f-4ebb-bc77-046b4f8bcd57,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202317Orig1s000TOC.cfm,
2013,VALCHLOR,MECHLORETHAMINE HYDROCHLORIDE,NDA202317,6a52e4c2-6a9f-4ebb-bc77-046b4f8bcd57,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202317Orig1s000SumR.pdf,
2018,XYOSTED,TESTOSTERONE ENANTHATE,NDA209863,8a3d204c-be26-49e0-8599-0ac12a272e81,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209863Orig1s000TOC.cfm,
2017,N/A,N/A,NDA208447,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208447_zejula_toc.cfm,
2017,RADICAVA,EDARAVONE,NDA209176,0ce2c1c4-2a40-485c-b7cb-96a9b85d9d11,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209176Orig1s000TOC.cfm,
2017,RADICAVA,EDARAVONE,NDA209176,0ce2c1c4-2a40-485c-b7cb-96a9b85d9d11,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209176Orig1s007.pdf,
2016,N/A,N/A,BLA761041,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761041Orig1_toc.cfm,
2016,N/A,N/A,BLA761041,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761041Orig1s000SumR.pdf,
2022,APONVIE,APREPITANT,NDA216457,d1b111eb-659a-496b-a86a-8f0fa370f147,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216457Orig1s000TOC.cfm,
2002,N/A,N/A,NDA020732,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-732_20-733_Subutex.cfm,
2008,KEPPRA XR,LEVETIRACETAM,NDA022285,2919e43b-69a8-434c-a2d2-1f3ecd7554c0,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022285_Levetiracetam_BPCA_Division_Director.pdf,
2008,KEPPRA XR,LEVETIRACETAM,NDA022285,2919e43b-69a8-434c-a2d2-1f3ecd7554c0,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22285_Levetiracetam_CDTL_PREA_BPCA.pdf,
2008,KEPPRA XR,LEVETIRACETAM,NDA022285,2919e43b-69a8-434c-a2d2-1f3ecd7554c0,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22285_Levetiracetam_Clinical_PREA_BPCA.pdf,
2008,KEPPRA XR,LEVETIRACETAM,NDA022285,2919e43b-69a8-434c-a2d2-1f3ecd7554c0,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22285_Levetiracetam_ Clinpharm_PREA_BPCA.pdf,
2008,KEPPRA XR,LEVETIRACETAM,NDA022285,2919e43b-69a8-434c-a2d2-1f3ecd7554c0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022285s000_TOC.cfm,
2008,KEPPRA XR,LEVETIRACETAM,NDA022285,2919e43b-69a8-434c-a2d2-1f3ecd7554c0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022285s000_SumR.pdf,
1998,COSOPT,DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE,NDA020869,23bdf1c1-3134-4ad1-8e7c-bc655156bdc6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020869_cosopt_toc.cfm,
1998,COSOPT,DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE,NDA020869,23bdf1c1-3134-4ad1-8e7c-bc655156bdc6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-869-s-001_cosopt.pdf,
2000,N/A,N/A,NDA021205,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021205_S014_TRIZIVIR_AP.pdf,
2000,N/A,N/A,NDA021205,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021205_S009_TRIZIVIR_AP.pdf,
2000,N/A,N/A,NDA021205,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021205_S012_TRIZIVIR_AP.pdf,
2000,N/A,N/A,NDA021205,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021205_S010_TRIZIVIR_AP.pdf,
2000,N/A,N/A,NDA021205,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021205_S005_TRIZIVIR_AP.pdf,
2000,N/A,N/A,NDA021205,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-205s003_Trizivir.cfm,
2000,N/A,N/A,NDA021205,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021205_S011_TRIZIVIR_AP.pdf,
2000,N/A,N/A,NDA021205,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-205s006_Trizivir.cfm,
2000,N/A,N/A,NDA021205,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-205_Trizinir.cfm,
2000,N/A,N/A,NDA021205,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-205s002_Trizivir.cfm,
2006,N/A,N/A,NDA021526,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021526Orig1s004TOC.cfm,
2006,N/A,N/A,NDA021526,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021526_s000_Ranexa.cfm,
2006,N/A,N/A,NDA021526,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021526Orig1s007.pdf,
2006,LUBIPROSTONE,LUBIPROSTONE,NDA021908,006b8b6c-f0eb-4246-87da-67582984b0e4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021908Orig1s008.pdf,
2006,LUBIPROSTONE,LUBIPROSTONE,NDA021908,006b8b6c-f0eb-4246-87da-67582984b0e4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021908Orig1s010.pdf,
2006,LUBIPROSTONE,LUBIPROSTONE,NDA021908,006b8b6c-f0eb-4246-87da-67582984b0e4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021908Orig1s011.pdf,
2006,LUBIPROSTONE,LUBIPROSTONE,NDA021908,006b8b6c-f0eb-4246-87da-67582984b0e4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021908s005TOC.cfm,
2006,LUBIPROSTONE,LUBIPROSTONE,NDA021908,006b8b6c-f0eb-4246-87da-67582984b0e4,http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/021908se1-005_SUMR.pdf,
2006,LUBIPROSTONE,LUBIPROSTONE,NDA021908,006b8b6c-f0eb-4246-87da-67582984b0e4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021908s000_AmitizaTOC.cfm,
2006,LUBIPROSTONE,LUBIPROSTONE,NDA021908,006b8b6c-f0eb-4246-87da-67582984b0e4,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/266_21908S16-lubiprostone-clinical-addendum-prea.pdf,
2006,LUBIPROSTONE,LUBIPROSTONE,NDA021908,006b8b6c-f0eb-4246-87da-67582984b0e4,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/267_21908S16-lubiprostone-clinpharm-prea.pdf,
2006,LUBIPROSTONE,LUBIPROSTONE,NDA021908,006b8b6c-f0eb-4246-87da-67582984b0e4,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/268_21908S16-lubiprostone-statistical-prea.pdf,
2011,N/A,N/A,NDA201153,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201153Orig1s000SumR.pdf,
2011,N/A,N/A,NDA201153,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/201153Orig1s000MedR.pdf,
2011,N/A,N/A,NDA201153,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/201153imiquimod_ClinPharm_PREA.pdf,
2011,N/A,N/A,NDA201153,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/201153 imiquimodStatR_PREA.pdf,
2011,N/A,N/A,NDA201153,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201153_zyclara_toc.cfm,
2013,FETZIMA,LEVOMILNACIPRAN HYDROCHLORIDE,NDA204168,f371258d-91b3-4b6a-ac99-434a1964c3af,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204168Orig1s000TOC.cfm,
2013,FETZIMA,LEVOMILNACIPRAN HYDROCHLORIDE,NDA204168,f371258d-91b3-4b6a-ac99-434a1964c3af,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204168Orig1s000SumR.pdf,
2017,JULUCA,DOLUTEGRAVIR SODIUM AND RILPIVIRINE HYDROCHLORIDE,NDA210192,806653d1-bf35-4924-b999-ad5d21821cc1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/210192Orig1s000TOC.cfm,
2025,QFITLIA,FITUSIRAN,NDA219019,6dd2f8ac-6f90-4cbf-b197-97d74964135c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219019Orig1s000TOC.cfm,
2016,N/A,N/A,BLA761042,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761042Orig1s01.pdf,
2016,N/A,N/A,BLA761042,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761042Orig1_toc.cfm,
2016,N/A,N/A,BLA761042,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761042Orig1s000SumR.pdf,
2016,N/A,N/A,BLA761042,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/132_761042 etanercept-SZZS_clinical prea.pdf,
2016,N/A,N/A,BLA761042,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/133_761042 etanercept-SZZS statistical prea.pdf,
2016,N/A,N/A,BLA761042,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/134_761042 etanercept-SZZS clinpharm prea.pdf,
2016,N/A,N/A,BLA761042,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/486_761042S10 etanercept-szzs prea.pdf,
1997,CRINONE,PROGESTERONE,NDA020701,75e97aa1-daa4-45f9-b2e2-1a371302914e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020701_S009_CRINONE.pdf,
1997,CRINONE,PROGESTERONE,NDA020701,75e97aa1-daa4-45f9-b2e2-1a371302914e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020701_crinone_toc.cfm,
2009,DEXILANT,DEXLANSOPRAZOLE,NDA022287,9819f033-3bbe-442e-8e92-45fec77b237d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000TOC.cfm,
2009,DEXILANT,DEXLANSOPRAZOLE,NDA022287,9819f033-3bbe-442e-8e92-45fec77b237d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_SumR.pdf,
1998,COMBIPATCH (ESTRADIOL/NORETHINDRONE ACETATE TRANSDERMAL SYSTEM),ESTRADIOL/NORETHINDRONE ACETATE TRANSDERMAL SYSTEM,NDA020870,83198ef1-11c4-11e4-9191-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20870_CombiPatch.cfm,
2004,ATROVENT HFA,IPRATROPIUM BROMIDE,NDA021527,170e98ef-5560-4068-be7d-e649068eb884,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021527s000TOC.cfm,
2007,CHILDRENS ALLEGRA ALLERGY,FEXOFENADINE HYDROCHLORIDE,NDA021909,06115cea-5a44-409d-85ed-bb71743491c1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021909_allegra_toc.cfm,
1996,N/A,N/A,NDA050725,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/050725_S017_Augmentin_APPROVAL_PACKAGE.pdf,
1996,N/A,N/A,NDA050725,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/050725_S021_Augmentin_APPROVAL_PACKAGE.pdf,
1996,N/A,N/A,NDA050725,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/050725_S013_Augmentin_APPROVAL_PACKAGE.pdf,
1996,N/A,N/A,NDA050725,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/050725_S008_Augmentin_APPROVAL_PACKAGE.pdf,
1996,N/A,N/A,NDA050725,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/050725_S011_Augmentin_APPROVAL_PACKAGE.pdf,
1996,N/A,N/A,NDA050725,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/050725_S006_Augmentin_APPROVAL_PACKAGE.pdf,
1996,N/A,N/A,NDA050725,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/050725_S004_Augmentin_APPROVAL PACKAGE.pdf,
1996,N/A,N/A,NDA050725,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/050725_S023_Augmentin_APPROVAL_PACKAGE.pdf,
1996,N/A,N/A,NDA050725,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/050725_S014_Augmentin_APPROVAL_PACKAGE.pdf,
1996,N/A,N/A,NDA050725,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/050725_S007_Augmentin_APPROVAL_PACKAGE.pdf,
1996,N/A,N/A,NDA050725,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/050725_S010_Augmentin_APPROVAL_PACKAGE.pdf,
1996,N/A,N/A,NDA050725,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/050725_S005_Augmentin_APPROVAL_PACKAGE.pdf,
1996,N/A,N/A,NDA050725,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/050725_S003_Augmentin_APPROVAL PACKAGE.pdf,
2016,ONZETRA XSAIL,SUMATRIPTAN SUCCINATE,NDA206099,a8a9889e-69b9-4a57-b8c0-d40b1025c559,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206099Orig1s000TOC.cfm,
1987,RETROVIR,ZIDOVUDINE,NDA019655,6df09f15-b102-431c-adde-d7aeef6f5d84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/019655s032_019910s021_020518s004_Retrovir.cfm,
2018,CALCIUM GLUCONATE IN SODIUM CHLORIDE,CALCIUM GLUCONATE,NDA210906,e6d531ec-fcdc-49f6-b0c4-878d3952827f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210906Orig1s000TOC.cfm,
2017,BENLYSTA,BELIMUMAB,BLA761043,2fa3c528-1777-4628-8a55-a69dae2381a3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761043Orig1s000TOC.cfm,
1996,SEROSTIM,SOMATROPIN,BLA020604,62b01d29-90f0-45b2-a0c4-3a750ba36c8a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020604_S026_ZORBITIVE.pdf,
1996,SEROSTIM,SOMATROPIN,BLA020604,62b01d29-90f0-45b2-a0c4-3a750ba36c8a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/020604_s040_serostim.pdf,
1996,SEROSTIM,SOMATROPIN,BLA020604,62b01d29-90f0-45b2-a0c4-3a750ba36c8a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020604_s012_SAIZEN INJECTION.pdf,
1996,SEROSTIM,SOMATROPIN,BLA020604,62b01d29-90f0-45b2-a0c4-3a750ba36c8a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020604_s027_SEROSTIM.pdf,
2009,BEPOTASTINE BESILATE,BEPOTASTINE BESILATE,NDA022288,70430ab5-cd0a-451e-acab-347a2f981898,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022288s000TOC.cfm,
2009,BEPOTASTINE BESILATE,BEPOTASTINE BESILATE,NDA022288,70430ab5-cd0a-451e-acab-347a2f981898,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022288s000_SumR.pdf,
2009,BEPOTASTINE BESILATE,BEPOTASTINE BESILATE,NDA022288,70430ab5-cd0a-451e-acab-347a2f981898,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022288_Bepotastine_Clinical_PREA.pdf,
2009,BEPOTASTINE BESILATE,BEPOTASTINE BESILATE,NDA022288,70430ab5-cd0a-451e-acab-347a2f981898,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022288_Bepotastine_ClinPharm_PREA.pdf,
2009,BEPOTASTINE BESILATE,BEPOTASTINE BESILATE,NDA022288,70430ab5-cd0a-451e-acab-347a2f981898,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022288_Bepotastine_Statistical_PREA.pdf,
2000,ALLEGRA HIVES 24HR,FEXOFENADINE HYDROCHLORIDE,NDA020872,490b4c5f-448b-4563-928b-837117b59b9f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-872S004_Allegra.pdf,
2000,ALLEGRA HIVES 24HR,FEXOFENADINE HYDROCHLORIDE,NDA020872,490b4c5f-448b-4563-928b-837117b59b9f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-872_Allegra.cfm,
2000,ALLEGRA HIVES 24HR,FEXOFENADINE HYDROCHLORIDE,NDA020872,490b4c5f-448b-4563-928b-837117b59b9f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-872S004_Allegra.pdf,
2000,ALLEGRA HIVES 24HR,FEXOFENADINE HYDROCHLORIDE,NDA020872,490b4c5f-448b-4563-928b-837117b59b9f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020872_s009_ALLEGRA_TABLETS.pdf,
2000,ALLEGRA HIVES 24HR,FEXOFENADINE HYDROCHLORIDE,NDA020872,490b4c5f-448b-4563-928b-837117b59b9f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020872_s010_ALLEGRA_TABLETS.pdf,
2000,ALLEGRA HIVES 24HR,FEXOFENADINE HYDROCHLORIDE,NDA020872,490b4c5f-448b-4563-928b-837117b59b9f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020872_s005_ALLEGRA_TABLETS.pdf,
2000,ALLEGRA HIVES 24HR,FEXOFENADINE HYDROCHLORIDE,NDA020872,490b4c5f-448b-4563-928b-837117b59b9f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-872S004_Allegra.pdf,
2000,ALLEGRA HIVES 24HR,FEXOFENADINE HYDROCHLORIDE,NDA020872,490b4c5f-448b-4563-928b-837117b59b9f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/020872Orig1s031.pdf,
2000,ALLEGRA HIVES 24HR,FEXOFENADINE HYDROCHLORIDE,NDA020872,490b4c5f-448b-4563-928b-837117b59b9f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020872_s008_ALLEGRA_TABLETS.pdf,
2001,REMERONSOLTAB,MIRTAZAPINE,NDA021208,98ad1917-a094-44f5-a28f-a64a8cfcd887,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/021208_remeron.cfm,
2003,ACULAR LS,KETOROLAC TROMETHAMINE,NDA021528,4fad0873-f79c-4f07-9fac-5060be6b38fe,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21528_Acular.cfm,
2006,N/A,N/A,NDA021910,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021910s000TOC.cfm,
1985,INDIUM IN 111 OXYQUINOLINE,INDIUM IN-111 OXYQUINOLINE,NDA019044,4c52c904-8137-4b10-8a85-d9b96c2d8a00,http://www.accessdata.fda.gov/drugsatfda_docs/nda/1999/019044Orig1s017.pdf,
1985,INDIUM IN 111 OXYQUINOLINE,INDIUM IN-111 OXYQUINOLINE,NDA019044,4c52c904-8137-4b10-8a85-d9b96c2d8a00,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019044_s009_indium in-111 oxyquinoline.pdf,
1985,INDIUM IN 111 OXYQUINOLINE,INDIUM IN-111 OXYQUINOLINE,NDA019044,4c52c904-8137-4b10-8a85-d9b96c2d8a00,http://www.accessdata.fda.gov/drugsatfda_docs/nda/1997/019044Orig1s015.pdf,
1985,INDIUM IN 111 OXYQUINOLINE,INDIUM IN-111 OXYQUINOLINE,NDA019044,4c52c904-8137-4b10-8a85-d9b96c2d8a00,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019044_s010_s011_s013_indium in-111 oxyquinoline.pdf,
1985,INDIUM IN 111 OXYQUINOLINE,INDIUM IN-111 OXYQUINOLINE,NDA019044,4c52c904-8137-4b10-8a85-d9b96c2d8a00,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019044_s005_indium-in-111 oxyquinoline.pdf,
1985,INDIUM IN 111 OXYQUINOLINE,INDIUM IN-111 OXYQUINOLINE,NDA019044,4c52c904-8137-4b10-8a85-d9b96c2d8a00,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019044_s010_s011_s013_indium in-111 oxyquinoline.pdf,
1985,INDIUM IN 111 OXYQUINOLINE,INDIUM IN-111 OXYQUINOLINE,NDA019044,4c52c904-8137-4b10-8a85-d9b96c2d8a00,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019044_s003_indium in 111 oxyquinoline.pdf,
1985,INDIUM IN 111 OXYQUINOLINE,INDIUM IN-111 OXYQUINOLINE,NDA019044,4c52c904-8137-4b10-8a85-d9b96c2d8a00,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019044_s018_indium in-111 oxyquinoline.pdf,
1985,INDIUM IN 111 OXYQUINOLINE,INDIUM IN-111 OXYQUINOLINE,NDA019044,4c52c904-8137-4b10-8a85-d9b96c2d8a00,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/019044_s016_indium in-111 oxyquinoline.pdf,
1985,INDIUM IN 111 OXYQUINOLINE,INDIUM IN-111 OXYQUINOLINE,NDA019044,4c52c904-8137-4b10-8a85-d9b96c2d8a00,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019044_s008_indium in-111 oxyquinoline.pdf,
1985,INDIUM IN 111 OXYQUINOLINE,INDIUM IN-111 OXYQUINOLINE,NDA019044,4c52c904-8137-4b10-8a85-d9b96c2d8a00,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019044_s006-_indium-in-111-oxyquinoline.pdf,
1985,INDIUM IN 111 OXYQUINOLINE,INDIUM IN-111 OXYQUINOLINE,NDA019044,4c52c904-8137-4b10-8a85-d9b96c2d8a00,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019044_s010_s011_s013_indium in-111 oxyquinoline.pdf,
1985,INDIUM IN 111 OXYQUINOLINE,INDIUM IN-111 OXYQUINOLINE,NDA019044,4c52c904-8137-4b10-8a85-d9b96c2d8a00,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019044_s002_indium in-111 oxyquinoline.pdf,
2016,SPINRAZA,NUSINERSEN,NDA209531,dd70cd5f-b0fc-4ba4-a5ea-89a34778bd94,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209531Orig1s000TOC.cfm,
2017,N/A,N/A,NDA209875,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209875Orig1s000TOC.cfm,
2018,INBRIJA,LEVODOPA,NDA209184,a906f8e1-6e1c-480a-8276-c01bc65dd3be,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209184Orig1s000TOC.cfm,
2020,NEXLIZET,BEMPEDOIC ACID AND EZETIMIBE,NDA211617,3fa2108c-0300-47b8-9d34-f762af7c93c6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/211617Orig1s000TOC.cfm,
2019,INREBIC,FEDRATINIB HYDROCHLORIDE,NDA212327,f0f55a2a-4e0c-4cba-8571-03e1424486d7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212327Orig1s000TOC.cfm,
2025,HERNEXEOS,ZONGERTINIB,NDA219042,d3fabf12-354e-4e5c-b5de-20fdb579b783,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219042Orig1s000TOC.cfm,
2017,BAVENCIO,AVELUMAB,BLA761049,5cd725a1-2fa4-408a-a651-57a7b84b2118,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761049Orig1s009.pdf,
2017,BAVENCIO,AVELUMAB,BLA761049,5cd725a1-2fa4-408a-a651-57a7b84b2118,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761049Orig1s000TOC.cfm,
2024,N/A,N/A,NDA216016,N/A,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/216016Orig1s000,216017Orig1s000TOC.cfm",
1997,ZITHROMAX,AZITHROMYCIN DIHYDRATE,NDA050733,3b631aa1-2d46-40bc-a614-d698301ea4f9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/050733ap.pdf,
1948,XYLOCAINE,"LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE",NDA006488,ba082c2f-64f4-419d-9c88-74f203316e17,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/006488Orig1s027.pdf,
1948,XYLOCAINE,"LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE",NDA006488,ba082c2f-64f4-419d-9c88-74f203316e17,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/006488Orig1s019.pdf,
2012,XTANDI,ENZALUTAMIDE,NDA203415,b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203415_xtandi_toc.cfm,
2012,XTANDI,ENZALUTAMIDE,NDA203415,b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203415Orig1s000SumR.pdf,
1987,N/A,N/A,NDA019558,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20507-s001_Teczem.pdf,
1987,N/A,N/A,NDA019558,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/19-558S043_Prinivil.cfm,
2018,IMBRUVICA,IBRUTINIB,NDA210563,0dfd0279-ff17-4ea9-89be-9803c71bab44,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210563Orig1s000,210563Orig2s000TOC.cfm",
2018,IMBRUVICA,IBRUTINIB,NDA210563,0dfd0279-ff17-4ea9-89be-9803c71bab44,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210563Orig1s000,210563Orig2s000TOC.cfm",
2018,N/A,N/A,NDA210910,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210910Orig1_toc.cfm,
2019,ACCRUFER,FERRIC MALTOL,NDA212320,367ac157-2d25-4f34-99ce-b126e0f03851,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212320Orig1s000TOC.cfm,
2019,ZIEXTENZO,PEGFILGRASTIM-BMEZ,BLA761045,7dada041-6528-4acf-809c-62d271538c9a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761045Orig1s000TOC.cfm,
1996,N/A,N/A,NDA020509,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020509_S029_GEMZAR_AP.pdf,
1996,N/A,N/A,NDA020509,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020509Orig1s000rev.pdf,
1996,N/A,N/A,NDA020509,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020509s033_Gemcitabine_Medical_BPCA.pdf,
1996,N/A,N/A,NDA020509,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020509_S033_GEMZAR.pdf,
2021,MAVYRET,GLECAPREVIR AND PIBRENTASVIR,NDA215110,7bf99777-0401-9095-8645-16c6e907fcc0,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215110Orig1s000TOC.cfm,
2008,PROMACTA,ELTROMBOPAG OLAMINE,NDA022291,7714a0ed-34bb-46e6-a0a5-b363908b22c2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022291s000_SumR.pdf,
2008,PROMACTA,ELTROMBOPAG OLAMINE,NDA022291,7714a0ed-34bb-46e6-a0a5-b363908b22c2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022291s000_TOC.cfm,
2008,PROMACTA,ELTROMBOPAG OLAMINE,NDA022291,7714a0ed-34bb-46e6-a0a5-b363908b22c2,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22291s015 eltrombopag clinical bpca.pdf,
2008,PROMACTA,ELTROMBOPAG OLAMINE,NDA022291,7714a0ed-34bb-46e6-a0a5-b363908b22c2,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22291s015 eltrombopag clinpharm bpca.pdf,
2008,PROMACTA,ELTROMBOPAG OLAMINE,NDA022291,7714a0ed-34bb-46e6-a0a5-b363908b22c2,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22291s015 eltrombopag statistical bpca.pdf,
2000,LEVOTHYROXINE SODIUM,LEVOTHYROXINE SODIUM,NDA021210,fca88c97-5cd4-4834-ba87-deb5bd637788,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021210_s002_Unithroid.pdf,
2000,LEVOTHYROXINE SODIUM,LEVOTHYROXINE SODIUM,NDA021210,fca88c97-5cd4-4834-ba87-deb5bd637788,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021210_S003_Unithroid.pdf,
2000,LEVOTHYROXINE SODIUM,LEVOTHYROXINE SODIUM,NDA021210,fca88c97-5cd4-4834-ba87-deb5bd637788,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21210_Unithroid.cfm,
2000,LEVOTHYROXINE SODIUM,LEVOTHYROXINE SODIUM,NDA021210,fca88c97-5cd4-4834-ba87-deb5bd637788,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021210_s006_unithroid tabs.pdf,
2004,MELOXICAM,MELOXICAM,NDA021530,55af77dd-2abc-49a6-990c-399d5a5e7a91,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021530s000_MobicTOC.cfm,
2006,BROVANA,ARFORMOTEROL TARTRATE,NDA021912,f9633c92-99e5-4b5e-ab51-fa77453e5761,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021912_brovana_toc.cfm,
2006,BROVANA,ARFORMOTEROL TARTRATE,NDA021912,f9633c92-99e5-4b5e-ab51-fa77453e5761,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021912s000_SumR.pdf,
2012,INLYTA,AXITINIB,NDA202324,8a903e31-936e-4ed7-8a59-59f32374f338,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000TOC.cfm,
2012,INLYTA,AXITINIB,NDA202324,8a903e31-936e-4ed7-8a59-59f32374f338,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000SumR.pdf,
2016,N/A,N/A,NDA204553,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/204553Orig1s000TOC.cfm,
2020,VESICARE LS,SOLIFENACIN SUCCINATE,NDA209529,e0300384-e980-45d5-8ed4-48a2618671ae,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209529Orig1s000TOC.cfm,
2019,N/A,N/A,NDA206927,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/206927Orig1s000TOC.cfm,
1995,ADVIL LIQUI-GELS,IBUPROFEN,NDA020402,ba5a9a04-993e-4fd6-bb40-6edfdfb69b34,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-402-s005_Advil.cfm,
2018,INVELTYS,LOTEPREDNOL ETABONATE,NDA210565,2ec16df8-2e5c-4e06-8d28-21df76f27d72,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210565Orig1s000TOC.cfm,
2016,ZINPLAVA,BEZLOTOXUMAB,BLA761046,8f479bfe-2bfa-4cc5-9aee-1357364480b0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761046_toc.cfm,
2016,ZINPLAVA,BEZLOTOXUMAB,BLA761046,8f479bfe-2bfa-4cc5-9aee-1357364480b0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761046Orig1s000SumR.pdf,
1998,NEURONTIN,GABAPENTIN,NDA020882,ee9ad9ed-6d9f-4ee1-9d7f-cfad438df388,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20882.cfm,
1998,NEURONTIN,GABAPENTIN,NDA020882,ee9ad9ed-6d9f-4ee1-9d7f-cfad438df388,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-216_20-235S15_20-882S2_21-129S5_Neurontin.cfm,
2004,FOLLISTIM AQ,FOLLITROPIN,BLA021211,48489027-e52b-4b10-ae74-4ba03839150c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021211s000_FollistimTOC.cfm,
2003,BENICAR HCT,OLMESARTAN MEDOXOMIL-HYDROCHLOROTHIAZIDE,NDA021532,881a1c32-c209-4038-9c5e-c5e46c6e0546,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021532_benicar_toc.cfm,
1996,N/A,N/A,NDA050730,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-670S015_Zithromax.cfm,
2016,XIIDRA,LIFITEGRAST,NDA208073,8589d376-ac10-4ddb-9c53-2e0c8d5675c4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208073Orig1s000TOC.cfm,
2018,N/A,N/A,NDA210566,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210566Orig1s000TOC.cfm,
2018,CEQUA,CYCLOSPORINE,NDA210913,48c3d8a3-4289-4b52-9189-58b48596095c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210913Orig1s000TOC.cfm,
2020,NEXLETOL,BEMPEDOIC ACID,NDA211616,88d06d89-a3da-40b4-b273-8f4f7d56c4c9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/211616Orig1s000TOC.cfm,
2019,N/A,N/A,NDA211929,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211929Orig1s000TOC.cfm,
1995,N/A,N/A,NDA020281,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020281s015_ultram_toc.cfm,
1995,N/A,N/A,NDA020281,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020281s014_ultram_toc.cfm,
1995,N/A,N/A,NDA020281,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020281Orig1s000rev.pdf,
1995,LOTREL,AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE,NDA020364,94ae6054-b7ae-4212-a567-4f803af8f2c7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20364S007_Latrel.pdf,
1995,LOTREL,AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE,NDA020364,94ae6054-b7ae-4212-a567-4f803af8f2c7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020364-s016_Lotrel.cfm,
1995,LOTREL,AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE,NDA020364,94ae6054-b7ae-4212-a567-4f803af8f2c7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-364S008_Lotrel.cfm,
2017,MEPSEVII,VESTRONIDASE ALFA,BLA761047,925d4e21-fd98-474d-a34d-a0b3558ed750,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761047Orig1s000TOC.cfm,
2024,NEFFY,EPINEPHRINE,NDA214697,a1758142-a905-401d-8961-05829f51023a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/214697Orig1s000TOC.cfm,
2008,N/A,N/A,NDA022292,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021814s005, 022292_aptivus_toc.cfm",
2008,N/A,N/A,NDA022292,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021814s005,%2022-292s000sumr.pdf",
2000,N/A,N/A,NDA020883,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020883se8-014_Argatroban_Clinical_PREA.pdf,
2000,N/A,N/A,NDA020883,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020883se8-014_Argatroban_Clinpharm_PREA.pdf,
2000,N/A,N/A,NDA020883,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-883_Acova.cfm,
2000,N/A,N/A,NDA020883,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/020883se8-014_sumr.pdf,
2002,CAVERJECT IMPULSE,ALPROSTADIL,NDA021212,4dec1dbd-c63b-4a1b-81cb-c8d29696cc40,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-212_Caverject.cfm,
2003,CLOBEX,CLOBETASOL PROPIONATE,NDA021535,54eca64c-af43-48ba-bf86-bab9d8e46bb6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-535_Clobex.cfm,
1998,DAUNORUBICIN HYDROCHLORIDE,DAUNORUBICIN HYDROCHLORIDE,NDA050731,227784a8-ce68-4dd4-8ac5-a65265969677,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/50731.pdf,
1985,SULCONAZOLE NITRATE,SULCONAZOLE NITRATE,NDA018738,cf6f4340-940c-4a61-b675-456e3297d810,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018738Orig1s000rev.pdf,
1986,HALOPERIDOL DECANOATE,HALOPERIDOL DECANOATE,NDA018701,9f0f42a8-5f7c-4be7-93ef-3ec225502cc6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/018701_S046_HALDOL_TABLETS_AP.pdf,
2010,TEFLARO,CEFTAROLINE FOSAMIL,NDA200327,3ecde48b-75a2-4beb-9999-369f3f61bb8a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/200327 ceftaroline clinical prea.pdf,
2010,TEFLARO,CEFTAROLINE FOSAMIL,NDA200327,3ecde48b-75a2-4beb-9999-369f3f61bb8a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/200327 ceftaroline clinical CDTL prea.pdf,
2010,TEFLARO,CEFTAROLINE FOSAMIL,NDA200327,3ecde48b-75a2-4beb-9999-369f3f61bb8a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/200327 ceftaroline clinpharm prea.pdf,
2010,TEFLARO,CEFTAROLINE FOSAMIL,NDA200327,3ecde48b-75a2-4beb-9999-369f3f61bb8a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/200327 ceftaroline statistical prea.pdf,
2010,TEFLARO,CEFTAROLINE FOSAMIL,NDA200327,3ecde48b-75a2-4beb-9999-369f3f61bb8a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/473_200327S22 ceftaroline fosamil unireview prea.pdf,
2010,TEFLARO,CEFTAROLINE FOSAMIL,NDA200327,3ecde48b-75a2-4beb-9999-369f3f61bb8a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200327Orig1s000TOC.cfm,
2010,TEFLARO,CEFTAROLINE FOSAMIL,NDA200327,3ecde48b-75a2-4beb-9999-369f3f61bb8a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200327Orig1s000SumR.pdf,
2010,TEFLARO,CEFTAROLINE FOSAMIL,NDA200327,3ecde48b-75a2-4beb-9999-369f3f61bb8a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/200327 ceftaroline clinical prea.pdf,
2010,TEFLARO,CEFTAROLINE FOSAMIL,NDA200327,3ecde48b-75a2-4beb-9999-369f3f61bb8a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/200327 ceftaroline clinical CDTL prea.pdf,
2010,TEFLARO,CEFTAROLINE FOSAMIL,NDA200327,3ecde48b-75a2-4beb-9999-369f3f61bb8a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/200327 ceftaroline clinpharm prea.pdf,
2010,TEFLARO,CEFTAROLINE FOSAMIL,NDA200327,3ecde48b-75a2-4beb-9999-369f3f61bb8a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/200327 ceftaroline statistical prea.pdf,
2011,EDARBYCLOR,AZILSARTAN KAMEDOXOMIL AND CHLORTHALIDONE,NDA202331,e60f795b-fce3-4361-aa03-f143451689d1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202331Orig1s000SumR.pdf,
2011,EDARBYCLOR,AZILSARTAN KAMEDOXOMIL AND CHLORTHALIDONE,NDA202331,e60f795b-fce3-4361-aa03-f143451689d1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202331_edarbyclor_toc_.cfm,
2016,AMELUZ,AMINOLEVULINIC ACID HYDROCHLORIDE,NDA208081,650daa9f-aeec-49ce-95b9-5fa20b988afd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208081Orig1s000TOC.cfm,
1991,NOVOLIN R,HUMAN INSULIN,BLA019938,aee7f1f3-612c-4027-8ce9-4fd1f41eed71,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019938a_s019.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
1991,NOVOLIN R,HUMAN INSULIN,BLA019938,aee7f1f3-612c-4027-8ce9-4fd1f41eed71,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019938ap.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
1991,N/A,N/A,NDA019898,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/019898_S024_PRAVACHOL_TABLETS.pdf,
1991,N/A,N/A,NDA019898,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/019898_S016_PRAVACOL_TABLETS.pdf,
1991,N/A,N/A,NDA019898,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/19898-S020_Pravachol.pdf,
1991,N/A,N/A,NDA019898,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019898_S049_PRAVACOL_TABLETS.pdf,
1991,N/A,N/A,NDA019898,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/019898Orig1s061.pdf,
1991,N/A,N/A,NDA019898,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/019898_s037_PRAVACHOL_TABLETS.pdf,
1991,N/A,N/A,NDA019898,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019898_S051_PRAVACOL_TABLETS.pdf,
1991,N/A,N/A,NDA019898,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/019898_s043_PRAVACHOL TABS.pdf,
1991,N/A,N/A,NDA019898,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/19898S34.PDF,
1991,N/A,N/A,NDA019898,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/19898s34_Pravachol.pdf,
1991,N/A,N/A,NDA019898,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/019898_s041_PRAVACHOL_TABLETS.pdf,
1991,N/A,N/A,NDA019898,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/019898_S025_PRAVACHOL_TABLETS.pdf,
1991,N/A,N/A,NDA019898,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019898a_s017_041597.pdf,
1991,N/A,N/A,NDA019898,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/019898_S031_PRAVACHOL_TABLETS_AP.pdf,
1991,N/A,N/A,NDA019898,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/019898_S023_PRAVACHOL_TABLETS.pdf,
1991,N/A,N/A,NDA019898,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/019898s062.pdf,
1991,N/A,N/A,NDA019898,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/019898_s054_PRAVACHOL TABS.pdf,
1991,N/A,N/A,NDA019898,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/019898_s044_PRAVACHOL TABS.pdf,
1991,N/A,N/A,NDA019898,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/019898_s036_PRAVACHOL_TABLETS.pdf,
1991,N/A,N/A,NDA019898,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019898_s050_PRAVACHOL TABS.pdf,
1991,N/A,N/A,NDA019898,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/19898s34_Pravachol.pdf,
1991,N/A,N/A,NDA019898,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/19898-S018_Pravachol.pdf,
1991,N/A,N/A,NDA019898,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/019898s032_Pravastatin.cfm,
1999,CAFFEINE CITRATE,CAFFEINE CITRATE,NDA020793,21489401-f2a7-47d3-897a-4b7efa04dd7a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020793_000_CafcitTOC.cfm,
2017,OCREVUS,OCRELIZUMAB,BLA761053,9da42362-3bb5-4b83-b4bb-b59fd4e55f0d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761053Orig1s000TOC.cfm,
2002,N/A,N/A,NDA020733,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-732_20-733_Subutex.cfm,
1998,N/A,N/A,NDA020763,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20763_Amerge.cfm,
2010,N/A,N/A,NDA021217,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021217s000TOC.cfm,
2010,N/A,N/A,NDA021217,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021217s000SumR.pdf,
2004,ACETADOTE,ACETYLCYSTEINE,NDA021539,472f158a-5ab9-4308-8e49-1116e6ea3d39,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-539_Acetadote.cfm,
2006,PIOGLITAZONE AND GLIMEPIRIDE,PIOGLITAZONE AND GLIMEPIRIDE,NDA021925,ea385b3d-cb4c-4550-97b0-93a86533f6dc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021925_duetact_toc.cfm,
2016,CASPOFUNGIN ACETATE,CASPOFUNGIN ACETATE,NDA206110,e76d8d83-3691-451c-a32c-d91448c54d16,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206110Orig1s000TOC.cfm,
2016,CASPOFUNGIN ACETATE,CASPOFUNGIN ACETATE,NDA206110,e76d8d83-3691-451c-a32c-d91448c54d16,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206110Orig1s000TOC.cfm,
2014,ALEVE PM,DIPHENHYDRAMINE HYDROCHLORIDE AND NAPROXEN SODIUM,NDA205352,82891458-ab0d-459a-8602-dcebd22c3010,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205352Orig1s000SumR.pdf,
2014,ALEVE PM,DIPHENHYDRAMINE HYDROCHLORIDE AND NAPROXEN SODIUM,NDA205352,82891458-ab0d-459a-8602-dcebd22c3010,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205352 naproxen clinical prea.pdf,
2014,ALEVE PM,DIPHENHYDRAMINE HYDROCHLORIDE AND NAPROXEN SODIUM,NDA205352,82891458-ab0d-459a-8602-dcebd22c3010,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205352 naproxen clinpharm prea.pdf,
2014,ALEVE PM,DIPHENHYDRAMINE HYDROCHLORIDE AND NAPROXEN SODIUM,NDA205352,82891458-ab0d-459a-8602-dcebd22c3010,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205352 naproxen statistical prea.pdf,
2014,ALEVE PM,DIPHENHYDRAMINE HYDROCHLORIDE AND NAPROXEN SODIUM,NDA205352,82891458-ab0d-459a-8602-dcebd22c3010,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205352Orig1s000TOC.cfm,
1995,N/A,N/A,NDA020212,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020212Orig1s000rev.pdf,
2018,POTELIGEO,MOGAMULIZUMAB-KPKC,BLA761051,e53960ab-42a1-40d1-9c7d-eb013fe7f18f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761051Orig1s000TOC.cfm,
2024,N/A,N/A,NDA216017,N/A,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/216016Orig1s000,216017Orig1s000TOC.cfm",
2009,N/A,N/A,NDA022294,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022294s000_SumR.pdf,
2009,N/A,N/A,NDA022294,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022294_zidovudine_toc.cfm,
1999,N/A,N/A,NDA020884,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20884_Aggrenox.cfm,
2005,LEVEMIR,INSULIN DETEMIR,BLA021536,d38d65c1-25bf-401d-9c7e-a2c3222da8af,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/021536Orig1s051.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2005,LEVEMIR,INSULIN DETEMIR,BLA021536,d38d65c1-25bf-401d-9c7e-a2c3222da8af,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021536Orig1s033.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2005,LEVEMIR,INSULIN DETEMIR,BLA021536,d38d65c1-25bf-401d-9c7e-a2c3222da8af,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/021536Orig1s031.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2005,LEVEMIR,INSULIN DETEMIR,BLA021536,d38d65c1-25bf-401d-9c7e-a2c3222da8af,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021-536_LevemirTOC.cfm,
2005,LEVEMIR,INSULIN DETEMIR,BLA021536,d38d65c1-25bf-401d-9c7e-a2c3222da8af,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021536Orig1s015.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2006,NAPROXEN SODIUM,NAPROXEN SODIUM,NDA021920,9343c79f-9994-4599-bcfe-0a93e49d726e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021920s000TOC.cfm,
1977,N/A,N/A,NDA017831,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/017831_S053_DIDRONEL_AP.pdf,
2015,SYNJARDY,EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE,NDA206111,0fdd0255-0055-65f3-b2c0-db8fbb87beae,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206111Orig1s000TOC.cfm,
2015,N/A,N/A,NDA205353,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205353Orig1s000TOC.cfm,
2015,N/A,N/A,NDA205353,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205353Orig1s000SumR.pdf,
2018,FIRDAPSE,AMIFAMPRIDINE PHOSPHATE,NDA208078,f015fe60-3128-4a43-8c31-19fc6b5def3f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208078Orig1_toc.cfm,
2022,BORTEZOMIB,BORTEZOMIB,NDA209191,9fdf6169-699f-40eb-bda1-760253062b3c,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/209191Orig1s000TOC.cfm,
2017,BRINEURA,CERLIPONASE ALFA,BLA761052,485ab3c5-0359-4878-872f-2fe1e7df4047,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761052Orig1s000TOC.cfm,
2022,ASPRUZYO SPRINKLE,RANOLAZINE,NDA216018,dd9f81e4-50da-4551-aed5-559d304df42e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216018Orig1s000TOC.cfm,
2000,N/A,N/A,NDA021214,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021214Orig1s006.pdf,
2000,N/A,N/A,NDA021214,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21214_Rescula.cfm,
2000,N/A,N/A,NDA021214,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021214Orig1s007.pdf,
2003,CIPRODEX,CIPROFLOXACIN AND DEXAMETHASONE,NDA021537,3e2cf3ea-a8f2-42e3-8424-9a6d6f0a4cb3,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/021537Orig1s019.pdf,
2003,CIPRODEX,CIPROFLOXACIN AND DEXAMETHASONE,NDA021537,3e2cf3ea-a8f2-42e3-8424-9a6d6f0a4cb3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021537_Ciprodex.cfm,
2003,CIPRODEX,CIPROFLOXACIN AND DEXAMETHASONE,NDA021537,3e2cf3ea-a8f2-42e3-8424-9a6d6f0a4cb3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021537Orig1s008.pdf,
2005,NEXAVAR,SORAFENIB,NDA021923,b50667e4-5ebc-4968-a646-d605058dbef0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021923_s000_NexavarTOC.cfm,
1966,ALLOPURINOL,ALLOPURINOL,NDA016084,30ad5ba2-1cef-4933-b104-0597f6a2aaa2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/016084_S041_Zyloprim Tablets.pdf,
2016,SERNIVO,BETAMETHASONE DIPROPIONATE,NDA208079,b1b3d1b0-da9b-11eb-ad76-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208079Orig1s000TOC.cfm,
1998,SINGULAIR,MONTELUKAST SODIUM,NDA020830,482dcc92-b47f-4ea6-854a-f5ac2aea7842,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20830s008_Singulair.cfm,
1998,SINGULAIR,MONTELUKAST SODIUM,NDA020830,482dcc92-b47f-4ea6-854a-f5ac2aea7842,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020830_S029_SINGULAIR_TABLETS_AP.pdf,
1998,SINGULAIR,MONTELUKAST SODIUM,NDA020830,482dcc92-b47f-4ea6-854a-f5ac2aea7842,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020830_S028_SINGULAIR_AP.pdf,
1998,SINGULAIR,MONTELUKAST SODIUM,NDA020830,482dcc92-b47f-4ea6-854a-f5ac2aea7842,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020829_S023 & 020830_S026 & 021409_S005_SINGULAR_AP.pdf,
1998,SINGULAIR,MONTELUKAST SODIUM,NDA020830,482dcc92-b47f-4ea6-854a-f5ac2aea7842,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20830-s001_singulair.pdf,
1998,SINGULAIR,MONTELUKAST SODIUM,NDA020830,482dcc92-b47f-4ea6-854a-f5ac2aea7842,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20830_Singulair.cfm,
2020,N/A,N/A,NDA214701,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214701Orig1s000TOC.cfm,
1999,PANRETIN,ALITRETINOIN,NDA020886,49c16717-7d86-4257-80c9-baa1417e5555,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20886.cfm,
2008,N/A,N/A,BLA021538,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021538_Somatropin_Clinical_PREA.pdf,
2008,N/A,N/A,BLA021538,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021538_Somatropin_Clinpharm_PREA.pdf,
2008,N/A,N/A,BLA021538,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021538_Somatropin_Statistical_PREA.pdf,
2008,N/A,N/A,BLA021538,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021538_accretropin_toc.cfm,
2008,N/A,N/A,BLA021538,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021538s000_SumR.pdf,
2006,LEVOTHYROXINE SODIUM,LEVOTHYROXINE SODIUM,NDA021924,686ba2cf-7651-44de-9b4d-eeaaf2a0e364,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021924s000TOC.cfm,
1964,N/A,N/A,NDA014214,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/17-430s026s027_14-214s050s051_Negram.cfm,
1964,N/A,N/A,NDA014214,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/17-430s026s027_14-214s050s051_Negram.cfm,
2012,ADRENALIN,EPINEPHRINE,NDA204200,3b7a4364-668d-4eb2-a20c-04adc35aabe4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/204200_adrenalin_toc.cfm,
2012,ADRENALIN,EPINEPHRINE,NDA204200,3b7a4364-668d-4eb2-a20c-04adc35aabe4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/204200Orig1Orig2s000SumR.pdf,
2012,ADRENALIN,EPINEPHRINE,NDA204200,3b7a4364-668d-4eb2-a20c-04adc35aabe4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/204200Orig1s007.pdf,
1987,EPIPEN,EPINEPHRINE,NDA019430,7560c201-9246-487c-a13b-6295db04274a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/019430Orig1s054.pdf,
1987,EPIPEN,EPINEPHRINE,NDA019430,7560c201-9246-487c-a13b-6295db04274a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/019430Orig1s059.pdf,
1987,EPIPEN,EPINEPHRINE,NDA019430,7560c201-9246-487c-a13b-6295db04274a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019430Orig1s001.pdf,
1987,EPIPEN,EPINEPHRINE,NDA019430,7560c201-9246-487c-a13b-6295db04274a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/019430Orig1s055.pdf,
1987,EPIPEN,EPINEPHRINE,NDA019430,7560c201-9246-487c-a13b-6295db04274a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/019430Orig1s061pkg.pdf,
1987,EPIPEN,EPINEPHRINE,NDA019430,7560c201-9246-487c-a13b-6295db04274a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/019430Orig1s015.pdf,
1987,EPIPEN,EPINEPHRINE,NDA019430,7560c201-9246-487c-a13b-6295db04274a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/019430Orig1s056.pdf,
2017,N/A,N/A,NDA209885,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209885Orig1s000TOC.cfm,
2015,VIBERZI,ELUXADOLINE,NDA206940,7821bd40-4c84-4984-951b-6436ae20421a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206940Orig1s000SumR.pdf,
2015,VIBERZI,ELUXADOLINE,NDA206940,7821bd40-4c84-4984-951b-6436ae20421a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206940Orig1s000TOC.cfm,
2017,ADMELOG,INSULIN LISPRO,BLA209196,0691def8-4a7b-4de3-866f-a280989f47f1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209196Orig1s000TOC.cfm,
1995,ULTANE,SEVOFLURANE,NDA020478,4c6e76bc-c964-4955-e0a3-511d3386a9cc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/020478Orig1S029.pdf,
1995,ULTANE,SEVOFLURANE,NDA020478,4c6e76bc-c964-4955-e0a3-511d3386a9cc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020478Orig1S011.pdf,
1995,ULTANE,SEVOFLURANE,NDA020478,4c6e76bc-c964-4955-e0a3-511d3386a9cc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020478_S006_ULTANE_AP.pdf,
1995,ULTANE,SEVOFLURANE,NDA020478,4c6e76bc-c964-4955-e0a3-511d3386a9cc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020478Orig1s000rev.pdf,
1995,ULTANE,SEVOFLURANE,NDA020478,4c6e76bc-c964-4955-e0a3-511d3386a9cc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020478s007TOC.cfm,
2018,ONPATTRO,PATISIRAN,NDA210922,e87ec36f-b4b4-49d4-aea4-d4ffb09b0970,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210922Orig1s000TOC.cfm,
2019,ADALIMUMAB-BWWD,ADALIMUMAB-BWWD,BLA761059,87321c6f-77d9-4ccc-9849-fe22f2652cb6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761059Orig1s000TOC.cfm,
2023,REZZAYO,REZAFUNGIN,NDA217417,90073508-6dca-4d27-aa5a-ed837737c35b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217417Orig1s000TOC.cfm,
2011,PUR-WASH,WATER,NDA022305,7289103a-5cbf-42f4-8848-e827149a43ca,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022305_purwash_toc.cfm,
2011,PUR-WASH,WATER,NDA022305,7289103a-5cbf-42f4-8848-e827149a43ca,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022305Orig1s000SumR.pdf,
1998,VALSTAR,VALRUBICIN,NDA020892,e96f30a0-6662-11de-8f80-0002a5d5c51b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20892.cfm,
2000,MIRENA,LEVONORGESTREL,NDA021225,dcbd6aa2-b3fa-479a-a676-56ea742962fc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/021225Orig1s033.pdf,
2000,MIRENA,LEVONORGESTREL,NDA021225,dcbd6aa2-b3fa-479a-a676-56ea742962fc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/021225Orig1s031.pdf,
2000,MIRENA,LEVONORGESTREL,NDA021225,dcbd6aa2-b3fa-479a-a676-56ea742962fc,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21225_mirena_clinical_PREA.pdf,
2000,MIRENA,LEVONORGESTREL,NDA021225,dcbd6aa2-b3fa-479a-a676-56ea742962fc,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21225_mirena_clinpharm_PREA.pdf,
2000,MIRENA,LEVONORGESTREL,NDA021225,dcbd6aa2-b3fa-479a-a676-56ea742962fc,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21225_mirena_statistical_PREA.pdf,
2000,MIRENA,LEVONORGESTREL,NDA021225,dcbd6aa2-b3fa-479a-a676-56ea742962fc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-225_Mirena.cfm,
2004,PATADAY ONCE DAILY RELIEF,OLOPATADINE HYDROCHLORIDE,NDA021545,1c7d2342-ba1c-4244-9814-d92a05725d4e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021545s000TOC.cfm,
2004,PATADAY ONCE DAILY RELIEF,OLOPATADINE HYDROCHLORIDE,NDA021545,1c7d2342-ba1c-4244-9814-d92a05725d4e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/021545Orig1s022.pdf,
2014,SPIRIVA RESPIMAT,TIOTROPIUM BROMIDE INHALATION SPRAY,NDA021936,7b656b14-fcaa-2741-f6f0-e0be48971c02,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/021936Orig1s000TOC.cfm,
2014,SPIRIVA RESPIMAT,TIOTROPIUM BROMIDE INHALATION SPRAY,NDA021936,7b656b14-fcaa-2741-f6f0-e0be48971c02,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/021936Orig1s000SumR.pdf,
2014,SPIRIVA RESPIMAT,TIOTROPIUM BROMIDE INHALATION SPRAY,NDA021936,7b656b14-fcaa-2741-f6f0-e0be48971c02,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/88_21936 tiotropium clinical prea.pdf,
2014,SPIRIVA RESPIMAT,TIOTROPIUM BROMIDE INHALATION SPRAY,NDA021936,7b656b14-fcaa-2741-f6f0-e0be48971c02,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/89_21936 tiotropium clinpharm prea.pdf,
2014,SPIRIVA RESPIMAT,TIOTROPIUM BROMIDE INHALATION SPRAY,NDA021936,7b656b14-fcaa-2741-f6f0-e0be48971c02,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/90_21936 tiotropium statistical prea.pdf,
1997,AMBISOME,AMPHOTERICIN B,NDA050740,f7be6506-4d20-401e-a0ff-02ad7c33158a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-740S2_AmBisome.cfm,
1997,AMBISOME,AMPHOTERICIN B,NDA050740,f7be6506-4d20-401e-a0ff-02ad7c33158a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/050740_ambisome_toc.cfm,
1997,AMBISOME,AMPHOTERICIN B,NDA050740,f7be6506-4d20-401e-a0ff-02ad7c33158a,http://www.accessdata.fda.gov/drugsatfda_docs/anda/2000/050740s001_ambisome_toc.cfm,
1982,N/A,N/A,NDA018668,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/18-782S023.pdf,
2015,TOUJEO,INSULIN GLARGINE,BLA206538,c9561d96-124d-48ca-982f-0aa1575bff36,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206538Orig1s000SumR.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2015,TOUJEO,INSULIN GLARGINE,BLA206538,c9561d96-124d-48ca-982f-0aa1575bff36,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206538Orig1s000TOC.cfm,
1998,N/A,N/A,NDA019832,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/19832.cfm,
2017,RENFLEXIS,INFLIXIMAB,BLA761054,dbf738c4-3fac-4422-a9d8-51d9c83a8789,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/120_761054 renflexis CDDD clinical prea.pdf,
2017,RENFLEXIS,INFLIXIMAB,BLA761054,dbf738c4-3fac-4422-a9d8-51d9c83a8789,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/123_761054 renflexis clinical prea.pdf,
2017,RENFLEXIS,INFLIXIMAB,BLA761054,dbf738c4-3fac-4422-a9d8-51d9c83a8789,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/124_761054 renflexis clinpharm prea.pdf,
2017,RENFLEXIS,INFLIXIMAB,BLA761054,dbf738c4-3fac-4422-a9d8-51d9c83a8789,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/126_761054 renflexis statistical prea.pdf,
2017,RENFLEXIS,INFLIXIMAB,BLA761054,dbf738c4-3fac-4422-a9d8-51d9c83a8789,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/125_761054 renflexis statistical 2 prea.pdf,
2017,RENFLEXIS,INFLIXIMAB,BLA761054,dbf738c4-3fac-4422-a9d8-51d9c83a8789,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/121_761054 renflexis clinical 2 prea.pdf,
2017,RENFLEXIS,INFLIXIMAB,BLA761054,dbf738c4-3fac-4422-a9d8-51d9c83a8789,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/122_761054 renflexis clinical 3 prea.pdf,
2017,RENFLEXIS,INFLIXIMAB,BLA761054,dbf738c4-3fac-4422-a9d8-51d9c83a8789,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761054Orig1s000TOC.cfm,
2021,SERTRALINE HYDROCHLORIDE,SERTRALINE HYDROCHLORIDE,NDA215133,e0e1f35e-114d-bb39-34f1-70208b94ac9e,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215133Orig1s000,215133Orig2TOC.cfm",
2021,SERTRALINE HYDROCHLORIDE,SERTRALINE HYDROCHLORIDE,NDA215133,e0e1f35e-114d-bb39-34f1-70208b94ac9e,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215133Orig1s000,215133Orig2TOC.cfm",
1996,N/A,N/A,NDA020634,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/020634se5-047,020635se5-051,021721se5-015_SUMR.pdf",
1996,N/A,N/A,NDA020634,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/020634Orig1s061, 020635Orig1s067, 021721Orig1s028TOC.cfm",
1996,N/A,N/A,NDA020634,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020634_levaquin_toc.cfm,
1996,N/A,N/A,NDA020634,N/A,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020634s043, 020635s046, 021721s011_levofloxacin_Levaquin_ClinPharmRev2.pdf",
1996,N/A,N/A,NDA020634,N/A,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020634s043, 020635s046, 021721s011_levofloxacin_Levaquin-StatRev.pdf",
1996,N/A,N/A,NDA020634,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20634 levofloxacin clinical PREA.pdf,
1996,N/A,N/A,NDA020634,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-634s008s009_20-635s007s008_Levaquin.cfm,
1996,N/A,N/A,NDA020634,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020634_S027_LEVAQUIN.pdf,
1996,N/A,N/A,NDA020634,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020634_S033_Levaquin.pdf,
1996,N/A,N/A,NDA020634,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020634s04.cfm,
1996,N/A,N/A,NDA020634,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-634s015s021s022_020635s012s019s020_LevaquinTOC.cfm,
1996,N/A,N/A,NDA020634,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-634s015s021s022_020635s012s019s020_LevaquinTOC.cfm,
1996,N/A,N/A,NDA020634,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020634Orig1s062s064.pdf,
1996,N/A,N/A,NDA020634,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020634Orig1s062s064.pdf,
1996,N/A,N/A,NDA020634,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-634s008s009_20-635s007s008_Levaquin.cfm,
1996,N/A,N/A,NDA020634,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020634_S028_LEVAQUIN.pdf,
1996,N/A,N/A,NDA020634,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020634_S034_Levaquin.pdf,
1996,N/A,N/A,NDA020634,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-634s015s021s022_020635s012s019s020_LevaquinTOC.cfm,
1996,LIPITOR,ATORVASTATIN CALCIUM,NDA020702,c6e131fe-e7df-4876-83f7-9156fc4e8228,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-702S025_Lipitor.cfm,
1996,LIPITOR,ATORVASTATIN CALCIUM,NDA020702,c6e131fe-e7df-4876-83f7-9156fc4e8228,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020702_S031_LIPITOR.pdf,
1996,LIPITOR,ATORVASTATIN CALCIUM,NDA020702,c6e131fe-e7df-4876-83f7-9156fc4e8228,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020702_S021_LIPITOR.pdf,
1996,LIPITOR,ATORVASTATIN CALCIUM,NDA020702,c6e131fe-e7df-4876-83f7-9156fc4e8228,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020702_S013_LIPITOR.pdf,
1996,LIPITOR,ATORVASTATIN CALCIUM,NDA020702,c6e131fe-e7df-4876-83f7-9156fc4e8228,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020702_S009_LIPITOR.pdf,
1996,LIPITOR,ATORVASTATIN CALCIUM,NDA020702,c6e131fe-e7df-4876-83f7-9156fc4e8228,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020702_S011_LIPITOR.pdf,
1996,LIPITOR,ATORVASTATIN CALCIUM,NDA020702,c6e131fe-e7df-4876-83f7-9156fc4e8228,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/020702Orig1s056.pdf,
1996,LIPITOR,ATORVASTATIN CALCIUM,NDA020702,c6e131fe-e7df-4876-83f7-9156fc4e8228,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20702s005.cfm,
1996,LIPITOR,ATORVASTATIN CALCIUM,NDA020702,c6e131fe-e7df-4876-83f7-9156fc4e8228,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/020702s060.pdf,
1996,LIPITOR,ATORVASTATIN CALCIUM,NDA020702,c6e131fe-e7df-4876-83f7-9156fc4e8228,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20702s005.cfm,
1996,LIPITOR,ATORVASTATIN CALCIUM,NDA020702,c6e131fe-e7df-4876-83f7-9156fc4e8228,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020702_S036_LIPITOR.pdf,
1996,LIPITOR,ATORVASTATIN CALCIUM,NDA020702,c6e131fe-e7df-4876-83f7-9156fc4e8228,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020702_s000.pdf,
1996,LIPITOR,ATORVASTATIN CALCIUM,NDA020702,c6e131fe-e7df-4876-83f7-9156fc4e8228,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020702_S028_LIPITOR.pdf,
1996,LIPITOR,ATORVASTATIN CALCIUM,NDA020702,c6e131fe-e7df-4876-83f7-9156fc4e8228,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020702-S018_Lipitor.cfm,
1996,LIPITOR,ATORVASTATIN CALCIUM,NDA020702,c6e131fe-e7df-4876-83f7-9156fc4e8228,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020702_S024_LIPITOR_TABLETS.pdf,
1996,LIPITOR,ATORVASTATIN CALCIUM,NDA020702,c6e131fe-e7df-4876-83f7-9156fc4e8228,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020702_S030_LIPITOR.pdf,
1996,LIPITOR,ATORVASTATIN CALCIUM,NDA020702,c6e131fe-e7df-4876-83f7-9156fc4e8228,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020702_S022_LIPITOR_AP.pdf,
1996,LIPITOR,ATORVASTATIN CALCIUM,NDA020702,c6e131fe-e7df-4876-83f7-9156fc4e8228,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020702A_S014.PDF,
1996,LIPITOR,ATORVASTATIN CALCIUM,NDA020702,c6e131fe-e7df-4876-83f7-9156fc4e8228,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020702_S012_LIPITOR.pdf,
1996,LIPITOR,ATORVASTATIN CALCIUM,NDA020702,c6e131fe-e7df-4876-83f7-9156fc4e8228,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020702_S008_LIPITOR_TABLETS_AP.pdf,
1996,LIPITOR,ATORVASTATIN CALCIUM,NDA020702,c6e131fe-e7df-4876-83f7-9156fc4e8228,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020702_S010_LIPITOR.pdf,
1996,LIPITOR,ATORVASTATIN CALCIUM,NDA020702,c6e131fe-e7df-4876-83f7-9156fc4e8228,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020702_s039_LIPITOR_TABLETS.pdf,
1996,LIPITOR,ATORVASTATIN CALCIUM,NDA020702,c6e131fe-e7df-4876-83f7-9156fc4e8228,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020702a_s004.pdf,
1996,LIPITOR,ATORVASTATIN CALCIUM,NDA020702,c6e131fe-e7df-4876-83f7-9156fc4e8228,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020702a_s002.pdf,
1996,LIPITOR,ATORVASTATIN CALCIUM,NDA020702,c6e131fe-e7df-4876-83f7-9156fc4e8228,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020702_s037_LIPITOR_TABLETS.pdf,
1996,LIPITOR,ATORVASTATIN CALCIUM,NDA020702,c6e131fe-e7df-4876-83f7-9156fc4e8228,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020702_S035_LIPITOR.pdf,
1996,LIPITOR,ATORVASTATIN CALCIUM,NDA020702,c6e131fe-e7df-4876-83f7-9156fc4e8228,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020702_s027_LIPITOR_TABLETS.pdf,
2024,DUVYZAT,GIVINOSTAT,NDA217865,1a28a3db-7880-4ac2-a2f2-2b4e362aafb6,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217865Orig1s000TOC.cfm,
2008,MESALAMINE,MESALAMINE,NDA022301,8d27a608-3ba1-4799-be38-c00fb08ce3ce,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022301s000_SumR.pdf,
2008,MESALAMINE,MESALAMINE,NDA022301,8d27a608-3ba1-4799-be38-c00fb08ce3ce,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022301_apriso_toc.cfm,
2001,N/A,N/A,NDA021222,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-222_Spectracef.cfm,
2004,AMLODIPINE AND ATORVASTATIN,AMLODIPINE AND ATORVASTATIN,NDA021540,14124e56-77ba-426d-8f5a-dbe42eda1a20,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021540S000_Caduet.cfm,
2008,TREXIMET,SUMATRIPTAN SUCCINATE AND NAPROXEN SODIUM,NDA021926,42ddf376-8dc0-4236-be2a-0c6ae92ece04,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021926s000_SumR.pdf,
2008,TREXIMET,SUMATRIPTAN SUCCINATE AND NAPROXEN SODIUM,NDA021926,42ddf376-8dc0-4236-be2a-0c6ae92ece04,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21926 sumatriptan naproxen clinical bpca.pdf,
2008,TREXIMET,SUMATRIPTAN SUCCINATE AND NAPROXEN SODIUM,NDA021926,42ddf376-8dc0-4236-be2a-0c6ae92ece04,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21926 sumatriptan naproxen clinpharm bpca.pdf,
2008,TREXIMET,SUMATRIPTAN SUCCINATE AND NAPROXEN SODIUM,NDA021926,42ddf376-8dc0-4236-be2a-0c6ae92ece04,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21926 sumatriptan naproxen statistical bpca.pdf,
2008,TREXIMET,SUMATRIPTAN SUCCINATE AND NAPROXEN SODIUM,NDA021926,42ddf376-8dc0-4236-be2a-0c6ae92ece04,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021926s000TOC.cfm,
1993,CLARITIN,LORATADINE,NDA019658,ac32d6f9-f553-4d5c-ad36-575af5ea56de,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/19658-S005_Claritin.pdf,
1993,CLARITIN,LORATADINE,NDA019658,ac32d6f9-f553-4d5c-ad36-575af5ea56de,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/19670s18,20470s16,19658s18,20704s8,20641s9_Claritin.cfm",
1993,CLARITIN,LORATADINE,NDA019658,ac32d6f9-f553-4d5c-ad36-575af5ea56de,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/1998/019670_s012,19658s14,20470s7,20641s3,20704s4_ClaritinDTOC.cfml",
1993,CLARITIN,LORATADINE,NDA019658,ac32d6f9-f553-4d5c-ad36-575af5ea56de,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/1998/019670_s008,19658s10,20470s3,20641s120704s3_Claritin-DTOC.cfml",
2014,BELSOMRA,SUVOREXANT,NDA204569,e5b72731-1acb-45b7-9c13-290ad12d3951,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204569Orig1s000TOC.cfm,
2014,BELSOMRA,SUVOREXANT,NDA204569,e5b72731-1acb-45b7-9c13-290ad12d3951,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204569Orig1s000SumR.pdf,
2014,RASUVO,METHOTREXATE,NDA205776,d0075461-0e7e-4967-9c9b-d6440e912c0e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205776Orig1s000TOC.cfm,
2015,NINLARO,IXAZOMIB,NDA208462,038f2461-834b-4488-9ebd-863c83eef5a7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208462Orig1s000TOC.cfm,
2015,NINLARO,IXAZOMIB,NDA208462,038f2461-834b-4488-9ebd-863c83eef5a7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208462Orig1s000SumR.pdf,
2017,AUSTEDO,DEUTETRABENAZINE,NDA208082,7ea3c60a-45c7-44cc-afc2-d87fa53993c0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208082Orig1s000TOC.cfm,
2017,DUPIXENT,DUPILUMAB,BLA761055,595f437d-2729-40bb-9c62-c8ece1f82780,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761055Orig1s000TOC.cfm,
2017,DUPIXENT,DUPILUMAB,BLA761055,595f437d-2729-40bb-9c62-c8ece1f82780,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761055Orig1s007.pdf,
2017,DUPIXENT,DUPILUMAB,BLA761055,595f437d-2729-40bb-9c62-c8ece1f82780,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761055Orig1s040.pdf,
2017,DUPIXENT,DUPILUMAB,BLA761055,595f437d-2729-40bb-9c62-c8ece1f82780,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761055Orig1s014rev.pdf,
2017,DUPIXENT,DUPILUMAB,BLA761055,595f437d-2729-40bb-9c62-c8ece1f82780,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761055Orig1s012.pdf,
1997,N/A,N/A,NDA020605,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020605_S004_ZOFRAN.pdf,
1997,N/A,N/A,NDA020605,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020605ap.pdf,
1997,N/A,N/A,NDA020605,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020605_s008_Zofran Tabs.pdf,
2022,IYUZEH,LATANOPROST OPHTHALMIC SOLUTION 0.005%,NDA216472,192fc081-cc38-4e83-b779-9592e060b915,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216472Orig1s000TOC.cfm,
1996,MONISTAT 3 COMBINATION PACK 3 OVULE INSERTS,MICONAZOLE NITRATE,NDA020670,910d81cd-67dc-4fdf-94cf-4eb3b1dca0fd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020670s009Approv.pdf,
1996,MONISTAT 3 COMBINATION PACK 3 OVULE INSERTS,MICONAZOLE NITRATE,NDA020670,910d81cd-67dc-4fdf-94cf-4eb3b1dca0fd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/020670Orig1s014.pdf,
2023,DAPTOMYCIN,DAPTOMYCIN,NDA217415,5e1f739a-eb81-43d8-9a14-89f32b7e1ba1,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217415Orig1s000TOC.cfm,
2001,N/A,N/A,NDA021223,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-386_Zometa.cfm,
2001,N/A,N/A,NDA021223,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021223_s004_ZOMETA.pdf,
2001,N/A,N/A,NDA021223,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021223_Zoledronic_Acid_Clinpharm_BPCA.pdf,
2001,N/A,N/A,NDA021223,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021223_Zoledronic_Acid_Statistical_BPCA.pdf,
2001,N/A,N/A,NDA021223,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021223_Zoledronic_Acid_Clinical_BPCA.pdf,
2001,N/A,N/A,NDA021223,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-223_Zometa.cfm,
2003,N/A,N/A,NDA021543,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-543_Striant.cfm,
2006,CHANTIX,VARENICLINE TARTRATE,NDA021928,f0ff4f27-5185-4881-a749-c6b7a0ca5696,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/021928Orig1s039.pdf,
2006,CHANTIX,VARENICLINE TARTRATE,NDA021928,f0ff4f27-5185-4881-a749-c6b7a0ca5696,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/021928Orig1s041.pdf,
2006,CHANTIX,VARENICLINE TARTRATE,NDA021928,f0ff4f27-5185-4881-a749-c6b7a0ca5696,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021928Orig1s019.pdf,
2006,CHANTIX,VARENICLINE TARTRATE,NDA021928,f0ff4f27-5185-4881-a749-c6b7a0ca5696,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021928Orig1s017.pdf,
2006,CHANTIX,VARENICLINE TARTRATE,NDA021928,f0ff4f27-5185-4881-a749-c6b7a0ca5696,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021928Orig1s021.pdf,
2006,CHANTIX,VARENICLINE TARTRATE,NDA021928,f0ff4f27-5185-4881-a749-c6b7a0ca5696,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021928Orig1s011.pdf,
2006,CHANTIX,VARENICLINE TARTRATE,NDA021928,f0ff4f27-5185-4881-a749-c6b7a0ca5696,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/021928Orig1s038.pdf,
2006,CHANTIX,VARENICLINE TARTRATE,NDA021928,f0ff4f27-5185-4881-a749-c6b7a0ca5696,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/021928Orig1s036.pdf,
2006,CHANTIX,VARENICLINE TARTRATE,NDA021928,f0ff4f27-5185-4881-a749-c6b7a0ca5696,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/021928orig1s040.pdf,
2006,CHANTIX,VARENICLINE TARTRATE,NDA021928,f0ff4f27-5185-4881-a749-c6b7a0ca5696,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/021928Orig1s032.pdf,
2006,CHANTIX,VARENICLINE TARTRATE,NDA021928,f0ff4f27-5185-4881-a749-c6b7a0ca5696,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021928Orig1s014.pdf,
2006,CHANTIX,VARENICLINE TARTRATE,NDA021928,f0ff4f27-5185-4881-a749-c6b7a0ca5696,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021928 varenicline_chantix_clinpharm_PREA.pdf,
2006,CHANTIX,VARENICLINE TARTRATE,NDA021928,f0ff4f27-5185-4881-a749-c6b7a0ca5696,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021928_s000_ChantixTOC.cfm,
2006,CHANTIX,VARENICLINE TARTRATE,NDA021928,f0ff4f27-5185-4881-a749-c6b7a0ca5696,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021928Orig1s020.pdf,
1970,N/A,N/A,NDA050297,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-207s054s55_50-297s018_50-611s018_Erthromycin.cfm,
1997,N/A,N/A,NDA050739,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/050739s000_050749s000_OmnicefTOC.cfm,
2014,N/A,N/A,NDA205777,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000TOC.cfm,
2019,MAYZENT,SIPONIMOD,NDA209884,44492772-5aed-4627-bd85-e8e89f308bb3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209884Orig1s000TOC.cfm,
1992,N/A,N/A,NDA019697,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/019697_s010_ORTHOTRICYCLEN.pdf,
1992,N/A,N/A,NDA019697,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021690_norgestimate_OrthoTri-Cyclen-MedRev.pdf,
1992,N/A,N/A,NDA019697,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021690_norgestimate_OrthoTri-Cyclen-ClinPharmRev.pdf,
1992,N/A,N/A,NDA019697,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021690_norgestimate_OrthoTri-Cyclen-StatRev.pdf,
1992,N/A,N/A,NDA019697,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/019697_s009_ORTHOTRICYCLEN.pdf,
1992,N/A,N/A,NDA019697,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019697_s029_ORTHOCYCLEN.pdf,
1992,N/A,N/A,NDA019697,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/019697_s027_ORTHO CYCLEN.pdf,
1992,N/A,N/A,NDA019697,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/019697_s005_ORTHOTRICYCLEN.pdf,
1992,N/A,N/A,NDA019697,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/019697_s019_ORTHOCYCLEN.pdf,
1992,N/A,N/A,NDA019697,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/019697_s025_ORTHO CYCLEN.pdf,
1992,N/A,N/A,NDA019697,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/019697_s015_ORTHOCYCLEN.pdf,
1992,N/A,N/A,NDA019697,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/019697_s021_ORTHO CYCLEN.pdf,
1992,N/A,N/A,NDA019697,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/019697_s013_ORTHOCYCLEN.pdf,
1992,N/A,N/A,NDA019697,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/019697_s011_ORTHO CYCLEN.pdf,
1992,N/A,N/A,NDA019697,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019697_s028_ORTHO CYCLEN.pdf,
1992,N/A,N/A,NDA019697,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019697_s004_ORTHOTRICYCLEN.pdf,
1992,N/A,N/A,NDA019697,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/019697_s018_ORTHO CYCLEN.pdf,
1992,N/A,N/A,NDA019697,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/019697_s032_ORTHOCYCLEN.pdf,
1992,N/A,N/A,NDA019697,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/01969_s002_Orthotricyclen.pdf,
1992,N/A,N/A,NDA019697,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/019697_s024_ORTHO CYCLEN.pdf,
1992,N/A,N/A,NDA019697,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/019697_s016_ORTHOCYCLEN.pdf,
1992,N/A,N/A,NDA019697,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019697_s030_ORTHOCYCLEN.pdf,
2016,VEMLIDY,TENOFOVIR ALAFENAMIDE,NDA208464,72e6b33c-0351-4070-9172-eeaa186c01d2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208464Orig1s000TOC.cfm,
2017,CLINDAMYCIN PHOSPHATE,CLINDAMYCIN PHOSPHATE,NDA208083,44fa506b-90ac-42de-831b-5f3f1a500fc0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208083Orig1s000TOC.cfm,
2017,VOSEVI,"SOFOSBUVIR, VELPATASVIR, AND VOXILAPREVIR",NDA209195,17ffc094-8ca7-45d2-80d8-fd043bc9a221,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209195_toc.cfm,
2021,NOREPINEPHRINE BITARTRATE,NOREPINEPHRINE BITARTRATE,NDA214313,6363e9b4-29df-4553-904d-a563e5adda6e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214313Orig1s000TOC.cfm,
2022,CIBINQO,ABROCITINIB,NDA213871,16c12a56-4550-414b-ac9d-b785b41fea6b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/213871Orig1s000TOC.cfm,
2019,TERIPARATIDE,TERIPARATIDE,NDA211939,1b007339-dd0d-f019-5e0a-9b1b0f75011c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211939Orig1s000TOC.cfm,
2017,ADALIMUMAB-ADBM,ADALIMUMAB-ADBM,BLA761058,f9986706-9c75-4335-a54f-09d7716dbcef,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761058Orig1s000TOC.cfm,
1995,ARIMIDEX,ANASTROZOLE,NDA020541,acbfaaa9-503c-4691-9828-76a7146ed6de,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020541Orig1s000rev.pdf,
1995,ARIMIDEX,ANASTROZOLE,NDA020541,acbfaaa9-503c-4691-9828-76a7146ed6de,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/20541Org1s020.pdf,
1995,ARIMIDEX,ANASTROZOLE,NDA020541,acbfaaa9-503c-4691-9828-76a7146ed6de,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-541s010_Arimidex.cfm,
1995,ARIMIDEX,ANASTROZOLE,NDA020541,acbfaaa9-503c-4691-9828-76a7146ed6de,http://www.accessdata.fda.gov/drugsatfda_docs/review/2018/20541Orig1s027.pdf,
1995,ARIMIDEX,ANASTROZOLE,NDA020541,acbfaaa9-503c-4691-9828-76a7146ed6de,http://www.accessdata.fda.gov/drugsatfda_docs/review/2018/20541Orig1s023.pdf,
1995,ARIMIDEX,ANASTROZOLE,NDA020541,acbfaaa9-503c-4691-9828-76a7146ed6de,http://www.accessdata.fda.gov/drugsatfda_docs/review/2018/20541Orig1s021.pdf,
1995,ARIMIDEX,ANASTROZOLE,NDA020541,acbfaaa9-503c-4691-9828-76a7146ed6de,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-541S006_Arimidex.cfm,
1996,CYSTADANE,BETAINE,NDA020576,31a684d0-cd98-4e46-b43a-ccbd17c41559,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020576Orig1s000rev.pdf,
2023,POSLUMA,FLOTUFOLASTAT F-18,NDA216023,907ac4a4-a088-4826-ab50-cfc31985c9d4,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216023Orig1s000TOC.cfm,
2008,NUCYNTA,TAPENTADOL HYDROCHLORIDE,NDA022304,80938c30-9fe3-4c7d-9d9c-5476638cfb2d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022304s000_TOC.cfm,
2008,NUCYNTA,TAPENTADOL HYDROCHLORIDE,NDA022304,80938c30-9fe3-4c7d-9d9c-5476638cfb2d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022304s000_SumR.pdf,
2001,N/A,N/A,NDA021224,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-224_Reminyl.cfm,
2003,JOLESSA,LEVONORGESTREL / ETHINYL ESTRADIOL,NDA021544,f1076019-6f2c-4c90-9f3c-ab0c7cdd9315,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-544_Seasonale.cfm,
2006,BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE,BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE,NDA021929,1d266fe8-52e3-4f85-a037-c5c1afa15e60,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021929Orig1s012.pdf,
2006,BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE,BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE,NDA021929,1d266fe8-52e3-4f85-a037-c5c1afa15e60,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021929_symbicort_toc.cfm,
2006,BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE,BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE,NDA021929,1d266fe8-52e3-4f85-a037-c5c1afa15e60,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/79_21929 budesonide formoterol fumarate dehydrate clinical prea.pdf,
2006,BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE,BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE,NDA021929,1d266fe8-52e3-4f85-a037-c5c1afa15e60,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/80_21929 budesonide formoterol fumarate dehydrate clinpharm prea.pdf,
2006,BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE,BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE,NDA021929,1d266fe8-52e3-4f85-a037-c5c1afa15e60,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/81_21929 budesonide formoterol fumarate dehydrate statistical prea.pdf,
2013,ESOMEPRAZOLE STRONTIUM,ESOMEPRAZOLE STRONTIUM,NDA202342,3c916d32-f9e9-1d15-e054-00144ff88e88,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202342Orig1s000TOC.cfm,
2016,XTAMPZA ER,OXYCODONE,NDA208090,b0a5ded2-8ee2-49ca-a86c-2b28ae40f60c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208090Orig1s004.pdf,
2016,XTAMPZA ER,OXYCODONE,NDA208090,b0a5ded2-8ee2-49ca-a86c-2b28ae40f60c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208090Orig1s000TOC.cfm,
2018,EMGALITY,GALCANEZUMAB-GNLM,BLA761063,33a147be-233a-40e8-a55e-e40936e28db0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761063Orig1s000TOC.cfm,
2021,SUCCINYLCHOLINE CHLORIDE,SUCCINYLCHOLINE CHLORIDE,NDA215143,cb5b3361-9099-4a12-b545-f1e50b0781dd,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215143Orig1s000TOC.cfm,
2009,EFFIENT,PRASUGREL HYDROCHLORIDE,NDA022307,69ea2d58-5353-4222-b61f-cab976fa7e5e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022307s000TOC.cfm,
2009,EFFIENT,PRASUGREL HYDROCHLORIDE,NDA022307,69ea2d58-5353-4222-b61f-cab976fa7e5e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022307s000_SumR.pdf,
2009,EFFIENT,PRASUGREL HYDROCHLORIDE,NDA022307,69ea2d58-5353-4222-b61f-cab976fa7e5e,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/15_22307 prasugrel clinical bpca.pdf,
2009,EFFIENT,PRASUGREL HYDROCHLORIDE,NDA022307,69ea2d58-5353-4222-b61f-cab976fa7e5e,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/16_22307 prasugrel clinpharm bpca.pdf,
2009,EFFIENT,PRASUGREL HYDROCHLORIDE,NDA022307,69ea2d58-5353-4222-b61f-cab976fa7e5e,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/17_22307 prasugrel statistical bpca.pdf,
2009,EFFIENT,PRASUGREL HYDROCHLORIDE,NDA022307,69ea2d58-5353-4222-b61f-cab976fa7e5e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022307Orig1s008TOC.cfm,
1998,N/A,N/A,NDA020897,N/A,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020897s009, 017577s033, 018211s016_oxybutynin-Ditropan-MedRev.pdf",
1998,N/A,N/A,NDA020897,N/A,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020897s009, 017577s033, 018211s016_oxybutynin-Ditropan-ClinPharmRev.pdf",
1998,N/A,N/A,NDA020897,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20897.cfm,
1998,N/A,N/A,NDA020897,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020897_S002_DITROPAN_AP.pdf,
2003,EMEND,APREPITANT,NDA021549,696f9e80-9cae-403b-de9e-078343ce4713,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021549Orig1S008.pdf,
2003,EMEND,APREPITANT,NDA021549,696f9e80-9cae-403b-de9e-078343ce4713,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021549_S002_EMEND.pdf,
2003,EMEND,APREPITANT,NDA021549,696f9e80-9cae-403b-de9e-078343ce4713,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-549_Emend.cfm,
2003,EMEND,APREPITANT,NDA021549,696f9e80-9cae-403b-de9e-078343ce4713,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/021549Orig1s010.pdf,
1997,N/A,N/A,NDA050746,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/050746_bactroban_toc.cfm,
1981,ALPRAZOLAM,ALPRAZOLAM,NDA018276,13930c94-d83a-414f-be35-b1fef35f738d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/018276_S038_Xanax Tablets_APPROVAL PACKAGE.pdf,
1981,ALPRAZOLAM,ALPRAZOLAM,NDA018276,13930c94-d83a-414f-be35-b1fef35f738d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/018276_S039_Xanax Tablets_APPROVAL PACKAGES.pdf,
1981,ALPRAZOLAM,ALPRAZOLAM,NDA018276,13930c94-d83a-414f-be35-b1fef35f738d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/018276_S035_Xanax Tablets_APPROVAL PACKAGE.pdf,
1981,ALPRAZOLAM,ALPRAZOLAM,NDA018276,13930c94-d83a-414f-be35-b1fef35f738d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/018276ap.pdf,
2015,N/A,N/A,NDA206544,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206544Orig1s000TOC.cfm,
2015,N/A,N/A,NDA206544,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206544Orig1s000SumR.pdf,
2016,NUPLAZID,PIMAVANSERIN TARTRATE,NDA207318,1e6bea44-57d6-4bac-9328-46e1ee59f83b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/207318Orig1s000SumR.pdf,
2016,NUPLAZID,PIMAVANSERIN TARTRATE,NDA207318,1e6bea44-57d6-4bac-9328-46e1ee59f83b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/207318Orig1s000TOC.cfm,
2018,N/A,N/A,NDA208085,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208085Orig1s000TOC.cfm,
1995,N/A,N/A,NDA020403,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020403_s014_Zofran Inj.pdf,
1995,N/A,N/A,NDA020403,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020403_s009_ZOFRAN_INJECTION.pdf,
1995,N/A,N/A,NDA020403,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20-007s022_Zofran.cfm,
2018,MULPLETA,LUSUTROMBOPAG,NDA210923,f9fd0cfd-717d-4a87-99bc-de7b38807e55,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210923Orig1s000TOC.cfm,
2017,MYLOTARG,GEMTUZUMAB OZOGAMICIN,BLA761060,32fd2bb2-1cfa-4250-feb8-d7956c794e05,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761060Orig1s000Orig1Orig2s000TOC.cfm,
2017,MYLOTARG,GEMTUZUMAB OZOGAMICIN,BLA761060,32fd2bb2-1cfa-4250-feb8-d7956c794e05,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761060Orig1s000Orig1Orig2s000TOC.cfm,
2021,LIVTENCITY,MARIBAVIR,NDA215596,c94fc2c5-e840-4f18-b7d8-d5eacb26d3a0,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215596Orig1s000TOC.cfm,
2024,MYHIBBIN,MYCOPHENOLATE MOFETIL,NDA216482,d9af72d6-7b3e-4c08-94b9-1d8b499cb7f9,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/216482Orig1s000TOC.cfm,
1998,SILDENAFIL CITRATE,SILDENAFIL CITRATE,NDA020895,98a9897b-0cbc-4ea6-9ac2-4dd719a2ede0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020895_S002_VIAGRA.pdf,
1998,SILDENAFIL CITRATE,SILDENAFIL CITRATE,NDA020895,98a9897b-0cbc-4ea6-9ac2-4dd719a2ede0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020895_S003_VIAGRA.pdf,
1998,SILDENAFIL CITRATE,SILDENAFIL CITRATE,NDA020895,98a9897b-0cbc-4ea6-9ac2-4dd719a2ede0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020895_S001_VIAGRA.pdf,
1998,SILDENAFIL CITRATE,SILDENAFIL CITRATE,NDA020895,98a9897b-0cbc-4ea6-9ac2-4dd719a2ede0,http://www.accessdata.fda.gov/drugsatfda_docs/NDA/98/viagra/viagra_toc.cfm,
2000,N/A,N/A,NDA021226,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-251S003_Kaletra.cfm,
2000,N/A,N/A,NDA021226,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21226s040 lopinavir-ritonavir clinical prea.pdf,
2000,N/A,N/A,NDA021226,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21226s040 lopinavir ritonavir clinpharm prea.pdf,
2000,N/A,N/A,NDA021226,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21226s040 lopinavir-ritonavir statistical prea.pdf,
2000,N/A,N/A,NDA021226,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021226_S014_KALETRA.pdf,
2000,N/A,N/A,NDA021226,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21226 lopinavir-ritonavir clinical prea.pdf,
2000,N/A,N/A,NDA021226,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21226 lopinavir ritonavir clinpharm prea.pdf,
2000,N/A,N/A,NDA021226,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21226 lopinavir-ritonavir statistical prea.pdf,
2000,N/A,N/A,NDA021226,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-226_Kaletra.cfm,
2000,N/A,N/A,NDA021226,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021226_S006_KALETRA.pdf,
2000,N/A,N/A,NDA021226,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-251S002_Kaletra.cfm,
2000,N/A,N/A,NDA021226,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021226_S017_KALETRA.pdf,
2003,N/A,N/A,NDA021546,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-546_Rebetol.cfm,
2006,N/A,N/A,NDA021937,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021937TOC2.cfm,
2002,N/A,N/A,NDA050741,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/050741_duac.cfm,
1972,N/A,N/A,NDA017105,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/017105_S059_TRANXENE_AP.pdf,
1972,N/A,N/A,NDA017105,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/017105_S070_Tranxene_APPROVAL_PACKAGE.pdf,
1972,N/A,N/A,NDA017105,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/017105_S062_TRANXENE_AP.pdf,
1989,N/A,N/A,NDA019151,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/19151.pdf,
2011,HYDROMORPHONE HYDROCHLORIDE,HYDROMORPHONE HYDROCHLORIDE,NDA200403,f9ca2ef5-46d8-475a-a26e-f7c8becd6db7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/200403Orig1s000SumR.pdf,
2011,HYDROMORPHONE HYDROCHLORIDE,HYDROMORPHONE HYDROCHLORIDE,NDA200403,f9ca2ef5-46d8-475a-a26e-f7c8becd6db7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/200403_hydromorphone_toc.cfm,
2012,N/A,N/A,NDA201194,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/201194_oxycodone_toc.cfm,
2012,N/A,N/A,NDA201194,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/201194Orig1s000SumR.pdf,
2014,N/A,N/A,NDA206545,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206545Orig1s000TOC.cfm,
2014,N/A,N/A,NDA206545,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206545Orig1s000SumR.pdf,
2016,INTRAROSA,PRASTERONE,NDA208470,ada639d4-bac0-2ad0-e053-2a95a90afce7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208470Orig1s000TOC.cfm,
2021,ASTEPRO ALLERGY,AZELASTINE HCL,NDA213872,e0640846-19a6-7f79-e053-2995a90a8176,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/213872Orig1s000TOC.cfm,
2017,TREMFYA,GUSELKUMAB,BLA761061,1e6dc9ae-1c4c-42d9-87aa-c315ecc51b56,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761061Orig1s000TOC.cfm,
2017,TREMFYA,GUSELKUMAB,BLA761061,1e6dc9ae-1c4c-42d9-87aa-c315ecc51b56,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761061Orig1s007.pdf,
2024,N/A,N/A,NDA216483,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/216483Orig1s000TOC.cfm,
2024,ZELSUVMI,BERDAZIMER,NDA217424,76b17622-bdb9-41ea-b962-c2acc0df71f7,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217424Orig1s000TOC.cfm,
1998,XELODA,CAPECITABINE,NDA020896,e702d84d-7162-4751-bf37-d724cc7e45a5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020896s032_Xeloda capecitabine clinical bpca.pdf,
1998,XELODA,CAPECITABINE,NDA020896,e702d84d-7162-4751-bf37-d724cc7e45a5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020896s032_Xeloda capecitabine clinpharm bpca.pdf,
1998,XELODA,CAPECITABINE,NDA020896,e702d84d-7162-4751-bf37-d724cc7e45a5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020896s032_Xeloda capecitabine statistical bpca.pdf,
1998,XELODA,CAPECITABINE,NDA020896,e702d84d-7162-4751-bf37-d724cc7e45a5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20896s6_Xeloda.cfm,
1998,XELODA,CAPECITABINE,NDA020896,e702d84d-7162-4751-bf37-d724cc7e45a5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-896S10S11_Xeloda.cfm,
1998,XELODA,CAPECITABINE,NDA020896,e702d84d-7162-4751-bf37-d724cc7e45a5,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/020896Orig1s044,s045,s046,s047,s048,s049,s050,s051.pdf",
1998,XELODA,CAPECITABINE,NDA020896,e702d84d-7162-4751-bf37-d724cc7e45a5,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/020896Orig1s044,s045,s046,s047,s048,s049,s050,s051.pdf",
1998,XELODA,CAPECITABINE,NDA020896,e702d84d-7162-4751-bf37-d724cc7e45a5,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/020896Orig1s044,s045,s046,s047,s048,s049,s050,s051.pdf",
1998,XELODA,CAPECITABINE,NDA020896,e702d84d-7162-4751-bf37-d724cc7e45a5,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/020896Orig1s044,s045,s046,s047,s048,s049,s050,s051.pdf",
1998,XELODA,CAPECITABINE,NDA020896,e702d84d-7162-4751-bf37-d724cc7e45a5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20896s6_Xeloda.cfm,
1998,XELODA,CAPECITABINE,NDA020896,e702d84d-7162-4751-bf37-d724cc7e45a5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20896.cfm,
1998,XELODA,CAPECITABINE,NDA020896,e702d84d-7162-4751-bf37-d724cc7e45a5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-896S10S11_Xeloda.cfm,
1998,XELODA,CAPECITABINE,NDA020896,e702d84d-7162-4751-bf37-d724cc7e45a5,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/020896Orig1s044,s045,s046,s047,s048,s049,s050,s051.pdf",
1998,XELODA,CAPECITABINE,NDA020896,e702d84d-7162-4751-bf37-d724cc7e45a5,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/020896Orig1s044,s045,s046,s047,s048,s049,s050,s051.pdf",
1998,XELODA,CAPECITABINE,NDA020896,e702d84d-7162-4751-bf37-d724cc7e45a5,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/020896Orig1s044,s045,s046,s047,s048,s049,s050,s051.pdf",
1998,XELODA,CAPECITABINE,NDA020896,e702d84d-7162-4751-bf37-d724cc7e45a5,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/020896Orig1s044,s045,s046,s047,s048,s049,s050,s051.pdf",
2001,CANCIDAS,CASPOFUNGIN ACETATE,NDA021227,3bad23a6-09a6-4194-9182-093ed61bc71c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021227_S014_CANCIDAS.pdf,
2001,CANCIDAS,CASPOFUNGIN ACETATE,NDA021227,3bad23a6-09a6-4194-9182-093ed61bc71c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21227_Cancidas.cfm,
2001,CANCIDAS,CASPOFUNGIN ACETATE,NDA021227,3bad23a6-09a6-4194-9182-093ed61bc71c,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021227_Caspofungin_Clinical_BPCA.pdf,
2001,CANCIDAS,CASPOFUNGIN ACETATE,NDA021227,3bad23a6-09a6-4194-9182-093ed61bc71c,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021227_Caspofungin_Clinpharm_BPCA.pdf,
2001,CANCIDAS,CASPOFUNGIN ACETATE,NDA021227,3bad23a6-09a6-4194-9182-093ed61bc71c,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021227_Caspofungin_Statistical_BPCA.pdf,
2003,N/A,N/A,NDA021548,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-548_Lexiva.cfm,
2003,N/A,N/A,NDA021548,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21548 fosamprenavir clinpharm bpca-prea.pdf,
2003,N/A,N/A,NDA021548,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21548 fosamprenavir clinical bpca-prea.pdf,
1996,STROMECTOL,IVERMECTIN,NDA050742,681888c9-af79-4b7d-ae80-c3f4f6f1effd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/050742ap.pdf,
1996,STROMECTOL,IVERMECTIN,NDA050742,681888c9-af79-4b7d-ae80-c3f4f6f1effd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/50-742s001_Stromectol.cfm,
2016,N/A,N/A,BLA208471,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208471Orig1s000TOC.cfm,
2022,TLANDO,TESTOSTERONE UNDECANOATE,NDA208088,4b0b92e9-6d3c-a0e5-e1c7-342999f72580,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/208088Orig1s000TOC.cfm,
2020,LAMPIT,NIFURTIMOX,NDA213464,90d09714-a8b1-4696-8ada-f99dc54d0721,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213464Orig1s000TOC.cfm,
1994,LAMICTAL,LAMOTRIGINE,NDA020241,d7e3572d-56fe-4727-2bb4-013ccca22678,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020764a.cfm,
1994,LAMICTAL,LAMOTRIGINE,NDA020241,d7e3572d-56fe-4727-2bb4-013ccca22678,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020764_s020_Lamictal-optimized.pdf,
1994,LAMICTAL,LAMOTRIGINE,NDA020241,d7e3572d-56fe-4727-2bb4-013ccca22678,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020241_S017_020764_S011TOC.cfm,
1994,LAMICTAL,LAMOTRIGINE,NDA020241,d7e3572d-56fe-4727-2bb4-013ccca22678,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020241_S011.pdf,
1994,LAMICTAL,LAMOTRIGINE,NDA020241,d7e3572d-56fe-4727-2bb4-013ccca22678,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020241s003.cfm,
1994,LAMICTAL,LAMOTRIGINE,NDA020241,d7e3572d-56fe-4727-2bb4-013ccca22678,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020241s032_020764s025_lamotrigine_Lamictal_ClinPharmRev.pdf,
1994,LAMICTAL,LAMOTRIGINE,NDA020241,d7e3572d-56fe-4727-2bb4-013ccca22678,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020241s032_020764s025_lamotrigine_Lamictal_ MedRev.pdf,
2021,N/A,N/A,NDA213072,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213072Orig1s000TOC.cfm,
2019,EVENITY,ROMOSOZUMAB-AQQG,BLA761062,471baba2-7154-4488-9891-0db2f46791e7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761062Orig1s000TOC.cfm,
2009,SOTALOL HYDROCHLORIDE,SOTALOL HYDROCHLORIDE,NDA022306,ff3061ab-d930-4318-a5be-684e38be229e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022306_sotalol_hydrochloride_toc.cfm,
2009,SOTALOL HYDROCHLORIDE,SOTALOL HYDROCHLORIDE,NDA022306,ff3061ab-d930-4318-a5be-684e38be229e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022306s000SumR.pdf,
2000,DETROL LA,TOLTERODINE TARTRATE,NDA021228,d7274947-4f88-47ee-a39f-bd5ac46fcf8d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/021228_S003_DetrolTOC.cfm,
2000,DETROL LA,TOLTERODINE TARTRATE,NDA021228,d7274947-4f88-47ee-a39f-bd5ac46fcf8d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/021228_S001_DetrolTOC.cfm,
2000,DETROL LA,TOLTERODINE TARTRATE,NDA021228,d7274947-4f88-47ee-a39f-bd5ac46fcf8d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/tolterodine_Detrol_StatsRev-21228s006.pdf,
2000,DETROL LA,TOLTERODINE TARTRATE,NDA021228,d7274947-4f88-47ee-a39f-bd5ac46fcf8d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/tolterodine_DetrolLA_ClinPharmRev-21228s006.pdf,
2000,DETROL LA,TOLTERODINE TARTRATE,NDA021228,d7274947-4f88-47ee-a39f-bd5ac46fcf8d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/Tolterodine_Detrol_MedRev-21228s006 (R).pdf,
2000,DETROL LA,TOLTERODINE TARTRATE,NDA021228,d7274947-4f88-47ee-a39f-bd5ac46fcf8d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/tolterodine_Detrol_MedRev(BPCA)-21228s006.pdf,
2000,DETROL LA,TOLTERODINE TARTRATE,NDA021228,d7274947-4f88-47ee-a39f-bd5ac46fcf8d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-228_Detrol.cfm,
2000,DETROL LA,TOLTERODINE TARTRATE,NDA021228,d7274947-4f88-47ee-a39f-bd5ac46fcf8d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021228_S006_DetrolTOC.cfm,
2000,DETROL LA,TOLTERODINE TARTRATE,NDA021228,d7274947-4f88-47ee-a39f-bd5ac46fcf8d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/021228_S002_DetrolTOC.cfm,
2006,SUTENT,SUNITINIB MALATE,NDA021938,a5d555f5-d66a-4f94-abcf-96fa6d71a32f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021938_s005_sutent.pdf,
2006,SUTENT,SUNITINIB MALATE,NDA021938,a5d555f5-d66a-4f94-abcf-96fa6d71a32f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021938_s003_sutent.pdf,
2006,SUTENT,SUNITINIB MALATE,NDA021938,a5d555f5-d66a-4f94-abcf-96fa6d71a32f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21938S36 sunitinib CDTL clinical bpca.pdf,
2006,SUTENT,SUNITINIB MALATE,NDA021938,a5d555f5-d66a-4f94-abcf-96fa6d71a32f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021938_s004_sutent.pdf,
2006,SUTENT,SUNITINIB MALATE,NDA021938,a5d555f5-d66a-4f94-abcf-96fa6d71a32f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021938_s002_sutent.pdf,
2006,SUTENT,SUNITINIB MALATE,NDA021938,a5d555f5-d66a-4f94-abcf-96fa6d71a32f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021938s000_021968s000_Stutent.cfm,
1952,N/A,N/A,NDA008306,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/008306_S029_PHENERGA-CODEINE_AP.pdf,
2020,ZEPOSIA 7-DAY STARTER PACK,OZANIMOD HYDROCHLORIDE,NDA209899,93ce2fab-edfb-4804-8074-963071de51e4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209899Orig1s000TOC.cfm,
2020,ZEPOSIA 7-DAY STARTER PACK,OZANIMOD HYDROCHLORIDE,NDA209899,93ce2fab-edfb-4804-8074-963071de51e4,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/209899Orig1s001.pdf,
2020,EYSUVIS,LOTEPREDNOL ETABONATE,NDA210933,a2169d82-4275-4ab6-a1c3-c274080b815c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/210933Orig1s000TOC.cfm,
2018,N/A,N/A,NDA211284,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211284Orig1s000TOC.cfm,
2018,N/A,N/A,NDA211284,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/357_211284 lamivudine-tenofovir DD clinical prea.pdf,
2018,N/A,N/A,NDA211284,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/358_211284 lamivudine-tenofovir clinpharm prea.pdf,
2019,N/A,N/A,BLA761066,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761066Orig1s000TOC.cfm,
2022,VOQUEZNA TRIPLE PAK,"VONOPRAZAN FUMARATE, AMOXICILLIN AND CLARITHROMYCIN",NDA215152,0cb2ee04-8581-46c8-a781-7be170ab5c86,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215152Orig1s000,215153Orig1s000TOC.cfm",
1996,N/A,N/A,NDA020635,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020635Orig1s068s070.pdf,
1996,N/A,N/A,NDA020635,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020635_S026_LEVAQUIN.pdf,
1996,N/A,N/A,NDA020635,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-634s008s009_20-635s007s008_Levaquin.cfm,
1996,N/A,N/A,NDA020635,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/020634Orig1s061, 020635Orig1s067, 021721Orig1s028TOC.cfm",
1996,N/A,N/A,NDA020635,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20635S043_levofloxacin_clinpharm_BPCA.pdf,
1996,N/A,N/A,NDA020635,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-634s015s021s022_020635s012s019s020_LevaquinTOC.cfm,
1996,N/A,N/A,NDA020635,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-634s015s021s022_020635s012s019s020_LevaquinTOC.cfm,
1996,N/A,N/A,NDA020635,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/020634se5-047,020635se5-051,021721se5-015_SUMR.pdf",
1996,N/A,N/A,NDA020635,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20635S043_levofloxacin_clinical_BPCA.pdf,
1996,N/A,N/A,NDA020635,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020635_S027_LEVAQUIN.pdf,
1996,N/A,N/A,NDA020635,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020635ap.pdf,
1996,N/A,N/A,NDA020635,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-634s015s021s022_020635s012s019s020_LevaquinTOC.cfm,
1996,N/A,N/A,NDA020635,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-634s008s009_20-635s007s008_Levaquin.cfm,
1996,N/A,N/A,NDA020635,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020635Orig1s068s070.pdf,
1996,N/A,N/A,NDA020635,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020634s04.cfm,
1996,CLARITIN REDITABS,LORATADINE,NDA020704,b681ea25-d00b-4c8a-8054-cc6f983ce337,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/1998/019670_s008,19658s10,20470s3,20641s120704s3_Claritin-DTOC.cfml",
1996,CLARITIN REDITABS,LORATADINE,NDA020704,b681ea25-d00b-4c8a-8054-cc6f983ce337,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/19670s18,20470s16,19658s18,20704s8,20641s9_Claritin.cfm",
1996,CLARITIN REDITABS,LORATADINE,NDA020704,b681ea25-d00b-4c8a-8054-cc6f983ce337,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/1998/019670_s012,19658s14,20470s7,20641s3,20704s4_ClaritinDTOC.cfml",
2008,MOZOBIL,PLERIXAFOR,NDA022311,0ed08d2b-5051-46b2-aa37-1d6275bf9003,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022311s000TOC.cfm,
2008,MOZOBIL,PLERIXAFOR,NDA022311,0ed08d2b-5051-46b2-aa37-1d6275bf9003,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022311s000_SumR.pdf,
1998,METRONIDAZOLE,METRONIDAZOLE,NDA020901,fce3e59e-8e08-47f1-947f-5a6d141ba1b2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20901.cfm,
2007,FLECTOR,DICLOFENAC EPOLAMINE,NDA021234,1f19a016-c4fc-43c5-9990-e5f2e2776a82,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021234s000TOC.cfm,
2010,ZORTRESS,EVEROLIMUS,NDA021560,e082a024-7850-400b-a5c2-2a140612562a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021560s000_zortress_toc.cfm,
2010,ZORTRESS,EVEROLIMUS,NDA021560,e082a024-7850-400b-a5c2-2a140612562a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021560s000sumr.pdf,
2006,FENTANYL BUCCAL,FENTANYL CITRATE,NDA021947,918d0e2a-3af3-46e8-ad06-528263e03ba0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021947s000FentoraTOC.cfm,
1962,N/A,N/A,NDA013217,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/013217s044_SkelexinTOC.cfm,
1962,N/A,N/A,NDA013217,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/013217_S040_SKELAXIN.pdf,
1962,N/A,N/A,NDA013217,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/013217_S045_SKELAXIN.pdf,
1962,N/A,N/A,NDA013217,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/013217_S037_SKELAXIN.pdf,
1962,N/A,N/A,NDA013217,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/013217_S043_SKELAXIN.pdf,
1962,N/A,N/A,NDA013217,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/013217_S041_SKELAXIN.pdf,
1998,ZOSYN IN GALAXY CONTAINERS,TAZOBACTAM SODIUM AND PIPERACILLIN SODIUM,NDA050750,8ab9d90d-2f7f-4599-a44f-3d0a8f8ab623,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/050684_S045_050750_s012_ZosynTOC.cfm,
1998,ZOSYN IN GALAXY CONTAINERS,TAZOBACTAM SODIUM AND PIPERACILLIN SODIUM,NDA050750,8ab9d90d-2f7f-4599-a44f-3d0a8f8ab623,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/50750.pdf,
2011,N/A,N/A,NDA202343,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202343Orig1s000TOC.cfm,
2011,N/A,N/A,NDA202343,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202343Orig1s000SumR.pdf,
2018,ARGATROBAN,ARGATROBAN,NDA209552,d9b975bd-e3f4-466e-96ca-7bef7899506d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209552Orig1s000TOC.cfm,
1953,NITROFURANTOIN,NITROFURANTOIN,NDA009175,89095f4d-e142-465e-b378-da24f6eeaf2b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/008693s025_009175s019_016620s045_MacrodantinTOC.cfm,
2015,LENVIMA,LENVATINIB,NDA206947,f4bedd21-efde-44c6-9d9c-b48b78d7ed1e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/206947Orig1s024.pdf,
2015,LENVIMA,LENVATINIB,NDA206947,f4bedd21-efde-44c6-9d9c-b48b78d7ed1e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206947Orig1s000TOC.cfm,
2015,LENVIMA,LENVATINIB,NDA206947,f4bedd21-efde-44c6-9d9c-b48b78d7ed1e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206947Orig1s000SumR.pdf,
2017,N/A,N/A,NDA209203,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209203Orig1s000TOC.cfm,
1992,N/A,N/A,NDA020103,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020103_s025_Zofran  Inj.pdf,
1992,N/A,N/A,NDA020103,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020103_S017_ZOFRAN.pdf,
1992,N/A,N/A,NDA020103,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20103S15_Zofran.cfm,
1992,N/A,N/A,NDA020103,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020103_s024_Zofran Tabs.pdf,
1992,N/A,N/A,NDA020103,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20103S15_Zofran.cfm,
2019,REYVOW,LASMIDITAN,NDA211280,aea3358c-ff41-4490-9e6d-c7bf7b3de13f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000TOC.cfm,
2021,XIPERE,TRIAMCINOLONE ACETONIDE,NDA211950,ea6ad429-967f-4f75-a33d-e06f849bee80,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/211950Orig1s000TOC.cfm,
2020,XYWAV,"CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES",NDA212690,1e0ae43a-037f-42af-8e23-a0e51d75abe8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212690Orig1s000TOC.cfm,
2020,XYWAV,"CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES",NDA212690,1e0ae43a-037f-42af-8e23-a0e51d75abe8,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/212690Orig1s006.pdf,
2024,LUMIFY PRESERVATIVE FREE EYE DROPS,BRIMONIDINE TARTRATE,NDA218424,ef5974b9-946c-4983-80e3-32b3aa28c207,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/218424Orig1s000TOC.cfm,
2017,RITUXAN HYCELA,RITUXIMAB AND HYALURONIDASE,BLA761064,3e5b7e82-f018-4eaf-ae78-d6145a906b20,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761064Orig1s000TOC.cfm,
2009,BESIVANCE,BESIFLOXACIN,NDA022308,a3e6d688-7e5e-4ca3-b27e-79756c322a32,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022308s000TOC.cfm,
2009,BESIVANCE,BESIFLOXACIN,NDA022308,a3e6d688-7e5e-4ca3-b27e-79756c322a32,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022308s000_SumR.pdf,
2009,BESIVANCE,BESIFLOXACIN,NDA022308,a3e6d688-7e5e-4ca3-b27e-79756c322a32,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022308s000_Besifloxacin hydrochloride_Clinical_PREA.pdf,
2009,BESIVANCE,BESIFLOXACIN,NDA022308,a3e6d688-7e5e-4ca3-b27e-79756c322a32,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022308s000_Besifloxacin hydrochloride_ClinPharm_PREA.pdf,
2009,BESIVANCE,BESIFLOXACIN,NDA022308,a3e6d688-7e5e-4ca3-b27e-79756c322a32,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022308s000_Besifloxacin hydrochloride_Statistical_PREA.pdf,
1998,THYROGEN,THYROTROPIN ALFA,BLA020898,b52dfa36-f90b-4e19-9b5e-26db9d04df2b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20898_Thyrogen.cfm,
2003,PRILOSEC OTC,OMEPRAZOLE MAGNESIUM,NDA021229,35a79458-79f6-44d6-b74c-b4f4aaf0dde0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-229_Prilosec.cfm,
2004,N/A,N/A,NDA021551,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021551s000_HalfLytelyTOC.cfm,
2004,N/A,N/A,NDA021551,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21551_HLB_Clinical_PREA.pdf,
2004,N/A,N/A,NDA021551,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21551_HLB_Clinpharm_PREA.pdf,
2004,N/A,N/A,NDA021551,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21551_HLB_Statistical_PREA.pdf,
2012,GATTEX,TEDUGLUTIDE,NDA203441,66b69c1e-b25c-44d3-b5ff-1c1de9a516fa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203441Orig1s000TOC.cfm,
2012,GATTEX,TEDUGLUTIDE,NDA203441,66b69c1e-b25c-44d3-b5ff-1c1de9a516fa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203441Orig1s000SumR.pdf,
2012,GATTEX,TEDUGLUTIDE,NDA203441,66b69c1e-b25c-44d3-b5ff-1c1de9a516fa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203441Orig1s002.pdf,
2011,DOCETAXEL,DOCETAXEL,NDA201195,f59f7811-70b7-4c44-99f7-4f4fdce3ed22,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201195_docetaxel_toc.cfm,
2011,DOCETAXEL,DOCETAXEL,NDA201195,f59f7811-70b7-4c44-99f7-4f4fdce3ed22,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201195Orig1s000SumR.pdf,
2012,BINOSTO,ALENDRONATE SODIUM,NDA202344,09765234-01bc-40f7-b9bb-c167056f3909,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202344_binosto_toc.cfm,
2012,BINOSTO,ALENDRONATE SODIUM,NDA202344,09765234-01bc-40f7-b9bb-c167056f3909,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202344Orig1s000SumR.pdf,
2012,PHENYLEPHRINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE,NDA203826,c3f358dd-4a36-4808-9943-e01f88604be5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203826_phenylephrine_toc.cfm,
2012,PHENYLEPHRINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE,NDA203826,c3f358dd-4a36-4808-9943-e01f88604be5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203826Orig1s000SumR.pdf,
2013,ISENTRESS,RALTEGRAVIR,NDA205786,89a5ec53-d956-4329-8004-0f40f51c88a3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/219_205786S006-raltegravir-clinical-prea.pdf,
2013,ISENTRESS,RALTEGRAVIR,NDA205786,89a5ec53-d956-4329-8004-0f40f51c88a3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/220_205786S006-raltegravir-clinpharm-prea.pdf,
2013,ISENTRESS,RALTEGRAVIR,NDA205786,89a5ec53-d956-4329-8004-0f40f51c88a3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205786Orig1s000TOC.cfm,
2013,ISENTRESS,RALTEGRAVIR,NDA205786,89a5ec53-d956-4329-8004-0f40f51c88a3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205786 raltegravir clinical prea.pdf,
2013,ISENTRESS,RALTEGRAVIR,NDA205786,89a5ec53-d956-4329-8004-0f40f51c88a3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205786 raltegravir clinpharm prea.pdf,
2013,ISENTRESS,RALTEGRAVIR,NDA205786,89a5ec53-d956-4329-8004-0f40f51c88a3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205786Orig1s000SumR.pdf,
2016,EUCRISA,CRISABOROLE,NDA207695,609b77de-1ca3-4783-b8f5-01a9c0f1d77d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/207695Orig1s000TOC.cfm,
2016,EUCRISA,CRISABOROLE,NDA207695,609b77de-1ca3-4783-b8f5-01a9c0f1d77d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/49_207695 crisaborole CDTL clinical prea.pdf,
2016,EUCRISA,CRISABOROLE,NDA207695,609b77de-1ca3-4783-b8f5-01a9c0f1d77d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/50_207695 crisaborole clinical prea-EMV.pdf,
2016,EUCRISA,CRISABOROLE,NDA207695,609b77de-1ca3-4783-b8f5-01a9c0f1d77d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/51_207695 crisaborole clinpharm prea.pdf,
2016,EUCRISA,CRISABOROLE,NDA207695,609b77de-1ca3-4783-b8f5-01a9c0f1d77d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/52_207695 crisaborole statistical prea.pdf,
2020,ALKINDI SPRINKLE,HYDROCORTISONE,NDA213876,26c13a5f-7119-4c6a-bf10-fda4e07d7682,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213876Orig1s000TOC.cfm,
2020,N/A,N/A,NDA210583,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210583Orig1s000TOC.cfm,
2020,N/A,N/A,NDA211281,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/211281Orig1s000TOC.cfm,
2001,N/A,N/A,NDA020831,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020831_S002_FORADIL_AP.pdf,
2001,N/A,N/A,NDA020831,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20831_Foradil.cfm,
2022,BACLOFEN,BACLOFEN,NDA215602,4585aafe-0af8-4786-a419-6a7e76671ca2,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215602Orig1s000TOC.cfm,
2024,YORVIPATH,PALOPEGTERIPARATIDE,NDA216490,a1fa23fd-c434-443e-9a17-5750578c8602,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/216490Orig1s000TOC.cfm,
2011,TESTOSTERONE,TESTOSTERONE,NDA022309,0d84e5a6-11e9-4940-8991-21c611c4c32f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022309Orig1s000SumR.pdf,
2011,TESTOSTERONE,TESTOSTERONE,NDA022309,0d84e5a6-11e9-4940-8991-21c611c4c32f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022309_androgel_toc.cfm,
2011,TESTOSTERONE,TESTOSTERONE,NDA022309,0d84e5a6-11e9-4940-8991-21c611c4c32f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022309Orig1s001.pdf,
2001,N/A,N/A,NDA021231,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-231_Zomig.cfm,
2001,N/A,N/A,NDA021231,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021231_S003_ZOMIG_TABLETS.pdf,
1999,N/A,N/A,NDA050748,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid.cfm,
1976,N/A,N/A,NDA017581,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/017581_S004_NAPROSYN_AP.pdf,
2014,N/A,N/A,NDA205787,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205787Orig1s000TOC.cfm,
2014,N/A,N/A,NDA205787,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205787Orig1s000SumR.pdf,
2022,TYVASO DPI,TREPROSTINIL,NDA214324,ddc3d400-bcb3-4b09-aae2-0768b10a5b0f,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214324Orig1s000TOC.cfm,
2020,VALTOCO,DIAZEPAM,NDA211635,1a8bcc90-68fa-474d-832c-0df01e825f39,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/211635Orig1s000TOC.cfm,
1998,LAMICTAL,LAMOTRIGINE,NDA020764,d7e3572d-56fe-4727-2bb4-013ccca22678,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020764_s020_Lamictal-optimized.pdf,
1998,LAMICTAL,LAMOTRIGINE,NDA020764,d7e3572d-56fe-4727-2bb4-013ccca22678,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020764_S005.pdf,
1998,LAMICTAL,LAMOTRIGINE,NDA020764,d7e3572d-56fe-4727-2bb4-013ccca22678,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020241s003.cfm,
1998,LAMICTAL,LAMOTRIGINE,NDA020764,d7e3572d-56fe-4727-2bb4-013ccca22678,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020241_S017_020764_S011TOC.cfm,
1998,LAMICTAL,LAMOTRIGINE,NDA020764,d7e3572d-56fe-4727-2bb4-013ccca22678,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020764a.cfm,
1999,ENTACAPONE,ENTACAPONE,NDA020796,205522fb-bb0e-414e-a413-a08bef727653,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20796_Comtan.cfm,
2018,TROGARZO,IBALIZUMAB,BLA761065,c548ad82-9d1f-4d16-95b6-4e6106badf43,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/TROGARZO_761065_TOC.cfm,
2023,VOQUEZNA,VONOPRAZAN FUMARATE,NDA215151,0cc52ac5-77ec-4d66-a770-762a1a960914,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/215151Orig1s000TOC.cfm,
2002,ORFADIN,NITISINONE,NDA021232,5d449b73-d503-4132-b978-d890491975df,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-232_Orfadin.cfm,
2002,CHLORAPREP ONE-STEP,CHLORHEXIDINE GLUCONATE AND ISOPROPYL ALCOHOL,NDA021555,f06e4f9d-6cef-b57a-e053-2a95a90a7337,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-555_Chloraprep.cfm,
2006,N/A,N/A,NDA021946,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021946s000TOC.cfm,
1997,N/A,N/A,NDA050749,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/050739s000_050749s000_OmnicefTOC.cfm,
1986,N/A,N/A,NDA019384,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019384_S036_NOROXIN.pdf,
1986,N/A,N/A,NDA019384,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/019384_S034_NOROXIN.pdf,
1986,N/A,N/A,NDA019384,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/019384_S032_NOROXIN.pdf,
1986,N/A,N/A,NDA019384,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019384_S024_NOROXIN.pdf,
1986,N/A,N/A,NDA019384,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/019384_S030_NOROXIN.pdf,
1986,N/A,N/A,NDA019384,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/019384_S029_NOROXIN.pdf,
1986,N/A,N/A,NDA019384,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/019384_S035_NOROXIN.pdf,
1986,N/A,N/A,NDA019384,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019384_S027_NOROXIN.pdf,
1986,N/A,N/A,NDA019384,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019384Orig1s000rev.pdf,
1986,N/A,N/A,NDA019384,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019384_S031_NOROXIN.pdf,
2013,N/A,N/A,NDA204592,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204592Orig1s000TOC.cfm,
2013,N/A,N/A,NDA204592,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204592Orig1s000SumR.pdf,
2013,N/A,N/A,NDA204592,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204592Orig1s004.pdf,
2013,N/A,N/A,NDA204592,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204592Orig1s002.pdf,
2017,BYDUREON BCISE,EXENATIDE,NDA209210,2d18cfc4-e0de-4814-a712-c1b7c504bff5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209210Orig1s000TOC.cfm,
2018,VIZIMPRO,DACOMITINIB,NDA211288,90da33c1-5689-4b4d-a2b5-377e1057a843,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211288Orig1s000TOC.cfm,
2019,VANCOMYCIN,VANCOMYCIN,NDA211962,60bee69b-be70-412c-9e83-a24a0a8a5e7b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211962Orig1s000TOC.cfm,
2017,FASENRA,BENRALIZUMAB,BLA761070,da6aca1a-19ed-44a4-abb7-696c7d58b784,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761070Orig1s000TOC.cfm,
2017,FASENRA,BENRALIZUMAB,BLA761070,da6aca1a-19ed-44a4-abb7-696c7d58b784,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/217_761070 benralizumab clinical prea.pdf,
2017,FASENRA,BENRALIZUMAB,BLA761070,da6aca1a-19ed-44a4-abb7-696c7d58b784,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/216_761070  benralizumab clinpharm prea.pdf,
2017,FASENRA,BENRALIZUMAB,BLA761070,da6aca1a-19ed-44a4-abb7-696c7d58b784,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/218_761070 benralizumab statistical prea.pdf,
2009,SEVELAMER CARBONATE,SEVELAMER CARBONATE,NDA022318,3abc32fe-1bfc-4759-8f7c-36095e221b06,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022318s000_renvela_toc.cfm,
2009,SEVELAMER CARBONATE,SEVELAMER CARBONATE,NDA022318,3abc32fe-1bfc-4759-8f7c-36095e221b06,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022318s000_SumR.pdf,
2003,REYATAZ,ATAZANAVIR,NDA021567,165cff62-b284-4a27-a65d-9ec8a5bfcdd8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021567a015_Atazanavir_Clinpharm_PREA.pdf,
2003,REYATAZ,ATAZANAVIR,NDA021567,165cff62-b284-4a27-a65d-9ec8a5bfcdd8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021567s015_Atazanavir_Clinical_PREA.pdf,
2003,REYATAZ,ATAZANAVIR,NDA021567,165cff62-b284-4a27-a65d-9ec8a5bfcdd8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/206352 atazanavir clinical both.pdf,
2003,REYATAZ,ATAZANAVIR,NDA021567,165cff62-b284-4a27-a65d-9ec8a5bfcdd8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/206352 atazanavir clinpharm both.pdf,
2003,REYATAZ,ATAZANAVIR,NDA021567,165cff62-b284-4a27-a65d-9ec8a5bfcdd8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/206352 atazanavir statistical both.pdf,
2003,REYATAZ,ATAZANAVIR,NDA021567,165cff62-b284-4a27-a65d-9ec8a5bfcdd8,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/206352Orig1s000, 021567Orig1s035_Atazanavir_Clinical.pdf",
2003,REYATAZ,ATAZANAVIR,NDA021567,165cff62-b284-4a27-a65d-9ec8a5bfcdd8,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/206352Orig1s000, 021567Orig1s035_Atazanavir_Clinical.pdf",
2003,REYATAZ,ATAZANAVIR,NDA021567,165cff62-b284-4a27-a65d-9ec8a5bfcdd8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021567_reyataz_toc.cfm,
2003,REYATAZ,ATAZANAVIR,NDA021567,165cff62-b284-4a27-a65d-9ec8a5bfcdd8,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/206352Orig1s000,021567Orig1s035_Atazanavir_Clinical.pdf",
2003,REYATAZ,ATAZANAVIR,NDA021567,165cff62-b284-4a27-a65d-9ec8a5bfcdd8,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/206352Orig1s000, 021567Orig1s035_Atazanavir_Statistical.pdf",
2003,REYATAZ,ATAZANAVIR,NDA021567,165cff62-b284-4a27-a65d-9ec8a5bfcdd8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206352Orig1s000_021567Orig1s035TOC.cfm,
2003,REYATAZ,ATAZANAVIR,NDA021567,165cff62-b284-4a27-a65d-9ec8a5bfcdd8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206352Orig1s000_021567Orig1s035SumR.pdf,
2003,REYATAZ,ATAZANAVIR,NDA021567,165cff62-b284-4a27-a65d-9ec8a5bfcdd8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021567Orig1s019.pdf,
2003,REYATAZ,ATAZANAVIR,NDA021567,165cff62-b284-4a27-a65d-9ec8a5bfcdd8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021567Orig1s025.pdf,
2008,N/A,N/A,NDA021952,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021952_claritin_toc.cfm,
2008,N/A,N/A,NDA021952,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/021952s000_SUMR.pdf,
1958,N/A,N/A,NDA011641,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/011641Orig1s065.pdf,
1958,N/A,N/A,NDA011641,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/011641_S061_DIABINESE_TABLETS_AP.pdf,
1958,N/A,N/A,NDA011641,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/011641_058&060_Diabinese_APPROVAL_PACKAGE.pdf,
1958,N/A,N/A,NDA011641,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/011641_058&060_Diabinese_APPROVAL_PACKAGE.pdf,
1998,N/A,N/A,NDA050754,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50-542s016_50-754s001_Amoxil.cfm,
1998,N/A,N/A,NDA050754,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-542s017_50-754s002_50-760s001_50-761s001_Amoxil.cfm,
1998,N/A,N/A,NDA050754,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/50754.pdf,
2011,ISENTRESS,RALTEGRAVIR,NDA203045,89a5ec53-d956-4329-8004-0f40f51c88a3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/203045Orig1s000SumR.pdf,
2011,ISENTRESS,RALTEGRAVIR,NDA203045,89a5ec53-d956-4329-8004-0f40f51c88a3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/203045_isentress_toc.cfm,
1989,CLOZARIL,CLOZAPINE,NDA019758,90876802-0e3a-44c9-9ff7-1754dfbe736a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019758Orig1s047.pdf,
1989,CLOZARIL,CLOZAPINE,NDA019758,90876802-0e3a-44c9-9ff7-1754dfbe736a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/019758Orig1s061.pdf,
1989,CLOZARIL,CLOZAPINE,NDA019758,90876802-0e3a-44c9-9ff7-1754dfbe736a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/019758Orig1s098.pdf,
1989,CLOZARIL,CLOZAPINE,NDA019758,90876802-0e3a-44c9-9ff7-1754dfbe736a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019758_S035_CLOZARIL_TABS.pdf,
1989,CLOZARIL,CLOZAPINE,NDA019758,90876802-0e3a-44c9-9ff7-1754dfbe736a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/019758Orig1s041.pdf,
1989,CLOZARIL,CLOZAPINE,NDA019758,90876802-0e3a-44c9-9ff7-1754dfbe736a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/019758Orig1s090.pdf,
1989,CLOZARIL,CLOZAPINE,NDA019758,90876802-0e3a-44c9-9ff7-1754dfbe736a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/019758Orig1s036.pdf,
1989,CLOZARIL,CLOZAPINE,NDA019758,90876802-0e3a-44c9-9ff7-1754dfbe736a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/019758Orig1s034.pdf,
2018,ILUMYA,TILDRAKIZUMAB-ASMN,BLA761067,c6a322bb-51b9-4f0e-8642-62a9682ffcde,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761067Orig1s000TOC.cfm,
2022,VOQUEZNA DUAL PAK,VONOPRAZAN FUMARATE AND AMOXICILLIN,NDA215153,0cb2ee04-8581-46c8-a781-7be170ab5c86,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215152Orig1s000,215153Orig1s000TOC.cfm",
1997,N/A,N/A,NDA020606,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/020606se8-014, 021140se8-011_SUMR.pdf",
1997,N/A,N/A,NDA020606,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020606ap.pdf,
1997,N/A,N/A,NDA020606,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020606_S009_IMODIUM_ADVANCED_CHEWABLE_TABLETS.pdf,
1996,HYCAMTIN,TOPOTECAN HYDROCHLORIDE,NDA020671,eeee060c-a9ec-423e-a374-8484009f8524,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20671s004.cfm,
1996,HYCAMTIN,TOPOTECAN HYDROCHLORIDE,NDA020671,eeee060c-a9ec-423e-a374-8484009f8524,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020671Orig1s000rev.pdf,
2024,TALZENNA,TALAZOPARIB,NDA217439,c6fd147f-a77e-4a0b-9280-e82ecc41b4be,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217439Orig1s000TOC.cfm,
2012,N/A,N/A,NDA022312,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022312Orig1s000SumR.pdf,
2012,N/A,N/A,NDA022312,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022312_docetaxel_toc.cfm,
2001,N/A,N/A,NDA021235,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021235Orig1s016.pdf,
2001,N/A,N/A,NDA021235,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-235_Prozac.cfm,
2004,N/A,N/A,NDA021563,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021563s000_ClarinexTOC.cfm,
1998,N/A,N/A,NDA050751,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/50751.cfm,
2018,OMEGAVEN,FISH OIL,NDA210589,5d9d0b24-e139-48bf-ab2d-536fb59cf8e0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210589Orig1s000TOC.cfm,
2020,XELJANZ,TOFACITINIB,NDA213082,cf74ba2f-afc5-4baa-8594-979c889a5831,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213082Orig1s000TOC.cfm,
2018,CRYSVITA,BUROSUMAB,BLA761068,102f96a0-6e3a-4fc1-b204-34d604683af6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761068Orig1s000TOC.cfm,
2009,EXFORGE HCT,AMLODIPINE VALSARTAN AND HYDROCHLOROTHIAZIDE,NDA022314,18d7820d-471f-4ee2-9ec6-25d8d27c77de,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022314s000TOC.cfm,
2009,EXFORGE HCT,AMLODIPINE VALSARTAN AND HYDROCHLOROTHIAZIDE,NDA022314,18d7820d-471f-4ee2-9ec6-25d8d27c77de,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022314s000_SumR.pdf,
1998,N/A,N/A,NDA020903,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-903S006S007_Rebetol.pdf,
1998,N/A,N/A,NDA020903,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/020903Orig1s013.pdf,
1998,N/A,N/A,NDA020903,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-903s008s011s012s016_Rebetol.cfm,
1998,N/A,N/A,NDA020903,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-903s008s011s012s016_Rebetol.cfm,
1998,N/A,N/A,NDA020903,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-903S006S007_Rebetol.pdf,
1998,N/A,N/A,NDA020903,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020903_S32_REBETOL RETETRON.pdf,
1998,N/A,N/A,NDA020903,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-903s008s011s012s016_Rebetol.cfm,
1998,N/A,N/A,NDA020903,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020903_S30_REBETOL REBETRON.pdf,
1998,N/A,N/A,NDA020903,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-903s020_Rebetol.cfm,
1998,N/A,N/A,NDA020903,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-903s008s011s012s016_Rebetol.cfm,
1998,N/A,N/A,NDA020903,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020903_rebetol_toc.cfm,
2003,N/A,N/A,NDA021565,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-565_Elestat.cfm,
2006,PULMICORT FLEXHALER,BUDESONIDE,NDA021949,10f2ae5b-a6fb-4804-9111-0cd067c2b1b2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021949_budesonide_toc.cfm,
2021,ACETAMINOPHEN,ACETAMINOPHEN,NDA204957,6d763554-913d-4bed-9efd-b9c9b936a2f4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/204957Orig1s000TOC.cfm,
2019,N/A,N/A,NDA209905,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209905Orig1s000TOC.cfm,
2019,GLOPERBA,COLCHICINE,NDA210942,467cd83f-d695-4040-9434-10e80b4271da,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210942Orig1s000TOC.cfm,
2017,IMFINZI,DURVALUMAB,BLA761069,8baba4ea-2855-42fa-9bd9-5a7548d4cec3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761069Orig1s000TOC.cfm,
2023,JESDUVROQ,DAPRODUSTAT,NDA216951,d82aa06e-5a33-4844-99b7-4701313455a4,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216951Orig1s000TOC.cfm,
2009,OZURDEX,DEXAMETHASONE,NDA022315,4b204f44-6e8a-4d17-803c-268f0b04679f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022315_ozurdex_toc.cfm,
2009,OZURDEX,DEXAMETHASONE,NDA022315,4b204f44-6e8a-4d17-803c-268f0b04679f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022315s000_SumR.pdf,
2009,OZURDEX,DEXAMETHASONE,NDA022315,4b204f44-6e8a-4d17-803c-268f0b04679f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022315Orig1s009.pdf,
1998,ARAVA,LEFLUNOMIDE,NDA020905,320f63f2-fac3-4aee-aff8-85724e00ef52,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/291_leflunomide_Arava-MedRev-20905s012.pdf,
1998,ARAVA,LEFLUNOMIDE,NDA020905,320f63f2-fac3-4aee-aff8-85724e00ef52,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/293_leflunomide_Arava-ClinPharmRev-20905s012.pdf,
1998,ARAVA,LEFLUNOMIDE,NDA020905,320f63f2-fac3-4aee-aff8-85724e00ef52,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/289_leflunomide_Arava-StatsRev-20905s012.pdf,
1998,ARAVA,LEFLUNOMIDE,NDA020905,320f63f2-fac3-4aee-aff8-85724e00ef52,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/290_leflunomide_Arava-StatsRev-20905s012-(R).pdf,
1998,ARAVA,LEFLUNOMIDE,NDA020905,320f63f2-fac3-4aee-aff8-85724e00ef52,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020905_S007_ARAVA.pdf,
1998,ARAVA,LEFLUNOMIDE,NDA020905,320f63f2-fac3-4aee-aff8-85724e00ef52,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020905_S006_ARAVA.pdf,
1998,ARAVA,LEFLUNOMIDE,NDA020905,320f63f2-fac3-4aee-aff8-85724e00ef52,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020905_S012_ARAVA.pdf,
2002,N/A,N/A,NDA021241,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021241_s003_OrthoTOC.cfm,
2002,N/A,N/A,NDA021241,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021241_sooo_Orthotricyclene.cfm,
2012,ABSORICA,ISOTRETINOIN,NDA021951,3ef0cff8-19c1-4441-b780-fca6c7ee1615,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021951_absorica_toc.cfm,
1997,TOBI,TOBRAMYCIN,NDA050753,6a3c3871-1d3a-44d6-8be3-526b30123ef7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/050753_tobi_toc.cfm,
2012,KYPROLIS,CARFILZOMIB,NDA202714,ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202714Orig1s000TOC.cfm,
2012,KYPROLIS,CARFILZOMIB,NDA202714,ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202714Orig1s000SumR.pdf,
2012,KYPROLIS,CARFILZOMIB,NDA202714,ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/202714Orig1s021TOC.cfm,
2019,TISSUEBLUE,BRILLIANT BLUE G,NDA209569,9d4b28b4-c582-4e2c-abd9-f7e203378e2d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209569Orig1s000TOC.cfm,
1992,PROSCAR,FINASTERIDE,NDA020180,6f988153-fc74-4ca4-b29a-111f750c4a4b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020180_S029_PROSCAR TABLETS.pdf,
1992,PROSCAR,FINASTERIDE,NDA020180,6f988153-fc74-4ca4-b29a-111f750c4a4b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020180_s027_ProscarTOC.cfm,
1992,PROSCAR,FINASTERIDE,NDA020180,6f988153-fc74-4ca4-b29a-111f750c4a4b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020180_s019_PROSCAR 5MG.pdf,
1992,PROSCAR,FINASTERIDE,NDA020180,6f988153-fc74-4ca4-b29a-111f750c4a4b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020180_S025_PROSCAR_TABS_AP.pdf,
1992,PROSCAR,FINASTERIDE,NDA020180,6f988153-fc74-4ca4-b29a-111f750c4a4b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20180-S017_PROSCAR.PDF,
1992,PROSCAR,FINASTERIDE,NDA020180,6f988153-fc74-4ca4-b29a-111f750c4a4b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020180_S023_PROSCAR TABLETS.pdf,
1992,PROSCAR,FINASTERIDE,NDA020180,6f988153-fc74-4ca4-b29a-111f750c4a4b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20180-S015&16_PROSCAR.PDF,
1992,PROSCAR,FINASTERIDE,NDA020180,6f988153-fc74-4ca4-b29a-111f750c4a4b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20180-S013_PROSCAR.PDF,
1992,PROSCAR,FINASTERIDE,NDA020180,6f988153-fc74-4ca4-b29a-111f750c4a4b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020180s011_proscar_toc.cfm,
1992,PROSCAR,FINASTERIDE,NDA020180,6f988153-fc74-4ca4-b29a-111f750c4a4b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020180_S026_PROSCAR TABLETS.pdf,
1992,PROSCAR,FINASTERIDE,NDA020180,6f988153-fc74-4ca4-b29a-111f750c4a4b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020180_s018_PROSCAR 5MG.pdf,
1992,PROSCAR,FINASTERIDE,NDA020180,6f988153-fc74-4ca4-b29a-111f750c4a4b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020180_S024_PROSCAR TABLETS.pdf,
1992,PROSCAR,FINASTERIDE,NDA020180,6f988153-fc74-4ca4-b29a-111f750c4a4b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20180-S015&16_PROSCAR.PDF,
1992,PROSCAR,FINASTERIDE,NDA020180,6f988153-fc74-4ca4-b29a-111f750c4a4b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020180_s022_PROSCAR 5MG.pdf,
1992,PROSCAR,FINASTERIDE,NDA020180,6f988153-fc74-4ca4-b29a-111f750c4a4b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/1997/020180_s014_ProscarTOC.cfm,
1992,PROSCAR,FINASTERIDE,NDA020180,6f988153-fc74-4ca4-b29a-111f750c4a4b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020180_S020_PROSCAR_TABS_AP.pdf,
1992,PROSCAR,FINASTERIDE,NDA020180,6f988153-fc74-4ca4-b29a-111f750c4a4b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020180_s010_ProscarTOC.cfm,
2017,OGIVRI,TRASTUZUMAB-DKST,BLA761074,b6465b44-a6dd-f99c-d009-6851cf05169c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761074Orig1s000TOC.cfm,
2008,NEXTERONE,AMIODARONE HYDROCHLORIDE,NDA022325,e9108958-b8d7-4fba-87c3-9a32990de551,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022325_nexterone_toc.cfm,
2008,NEXTERONE,AMIODARONE HYDROCHLORIDE,NDA022325,e9108958-b8d7-4fba-87c3-9a32990de551,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022325s000_SumR.pdf,
2008,NEXTERONE,AMIODARONE HYDROCHLORIDE,NDA022325,e9108958-b8d7-4fba-87c3-9a32990de551,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/022325Orig1s001.pdf,
2000,N/A,N/A,NDA020911,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-911_Qvar.cfm,
2000,TRISENOX,ARSENIC TRIOXIDE,NDA021248,101fc347-d0ad-4aee-8b06-9feb187fd741,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-248_Trisenox.cfm,
2003,N/A,N/A,NDA021572,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/179_21572S57 daptomycin clinpharm prea.pdf,
2003,N/A,N/A,NDA021572,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/181_21572S57 daptomycin clinical prea.pdf,
2003,N/A,N/A,NDA021572,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/180_21572S57 daptomycin statistical prea.pdf,
2003,N/A,N/A,NDA021572,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/94_21572s055-daptomycin-clinical-prea.pdf,
2003,N/A,N/A,NDA021572,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/95_21572s055-daptomycin-clinpharm-prea.pdf,
2003,N/A,N/A,NDA021572,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/97_21872s055-daptomycin-statistical-prea.pdf,
2003,N/A,N/A,NDA021572,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/021572Orig1s053.pdf,
2003,N/A,N/A,NDA021572,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/021572Orig1s008.pdf,
2003,N/A,N/A,NDA021572,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin.cfm,
2003,N/A,N/A,NDA021572,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/021572Orig1s052.pdf,
2006,N/A,N/A,NDA021958,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021958TOC.cfm,
1998,CELLCEPT,MYCOPHENOLATE MOFETIL HYDROCHLORIDE,NDA050758,37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/505758.cfm,
1998,CELLCEPT,MYCOPHENOLATE MOFETIL HYDROCHLORIDE,NDA050758,37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-722s004_50-723s003_50-758s003_50-759s004_CellCept.cfm,
1998,CELLCEPT,MYCOPHENOLATE MOFETIL HYDROCHLORIDE,NDA050758,37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-722S005_CellCept.cfm,
2015,KENGREAL,CANGRELOR,NDA204958,88b434fa-8891-4fd5-9d86-7ea64667c08f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204958Orig1s000TOC.cfm,
2015,KENGREAL,CANGRELOR,NDA204958,88b434fa-8891-4fd5-9d86-7ea64667c08f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204958Orig1s000SumR.pdf,
2014,INCRUSE ELLIPTA,UMECLIDINIUM,NDA205382,dbb64747-1505-49d7-9a33-99dd402e96d3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205382Orig1s000SumR.pdf,
2014,INCRUSE ELLIPTA,UMECLIDINIUM,NDA205382,dbb64747-1505-49d7-9a33-99dd402e96d3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205382Orig1s000TOC.cfm,
2021,N/A,N/A,NDA213895,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/213895Orig1s000TOC.cfm,
2019,DUAKLIR PRESSAIR,ACLIDINIUM BROMIDE AND FORMOTEROL FUMARATE,NDA210595,2eba3089-28b4-4190-9fba-2511246cfd16,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210595Orig1s000TOC.cfm,
1994,FRAGMIN,DALTEPARIN SODIUM,NDA020287,23527b8b-9b28-4e6d-9751-33b143975ac7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020287_S015_FRAGMIN_AP.pdf,
1994,FRAGMIN,DALTEPARIN SODIUM,NDA020287,23527b8b-9b28-4e6d-9751-33b143975ac7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020287S008_Fragmin.cfm,
1994,FRAGMIN,DALTEPARIN SODIUM,NDA020287,23527b8b-9b28-4e6d-9751-33b143975ac7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020287_s002_FRAGMIN INJECTION.pdf,
1994,FRAGMIN,DALTEPARIN SODIUM,NDA020287,23527b8b-9b28-4e6d-9751-33b143975ac7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020287_s034_FRAGMIN INJECTION.pdf,
1994,FRAGMIN,DALTEPARIN SODIUM,NDA020287,23527b8b-9b28-4e6d-9751-33b143975ac7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020287_s032_FRAGMIN INJECTION.pdf,
1994,FRAGMIN,DALTEPARIN SODIUM,NDA020287,23527b8b-9b28-4e6d-9751-33b143975ac7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020287S10_Fragmin.cfm,
1994,FRAGMIN,DALTEPARIN SODIUM,NDA020287,23527b8b-9b28-4e6d-9751-33b143975ac7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020287a_s005edt.pdf,
1994,FRAGMIN,DALTEPARIN SODIUM,NDA020287,23527b8b-9b28-4e6d-9751-33b143975ac7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/020287Orig1s035.pdf,
1994,FRAGMIN,DALTEPARIN SODIUM,NDA020287,23527b8b-9b28-4e6d-9751-33b143975ac7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020287_S017_FRAGMIN_AP.pdf,
1994,FRAGMIN,DALTEPARIN SODIUM,NDA020287,23527b8b-9b28-4e6d-9751-33b143975ac7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020287_s031_FRAGMIN INJECTION.pdf,
1998,CILOXAN,CIPROFLOXACIN HYDROCHLORIDE,NDA020369,09ca5374-2a16-4a95-91b3-70591d78254e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020369_ciloxan.cfm,
2018,ADALIMUMAB,ADALIMUMAB-ADAZ,BLA761071,3468792f-63ef-4916-8ed1-8214f327d9dd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761071Orig1s000TOC.cfm,
1998,LOPREEZA,ESTRADIOL/NORETHINDRONE ACETATE,NDA020907,bf0e39cb-95e7-4831-92d2-0b3f071aeaae,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020907_S007.pdf,
1998,LOPREEZA,ESTRADIOL/NORETHINDRONE ACETATE,NDA020907,bf0e39cb-95e7-4831-92d2-0b3f071aeaae,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20907.cfm,
1998,LOPREEZA,ESTRADIOL/NORETHINDRONE ACETATE,NDA020907,bf0e39cb-95e7-4831-92d2-0b3f071aeaae,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020907_S003.pdf,
1998,LOPREEZA,ESTRADIOL/NORETHINDRONE ACETATE,NDA020907,bf0e39cb-95e7-4831-92d2-0b3f071aeaae,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020907_S001.pdf,
1998,LOPREEZA,ESTRADIOL/NORETHINDRONE ACETATE,NDA020907,bf0e39cb-95e7-4831-92d2-0b3f071aeaae,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020907_S006.pdf,
1998,LOPREEZA,ESTRADIOL/NORETHINDRONE ACETATE,NDA020907,bf0e39cb-95e7-4831-92d2-0b3f071aeaae,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020907_S004.pdf,
1998,LOPREEZA,ESTRADIOL/NORETHINDRONE ACETATE,NDA020907,bf0e39cb-95e7-4831-92d2-0b3f071aeaae,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020907_S002.pdf,
2000,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021246,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021246Orig1s034.pdf,
2000,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021246,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021087_S010_021246s007_TamifluTOC.cfm,
2000,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021246,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/021087_S008_021246s003_TamifluTOC.cfm,
2000,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021246,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/021087_s005s006_021246s001_TamifluTOC.cfm,
2000,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021246,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021087_S016_021246s010TamifluTOC.cfm,
2000,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021246,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021246Orig1s039.pdf,
2000,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021246,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021246Orig1s045_021087Orig1s062_tamiflu_toc.cfm,
2000,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021246,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2012/021087Orig1s062021246Orig1s045SumR.pdf,
2000,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021246,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-246_Tamiflu.cfm,
2000,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021246,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021246Orig1s035.pdf,
2000,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021246,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021246Orig1s027.pdf,
2000,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021246,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021246_S006_TamifluTOC.cfm,
2000,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021246,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021246Orig1s017.pdf,
2000,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021246,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/021087_S009_021246s004TamifluTOC.cfm,
2000,TAMIFLU,OSELTAMIVIR PHOSPHATE,NDA021246,ee3c9555-60f2-4f82-a760-11983c86e97b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/021246_S002_TamifluTOC.cfm,
2006,SODIUM CHLORIDE,SODIUM CHLORIDE,NDA021569,e4540d03-06b4-4b4d-b859-75c13e5c20dd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021569s000TOC.cfm,
2001,AUGMENTIN ES-600,AMOXICILLIN AND CLAVULANATE POTASSIUM,NDA050755,59979859-8c9b-4173-a5e3-2e6312fd9d79,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/50-755s003_AugmentinTOC.cfm,
2001,AUGMENTIN ES-600,AMOXICILLIN AND CLAVULANATE POTASSIUM,NDA050755,59979859-8c9b-4173-a5e3-2e6312fd9d79,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/50755_Augmentin.cfm,
2001,AUGMENTIN ES-600,AMOXICILLIN AND CLAVULANATE POTASSIUM,NDA050755,59979859-8c9b-4173-a5e3-2e6312fd9d79,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/050755_S010.pdf,
1970,LYSODREN,MITOTANE,NDA016885,4046a224-8832-daa2-e063-6294a90a11d7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/016885_S022_Lysodren.pdf,
2012,ARGATROBAN,ARGATROBAN,NDA203049,41f56fe7-4824-4032-aa73-cfb4f8db2252,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/203049Orig1s004.pdf,
2012,ARGATROBAN,ARGATROBAN,NDA203049,41f56fe7-4824-4032-aa73-cfb4f8db2252,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203049_argatroban_toc.cfm,
2012,ARGATROBAN,ARGATROBAN,NDA203049,41f56fe7-4824-4032-aa73-cfb4f8db2252,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203049Orig1s000SumR.pdf,
2012,AMYVID,FLORBETAPIR F 18,NDA202008,bb5a5043-0f51-11df-8a39-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202008_Florbetapir_Orig1s000TOC.cfm,
1987,N/A,N/A,NDA019111,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/019111_s011_TUSSIONEX KINETIC.pdf,
2013,MORPHINE SULFATE,MORPHINE SULFATE,NDA204223,1f53de80-efc8-4930-b3e3-fba0d026af05,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204223Orig1s000TOC.cfm,
2013,MORPHINE SULFATE,MORPHINE SULFATE,NDA204223,1f53de80-efc8-4930-b3e3-fba0d026af05,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204223Orig1s000SumR.pdf,
2015,N/A,N/A,NDA205383,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205383 iohexol clinical prea.pdf,
2015,N/A,N/A,NDA205383,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205383 iohexol clinpharm prea.pdf,
2015,N/A,N/A,NDA205383,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205383 iohexol statistical prea.pdf,
2015,N/A,N/A,NDA205383,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205383Orig1s000TOC.cfm,
2015,N/A,N/A,NDA205383,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205383Orig1s000SumR.pdf,
2018,SEIZALAM,MIDAZOLAM HYDROCHLORIDE,NDA209566,cb2381bf-984a-48a8-95c0-3017c34cc170,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209566Orig1s000TOC.cfm,
2017,N/A,N/A,BLA761072,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761072Orig1s000TOC.cfm,
2023,VELSIPITY,ETRASIMOD,NDA216956,65171e4a-d136-4abc-b08c-c40c1b486ff6,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216956Orig1s000TOC.cfm,
2008,EPIDUO,ADAPALENE AND BENZOYL PEROXIDE,NDA022320,a0610f87-3b39-458a-afa3-66be1fefd1de,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022320_epiduo_toc.cfm,
2008,EPIDUO,ADAPALENE AND BENZOYL PEROXIDE,NDA022320,a0610f87-3b39-458a-afa3-66be1fefd1de,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022320s000_Adapalene_(Epiduo)_Clinical_PREA.pdf,
2008,EPIDUO,ADAPALENE AND BENZOYL PEROXIDE,NDA022320,a0610f87-3b39-458a-afa3-66be1fefd1de,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022320s000_Adapalene_(Epiduo)_ClinPharm_PREA.pdf,
2008,EPIDUO,ADAPALENE AND BENZOYL PEROXIDE,NDA022320,a0610f87-3b39-458a-afa3-66be1fefd1de,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022320s000_Adapalene_(Epiduo)_Statistical_PREA.pdf,
2008,EPIDUO,ADAPALENE AND BENZOYL PEROXIDE,NDA022320,a0610f87-3b39-458a-afa3-66be1fefd1de,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022320s000_SumR.pdf,
2008,EPIDUO,ADAPALENE AND BENZOYL PEROXIDE,NDA022320,a0610f87-3b39-458a-afa3-66be1fefd1de,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22320 adapalene benzyoyl clinical prea.pdf,
2008,EPIDUO,ADAPALENE AND BENZOYL PEROXIDE,NDA022320,a0610f87-3b39-458a-afa3-66be1fefd1de,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22320 adapalene benzoyl clinpharm prea.pdf,
2008,EPIDUO,ADAPALENE AND BENZOYL PEROXIDE,NDA022320,a0610f87-3b39-458a-afa3-66be1fefd1de,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22320 adapalene benzoyl statistical prea.pdf,
2008,EPIDUO,ADAPALENE AND BENZOYL PEROXIDE,NDA022320,a0610f87-3b39-458a-afa3-66be1fefd1de,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/22320Orig1s002.pdf,
2006,N/A,N/A,NDA021247,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021247_aerospan_toc.cfm,
2006,N/A,N/A,NDA021956,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021956s000TOC.cfm,
2000,BENZACLIN,CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE,NDA050756,4c6b2aca-d940-42af-a068-418f015d277a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-756_Benzaclin.cfm,
2016,POSFREA,PALONOSETRON,NDA203050,13a201ba-c86d-48c5-a0e1-a3e0b4e6a2a7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/203050Orig1s000TOC.cfm,
2014,N/A,N/A,NDA202356,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202356Orig1s000SumR.pdf,
2014,N/A,N/A,NDA202356,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202356Orig1s000TOC.cfm,
2022,HYFTOR,SIROLIMUS,NDA213478,edb3ea90-5adc-48ec-99f5-ab963e302f18,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/213478Orig1s000TOC.cfm,
1985,NITROGLYCERIN TRANSDERMAL INFUSION SYSTEM,NITROGLYCERIN,NDA020145,4f85d2e0-2e37-fcd1-276d-5a6466554289,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020145s006_nitro-dur_toc.cfm,
1985,NITROGLYCERIN TRANSDERMAL INFUSION SYSTEM,NITROGLYCERIN,NDA020145,4f85d2e0-2e37-fcd1-276d-5a6466554289,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020145s007_nitro-dur_toc.cfm,
1954,N/A,N/A,NDA009218,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/09218S097_Coumadin.pdf,
1954,N/A,N/A,NDA009218,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/009218a.pdf,
1954,N/A,N/A,NDA009218,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/009218_s101_coumadin.pdf,
1954,N/A,N/A,NDA009218,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/009218a.pdf,
1954,N/A,N/A,NDA009218,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/009218a.pdf,
1994,N/A,N/A,NDA020214,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020214s030_Rocuronium_Clinical_BPCA.pdf,
1994,N/A,N/A,NDA020214,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020214s030_Rocuronium_Clinpharm_BPCA.pdf,
2021,QELBREE,VILOXAZINE HYDROCHLORIDE,NDA211964,aedf408d-0f84-418d-9416-7c39ddb0d29a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211964Orig1s000TOC.cfm,
2024,IMKELDI,IMATINIB ORAL,NDA219097,26658bb7-9ba1-a10e-e063-6394a90a172e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219097Orig1s000TOC.cfm,
2019,KANJINTI,TRASTUZUMAB-ANNS,BLA761073,9a94f5b2-b84e-4987-8ea1-c4346db5a5fa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761073Orig1s000TOC.cfm,
2024,N/A,N/A,NDA215168,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/215168Orig1s000TOC.cfm,
2023,JAYPIRCA,PIRTOBRUTINIB,NDA216059,bd551845-0878-49a4-860f-839b83f6b801,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216059Orig1s000TOC.cfm,
2009,N/A,N/A,NDA022321,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022321s000TOC.cfm,
1999,VAGIFEM,ESTRADIOL,NDA020908,e5ad3cf6-dd96-4e64-af21-c1eee38d0b88,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/020908Orig1s013.pdf,
1999,VAGIFEM,ESTRADIOL,NDA020908,e5ad3cf6-dd96-4e64-af21-c1eee38d0b88,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020908_000_VagifemTOC.cfm,
2004,N/A,N/A,NDA021571,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/NDA21-271_Iquix.cfm,
2006,NEXIUM,ESOMEPRAZOLE MAGNESIUM,NDA021957,f4853677-1622-4037-688b-fdf533a11d96,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021957se5-004_se8-005_Esomeprazole (Nexium)_Clinical_BPCA.pdf,
2006,NEXIUM,ESOMEPRAZOLE MAGNESIUM,NDA021957,f4853677-1622-4037-688b-fdf533a11d96,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021957se5-004_se8-005_Esomeprazole (Nexium)_Clinpharm_BPCA.pdf,
2006,NEXIUM,ESOMEPRAZOLE MAGNESIUM,NDA021957,f4853677-1622-4037-688b-fdf533a11d96,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021957_nexium_toc.cfm,
1997,N/A,N/A,NDA050757,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50-757s003_Prevpac.cfm,
1997,N/A,N/A,NDA050757,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/050757a.pdf,
1997,N/A,N/A,NDA050757,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50-757s004_Prevpac.cfm,
1997,N/A,N/A,NDA050757,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50-757s002_Prevpac.cfm,
1968,TEGRETOL,CARBAMAZEPINE,NDA016608,8d409411-aa9f-4f3a-a52c-fbcb0c3ec053,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/016608_S090_TEGRETOL_AP.pdf,
1968,TEGRETOL,CARBAMAZEPINE,NDA016608,8d409411-aa9f-4f3a-a52c-fbcb0c3ec053,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/016608_Tegretol.cfm,
2016,VARIBAR PUDDING,BARIUM SULFATE,NDA208844,553285e2-d0e9-8b7b-4766-a0a6b9496f87,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208844_toc.cfm,
2016,VARIBAR PUDDING,BARIUM SULFATE,NDA208844,553285e2-d0e9-8b7b-4766-a0a6b9496f87,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208844 barium sulfate DD review prea.pdf,
2017,N/A,N/A,BLA761078,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761078Orig1s000TOC.cfm,
1997,DICLOFENAC SODIUM AND MISOPROSTOL,DICLOFENAC SODIUM AND MISOPROSTOL,NDA020607,a7701e8c-4e16-4165-8b83-de2c08d5ded3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20607s4.pdf,
1997,DICLOFENAC SODIUM AND MISOPROSTOL,DICLOFENAC SODIUM AND MISOPROSTOL,NDA020607,a7701e8c-4e16-4165-8b83-de2c08d5ded3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020607_arthrotec_toc.cfm,
1997,URSO 250,URSODIOL,NDA020675,e8fc4fc2-fe5c-4cba-b6e0-5ceaf2157a61,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20675a.cfm,
2024,LIVDELZI,SELADELPAR LYSINE,NDA217899,89f79d98-135c-40b2-a585-6996c04e599c,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217899Orig1s000TOC.cfm,
2009,ADCIRCA,TADALAFIL,NDA022332,ff61b237-be8e-461b-8114-78c52a8ad0ae,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022332_adcirca_toc.cfm,
2002,GEODON,ZIPRASIDONE MESYLATE,NDA020919,a2b4cc65-6a6d-49c4-adfc-a4458562a167,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-919_Geodon.cfm,
2002,GEODON,ZIPRASIDONE MESYLATE,NDA020919,a2b4cc65-6a6d-49c4-adfc-a4458562a167,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/020919_s012_GEODON.pdf,
2006,ADVAIR HFA,FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE,NDA021254,dfaca6f9-3277-47b2-319d-1377917cb54c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021254s000TOC.cfm,
2006,ADVAIR HFA,FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE,NDA021254,dfaca6f9-3277-47b2-319d-1377917cb54c,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021254_fluticasone-salmeterol_clinical_prea.pdf,
2006,ADVAIR HFA,FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE,NDA021254,dfaca6f9-3277-47b2-319d-1377917cb54c,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021254_fluticasone-salmeterol_clinpharm_prea.pdf,
2006,ADVAIR HFA,FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE,NDA021254,dfaca6f9-3277-47b2-319d-1377917cb54c,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021254_fluticasone-salmeterol_statistical_prea.pdf,
2004,GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE,GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE,NDA021585,310d14be-e7ea-44b8-8b04-cffa39440d50,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021585s000_MucinexTOC.cfm,
2008,RELISTOR,METHYLNALTREXONE BROMIDE,NDA021964,c488fb7c-0a5b-487c-b452-996809d1cb99,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021964s000TOC.cfm,
1982,HUMULIN R,INSULIN HUMAN,BLA018780,b519bd83-038c-4ec5-a231-a51ec5cc291f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018780_s037.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2015,CORLANOR,IVABRADINE,NDA206143,92018a65-38f6-45f7-91d4-a34921b81d0d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/402_209964 ivabradine clinical bpca.pdf,
2015,CORLANOR,IVABRADINE,NDA206143,92018a65-38f6-45f7-91d4-a34921b81d0d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/401_209964 ivabradine CDTL bpca.pdf,
2015,CORLANOR,IVABRADINE,NDA206143,92018a65-38f6-45f7-91d4-a34921b81d0d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/403_209964 ivabradine clinpharm bpca.pdf,
2015,CORLANOR,IVABRADINE,NDA206143,92018a65-38f6-45f7-91d4-a34921b81d0d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/404_209964 ivabradine statistics bpca.pdf,
2015,CORLANOR,IVABRADINE,NDA206143,92018a65-38f6-45f7-91d4-a34921b81d0d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206143Orig1s000TOC.cfm,
2014,OMIDRIA,PHENYLEPHRINE AND KETOROLAC,NDA205388,f25d7a42-da2a-7310-e053-2995a90a590f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205388Orig1s000TOC.cfm,
2014,OMIDRIA,PHENYLEPHRINE AND KETOROLAC,NDA205388,f25d7a42-da2a-7310-e053-2995a90a590f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205388Orig1s000SumR.pdf,
2014,OMIDRIA,PHENYLEPHRINE AND KETOROLAC,NDA205388,f25d7a42-da2a-7310-e053-2995a90a590f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/213_205388S6 phenylephrine and ketorolac CDTL clinical bpca.pdf,
2014,OMIDRIA,PHENYLEPHRINE AND KETOROLAC,NDA205388,f25d7a42-da2a-7310-e053-2995a90a590f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/214_205388S6 phenylephrine and ketorolac clinical bpca.pdf,
2014,OMIDRIA,PHENYLEPHRINE AND KETOROLAC,NDA205388,f25d7a42-da2a-7310-e053-2995a90a590f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/215_205388S6 phenylephrine and ketorolac statistical bpca.pdf,
1992,N/A,N/A,NDA020021,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020021_S006_SUDAFED_AP.pdf,
1992,N/A,N/A,NDA020021,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/1998/020021_S004_EFIDAC_AP.pdf,
1992,N/A,N/A,NDA020021,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20021_S002_EFIDAC 24_AP.pdf,
1992,N/A,N/A,NDA020021,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020021_S005_SUDAFED_AP.pdf,
1992,N/A,N/A,NDA020021,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20021_S003_EFIDAC 24_AP.pdf,
1992,N/A,N/A,NDA020021,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20021_S001_EFIDAC 24_AP.pdf,
1992,"NICORETTE 4MG FRUIT CHILL GUM, LIL DRUG STORE",NICOTINE POLACRILEX,NDA020066,0e85dcfa-d9e1-5fbb-e063-6394a90aeae6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020066_S016_NICORETTE_GUM_AP.pdf,
1992,"NICORETTE 4MG FRUIT CHILL GUM, LIL DRUG STORE",NICOTINE POLACRILEX,NDA020066,0e85dcfa-d9e1-5fbb-e063-6394a90aeae6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-066s10_Nicorette.cfm,
1992,"NICORETTE 4MG FRUIT CHILL GUM, LIL DRUG STORE",NICOTINE POLACRILEX,NDA020066,0e85dcfa-d9e1-5fbb-e063-6394a90aeae6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/18-612s025_Nicorette.cfm,
1992,"NICORETTE 4MG FRUIT CHILL GUM, LIL DRUG STORE",NICOTINE POLACRILEX,NDA020066,0e85dcfa-d9e1-5fbb-e063-6394a90aeae6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/020066Orig1s031.pdf,
2017,N/A,N/A,NDA208109,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208109Orig1s000TOC.cfm,
2018,YUPELRI,REVEFENACIN,NDA210598,6dfebf04-7c90-436a-9b16-750d3c1ee0a6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210598Orig1s000TOC.cfm,
2018,ERLEADA,APALUTAMIDE,NDA210951,d1cda4f7-cb33-46ea-b9ac-431f6452b1a5,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/Erleada_210951_toc.cfm,
2024,PREVYMIS,LETERMOVIR,NDA219104,1b49df80-be4f-47e0-a0b7-123f3e69395b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219104Orig1s000TOC.cfm,
2000,CHLORAPREP ONE-STEP,CHLORHEXIDINE GLUCONATE AND ISOPROPYL ALCOHOL,NDA020832,8529596f-37e4-c44e-e053-2a91aa0ad014,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-832_CHLORAPREP.cfm,
2000,CHLORAPREP ONE-STEP,CHLORHEXIDINE GLUCONATE AND ISOPROPYL ALCOHOL,NDA020832,8529596f-37e4-c44e-e053-2a91aa0ad014,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020832_S008_CHLORAPREP_WITH_TINT.pdf,
2009,PREVACID 24 HR,LANSOPRAZOLE,NDA022327,99a97004-e247-4f4d-a38c-f28f521de1c4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022327_prevacid_24hr_toc.cfm,
2009,PREVACID 24 HR,LANSOPRAZOLE,NDA022327,99a97004-e247-4f4d-a38c-f28f521de1c4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022327s000_SumR.pdf,
1998,AGGRASTAT,TIROFIBAN,NDA020912,fe0ced75-ccbf-4d2e-bd0d-b57e60ab913f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20912-s004_aggrasat.pdf,
1998,AGGRASTAT,TIROFIBAN,NDA020912,fe0ced75-ccbf-4d2e-bd0d-b57e60ab913f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20912S001_Aggrastat.cfm,
2000,KALETRA,LOPINAVIR AND RITONAVIR,NDA021251,8290add3-4449-4e58-6c97-8fe1eec972e3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-251S002_Kaletra.cfm,
2000,KALETRA,LOPINAVIR AND RITONAVIR,NDA021251,8290add3-4449-4e58-6c97-8fe1eec972e3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021251_S005_KALETRA.pdf,
2000,KALETRA,LOPINAVIR AND RITONAVIR,NDA021251,8290add3-4449-4e58-6c97-8fe1eec972e3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-226_Kaletra.cfm,
2000,KALETRA,LOPINAVIR AND RITONAVIR,NDA021251,8290add3-4449-4e58-6c97-8fe1eec972e3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021226-21251_Lopinavir-Ritonavir_Clinpharm_BPCAini.pdf,
2000,KALETRA,LOPINAVIR AND RITONAVIR,NDA021251,8290add3-4449-4e58-6c97-8fe1eec972e3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021251_Lopinavir-Ritonavir_Clinical_BPCA.pdf,
2000,KALETRA,LOPINAVIR AND RITONAVIR,NDA021251,8290add3-4449-4e58-6c97-8fe1eec972e3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021251_S010_KALETRA.pdf,
2000,KALETRA,LOPINAVIR AND RITONAVIR,NDA021251,8290add3-4449-4e58-6c97-8fe1eec972e3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-251S003_Kaletra.cfm,
2004,N/A,N/A,NDA021574,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021574s000_ForametTOC.cfm,
2006,ORAPRED ODT,PREDNISOLONE SODIUM PHOSPHATE,NDA021959,1e379543-c4cf-4e72-953b-db15b7f0c2a1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021959TOC.cfm,
1998,CELLCEPT,MYCOPHENOLATE MOFETIL,NDA050759,37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-722S007_CellCept.cfm,
1998,CELLCEPT,MYCOPHENOLATE MOFETIL,NDA050759,37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/050759_s000_CellCeptTOC.cfm,
1998,CELLCEPT,MYCOPHENOLATE MOFETIL,NDA050759,37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-722S005_CellCept.cfm,
1998,CELLCEPT,MYCOPHENOLATE MOFETIL,NDA050759,37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-722s004_50-723s003_50-758s003_50-759s004_CellCept.cfm,
1967,EDECRIN,ETHACRYNIC ACID,NDA016092,1efe378e-fee1-4ae9-8ea5-0fe2265fe2d8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/16092s037_Edecrin.pdf,
2017,BENZNIDAZOLE,BENZNIDAZOLE,NDA209570,8983d6a0-f63f-4f8e-bba4-38223f39e29b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209570Orig1s000TOC.cfm,
1992,N/A,N/A,NDA019941,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019941_S002_EMLA_CREAM.pdf,
1992,N/A,N/A,NDA019941,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/19-941S011.pdf,
1992,N/A,N/A,NDA019941,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/019941s008_emla.pdf,
1992,N/A,N/A,NDA019941,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/019941s008_emla.pdf,
1992,N/A,N/A,NDA019941,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/019941_S012_EMLA_CREAM.pdf,
1992,N/A,N/A,NDA019941,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/019941s008_emla.pdf,
1992,N/A,N/A,NDA019941,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/019941_S017_EMLA_CREAM.pdf,
1991,ALTACE,RAMIPRIL,NDA019901,0fc34cd8-86e6-4034-73bd-4263a68ba046,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/19901s025_Altace.pdf,
1991,ALTACE,RAMIPRIL,NDA019901,0fc34cd8-86e6-4034-73bd-4263a68ba046,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/019901_s046_altace.pdf,
1991,ALTACE,RAMIPRIL,NDA019901,0fc34cd8-86e6-4034-73bd-4263a68ba046,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/019901_s028_Altace.cfm,
1999,XENICAL,ORLISTAT,NDA020766,6240792b-9224-2d10-e053-2a91aa0a2c3e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020766_S009_XENICAL_CAPS_AP.pdf,
1999,XENICAL,ORLISTAT,NDA020766,6240792b-9224-2d10-e053-2a91aa0a2c3e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020766_S019_XENICAL_CAPS_AP.pdf,
1999,XENICAL,ORLISTAT,NDA020766,6240792b-9224-2d10-e053-2a91aa0a2c3e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020766_S021_XENICAL_CAPS_AP.pdf,
1999,XENICAL,ORLISTAT,NDA020766,6240792b-9224-2d10-e053-2a91aa0a2c3e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020766_S013_XENICAL_CAPS_AP.pdf,
1999,XENICAL,ORLISTAT,NDA020766,6240792b-9224-2d10-e053-2a91aa0a2c3e,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020766s018_orlistat_Xenical-MedRev.pdf,
1999,XENICAL,ORLISTAT,NDA020766,6240792b-9224-2d10-e053-2a91aa0a2c3e,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020766s018_orlistat_Xenical-ClinPhamRev.pdf,
1999,XENICAL,ORLISTAT,NDA020766,6240792b-9224-2d10-e053-2a91aa0a2c3e,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020766s018_orlistat_Xenical-StatsRev.pdf,
1999,XENICAL,ORLISTAT,NDA020766,6240792b-9224-2d10-e053-2a91aa0a2c3e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020766_S018_XENICAL_CAPSULES_AP.pdf,
1999,XENICAL,ORLISTAT,NDA020766,6240792b-9224-2d10-e053-2a91aa0a2c3e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020766a.cfm,
2018,FULPHILA,PEGFILGRASTIM-JMDB,BLA761075,9bfc4d3e-6120-7fec-f1d6-0b3743752034,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761075Orig1s000TOC.cfm,
1997,N/A,N/A,NDA020738,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020738s001_teveten_toc.cfm,
1997,N/A,N/A,NDA020738,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020738_tevetan_toc.cfm,
1997,N/A,N/A,NDA020738,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20738-s004_teveten.pdf,
2011,N/A,N/A,NDA022328,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022328Orig1s000TOC.cfm,
2011,N/A,N/A,NDA022328,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022328Orig1s000SumR.pdf,
1998,AGGRASTAT,TIROFIBAN,NDA020913,fe0ced75-ccbf-4d2e-bd0d-b57e60ab913f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20913.pdf,
1998,AGGRASTAT,TIROFIBAN,NDA020913,fe0ced75-ccbf-4d2e-bd0d-b57e60ab913f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20912-s004_aggrasat.pdf,
1998,AGGRASTAT,TIROFIBAN,NDA020913,fe0ced75-ccbf-4d2e-bd0d-b57e60ab913f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20912S001_Aggrastat.cfm,
2001,CANASA,MESALAMINE,NDA021252,89d91601-152b-4398-bebe-af1c023e9935,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/11_21252 mesalamine clinical prea.pdf,
2001,CANASA,MESALAMINE,NDA021252,89d91601-152b-4398-bebe-af1c023e9935,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/10_21252 mesalamine clinpharm prea.pdf,
2001,CANASA,MESALAMINE,NDA021252,89d91601-152b-4398-bebe-af1c023e9935,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/9_21252 mesalamine statistical prea.pdf,
2001,CANASA,MESALAMINE,NDA021252,89d91601-152b-4398-bebe-af1c023e9935,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-252_Canasa.cfm,
2003,N/A,N/A,NDA021575,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020560s038_021575s007lbl.pdf,
2003,N/A,N/A,NDA021575,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020560_S042 & 021575_S003_FOSAMAX_TABS_ORAL_SOLUTION_AP.pdf,
2003,N/A,N/A,NDA021575,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-575_Fosamax.cfm,
2003,N/A,N/A,NDA021575,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021575_s004_FOSAMAX TABS.pdf,
1999,AMOXICILLIN,AMOXICILLIN,NDA050760,06e5c07d-d95c-4955-8d35-a4703ca2359e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/050760_s000_AmoxilTOC.cfm,
1999,AMOXICILLIN,AMOXICILLIN,NDA050760,06e5c07d-d95c-4955-8d35-a4703ca2359e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-542s017_50-754s002_50-760s001_50-761s001_Amoxil.cfm,
2011,GADAVIST,GADOBUTROL,NDA201277,bd28560f-de4d-4140-874e-31df823f4dbb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201277Orig1s000SumR.pdf,
2011,GADAVIST,GADOBUTROL,NDA201277,bd28560f-de4d-4140-874e-31df823f4dbb,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/201277_Gadavist_ gadobutrol clinical prea.pdf,
2011,GADAVIST,GADOBUTROL,NDA201277,bd28560f-de4d-4140-874e-31df823f4dbb,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/201277_Gadavist_ gadobutrol statistical prea.pdf,
2011,GADAVIST,GADOBUTROL,NDA201277,bd28560f-de4d-4140-874e-31df823f4dbb,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/Gadavist-Clinial-Review.pdf,
2011,GADAVIST,GADOBUTROL,NDA201277,bd28560f-de4d-4140-874e-31df823f4dbb,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/Gadavist-Pharmacology-Review.pdf,
2011,GADAVIST,GADOBUTROL,NDA201277,bd28560f-de4d-4140-874e-31df823f4dbb,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/Gadavist-Statistical-Review.pdf,
2011,GADAVIST,GADOBUTROL,NDA201277,bd28560f-de4d-4140-874e-31df823f4dbb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201277Orig1s000TOC.cfm,
2011,GADAVIST,GADOBUTROL,NDA201277,bd28560f-de4d-4140-874e-31df823f4dbb,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/201277s008 gadobutrol clinical prea.pdf,
2011,GADAVIST,GADOBUTROL,NDA201277,bd28560f-de4d-4140-874e-31df823f4dbb,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/201277s008 gadobutrol clinpharm prea.pdf,
2011,GADAVIST,GADOBUTROL,NDA201277,bd28560f-de4d-4140-874e-31df823f4dbb,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/201277s008 gadobutrol statistical prea.pdf,
1992,BETAPACE,SOTALOL HYDROCHLORIDE,NDA019865,a6a7702f-36c9-45db-b640-453dc324baee,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/19-865s10_Betapace.cfm,
1991,N/A,N/A,NDA019834,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/019834S009_plendil_toc.cfm,
1991,N/A,N/A,NDA019834,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019834_S019_PLENDIL.pdf,
1991,N/A,N/A,NDA019834,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/019834_s007_PLENDIL.pdf,
1991,N/A,N/A,NDA019834,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019834_017_PLENDIL.pdf,
1991,N/A,N/A,NDA019834,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/019834_s005_PLENDIL.pdf,
1991,N/A,N/A,NDA019834,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/019834_s013.pdf,
1991,N/A,N/A,NDA019834,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/019834_s006_PLENDIL.pdf,
1991,N/A,N/A,NDA019834,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/019834_016_PLENDIL.pdf,
1991,N/A,N/A,NDA019834,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/019834_S022_PLENDIL.pdf,
1991,N/A,N/A,NDA019834,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019834_S004_PLENDIL.pdf,
1991,N/A,N/A,NDA019834,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/019834_s014_PLENDIL.pdf,
1991,N/A,N/A,NDA019834,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019834S002_plendil_toc.cfm,
1991,N/A,N/A,NDA019834,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019834_S020_PLENDIL.pdf,
1991,N/A,N/A,NDA019834,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019834_s012_PLENDIL.pdf,
2017,SIKLOS,HYDROXYUREA,NDA208843,76957c0d-0f98-4376-bb06-eee651adc09d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208843Orig1s000TOC.cfm,
2018,AIMOVIG,ERENUMAB-AOOE,BLA761077,b998ed05-94b0-47fd-b28f-cddd1e128fd8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761077Orig1s000TOC.cfm,
2023,PEMRYDI RTU,PEMETREXED DISODIUM,NDA215179,0f006b06-ab85-423d-ba0c-dfc3fc25844e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/215179Orig1s000TOC.cfm,
1942,PREMARIN,"ESTROGENS, CONJUGATED",NDA004782,258e1602-a3cf-4ccc-ca80-73dbbfb812ff,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/004782_S115&S130_PREMARIN_TABLETS.pdf,
1942,PREMARIN,"ESTROGENS, CONJUGATED",NDA004782,258e1602-a3cf-4ccc-ca80-73dbbfb812ff,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/04782s093.cfm,
1942,PREMARIN,"ESTROGENS, CONJUGATED",NDA004782,258e1602-a3cf-4ccc-ca80-73dbbfb812ff,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/004782_S115&S130_PREMARIN_TABLETS.pdf,
2024,VYALEV,FOSCARBIDOPA/FOSLEVODOPA,NDA216962,28e806e4-951c-40a9-9f0c-d0929caf054c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/216962Orig1s000TOC.cfm,
1997,N/A,N/A,NDA020705,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020705_S009_Rescriptor Tablets_APPROVAL PACKAGE.pdf,
1997,N/A,N/A,NDA020705,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-705S003.pdf,
1997,N/A,N/A,NDA020705,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020705_S008_RescriptorTOC.cfm,
1997,N/A,N/A,NDA020705,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020705_S004_Rescriptor Tablets_APPROVAL PACKAGE.pdf,
1997,N/A,N/A,NDA020705,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020705_S002_Rescriptor Tablets_APPROVAL PACKAGE.pdf,
2009,N/A,N/A,NDA022331,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf,
2009,N/A,N/A,NDA022331,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22331-Clonidine-ClinPharm-PREA-1.pdf,
2009,N/A,N/A,NDA022331,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22331-Clonidine-ClinPharm-PREA.pdf,
2009,N/A,N/A,NDA022331,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22331-Clonidine-Statistical-PREA.pdf,
2009,N/A,N/A,NDA022331,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022331_jenloga_toc.cfm,
1998,N/A,N/A,NDA020918,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020918_S008_GLUCAGEN.pdf,
1998,N/A,N/A,NDA020918,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020918_S003_GLUCAGEN.pdf,
1998,N/A,N/A,NDA020918,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020918s000_GlucagenTOC.cfm,
2004,ZYPREXA INTRAMUSCULAR,OLANZAPINE,NDA021253,d5051fbc-846b-4946-82df-341fb1216341,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21253_Zyprexa.TOC.cfm,
2004,DEPO-SUBQ PROVERA,MEDROXYPROGESTERONE ACETATE,NDA021583,390087a6-f3c3-4f0b-a930-79acf412f153,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021583s000TOC.cfm,
2006,N/A,N/A,NDA021963,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021963TOC.cfm,
1999,N/A,N/A,NDA050761,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/050761_s000_AmoxilTOC.cfm,
1999,N/A,N/A,NDA050761,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-542s017_50-754s002_50-760s001_50-761s001_Amoxil.cfm,
1979,THALLOUS CHLORIDE TL 201,"THALLOUS CHLORIDE, TL 201",NDA018150,0da81fc0-a137-46d3-9378-d8053a82e61a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/018150_S019_Thallous Chloride T1-201_APPROVAL_PACKAGE.pdf,
1985,N/A,N/A,NDA019155,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/019155_S019 & S020_LAC_HYDRIN_LOTION_AP.pdf,
1985,N/A,N/A,NDA019155,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/019155_S019 & S020_LAC_HYDRIN_LOTION_AP.pdf,
2013,GILOTRIF,AFATINIB,NDA201292,fd638e5e-8032-e7ca-0179-95e96ab5d387,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/201292Orig1s000TOC.cfm,
2013,GILOTRIF,AFATINIB,NDA201292,fd638e5e-8032-e7ca-0179-95e96ab5d387,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/201292Orig1s000SumR.pdf,
2013,GILOTRIF,AFATINIB,NDA201292,fd638e5e-8032-e7ca-0179-95e96ab5d387,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/201292Orig1s001.pdf,
2011,EDURANT,RILPIVIRINE HYDROCHLORIDE,NDA202022,03880372-2c68-45c6-a53a-f420c49541d6,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202022 rilpivirine clinical prea.pdf,
2011,EDURANT,RILPIVIRINE HYDROCHLORIDE,NDA202022,03880372-2c68-45c6-a53a-f420c49541d6,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202022 rilpivirine clinpharm prea.pdf,
2011,EDURANT,RILPIVIRINE HYDROCHLORIDE,NDA202022,03880372-2c68-45c6-a53a-f420c49541d6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202022Orig1s000SumR.pdf,
2011,EDURANT,RILPIVIRINE HYDROCHLORIDE,NDA202022,03880372-2c68-45c6-a53a-f420c49541d6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202022Orig1s000TOC.cfm,
2018,ARAKODA,TAFENOQUINE,NDA210607,299e49d8-470f-4779-a010-4a1ee0e0c6cd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210607Orig1s000TOC.cfm,
1994,GLUCOTROL XL,GLIPIZIDE,NDA020329,eed99b60-d043-4249-9b2a-f05e46fb588d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020329_S015_GLUCOTROL XP_AP.pdf,
1994,GLUCOTROL XL,GLIPIZIDE,NDA020329,eed99b60-d043-4249-9b2a-f05e46fb588d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020329_S003_Glucotrol XL_APPROVAL PACKAGES.pdf,
1996,MYOVIEW,TETROFOSMIN,NDA020372,98c85037-a907-4a3a-8864-c3a5298b4759,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20372_Myoview.cfm,
1996,MYOVIEW,TETROFOSMIN,NDA020372,98c85037-a907-4a3a-8864-c3a5298b4759,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/20-372s013_Myoview.cfm,
2022,RELEUKO,FILGRASTIM,BLA761082,74e1ec6e-1630-4654-895c-2bd355f939e7,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761082Orig1s000TOC.cfm,
2001,METADATE CD,METHYLPHENIDATE HYDROCHLORIDE,NDA021259,be59f8b4-7842-42cc-9559-bfa747f0baa5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-259_Metadate.cfm,
2000,N/A,N/A,NDA050769,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-769_Benamycin.cfm,
2011,TRADJENTA,LINAGLIPTIN,NDA201280,c797ea5c-cab7-494b-9044-27eba0cfe40f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/201280Orig1s002.pdf,
2011,TRADJENTA,LINAGLIPTIN,NDA201280,c797ea5c-cab7-494b-9044-27eba0cfe40f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201280Orig1s000TOC.cfm,
2011,TRADJENTA,LINAGLIPTIN,NDA201280,c797ea5c-cab7-494b-9044-27eba0cfe40f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201280Orig1s000SumR.pdf,
2023,N/A,N/A,NDA205394,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/205394Orig1s000TOC.cfm,
2017,ZILRETTA,TRIAMCINOLONE ACETONIDE EXTENDED-RELEASE INJECTABLE SUSPENSION,NDA208845,cd5c4673-21f2-4126-9556-da847b3a228b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208845Orig1s000TOC.cfm,
2020,PROCYSBI,CYSTEAMINE BITARTRATE,NDA213491,d3a3ec28-f746-463a-bb92-3bc8826db09e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213491Orig1s000TOC.cfm,
2018,TALZENNA,TALAZOPARIB,NDA211651,f2423edd-6d24-495c-aec1-c2f457f08d9a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000TOC.cfm,
2019,VYONDYS 53,GOLODIRSEN,NDA211970,35c227d1-5b24-44b0-b5d3-f0f6b1c46bd5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211970Orig1s000TOC.cfm,
2018,PALYNZIQ,PEGVALIASE-PQPZ,BLA761079,6dba844a-db02-44f8-8593-ce497ed9406c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761079Orig1s000TOC.cfm,
1996,ZOLADEX,GOSERELIN,NDA020578,e4cb3c20-2738-400a-b522-3f36f71fe6c5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/19726-s024_Zoladax.cfm,
1996,N/A,N/A,NDA020636,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020636_S025_VIRAMUNE.pdf,
1996,N/A,N/A,NDA020636,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020636s017_020933s007_Viramune.cfm,
1996,N/A,N/A,NDA020636,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020636Orig1s000rev.pdf,
1996,N/A,N/A,NDA020636,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020636_S002_VIRAMUNE.pdf,
1996,N/A,N/A,NDA020636,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20-933_20-636S009_Viramune.cfm,
1996,N/A,N/A,NDA020636,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020636_S007_VIRAMUNE.pdf,
1996,N/A,N/A,NDA020636,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020636_S005_VIRAMUNE.pdf,
1996,N/A,N/A,NDA020636,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020636_S012_VIRAMUNE.pdf,
2024,LEQSELVI,DEURUXOLITINIB PHOSPHATE,NDA217900,a603f231-d09e-4bad-ad5e-b55f865da095,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217900Orig1s000TOC.cfm,
2009,AFINITOR,EVEROLIMUS,NDA022334,2150f73a-179b-4afc-b8ce-67c85cc72f04,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022334Orig1s016.pdf,
2009,AFINITOR,EVEROLIMUS,NDA022334,2150f73a-179b-4afc-b8ce-67c85cc72f04,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22334 everolimus clinpharm bpca.pdf,
2009,AFINITOR,EVEROLIMUS,NDA022334,2150f73a-179b-4afc-b8ce-67c85cc72f04,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22334 everolinus clinical bpca.pdf,
2009,AFINITOR,EVEROLIMUS,NDA022334,2150f73a-179b-4afc-b8ce-67c85cc72f04,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022334s000TOC.cfm,
2009,AFINITOR,EVEROLIMUS,NDA022334,2150f73a-179b-4afc-b8ce-67c85cc72f04,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022334s000_SumR.pdf,
2001,N/A,N/A,NDA020920,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-920_Natrecor.cfm,
2004,CHIRHOSTIM,HUMAN SECRETIN,NDA021256,b4dfe70f-0a86-4488-9ba1-dcd8f86cbfcd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-256_SyntheticHS.cfm,
2006,3M DURAPREP SURGICAL,IODINE POVACRYLEX AND ISOPROPYL ALCOHOL,NDA021586,22a10a54-6a04-48b3-9ec4-b26526183daf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021586s000TOC.cfm,
1959,N/A,N/A,NDA011961,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/11961-s017.cfm,
2012,JENTADUETO,LINAGLIPTIN AND METFORMIN HYDROCHLORIDE,NDA201281,f6dd9b86-0d18-95d4-2bc7-05591bfdd597,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/201281_linagliptin_toc.cfm,
2012,JENTADUETO,LINAGLIPTIN AND METFORMIN HYDROCHLORIDE,NDA201281,f6dd9b86-0d18-95d4-2bc7-05591bfdd597,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/201281Orig1s000SumR.pdf,
2015,PREZCOBIX,DARUNAVIR ETHANOLATE AND COBICISTAT,NDA205395,9c38fdb6-d0ba-4f16-a0e3-85d9ec334d9f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205395Orig1s000TOC.cfm,
2015,PREZCOBIX,DARUNAVIR ETHANOLATE AND COBICISTAT,NDA205395,9c38fdb6-d0ba-4f16-a0e3-85d9ec334d9f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205395Orig1s000SumR.pdf,
2020,NUMBRINO,COCAINE HYDROCHLORIDE NASAL,NDA209575,d724b5b4-6654-4bf5-9eed-e2c7943084ed,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209575Orig1s000TOC.cfm,
2020,XEGLYZE,ABAMETAPIR,NDA206966,4fe38e95-8738-a28f-4079-43eff7318cb9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000TOC.cfm,
2016,DEFITELIO,DEFIBROTIDE SODIUM,NDA208114,2c3db989-d7ad-41ed-9ebf-698dcf6c24ec,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208114Orig1s000TOC.cfm,
2016,DEFITELIO,DEFIBROTIDE SODIUM,NDA208114,2c3db989-d7ad-41ed-9ebf-698dcf6c24ec,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208114Orig1s000SumR.pdf,
1995,N/A,N/A,NDA020482,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020482S010_Precose.cfm,
1995,N/A,N/A,NDA020482,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020482Orig1s000rev.pdf,
1995,N/A,N/A,NDA020482,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020482a_s007_s008.pdf,
1995,N/A,N/A,NDA020482,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020482a_s007_s008.pdf,
2020,N/A,N/A,BLA210605,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210605Orig1s000TOC.cfm,
2018,NIVESTYM,FILGRASTIM-AAFI,BLA761080,d23ab39c-b6ec-41cf-a529-9dd2852c9d9a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761080Orig1s000TOC.cfm,
2018,NIVESTYM,FILGRASTIM-AAFI,BLA761080,d23ab39c-b6ec-41cf-a529-9dd2852c9d9a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/303_761080-filgrastim-aafi-CDTL-clinical-prea.pdf,
2018,NIVESTYM,FILGRASTIM-AAFI,BLA761080,d23ab39c-b6ec-41cf-a529-9dd2852c9d9a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/304_761080-filgrastim-aafi-clinical-prea.pdf,
2018,NIVESTYM,FILGRASTIM-AAFI,BLA761080,d23ab39c-b6ec-41cf-a529-9dd2852c9d9a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/305_761080-filgrastim-aafi-clinpharm-prea.pdf,
2018,NIVESTYM,FILGRASTIM-AAFI,BLA761080,d23ab39c-b6ec-41cf-a529-9dd2852c9d9a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/306_761080-filgrastim-aafi-statistical-prea.pdf,
2023,TECHNEGAS,KIT FOR THE PREPARATION OF TECHNETIUM TC 99M-LABELED CARBON INHALATION AEROSOL,NDA022335,10ab1c14-3e01-e12b-e063-6394a90aea2f,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/022335Orig1s000TOC.cfm,
1999,N/A,N/A,NDA020922,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-922_Solage.cfm,
2001,N/A,N/A,NDA021257,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21257_Travatan.cfm,
2004,N/A,N/A,NDA021587,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-587_Advil.cfm,
1981,N/A,N/A,NDA018281,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/018281_S039_TEGRETOL_AP.PDF,
1981,N/A,N/A,NDA018281,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/018927_S031_TEGRETOL_AP.PDF,
2012,RAYOS,PREDNISONE,NDA202020,281ab967-7565-4bef-9c0c-a646589c671e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000SumR.pdf,
2012,RAYOS,PREDNISONE,NDA202020,281ab967-7565-4bef-9c0c-a646589c671e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020_rayos_toc.cfm,
2022,ACETAMINOPHEN,ACETAMINOPHEN,NDA206968,88c29438-3648-4b09-bd43-70ad7a35bcb5,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/206968Orig1s000TOC.cfm,
1997,LANOXIN,DIGOXIN,NDA020405,d91e3646-4c63-4512-ab22-db39c085c4dc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020405_lanoxin_toc.cfm,
1995,FLOLAN,EPOPROSTENOL SODIUM,NDA020444,8e4b636e-ee9c-4111-779d-28c8369d283b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020444Orig1s000rev.pdf,
1995,FLOLAN,EPOPROSTENOL SODIUM,NDA020444,8e4b636e-ee9c-4111-779d-28c8369d283b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-444S003_Flolan.cfm,
2019,TRAZIMERA,TRASTUZUMAB-QYYP,BLA761081,b9c5e894-27d2-4245-a653-df986fed3c56,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761081Orig1s000TOC.cfm,
2010,LIRAGLUTIDE,LIRAGLUTIDE,NDA022341,14bf9812-14ee-46ce-93b1-686e4906cbbc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/022341Orig1s027.pdf,
2010,LIRAGLUTIDE,LIRAGLUTIDE,NDA022341,14bf9812-14ee-46ce-93b1-686e4906cbbc,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/430_22341S31 liraglutide statistical bpca.pdf,
2010,LIRAGLUTIDE,LIRAGLUTIDE,NDA022341,14bf9812-14ee-46ce-93b1-686e4906cbbc,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/429_22341S31 liraglutide clinpharm bpca_0.pdf,
2010,LIRAGLUTIDE,LIRAGLUTIDE,NDA022341,14bf9812-14ee-46ce-93b1-686e4906cbbc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022341s000TOC.cfm,
2010,LIRAGLUTIDE,LIRAGLUTIDE,NDA022341,14bf9812-14ee-46ce-93b1-686e4906cbbc,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/431_22341S31 liraglutide clinical bpca.pdf,
1998,OPTIRAY 320,IOVERSOL,NDA020923,6cb6ca5f-b249-49b0-a9eb-8aa583da7c74,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20923_Optiray.cfm,
2003,CLIMARA PRO,ESTRADIOL AND LEVONORGESTREL,NDA021258,184d3092-7fc6-4375-816b-1ab06bb99cfd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021258s000_ClimaraTOC.cfm,
2003,GLEEVEC,IMATINIB MESYLATE,NDA021588,211ef2da-2868-4a77-8055-1cb2cd78e24b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021588s000_GleevecTOC.cfm,
2003,GLEEVEC,IMATINIB MESYLATE,NDA021588,211ef2da-2868-4a77-8055-1cb2cd78e24b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021588_s017_gleevec.pdf,
2003,GLEEVEC,IMATINIB MESYLATE,NDA021588,211ef2da-2868-4a77-8055-1cb2cd78e24b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-588s002_Gleevec.cfm,
2003,GLEEVEC,IMATINIB MESYLATE,NDA021588,211ef2da-2868-4a77-8055-1cb2cd78e24b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021588_s013_gleevic.pdf,
2003,GLEEVEC,IMATINIB MESYLATE,NDA021588,211ef2da-2868-4a77-8055-1cb2cd78e24b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021588_s011_gleevec.pdf,
2003,GLEEVEC,IMATINIB MESYLATE,NDA021588,211ef2da-2868-4a77-8055-1cb2cd78e24b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021588_s005_GLEVAC.pdf,
2003,GLEEVEC,IMATINIB MESYLATE,NDA021588,211ef2da-2868-4a77-8055-1cb2cd78e24b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021588s016_imatinib_Gleevec-Med&StatsRev.pdf,
2003,GLEEVEC,IMATINIB MESYLATE,NDA021588,211ef2da-2868-4a77-8055-1cb2cd78e24b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021588s016_imatinib_Gleevec-ClinPharmRev.pdf,
2003,GLEEVEC,IMATINIB MESYLATE,NDA021588,211ef2da-2868-4a77-8055-1cb2cd78e24b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021588s016_imatinib_Gleevec-Med&StatsRev.pdf,
2003,GLEEVEC,IMATINIB MESYLATE,NDA021588,211ef2da-2868-4a77-8055-1cb2cd78e24b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-335s003_21-588s001_Gleevec.cfm,
2003,GLEEVEC,IMATINIB MESYLATE,NDA021588,211ef2da-2868-4a77-8055-1cb2cd78e24b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021588_s014_gleevec.pdf,
2003,GLEEVEC,IMATINIB MESYLATE,NDA021588,211ef2da-2868-4a77-8055-1cb2cd78e24b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021588_s012_gleevic.pdf,
1999,CLEOCIN,CLINDAMYCIN PHOSPHATE,NDA050767,3db26227-208d-4fdd-8426-1d9be5cda9b4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50767_Cleocin.cfm,
1982,HUMULIN N,INSULIN HUMAN,BLA018781,f6edd793-440b-40c2-96b5-c16133b7a921,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018781_s027_Humulin N.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
1952,ANECTINE,SUCCINYLCHOLINE CHLORIDE,NDA008453,04a4e6f5-6fa1-42e1-a3f9-21fca7786b15,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/8453S1S4S6S12_Anectine.pdf,
1952,ANECTINE,SUCCINYLCHOLINE CHLORIDE,NDA008453,04a4e6f5-6fa1-42e1-a3f9-21fca7786b15,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/8453S1S4S6S12_Anectine.pdf,
1952,ANECTINE,SUCCINYLCHOLINE CHLORIDE,NDA008453,04a4e6f5-6fa1-42e1-a3f9-21fca7786b15,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/8453S1S4S6S12_Anectine.pdf,
1952,ANECTINE,SUCCINYLCHOLINE CHLORIDE,NDA008453,04a4e6f5-6fa1-42e1-a3f9-21fca7786b15,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/8453S1S4S6S12_Anectine.pdf,
1985,VIRAZOLE,RIBAVIRIN,NDA018859,adf16e64-345f-469a-b987-3fbdd17e0ac2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018859Orig1s000rev.pdf,
2013,ZUBSOLV,BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE,NDA204242,5f5cfcfe-d52b-49e6-8fe4-550477332dd2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204242Orig1s000TOC.cfm,
2018,LICART,DICLOFENAC EPOLAMINE,NDA206976,851c8b39-6056-4bbc-812e-b9b13977c1ac,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206976Orig1s000TOC.cfm,
2018,N/A,N/A,NDA208855,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208855Orig1s000TOC.cfm,
2024,VIJOICE,ALPELISIB,NDA218466,638069a4-aee0-46c9-9e21-54ad449c163c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/218466Orig1s000TOC.cfm,
2000,FLUTICASONE PROPIONATE DISKUS,FLUTICASONE PROPIONATE,NDA020833,44d009ba-d4b8-410f-b2bc-71ab2d05ac9e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-833_Flovent.cfm,
2011,N/A,N/A,NDA022345,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000SumR.pdf,
2011,N/A,N/A,NDA022345,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000TOC.cfm,
2001,ALPHAGAN P,BRIMONIDINE TARTRATE,NDA021262,264c4494-c225-486f-888a-caaf36be46b3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-262_AlphaganP.cfm,
2001,ALPHAGAN P,BRIMONIDINE TARTRATE,NDA021262,264c4494-c225-486f-888a-caaf36be46b3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-490s007_Alphagan.cfm,
2006,N/A,N/A,NDA021978,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021978s000_SumR.pdf,
2006,N/A,N/A,NDA021978,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021978_verdeso_toc.cfm,
2000,CEFAZOLIN SODIUM,CEFAZOLIN SODIUM,NDA050779,17f8f038-c204-4dab-80d7-6f7ac41ddbec,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/050779s013ltr.pdf,
2000,CEFAZOLIN SODIUM,CEFAZOLIN SODIUM,NDA050779,17f8f038-c204-4dab-80d7-6f7ac41ddbec,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50779_Cefazolin.cfm,
1977,N/A,N/A,NDA018012,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/018012_s024_PAMELOR CAPSULES.pdf,
2012,ICLUSIG,PONATINIB HYDROCHLORIDE,NDA203469,16d804b6-4957-43ee-b18c-3b36ec37c5ac,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203469Orig1s007,s008.pdf",
2012,ICLUSIG,PONATINIB HYDROCHLORIDE,NDA203469,16d804b6-4957-43ee-b18c-3b36ec37c5ac,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203469Orig1s000TOC.cfm,
2012,ICLUSIG,PONATINIB HYDROCHLORIDE,NDA203469,16d804b6-4957-43ee-b18c-3b36ec37c5ac,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203469Orig1s000SumR.pdf,
2012,ICLUSIG,PONATINIB HYDROCHLORIDE,NDA203469,16d804b6-4957-43ee-b18c-3b36ec37c5ac,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203469Orig1s007,s008.pdf",
2018,DOPTELET,AVATROMBOPAG MALEATE,NDA210238,e2d5960d-6c18-46cc-86bd-089222b09852,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000TOC.cfm,
2020,CYSTADROPS,CYSTEAMINE HYDROCHLORIDE,NDA211302,5d2bcce3-9b89-4141-aeb7-db00449047f5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/211302Orig1s000TOC.cfm,
1992,MEDROXYPROGESTERONE ACETATE,MEDROXYPROGESTERONE ACETATE,NDA020246,987496bf-b4b0-409b-b745-f52ed0871f4e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/20246Orig1s048.pdf,
1992,MEDROXYPROGESTERONE ACETATE,MEDROXYPROGESTERONE ACETATE,NDA020246,987496bf-b4b0-409b-b745-f52ed0871f4e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/020246Orig1s060s062.pdf,
1992,MEDROXYPROGESTERONE ACETATE,MEDROXYPROGESTERONE ACETATE,NDA020246,987496bf-b4b0-409b-b745-f52ed0871f4e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/20246Orig1s052.pdf,
1992,MEDROXYPROGESTERONE ACETATE,MEDROXYPROGESTERONE ACETATE,NDA020246,987496bf-b4b0-409b-b745-f52ed0871f4e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/20246Orig1s050.pdf,
1992,MEDROXYPROGESTERONE ACETATE,MEDROXYPROGESTERONE ACETATE,NDA020246,987496bf-b4b0-409b-b745-f52ed0871f4e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/20246Orig1s049.pdf,
1992,MEDROXYPROGESTERONE ACETATE,MEDROXYPROGESTERONE ACETATE,NDA020246,987496bf-b4b0-409b-b745-f52ed0871f4e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/020246Orig1s060s062.pdf,
1992,MEDROXYPROGESTERONE ACETATE,MEDROXYPROGESTERONE ACETATE,NDA020246,987496bf-b4b0-409b-b745-f52ed0871f4e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020246Orig1s025.pdf,
2017,HEMLIBRA,EMICIZUMAB,BLA761083,2483adba-fab6-4d1b-96c5-c195577ed071,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761083Orig1s000TOC.cfm,
2023,LUMRYZ,SODIUM OXYBATE,NDA214755,10e5e40c-52f3-4c73-8a34-2c29c690a934,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/214755Orig1s000TOC.cfm,
2023,LUMRYZ,SODIUM OXYBATE,NDA214755,10e5e40c-52f3-4c73-8a34-2c29c690a934,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/214755Orig1s007.pdf,
2023,LUMRYZ,SODIUM OXYBATE,NDA214755,10e5e40c-52f3-4c73-8a34-2c29c690a934,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/214755Orig1s003.pdf,
2002,N/A,N/A,NDA021260,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-260_Avinza.cfm,
2000,N/A,N/A,NDA050775,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50775S1_Biaxin.cfm,
2000,N/A,N/A,NDA050775,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50755_BiaxinXL.cfm,
2000,N/A,N/A,NDA050775,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/50-775s004_BiaxinXL.cfm,
1982,HALCION,TRIAZOLAM,NDA017892,a0da0dba-a56d-486b-a45b-e8a7cdfbeac6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/017892_s034_HalcionTOC.cfm,
2017,VYVANSE,LISDEXAMFETAMINE DIMESYLATE,NDA208510,704e4378-ca83-445c-8b45-3cfa51c1ecad,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208510Orig1s000TOC.cfm,
2017,VYVANSE,LISDEXAMFETAMINE DIMESYLATE,NDA208510,704e4378-ca83-445c-8b45-3cfa51c1ecad,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/63_208510 Vyvanse clinical prea.pdf,
2017,VYVANSE,LISDEXAMFETAMINE DIMESYLATE,NDA208510,704e4378-ca83-445c-8b45-3cfa51c1ecad,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/64_208510 Vyvanse clinpharm prea.pdf,
2018,LUCEMYRA,LOFEXIDINE HYDROCHLORIDE,NDA209229,b748f308-ba71-4fd9-84ec-ec7e0f210885,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209229Orig1s000TOC.cfm,
2021,PONVORY,PONESIMOD,NDA213498,5be69660-738c-4db7-b0d4-517aa873dc41,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000TOC.cfm,
2025,BRYNOVIN,SITAGLIPTIN HYDROCHLORIDE ORAL,NDA219122,9468a2f3-3ebe-40bd-a3b4-d78d9eb47e04,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219122Orig1s000TOC.cfm,
2022,FYLNETRA,PEGFILGRASTIM,BLA761084,eeadd641-573d-47fe-897a-61006e5f9e03,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761084Orig1s000TOC.cfm,
2024,VAFSEO,VADADUSTAT,NDA215192,ac9da724-5a62-4ab6-a89c-376a25f6195b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/215192Orig1s000TOC.cfm,
2022,BENDAMUSTINE HYDROCHLORIDE,BENDAMUSTINE HYDROCHLORIDE,NDA216078,766b73e2-49bb-47f9-bbb1-44cfa1a3197e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216078Orig1s000TOC.cfm,
2022,PHEBURANE,SODIUM PHENYLBUTYRATE,NDA216513,d15f2cbf-4d22-40b5-8ef9-16b9d323a7f9,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216513Orig1s000TOC.cfm,
2023,VEVYE,CYCLOSPORINE OPHTHALMIC SOLUTION,NDA217469,0a60fccf-7e1b-44fe-e063-6394a90aadd5,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217469Orig1s000TOC.cfm,
2018,N/A,N/A,NDA022343,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/022343Orig1s000TOC.cfm,
2018,N/A,N/A,NDA022343,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22343-efavirenz-lamivudine-tenofovir-DDreview-prea.pdf,
2018,N/A,N/A,NDA022343,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22343-Efavirenz--Lamivudine-and-Tenofovir-clinpharm-prea.pdf,
2004,N/A,N/A,NDA021590,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021590s000_FazacloTOC.cfm,
2006,PREZISTA,DARUNAVIR,NDA021976,814301f9-c990-46a5-b481-2879a521a16f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21976 darunavir clinical prea.pdf,
2006,PREZISTA,DARUNAVIR,NDA021976,814301f9-c990-46a5-b481-2879a521a16f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21976 darunavir clinpharm prea.pdf,
2006,PREZISTA,DARUNAVIR,NDA021976,814301f9-c990-46a5-b481-2879a521a16f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021976s000_SprycelTOC.cfm,
2000,TACROLIMUS,TACROLIMUS,NDA050777,6b601eaf-4f3a-4a8b-8cd8-1000defa9822,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50777_protopic.cfm,
2014,N/A,N/A,NDA206162,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206162Orig1s000TOC.cfm,
2014,N/A,N/A,NDA206162,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206162Orig1s000SumR.pdf,
2014,N/A,N/A,NDA206162,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/206162Orig1s007.pdf,
2014,N/A,N/A,NDA204977,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204977Orig1s000TOC.cfm,
2018,ARIKAYCE,AMIKACIN,NDA207356,499ab990-2b21-474f-aaba-d86388965f40,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/207356Orig1s000TOC.cfm,
2017,SYMPROIC,NALDEMEDINE,NDA208854,b1a1256c-a1eb-4abe-ab1e-30e4711afd16,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208854Orig1s000TOC.cfm,
2019,JEUVEAU,PRABOTULINUM TOXIN TYPE A,BLA761085,17a914c1-e54b-4b50-965d-b0fd9111bba4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761085Orig1s000TOC.cfm,
2023,OPVEE,NALMEFENE HYDROCHLORIDE,NDA217470,999a4269-9e54-4801-b2ac-2a7276f0b94f,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217470Orig1s000TOC.cfm,
2018,N/A,N/A,NDA022344,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/022344Orig1s000TOC.cfm,
2001,MONISTAT 3 COMBINATION PACK,MICONAZOLE NITRATE,NDA021261,e1b8ad40-5adb-482a-b532-3f8e30d90128,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-261_Monistat3.cfm,
2003,RIOMET,METFORMIN HYDROCHLORIDE,NDA021591,05d4df4b-dfe8-4828-b423-a3d4f2c4114a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-591_Riomet.cfm,
2007,VYVANSE,LISDEXAMFETAMINE DIMESYLATE,NDA021977,704e4378-ca83-445c-8b45-3cfa51c1ecad,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/021977Orig1s037.pdf,
2007,VYVANSE,LISDEXAMFETAMINE DIMESYLATE,NDA021977,704e4378-ca83-445c-8b45-3cfa51c1ecad,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21977s027 lisdexamfetamine clinical prea.pdf,
2007,VYVANSE,LISDEXAMFETAMINE DIMESYLATE,NDA021977,704e4378-ca83-445c-8b45-3cfa51c1ecad,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21977s027 lisdexamfetamine statistical prea.pdf,
2007,VYVANSE,LISDEXAMFETAMINE DIMESYLATE,NDA021977,704e4378-ca83-445c-8b45-3cfa51c1ecad,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021977s000TOC.cfm,
2007,VYVANSE,LISDEXAMFETAMINE DIMESYLATE,NDA021977,704e4378-ca83-445c-8b45-3cfa51c1ecad,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21977 lisdexamfetamine clinical prea.pdf,
2007,VYVANSE,LISDEXAMFETAMINE DIMESYLATE,NDA021977,704e4378-ca83-445c-8b45-3cfa51c1ecad,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21977_lisdexamfetamine_clinical_PREA .pdf,
2007,VYVANSE,LISDEXAMFETAMINE DIMESYLATE,NDA021977,704e4378-ca83-445c-8b45-3cfa51c1ecad,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21977 lisdexamfetamine statistical prea.pdf,
2007,VYVANSE,LISDEXAMFETAMINE DIMESYLATE,NDA021977,704e4378-ca83-445c-8b45-3cfa51c1ecad,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21977_lisdexamfetamine_statistical_PREA.pdf,
2007,VYVANSE,LISDEXAMFETAMINE DIMESYLATE,NDA021977,704e4378-ca83-445c-8b45-3cfa51c1ecad,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/021977Orig1s036.pdf,
1999,ELLENCE,EPIRUBICIN HYDROCHLORIDE,NDA050778,0a03c798-a652-4895-b29c-3b521a89ba42,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50-778_Ellence.cfm,
2012,SKLICE,IVERMECTIN,NDA202736,7579bdfe-a538-4bff-b7c7-df2c4b6f13db,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202736_sklice_toc.cfm,
2012,SKLICE,IVERMECTIN,NDA202736,7579bdfe-a538-4bff-b7c7-df2c4b6f13db,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202736_ ivermectin_ clinical_ prea_2.pdf,
2012,SKLICE,IVERMECTIN,NDA202736,7579bdfe-a538-4bff-b7c7-df2c4b6f13db,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202736_ ivermectin_clinpharm_ prea_2.pdf,
2012,SKLICE,IVERMECTIN,NDA202736,7579bdfe-a538-4bff-b7c7-df2c4b6f13db,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/202736_ivermectin_ statistical_ prea_2.pdf,
2012,SKLICE,IVERMECTIN,NDA202736,7579bdfe-a538-4bff-b7c7-df2c4b6f13db,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202736Orig1s000SumR.pdf,
1992,ACULAR,KETOROLAC TROMETHAMINE,NDA019700,c94644d3-7b64-4f3d-a0c7-12c77466a0fc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019700_S019_ACULAR.pdf,
2019,ROZLYTREK,ENTRECTINIB,NDA212725,c7c71b0c-2549-4495-86b6-c2807fa54908,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212725Orig1s000, 212726Orig1s000TOC.cfm",
2018,TAKHZYRO,LANADELUMAB-FLYO,BLA761090,15f99d8c-efe7-4f7d-aa20-0d0f1e30c6e8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761090Orig1s000TOC.cfm,
1997,FLOMAX,TAMSULOSIN HYDROCHLORIDE,NDA020579,6771ad8e-ac92-4aec-b484-5d8350a353f8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020579_s000.pdf,
1997,FLOMAX,TAMSULOSIN HYDROCHLORIDE,NDA020579,6771ad8e-ac92-4aec-b484-5d8350a353f8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020579_Tamsulosin_Statistical_BPCA.pdf,
1997,FLOMAX,TAMSULOSIN HYDROCHLORIDE,NDA020579,6771ad8e-ac92-4aec-b484-5d8350a353f8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020579_Tamsulosin_Clinpharm_BPCA.pdf,
1997,FLOMAX,TAMSULOSIN HYDROCHLORIDE,NDA020579,6771ad8e-ac92-4aec-b484-5d8350a353f8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020579_Tamsulosin_Clinical_BPCA.pdf,
1996,GLIADEL,CARMUSTINE,NDA020637,38962a55-a514-4c48-bea5-f99a8da4beec,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/20-637s016_Gliadel.cfm,
1996,GLIADEL,CARMUSTINE,NDA020637,38962a55-a514-4c48-bea5-f99a8da4beec,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020637Orig1s000.pdf,
2009,ONGLYZA,SAXAGLIPTIN,NDA022350,c5116390-e0fe-4969-94cb-e9de5165fbab,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_SumR.pdf,
2009,ONGLYZA,SAXAGLIPTIN,NDA022350,c5116390-e0fe-4969-94cb-e9de5165fbab,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000TOC.cfm,
2002,VFEND,VORICONAZOLE,NDA021267,dac26bcd-7a59-401f-9f66-a0649767cece,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021266s005s006,021267s005s006,021630s001_VfendTOC.cfm",
2002,VFEND,VORICONAZOLE,NDA021267,dac26bcd-7a59-401f-9f66-a0649767cece,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/269_21266S39-voriconazole-clinical-prea.pdf,
2002,VFEND,VORICONAZOLE,NDA021267,dac26bcd-7a59-401f-9f66-a0649767cece,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/504_21267S50 voriconazole clinical2 prea.pdf,
2002,VFEND,VORICONAZOLE,NDA021267,dac26bcd-7a59-401f-9f66-a0649767cece,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/270_21266S39-voriconazole-clinpharm-prea.pdf,
2002,VFEND,VORICONAZOLE,NDA021267,dac26bcd-7a59-401f-9f66-a0649767cece,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/271_21266S39-voriconazole-statistical-prea.pdf,
2002,VFEND,VORICONAZOLE,NDA021267,dac26bcd-7a59-401f-9f66-a0649767cece,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-266_21-267_Vfend.cfm,
2002,VFEND,VORICONAZOLE,NDA021267,dac26bcd-7a59-401f-9f66-a0649767cece,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021266s005s006,021267s005s006,021630s001_VfendTOC.cfm",
2002,VFEND,VORICONAZOLE,NDA021267,dac26bcd-7a59-401f-9f66-a0649767cece,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021267Orig1s009.pdf,
2003,VIGAMOX,MOXIFLOXACIN HYDROCHLORIDE,NDA021598,12053b08-7e66-c6f3-e063-6394a90a9cd9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-598_Vigamox.cfm,
2003,VIGAMOX,MOXIFLOXACIN HYDROCHLORIDE,NDA021598,12053b08-7e66-c6f3-e063-6394a90a9cd9,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/104_21598 moxifloxacin clinical bpca.pdf,
2003,VIGAMOX,MOXIFLOXACIN HYDROCHLORIDE,NDA021598,12053b08-7e66-c6f3-e063-6394a90a9cd9,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/105_21598 moxifloxacin DDclinical bpca.pdf,
2006,DASATINIB,DASATINIB,NDA021986,1931e73f-918c-4d69-9543-de9643513d05,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021986_s001_s002.pdf,
2006,DASATINIB,DASATINIB,NDA021986,1931e73f-918c-4d69-9543-de9643513d05,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021986_022072_SprycelTOC.cfm,
2006,DASATINIB,DASATINIB,NDA021986,1931e73f-918c-4d69-9543-de9643513d05,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/379_21986S21 dasatinib CDTL clinical bpca.pdf,
2006,DASATINIB,DASATINIB,NDA021986,1931e73f-918c-4d69-9543-de9643513d05,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/381_21986S21 dasatinib statistical memo bpca.pdf,
2006,DASATINIB,DASATINIB,NDA021986,1931e73f-918c-4d69-9543-de9643513d05,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021986_s001_s002.pdf,
2013,CYCLOPHOSPHAMIDE,CYCLOPHOSPHAMIDE,NDA203856,8135b917-882f-4b4c-99b7-fa8ea54af4bf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203856Orig1s000TOC.cfm,
2013,CYCLOPHOSPHAMIDE,CYCLOPHOSPHAMIDE,NDA203856,8135b917-882f-4b4c-99b7-fa8ea54af4bf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203856Orig1s000SumR.pdf,
2016,TIROSINT SOL,LEVOTHYROXINE SODIUM,NDA206977,5d378add-f13d-40f2-99dc-0f2340ab44b7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206977Orig1s000TOC.cfm,
2016,TIROSINT SOL,LEVOTHYROXINE SODIUM,NDA206977,5d378add-f13d-40f2-99dc-0f2340ab44b7,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/92_206977 levothyroxine clinical prea.pdf,
2016,TIROSINT SOL,LEVOTHYROXINE SODIUM,NDA206977,5d378add-f13d-40f2-99dc-0f2340ab44b7,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/91_206977 levothyroxine CDTL clinical prea.pdf,
2016,TIROSINT SOL,LEVOTHYROXINE SODIUM,NDA206977,5d378add-f13d-40f2-99dc-0f2340ab44b7,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/93_206977 levothyroxine clinpharm prea.pdf,
1993,INTRALIPID,I. V. FAT EMULSION,NDA019942,dd269651-30e8-43f0-880f-484346eaafeb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019942_ORIGINAL_APPROVAL_PACKAGE.pdf,
2003,EPINEPHRINE,EPINEPHRINE,NDA020800,e13f05f1-7d21-49bb-b8d5-24bf9301c3d7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/020800Orig1s023.pdf,
2003,EPINEPHRINE,EPINEPHRINE,NDA020800,e13f05f1-7d21-49bb-b8d5-24bf9301c3d7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/20-800_Twinject.cfm,
2003,EPINEPHRINE,EPINEPHRINE,NDA020800,e13f05f1-7d21-49bb-b8d5-24bf9301c3d7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/020800Orig1s034pkg.pdf,
2019,AVSOLA,INFLIXIMAB-AXXQ,BLA761086,de34bcb7-b524-45c8-9181-61c6f48d540e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761086Orig1s000TOC.cfm,
2025,GRAFAPEX,TREOSULFAN,NDA214759,2d06b03c-17aa-0492-e063-6294a90abd8f,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/214759Orig1s000TOC.cfm,
2023,N/A,N/A,NDA216974,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216974Orig1s000TOC.cfm,
1998,N/A,N/A,NDA020928,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20928.pdf,
2004,N/A,N/A,NDA021264,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-264_Apokyn.cfm,
2006,FLUORESCITE,FLUORESCEIN SODIUM,NDA021980,ebb3883c-71f6-4fd0-a7e6-0ba8e1136dd9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021980s000TOC.cfm,
2001,CEFUROXIME AND DEXTROSE,CEFUROXIME AND DEXTROSE,NDA050780,07170ee3-1a24-424f-a2a2-00bc92e98f85,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/50780_Cefuroxime.cfm,
1984,N/A,N/A,NDA018631,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/018631_s030ap.pdf,
2013,VERSACLOZ,CLOZAPINE,NDA203479,2592c9a8-fd74-4e0d-a895-b07b014cf355,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203479_versacloz_toc.cfm,
2013,VERSACLOZ,CLOZAPINE,NDA203479,2592c9a8-fd74-4e0d-a895-b07b014cf355,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203479Orig1s000SumR.pdf,
2011,ZYTIGA,ABIRATERONE ACETATE,NDA202379,4e338e89-3cf2-48eb-b6e2-a06c608c6513,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202379Orig1s006.pdf,
2011,ZYTIGA,ABIRATERONE ACETATE,NDA202379,4e338e89-3cf2-48eb-b6e2-a06c608c6513,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202379Orig1s000TOC.cfm,
2011,ZYTIGA,ABIRATERONE ACETATE,NDA202379,4e338e89-3cf2-48eb-b6e2-a06c608c6513,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202379Orig1s000SumR.pdf,
2011,ZYTIGA,ABIRATERONE ACETATE,NDA202379,4e338e89-3cf2-48eb-b6e2-a06c608c6513,http://www.accessdata.fda.gov/drugsatfda_docs/review/2018/202379Orig1s007.pdf,
2011,ZYTIGA,ABIRATERONE ACETATE,NDA202379,4e338e89-3cf2-48eb-b6e2-a06c608c6513,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202379Orig1s005.pdf,
2014,HEMANGEOL,PROPRANOLOL HYDROCHLORIDE,NDA205410,b6f9dd2a-632b-87eb-70f0-b2064d7ed48a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205410Orig1s000TOC.cfm,
1995,ZYRTEC HIVES,CETIRIZINE HYDROCHLORIDE,NDA019835,31136e3a-94fa-0860-e063-6394a90a008d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019835_S016_ZYRTEC SYRUP_.pdf,
1995,ZYRTEC HIVES,CETIRIZINE HYDROCHLORIDE,NDA019835,31136e3a-94fa-0860-e063-6394a90a008d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/019835s022_021621s005TOC.cfm,
1995,ZYRTEC HIVES,CETIRIZINE HYDROCHLORIDE,NDA019835,31136e3a-94fa-0860-e063-6394a90a008d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/19835-S005_Zyrtec.pdf,
1995,ZYRTEC HIVES,CETIRIZINE HYDROCHLORIDE,NDA019835,31136e3a-94fa-0860-e063-6394a90a008d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019835Orig1s000rev.pdf,
1995,ZYRTEC HIVES,CETIRIZINE HYDROCHLORIDE,NDA019835,31136e3a-94fa-0860-e063-6394a90a008d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019835_S015_ZYRTEC TABLETS.pdf,
2018,TRUXIMA,RITUXIMAB-ABBS,BLA761088,9af3ddc7-4217-417a-ac89-8704edc5bc44,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761088Orig1s000TOC.cfm,
2000,PULMICORT RESPULES,BUDESONIDE,NDA020929,33cd9834-76df-4f26-3fa2-aab6b9eee8f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020929_S013_PULMICORT_RESPULES_AP.pdf,
2000,PULMICORT RESPULES,BUDESONIDE,NDA020929,33cd9834-76df-4f26-3fa2-aab6b9eee8f2,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/budesonide_Pulmicort-MedRev-20929s013.pdf,
2000,PULMICORT RESPULES,BUDESONIDE,NDA020929,33cd9834-76df-4f26-3fa2-aab6b9eee8f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-929_Pulmicort.cfm,
2000,PULMICORT RESPULES,BUDESONIDE,NDA020929,33cd9834-76df-4f26-3fa2-aab6b9eee8f2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020929_S015_PULMICORT_TURBOHALER_AP.pdf,
2001,INFUVITE PEDIATRIC,MULTIPLE VITAMINS INJECTION,NDA021265,6d06546e-8b0a-4490-82d9-397bd902a044,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-265_Infuvite.cfm,
2004,N/A,N/A,NDA021595,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-595_Sanctura.cfm,
2006,DUODOTE,ATROPINE AND PRALIDOXIME CHLORIDE,NDA021983,241f42a0-1a33-40e8-8221-201767d999e5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021983_duodote_toc.cfm,
2006,DUODOTE,ATROPINE AND PRALIDOXIME CHLORIDE,NDA021983,241f42a0-1a33-40e8-8221-201767d999e5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/190_21983s23 pralidoxime atropine CDTL clinical prea.pdf,
2006,DUODOTE,ATROPINE AND PRALIDOXIME CHLORIDE,NDA021983,241f42a0-1a33-40e8-8221-201767d999e5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/191_21983s23 pralidoxime atropine clinical prea.pdf,
2006,DUODOTE,ATROPINE AND PRALIDOXIME CHLORIDE,NDA021983,241f42a0-1a33-40e8-8221-201767d999e5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/192_21983s23 pralidoxime atropine clinpharm prea.pdf,
2001,ARESTIN,MINOCYCLINE HYDROCHLORIDE,NDA050781,8515df41-1936-4f3b-86ba-d2bb2a8441fb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/50781_Arestin.cfm,
1977,CARMUSTINE,CARMUSTINE,NDA017422,b9b47082-32ee-4abb-a7b2-52292894d3f8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/017422Orig1s045.pdf,
1977,CARMUSTINE,CARMUSTINE,NDA017422,b9b47082-32ee-4abb-a7b2-52292894d3f8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/017422Orig1s037.pdf,
1977,CARMUSTINE,CARMUSTINE,NDA017422,b9b47082-32ee-4abb-a7b2-52292894d3f8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/017422Orig1s047.pdf,
2012,JUXTAPID,LOMITAPIDE MESYLATE,NDA203858,e4c45bb5-15f4-437e-ab98-a649b3676d14,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/203858Orig1s023.pdf,
2012,JUXTAPID,LOMITAPIDE MESYLATE,NDA203858,e4c45bb5-15f4-437e-ab98-a649b3676d14,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/2038858_juxtapid_toc.cfm,
2013,SIMBRINZA,BRINZOLAMIDE/BRIMONIDINE TARTRATE,NDA204251,a49c157e-6310-0011-7b7f-e26fc1820d59,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204251_simbrinza_toc.cfm,
2013,SIMBRINZA,BRINZOLAMIDE/BRIMONIDINE TARTRATE,NDA204251,a49c157e-6310-0011-7b7f-e26fc1820d59,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204251Orig1s000SumR.pdf,
2017,CLENPIQ,"SODIUM PICOSULFATE, MAGNESIUM OXIDE, AND ANHYDROUS CITRIC ACID",NDA209589,e95fff66-4ec0-4001-a727-33e66a5ec7d5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209589Orig1s000TOC.cfm,
2021,ZYNRELEF,BUPIVACAINE AND MELOXICAM,NDA211988,dab484a7-9353-43ba-9e74-7fab910c712b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/211988Orig1s013.pdf,
2021,ZYNRELEF,BUPIVACAINE AND MELOXICAM,NDA211988,dab484a7-9353-43ba-9e74-7fab910c712b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/211988Orig1s005.pdf,
2021,ZYNRELEF,BUPIVACAINE AND MELOXICAM,NDA211988,dab484a7-9353-43ba-9e74-7fab910c712b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/211988Orig1s000TOC.cfm,
2024,AQNEURSA,LEVACETYLLEUCINE,NDA219132,0f248e55-d1bb-13f9-e063-6294a90a05ce,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/219132Orig1s000TOC.cfm,
2018,AJOVY,FREMANEZUMAB-VFRM,BLA761089,98e344ea-5916-4947-b6f2-4a76ccc04b6b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761089Orig1s000TOC.cfm,
1997,N/A,N/A,NDA020676,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020676_vagistat-1_toc.cfm,
2009,CALDOLOR,IBUPROFEN,NDA022348,1eaa7790-f1a1-4f51-b10a-cbbaf033f684,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022348_caldolor_toc.cfm,
2009,CALDOLOR,IBUPROFEN,NDA022348,1eaa7790-f1a1-4f51-b10a-cbbaf033f684,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022348s000SumR.pdf,
2009,CALDOLOR,IBUPROFEN,NDA022348,1eaa7790-f1a1-4f51-b10a-cbbaf033f684,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22348 ibuprofen clinpharm prea.pdf,
2009,CALDOLOR,IBUPROFEN,NDA022348,1eaa7790-f1a1-4f51-b10a-cbbaf033f684,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22348 ibuprofen clinical prea.pdf,
2009,CALDOLOR,IBUPROFEN,NDA022348,1eaa7790-f1a1-4f51-b10a-cbbaf033f684,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22348_ibuprofen_DD clinical_PREA.pdf,
2009,CALDOLOR,IBUPROFEN,NDA022348,1eaa7790-f1a1-4f51-b10a-cbbaf033f684,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22348 ibuprofen statistical prea.pdf,
1999,TIKOSYN,DOFETILIDE,NDA020931,02438044-d6a3-49e9-a1ac-3aad21ef2c8c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/020931s013.pdf,
1999,TIKOSYN,DOFETILIDE,NDA020931,02438044-d6a3-49e9-a1ac-3aad21ef2c8c,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/020931Orig1s001.pdf,
1999,TIKOSYN,DOFETILIDE,NDA020931,02438044-d6a3-49e9-a1ac-3aad21ef2c8c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-931_Tikosyn.cfm,
1999,TIKOSYN,DOFETILIDE,NDA020931,02438044-d6a3-49e9-a1ac-3aad21ef2c8c,http://www.accessdata.fda.gov/drugsatfda_docs/review/2018/020931Orig1s013REMS.pdf,
2002,VFEND,VORICONAZOLE,NDA021266,ce3ef5cf-3087-4d92-9d94-9eb8287228db,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021266s005s006,021267s005s006,021630s001_VfendTOC.cfm",
2002,VFEND,VORICONAZOLE,NDA021266,ce3ef5cf-3087-4d92-9d94-9eb8287228db,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-266_21-267_Vfend.cfm,
2002,VFEND,VORICONAZOLE,NDA021266,ce3ef5cf-3087-4d92-9d94-9eb8287228db,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021266s005s006,021267s005s006,021630s001_VfendTOC.cfm",
2002,VFEND,VORICONAZOLE,NDA021266,ce3ef5cf-3087-4d92-9d94-9eb8287228db,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021266Orig1s009.pdf,
2007,ALISKIREN,ALISKIREN HEMIFUMARATE,NDA021985,41c0e5e0-eb26-4d9e-bcd2-d0f2cc8fc6db,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021985s000TOC.cfm,
2007,ALISKIREN,ALISKIREN HEMIFUMARATE,NDA021985,41c0e5e0-eb26-4d9e-bcd2-d0f2cc8fc6db,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/206_210709 aliskiren CDTL clinical bpca.pdf,
2007,ALISKIREN,ALISKIREN HEMIFUMARATE,NDA021985,41c0e5e0-eb26-4d9e-bcd2-d0f2cc8fc6db,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/207_210709 aliskiren clin and clinpharm bpca.pdf,
2007,ALISKIREN,ALISKIREN HEMIFUMARATE,NDA021985,41c0e5e0-eb26-4d9e-bcd2-d0f2cc8fc6db,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208_210709 aliskiren statistical bpca.pdf,
1977,PAMELOR,NORTRIPTYLINE HYDROCHLORIDE,NDA018013,e17dc299-f52d-414d-ab6e-e809bd6f8acb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/018013_s053_PAMELOR CAPSULES.pdf,
2015,REXULTI,BREXPIPRAZOLE,NDA205422,2d301358-6291-4ec1-bd87-37b4ad9bd850,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/205422Orig1s009TOC.cfm,
2015,REXULTI,BREXPIPRAZOLE,NDA205422,2d301358-6291-4ec1-bd87-37b4ad9bd850,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205422s000TOC.cfm,
2017,N/A,N/A,NDA209936,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209936Orig1_toc.cfm,
2020,NURTEC ODT,RIMEGEPANT SULFATE,NDA212728,9ef08e09-1098-35cc-e053-2a95a90a3e1d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212728Orig1s000TOC.cfm,
2024,OPSYNVI,MACITENTAN AND TADALAFIL,NDA218490,6945b183-18d3-40de-afd1-c88e33cc1a63,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/218490Orig1s000TOC.cfm,
2018,LIBTAYO,CEMIPLIMAB-RWLC,BLA761097,4347ae1f-d397-4f18-8b70-03897e1c054a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761097Orig1s000TOC.cfm,
2018,LIBTAYO,CEMIPLIMAB-RWLC,BLA761097,4347ae1f-d397-4f18-8b70-03897e1c054a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761097Orig1s003.pdf,
2022,VUEWAY,GADOPICLENOL,NDA216986,192725e9-e83e-1a36-33f2-abee55792ab3,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216986Orig1s000TOC.cfm,
2023,COXANTO,OXAPROZIN,NDA217927,1c54398b-0f57-42b7-9067-0f8012c7813e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217927Orig1s000TOC.cfm,
1999,N/A,N/A,NDA020937,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20937_OptiMark.cfm,
1999,N/A,N/A,NDA020937,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/20-937s3,20-975s3,20-976s3_OptiMark.cfm",
2002,REMODULIN,TREPROSTINIL,NDA021272,6c80bb38-e8db-4138-9f0d-dbbf9c673185,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021272Orig1s020.pdf,
2002,REMODULIN,TREPROSTINIL,NDA021272,6c80bb38-e8db-4138-9f0d-dbbf9c673185,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-272_Remodulin.cfm,
2002,REMODULIN,TREPROSTINIL,NDA021272,6c80bb38-e8db-4138-9f0d-dbbf9c673185,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021272Orig1s005.pdf,
2002,REMODULIN,TREPROSTINIL,NDA021272,6c80bb38-e8db-4138-9f0d-dbbf9c673185,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021272Orig1s002.pdf,
2006,PYLERA,"BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, AND TETRACYCLINE HYDROCHLORIDE",NDA050786,5cdacbf5-67be-42eb-bd54-8acc32ea1abc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/050786s000_PyleraTOC.cfm,
1980,FEVERALL CHILDRENS,ACETAMINOPHEN,NDA018337,861e2987-5473-45b0-b2a6-f980a9b0e809,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018337Orig1s013.pdf,
1988,SANDOSTATIN,OCTREOTIDE ACETATE,NDA019667,4e2c9856-1836-49f0-9472-4dbeeb408f39,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019667-s04.pdf,
2017,INGREZZA,VALBENAZINE,NDA209241,4c970164-cafb-421f-9eb5-c226ef0a3417,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/209241Orig1s016.pdf,
2017,INGREZZA,VALBENAZINE,NDA209241,4c970164-cafb-421f-9eb5-c226ef0a3417,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209241Orig1s000TOC.cfm,
2017,INGREZZA,VALBENAZINE,NDA209241,4c970164-cafb-421f-9eb5-c226ef0a3417,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209241Orig1s000SumR.pdf,
2019,N/A,N/A,NDA212726,N/A,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212725Orig1s000,%20212726Orig1s000TOC.cfm",
2025,INZIRQO,HYDROCHLOROTHIAZIDE,NDA219141,41aaea48-6c1b-42c8-a96f-5923d49dc934,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219141Orig1s000TOC.cfm,
2018,HERZUMA,TRASTUZUMAB,BLA761091,ae71c003-883a-4cd8-ad50-e8cc9a54e971,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761091Orig1s000TOC.cfm,
1995,CHILDRENS MOTRIN,IBUPROFEN,NDA020516,9e1cdef7-921f-4163-869c-6c062e31c5bb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-603s002_Ibuprofen.cfm,
1998,N/A,N/A,NDA020933,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20-933_20-636S009_Viramune.cfm,
1998,N/A,N/A,NDA020933,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020636s017_020933s007_Viramune.cfm,
1998,N/A,N/A,NDA020933,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020933_S014_VIRAMUNE.pdf,
2001,N/A,N/A,NDA021268,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-268_Teveten.cfm,
2003,VELCADE,BORTEZOMIB,NDA021602,1521d321-e724-4ffc-adad-34bf4f44fac7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021602_s010_velcade.pdf,
2003,VELCADE,BORTEZOMIB,NDA021602,1521d321-e724-4ffc-adad-34bf4f44fac7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/021602Orig1s027.pdf,
2003,VELCADE,BORTEZOMIB,NDA021602,1521d321-e724-4ffc-adad-34bf4f44fac7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021602Orig1s015.pdf,
2003,VELCADE,BORTEZOMIB,NDA021602,1521d321-e724-4ffc-adad-34bf4f44fac7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21602_Velcade.cfm,
2003,VELCADE,BORTEZOMIB,NDA021602,1521d321-e724-4ffc-adad-34bf4f44fac7,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21602 bortezomib clinica bpca.pdf,
2003,VELCADE,BORTEZOMIB,NDA021602,1521d321-e724-4ffc-adad-34bf4f44fac7,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21602 bortezomib clinpharm bpca.pdf,
2003,VELCADE,BORTEZOMIB,NDA021602,1521d321-e724-4ffc-adad-34bf4f44fac7,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21602 bortezomib statistical bpca.pdf,
2001,N/A,N/A,NDA050783,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/50-783_Periostat.cfm,
1986,BREVIBLOC,ESMOLOL HYDROCHLORIDE,NDA019386,220a07b8-5c68-41a3-8705-fd91f14c50b4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/19-386_ Brevibloc.cfm,
1986,BREVIBLOC,ESMOLOL HYDROCHLORIDE,NDA019386,220a07b8-5c68-41a3-8705-fd91f14c50b4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019386_S011_BREVIBLOC.pdf,
1986,BREVIBLOC,ESMOLOL HYDROCHLORIDE,NDA019386,220a07b8-5c68-41a3-8705-fd91f14c50b4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019386_S001&S002_BREVIBLOC_INJ.pdf,
1986,BREVIBLOC,ESMOLOL HYDROCHLORIDE,NDA019386,220a07b8-5c68-41a3-8705-fd91f14c50b4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/019386_S018_BREVIBLOC_INJECTION.pdf,
1986,BREVIBLOC,ESMOLOL HYDROCHLORIDE,NDA019386,220a07b8-5c68-41a3-8705-fd91f14c50b4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/019386_S022_Brevibloc.pdf,
1986,BREVIBLOC,ESMOLOL HYDROCHLORIDE,NDA019386,220a07b8-5c68-41a3-8705-fd91f14c50b4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019386_S004&S006_BREVIBLOC.pdf,
1986,BREVIBLOC,ESMOLOL HYDROCHLORIDE,NDA019386,220a07b8-5c68-41a3-8705-fd91f14c50b4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019386_S012_BREVIBLOC.pdf,
1986,BREVIBLOC,ESMOLOL HYDROCHLORIDE,NDA019386,220a07b8-5c68-41a3-8705-fd91f14c50b4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019386_S004&S006_BREVIBLOC.pdf,
1986,BREVIBLOC,ESMOLOL HYDROCHLORIDE,NDA019386,220a07b8-5c68-41a3-8705-fd91f14c50b4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019386_S010_BREVIBLOC_INJECTION.pdf,
1986,BREVIBLOC,ESMOLOL HYDROCHLORIDE,NDA019386,220a07b8-5c68-41a3-8705-fd91f14c50b4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019386_S001&S002_BREVIBLOC_INJ.pdf,
1986,BREVIBLOC,ESMOLOL HYDROCHLORIDE,NDA019386,220a07b8-5c68-41a3-8705-fd91f14c50b4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/019386_S017_BREVIBLOC_INJECTION.pdf,
1986,BREVIBLOC,ESMOLOL HYDROCHLORIDE,NDA019386,220a07b8-5c68-41a3-8705-fd91f14c50b4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019386_S009_BREVIBLOC_INJECTION.pdf,
1986,BREVIBLOC,ESMOLOL HYDROCHLORIDE,NDA019386,220a07b8-5c68-41a3-8705-fd91f14c50b4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/019386_S015_BREVIBLOC_INJECTION.pdf,
1986,BREVIBLOC,ESMOLOL HYDROCHLORIDE,NDA019386,220a07b8-5c68-41a3-8705-fd91f14c50b4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/19-386s021.cfm,
1986,BREVIBLOC,ESMOLOL HYDROCHLORIDE,NDA019386,220a07b8-5c68-41a3-8705-fd91f14c50b4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019386_S007_BREVIBLOC.pdf,
1986,BREVIBLOC,ESMOLOL HYDROCHLORIDE,NDA019386,220a07b8-5c68-41a3-8705-fd91f14c50b4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019386_S005_BREVIBLOC.pdf,
2016,TETRACAINE HYDROCHLORIDE,TETRACAINE HYDROCHLORIDE,NDA208135,5c7b1de4-9f55-1d0e-ef6d-b0ba2cbaba79,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208135Orig1s000TOC.cfm,
2016,TETRACAINE HYDROCHLORIDE,TETRACAINE HYDROCHLORIDE,NDA208135,5c7b1de4-9f55-1d0e-ef6d-b0ba2cbaba79,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208135Orig1s000SumR.pdf,
2016,TETRACAINE HYDROCHLORIDE,TETRACAINE HYDROCHLORIDE,NDA208135,5c7b1de4-9f55-1d0e-ef6d-b0ba2cbaba79,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208135 tetracaine DD clinical prea.pdf,
2016,TETRACAINE HYDROCHLORIDE,TETRACAINE HYDROCHLORIDE,NDA208135,5c7b1de4-9f55-1d0e-ef6d-b0ba2cbaba79,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208135 tetracaine clinical prea.pdf,
2016,TETRACAINE HYDROCHLORIDE,TETRACAINE HYDROCHLORIDE,NDA208135,5c7b1de4-9f55-1d0e-ef6d-b0ba2cbaba79,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208135 tetracaine clinpharm prea.pdf,
2016,TETRACAINE HYDROCHLORIDE,TETRACAINE HYDROCHLORIDE,NDA208135,5c7b1de4-9f55-1d0e-ef6d-b0ba2cbaba79,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208135 tetracaine statistical prea.pdf,
2021,PRADAXA,DABIGATRAN ETEXILATE,NDA214358,9ac0a64a-8666-45f7-9d4f-40fd894f7e6d,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214358Orig1s000TOC.cfm,
1997,N/A,N/A,NDA020448,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020448_imodium-ad_toc.cfm,
2019,DOVATO,DOLUTEGRAVIR SODIUM AND LAMIVUDINE,NDA211994,68e45422-43ed-4cfb-9356-fae88d14a53a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211994Orig1s000TOC.cfm,
2018,REVCOVI,ELAPEGADEMASE-LVLR,BLA761092,8c073f84-cdd0-40e4-b3a9-172687267f28,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761092Orig1s000TOC.cfm,
2021,NOXAFIL,POSACONAZOLE,NDA214770,b073b082-7b57-4423-8c06-4fd4263d6f84,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214770Orig1s000TOC.cfm,
2021,QULIPTA,ATOGEPANT,NDA215206,8c8ab8f4-32bd-497a-befa-70c8a51d8d52,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215206Orig1s000TOC.cfm,
2021,XACIATO,CLINDAMYCIN PHOSPHATE,NDA215650,0423007f-28fa-4159-bf58-9174626d2347,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215650Orig1s000TOC.cfm,
2009,COLCRYS,COLCHICINE,NDA022352,56c130d1-7581-4152-99a2-0014ee9366c0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022352_colcrys_toc.cfm,
2009,COLCRYS,COLCHICINE,NDA022352,56c130d1-7581-4152-99a2-0014ee9366c0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022352s000_SumR.pdf,
2005,CARDURA XL,DOXAZOSIN MESYLATE,NDA021269,355bcdce-0481-48ba-8ebd-2009106aaf77,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021269_carduraxl_toc.cfm,
2004,N/A,N/A,NDA021604,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021604s000_Childrens_ElixSureTOC.cfm,
2007,EXFORGE,AMLODIPINE BESYLATE AND VALSARTAN,NDA021990,d0caec89-96ec-411d-a933-63eda74a6da7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021990_exforge_toc.cfm,
2007,EXFORGE,AMLODIPINE BESYLATE AND VALSARTAN,NDA021990,d0caec89-96ec-411d-a933-63eda74a6da7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021990Orig1s003.pdf,
2002,ZITHROMAX,AZITHROMYCIN DIHYDRATE,NDA050784,db52b91e-79f7-4cc1-9564-f2eee8e31c45,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/050784_S004_S006_ZithromaxTOC.cfm,
2002,ZITHROMAX,AZITHROMYCIN DIHYDRATE,NDA050784,db52b91e-79f7-4cc1-9564-f2eee8e31c45,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/050784_S004_S006_ZithromaxTOC.cfm,
2002,ZITHROMAX,AZITHROMYCIN DIHYDRATE,NDA050784,db52b91e-79f7-4cc1-9564-f2eee8e31c45,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50-784_Zithromax.cfm,
1986,PREDNISOLONE SODIUM PHOSPHATE,PREDNISOLONE SODIUM PHOSPHATE,NDA019157,833ba492-8823-43b4-9a91-8b28d94a740b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/019157_018_PrediapredTOC.cfm,
1986,PREDNISOLONE SODIUM PHOSPHATE,PREDNISOLONE SODIUM PHOSPHATE,NDA019157,833ba492-8823-43b4-9a91-8b28d94a740b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/19-157S016.pdf,
1986,PREDNISOLONE SODIUM PHOSPHATE,PREDNISOLONE SODIUM PHOSPHATE,NDA019157,833ba492-8823-43b4-9a91-8b28d94a740b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019157_PEDIAPRED_ORIGINAL_AP.pdf,
2014,PENNSAID,DICLOFENAC SODIUM,NDA204623,802cd382-443d-48e3-9c9d-fd946c73c79f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204623Orig1s000TOC.cfm,
2014,PENNSAID,DICLOFENAC SODIUM,NDA204623,802cd382-443d-48e3-9c9d-fd946c73c79f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204623Orig1s000SumR.pdf,
2017,KISQALI FEMARA CO-PACK,LETROZOLE AND RIBOCICLIB,NDA209935,aa5e4446-19cd-4235-a382-5b48bf6c3b2f,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/209092s018,209935s027MultidisciplineR.pdf",
2017,KISQALI FEMARA CO-PACK,LETROZOLE AND RIBOCICLIB,NDA209935,aa5e4446-19cd-4235-a382-5b48bf6c3b2f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209935Orig1s000TOC.cfm,
2018,BIKTARVY,"BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE",NDA210251,664cb8f0-1f65-441b-b0d9-ba3d798be309,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210251Orig1s000TOC.cfm,
2018,BIKTARVY,"BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE",NDA210251,664cb8f0-1f65-441b-b0d9-ba3d798be309,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/432_210251S5 bictegravir emtricitabine tenofovir clinpharm prea.pdf,
2018,BIKTARVY,"BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE",NDA210251,664cb8f0-1f65-441b-b0d9-ba3d798be309,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/433_210251S5 bictegravir emtricitabine tenofovir CDTL prea_0.pdf,
2018,BIKTARVY,"BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE",NDA210251,664cb8f0-1f65-441b-b0d9-ba3d798be309,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/434_210251S5 bictegravir emtricitabine tenofovir CDTL1 prea_0.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020406_S048_PREVACID.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020406_s006_Prevacid_Delayed_Release_Capsules.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21428_20406s052_21281s007_PrevacidTOC.cfm,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020406_s004_Prevacid_Delayed_Release_Capsules.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020406_s044_Prevacid_Delayed_Release_Capsules.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20406S016.cfm,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20406-S034_Prevacid.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020406_s026_Prevacid_Delayed_Release_Capsules.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020406_s018_Prevacid_Delayed_Release_Capsules.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020406_prevacid_toc.cfm,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20406s067_21281s024_21428s017_Lansoprazole (Prevacid) Clinical_BPCA.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20406s067_21281s024_21428s017_Lansoprazole (Prevacid) Clinpharm_BPCA.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20406s067_21281s024_21428s017_Lansoprazole (Prevacid) Statistical_BPCA.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020406_s024_Prevacid_Delayed_Release_Capsules.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20406S016.cfm,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20406-S030_Prevacid.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020406_S022_PREVACID.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020406s057_lansoprazole_Prevacid-Med&ClinPharmRev.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020406s057_lansoprazole_Prevacid-StatRev.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20406s057_lansoprazole_Prevacid-ClinpharmRev.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020406_s020_Prevacid_Delayed_Release_Capsules.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020406_s009_PrevacidDelayedReleaseCaps.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020406_s007_Prevacid_Delayed_Release_Capsules.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020406_s039_Prevacid_Delayed_Release_Capsules.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020406_s005_Prevacid_Delayed_Release_Capsules.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020406_s043_Prevacid_Delayed_Release_Capsules.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020406_s035_Prevacid Caps.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20406-S030_Prevacid.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020406_s041_Prevacid_Delayed_Release_Capsules.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020406_s019_Prevacid_Delayed_Release_Capsules.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020406_s025_Prevacid_Delayed_Release_Capsules.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020406Orig1s017.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020406_s023_Prevacid_Delayed_Release_Capsules.pdf,
1995,PREVACID,LANSOPRAZOLE,NDA020406,71ba78cb-7e46-43eb-9425-fa130f537f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20406-s021.cfm,
1993,TIMOPTIC-XE,TIMOLOL MALEATE,NDA020330,a4d03de7-06b7-4cfc-9d1b-616969df209c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020330_s017_TimopticTOC.cfm,
1993,TIMOPTIC-XE,TIMOLOL MALEATE,NDA020330,a4d03de7-06b7-4cfc-9d1b-616969df209c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20-330S011.pdf,
2018,OXERVATE,CENEGERMIN-BKBJ,BLA761094,89e4bfec-d710-40ed-8885-5d13ba46b1cd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761094Orig1s000TOC.cfm,
2024,TEPYLUTE,THIOTEPA,NDA216984,add44e98-a042-4e38-b870-beb36693805b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/216984Orig1s000TOC.cfm,
1999,PAROXETINE HYDROCHLORIDE,PAROXETINE HYDROCHLORIDE,NDA020936,087ff0d3-1761-47ea-a8c1-7c4cb679af97,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020936_S012_PAXIL_AP.pdf,
1999,PAROXETINE HYDROCHLORIDE,PAROXETINE HYDROCHLORIDE,NDA020936,087ff0d3-1761-47ea-a8c1-7c4cb679af97,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-936s008_Paroxetine_PaxilCR.cfm,
1999,PAROXETINE HYDROCHLORIDE,PAROXETINE HYDROCHLORIDE,NDA020936,087ff0d3-1761-47ea-a8c1-7c4cb679af97,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020936Orig1s006.pdf,
1999,PAROXETINE HYDROCHLORIDE,PAROXETINE HYDROCHLORIDE,NDA020936,087ff0d3-1761-47ea-a8c1-7c4cb679af97,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020936Orig1s004.pdf,
1999,PAROXETINE HYDROCHLORIDE,PAROXETINE HYDROCHLORIDE,NDA020936,087ff0d3-1761-47ea-a8c1-7c4cb679af97,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020936Orig1s002.pdf,
1999,PAROXETINE HYDROCHLORIDE,PAROXETINE HYDROCHLORIDE,NDA020936,087ff0d3-1761-47ea-a8c1-7c4cb679af97,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020936_S011_PAXIL CR.pdf,
1999,PAROXETINE HYDROCHLORIDE,PAROXETINE HYDROCHLORIDE,NDA020936,087ff0d3-1761-47ea-a8c1-7c4cb679af97,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020936Orig1s007.pdf,
1999,PAROXETINE HYDROCHLORIDE,PAROXETINE HYDROCHLORIDE,NDA020936,087ff0d3-1761-47ea-a8c1-7c4cb679af97,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020936Orig1s003.pdf,
1999,PAROXETINE HYDROCHLORIDE,PAROXETINE HYDROCHLORIDE,NDA020936,087ff0d3-1761-47ea-a8c1-7c4cb679af97,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020936Orig1s001.pdf,
1999,PAROXETINE HYDROCHLORIDE,PAROXETINE HYDROCHLORIDE,NDA020936,087ff0d3-1761-47ea-a8c1-7c4cb679af97,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-936_Paxil.cfm,
2003,N/A,N/A,BLA021271,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-271_Iprivask.cfm,
2005,N/A,N/A,NDA021605,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021605s000TOC.cfm,
2002,N/A,N/A,NDA050785,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50785_AugmentinXR.cfm,
2002,N/A,N/A,NDA050785,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/50785_amoxicillin_clinical_PREA.pdf,
2002,N/A,N/A,NDA050785,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/50785_amoxicillin_clinpharm_PREA.pdf,
2011,BANZEL,RUFINAMIDE,NDA201367,0a3fa925-1abd-458a-bd57-4ae780a1ef2d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201367Orig1s000SumR.pdf,
2011,BANZEL,RUFINAMIDE,NDA201367,0a3fa925-1abd-458a-bd57-4ae780a1ef2d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/201367 rufinamide clinical bpca.pdf,
2011,BANZEL,RUFINAMIDE,NDA201367,0a3fa925-1abd-458a-bd57-4ae780a1ef2d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/201367 rufinamide clinpharm bpca.pdf,
2011,BANZEL,RUFINAMIDE,NDA201367,0a3fa925-1abd-458a-bd57-4ae780a1ef2d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201367_banzel_toc.cfm,
2013,BREO ELLIPTA,FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE,NDA204275,96428df1-ea05-431a-98d3-1ec2c4b63878,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204275Orig1s000TOC.cfm,
1992,PAXIL,PAROXETINE HYDROCHLORIDE,NDA020031,ef3b5cbe-f9e1-c1ac-79da-cfe14e3a7e7e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020031Orig1s052.pdf,
1992,PAXIL,PAROXETINE HYDROCHLORIDE,NDA020031,ef3b5cbe-f9e1-c1ac-79da-cfe14e3a7e7e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020031_S028_PAXIL_AP.pdf,
1992,PAXIL,PAROXETINE HYDROCHLORIDE,NDA020031,ef3b5cbe-f9e1-c1ac-79da-cfe14e3a7e7e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-031S026_Paxil.cfm,
1992,PAXIL,PAROXETINE HYDROCHLORIDE,NDA020031,ef3b5cbe-f9e1-c1ac-79da-cfe14e3a7e7e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020031_S030_PAXIL_AP.pdf,
1992,PAXIL,PAROXETINE HYDROCHLORIDE,NDA020031,ef3b5cbe-f9e1-c1ac-79da-cfe14e3a7e7e,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020031s037_paroxetine_Paxil-MedRev.pdf,
1992,PAXIL,PAROXETINE HYDROCHLORIDE,NDA020031,ef3b5cbe-f9e1-c1ac-79da-cfe14e3a7e7e,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020031s037_paroxetine_Paxil-ClinPharmRev.pdf,
1992,PAXIL,PAROXETINE HYDROCHLORIDE,NDA020031,ef3b5cbe-f9e1-c1ac-79da-cfe14e3a7e7e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-031S029.pdf,
1992,PAXIL,PAROXETINE HYDROCHLORIDE,NDA020031,ef3b5cbe-f9e1-c1ac-79da-cfe14e3a7e7e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020031_S027_PAXIL_AP.pdf,
1992,PAXIL,PAROXETINE HYDROCHLORIDE,NDA020031,ef3b5cbe-f9e1-c1ac-79da-cfe14e3a7e7e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020031_S025_PAXIL_AP.pdf,
1992,PAXIL,PAROXETINE HYDROCHLORIDE,NDA020031,ef3b5cbe-f9e1-c1ac-79da-cfe14e3a7e7e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020031_S031_PAXIL_AP.pdf,
2021,N/A,N/A,NDA206610,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/206610Orig1s000TOC.cfm,
2015,IRESSA,GEFITINIB,NDA206995,827d60e8-7e07-41b7-c28b-49ef1c4a5a41,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206995Orig1s000TOC.cfm,
2015,DYANAVEL XR,AMPHETAMINE,NDA208147,ae304b29-0b40-40ec-ad0d-76b742d4a9b9,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208147 amphetamine clinical prea.pdf,
2015,DYANAVEL XR,AMPHETAMINE,NDA208147,ae304b29-0b40-40ec-ad0d-76b742d4a9b9,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208147 amphetamine clinpharm prea.pdf,
2015,DYANAVEL XR,AMPHETAMINE,NDA208147,ae304b29-0b40-40ec-ad0d-76b742d4a9b9,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208147 amphetamine statistical prea.pdf,
2015,DYANAVEL XR,AMPHETAMINE,NDA208147,ae304b29-0b40-40ec-ad0d-76b742d4a9b9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208147Orig1DyanavelTOC.cfm,
2015,DYANAVEL XR,AMPHETAMINE,NDA208147,ae304b29-0b40-40ec-ad0d-76b742d4a9b9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208147Orig1s000SumR_6pgs_rev1rev2kc_Redacted.pdf,
1995,N/A,N/A,NDA019943,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/019943_S024_Lupron Depot_APPROVAL PACKAGE.pdf,
1995,N/A,N/A,NDA019943,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/019943_S022_Lupron Depot_APPROVAL PACKAGE.pdf,
1995,N/A,N/A,NDA019943,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019943_S003_Lupron Depot_APPROVAL PACKAGE.pdf,
1995,N/A,N/A,NDA019943,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/1999/019943_S010_Lupron Depot_APPROVAL PACKAGE.pdf,
1995,N/A,N/A,NDA019943,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019943_LupronTOC.cfm,
1997,N/A,N/A,NDA020768,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20768s012_zolmitriptan_Zomig-MedRev_BPCA.pdf,
1997,N/A,N/A,NDA020768,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20768s012_zolmitriptan_Zomig-MedRev2_BPCA.pdf,
1997,N/A,N/A,NDA020768,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20768s012_zolmitriptan_Zomig-ClinPharmRev_BPCA.pdf,
1997,N/A,N/A,NDA020768,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/N20-768S012-Zolmitriptan-Statistical-BPCA.pdf,
1997,N/A,N/A,NDA020768,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020768_S010_ZOMIG_TABLETS.pdf,
1997,N/A,N/A,NDA020768,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020768_toc.cfm,
1998,N/A,N/A,NDA020801,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20801.cfm,
1998,N/A,N/A,NDA020801,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/020801Orig1s012.pdf,
1997,MENS ROGAINE EXTRA STRENGTH UNSCENTED,MINOXIDIL,NDA020834,ccaecec5-5348-4b24-9190-5464c50f6d80,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020834_rogaine_toc.cfm,
2009,WELCHOL,COLESEVELAM HYDROCHLORIDE,NDA022362,89cbd0a3-2d1b-41db-8c97-35ec67b7b09f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022362_welchol_toc.cfm,
2009,WELCHOL,COLESEVELAM HYDROCHLORIDE,NDA022362,89cbd0a3-2d1b-41db-8c97-35ec67b7b09f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022362s000sumr.pdf,
2000,ABREVA,DOCOSANOL,NDA020941,c39b38a7-dcdd-4c32-8f35-b565c4d3cec6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-941_Abreva.cfm,
2001,N/A,N/A,NDA021277,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21277_Avelox.cfm,
2001,N/A,N/A,NDA021277,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021277_S007_AVELOX.pdf,
2001,N/A,N/A,NDA021277,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021277_S017_AVELOX_TABLETS.pdf,
2006,N/A,N/A,NDA021611,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021610s000_021611s000TOC.cfm,
2006,N/A,N/A,NDA021611,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/505_21611S16 oxymorphone clinical prea.pdf,
2006,N/A,N/A,NDA021611,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/506_21611S16 oxymorphone clinpharm prea.pdf,
2006,TRAVATAN Z,TRAVOPROST,NDA021994,028455e0-ae77-4213-8819-3b58ef7d6a14,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021994s000TOC.cfm,
2004,MYFORTIC,MYCOPHENOLIC ACID,NDA050791,eed26501-890d-4ff6-88e7-6dbea4726e53,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/50-791_Myfortic.cfm,
1985,N/A,N/A,NDA019010,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019010_S024_Lupron Injection_APPROVAL_PACKAGE.pdf,
1985,N/A,N/A,NDA019010,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019010_S006_Lupron Injection_APPROVAL PACKAGE.pdf,
1985,N/A,N/A,NDA019010,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/019010_S031_Lupron Injection_APPROVAL_PACKAGE.pdf,
1985,N/A,N/A,NDA019010,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019010_S023_Lupron Injection_APPROVAL_PACKAGE.pdf,
1985,N/A,N/A,NDA019010,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/019010Orig1s038.pdf,
1985,N/A,N/A,NDA019010,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019010Orig1s000rev.pdf,
2016,VARIBAR NECTAR,BARIUM SULFATE,NDA208143,5e7045f7-b771-d8af-ce30-be95b2597c10,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208143_toc.cfm,
2016,VARIBAR NECTAR,BARIUM SULFATE,NDA208143,5e7045f7-b771-d8af-ce30-be95b2597c10,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208143 barium sulfate clinical prea.pdf,
2016,VARIBAR NECTAR,BARIUM SULFATE,NDA208143,5e7045f7-b771-d8af-ce30-be95b2597c10,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208143-barium-sulfate-clinical-prea.pdf,
2016,VARIBAR NECTAR,BARIUM SULFATE,NDA208143,5e7045f7-b771-d8af-ce30-be95b2597c10,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208143-barium-sulfate-clinpharm-prea.pdf,
2016,VARIBAR NECTAR,BARIUM SULFATE,NDA208143,5e7045f7-b771-d8af-ce30-be95b2597c10,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/208143-barium-sulfate-statistical-prea.pdf,
2023,XPHOZAH 10 MG,TENAPANOR,NDA213931,c57e279c-0f1b-4238-81b7-4e0dc0cc60c5,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/213931Orig1s000TOC.cfm,
1997,DIHYDROERGOTAMINE MESYLATE,DIHYDROERGOTAMINE MESYLATE,NDA020148,977de209-c53a-4cb4-9f3f-1e850600a9dc,http://www.accessdata.fda.gov/drugsatfda_docs/NDA/97/020148_migranal_toc.cfm,
1978,PREMARIN VAGINAL,CONJUGATED ESTROGENS,NDA020216,96609623-528e-4aba-cabe-7254aed816d5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020216_s033_premarin_vaginal_cream.pdf,
1978,PREMARIN VAGINAL,CONJUGATED ESTROGENS,NDA020216,96609623-528e-4aba-cabe-7254aed816d5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/020216Orig1s060.pdf,
1978,PREMARIN VAGINAL,CONJUGATED ESTROGENS,NDA020216,96609623-528e-4aba-cabe-7254aed816d5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020216_original_approval.pdf,
1978,PREMARIN VAGINAL,CONJUGATED ESTROGENS,NDA020216,96609623-528e-4aba-cabe-7254aed816d5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020216_s018_premarin vaginal cream.pdf,
1978,PREMARIN VAGINAL,CONJUGATED ESTROGENS,NDA020216,96609623-528e-4aba-cabe-7254aed816d5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020216_s030_premarin vaginal cream.pdf,
1978,PREMARIN VAGINAL,CONJUGATED ESTROGENS,NDA020216,96609623-528e-4aba-cabe-7254aed816d5,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/20216Orig1s043.pdf,
2019,VYNDAQEL,TAFAMIDIS MEGLUMINE,NDA211996,1b4121ee-a733-4456-a917-be2603477839,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211996Orig1s000,%20212161Orig1s000TOC.cfm",
2019,AMZEEQ,MINOCYCLINE,NDA212379,cc251492-977b-4eb1-a088-a90831324bad,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212379Orig1s000TOC.cfm,
2019,ZIRABEV,BEVACIZUMAB-BVZR,BLA761099,aa27acbd-d117-4350-aeee-17bc2e2c0ca4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761099Orig1s000TOC.cfm,
2024,AURLUMYN,ILOPROST,NDA217933,f3306add-2edd-8494-e053-2a95a90a7a78,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/217933Orig1s000TOC.cfm,
2005,ZEMPLAR,PARICALCITOL,NDA021606,1b27c026-2d60-47b4-2a9c-ded1818f21b5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021606s000TOC.cfm,
2006,ZOLINZA,VORINOSTAT,NDA021991,cd86ee78-2781-468b-930c-3c4677bcc092,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021991s000_ZolinzaTOC.cfm,
2002,N/A,N/A,NDA050788,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/050788_mupirocin.cfm,
1970,NITROFURANTOIN MACROCRYSTALS,NITROFURANTOIN MACROCRYSTALS,NDA016620,62c1bb9c-79a2-41e3-9dfa-352f92253881,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/016620_S019_Macrodantin Capsules.pdf,
1970,NITROFURANTOIN MACROCRYSTALS,NITROFURANTOIN MACROCRYSTALS,NDA016620,62c1bb9c-79a2-41e3-9dfa-352f92253881,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/016620_S017_Macrodantin Capsules.pdf,
1970,NITROFURANTOIN MACROCRYSTALS,NITROFURANTOIN MACROCRYSTALS,NDA016620,62c1bb9c-79a2-41e3-9dfa-352f92253881,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/016620_S064_MACRODANTIN.pdf,
1970,NITROFURANTOIN MACROCRYSTALS,NITROFURANTOIN MACROCRYSTALS,NDA016620,62c1bb9c-79a2-41e3-9dfa-352f92253881,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/016620_S062_MACRODANTIN.pdf,
1970,NITROFURANTOIN MACROCRYSTALS,NITROFURANTOIN MACROCRYSTALS,NDA016620,62c1bb9c-79a2-41e3-9dfa-352f92253881,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/016620_S054_MACRODANTIN.pdf,
1970,NITROFURANTOIN MACROCRYSTALS,NITROFURANTOIN MACROCRYSTALS,NDA016620,62c1bb9c-79a2-41e3-9dfa-352f92253881,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/016620_S018_Macodantin.pdf,
1970,NITROFURANTOIN MACROCRYSTALS,NITROFURANTOIN MACROCRYSTALS,NDA016620,62c1bb9c-79a2-41e3-9dfa-352f92253881,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/016620_S016_Macrodantin Capsules.pdf,
1970,NITROFURANTOIN MACROCRYSTALS,NITROFURANTOIN MACROCRYSTALS,NDA016620,62c1bb9c-79a2-41e3-9dfa-352f92253881,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/016620_S020_Macrodantin Capsules.pdf,
1970,NITROFURANTOIN MACROCRYSTALS,NITROFURANTOIN MACROCRYSTALS,NDA016620,62c1bb9c-79a2-41e3-9dfa-352f92253881,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/016620_S059_MACRODANTIN.pdf,
1970,NITROFURANTOIN MACROCRYSTALS,NITROFURANTOIN MACROCRYSTALS,NDA016620,62c1bb9c-79a2-41e3-9dfa-352f92253881,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/016620_S065_MACRODANTIN.pdf,
1970,NITROFURANTOIN MACROCRYSTALS,NITROFURANTOIN MACROCRYSTALS,NDA016620,62c1bb9c-79a2-41e3-9dfa-352f92253881,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/016620_S057_MACRODANTIN.pdf,
1970,NITROFURANTOIN MACROCRYSTALS,NITROFURANTOIN MACROCRYSTALS,NDA016620,62c1bb9c-79a2-41e3-9dfa-352f92253881,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/016620_S063_MACRODANTIN.pdf,
1970,NITROFURANTOIN MACROCRYSTALS,NITROFURANTOIN MACROCRYSTALS,NDA016620,62c1bb9c-79a2-41e3-9dfa-352f92253881,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/016620_S055_MACRODANTIN.pdf,
1970,NITROFURANTOIN MACROCRYSTALS,NITROFURANTOIN MACROCRYSTALS,NDA016620,62c1bb9c-79a2-41e3-9dfa-352f92253881,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/16620_S047_MacrodantinTOC.cfm,
1970,NITROFURANTOIN MACROCRYSTALS,NITROFURANTOIN MACROCRYSTALS,NDA016620,62c1bb9c-79a2-41e3-9dfa-352f92253881,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/016620_S053_MACRODANTIN.pdf,
1970,NITROFURANTOIN MACROCRYSTALS,NITROFURANTOIN MACROCRYSTALS,NDA016620,62c1bb9c-79a2-41e3-9dfa-352f92253881,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/008693s025_009175s019_016620s045_MacrodantinTOC.cfm,
2012,STIVARGA,REGORAFENIB,NDA203085,824f19c9-0546-4a8a-8d8f-c4055c04f7c7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/203085Orig1s007.pdf,
2012,STIVARGA,REGORAFENIB,NDA203085,824f19c9-0546-4a8a-8d8f-c4055c04f7c7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203085Orig1s000TOC.cfm,
2012,STIVARGA,REGORAFENIB,NDA203085,824f19c9-0546-4a8a-8d8f-c4055c04f7c7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203085Orig1s000SumR.pdf,
2012,ILEVRO,NEPAFENAC,NDA203491,10f411d3-a81e-074a-e063-6294a90ab547,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491_nepafenac_toc.cfm,
2012,ILEVRO,NEPAFENAC,NDA203491,10f411d3-a81e-074a-e063-6294a90ab547,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000SumR.pdf,
2014,JARDIANCE,EMPAGLIFLOZIN,NDA204629,faf3dd6a-9cd0-39c2-0d2e-232cb3f67565,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/204629Orig1s008.pdf,
2014,JARDIANCE,EMPAGLIFLOZIN,NDA204629,faf3dd6a-9cd0-39c2-0d2e-232cb3f67565,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/204629Orig1s002.pdf,
2014,JARDIANCE,EMPAGLIFLOZIN,NDA204629,faf3dd6a-9cd0-39c2-0d2e-232cb3f67565,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204629Orig1s000TOC.cfm,
2014,JARDIANCE,EMPAGLIFLOZIN,NDA204629,faf3dd6a-9cd0-39c2-0d2e-232cb3f67565,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204629Orig1s000SumR.pdf,
2014,JARDIANCE,EMPAGLIFLOZIN,NDA204629,faf3dd6a-9cd0-39c2-0d2e-232cb3f67565,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/204629Orig1s007.pdf,
2014,JARDIANCE,EMPAGLIFLOZIN,NDA204629,faf3dd6a-9cd0-39c2-0d2e-232cb3f67565,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/204629Orig1s005.pdf,
2014,JARDIANCE,EMPAGLIFLOZIN,NDA204629,faf3dd6a-9cd0-39c2-0d2e-232cb3f67565,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/204629Orig1s033.pdf,
2014,JARDIANCE,EMPAGLIFLOZIN,NDA204629,faf3dd6a-9cd0-39c2-0d2e-232cb3f67565,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/204629Orig1s003.pdf,
2014,JARDIANCE,EMPAGLIFLOZIN,NDA204629,faf3dd6a-9cd0-39c2-0d2e-232cb3f67565,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/204629Orig1s001.pdf,
2017,LUMIFY REDNESS RELIEVER EYE DROPS,BRIMONIDINE TARTRATE,NDA208144,022de945-0b26-40ae-8e88-d3fe2464d106,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208144Orig1s000TOC.cfm,
2017,LUMIFY REDNESS RELIEVER EYE DROPS,BRIMONIDINE TARTRATE,NDA208144,022de945-0b26-40ae-8e88-d3fe2464d106,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/227_208144 brimonidine clinical prea.pdf,
2017,LUMIFY REDNESS RELIEVER EYE DROPS,BRIMONIDINE TARTRATE,NDA208144,022de945-0b26-40ae-8e88-d3fe2464d106,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/228_208144 brimonidine CDTL clinical prea.pdf,
2017,LUMIFY REDNESS RELIEVER EYE DROPS,BRIMONIDINE TARTRATE,NDA208144,022de945-0b26-40ae-8e88-d3fe2464d106,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/225_208144 brimonidine statistical prea.pdf,
1992,CARNITOR,LEVOCARNITINE,NDA020182,cf801cc4-775e-433d-9d32-e5d9a98981d3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20182S6_Carnitor.cfm,
2019,ONTRUZANT,TRASTUZUMAB,BLA761100,ce2a2492-85e3-4b0a-872a-047f44e4203d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761100Orig1s000TOC.cfm,
2023,OPFOLDA,MIGLUSTAT,NDA215211,d7c38298-37db-5a80-e053-2995a90aee40,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215211Orig1s000TOC.cfm,
2023,PHYRAGO,DASATINIB,NDA216099,60976d1e-c415-417f-8168-4e07999a7281,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/216099Orig1s000TOC.cfm,
2000,N/A,N/A,NDA020938,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020938s013_meloxicam_Mobic-Med.pdf,
2000,N/A,N/A,NDA020938,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020938s013_meloxicam_Mobic-Stat.pdf,
2000,N/A,N/A,NDA020938,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-938_Mobic.cfm,
2005,N/A,N/A,BLA021273,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021273s000TOC.cfm,
2008,PRISTIQ EXTENDED-RELEASE,DESVENLAFAXINE SUCCINATE,NDA021992,0f43610c-f290-46ea-d186-4f998ed99fce,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/258_021992s042 desvenlaxafine clinical both.pdf,
2008,PRISTIQ EXTENDED-RELEASE,DESVENLAFAXINE SUCCINATE,NDA021992,0f43610c-f290-46ea-d186-4f998ed99fce,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/256_021992s042 desvenlaxafine clinpharm both.pdf,
2008,PRISTIQ EXTENDED-RELEASE,DESVENLAFAXINE SUCCINATE,NDA021992,0f43610c-f290-46ea-d186-4f998ed99fce,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/257_021992s042 desvenlaxafine statistical both.pdf,
2008,PRISTIQ EXTENDED-RELEASE,DESVENLAFAXINE SUCCINATE,NDA021992,0f43610c-f290-46ea-d186-4f998ed99fce,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021992s000TOC.cfm,
2004,TOBRAMYCIN,TOBRAMYCIN SULFATE,NDA050789,d62ff359-912b-4be1-9fc2-2dde8777eefb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/050789s000_TobramycinTOC.cfm,
1982,N/A,N/A,NDA018782,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/18-782S023.pdf,
2016,PROVAYBLUE,METHYLENE BLUE,NDA204630,4f6848e5-35ed-4046-b13c-3032b5ba3232,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/204630Orig1_toc.cfm,
2016,PROVAYBLUE,METHYLENE BLUE,NDA204630,4f6848e5-35ed-4046-b13c-3032b5ba3232,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/204630Orig1s000SumR.pdf,
2016,PROVAYBLUE,METHYLENE BLUE,NDA204630,4f6848e5-35ed-4046-b13c-3032b5ba3232,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/204630Orig1s023.pdf,
2023,MEROPENEM,MEROPENEM,NDA215212,240325ba-47a8-4ad1-bcab-6772069ee790,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/215212Orig1s000TOC.cfm,
2024,ATTRUBY,ACORAMIDIS HYDROCHLORIDE,NDA216540,913552ef-875d-4cb7-bf05-a7d20a394c38,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/216540Orig1s000TOC.cfm,
2023,VANFLYTA,QUIZARTINIB,NDA216993,29cdbcfe-497d-4e78-bb7b-2d4acafe8e86,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216993Orig1s000TOC.cfm,
2009,NICORETTE,NICOTINE POLACRILEX,NDA022360,c7f32ab1-f6bd-46f5-9852-8eb5b78a3326,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022360Orig1S005.pdf,
2009,NICORETTE,NICOTINE POLACRILEX,NDA022360,c7f32ab1-f6bd-46f5-9852-8eb5b78a3326,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022360_nicorette_toc.cfm,
2009,NICORETTE,NICOTINE POLACRILEX,NDA022360,c7f32ab1-f6bd-46f5-9852-8eb5b78a3326,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022360s000_SumR.pdf,
2009,NICORETTE,NICOTINE POLACRILEX,NDA022360,c7f32ab1-f6bd-46f5-9852-8eb5b78a3326,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022360Orig1s008.pdf,
2001,N/A,N/A,NDA021275,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021275_S013_LUMIGAN.pdf,
2001,N/A,N/A,NDA021275,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21275_Lumigan.cfm,
2006,CLARITIN REDITABS,LORATADINE,NDA021993,7dc04b48-f053-4e4b-a493-9e8286d2a791,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021993_claritin_toc.cfm,
2002,CYCLOSPORINE,CYCLOSPORINE,NDA050790,70c8a4a6-ebe2-457f-a626-400c338cec2d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/50790Orig1s025.pdf,
2002,CYCLOSPORINE,CYCLOSPORINE,NDA050790,70c8a4a6-ebe2-457f-a626-400c338cec2d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/050790_S002_RestasisTOC.cfm,
2002,CYCLOSPORINE,CYCLOSPORINE,NDA050790,70c8a4a6-ebe2-457f-a626-400c338cec2d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-023_Restasis.cfm,
2002,CYCLOSPORINE,CYCLOSPORINE,NDA050790,70c8a4a6-ebe2-457f-a626-400c338cec2d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/50790Orig1s024.pdf,
2012,STRIBILD,"ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",NDA203100,74ae2a93-b267-444c-8f0f-a2a6522260ee,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203100Orig1s000SumR.pdf,
2012,STRIBILD,"ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",NDA203100,74ae2a93-b267-444c-8f0f-a2a6522260ee,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/73_203100 Stribild CDTL prea.pdf,
2012,STRIBILD,"ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",NDA203100,74ae2a93-b267-444c-8f0f-a2a6522260ee,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/74_203100 Stribild clinpharm prea.pdf,
2012,STRIBILD,"ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",NDA203100,74ae2a93-b267-444c-8f0f-a2a6522260ee,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203100Orig1s000TOC.cfm,
1986,N/A,N/A,BLA103132,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/103132Orig1s000rev.pdf,
1986,N/A,N/A,BLA103132,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/bla/1997/ifnasch110697r.pdf,
2014,CHILDRENS FLONASE ALLERGY RELIEF,FLUTICASONE PROPIONATE,NDA205434,fab7a1f4-75e0-416f-9644-07aff08e6ab0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205434Orig1s000TOC.cfm,
2019,RINVOQ,UPADACITINIB,NDA211675,2966aec7-2ef0-923c-d8ff-fe1a957bf095,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000TOC.cfm,
2019,RINVOQ,UPADACITINIB,NDA211675,2966aec7-2ef0-923c-d8ff-fe1a957bf095,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/211675Orig1s004.pdf,
2019,SKYRIZI,RISANKIZUMAB-RZAA,BLA761105,7148c8eb-b39e-e20a-6494-a6df82392858,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761105Orig1s009,s010.pdf",
2019,SKYRIZI,RISANKIZUMAB-RZAA,BLA761105,7148c8eb-b39e-e20a-6494-a6df82392858,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761105Orig1s000TOC.cfm,
2019,SKYRIZI,RISANKIZUMAB-RZAA,BLA761105,7148c8eb-b39e-e20a-6494-a6df82392858,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761105Orig1s014.pdf,
2019,SKYRIZI,RISANKIZUMAB-RZAA,BLA761105,7148c8eb-b39e-e20a-6494-a6df82392858,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761105Orig1s009,s010.pdf",
1996,ACCOLATE,ZAFIRLUKAST,NDA020547,3bbd0e85-6014-46cd-a363-60102c4bc5a2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-547-S007_Accolate.cfm,
1996,ACCOLATE,ZAFIRLUKAST,NDA020547,3bbd0e85-6014-46cd-a363-60102c4bc5a2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020547Orig1s000rev.pdf,
1996,ACCOLATE,ZAFIRLUKAST,NDA020547,3bbd0e85-6014-46cd-a363-60102c4bc5a2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20547-S011_Accolate.pdf,
1996,ACCOLATE,ZAFIRLUKAST,NDA020547,3bbd0e85-6014-46cd-a363-60102c4bc5a2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20547-s008_accolate.pdf,
2010,TRAMADOL HYDROCHLORIDE EXTENDED-RELEASE,TRAMADOL HYDROCHLORIDE,NDA022370,c0bc7218-3fd0-4646-96f4-25355fc84aa9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022370s000_tramadol_toc.cfm,
1999,N/A,N/A,NDA020945,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-945_Ritonovir.cfm,
1999,N/A,N/A,NDA020945,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020945_S016_NORVIR.pdf,
1999,N/A,N/A,NDA020945,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020945_S017_NORVIR.pdf,
2002,MUCINEX,GUAIFENESIN,NDA021282,dd379cdd-90ab-42e0-ad89-f50d3220f611,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-282_Mucinex.cfm,
2004,MUCINEX DM MAXIMUM STRENGTH,GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE,NDA021620,588eddc1-fa30-41cc-8ed9-c01319ea21c6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021620s000_MucinexTOC.cfm,
2009,PLAN B ONE-STEP,LEVONORGESTREL,NDA021998,6ce6b40e-14ac-47bd-a648-ddf9e452e559,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021998_planb_onestep_toc.cfm,
2009,PLAN B ONE-STEP,LEVONORGESTREL,NDA021998,6ce6b40e-14ac-47bd-a648-ddf9e452e559,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21998 levonorgestrel clinical prea.pdf,
2009,PLAN B ONE-STEP,LEVONORGESTREL,NDA021998,6ce6b40e-14ac-47bd-a648-ddf9e452e559,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21998 DD Clinical Review PREA.pdf,
2009,PLAN B ONE-STEP,LEVONORGESTREL,NDA021998,6ce6b40e-14ac-47bd-a648-ddf9e452e559,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21998 levonorgestrel clinpharm prea.pdf,
2009,PLAN B ONE-STEP,LEVONORGESTREL,NDA021998,6ce6b40e-14ac-47bd-a648-ddf9e452e559,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21998 clinpharm add Review_Prea.pdf,
2009,PLAN B ONE-STEP,LEVONORGESTREL,NDA021998,6ce6b40e-14ac-47bd-a648-ddf9e452e559,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21998 levonorgestrel statistical prea.pdf,
2009,PLAN B ONE-STEP,LEVONORGESTREL,NDA021998,6ce6b40e-14ac-47bd-a648-ddf9e452e559,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021998s000_SumR.pdf,
2009,PLAN B ONE-STEP,LEVONORGESTREL,NDA021998,6ce6b40e-14ac-47bd-a648-ddf9e452e559,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021998Orig1s002.pdf,
2009,PLAN B ONE-STEP,LEVONORGESTREL,NDA021998,6ce6b40e-14ac-47bd-a648-ddf9e452e559,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021998Orig1s005SumR.pdf,
1959,SOMA,CARISOPRODOL,NDA011792,6297cf20-830a-11dc-94c8-0002a5d5c51b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf,
2004,VIDAZA,AZACITIDINE,NDA050794,3495a71a-cc04-4776-851f-f185956f32af,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/50-794_Vidaza.cfm,
2014,N/A,N/A,NDA203093,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203093Orig1VITEKTAtoc.cfm,
2011,HEPARIN SODIUM,HEPARIN SODIUM,NDA201370,56dc3074-f1c5-45a3-b923-f1d14858e06d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201370_heparin_toc.cfm,
2011,HEPARIN SODIUM,HEPARIN SODIUM,NDA201370,56dc3074-f1c5-45a3-b923-f1d14858e06d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201370Orig1s000SumR.pdf,
2015,APTENSIO XR,METHYLPHENIDATE HYDROCHLORIDE,NDA205831,5adedc01-ebf0-11e3-ac10-0800200c9a66,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205831_methylphenidate clinical prea.pdf,
2015,APTENSIO XR,METHYLPHENIDATE HYDROCHLORIDE,NDA205831,5adedc01-ebf0-11e3-ac10-0800200c9a66,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205831_methylphenidate clinpharm prea.pdf,
2015,APTENSIO XR,METHYLPHENIDATE HYDROCHLORIDE,NDA205831,5adedc01-ebf0-11e3-ac10-0800200c9a66,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205831_methylphenidate Statistical  prea.pdf,
2015,APTENSIO XR,METHYLPHENIDATE HYDROCHLORIDE,NDA205831,5adedc01-ebf0-11e3-ac10-0800200c9a66,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/205831_methylphenidate Statistical 1  prea.pdf,
2015,APTENSIO XR,METHYLPHENIDATE HYDROCHLORIDE,NDA205831,5adedc01-ebf0-11e3-ac10-0800200c9a66,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/446_205831S5 methylphenidate CDTL bpca_0.pdf,
2015,APTENSIO XR,METHYLPHENIDATE HYDROCHLORIDE,NDA205831,5adedc01-ebf0-11e3-ac10-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205831Orig1s000TOC.cfm,
2015,APTENSIO XR,METHYLPHENIDATE HYDROCHLORIDE,NDA205831,5adedc01-ebf0-11e3-ac10-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205831Orig1s000SumR.pdf,
2018,XELPROS,LATANOPROST,NDA206185,34ad5cf6-4df0-4104-bddd-4c7631133ded,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206185Orig1s000TOC.cfm,
2017,PREVYMIS,LETERMOVIR,NDA209939,1b49df80-be4f-47e0-a0b7-123f3e69395b,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209939Orig1s000,209940Orig1s000TOC.cfm",
1989,CLOMIPRAMINE HYDROCHLORIDE,CLOMIPRAMINE HYDROCHLORIDE,NDA019906,d7cee3fa-d05c-4702-8f75-f446627bdb49,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/019906_S022_ANAFRANIL_AP.pdf,
2019,NAYZILAM,MIDAZOLAM,NDA211321,2b29422e-54d5-4a49-8522-e9cf752368c3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211321Orig1s000TOC.cfm,
2019,XENLETA,LEFAMULIN ACETATE,NDA211672,101db63d-2fe2-48df-8506-1382d6dcd4a3,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211672Orig1s000, 211673Orig1s000TOC.cfm",
2025,ANZUPGO,DELGOCITINIB,NDA219155,a59bf36e-6f04-4b47-b385-8040c95f040c,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219155Orig1s000TOC.cfm,
2018,ASPARLAS,CALASPARGASE PEGOL,BLA761102,6585bd0d-bd78-4341-9e87-0f7664821f05,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761102Orig1s000TOC.cfm,
2021,REZUROCK,BELUMOSUDIL,NDA214783,102e4ef4-7f84-4e34-8df1-479c24d1575d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214783Orig1s000TOC.cfm,
2022,CEFAZOLIN,CEFAZOLIN,NDA216109,6c7761d3-c154-4802-9876-627cd42913f0,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216109Orig1s000TOC.cfm,
1997,N/A,N/A,NDA020741,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020741_S009_PRANDIN_TABS_AP.pdf,
1997,N/A,N/A,NDA020741,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020741_S019_PRANDIN_TABS_AP.pdf,
1997,N/A,N/A,NDA020741,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020741_S015_PRANDIN_TABS_AP.pdf,
1997,N/A,N/A,NDA020741,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020741_S016_PRANDIN_TABS_AP.pdf,
1997,N/A,N/A,NDA020741,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020741_S030_PRANDIN_TABS_AP.pdf,
2009,LIVALO,PITAVASTATIN CALCIUM,NDA022363,44dcbf97-99ec-427c-ba50-207e0069d6d2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022363s008s009.pdf,
2009,LIVALO,PITAVASTATIN CALCIUM,NDA022363,44dcbf97-99ec-427c-ba50-207e0069d6d2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022363s000TOC.cfm,
2009,LIVALO,PITAVASTATIN CALCIUM,NDA022363,44dcbf97-99ec-427c-ba50-207e0069d6d2,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/416_22363S15 pitavastatin clinical bpca.pdf,
2009,LIVALO,PITAVASTATIN CALCIUM,NDA022363,44dcbf97-99ec-427c-ba50-207e0069d6d2,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/415_22363S15 pitavastatin CDTL clinical bpca.pdf,
2009,LIVALO,PITAVASTATIN CALCIUM,NDA022363,44dcbf97-99ec-427c-ba50-207e0069d6d2,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/417_22363S15 pitavastatin clinpharm bpca.pdf,
2009,LIVALO,PITAVASTATIN CALCIUM,NDA022363,44dcbf97-99ec-427c-ba50-207e0069d6d2,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/418_22363S15 pitavastatin statistical bpca.pdf,
2009,LIVALO,PITAVASTATIN CALCIUM,NDA022363,44dcbf97-99ec-427c-ba50-207e0069d6d2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022363s008s009.pdf,
2001,FOCALIN,DEXMETHYLPHENIDATE HYDROCHLORIDE,NDA021278,2016f5c2-95d2-4655-af65-c588c2bf5e6d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-278_Focalin.cfm,
2006,LIPOFEN,FENOFIBRATE,NDA021612,78b789b9-854f-46b9-97f3-a48759a6ff89,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021612_lipofen_toc.cfm,
2006,JANUVIA,SITAGLIPTIN,NDA021995,f85a48d0-0407-4c50-b0fa-7673a160bf01,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000TOC.cfm,
2006,JANUVIA,SITAGLIPTIN,NDA021995,f85a48d0-0407-4c50-b0fa-7673a160bf01,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021995Orig1s013.pdf,
2006,JANUVIA,SITAGLIPTIN,NDA021995,f85a48d0-0407-4c50-b0fa-7673a160bf01,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021995Orig1s014.pdf,
1963,VALIUM,DIAZEPAM,NDA013263,554baee5-b171-4452-a50a-41a0946f956c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/013263_S086_VALIUM_AP.pdf,
1963,VALIUM,DIAZEPAM,NDA013263,554baee5-b171-4452-a50a-41a0946f956c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/013263_S082_Valium_APPROVAL PACKAGE.pdf,
1963,VALIUM,DIAZEPAM,NDA013263,554baee5-b171-4452-a50a-41a0946f956c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/013263_S072_VALIUM_AP.pdf,
1963,VALIUM,DIAZEPAM,NDA013263,554baee5-b171-4452-a50a-41a0946f956c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/013263_S075_VALIUM_AP.pdf,
1963,VALIUM,DIAZEPAM,NDA013263,554baee5-b171-4452-a50a-41a0946f956c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/016087_S081_VALIUM_AP.pdf,
2014,TYBOST,COBICISTAT,NDA203094,3784c35c-e87f-410c-900b-8fd6313c6010,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/454_203094s13 cobicstat CDTL prea.pdf,
2014,TYBOST,COBICISTAT,NDA203094,3784c35c-e87f-410c-900b-8fd6313c6010,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/453_203094s13 cobicstat clinpharm prea.pdf,
2014,TYBOST,COBICISTAT,NDA203094,3784c35c-e87f-410c-900b-8fd6313c6010,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203094Orig1Orig2s000TOC.cfm,
2014,TYBOST,COBICISTAT,NDA203094,3784c35c-e87f-410c-900b-8fd6313c6010,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203094Orig1Orig2s000SumR.pdf,
2013,ORENITRAM,TREPROSTINIL,NDA203496,8ed2003a-c801-411e-831e-d06079bb0d7c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203496Orig1s000TOC.cfm,
2013,ORENITRAM,TREPROSTINIL,NDA203496,8ed2003a-c801-411e-831e-d06079bb0d7c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203496Orig1s000SumR.pdf,
2011,CHILDRENS ALLEGRA ALLERGY,FEXOFENADINE HYDROCHLORIDE,NDA201373,e2bd23c7-dfba-463a-adbe-2183970da740,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201373_allegra_toc.cfm,
2011,CHILDRENS ALLEGRA ALLERGY,FEXOFENADINE HYDROCHLORIDE,NDA201373,e2bd23c7-dfba-463a-adbe-2183970da740,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201373Orig1s000SumR.pdf,
2014,OFEV,NINTEDANIB,NDA205832,da1c9f37-779e-4682-816f-93d0faa4cfc9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/205832Orig1s013.pdf,
2014,OFEV,NINTEDANIB,NDA205832,da1c9f37-779e-4682-816f-93d0faa4cfc9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000TOC.cfm,
2014,OFEV,NINTEDANIB,NDA205832,da1c9f37-779e-4682-816f-93d0faa4cfc9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000SumR.pdf,
2014,OFEV,NINTEDANIB,NDA205832,da1c9f37-779e-4682-816f-93d0faa4cfc9,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/205832Orig1s012.pdf,
2017,PREVYMIS,LETERMOVIR,NDA209940,1b49df80-be4f-47e0-a0b7-123f3e69395b,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209939Orig1s000,209940Orig1s000TOC.cfm",
2017,N/A,N/A,NDA210259,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210259Orig1s006, s007.pdf",
2017,N/A,N/A,NDA210259,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/210259Orig1s000TOC.cfm,
2017,N/A,N/A,NDA210259,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210259Orig1s006, s007.pdf",
2017,DRAX EXAMETAZIME,KIT FOR THE PREPARATION OF TECHNETIUM TC 99M EXAMETAZIME FOR LEUKOCYTE LABELING,NDA208870,fa7811f9-2803-4126-8037-8f3e56462f9c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208870Orig1s000TOC.cfm,
2019,LEVOTHYROXINE SODIUM,LEVOTHYROXINE SODIUM,NDA210632,50b1c8a4-75b6-49c8-80fc-3841ee80b183,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210632Orig1s000TOC.cfm,
2019,LEVOTHYROXINE SODIUM,LEVOTHYROXINE SODIUM,NDA210632,50b1c8a4-75b6-49c8-80fc-3841ee80b183,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210632Orig1s000SumR.pdf,
2019,CITRIC BUFFERED NORMAL SALINE,ANHYDROUS CITRIC ACID,NDA211673,101db63d-2fe2-48df-8506-1382d6dcd4a3,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211672Orig1s000,%20211673Orig1s000TOC.cfm",
2019,RUXIENCE,RITUXIMAB-PVVR,BLA761103,f941fc61-f7a3-4e4a-ab7c-87c1667fa05b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761103Orig1s000TOC.cfm,
2000,N/A,N/A,NDA020610,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020610s016_balsalazide_Colazal-ClinPharRev.pdf,
2000,N/A,N/A,NDA020610,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020610s016_balsalazide_Colazal-MedRev.pdf,
2000,N/A,N/A,NDA020610,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020610s016_balsalazide_Colazal-MedRev.pdf,
2000,N/A,N/A,NDA020610,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020610s016_balsalazide_Colazal-ClinPharRev.pdf,
2000,N/A,N/A,NDA020610,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020610s016_balsalazide_Colazal-StatRev.pdf,
2000,N/A,N/A,NDA020610,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-610_Colazal.cfm,
2010,ARIDOL BRONCHIAL CHALLENGE TEST KIT,MANNITOL,NDA022368,5387a4fb-b894-4cba-88a3-a947217d34da,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022368Orig1s000SumR.pdf,
2010,ARIDOL BRONCHIAL CHALLENGE TEST KIT,MANNITOL,NDA022368,5387a4fb-b894-4cba-88a3-a947217d34da,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022368_Mannitol_Clinical_PREA.pdf,
2010,ARIDOL BRONCHIAL CHALLENGE TEST KIT,MANNITOL,NDA022368,5387a4fb-b894-4cba-88a3-a947217d34da,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22368_Mannitol_Clinpharm_PREA_REVISED_CD_4-10.11.pdf,
2010,ARIDOL BRONCHIAL CHALLENGE TEST KIT,MANNITOL,NDA022368,5387a4fb-b894-4cba-88a3-a947217d34da,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022368_Mannitol_Statistical_PREA.pdf,
2010,ARIDOL BRONCHIAL CHALLENGE TEST KIT,MANNITOL,NDA022368,5387a4fb-b894-4cba-88a3-a947217d34da,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022368_aridol_toc.cfm,
1998,VERAPAMIL HYDROCHLORIDE,VERAPAMIL HYDROCHLORIDE,NDA020943,5f665d08-e1e4-422a-88c2-d8834abf9e1a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20-943_VerelanPM.cfm,
2005,N/A,N/A,NDA021615,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021615s000_RazadyneTOC.cfm,
2006,EYE ITCH RELIEF,KETOTIFEN FUMARATE,NDA021996,b25106f8-436e-4c06-8780-b12368ede9fe,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021996_alaway_toc.cfm,
2004,CLINDESSE,CLINDAMYCIN PHOSPHATE,NDA050793,fe8bb204-f173-44fe-803b-b08f2ec5aa31,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/050793s000_ClinesseTOC.cfm,
2013,N/A,N/A,NDA203098,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203098Orig1s000TOC.cfm,
2013,N/A,N/A,NDA203098,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203098Orig1s000SumR.pdf,
1991,BOTOX COSMETIC,ONABOTULINUMTOXINA,BLA103000,485d9b71-6881-42c5-a620-a4360c7192ab,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/103000Orig1s5050.pdf,
1991,BOTOX COSMETIC,ONABOTULINUMTOXINA,BLA103000,485d9b71-6881-42c5-a620-a4360c7192ab,https://web.archive.org/web/20090119110807/http://www.fda.gov/cder/biologics/products/botaller122100.htm,
1991,BOTOX COSMETIC,ONABOTULINUMTOXINA,BLA103000,485d9b71-6881-42c5-a620-a4360c7192ab,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/331_103000S5308 onabotulinumtoxinA clinical prea_1.pdf,
1991,BOTOX COSMETIC,ONABOTULINUMTOXINA,BLA103000,485d9b71-6881-42c5-a620-a4360c7192ab,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/332_103000S5308 onabotulinumtoxinA statistical prea.pdf,
1991,BOTOX COSMETIC,ONABOTULINUMTOXINA,BLA103000,485d9b71-6881-42c5-a620-a4360c7192ab,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/449_103000S5309 onabotulinumtoxinA clinical prea.pdf,
1991,BOTOX COSMETIC,ONABOTULINUMTOXINA,BLA103000,485d9b71-6881-42c5-a620-a4360c7192ab,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/450_103000S5309 onabotulinumtoxinA clinical 2 prea_0.pdf,
1991,BOTOX COSMETIC,ONABOTULINUMTOXINA,BLA103000,485d9b71-6881-42c5-a620-a4360c7192ab,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/448_103000S5309 onabotulinumtoxinA statistical prea.pdf,
1991,BOTOX COSMETIC,ONABOTULINUMTOXINA,BLA103000,485d9b71-6881-42c5-a620-a4360c7192ab,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/103000Orig1s5320.pdf,
1991,BOTOX COSMETIC,ONABOTULINUMTOXINA,BLA103000,485d9b71-6881-42c5-a620-a4360c7192ab,http://www.accessdata.fda.gov/drugsatfda_docs/bla/2010/103000Orig1s5189.pdf,
1991,BOTOX COSMETIC,ONABOTULINUMTOXINA,BLA103000,485d9b71-6881-42c5-a620-a4360c7192ab,https://web.archive.org/web/20170113111252/http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080509.htm,
1991,BOTOX COSMETIC,ONABOTULINUMTOXINA,BLA103000,485d9b71-6881-42c5-a620-a4360c7192ab,http://www.accessdata.fda.gov/drugsatfda_docs/bla/2010/103000Orig1s5215.pdf,
1991,BOTOX COSMETIC,ONABOTULINUMTOXINA,BLA103000,485d9b71-6881-42c5-a620-a4360c7192ab,http://www.accessdata.fda.gov/drugsatfda_docs/bla/2011/103000Orig1s5232.pdf,
2014,TOBRAMYCIN INHALATION SOLUTION PAK,TOBRAMYCIN,NDA205433,dad13445-f591-4829-96f9-1598ba03dff8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205433Orig1s000TOC.cfm,
2016,ATROPINE SULFATE,ATROPINE SULFATE,NDA208151,c8093125-ed1a-4eb6-9c81-52c5c7376481,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208151Orig1s000TOC.cfm,
2016,ATROPINE SULFATE,ATROPINE SULFATE,NDA208151,c8093125-ed1a-4eb6-9c81-52c5c7376481,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/53_208151 atropine sulfate clinical prea.pdf,
2016,ATROPINE SULFATE,ATROPINE SULFATE,NDA208151,c8093125-ed1a-4eb6-9c81-52c5c7376481,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/54_208151 atropine sulfate clinpharm prea.pdf,
2016,ATROPINE SULFATE,ATROPINE SULFATE,NDA208151,c8093125-ed1a-4eb6-9c81-52c5c7376481,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/55_208151 atropine sulfate statistical prea.pdf,
2018,N/A,N/A,BLA761104,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761104Orig1s000TOC.cfm,
1996,N/A,N/A,NDA020638,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020638Orig1s000rev.pdf,
2008,LATISSE,BIMATOPROST,NDA022369,34f83d9d-2c64-463e-8a90-9a460fedfead,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022369_latisse_toc.cfm,
2008,LATISSE,BIMATOPROST,NDA022369,34f83d9d-2c64-463e-8a90-9a460fedfead,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022369s000_SumR.pdf,
2008,LATISSE,BIMATOPROST,NDA022369,34f83d9d-2c64-463e-8a90-9a460fedfead,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22369_Bimatoprost_Division_Director_PREA.pdf,
2008,LATISSE,BIMATOPROST,NDA022369,34f83d9d-2c64-463e-8a90-9a460fedfead,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22369_Bimatoprost_CDTL_PREA.pdf,
2008,LATISSE,BIMATOPROST,NDA022369,34f83d9d-2c64-463e-8a90-9a460fedfead,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22369_Bimatoprost_Clinical_PREA.pdf,
2008,LATISSE,BIMATOPROST,NDA022369,34f83d9d-2c64-463e-8a90-9a460fedfead,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22369_Bimatoprost_Stats_PREA.pdf,
2008,LATISSE,BIMATOPROST,NDA022369,34f83d9d-2c64-463e-8a90-9a460fedfead,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22369_Bimatoprost_Stat_Add_PREA.pdf,
2008,LATISSE,BIMATOPROST,NDA022369,34f83d9d-2c64-463e-8a90-9a460fedfead,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22369_Bimatoprost_Division_Director_PREA.pdf,
2008,LATISSE,BIMATOPROST,NDA022369,34f83d9d-2c64-463e-8a90-9a460fedfead,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22369_Bimatoprost_CDTL_PREA.pdf,
1998,JUNIOR STRENGTH ADVIL,IBUPROFEN,NDA020944,07d4c400-b182-92f7-7574-9e0e94c39cce,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020944Orig1s002_s003.pdf,
1998,JUNIOR STRENGTH ADVIL,IBUPROFEN,NDA020944,07d4c400-b182-92f7-7574-9e0e94c39cce,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20944_Advil.cfm,
1998,JUNIOR STRENGTH ADVIL,IBUPROFEN,NDA020944,07d4c400-b182-92f7-7574-9e0e94c39cce,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020944Orig1s002_s003.pdf,
2004,TINDAMAX,TINIDAZOLE,NDA021618,a0d01539-8413-4703-94cc-d221918630a1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-618_21-681_21-682_Tindamax.cfm,
2009,EDLUAR,ZOLPIDEM TARTRATE,NDA021997,a32884d0-85b5-11de-8a39-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021997s000TOC.cfm,
2009,EDLUAR,ZOLPIDEM TARTRATE,NDA021997,a32884d0-85b5-11de-8a39-0800200c9a66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021997s000TOC.cfm,
1992,PROLEUKIN,ALDESLEUKIN,BLA103293,f3c516ad-d405-4fbe-af6a-962080dbfa7d,https://web.archive.org/web/20170113111500/http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080733.htm,
2016,BRIVIACT,BRIVARACETAM,NDA205837,3cf2f439-0e97-443e-8e33-25ecef616f6c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205836-205837-205838-Briviact-TOC.cfm,
2014,OTEZLA,APREMILAST,NDA205437,f6b1f516-4972-4d82-bced-113e47b41cc5,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/205437Orig1s011.pdf,
2014,OTEZLA,APREMILAST,NDA205437,f6b1f516-4972-4d82-bced-113e47b41cc5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205437Orig1s000TOC.cfm,
2017,IDHIFA,ENASIDENIB MESYLATE,NDA209606,a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209606Orig1s000TOC.cfm,
2015,VISTOGARD,URIDINE TRIACETATE,NDA208159,269f7363-63ed-444e-85f1-f0009e44818b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208159Orig1s000TOC.cfm,
2016,NETSPOT,68GA-DOTATATE,NDA208547,b2b3be70-17d8-4093-896c-f1c54a2cf242,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208547Orig1s000TOC.cfm,
2016,NETSPOT,68GA-DOTATATE,NDA208547,b2b3be70-17d8-4093-896c-f1c54a2cf242,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208547Orig1s000SumR.pdf,
2022,KYZATREX,TESTOSTERONE UNDECANOATE,NDA213953,7f7167a7-2a25-47e2-acf5-33f499fce971,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/213953Orig1s000TOC.cfm,
2019,TRANEXAMIC ACID IN SODIUM CHLORIDE,TRANEXAMIC ACID,NDA212020,db36ddf2-4ac5-47ac-bdce-e3fa6983073e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212020Orig1s000TOC.cfm,
2024,N/A,N/A,NDA218527,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/218527Orig1s000TOC.cfm,
2020,LYUMJEV,INSULIN LISPRO-AABC,BLA761109,c5a056e2-b568-4ca6-9ed8-79c010942d00,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761109Orig1s000TOC.cfm,
2023,ABILIFY ASIMTUFII,ARIPIPRAZOLE,NDA217006,da4c07fd-1130-4341-bb44-63acfa4162be,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217006Orig1s000TOC.cfm,
2010,N/A,N/A,NDA022377,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022377_alsuma_toc.cfm,
2010,N/A,N/A,NDA022377,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022377Orig1s000SumR.pdf,
1947,METHADONE HYDROCHLORIDE,METHADONE HYDROCHLORIDE,NDA021624,092d78eb-6423-495c-bf0d-e6532bea7138,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021624Orig1s001.pdf,
2004,N/A,N/A,NDA050801,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/050801s000_EvoclinTOC.cfm,
2011,NUCYNTA ER,TAPENTADOL HYDROCHLORIDE,NDA200533,c3d04d70-0155-4147-9ce4-a3b1fad4b373,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/200533Orig1s000TOC.cfm,
2014,LEDIPASVIR AND SOFOSBUVIR,LEDIPASVIR AND SOFOSBUVIR,NDA205834,46f4a73b-0cd6-4902-9092-3ac79e882c1a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/116_205834S017 ledipasvir-sofosbuvir CD clinical.pdf,
2014,LEDIPASVIR AND SOFOSBUVIR,LEDIPASVIR AND SOFOSBUVIR,NDA205834,46f4a73b-0cd6-4902-9092-3ac79e882c1a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/114_205834 ledipasvir-sofosbuvir clinpharm prea.pdf,
2014,LEDIPASVIR AND SOFOSBUVIR,LEDIPASVIR AND SOFOSBUVIR,NDA205834,46f4a73b-0cd6-4902-9092-3ac79e882c1a,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/115_205834 ledipasvir-sofosbuvir statistical prea.pdf,
2014,LEDIPASVIR AND SOFOSBUVIR,LEDIPASVIR AND SOFOSBUVIR,NDA205834,46f4a73b-0cd6-4902-9092-3ac79e882c1a,"http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2016/205834Orig1s007, s008, s009SumR.pdf",
2014,LEDIPASVIR AND SOFOSBUVIR,LEDIPASVIR AND SOFOSBUVIR,NDA205834,46f4a73b-0cd6-4902-9092-3ac79e882c1a,"http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2016/205834Orig1s007, s008, s009SumR.pdf",
2014,LEDIPASVIR AND SOFOSBUVIR,LEDIPASVIR AND SOFOSBUVIR,NDA205834,46f4a73b-0cd6-4902-9092-3ac79e882c1a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205834Orig1s000TOC.cfm,
2014,LEDIPASVIR AND SOFOSBUVIR,LEDIPASVIR AND SOFOSBUVIR,NDA205834,46f4a73b-0cd6-4902-9092-3ac79e882c1a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205834Orig1s000SumR.pdf,
2014,LEDIPASVIR AND SOFOSBUVIR,LEDIPASVIR AND SOFOSBUVIR,NDA205834,46f4a73b-0cd6-4902-9092-3ac79e882c1a,"http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2016/205834Orig1s007, s008, s009SumR.pdf",
2015,N/A,N/A,NDA205003,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205003Orig1s000TOC.cfm,
2023,BRENZAVVY,BEXAGLIFLOZIN,NDA214373,3cdf28fc-4194-4ad6-aa03-c9eaa68da83e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/214373Orig1s000TOC.cfm,
1996,DOCETAXEL,DOCETAXEL,NDA020449,dd0ca36d-1f54-4568-8d19-a7152addcd52,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20449-S011_Taxotere.cfm,
1996,DOCETAXEL,DOCETAXEL,NDA020449,dd0ca36d-1f54-4568-8d19-a7152addcd52,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20449S004_Taxotere.pdf,
1996,DOCETAXEL,DOCETAXEL,NDA020449,dd0ca36d-1f54-4568-8d19-a7152addcd52,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/020449Orig1s054.pdf,
1996,DOCETAXEL,DOCETAXEL,NDA020449,dd0ca36d-1f54-4568-8d19-a7152addcd52,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020449_docetaxel_clinical_BPCA.pdf,
1996,DOCETAXEL,DOCETAXEL,NDA020449,dd0ca36d-1f54-4568-8d19-a7152addcd52,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020449_docetaxel_clinpharm_BPCA.pdf,
1996,DOCETAXEL,DOCETAXEL,NDA020449,dd0ca36d-1f54-4568-8d19-a7152addcd52,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020449_docetaxel_statistical_BPCA.pdf,
1996,DOCETAXEL,DOCETAXEL,NDA020449,dd0ca36d-1f54-4568-8d19-a7152addcd52,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020449Orig1s000rev.pdf,
1996,DOCETAXEL,DOCETAXEL,NDA020449,dd0ca36d-1f54-4568-8d19-a7152addcd52,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/20-449s028_Taxotere.cfm,
1996,DOCETAXEL,DOCETAXEL,NDA020449,dd0ca36d-1f54-4568-8d19-a7152addcd52,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/020449Orig1s079.pdf,
1996,DOCETAXEL,DOCETAXEL,NDA020449,dd0ca36d-1f54-4568-8d19-a7152addcd52,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-449s018_Taxotere.cfm,
1996,DOCETAXEL,DOCETAXEL,NDA020449,dd0ca36d-1f54-4568-8d19-a7152addcd52,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/020449Orig1s075.pdf,
1996,DOCETAXEL,DOCETAXEL,NDA020449,dd0ca36d-1f54-4568-8d19-a7152addcd52,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/020449Orig1s071.pdf,
1996,DOCETAXEL,DOCETAXEL,NDA020449,dd0ca36d-1f54-4568-8d19-a7152addcd52,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020449s039.pdf,
1996,DOCETAXEL,DOCETAXEL,NDA020449,dd0ca36d-1f54-4568-8d19-a7152addcd52,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/20-449s029_Taxotere.cfm,
1996,DOCETAXEL,DOCETAXEL,NDA020449,dd0ca36d-1f54-4568-8d19-a7152addcd52,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/020449Orig1s043.pdf,
1996,DOCETAXEL,DOCETAXEL,NDA020449,dd0ca36d-1f54-4568-8d19-a7152addcd52,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020449Orig1s035.pdf,
1996,DOCETAXEL,DOCETAXEL,NDA020449,dd0ca36d-1f54-4568-8d19-a7152addcd52,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/020449Orig1s017.pdf,
1996,DOCETAXEL,DOCETAXEL,NDA020449,dd0ca36d-1f54-4568-8d19-a7152addcd52,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/20449Orig1s084.pdf,
2019,BALVERSA,ERDAFITINIB,NDA212018,2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212018Orig1s000TOC.cfm,
2019,HERCEPTIN HYLECTA,TRASTUZUMAB AND HYALURONIDASE-OYSK,BLA761106,ebf30894-41cf-480c-8bc3-56f592a13813,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761106Orig1s000TOC.cfm,
1995,LUPRON DEPOT,LEUPROLIDE ACETATE,NDA020517,cbc8f94e-7330-4465-05ad-16d64493a5dd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020517_S018_Lupron Depot_APPROVAL PACKAGE.pdf,
1995,LUPRON DEPOT,LEUPROLIDE ACETATE,NDA020517,cbc8f94e-7330-4465-05ad-16d64493a5dd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020517orig1s025s030s032Review.pdf,
1995,LUPRON DEPOT,LEUPROLIDE ACETATE,NDA020517,cbc8f94e-7330-4465-05ad-16d64493a5dd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020517orig1s025s030s032Review.pdf,
1995,LUPRON DEPOT,LEUPROLIDE ACETATE,NDA020517,cbc8f94e-7330-4465-05ad-16d64493a5dd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/20517S001_Lupron.pdf,
1995,LUPRON DEPOT,LEUPROLIDE ACETATE,NDA020517,cbc8f94e-7330-4465-05ad-16d64493a5dd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020517_S000_Lupron_Depot.PDF,
1995,LUPRON DEPOT,LEUPROLIDE ACETATE,NDA020517,cbc8f94e-7330-4465-05ad-16d64493a5dd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020517_S019_Lupron Depot_APPROVAL PACKAGE.pdf,
1995,LUPRON DEPOT,LEUPROLIDE ACETATE,NDA020517,cbc8f94e-7330-4465-05ad-16d64493a5dd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020517_S006_Lupron Depot_APPROVAL PACKAGE.pdf,
1995,LUPRON DEPOT,LEUPROLIDE ACETATE,NDA020517,cbc8f94e-7330-4465-05ad-16d64493a5dd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020517orig1s025s030s032Review.pdf,
1995,LUPRON DEPOT,LEUPROLIDE ACETATE,NDA020517,cbc8f94e-7330-4465-05ad-16d64493a5dd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020517_s002ap.pdf,
2022,METHYLPHENIDATE HYDROCHLORIDE,METHYLPHENIDATE HYDROCHLORIDE,NDA216117,dd8d7b6e-c23d-4e16-bb53-959e9127ebc6,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216117Orig1s000TOC.cfm,
2001,DIOVAN,VALSARTAN,NDA021283,5ddba454-f3e6-43c2-a7a6-58365d297213,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-283s001_Diovan.cfm,
2001,DIOVAN,VALSARTAN,NDA021283,5ddba454-f3e6-43c2-a7a6-58365d297213,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021283_S011_DIOVANTOC.cfm,
2001,DIOVAN,VALSARTAN,NDA021283,5ddba454-f3e6-43c2-a7a6-58365d297213,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021283Orig1s024.pdf,
2001,DIOVAN,VALSARTAN,NDA021283,5ddba454-f3e6-43c2-a7a6-58365d297213,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020665s004_diovan_toc.cfm,
2001,DIOVAN,VALSARTAN,NDA021283,5ddba454-f3e6-43c2-a7a6-58365d297213,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-283s002_Diovan.cfm,
2001,DIOVAN,VALSARTAN,NDA021283,5ddba454-f3e6-43c2-a7a6-58365d297213,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021283_Valsartan_Clinical_PREA.pdf,
2001,DIOVAN,VALSARTAN,NDA021283,5ddba454-f3e6-43c2-a7a6-58365d297213,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021283_Valsartan_ClinpharmBPCA.pdf,
2001,DIOVAN,VALSARTAN,NDA021283,5ddba454-f3e6-43c2-a7a6-58365d297213,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021283_Valsartan_Statistical_PREA.pdf,
2001,DIOVAN,VALSARTAN,NDA021283,5ddba454-f3e6-43c2-a7a6-58365d297213,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/021283_ORIGINAL_APPROVAL_PACKAGE.PDF,
2001,DIOVAN,VALSARTAN,NDA021283,5ddba454-f3e6-43c2-a7a6-58365d297213,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021283Orig1s021.pdf,
2004,ZYRTEC,CETIRIZINE HYDROCHLORIDE,NDA021621,dc613bd5-70fd-1d9b-e053-2995a90a41cd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-621_Zyrtec.cfm,
2004,ZYRTEC,CETIRIZINE HYDROCHLORIDE,NDA021621,dc613bd5-70fd-1d9b-e053-2995a90a41cd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/019835s022_021621s005TOC.cfm,
2006,INVEGA,PALIPERIDONE,NDA021999,7b8e5b26-b9e4-4704-921b-3c3c0d159916,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021999Orig1s004.pdf,
2006,INVEGA,PALIPERIDONE,NDA021999,7b8e5b26-b9e4-4704-921b-3c3c0d159916,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021999s000_TOC.cfm,
2006,INVEGA,PALIPERIDONE,NDA021999,7b8e5b26-b9e4-4704-921b-3c3c0d159916,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21999 Paliperidone clinical prea.pdf,
2006,INVEGA,PALIPERIDONE,NDA021999,7b8e5b26-b9e4-4704-921b-3c3c0d159916,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21999 Paliperidone Clinpharm Prea.pdf,
2006,INVEGA,PALIPERIDONE,NDA021999,7b8e5b26-b9e4-4704-921b-3c3c0d159916,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21999 paliperidone statistical prea.pdf,
1958,N/A,N/A,NDA011664,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/011664_S062_DECADRON.pdf,
2005,DOXYCYCLINE HYCLATE,DOXYCYCLINE HYCLATE,NDA050795,f9c63af9-d613-43fc-b8e5-ab6219f24c70,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/050795Orig1s022.pdf,
2005,DOXYCYCLINE HYCLATE,DOXYCYCLINE HYCLATE,NDA050795,f9c63af9-d613-43fc-b8e5-ab6219f24c70,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/050795s010 doxycyclene clinpharm prea.pdf,
2005,DOXYCYCLINE HYCLATE,DOXYCYCLINE HYCLATE,NDA050795,f9c63af9-d613-43fc-b8e5-ab6219f24c70,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/050795s010 doxycycline statistical prea.pdf,
2005,DOXYCYCLINE HYCLATE,DOXYCYCLINE HYCLATE,NDA050795,f9c63af9-d613-43fc-b8e5-ab6219f24c70,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/050795s010 doxycycline clinical prea.pdf,
2005,DOXYCYCLINE HYCLATE,DOXYCYCLINE HYCLATE,NDA050795,f9c63af9-d613-43fc-b8e5-ab6219f24c70,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/050795Orig1s019.pdf,
2005,DOXYCYCLINE HYCLATE,DOXYCYCLINE HYCLATE,NDA050795,f9c63af9-d613-43fc-b8e5-ab6219f24c70,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/050795s000_DoryxTOC.cfm,
1980,OXYTOCIN,OXYTOCIN,NDA018248,6d7d1280-f286-4f39-89f3-2b96571810e6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/018248_S026_OXYTOCIN_AP.pdf,
1980,OXYTOCIN,OXYTOCIN,NDA018248,6d7d1280-f286-4f39-89f3-2b96571810e6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/018248_S027_OXYTOCIN_AP.pdf,
1987,CATHFLO ACTIVASE,ALTEPLASE,BLA103172,91ecdef2-95ff-42dd-a31c-c8a09cab3ad9,http://www.accessdata.fda.gov/drugsatfda_docs/bla/2015/103172Orig1s5203.pdf,
1987,CATHFLO ACTIVASE,ALTEPLASE,BLA103172,91ecdef2-95ff-42dd-a31c-c8a09cab3ad9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/alteplase_toc.cfm,
2010,OXYCODONE HYDROCHLORIDE,OXYCODONE HYDROCHLORIDE,NDA200534,061cf52b-4432-422d-a97b-c3e1f8c4bab6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200534Orig1s000SumR.pdf,
2010,OXYCODONE HYDROCHLORIDE,OXYCODONE HYDROCHLORIDE,NDA200534,061cf52b-4432-422d-a97b-c3e1f8c4bab6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200534s000_oxycodone_toc.cfm,
2020,BRONCHITOL,MANNITOL,NDA202049,2142460a-5afa-f3f3-e063-6394a90ab647,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/202049Orig1s000TOC.cfm,
2014,SIVEXTRO,TEDIZOLID PHOSPHATE,NDA205435,75672079-589f-451a-bdbf-eaebcfcc80a9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000SumR.pdf,
2014,SIVEXTRO,TEDIZOLID PHOSPHATE,NDA205435,75672079-589f-451a-bdbf-eaebcfcc80a9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000TOC.cfm,
2017,GEMCITABINE,GEMCITABINE,NDA209604,5a335d36-408b-478f-9563-4bc140b69bb6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209604Orig1s000TOC.cfm,
2014,N/A,N/A,NDA206619,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206619Orig1s000SumR.pdf,
2014,N/A,N/A,NDA206619,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206619Orig1s000TOC.cfm,
2019,MYXREDLIN,INSULIN HUMAN,BLA208157,afca6e80-a802-49fb-a978-5fe28a173001,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/208157Orig1s000TOC.cfm,
2018,ATROPINE SULFATE,ATROPINE SULFATE,NDA209260,310c8a74-ea24-4357-8099-81e394b1634e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209260Orig1s0000TOC.cfm,
1994,N/A,N/A,NDA020408,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020408s033_dorzolamide_Trusopt-MedRev.pdf,
1994,N/A,N/A,NDA020408,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020408s033_dorzolamide_Trusopt-StatsRev.pdf,
1994,N/A,N/A,NDA020408,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020408_S033_TRUSOPT.pdf,
2018,GLYRX-PF,GLYCOPYRROLATE,NDA210997,2189f3f5-39dc-4e85-b7c6-9515ded59686,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210997Orig1s000,210997Orig2s000TOC.cfm",
2018,GLYRX-PF,GLYCOPYRROLATE,NDA210997,2189f3f5-39dc-4e85-b7c6-9515ded59686,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210997Orig1s000,210997Orig2s000TOC.cfm",
1997,AGRYLIN,ANAGRELIDE HYDROCHLORIDE,NDA020333,cb960074-99c1-4a73-941f-f0644a7ec219,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020333s008_anagrelide_Agrylin_MedR.pdf,
1997,AGRYLIN,ANAGRELIDE HYDROCHLORIDE,NDA020333,cb960074-99c1-4a73-941f-f0644a7ec219,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020333s008_anagrelide_Agrylin_ClinPharmR.pdf,
1997,AGRYLIN,ANAGRELIDE HYDROCHLORIDE,NDA020333,cb960074-99c1-4a73-941f-f0644a7ec219,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20333-S002_Agrylin.pdf,
1997,AGRYLIN,ANAGRELIDE HYDROCHLORIDE,NDA020333,cb960074-99c1-4a73-941f-f0644a7ec219,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/020333Orig1s013.pdf,
1994,MENOSTAR,ESTRADIOL,NDA020375,a78708cd-04d4-4221-a4e4-53680bbe2912,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020375-S5_Climara_toc.cfm,
1994,MENOSTAR,ESTRADIOL,NDA020375,a78708cd-04d4-4221-a4e4-53680bbe2912,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020375s12_climara.cfm,
1994,MENOSTAR,ESTRADIOL,NDA020375,a78708cd-04d4-4221-a4e4-53680bbe2912,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020375-S3_Climara_toc.cfm,
1994,MENOSTAR,ESTRADIOL,NDA020375,a78708cd-04d4-4221-a4e4-53680bbe2912,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020375-S1_Climara_toc.cfm,
1994,MENOSTAR,ESTRADIOL,NDA020375,a78708cd-04d4-4221-a4e4-53680bbe2912,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020375s10_climara.cfm,
1994,MENOSTAR,ESTRADIOL,NDA020375,a78708cd-04d4-4221-a4e4-53680bbe2912,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020375s8_climara.cfm,
1994,MENOSTAR,ESTRADIOL,NDA020375,a78708cd-04d4-4221-a4e4-53680bbe2912,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20375-s013_climara.pdf,
1994,MENOSTAR,ESTRADIOL,NDA020375,a78708cd-04d4-4221-a4e4-53680bbe2912,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020375-S4_Climara_toc.cfm,
1994,MENOSTAR,ESTRADIOL,NDA020375,a78708cd-04d4-4221-a4e4-53680bbe2912,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020994.cfm,
1994,MENOSTAR,ESTRADIOL,NDA020375,a78708cd-04d4-4221-a4e4-53680bbe2912,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020375-S2_Climara_toc.cfm,
1994,MENOSTAR,ESTRADIOL,NDA020375,a78708cd-04d4-4221-a4e4-53680bbe2912,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20375s009_Climara.cfm,
1994,MENOSTAR,ESTRADIOL,NDA020375,a78708cd-04d4-4221-a4e4-53680bbe2912,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-375s016_Berlex.cfm,
1994,MENOSTAR,ESTRADIOL,NDA020375,a78708cd-04d4-4221-a4e4-53680bbe2912,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020375-S7_Climara_toc.cfm,
2018,GAMIFANT,EMAPALUMAB-LZSG,BLA761107,a865e0ef-8685-4f69-8838-648c4f3bab47,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761107Orig1s000TOC.cfm,
2020,VEKLURY,REMDESIVIR,NDA214787,c0978fa8-53ff-4ca2-82a7-567fd3e958ca,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214787Orig1s011JointReview.pdf,
2020,VEKLURY,REMDESIVIR,NDA214787,c0978fa8-53ff-4ca2-82a7-567fd3e958ca,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214787Orig1s011.pdf,
2020,VEKLURY,REMDESIVIR,NDA214787,c0978fa8-53ff-4ca2-82a7-567fd3e958ca,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214787Orig1s000Sumr.pdf,
2020,VEKLURY,REMDESIVIR,NDA214787,c0978fa8-53ff-4ca2-82a7-567fd3e958ca,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214787Orig1s000TOC.cfm,
2020,VEKLURY,REMDESIVIR,NDA214787,c0978fa8-53ff-4ca2-82a7-567fd3e958ca,https://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2024/214787Orig1s026SumR.pdf,
2020,VEKLURY,REMDESIVIR,NDA214787,c0978fa8-53ff-4ca2-82a7-567fd3e958ca,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214787Orig1s010JointReview.pdf,
2020,VEKLURY,REMDESIVIR,NDA214787,c0978fa8-53ff-4ca2-82a7-567fd3e958ca,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214787Orig1s010.pdf,
2009,N/A,N/A,NDA020947,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/020947_pennsaid_toc.cfm,
2009,N/A,N/A,NDA020947,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/020947s000sumr.pdf,
2002,METHYLPHENIDATE,METHYLPHENIDATE,NDA021284,1f8983ce-71b8-4c62-830d-e4692ddededa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-284_Ritalin.cfm,
2005,N/A,N/A,NDA021623,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021623TOC.cfm,
2007,LIALDA,MESALAMINE,NDA022000,3098a080-be86-4265-9818-7fc4beab77b7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022000Orig1s005.pdf,
2007,LIALDA,MESALAMINE,NDA022000,3098a080-be86-4265-9818-7fc4beab77b7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022000s000TOC.cfm,
1972,N/A,N/A,NDA050445,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50-444S036_Minocin.cfm,
2005,CEFTRIAXONE AND DEXTROSE,CEFTRIAXONE,NDA050796,67153914-16bc-490d-82d7-638061618467,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/050796s000TOC.cfm,
1989,PROCRIT,ERYTHROPOIETIN,BLA103234,0c721ba4-ae19-417f-aae1-221ed1a0866a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/103234s5033.pdf,
1989,PROCRIT,ERYTHROPOIETIN,BLA103234,0c721ba4-ae19-417f-aae1-221ed1a0866a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/103234s5076_AP_PKG.pdf,
1989,PROCRIT,ERYTHROPOIETIN,BLA103234,0c721ba4-ae19-417f-aae1-221ed1a0866a,https://web.archive.org/web/20170113111355/http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080580.htm,
1989,PROCRIT,ERYTHROPOIETIN,BLA103234,0c721ba4-ae19-417f-aae1-221ed1a0866a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/103234s5093_AP_PKG.pdf,
1989,PROCRIT,ERYTHROPOIETIN,BLA103234,0c721ba4-ae19-417f-aae1-221ed1a0866a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/103234_epogen_procrit_toc.cfm,
1989,PROCRIT,ERYTHROPOIETIN,BLA103234,0c721ba4-ae19-417f-aae1-221ed1a0866a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103234Orig1s5166SumR.pdf,
1989,PROCRIT,ERYTHROPOIETIN,BLA103234,0c721ba4-ae19-417f-aae1-221ed1a0866a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/103234s5053.pdf,
2010,OXYCODONE HYDROCHLORIDE,OXYCODONE HYDROCHLORIDE,NDA200535,6869fec9-1837-4221-afd8-5cc6fadd025d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200535s000_oxycodone_toc.cfm,
2010,OXYCODONE HYDROCHLORIDE,OXYCODONE HYDROCHLORIDE,NDA200535,6869fec9-1837-4221-afd8-5cc6fadd025d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200535Orig1s000SumR.pdf,
2016,BRIVIACT,BRIVARACETAM,NDA205836,3cf2f439-0e97-443e-8e33-25ecef616f6c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205836-205837-205838-Briviact-TOC.cfm,
2015,COTELLIC,COBIMETINIB,NDA206192,c387579e-cee0-4334-bd1e-73f93ac1bde6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206192Orig1s000SumR.pdf,
2015,COTELLIC,COBIMETINIB,NDA206192,c387579e-cee0-4334-bd1e-73f93ac1bde6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206192Orig1s000TOC.cfm,
2013,NAFTIN,NAFTIFINE HYDROCHLORIDE,NDA204286,6c6ee055-4031-45a7-8561-ccd989343580,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204286_naftin_toc.cfm,
2013,NAFTIN,NAFTIFINE HYDROCHLORIDE,NDA204286,6c6ee055-4031-45a7-8561-ccd989343580,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/204286 nafttifine clinical prea.pdf,
2013,NAFTIN,NAFTIFINE HYDROCHLORIDE,NDA204286,6c6ee055-4031-45a7-8561-ccd989343580,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/204286 naftifine clinpharm prea.pdf,
2013,NAFTIN,NAFTIFINE HYDROCHLORIDE,NDA204286,6c6ee055-4031-45a7-8561-ccd989343580,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204286Orig1s000SumR.pdf,
2017,N/A,N/A,NDA205004,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/205004Orig1s002.pdf,
2017,N/A,N/A,NDA205004,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/205004Orig1s000TOC.cfm,
2014,SIVEXTRO,TEDIZOLID PHOSPHATE,NDA205436,75672079-589f-451a-bdbf-eaebcfcc80a9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205436Orig1s000TOC.cfm,
2014,SIVEXTRO,TEDIZOLID PHOSPHATE,NDA205436,75672079-589f-451a-bdbf-eaebcfcc80a9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205436Orig1s000SumR.pdf,
2022,XENOVIEW,XENON XE 129 HYPERPOLARIZED,NDA214375,70e33fe3-c722-439b-b3db-c2a22f229c8a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/214375Orig1s000TOC.cfm,
2020,SUTAB,"SODIUM SULFATE, MAGNESIUM SULFATE, AND POTASSIUM CHLORIDE",NDA213135,dddd2701-4d46-44de-a9f8-303d4dcceef7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213135Orig1s000TOC.cfm,
2018,ULTOMIRIS,RAVULIZUMAB,BLA761108,a9a590d9-0217-43c7-908d-e62a71279791,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761108Orig1s000TOC.cfm,
2022,IMBRUVICA,IBRUTINIB,NDA217003,0dfd0279-ff17-4ea9-89be-9803c71bab44,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217003Orig1s000TOC.cfm,
2010,SUPREP BOWEL PREP,"SODIUM SULFATE, POTASSIUM SULFATE, MAGNESIUM SULFATE",NDA022372,2f5f06de-ee98-44c0-be7e-9a998d1e5c16,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022372_suprep_toc.cfm,
2010,SUPREP BOWEL PREP,"SODIUM SULFATE, POTASSIUM SULFATE, MAGNESIUM SULFATE",NDA022372,2f5f06de-ee98-44c0-be7e-9a998d1e5c16,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022372Orig1s000SumR.pdf,
2001,N/A,N/A,NDA020949,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-949_AccuNeb.cfm,
2001,OXCARBAZEPINE,OXCARBAZEPINE,NDA021285,1ccdb12e-3c52-4fb4-a2db-aeb8ca5757f7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-285_Trileptal.cfm,
2005,N/A,N/A,NDA050797,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/050797s008_Azithromycin_Clinical_PREA.pdf,
2005,N/A,N/A,NDA050797,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/050797s008_Azithromycin_Clinpharm_PREA.pdf,
2005,N/A,N/A,NDA050797,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/050797s000TOC.cfm,
2023,VANCOMYCIN HYDROCHLORIDE,VANCOMYCIN HYDROCHLORIDE,NDA210274,e4ce7b87-fab4-4b7a-b121-eba136c464ce,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/210274Orig1s000TOC.cfm,
2017,N/A,N/A,NDA209269,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209269Orig1s000TOC.cfm,
2020,SARCLISA,ISATUXIMAB,BLA761113,a0473462-6f9d-4eca-a5bf-8620aea68e8a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761113Orig1s000TOC.cfm,
1997,LUPRON DEPOT,LEUPROLIDE ACETATE,NDA020708,60aad237-e1da-4705-cbbb-b3ca79e89ad8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-708S011_Lupron.cfm,
1997,LUPRON DEPOT,LEUPROLIDE ACETATE,NDA020708,60aad237-e1da-4705-cbbb-b3ca79e89ad8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20708s5.cfm,
1997,LUPRON DEPOT,LEUPROLIDE ACETATE,NDA020708,60aad237-e1da-4705-cbbb-b3ca79e89ad8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020708_S020_Lupron Depot_APPROVAL PACKAGE.pdf,
1997,LUPRON DEPOT,LEUPROLIDE ACETATE,NDA020708,60aad237-e1da-4705-cbbb-b3ca79e89ad8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20011-s014_Lupron.cfm,
1997,LUPRON DEPOT,LEUPROLIDE ACETATE,NDA020708,60aad237-e1da-4705-cbbb-b3ca79e89ad8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020708_lupron_toc.cfm,
1997,LUPRON DEPOT,LEUPROLIDE ACETATE,NDA020708,60aad237-e1da-4705-cbbb-b3ca79e89ad8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020708_S006_Lupron Depot_APPROVAL PACKAGE.pdf,
1997,LUPRON DEPOT,LEUPROLIDE ACETATE,NDA020708,60aad237-e1da-4705-cbbb-b3ca79e89ad8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020708_S021_Lupron Depot_APPROVAL PACKAGE.pdf,
2009,TYVASO,TREPROSTINIL,NDA022387,cbc31ab1-a80f-4b50-a3b1-39910b0fb609,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022387s000TOC.cfm,
2009,TYVASO,TREPROSTINIL,NDA022387,cbc31ab1-a80f-4b50-a3b1-39910b0fb609,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/022387Orig1s017.pdf,
1999,FERRLECIT,SODIUM FERRIC GLUCONATE COMPLEX,NDA020955,1fe028ff-42ac-4329-b1a5-a9dadfcb79f6,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20955s006_sodium ferric gluconate_Ferrlecit-MedRev.pdf,
1999,FERRLECIT,SODIUM FERRIC GLUCONATE COMPLEX,NDA020955,1fe028ff-42ac-4329-b1a5-a9dadfcb79f6,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20955s006_sodium ferric gluconate_Ferrlecit-ClinPharmRev.pdf,
1999,FERRLECIT,SODIUM FERRIC GLUCONATE COMPLEX,NDA020955,1fe028ff-42ac-4329-b1a5-a9dadfcb79f6,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20955s006_sodium ferric gluconate_Ferrlecit-StatsRev.pdf,
1999,FERRLECIT,SODIUM FERRIC GLUCONATE COMPLEX,NDA020955,1fe028ff-42ac-4329-b1a5-a9dadfcb79f6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20955_Ferrlecit.cfm,
1999,FERRLECIT,SODIUM FERRIC GLUCONATE COMPLEX,NDA020955,1fe028ff-42ac-4329-b1a5-a9dadfcb79f6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020955_S003_FERRLECIT_AP.pdf,
1999,FERRLECIT,SODIUM FERRIC GLUCONATE COMPLEX,NDA020955,1fe028ff-42ac-4329-b1a5-a9dadfcb79f6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020955_S001_FERRLECIT_AP.pdf,
2002,N/A,N/A,BLA021289,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-289_Bravelle.cfm,
2004,APIDRA,INSULIN GLULISINE,BLA021629,e7af6a7a-8046-4fb4-9979-4ec4230b23aa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-629_Apidra.cfm,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2004,APIDRA,INSULIN GLULISINE,BLA021629,e7af6a7a-8046-4fb4-9979-4ec4230b23aa,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021629s015_Insulin Glulisine (Apidra)_Statistics_PREA.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2004,APIDRA,INSULIN GLULISINE,BLA021629,e7af6a7a-8046-4fb4-9979-4ec4230b23aa,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021629s015_Insulin Glulisine (Apidra) (NO-AP-LBL)_Clinpharm_PREA.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2004,APIDRA,INSULIN GLULISINE,BLA021629,e7af6a7a-8046-4fb4-9979-4ec4230b23aa,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021629s015_Insulin Glulisine (Apidra)_Clinical_PREA.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2004,APIDRA,INSULIN GLULISINE,BLA021629,e7af6a7a-8046-4fb4-9979-4ec4230b23aa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021629Orig1s008.pdf,"This Former NDA Was Deemed To Be a BLA on March 23, 2020."
2007,FORMOTEROL FUMARATE,FORMOTEROL FUMARATE DIHYDRATE,NDA022007,6c1a6c53-af85-4220-9ce3-2373e0928f7f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022007_perforomist_toc.cfm,
2006,ORACEA,DOXYCYCLINE,NDA050805,aa15c93a-ff4c-447a-8a21-96da506d8997,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/050805s000TOC.cfm,
2013,OSPHENA,OSPEMIFENE,NDA203505,9accbcc9-78ee-4f84-9b7e-704f2ab1c413,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203505Orig1s000TOC.cfm,
2012,N/A,N/A,NDA202763,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202763Orig1s000TOC.cfm,
2012,N/A,N/A,NDA202763,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202763Orig1s000SumR.pdf,
2016,BRIVIACT,BRIVARACETAM,NDA205838,3cf2f439-0e97-443e-8e33-25ecef616f6c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205836-205837-205838-Briviact-TOC.cfm,
2013,ADRENALIN,EPINEPHRINE,NDA204640,b27e06aa-5b40-44bc-8de7-80b027580a3b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204640Orig1s000TOC.cfm,
2013,ADRENALIN,EPINEPHRINE,NDA204640,b27e06aa-5b40-44bc-8de7-80b027580a3b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204640Orig1s000SumR.pdf,
2013,ADRENALIN,EPINEPHRINE,NDA204640,b27e06aa-5b40-44bc-8de7-80b027580a3b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/204640Orig1s008.pdf,
2018,N/A,N/A,NDA209607,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209607Orig1s000TOC.cfm,
2017,DAPTOMYCIN,DAPTOMYCIN,NDA209949,bcacf746-a3ee-48b5-bfbe-6a2b548ad24c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209949Orig1s000TOC.cfm,
2014,HYSINGLA ER,HYDROCODONE BITARTRATE,NDA206627,b7d23ac2-e776-9f62-3290-c64c2d6eb353,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000TOC.cfm,
2014,HYSINGLA ER,HYDROCODONE BITARTRATE,NDA206627,b7d23ac2-e776-9f62-3290-c64c2d6eb353,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000SumR.pdf,
2021,VERQUVO,VERICIGUAT,NDA214377,17056d73-1b1b-4bf2-9c07-b7a9367f0d6d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214377Orig1s000TOC.cfm,
1996,N/A,N/A,NDA020114,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020114Orig1s000rev.pdf,
1996,N/A,N/A,NDA020114,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20114S006_Astelin.cfm,
1993,N/A,N/A,NDA020151,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020151s017s018,020699s015s016EffexorTOC.cfm",
1993,N/A,N/A,NDA020151,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020151s16s19s20s21s22s23s25,020699s14s18s21s23s26s27s34TOC.cfm",
1993,N/A,N/A,NDA020151,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020151s16s19s20s21s22s23s25,020699s14s18s21s23s26s27s34TOC.cfm",
1993,N/A,N/A,NDA020151,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020151_S028_EFFEXOR_TABLETS.pdf,
1993,N/A,N/A,NDA020151,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020151s017s018,020699s015s016EffexorTOC.cfm",
1993,N/A,N/A,NDA020151,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020151_S032_EFFEXOR_TABLETS.pdf,
1993,N/A,N/A,NDA020151,N/A,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20151Orig1s024, 20699Orig1s030_venlafaxine_Effexor-ClinicalR.pdf",
1993,N/A,N/A,NDA020151,N/A,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20151Orig1s024, 20699Orig1s030_venlafaxine_Effexor-ClinPharmR.pdf",
1993,N/A,N/A,NDA020151,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020151s16s19s20s21s22s23s25,020699s14s18s21s23s26s27s34TOC.cfm",
1993,N/A,N/A,NDA020151,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020151_S030_EFFEXOR_TABLETS.pdf,
1993,N/A,N/A,NDA020151,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020151s16s19s20s21s22s23s25,020699s14s18s21s23s26s27s34TOC.cfm",
1993,N/A,N/A,NDA020151,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020151s16s19s20s21s22s23s25,020699s14s18s21s23s26s27s34TOC.cfm",
1993,N/A,N/A,NDA020151,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020151s16s19s20s21s22s23s25,020699s14s18s21s23s26s27s34TOC.cfm",
1993,N/A,N/A,NDA020151,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020151s16s19s20s21s22s23s25,020699s14s18s21s23s26s27s34TOC.cfm",
1992,DIANEAL LOW CALCIUM WITH DEXTROSE,"SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE",NDA020183,aa268d3f-7389-4f25-801f-5d4825495f08,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020183_S015_VIDEX.pdf,
2019,OXBRYTA,VOXELOTOR,NDA213137,3c557fac-29ec-483f-b691-8a935d4decc3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/213137Orig1s000TOC.cfm,
2020,NYVEPRIA,PEGFILGRASTIM-APGF,BLA761111,99d30b99-2743-446b-98f3-0430bf4ea869,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761111Orig1s000TOC.cfm,
2024,PANTOPRAZOLE SODIUM,PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE,NDA217512,a476e063-9450-4793-9a22-16b0a0a61cd0,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217512Orig1s000TOC.cfm,
2010,SPRIX,KETOROLAC TROMETHAMINE,NDA022382,97005a1c-167e-4676-bae7-e49b38c36f9e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022382_sprix_toc.cfm,
2010,SPRIX,KETOROLAC TROMETHAMINE,NDA022382,97005a1c-167e-4676-bae7-e49b38c36f9e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022382Orig1s000SumR.pdf,
2001,N/A,N/A,NDA020950,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20950_DuoNeb.cfm,
2002,BENICAR,OLMESARTAN MEDOXOMIL,NDA021286,5b6f8a18-8f8a-4521-81c3-3a39c73c6646,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021286_Olmesartan_Clinical_BPCA.pdf,
2002,BENICAR,OLMESARTAN MEDOXOMIL,NDA021286,5b6f8a18-8f8a-4521-81c3-3a39c73c6646,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021286_Olmesartan_Clinpharm_BPCA.pdf,
2002,BENICAR,OLMESARTAN MEDOXOMIL,NDA021286,5b6f8a18-8f8a-4521-81c3-3a39c73c6646,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021286_Olmesartan_Statistical_BPCA.pdf,
2002,BENICAR,OLMESARTAN MEDOXOMIL,NDA021286,5b6f8a18-8f8a-4521-81c3-3a39c73c6646,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-286_Benicar.cfm,
2002,BENICAR,OLMESARTAN MEDOXOMIL,NDA021286,5b6f8a18-8f8a-4521-81c3-3a39c73c6646,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021286Orig1s010.pdf,
2004,N/A,N/A,NDA021625,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21625s000_MVI_AdultTOC.cfm,
2006,NOXAFIL,POSACONAZOLE,NDA022003,b073b082-7b57-4423-8c06-4fd4263d6f84,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022003s000_NoxafilTOC.cfm,
2006,NOXAFIL,POSACONAZOLE,NDA022003,b073b082-7b57-4423-8c06-4fd4263d6f84,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/8_22003 posaconazole clinical prea.pdf,
2006,NOXAFIL,POSACONAZOLE,NDA022003,b073b082-7b57-4423-8c06-4fd4263d6f84,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/7_22003 posaconazole clinpharm prea.pdf,
2006,ZIANA,CLINDAMYCIN PHOSPHATE AND TRETINOIN,NDA050802,78c329f9-f0c9-486d-9e54-0123699fb9e1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/050802_ziana_toc.cfm,
1967,DROXIA,HYDROXYUREA,NDA016295,4ad13dc6-a2ab-4308-96b3-7c642c92cc23,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/16-295S036_Droxia.cfm,
2014,STRIVERDI RESPIMAT,OLODATEROL RESPIMAT INHALATION SPRAY,NDA203108,5d9a5433-857e-44ea-b3d6-2a400ca0cef5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203108Orig1s000TOC.cfm,
2014,STRIVERDI RESPIMAT,OLODATEROL RESPIMAT INHALATION SPRAY,NDA203108,5d9a5433-857e-44ea-b3d6-2a400ca0cef5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203108Orig1s000SumR.pdf,
1991,NEUPOGEN,FILGRASTIM,BLA103353,97cc73cc-b5b7-458a-a933-77b00523e193,http://www.accessdata.fda.gov/drugsatfda_docs/bla/pre96/103353Orig1s000.pdf,
2015,DEXMEDETOMIDINE,DEXMEDETOMIDINE,NDA206628,0d2710f2-ee47-4114-ab5c-8dca74cdcb8d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206628Orig1s000TOC.cfm,
2016,N/A,N/A,NDA208551,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208551Orig1s000TOC.cfm,
2016,N/A,N/A,NDA208551,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208341Orig1s000SumR.pdf,
2019,N/A,N/A,NDA210649,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210649Orig1s000TOC.cfm,
2019,N/A,N/A,NDA210649,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/392_210649 efavirenz  medical prea.pdf,
2019,N/A,N/A,NDA210649,N/A,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/391_210649 efavirenz, lamivudine, tenofovir disoproxil fumarate clinpharm prea.pdf",
2020,DIFICID,FIDAXOMICIN,NDA213138,dd966338-c820-4270-b704-09ef75fa3ceb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213138Orig1s000TOC.cfm,
2019,CABLIVI,CAPLACIZUMAB,BLA761112,2348f06e-8004-4040-832e-e9e86a39f905,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761112Orig1s000TOC.cfm,
2021,PYLARIFY,PIFLUFOLASTAT F-18,NDA214793,a00e5cbc-4fd5-4280-82ec-cd3498df4553,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214793Orig1s000TOC.cfm,
2023,MEKINIST,TRAMETINIB,NDA217513,0002ad27-779d-42ab-83b5-bc65453412a1,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217513Orig1s000TOC.cfm,
2011,N/A,N/A,NDA022383,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000TOC.cfm,
2011,N/A,N/A,NDA022383,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000SumR.pdf,
2003,UROXATRAL,ALFUZOSIN HCL,NDA021287,9fc7f119-f36b-44cf-945d-940160f3afe3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021287_S001_UROXATRALTOC.cfml,
2003,UROXATRAL,ALFUZOSIN HCL,NDA021287,9fc7f119-f36b-44cf-945d-940160f3afe3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021287_uroxatral_toc.cfm,
2003,UROXATRAL,ALFUZOSIN HCL,NDA021287,9fc7f119-f36b-44cf-945d-940160f3afe3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21287s016_Alfuzosin_clinicalltr.pdf,
2003,UROXATRAL,ALFUZOSIN HCL,NDA021287,9fc7f119-f36b-44cf-945d-940160f3afe3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21287s016_Alfuzosin_Cllinpharmltr.pdf,
2003,UROXATRAL,ALFUZOSIN HCL,NDA021287,9fc7f119-f36b-44cf-945d-940160f3afe3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21287s016_Alfuzosin_Statisticalltr.pdf,
2003,RADIOGARDASE,PRUSSIAN BLUE INSOLUBLE CAPSULES,NDA021626,baa68c79-5f3d-468a-a510-58b9e978cd50,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-626_Radiogardase.cfm,
2006,OMNARIS,CICLESONIDE,NDA022004,15fefd46-ac7e-40d0-b635-e6c3d653c666,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022004s000TOC.cfm,
2012,REVATIO,SILDENAFIL CITRATE,NDA203109,f158fe10-d5dc-4432-b2c9-fc665401291b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203109Orig1s000SumR.pdf,
2012,REVATIO,SILDENAFIL CITRATE,NDA203109,f158fe10-d5dc-4432-b2c9-fc665401291b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/203109 sildenafil clinical both.pdf,
2012,REVATIO,SILDENAFIL CITRATE,NDA203109,f158fe10-d5dc-4432-b2c9-fc665401291b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/203109 sildenafil clinpharm both.pdf,
2012,REVATIO,SILDENAFIL CITRATE,NDA203109,f158fe10-d5dc-4432-b2c9-fc665401291b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/203109 sildenafil statistical both.pdf,
2012,REVATIO,SILDENAFIL CITRATE,NDA203109,f158fe10-d5dc-4432-b2c9-fc665401291b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203109_revatio_toc.cfm,
1991,LEUKINE,SARGRAMOSTIM,BLA103362,bb9a3820-f31a-4dd9-bef4-97094c01a398,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/103362Orig1s5240.pdf,
2019,N/A,N/A,NDA202408,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/202408Orig1s000TOC.cfm,
2015,N/A,N/A,NDA207768,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207768Orig1s000SumR.pdf,
2015,N/A,N/A,NDA207768,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207768Orig1s000TOC.cfm,
2017,RHOFADE,OXYMETAZOLINE HYDROCHLORIDE,NDA208552,e82b5788-a855-4165-a81f-7f15cb874612,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208552Orig1s000TOC.cfm,
1997,HYDROCORTISONE BUTYRATE,HYDROCORTISONE BUTYRATE,NDA020769,ddf699f4-1ae0-48c3-8d2a-56aa1a2c5bc1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020769_locoid_toc.cfm,
1998,EXCEDRIN MIGRAINE GELTABS,"ACETAMINOPHEN, ASPRIN, CAFFEINE",NDA020802,cc2f4a6f-2a27-4a60-b5ef-ae0bb0988ff8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-802s002_Excedrin.cfm,
1998,EXCEDRIN MIGRAINE GELTABS,"ACETAMINOPHEN, ASPRIN, CAFFEINE",NDA020802,cc2f4a6f-2a27-4a60-b5ef-ae0bb0988ff8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020802_s000_ExcedrinTOC.cfm,
1998,ACTONEL,RISEDRONATE SODIUM,NDA020835,24ed00e0-25e2-49a8-97fc-66c1b417dc0b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020835_S014_ACTONEL TABLETS.pdf,
1998,ACTONEL,RISEDRONATE SODIUM,NDA020835,24ed00e0-25e2-49a8-97fc-66c1b417dc0b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020835_S012_ACTONEL.pdf,
1998,ACTONEL,RISEDRONATE SODIUM,NDA020835,24ed00e0-25e2-49a8-97fc-66c1b417dc0b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20835S001_Actonel.cfm,
1998,ACTONEL,RISEDRONATE SODIUM,NDA020835,24ed00e0-25e2-49a8-97fc-66c1b417dc0b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020835_S010_ACTENOL.pdf,
1998,ACTONEL,RISEDRONATE SODIUM,NDA020835,24ed00e0-25e2-49a8-97fc-66c1b417dc0b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20835S001_Actonel.cfm,
1998,ACTONEL,RISEDRONATE SODIUM,NDA020835,24ed00e0-25e2-49a8-97fc-66c1b417dc0b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020835s035_Risedronate_Clinpharm_BPCA.pdf,
1998,ACTONEL,RISEDRONATE SODIUM,NDA020835,24ed00e0-25e2-49a8-97fc-66c1b417dc0b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020835s035_Risedronate_Statistical_BPCA.pdf,
1998,ACTONEL,RISEDRONATE SODIUM,NDA020835,24ed00e0-25e2-49a8-97fc-66c1b417dc0b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020835s035_Risedronate_Clinical_BPCA.pdf,
1998,ACTONEL,RISEDRONATE SODIUM,NDA020835,24ed00e0-25e2-49a8-97fc-66c1b417dc0b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20835_Actonel.cfm,
1998,ACTONEL,RISEDRONATE SODIUM,NDA020835,24ed00e0-25e2-49a8-97fc-66c1b417dc0b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22055_retapumulin_clinical_PREA.pdf,
1998,ACTONEL,RISEDRONATE SODIUM,NDA020835,24ed00e0-25e2-49a8-97fc-66c1b417dc0b,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22055_retapumulin_clinpharm_PREA.pdf,
1998,ACTONEL,RISEDRONATE SODIUM,NDA020835,24ed00e0-25e2-49a8-97fc-66c1b417dc0b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020835_S011_ACTONEL.pdf,
1998,ACTONEL,RISEDRONATE SODIUM,NDA020835,24ed00e0-25e2-49a8-97fc-66c1b417dc0b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20835S001_Actonel.cfm,
1998,ACTONEL,RISEDRONATE SODIUM,NDA020835,24ed00e0-25e2-49a8-97fc-66c1b417dc0b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20835S001_Actonel.cfm,
2023,TAFINLAR,DABRAFENIB,NDA217514,fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217514Orig1s000TOC.cfm,
2008,N/A,N/A,NDA022386,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022386_prandimet_toc.cfm,
2008,N/A,N/A,NDA022386,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022386s000_SumR.pdf,
1999,BUSULFEX,BUSULFAN,NDA020954,5cb9d285-1803-4a99-946a-d0b239b32df6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-954S004_Busulfex.cfm,
1999,BUSULFEX,BUSULFAN,NDA020954,5cb9d285-1803-4a99-946a-d0b239b32df6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-954s005_Busulfex.cfm,
1999,BUSULFEX,BUSULFAN,NDA020954,5cb9d285-1803-4a99-946a-d0b239b32df6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20954-S003_BUSULFEX.pdf,
1999,BUSULFEX,BUSULFAN,NDA020954,5cb9d285-1803-4a99-946a-d0b239b32df6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20954-S001_BUSULFEX.pdf,
1999,BUSULFEX,BUSULFAN,NDA020954,5cb9d285-1803-4a99-946a-d0b239b32df6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20954.cfm,
2001,TRELSTAR,TRIPTORELIN PAMOATE,NDA021288,b1b84d62-a369-a4b7-5c41-dd1f553a18f3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-288_Trelstar.cfm,
2005,N/A,N/A,NDA021627,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021627s000_NamendaTOC.cfm,
2009,SABRIL,VIGABATRIN,NDA022006,a88ac1b4-e2c9-45c0-b321-4785902172e3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022006s000TOC.cfm,
2009,SABRIL,VIGABATRIN,NDA022006,a88ac1b4-e2c9-45c0-b321-4785902172e3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022006s000_SumR.pdf,
2004,ZYLET,LOTEPREDNOL ETABONATE AND TOBRAMYCIN,NDA050804,3dd9b060-5355-404d-bdf1-09ee8b52a9f5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/50804_ZyletTOC.cfm,
2004,ZYLET,LOTEPREDNOL ETABONATE AND TOBRAMYCIN,NDA050804,3dd9b060-5355-404d-bdf1-09ee8b52a9f5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/50804 lo-tob clinical Prea.pdf,
2004,ZYLET,LOTEPREDNOL ETABONATE AND TOBRAMYCIN,NDA050804,3dd9b060-5355-404d-bdf1-09ee8b52a9f5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/50804 .lo-tob clinical2 prea.pdf,
2004,ZYLET,LOTEPREDNOL ETABONATE AND TOBRAMYCIN,NDA050804,3dd9b060-5355-404d-bdf1-09ee8b52a9f5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/050804-Loteprednol-etabonate-and-Tobramycin-Clinical-PREA 3.pdf,
1971,N/A,N/A,NDA015923,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/015923_S072_HALDOL_TABLETS_AP.pdf,
1996,N/A,N/A,BLA103608,N/A,https://web.archive.org/web/20170118085129/http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080734.htm,
2011,NITHIODOTE,SODIUM NITRITE AND SODIUM THIOSULFATE,NDA201444,ff4941b3-9901-4aab-adcf-c5327bede34e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201444_nithiodote_toc.cfm,
2011,NITHIODOTE,SODIUM NITRITE AND SODIUM THIOSULFATE,NDA201444,ff4941b3-9901-4aab-adcf-c5327bede34e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201444Orig1s000SumR.pdf,
2015,XURIDEN,URIDINE TRIACETATE,NDA208169,88ca4d2b-3905-474b-9fd6-c81474f2fb4b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208169Orig1s000SumR.pdf,
2015,XURIDEN,URIDINE TRIACETATE,NDA208169,88ca4d2b-3905-474b-9fd6-c81474f2fb4b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208169Orig1s000TOC.cfm,
2017,LYNPARZA,OLAPARIB,NDA208558,741ff3e3-dc1a-45a6-84e5-2481b27131aa,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/208558Orig1s025.pdf,
2017,LYNPARZA,OLAPARIB,NDA208558,741ff3e3-dc1a-45a6-84e5-2481b27131aa,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208558_toc.cfm,
1996,CEREBYX,FOSPHENYTOIN SODIUM,NDA020450,de5a6711-4abb-4c3d-a18b-266b094ace11,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020450Orig1s000rev.pdf,
1996,CEREBYX,FOSPHENYTOIN SODIUM,NDA020450,de5a6711-4abb-4c3d-a18b-266b094ace11,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020450_s004TOC.cfm,
1996,CEREBYX,FOSPHENYTOIN SODIUM,NDA020450,de5a6711-4abb-4c3d-a18b-266b094ace11,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020450_s005TOC.cfm,
1996,CEREBYX,FOSPHENYTOIN SODIUM,NDA020450,de5a6711-4abb-4c3d-a18b-266b094ace11,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020450s003 fosphenytoin CDTL clinical bpca.pdf,
1996,CEREBYX,FOSPHENYTOIN SODIUM,NDA020450,de5a6711-4abb-4c3d-a18b-266b094ace11,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020450s003 fosphenytoin clinpharm bpca.pdf,
1996,CEREBYX,FOSPHENYTOIN SODIUM,NDA020450,de5a6711-4abb-4c3d-a18b-266b094ace11,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020450s003 fosphenytoin clinical bpca.pdf,
1996,CEREBYX,FOSPHENYTOIN SODIUM,NDA020450,de5a6711-4abb-4c3d-a18b-266b094ace11,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020450a_s001.pdf,
2018,DAURISMO,GLASDEGIB,NDA210656,204a6f7e-c9a4-472b-abd2-9527bda64d17,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210656Orig1s000TOC.cfm,
2020,FENSOLVI,LEUPROLIDE ACETATE,NDA213150,dfb6e01c-f138-471d-bf5b-2be38247e3f0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213150Orig1s000TOC.cfm,
2025,JOURNAVX,SUZETRIGINE,NDA219209,f0976da4-1d20-4517-945c-b60ed2f41c12,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219209Orig1s000TOC.cfm,
2020,VYEPTI,EPTINEZUMAB-JJMR,BLA761119,79065861-6aa5-4d1f-829f-3a6471286b36,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761119Orig1s000TOC.cfm,
1995,N/A,N/A,NDA020518,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/019655s032_019910s021_020518s004_Retrovir.cfm,
2023,AGAMREE,VAMOROLONE,NDA215239,fb376f09-cf9c-42b5-b4dd-02d5bcd73211,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215239Orig1s000TOC.cfm,
2014,N/A,N/A,NDA022396,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022396Orig1s000TOC.cfm,
1998,TIMOLOL GFS,TIMOLOL MALEATE,NDA020963,72b0d0ec-832a-4c25-b845-2537ab506354,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020963_timolol.cfm,
1998,TIMOLOL GFS,TIMOLOL MALEATE,NDA020963,72b0d0ec-832a-4c25-b845-2537ab506354,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/40_19845 timolol clinical bpca.pdf,
2003,N/A,N/A,NDA021299,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-299_Paroxetine.cfm,
2003,N/A,N/A,NDA021299,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021299_S001_PEXEVA_TABLETS.pdf,
2004,OMEPRAZOLE AND SODIUM BICARBONATE,"OMEPRAZOLE, SODIUM BICARBONATE",NDA021636,c26b6893-8264-4d4a-ac7e-1ddda933451e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021636s000_ZegeridTOC.cfm,
2006,N/A,N/A,NDA022011,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/22011s000TOC.cfm,
2013,PHENYLEPHRINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE,NDA203510,dcd09e27-93ec-463f-8062-a7dad96c4d0f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/203510 phenylephrine clinical prea.pdf,
2013,PHENYLEPHRINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE,NDA203510,dcd09e27-93ec-463f-8062-a7dad96c4d0f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/203510 phenylephrine clinpharm prea.pdf,
2013,PHENYLEPHRINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE,NDA203510,dcd09e27-93ec-463f-8062-a7dad96c4d0f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/203510 phenylephrine statistical prea.pdf,
2013,PHENYLEPHRINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE,NDA203510,dcd09e27-93ec-463f-8062-a7dad96c4d0f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203510_phenylephrine_toc.cfm,
2013,PHENYLEPHRINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE,NDA203510,dcd09e27-93ec-463f-8062-a7dad96c4d0f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203510Orig1s000SumR.pdf,
1993,BETASERON,INTERFERON BETA-1B,BLA103471,66311f74-0472-4fa3-848a-06002ca0def5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/103471Orig1s5186.pdf,
1993,BETASERON,INTERFERON BETA-1B,BLA103471,66311f74-0472-4fa3-848a-06002ca0def5,https://web.archive.org/web/20170118085127/http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080486.htm,
1993,BETASERON,INTERFERON BETA-1B,BLA103471,66311f74-0472-4fa3-848a-06002ca0def5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/103471s0000TOC.cfm,
1993,BETASERON,INTERFERON BETA-1B,BLA103471,66311f74-0472-4fa3-848a-06002ca0def5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/103471Orig1s5189.pdf,
2012,VASCEPA,ICOSAPENT ETHYL,NDA202057,9c1a2828-1583-4414-ab22-a60480e8e508,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202057_vascepa_toc.cfm,
2012,VASCEPA,ICOSAPENT ETHYL,NDA202057,9c1a2828-1583-4414-ab22-a60480e8e508,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202057Orig1s000SumR.pdf,
1989,N/A,N/A,NDA019805,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019085Orig1s000rev.pdf,
2020,TRODELVY,SACITUZUMAB GOVITECAN,BLA761115,57a597d2-03f0-472e-b148-016d7169169d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761115Orig1s000TOC.cfm,
2022,LYTGOBI,FUTIBATINIB,NDA214801,0b1332a1-0581-4707-9bf6-1eccfa39bef4,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000TOC.cfm,
1997,CLINIMIX E,"LEUCINE, PHENYLALANINE, LYSINE, METHIONINE, ISOLEUCINE, VALINE, HISTIDINE, THREONINE, TRYPTOPHAN, ALANINE, GLYCINE, ARGININE, PROLINE, SERINE, TYROSINE, DIBASIC POTASSIUM PHOSPHATE, MAGNESIUM CHLORIDE, SODIUM CHLORIDE, CALCIUM CHLORIDE, DEXTROSE",NDA020678,8469d6fb-d6ef-476f-8cc3-0905192de0a8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020678ap.pdf,
1997,CLINIMIX E,"LEUCINE, PHENYLALANINE, LYSINE, METHIONINE, ISOLEUCINE, VALINE, HISTIDINE, THREONINE, TRYPTOPHAN, ALANINE, GLYCINE, ARGININE, PROLINE, SERINE, TYROSINE, DIBASIC POTASSIUM PHOSPHATE, MAGNESIUM CHLORIDE, SODIUM CHLORIDE, CALCIUM CHLORIDE, DEXTROSE",NDA020678,8469d6fb-d6ef-476f-8cc3-0905192de0a8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-678s003_Clinimax%20E.cfm,
2022,N/A,N/A,NDA022388,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/022388Orig1s000TOC.cfm,
2000,PEPCID COMPLETE,"FAMOTIDINE, CALCIUM CARBONATE, MAGNESIUM HYDROXIDE CHEWABLE TABLET",NDA020958,d08984b8-ce03-9e95-e053-2995a90ae6f0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-958_Pepcid.cfm,
2000,PEPCID COMPLETE,"FAMOTIDINE, CALCIUM CARBONATE, MAGNESIUM HYDROXIDE CHEWABLE TABLET",NDA020958,d08984b8-ce03-9e95-e053-2995a90ae6f0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/020958Orig1s015.pdf,
2000,PEPCID COMPLETE,"FAMOTIDINE, CALCIUM CARBONATE, MAGNESIUM HYDROXIDE CHEWABLE TABLET",NDA020958,d08984b8-ce03-9e95-e053-2995a90ae6f0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020958_S002_PEPCIDTOC.cfm,
2001,TRACLEER,BOSENTAN,NDA021290,749e42fb-2fe0-45dd-9268-b43bb3f4081c,http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021290s012SUMR.pdf,
2001,TRACLEER,BOSENTAN,NDA021290,749e42fb-2fe0-45dd-9268-b43bb3f4081c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-290_Tracleer.cfm,
2001,TRACLEER,BOSENTAN,NDA021290,749e42fb-2fe0-45dd-9268-b43bb3f4081c,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/021290Orig1s043.pdf,
2001,TRACLEER,BOSENTAN,NDA021290,749e42fb-2fe0-45dd-9268-b43bb3f4081c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-290S001_Tracleer.cfm,
2003,VFEND,VORICONAZOLE,NDA021630,ce3ef5cf-3087-4d92-9d94-9eb8287228db,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021630Orig1s003.pdf,
2003,VFEND,VORICONAZOLE,NDA021630,ce3ef5cf-3087-4d92-9d94-9eb8287228db,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021266s005s006,021267s005s006,021630s001_VfendTOC.cfm",
2003,VFEND,VORICONAZOLE,NDA021630,ce3ef5cf-3087-4d92-9d94-9eb8287228db,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021630s000_VfendTOC.cfm,
2008,N/A,N/A,NDA022008,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022008_requip_toc.cfm,
2006,N/A,N/A,NDA050807,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/050807s000TOC.cfm,
2006,N/A,N/A,NDA050807,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/050807s000_SumR.pdf,
1988,OPTIRAY 320,IOVERSOL,NDA019710,549d38db-d4ed-4708-8f76-7cdaa157063f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019710a_so21_052397.pdf,
1996,N/A,N/A,BLA019764,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/019764_s011_SAIZEN INJECTION.pdf,
2020,EVRYSDI,RISDIPLAM,NDA213535,eceb9a99-7191-4be5-87c3-0102707cf98e,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213535Orig1s000TOC.cfm,
2019,KATERZIA,AMLODIPINE,NDA211340,df673a4d-acb8-444c-a472-c87ab8cbd366,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211340Orig1s000TOC.cfm,
2019,KATERZIA,AMLODIPINE,NDA211340,df673a4d-acb8-444c-a472-c87ab8cbd366,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/463_211340 amlodipine CDTL prea.pdf,
2019,KATERZIA,AMLODIPINE,NDA211340,df673a4d-acb8-444c-a472-c87ab8cbd366,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/464_211340 amlodipine clinpharm prea.pdf,
2019,DAYVIGO,LEMBOREXANT,NDA212028,7074cb65-77b3-45d2-8e8d-da8dc0f70bfd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000TOC.cfm,
2018,ELZONRIS,TAGRAXOFUSP,BLA761116,80eb1080-fe20-4af0-b2a5-a67999923fa8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761116Orig1s000TOC.cfm,
1997,SEROQUEL,QUETIAPINE,NDA020639,8ae62aaf-f8c5-417f-baac-0098369ca322,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020639_seroquel_toc.cfm,
1997,SEROQUEL,QUETIAPINE,NDA020639,8ae62aaf-f8c5-417f-baac-0098369ca322,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/020639Orig1s046.pdf,
1997,SEROQUEL,QUETIAPINE,NDA020639,8ae62aaf-f8c5-417f-baac-0098369ca322,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20639_seroquel_toc.cfm,
1997,SEROQUEL,QUETIAPINE,NDA020639,8ae62aaf-f8c5-417f-baac-0098369ca322,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020639_S016&S017_SEROQUEL TABLETS.pdf,
1997,SEROQUEL,QUETIAPINE,NDA020639,8ae62aaf-f8c5-417f-baac-0098369ca322,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020639_quetiapine fumarate_seroquel CDTL review prea.pdf,
1997,SEROQUEL,QUETIAPINE,NDA020639,8ae62aaf-f8c5-417f-baac-0098369ca322,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020639_quetiapine fumarate_seroquel clinical prea.pdf,
1997,SEROQUEL,QUETIAPINE,NDA020639,8ae62aaf-f8c5-417f-baac-0098369ca322,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020639_quetiapine fumarate_seroquel clinpharm prea.pdf,
1997,SEROQUEL,QUETIAPINE,NDA020639,8ae62aaf-f8c5-417f-baac-0098369ca322,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020639_quetiapine fumarate_seroquel statistical prea.pdf,
1997,SEROQUEL,QUETIAPINE,NDA020639,8ae62aaf-f8c5-417f-baac-0098369ca322,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020639_seroquel_toc.cfm,
1997,SEROQUEL,QUETIAPINE,NDA020639,8ae62aaf-f8c5-417f-baac-0098369ca322,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020639_quetiapine fumarate_seroquel statistical prea.pdf,
1997,SEROQUEL,QUETIAPINE,NDA020639,8ae62aaf-f8c5-417f-baac-0098369ca322,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020639_quetiapine fumarate_seroquel clinical prea.pdf,
1997,SEROQUEL,QUETIAPINE,NDA020639,8ae62aaf-f8c5-417f-baac-0098369ca322,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020639_quetiapine fumarate_seroquel CDTL review prea.pdf,
1997,SEROQUEL,QUETIAPINE,NDA020639,8ae62aaf-f8c5-417f-baac-0098369ca322,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020639_quetiapine fumarate_seroquel clinpharm prea.pdf,
1997,SEROQUEL,QUETIAPINE,NDA020639,8ae62aaf-f8c5-417f-baac-0098369ca322,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/020639s037.pdf,
1997,SEROQUEL,QUETIAPINE,NDA020639,8ae62aaf-f8c5-417f-baac-0098369ca322,http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/020639se1-037_SUMR.pdf,
1997,SEROQUEL,QUETIAPINE,NDA020639,8ae62aaf-f8c5-417f-baac-0098369ca322,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020639_S016&S017_SEROQUEL TABLETS.pdf,
2009,ISTODAX,ROMIDEPSIN,NDA022393,03b39d40-90fe-11df-9de6-0002a5d5c51b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022393s000TOC.cfm,
2009,ISTODAX,ROMIDEPSIN,NDA022393,03b39d40-90fe-11df-9de6-0002a5d5c51b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022393s000_SumR.pdf,
2002,EUTHYROX,LEVOTHYROXINE SODIUM,NDA021292,bc3c6830-ba68-4ba3-9896-a12d0ad0b275,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-292_Novothyrox.cfm,
2006,ERAXIS,ANIDULAFUNGIN,NDA021632,a88d9010-55fb-4a02-baff-042cd27688ea,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021632_021948_EraxisTOC.cfm,
2008,N/A,N/A,NDA022009,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022009_Ecamsule-Anthelios_Clinical_PREA_june.pdf,
2008,N/A,N/A,NDA022009,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022009_Ecamsule-Anthelios_ClinPharm_PREA_june.pdf,
2008,N/A,N/A,NDA022009,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022009_avobenzone_ecamsule_octocrylene_titanium_dioxide_cream_toc.cfm,
2008,N/A,N/A,NDA022009,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022009s000_SumR.pdf,
1994,N/A,N/A,BLA103575,N/A,https://web.archive.org/web/20170113111532/http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm093336.htm,
1994,N/A,N/A,BLA103575,N/A,https://web.archive.org/web/20170113111532/http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm093336.htm,
1989,DIPRIVAN,PROPOFOL,NDA019627,e3105799-a4b6-f3f4-e6e2-b2b29bbdb538,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/019627Orig1s060.pdf,
1989,DIPRIVAN,PROPOFOL,NDA019627,e3105799-a4b6-f3f4-e6e2-b2b29bbdb538,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019627_S002_Diprivan.pdf,
1989,DIPRIVAN,PROPOFOL,NDA019627,e3105799-a4b6-f3f4-e6e2-b2b29bbdb538,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/019627_S045_DIPRIVAN.pdf,
1989,DIPRIVAN,PROPOFOL,NDA019627,e3105799-a4b6-f3f4-e6e2-b2b29bbdb538,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/019627_S035_DiprivanTOC.cfm,
1989,DIPRIVAN,PROPOFOL,NDA019627,e3105799-a4b6-f3f4-e6e2-b2b29bbdb538,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/019627_S027_Diprivan_APPROVAL_PACKAGE.pdf,
2021,N/A,N/A,NDA213536,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213536Orig1s000TOC.cfm,
2020,ZOKINVY,LONAFARNIB,NDA213969,97391d0c-943e-4c5a-8423-68e163aa7f50,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213969Orig1s000TOC.cfm,
2018,PERSERIS,RISPERIDONE,NDA210655,a4f21b1a-5691-4b14-a56d-651962d06f39,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210655Orig1s000TOC.cfm,
2025,VANRAFIA,ATRASENTAN,NDA219208,9a7e7f85-bfd0-44a0-beda-3bcfa8215c64,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219208Orig1s000TOC.cfm,
2019,ABRILADA,ADALIMUMAB-AFZB,BLA761118,81a33cfa-262f-4432-a05d-7dd260928437,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761118Orig1s000TOC.cfm,
2009,QUTENZA,CAPSAICIN,NDA022395,3ffbbcb0-ad93-4f15-bb38-5da76a71c735,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022395s000Sumr.pdf,
2009,QUTENZA,CAPSAICIN,NDA022395,3ffbbcb0-ad93-4f15-bb38-5da76a71c735,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022395_qutenza_toc.cfm,
2004,N/A,N/A,NDA021633,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021633s000_FemtraceTOC.cfm,
1984,CATAPRES-TTS-1,CLONIDINE TRANSDERMAL SYSTEM,NDA018891,d4a55825-7041-42f4-b3b2-dd7a25dbe793,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/018891-S15_Catapres-TTS_toc.cfm,
2011,ONFI,CLOBAZAM,NDA202067,de03bd69-2dca-459c-93b4-541fd3e9571c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000TOC.cfm,
2019,CORLANOR,IVABRADINE,NDA209964,92018a65-38f6-45f7-91d4-a34921b81d0d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209964Orig1s000TOC.cfm,
2019,CORLANOR,IVABRADINE,NDA209964,92018a65-38f6-45f7-91d4-a34921b81d0d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/209964 ivabradine CDTL bpca.pdf,
2019,CORLANOR,IVABRADINE,NDA209964,92018a65-38f6-45f7-91d4-a34921b81d0d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/209964 ivabradine clinical bpca.pdf,
2019,CORLANOR,IVABRADINE,NDA209964,92018a65-38f6-45f7-91d4-a34921b81d0d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/209964 ivabradine clinpharm bpca.pdf,
2015,PHOXILLUM BK4/2.5,"CALCIUM CHLORIDE, MAGNESIUM CHLORIDE, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE, AND SODIUM PHOSPHATE DIBASIC DIHYDRATE",NDA207026,7f675fee-8940-4ece-bb0c-75ac79d8708c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207026Orig1s000TOC.cfm,
2015,PHOXILLUM BK4/2.5,"CALCIUM CHLORIDE, MAGNESIUM CHLORIDE, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE, AND SODIUM PHOSPHATE DIBASIC DIHYDRATE",NDA207026,7f675fee-8940-4ece-bb0c-75ac79d8708c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207026Orig1s000SumR.pdf,
2017,VORICONAZOLE,VORICONAZOLE,NDA208562,9ec6eda2-2f15-423b-9ec6-819379a426e1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208562Orig1s000TOC.cfm,
1992,SUPRANE,DESFLURANE,NDA020118,efbb228b-7b38-4176-8bae-826103178c35,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/desflurane_Suprane-MedRev-20118s012.pdf,
1992,SUPRANE,DESFLURANE,NDA020118,efbb228b-7b38-4176-8bae-826103178c35,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20118Orig1s007.pdf,
1992,SUPRANE,DESFLURANE,NDA020118,efbb228b-7b38-4176-8bae-826103178c35,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20118Orig1s008.pdf,
1993,N/A,N/A,NDA020184,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020184_S009_ACEON.pdf,
1993,N/A,N/A,NDA020184,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020184ap.pdf,
2019,BEOVU,BROLUCIZUMAB,BLA761125,5d1dc1fa-a2d3-46ed-9e9a-c1a036590d3d,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761125_Orig1_toc.cfm,
2019,BEOVU,BROLUCIZUMAB,BLA761125,5d1dc1fa-a2d3-46ed-9e9a-c1a036590d3d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761125Orig1s004.pdf,
2009,CODEINE SULFATE,CODEINE SULFATE,NDA022402,010905f9-3bcb-4b50-9fe8-a3ad0010f14c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022402_codeine_sulfate_toc.cfm,
2009,CODEINE SULFATE,CODEINE SULFATE,NDA022402,010905f9-3bcb-4b50-9fe8-a3ad0010f14c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022402s000_SumR.pdf,
1999,N/A,N/A,NDA020968,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20968_Monistat.cfm,
2001,PIMECROLIMUS,PIMECROLIMUS,NDA021302,6601e43e-ce7d-446a-8568-8e7b24b86f06,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-302_Elidel.cfm,
2005,NASCOBAL,CYANOCOBALAMIN,NDA021642,697e0e52-c01b-4b53-9994-f79c46eb6b4f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021642s000_NascobalTOC.cfm,
2005,NASCOBAL,CYANOCOBALAMIN,NDA021642,697e0e52-c01b-4b53-9994-f79c46eb6b4f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/021642Orig1s020.pdf,
2007,EVAMIST,ESTRADIOL,NDA022014,9a0aa631-133d-406b-9d32-8a1a99af4e50,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022014_evamist_toc.cfm,
2007,EVAMIST,ESTRADIOL,NDA022014,9a0aa631-133d-406b-9d32-8a1a99af4e50,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022014s000_SumR.pdf,
2008,N/A,N/A,NDA050813,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/050813_moxatag_toc.cfm,
2008,N/A,N/A,NDA050813,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/050813s000_Amoxicillin_Clinical_PREA.pdf,
2008,N/A,N/A,NDA050813,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/050813s000_Amoxicillin_Clinpharm_PREA.pdf,
2008,N/A,N/A,NDA050813,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/050813s000_Amoxicillin_Statistics_PREA.pdf,
2008,N/A,N/A,NDA050813,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/050813s000sumr.pdf,
1993,CARAFATE,SUCRALFATE,NDA019183,0fb67b1c-b4c0-46f2-8a81-df1510e006aa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019183_biopharm.pdf,
1996,AVONEX,INTERFERON BETA-1A,BLA103628,d70a39cc-de15-4c12-a1ec-8063b69ea0e1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/103628Orig1s000rev.pdf,
1996,AVONEX,INTERFERON BETA-1A,BLA103628,d70a39cc-de15-4c12-a1ec-8063b69ea0e1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/103628s5021TOC.cfm,
2014,VAZCULEP,PHENYLEPHRINE HYDROCHLORIDE,NDA204300,c73fc68d-6a3d-4d99-8869-cc64d7c6bf94,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204300Orig1s000TOC.cfm,
2014,VAZCULEP,PHENYLEPHRINE HYDROCHLORIDE,NDA204300,c73fc68d-6a3d-4d99-8869-cc64d7c6bf94,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204300Orig1s000SumR.pdf,
2013,N/A,N/A,NDA204654,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204654Orig1s000TOC.cfm,
2013,N/A,N/A,NDA204654,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204654Orig1s000SumR.pdf,
2021,DAPTOMYCIN,DAPTOMYCIN,NDA210282,1957b6ce-7382-4a7b-bf02-3595948d09c6,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/210282Orig1s000TOC.cfm,
2024,ORLYNVAH,SULOPENEM ETZADROXIL AND PROBENECID,NDA213972,24c451c0-4cfb-37f3-e063-6394a90a895e,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/213972Orig1s000TOC.cfm,
2021,ARGATROBAN,ARGATROBAN,NDA212035,46cdf9e6-839c-49c8-9ee1-c30cfdd9368d,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212035Orig1s000TOC.cfm,
2024,ZUNVEYL,BENZGALANTAMINE,NDA218549,af47bf67-1f07-4650-8064-24c38afc4656,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/218549Orig1s000TOC.cfm,
2019,POLIVY,POLATUZUMAB VEDOTIN,BLA761121,20a16ab2-f338-4abb-9dcd-254bd949a2bc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761121Orig1s000TOC.cfm,
2019,POLIVY,POLATUZUMAB VEDOTIN,BLA761121,20a16ab2-f338-4abb-9dcd-254bd949a2bc,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761121Orig1s008TOC.cfm,
2023,DAYBUE,TROFINETIDE,NDA217026,67e6f2d9-21f6-466f-9def-826c6a4b8257,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217026Orig1s000TOC.cfm,
1999,LEVULAN KERASTICK,AMINOLEVULINIC ACID HYDROCHLORIDE,NDA020965,e45cc371-9ebc-4904-12bc-65cb4e2817ad,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-965_Levulan.cfm,
2004,N/A,N/A,NDA021300,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_ClarinexTOC.cfm,
2004,VITRASE,"HYALURONIDASE, OVINE",BLA021640,21fbd12e-4a12-4ad1-ad01-964cd5ec9996,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-640_Vitrase.cfm,
2006,COREG CR,CARVEDILOL PHOSPHATE,NDA022012,d3625d78-6eb6-41fe-8f6f-664965c104c4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022012s000TOC.cfm,
2006,N/A,N/A,NDA050808,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/050808s000TOC.cfm,
2006,N/A,N/A,NDA050808,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/050808Orig1s014.pdf,
2011,TOPOTECAN,TOPOTECAN,NDA200582,1d4e1cce-c57e-4a8b-be96-f95a2778e221,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/200582_topotecan_toc.cfm,
2011,TOPOTECAN,TOPOTECAN,NDA200582,1d4e1cce-c57e-4a8b-be96-f95a2778e221,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/200582Orig1s000SumR.pdf,
2014,NEXIUM 24HR,ESOMEPRAZOLE MAGNESIUM,NDA204655,4513934d-0cf0-40fc-a348-b4e75a33b094,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204655Orig1s000TOC.cfm,
2014,NEXIUM 24HR,ESOMEPRAZOLE MAGNESIUM,NDA204655,4513934d-0cf0-40fc-a348-b4e75a33b094,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204655Orig1s000SumR.pdf,
2020,MONOFERRIC,FERRIC DERISOMALTOSE,NDA208171,55859d2d-0456-4fa9-b41f-f535accc97db,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/208171Orig1s000TOC.cfm,
2017,TRACLEER,BOSENTAN,NDA209279,749e42fb-2fe0-45dd-9268-b43bb3f4081c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209279Orig1s000TOC.cfm,
2017,TRACLEER,BOSENTAN,NDA209279,749e42fb-2fe0-45dd-9268-b43bb3f4081c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209279Orig1s000TOC.cfm,
2020,QINLOCK,RIPRETINIB,NDA213973,9f18e462-03dd-4296-a02a-a0577e3ee78d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213973Orig1s000TOC.cfm,
2023,ROZLYTREK,ENTRECTINIB,NDA218550,c7c71b0c-2549-4495-86b6-c2807fa54908,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/218550Orig1s000TOC.cfm,
2019,NUCALA,MEPOLIZUMAB,BLA761122,fefb887c-e4ac-431e-8893-e9d1a5a63fea,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761122Orig1s000TOC.cfm,
2019,NUCALA,MEPOLIZUMAB,BLA761122,fefb887c-e4ac-431e-8893-e9d1a5a63fea,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/447_761122_mepolizumab unireview prea.pdf,
2023,VEOZAH,FEZOLINETANT,NDA216578,cae9f798-24f9-4580-a4fc-e6c710cbda3c,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216578Orig1s000TOC.cfm,
2011,HORIZANT,GABAPENTIN ENACARBIL,NDA022399,4c486fc7-c8c4-4c6c-b30c-366dabaeaadd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022399Orig1s000SumR.pdf,
2011,HORIZANT,GABAPENTIN ENACARBIL,NDA022399,4c486fc7-c8c4-4c6c-b30c-366dabaeaadd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022399Orig1s000TOC.cfm,
2011,HORIZANT,GABAPENTIN ENACARBIL,NDA022399,4c486fc7-c8c4-4c6c-b30c-366dabaeaadd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022399Orig1s005.pdf,
2011,HORIZANT,GABAPENTIN ENACARBIL,NDA022399,4c486fc7-c8c4-4c6c-b30c-366dabaeaadd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022399Orig1s003.pdf,
2001,LEVOXYL,LEVOTHYROXINE SODIUM,NDA021301,758588c3-c63e-491b-0aa2-4f50d80cb174,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021301_s028_levoxyl tablets.pdf,
2001,LEVOXYL,LEVOTHYROXINE SODIUM,NDA021301,758588c3-c63e-491b-0aa2-4f50d80cb174,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-301_Levoxyl.cfm,
1997,REGRANEX GEL 0.01%,BECAPLERMIN GEL 0.01%,BLA103691,377b3021-13d7-96d5-e063-6394a90a8ca3,https://web.archive.org/web/20170113111514/http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080740.htm,
1997,REGRANEX GEL 0.01%,BECAPLERMIN GEL 0.01%,BLA103691,377b3021-13d7-96d5-e063-6394a90a8ca3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/103691Orig1s5015Approv.pdf,
1984,MOTRIN IB,IBUPROFEN,NDA019012,5715910e-33be-49bd-8a1f-eeb46320e28d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/019012Orig1s053.pdf,
1984,MOTRIN IB,IBUPROFEN,NDA019012,5715910e-33be-49bd-8a1f-eeb46320e28d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/019012Orig1s052.pdf,
1984,MOTRIN IB,IBUPROFEN,NDA019012,5715910e-33be-49bd-8a1f-eeb46320e28d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/19-012S016.cfm,
2017,COCAINE HYDROCHLORIDE,COCAINE HYDROCHLORIDE,NDA209963,b555c752-eae8-4d17-bb35-813ba9805448,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000TOC.cfm,
2018,TOLSURA,ITRACONAZOLE,NDA208901,306352d1-9d5a-49ad-b72d-893b99546861,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208901Orig1s000TOC.cfm,
2024,EOHILIA,BUDESONIDE,NDA213976,56f2023a-69b2-4470-b4ad-af7ec1be527a,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/213976Orig1s000TOC.cfm,
2019,ELCYS,CYSTEINE HYDROCHLORIDE,NDA210660,9a52ae2f-1cea-4ad5-a074-66bbf06578d3,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210660Orig1s000TOC.cfm,
2021,SAPHNELO,ANIFROLUMAB-FNIA,BLA761123,d6203302-2128-41a7-b0b4-0e6c0704d4dc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761123Orig1s000TOC.cfm,
2025,N/A,N/A,NDA215244,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/215244Orig1s000TOC.cfm,
2023,N/A,N/A,NDA216579,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/216579Orig1s000TOC.cfm,
2009,N/A,N/A,NDA022401,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022401_twynsta_toc.cfm,
2009,N/A,N/A,NDA022401,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/22401s000sumr.pdf,
2006,AZILECT,RASAGILINE MESYLATE,NDA021641,a40d0e73-3f9f-4b01-979d-402c9cdaeb60,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021641S008TOC.cfm,
2006,AZILECT,RASAGILINE MESYLATE,NDA021641,a40d0e73-3f9f-4b01-979d-402c9cdaeb60,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021641S008_SumR.pdf,
2006,AZILECT,RASAGILINE MESYLATE,NDA021641,a40d0e73-3f9f-4b01-979d-402c9cdaeb60,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021641s000_AzilectTOC.cfm,
2007,N/A,N/A,NDA022013,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022013_oluxe_toc.cfm,
2007,AZASITE,AZITHROMYCIN MONOHYDRATE,NDA050810,0c5d6f5e-18ea-436f-8c62-bbaf66effe3d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/050810Orig1s012.pdf,
2007,AZASITE,AZITHROMYCIN MONOHYDRATE,NDA050810,0c5d6f5e-18ea-436f-8c62-bbaf66effe3d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/050810_azasite_toc.cfm,
1998,SYNAGIS,PALIVIZUMAB,BLA103770,3a0096c7-8139-44cd-bba4-520ab05c2cb2,http://www.accessdata.fda.gov/drugsatfda_docs/bla/2003/103770Orig1s5033.pdf,
1998,SYNAGIS,PALIVIZUMAB,BLA103770,3a0096c7-8139-44cd-bba4-520ab05c2cb2,https://web.archive.org/web/20160723194308/http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm093366.htm,
1998,SYNAGIS,PALIVIZUMAB,BLA103770,3a0096c7-8139-44cd-bba4-520ab05c2cb2,http://www.accessdata.fda.gov/drugsatfda_docs/bla/2004/103770Orig1s5059.pdf,
1994,TYLENOL 8 HR ARTHRITIS PAIN,ACETAMINOPHEN,NDA019872,3af22fc8-e4e0-4863-8696-6bc1257047cb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/019872Orig1s006.pdf,
1994,TYLENOL 8 HR ARTHRITIS PAIN,ACETAMINOPHEN,NDA019872,3af22fc8-e4e0-4863-8696-6bc1257047cb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/019872Orig1_s029.pdf,
1994,TYLENOL 8 HR ARTHRITIS PAIN,ACETAMINOPHEN,NDA019872,3af22fc8-e4e0-4863-8696-6bc1257047cb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/019872Orig1s009.pdf,
2019,ADAKVEO,CRIZANLIZUMAB,BLA761128,b2b7f8b4-fe9a-4a86-8129-9e43f99a20c6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761128Orig1s000TOC.cfm,
1997,N/A,N/A,NDA020710,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020710Orig1s011.pdf,
1997,N/A,N/A,NDA020710,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020710_S004_PAXIL_TABLETS.pdf,
1997,N/A,N/A,NDA020710,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020710_S002_PAXIL_TABLETS.pdf,
1997,N/A,N/A,NDA020710,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020710Orig1s007.pdf,
1997,N/A,N/A,NDA020710,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020710Orig1s010.pdf,
1997,N/A,N/A,NDA020710,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/1997/020710_S001_PAXIL_TABLETS.pdf,
2013,N/A,N/A,NDA022407,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022407_vibativ_toc.cfm,
2013,N/A,N/A,NDA022407,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022407Orig1s000SumR.pdf,
1999,ACIPHEX,RABEPRAZOLE SODIUM,NDA020973,1eb38279-0237-4967-be7a-c53a826c1138,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20973_stat.pdf,
1999,ACIPHEX,RABEPRAZOLE SODIUM,NDA020973,1eb38279-0237-4967-be7a-c53a826c1138,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20973_clinpharm_review.pdf,
1999,ACIPHEX,RABEPRAZOLE SODIUM,NDA020973,1eb38279-0237-4967-be7a-c53a826c1138,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20973_Aciphex.cfm,
1999,ACIPHEX,RABEPRAZOLE SODIUM,NDA020973,1eb38279-0237-4967-be7a-c53a826c1138,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020973s022_Rabeprazole_Clinical_PREA.pdf.pdf,
1999,ACIPHEX,RABEPRAZOLE SODIUM,NDA020973,1eb38279-0237-4967-be7a-c53a826c1138,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020973s022_Rabeprazole_Clinpharm_PREA.pdf,
1999,ACIPHEX,RABEPRAZOLE SODIUM,NDA020973,1eb38279-0237-4967-be7a-c53a826c1138,http://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/020973se022_SUMR.pdf,
1999,ACIPHEX,RABEPRAZOLE SODIUM,NDA020973,1eb38279-0237-4967-be7a-c53a826c1138,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020973Orig1s009.pdf,
1999,ACIPHEX,RABEPRAZOLE SODIUM,NDA020973,1eb38279-0237-4967-be7a-c53a826c1138,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021456_aciphex.cfm,
1999,ACIPHEX,RABEPRAZOLE SODIUM,NDA020973,1eb38279-0237-4967-be7a-c53a826c1138,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020973_S008_ACIPHEX_DELAYED_RELEASE_TABS.pdf,
2010,BUTRANS,BUPRENORPHINE,NDA021306,794aa355-66de-41b8-aedf-f2c40f6bc664,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/193_21306S27 buprenorphine clinical prea.pdf,
2010,BUTRANS,BUPRENORPHINE,NDA021306,794aa355-66de-41b8-aedf-f2c40f6bc664,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/194_21306S27 buprenorphine clinpharm prea.pdf,
2010,BUTRANS,BUPRENORPHINE,NDA021306,794aa355-66de-41b8-aedf-f2c40f6bc664,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021306_butrans_toc.cfm,
2010,BUTRANS,BUPRENORPHINE,NDA021306,794aa355-66de-41b8-aedf-f2c40f6bc664,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021306Orig1s000SumR.pdf,
2004,DIGOXIN,DIGOXIN,NDA021648,1b7e5c6e-e052-41b0-a4ce-05dfe62faaaf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021648Orig1REVs004.pdf,
2004,DIGOXIN,DIGOXIN,NDA021648,1b7e5c6e-e052-41b0-a4ce-05dfe62faaaf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021648s000TOC.cfm,
2007,PROTONIX DELAYED-RELEASE,PANTOPRAZOLE SODIUM,NDA022020,08098cb2-c048-4640-f387-6beec4a38936,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022020_protonix_toc.cfm,
2007,PROTONIX DELAYED-RELEASE,PANTOPRAZOLE SODIUM,NDA022020,08098cb2-c048-4640-f387-6beec4a38936,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022020s000_SumR.pdf,
2007,PROTONIX DELAYED-RELEASE,PANTOPRAZOLE SODIUM,NDA022020,08098cb2-c048-4640-f387-6beec4a38936,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022020_Pantoprazole_Clinical_BPCA.pdf,
2007,PROTONIX DELAYED-RELEASE,PANTOPRAZOLE SODIUM,NDA022020,08098cb2-c048-4640-f387-6beec4a38936,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022020_Pantoprazole_Clinpharm_BPCA.pdf,
2007,PROTONIX DELAYED-RELEASE,PANTOPRAZOLE SODIUM,NDA022020,08098cb2-c048-4640-f387-6beec4a38936,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022020_Pantoprazole_Statistical_BPCA.pdf,
2007,PROTONIX DELAYED-RELEASE,PANTOPRAZOLE SODIUM,NDA022020,08098cb2-c048-4640-f387-6beec4a38936,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022020_Pantoprazole_DDSummary_BPCA.pdf,
2007,PROTONIX DELAYED-RELEASE,PANTOPRAZOLE SODIUM,NDA022020,08098cb2-c048-4640-f387-6beec4a38936,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/022020_Pantoprazole_DDSummary_BPCA.pdf,
2008,ACANYA,CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE,NDA050819,3dcd2c96-72b1-4a9f-b65c-08198d63b7df,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/050819Orig1s012.pdf,
2008,ACANYA,CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE,NDA050819,3dcd2c96-72b1-4a9f-b65c-08198d63b7df,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/050819_acanya_toc.cfm,
2008,ACANYA,CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE,NDA050819,3dcd2c96-72b1-4a9f-b65c-08198d63b7df,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/050819s000_SumR_P1.pdf,
1997,RITUXAN,RITUXIMAB,BLA103705,b172773b-3905-4a1c-ad95-bab4b6126563,https://web.archive.org/web/20170210011738/http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm093345.htm,
1997,RITUXAN,RITUXIMAB,BLA103705,b172773b-3905-4a1c-ad95-bab4b6126563,http://www.accessdata.fda.gov/drugsatfda_docs/bla/2011/103705Orig1s5344.pdf,
2010,LATUDA,LURASIDONE HYDROCHLORIDE,NDA200603,afad3051-9df2-4c54-9684-e8262a133af8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/200603Orig1s011.pdf,
2010,LATUDA,LURASIDONE HYDROCHLORIDE,NDA200603,afad3051-9df2-4c54-9684-e8262a133af8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200603Orig1s000TOC.cfm,
2010,LATUDA,LURASIDONE HYDROCHLORIDE,NDA200603,afad3051-9df2-4c54-9684-e8262a133af8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200603Orig1s000SumR.pdf,
2010,LATUDA,LURASIDONE HYDROCHLORIDE,NDA200603,afad3051-9df2-4c54-9684-e8262a133af8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/499_200603S35 lurasidone clinical prea.pdf,
2010,LATUDA,LURASIDONE HYDROCHLORIDE,NDA200603,afad3051-9df2-4c54-9684-e8262a133af8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/499_200603S35 lurasidone clinical prea.pdf,
2010,LATUDA,LURASIDONE HYDROCHLORIDE,NDA200603,afad3051-9df2-4c54-9684-e8262a133af8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/499_200603S35 lurasidone clinical prea.pdf,
2010,LATUDA,LURASIDONE HYDROCHLORIDE,NDA200603,afad3051-9df2-4c54-9684-e8262a133af8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/68_200603s026 lurasidone clinical prea.pdf,
2010,LATUDA,LURASIDONE HYDROCHLORIDE,NDA200603,afad3051-9df2-4c54-9684-e8262a133af8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/69_200603s026 lurasidone statistical prea.pdf,
2010,LATUDA,LURASIDONE HYDROCHLORIDE,NDA200603,afad3051-9df2-4c54-9684-e8262a133af8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/200603Orig1s010.pdf,
2010,LATUDA,LURASIDONE HYDROCHLORIDE,NDA200603,afad3051-9df2-4c54-9684-e8262a133af8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/200603s29 lurasidone CDTL clinical prea.pdf,
2010,LATUDA,LURASIDONE HYDROCHLORIDE,NDA200603,afad3051-9df2-4c54-9684-e8262a133af8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/200603s29 lurasidone clinical prea.pdf,
2010,LATUDA,LURASIDONE HYDROCHLORIDE,NDA200603,afad3051-9df2-4c54-9684-e8262a133af8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/200603s29 lurasidone clinpharm prea_0.pdf,
2010,LATUDA,LURASIDONE HYDROCHLORIDE,NDA200603,afad3051-9df2-4c54-9684-e8262a133af8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/200603s29 lurasidone statistical prea.pdf,
2010,LATUDA,LURASIDONE HYDROCHLORIDE,NDA200603,afad3051-9df2-4c54-9684-e8262a133af8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/71_200603s027 lurasidone clinical prea.pdf,
2010,LATUDA,LURASIDONE HYDROCHLORIDE,NDA200603,afad3051-9df2-4c54-9684-e8262a133af8,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/72_200603s027 lurasidone statistical prea.pdf,
2010,LATUDA,LURASIDONE HYDROCHLORIDE,NDA200603,afad3051-9df2-4c54-9684-e8262a133af8,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/70_200603s026, 027 lurasidone clinpharm prea.pdf",
2013,N/A,N/A,NDA204307,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204307_vituz_toc.cfm,
2013,N/A,N/A,NDA204307,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204307Orig1s000SumR.pdf,
2015,PROMACTA,ELTROMBOPAG OLAMINE,NDA207027,7714a0ed-34bb-46e6-a0a5-b363908b22c2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207027Orig1s000TOC.cfm,
2015,PROMACTA,ELTROMBOPAG OLAMINE,NDA207027,7714a0ed-34bb-46e6-a0a5-b363908b22c2,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/207027S6 eltrombopag clinical prea.pdf,
2015,PROMACTA,ELTROMBOPAG OLAMINE,NDA207027,7714a0ed-34bb-46e6-a0a5-b363908b22c2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207027Orig1s000SumR.pdf,
2015,PROMACTA,ELTROMBOPAG OLAMINE,NDA207027,7714a0ed-34bb-46e6-a0a5-b363908b22c2,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/207027S6 eltrombopag clinical prea.pdf,
2015,ONIVYDE,IRINOTECAN HYDROCHLORIDE,NDA207793,c8b58efa-1820-48a4-b70d-62918fc4abfc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207793Orig1s000TOC.cfm,
2021,TYRVAYA,VARENICLINE,NDA213978,014c93dc-5737-479c-a9f0-aaadac1ac298,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/213978Orig1s000TOC.cfm,
2024,AXTLE,PEMETREXED,NDA210661,9582c46c-d8b0-44b7-a2ee-9c86f5e9b7b1,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/210661Orig1s000TOC.cfm,
2019,N/A,N/A,NDA212038,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212038Orig1s000TOC.cfm,
2019,N/A,N/A,NDA212038,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/395_212038 methylphenidate clinpharm prea.pdf,
2019,N/A,N/A,NDA212038,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/212038 methylphenidate statistics prea.pdf,
2019,N/A,N/A,NDA212038,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/212038 methylphenidate statistics 2 prea_0.pdf,
2019,N/A,N/A,NDA212038,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/212038 methylphenidate clinical prea_0.pdf,
2024,NYPOZI TXID,FILGRASTIM-TXID,BLA761126,89092bb8-6a20-e23e-e053-2a95a90aa750,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761126Orig1s000TOC.cfm,
2010,ORAVIG,MICONAZOLE,NDA022404,dc2427ff-e566-4b48-b289-9e51c011250a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022404s000_oravig_toc.cfm,
2010,ORAVIG,MICONAZOLE,NDA022404,dc2427ff-e566-4b48-b289-9e51c011250a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022404Orig1s000SumR.pdf,
1999,UVADEX,METHOXSALEN,NDA020969,5ad333bd-845f-43f8-9ecf-43491f26c7c7,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20969.cfm,
2001,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE","DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE",NDA021303,f85af6ee-9029-42de-adea-6dbb8642952c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021303Orig1s005.pdf,
2001,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE","DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE",NDA021303,f85af6ee-9029-42de-adea-6dbb8642952c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21303_Adderall.cfm,
2001,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE","DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE",NDA021303,f85af6ee-9029-42de-adea-6dbb8642952c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021303_S001_AdderallTOC.cfm,
2001,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE","DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE",NDA021303,f85af6ee-9029-42de-adea-6dbb8642952c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021303Orig1s009.pdf,
2001,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE","DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE",NDA021303,f85af6ee-9029-42de-adea-6dbb8642952c,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021303s009_amphetamine (mixed salts)_Adderall-MedRev.pdf,
2001,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE","DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE",NDA021303,f85af6ee-9029-42de-adea-6dbb8642952c,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021303s009_amphetamine (mixed salts)_Adderall-ClinPharmRev.pdf,
2001,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE","DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE",NDA021303,f85af6ee-9029-42de-adea-6dbb8642952c,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021303s009_amphetamine (mixed salts)_Adderall-StatsRev.pdf,
2004,N/A,N/A,NDA021643,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021643s000_MVI_AdultTOC.cfm,
2006,MIRALAX,POLYETHYLENE GLYCOL 3350,NDA022015,d69ce3d4-7ca4-4fe3-b49e-6655e48d6963,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022015s000_TOC.cfm,
2010,CAYSTON,AZTREONAM,NDA050814,67300ca3-8c53-4ce4-8e86-2c03be1f9b8a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/050814Orig1s000SumR.pdf,
2010,CAYSTON,AZTREONAM,NDA050814,67300ca3-8c53-4ce4-8e86-2c03be1f9b8a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/050814s000_cayston_toc.cfm,
2010,CAYSTON,AZTREONAM,NDA050814,67300ca3-8c53-4ce4-8e86-2c03be1f9b8a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/050814Orig1s001.pdf,
1983,DOPAMINE HYDROCHLORIDE IN DEXTROSE,DOPAMINE HYDROCHLORIDE IN DEXTROSE,NDA018826,08f23f6e-150d-45ea-098e-f2edf64c21a1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/18-826S027.pdf,
2013,N/A,N/A,NDA204308,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204308Orig1s000TOC.cfm,
2013,N/A,N/A,NDA204308,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204308Orig1s000SumR.pdf,
2018,IMVEXXY,ESTRADIOL,NDA208564,104be9f2-a8f6-430e-9e01-2ee7cc1861f1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208564Orig1s000TOC.cfm,
2018,XOSPATA,GILTERITINIB,NDA211349,b5ff59aa-9c0d-49a8-9053-1f179b482383,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211349Orig1s001.pdf,
2018,XOSPATA,GILTERITINIB,NDA211349,b5ff59aa-9c0d-49a8-9053-1f179b482383,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211349Orig1_toc.cfm,
1998,DETROL,TOLTERODINE TARTRATE,NDA020771,42f819c9-4108-4ca7-92c5-a213037dd4db,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20771_Detrol.cfm,
1998,DETROL,TOLTERODINE TARTRATE,NDA020771,42f819c9-4108-4ca7-92c5-a213037dd4db,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020771_S004_DetrolTOC2.cfm,
1998,DETROL,TOLTERODINE TARTRATE,NDA020771,42f819c9-4108-4ca7-92c5-a213037dd4db,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020771_s011_DELTROL 1 & 2 MG.pdf,
1998,DETROL,TOLTERODINE TARTRATE,NDA020771,42f819c9-4108-4ca7-92c5-a213037dd4db,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020771_s009_DETROL.pdf,
1998,LOTEPREDNOL ETABONATE,LOTEPREDNOL ETABONATE,NDA020803,7714824b-29ed-442a-ad2d-13ee2fc6bc42,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020803_alrex_toc.cfm,
1999,N/A,N/A,NDA020837,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020837_S010_Xopenex_APPROVAL PACKAGE.pdf,
1999,N/A,N/A,NDA020837,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20837 levalbuterol clinical prea.pdf,
1999,N/A,N/A,NDA020837,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20837 levalbuterol clinpharm prea.pdf,
1999,N/A,N/A,NDA020837,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20837 levalbuterol statistical prea.pdf,
1999,N/A,N/A,NDA020837,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20837_Xenopex.cfm,
2021,N/A,N/A,NDA215252,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215252Orig1s000TOC.cfm,
2023,MICAFUNGIN IN SODIUM CHLORIDE,MICAFUNGIN IN SODIUM CHLORIDE,NDA216142,a95f901e-0ac4-4ec0-9720-9c6a066cd06c,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/216142Orig1s000TOC.cfm,
2011,CAPRELSA,VANDETANIB,NDA022405,e5721cb8-4185-47b9-bbb3-1c587e558a03,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000TOC.cfm,
2011,CAPRELSA,VANDETANIB,NDA022405,e5721cb8-4185-47b9-bbb3-1c587e558a03,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000SumR.pdf,
2000,ARTICAINE,ARTICAINE HYDROCHLORIDE AND EPINEPHRINE,NDA020971,4524cb96-40f7-471f-bfc6-1dcab47628ec,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020971_SeptocaineTOC.cfm,
2000,ARTICAINE,ARTICAINE HYDROCHLORIDE AND EPINEPHRINE,NDA020971,4524cb96-40f7-471f-bfc6-1dcab47628ec,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020971Orig1s009.pdf,
2000,ARTICAINE,ARTICAINE HYDROCHLORIDE AND EPINEPHRINE,NDA020971,4524cb96-40f7-471f-bfc6-1dcab47628ec,http://www.accessdata.fda.gov/drugsatfda_docs/2010/020971Orig1s023.pdf,
2000,ARTICAINE,ARTICAINE HYDROCHLORIDE AND EPINEPHRINE,NDA020971,4524cb96-40f7-471f-bfc6-1dcab47628ec,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/020971Orig1s021.pdf,
2000,ARTICAINE,ARTICAINE HYDROCHLORIDE AND EPINEPHRINE,NDA020971,4524cb96-40f7-471f-bfc6-1dcab47628ec,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020971Orig1s013.pdf,
2001,VALCYTE,VALGANCICLOVIR,NDA021304,4c517a39-2ded-4c5a-8d56-276853414b31,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022257_021304s007_valcyte_valganciclovir hydrochloride_toc.cfm,
2001,VALCYTE,VALGANCICLOVIR,NDA021304,4c517a39-2ded-4c5a-8d56-276853414b31,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022257Original-1_021304s007sumr.pdf,
2001,VALCYTE,VALGANCICLOVIR,NDA021304,4c517a39-2ded-4c5a-8d56-276853414b31,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021304_S001_VALCYTE.pdf,
2001,VALCYTE,VALGANCICLOVIR,NDA021304,4c517a39-2ded-4c5a-8d56-276853414b31,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21304 valganciclovir clinical prea.pdf,
2001,VALCYTE,VALGANCICLOVIR,NDA021304,4c517a39-2ded-4c5a-8d56-276853414b31,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21304 valganciclovir clinpharm prea.pdf,
2001,VALCYTE,VALGANCICLOVIR,NDA021304,4c517a39-2ded-4c5a-8d56-276853414b31,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21304_Valcyte.cfm,
2004,CLOBETASOL PROPIONATE,CLOBETASOL PROPIONATE,NDA021644,524397b3-84c4-49d7-af5e-bb229dfee68b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-644_Clobex.cfm,
1975,N/A,N/A,NDA050479,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50479S015_Cortisporin.pdf,
2008,CEFEPIME,CEFEPIME,NDA050817,be5f8ca6-7232-423a-a2d5-cccb7abe7921,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/050817_cefepime_toc.cfm,
2008,CEFEPIME,CEFEPIME,NDA050817,be5f8ca6-7232-423a-a2d5-cccb7abe7921,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/050817s000_SumR.pdf,
1975,SINEMET,CARBIDOPA AND LEVODOPA,NDA017555,9b17b028-964a-473c-823d-81423535bd66,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/017555Orig1s069.pdf,
1999,N/A,N/A,BLA103767,N/A,https://web.archive.org/web/20120303004301/http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080717.htm,
2014,ZYDELIG,IDELALISIB,NDA205858,efbdafa9-d18c-4e85-b4a2-1e620fc74e50,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205858Orig1s000SumR.pdf,
2014,ZYDELIG,IDELALISIB,NDA205858,efbdafa9-d18c-4e85-b4a2-1e620fc74e50,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205858Orig1s000TOC.cfm,
2017,VYZULTA,LATANOPROSTENE BUNOD,NDA207795,60ce7900-a677-4fc2-88d0-1603baa9dbd4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207795Orig1s000TOC.cfm,
1991,ZOLOFT,SERTRALINE HYDROCHLORIDE,NDA019839,fe9e8b7d-61ea-409d-84aa-3ebd79a046b5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/19-839S35_Zoloft.cfm,
1991,ZOLOFT,SERTRALINE HYDROCHLORIDE,NDA019839,fe9e8b7d-61ea-409d-84aa-3ebd79a046b5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019839ap.pdf,
1991,ZOLOFT,SERTRALINE HYDROCHLORIDE,NDA019839,fe9e8b7d-61ea-409d-84aa-3ebd79a046b5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019839_s011ap.pdf,
1991,ZOLOFT,SERTRALINE HYDROCHLORIDE,NDA019839,fe9e8b7d-61ea-409d-84aa-3ebd79a046b5,"https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/019839s044, 020990s010_sertraline_Zoloft-MedRev_PREA.pdf",
1991,ZOLOFT,SERTRALINE HYDROCHLORIDE,NDA019839,fe9e8b7d-61ea-409d-84aa-3ebd79a046b5,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/019839s044_sertraline_Zoloft_StatsRev_PREA.pdf,
1991,ZOLOFT,SERTRALINE HYDROCHLORIDE,NDA019839,fe9e8b7d-61ea-409d-84aa-3ebd79a046b5,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/019839s044,020990s010_ZoloftTOC.cfm",
1991,ZOLOFT,SERTRALINE HYDROCHLORIDE,NDA019839,fe9e8b7d-61ea-409d-84aa-3ebd79a046b5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/19-839S026_Zoloft.cfm,
1991,ZOLOFT,SERTRALINE HYDROCHLORIDE,NDA019839,fe9e8b7d-61ea-409d-84aa-3ebd79a046b5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019839ap.pdf,
1992,AMBIEN,ZOLPIDEM TARTRATE,NDA019908,747949c5-2c91-4909-8a07-71b6826f8e97,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/019908Orig1s032,s034,021774Orig1s013,s015review.pdf",
1992,AMBIEN,ZOLPIDEM TARTRATE,NDA019908,747949c5-2c91-4909-8a07-71b6826f8e97,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/019908Orig1s032,s034,021774Orig1s013,s015review.pdf",
1992,AMBIEN,ZOLPIDEM TARTRATE,NDA019908,747949c5-2c91-4909-8a07-71b6826f8e97,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/019908s022_zolpidem_Ambien_MedRev_PREA.pdf,
1992,AMBIEN,ZOLPIDEM TARTRATE,NDA019908,747949c5-2c91-4909-8a07-71b6826f8e97,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/019908s022_zolpidem_Ambien_ClinPharmRev_PREA.pdf,
1992,AMBIEN,ZOLPIDEM TARTRATE,NDA019908,747949c5-2c91-4909-8a07-71b6826f8e97,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019908_S002_AMBIEN_AP.pdf,
1992,AMBIEN,ZOLPIDEM TARTRATE,NDA019908,747949c5-2c91-4909-8a07-71b6826f8e97,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/019908Orig1s027.pdf,
1992,AMBIEN,ZOLPIDEM TARTRATE,NDA019908,747949c5-2c91-4909-8a07-71b6826f8e97,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/019908Orig1s025.pdf,
1992,AMBIEN,ZOLPIDEM TARTRATE,NDA019908,747949c5-2c91-4909-8a07-71b6826f8e97,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019908_S000_AmbienTOC.cfm,
2022,DAXXIFY,BOTULINUM TOXIN TYPE A,BLA761127,3aaa6e14-a3f7-4fb2-b9f9-d3a9c3ae1f74,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761127Orig1s000TOC.cfm,
1997,METRONIDAZOLE,METRONIDAZOLE,NDA020743,cdf2e251-4bbc-4434-9b00-bef6284491e4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020743_noritate_toc.cfm,
2011,XARELTO,RIVAROXABAN,NDA022406,10db92f9-2300-4a80-836b-673e1ae91610,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022406Orig1s000TOC.cfm,
1998,N/A,N/A,NDA020972,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20972 efavirenz clinical bpca.pdf,
1998,N/A,N/A,NDA020972,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20972 efavirenz clinpharm bpca.pdf,
1998,N/A,N/A,NDA020972,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020972_S027_SUSTIVA.pdf,
1998,N/A,N/A,NDA020972,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-972_S001_Sustiva.cfm,
1998,N/A,N/A,NDA020972,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20972.cfm,
1998,N/A,N/A,NDA020972,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020972_S022_SUSTIVA.pdf,
1998,N/A,N/A,NDA020972,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020972_S014_SUSTIVA.pdf,
2003,HICON,SODIUM IODIDE I 131,NDA021305,524a0dac-6e2b-2c0c-04b4-76d85dba63c5,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021305_sodiumiodide.cfm,
2017,N/A,N/A,NDA022018,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/022018Orig1s000TOC.cfm,
2017,N/A,N/A,NDA022018,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/022018Orig1s000SumR.pdf,
2009,TOBRADEX ST,TOBRAMYCIN / DEXAMETHASONE,NDA050818,3b99dbb3-ac84-4d0d-b30f-a5db44fdc316,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/050818_tobradex_st_toc.cfm,
2009,TOBRADEX ST,TOBRAMYCIN / DEXAMETHASONE,NDA050818,3b99dbb3-ac84-4d0d-b30f-a5db44fdc316,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/050818s000sumr.pdf,
1998,HERCEPTIN,TRASTUZUMAB,BLA103792,492dbdb2-077e-4064-bff3-372d6af0a7a2,http://www.accessdata.fda.gov/drugsatfda_docs/bla/2008/103792s5187-5189_Herceptin_toc.cfm,
1998,HERCEPTIN,TRASTUZUMAB,BLA103792,492dbdb2-077e-4064-bff3-372d6af0a7a2,http://www.accessdata.fda.gov/drugsatfda_docs/bla/2008/103792s5187-5189_Herceptin_toc.cfm,
1998,HERCEPTIN,TRASTUZUMAB,BLA103792,492dbdb2-077e-4064-bff3-372d6af0a7a2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/103792Orig1s5175.pdf,
1998,HERCEPTIN,TRASTUZUMAB,BLA103792,492dbdb2-077e-4064-bff3-372d6af0a7a2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/103792Orig1s5337.pdf,
1998,HERCEPTIN,TRASTUZUMAB,BLA103792,492dbdb2-077e-4064-bff3-372d6af0a7a2,https://web.archive.org/web/20170128163102/http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080591.htm,
1998,HERCEPTIN,TRASTUZUMAB,BLA103792,492dbdb2-077e-4064-bff3-372d6af0a7a2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/103792Orig1s5311TOC.cfm,
1998,HERCEPTIN,TRASTUZUMAB,BLA103792,492dbdb2-077e-4064-bff3-372d6af0a7a2,http://www.accessdata.fda.gov/drugsatfda_docs/bla/2012/103792Orig1s5275.pdf,
2011,ZELBORAF,VEMURAFENIB,NDA202429,38eea320-7e0c-485a-bc30-98c3c45e2763,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/202429Orig1s016TOC.cfm,
2011,ZELBORAF,VEMURAFENIB,NDA202429,38eea320-7e0c-485a-bc30-98c3c45e2763,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202429s000TOC.cfm,
2011,ZELBORAF,VEMURAFENIB,NDA202429,38eea320-7e0c-485a-bc30-98c3c45e2763,http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202429Orig1s000SumR.pdf,
2012,N/A,N/A,NDA202788,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202788Orig1s000SumR.pdf,
2012,N/A,N/A,NDA202788,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202788_subsys_toc.cfm,
2016,VENCLEXTA,VENETOCLAX,NDA208573,b118a40d-6b56-cee3-10f6-ded821a97018,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/208573Orig1s020, s021.pdf",
2016,VENCLEXTA,VENETOCLAX,NDA208573,b118a40d-6b56-cee3-10f6-ded821a97018,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208573Orig1s000TOC.cfm,
2016,VENCLEXTA,VENETOCLAX,NDA208573,b118a40d-6b56-cee3-10f6-ded821a97018,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208573Orig1s000SumR.pdf,
2016,VENCLEXTA,VENETOCLAX,NDA208573,b118a40d-6b56-cee3-10f6-ded821a97018,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/208573Orig1s020, s021.pdf",
2016,VENCLEXTA,VENETOCLAX,NDA208573,b118a40d-6b56-cee3-10f6-ded821a97018,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/208573Orig1s013TOC.cfm,
1954,LANOXIN,DIGOXIN,NDA009330,9ec84cac-6ecc-43dc-8006-6ccc029e2707,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/9330-s020_lanoxin.pdf,
2019,PADCEV EJFV,ENFORTUMAB VEDOTIN,BLA761137,b5631d3e-4604-4363-8f20-11dfc5a4a8ed,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761137Orig1s000TOC.cfm,
2022,NOREPINEPHRINE BITARTRATE IN SODIUM CHLORIDE,NOREPINEPHRINE BITARTRATE,NDA215700,ddbef60d-c20a-4ada-928f-e87074c08a54,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215700Orig1s000TOC.cfm,
1998,N/A,N/A,NDA020977,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020977_S014_ZIAGEN.pdf,
1998,N/A,N/A,NDA020977,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-977S-002_review.pdf,
1998,N/A,N/A,NDA020977,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020977_S012_Ziagen.pdf,
1998,N/A,N/A,NDA020977,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/20977 abacavir statistical prea.pdf,
1998,N/A,N/A,NDA020977,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20-977_Ziagen.cfm,
1998,N/A,N/A,NDA020977,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020977s019_Abacavir_Clinical_PREA.pdf,
1998,N/A,N/A,NDA020977,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020977s019_Abacavir_Clinpharm_PREA.pdf,
2008,ALVESCO,CICLESONIDE,NDA021658,9f6112fb-78ef-43cf-8ae3-36370eb45468,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021658s000TOC.cfm,
2008,ALVESCO,CICLESONIDE,NDA021658,9f6112fb-78ef-43cf-8ae3-36370eb45468,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/r_021658s000_Ciclesonide(Alvesco)_Clinical_PREA.pdf,
2008,ALVESCO,CICLESONIDE,NDA021658,9f6112fb-78ef-43cf-8ae3-36370eb45468,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/r_021658s000_Ciclesonide(Alvesco)_Clinpharm_PREA.pdf,
2008,ALVESCO,CICLESONIDE,NDA021658,9f6112fb-78ef-43cf-8ae3-36370eb45468,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/r_021658s000_Ciclesonide(Alvesco)_Statistical_PREA.pdf,
2008,ALVESCO,CICLESONIDE,NDA021658,9f6112fb-78ef-43cf-8ae3-36370eb45468,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021658s000_SumR.pdf,
2007,N/A,N/A,NDA022025,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022025_totect_toc.cfm,
2007,N/A,N/A,NDA022025,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022025s000_SumR.pdf,
2011,N/A,N/A,NDA050824,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/050824_omeprazole_clarithromycin_amoxicillin_toc.cfm,
2011,N/A,N/A,NDA050824,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/050824Orig1s000SumR.pdf,
1998,INFLIXIMAB,INFLIXIMAB,BLA103772,b05c174f-832c-4321-b34f-2c4ad3742269,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/103772_S5056_REMIICADE.pdf,
1998,INFLIXIMAB,INFLIXIMAB,BLA103772,b05c174f-832c-4321-b34f-2c4ad3742269,https://web.archive.org/web/20170118085130/http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm093335.htm,
1998,INFLIXIMAB,INFLIXIMAB,BLA103772,b05c174f-832c-4321-b34f-2c4ad3742269,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/103772Orig1s5113.pdf,
1998,INFLIXIMAB,INFLIXIMAB,BLA103772,b05c174f-832c-4321-b34f-2c4ad3742269,https://web.archive.org/web/20170118085130/http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm093327.htm,
1998,INFLIXIMAB,INFLIXIMAB,BLA103772,b05c174f-832c-4321-b34f-2c4ad3742269,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/103772Orig1s5189Approv.pdf,
1998,INFLIXIMAB,INFLIXIMAB,BLA103772,b05c174f-832c-4321-b34f-2c4ad3742269,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/103772_S1007_REMICADE.pdf,
2023,N/A,N/A,NDA204311,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/204311Orig1s000TOC.cfm,
2014,EPINEPHRINE,EPINEPHRINE,NDA205029,db18519b-82a9-435b-85c7-a040d644f057,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205029Orig1s000TOC.cfm,
2018,ANNOVERA,SEGESTERONE ACETATE AND ETHINYL ESTRADIOL,NDA209627,eb18194f-2021-41fa-8bdf-31e0c0eb646b,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209627Orig1s000TOC.cfm,
2020,BAFIERTAM,MONOMETHYL FUMARATE,NDA210296,a161f9d4-70f1-4097-957a-eafb35d3274f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210296Orig1s000TOC.cfm,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019766_S022_ZOCOR_TABLETS.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019766_s014_ZOCOR_TABLETS.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/019766_S067&S068_ZOCAR TABS_AP.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019766_s012_ZOCOR_TABLETS.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019766_s008_ZOCOR_TABLETS.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/019766_S049_ZOCOR.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019766_S055_ZOCOR.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/019766_S047_ZOCOR.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/019766_S053_ZOCOR.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/019766_S045_ZOCOR.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/019766a_s029.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/019766_S043_ZOCOR_TABLETS.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/019766_s035_ZOCOR TABLETS.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/019766s027_Zocor.cfm,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/019766_s041_ZOCOR_TABLETS.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/019766_S033_ZOCOR_TABLET.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019766_S025_ZOCOR_TABLETS.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/019766_s031_ZOCOR_TABLETS.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019766_S023_ZOCOR_TABLETS.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/019766_S067&S068_ZOCAR TABS_AP.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/019766_S058_ZOCOR_TABS_AP.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/019766_S048_ZOCOR.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019766_S054_ZOCOR.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/19-766s052_Zocor.cfm,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/019766_S044_ZOCOR_TABLET.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/19766s34_Zocor.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/019766_S050_ZOCOR.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/119766-s28.cfm,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/19766s34_Zocor.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/119766-s28.cfm,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/19766-S040_Zocor.cfm,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019766a_s018.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/019766s077.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019766_S016_ZOCOR_TABLETS.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/019766_S030_ZOCOR_TABLETS.pdf,
1991,ZOCOR,SIMVASTATIN,NDA019766,8f55d5de-5a4f-4a39-8c84-c53976dd6af9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/019766Orig1s083.pdf,
2018,VANCOMYCIN HYDROCHLORIDE FOR ORAL SOLUTION,VANCOMYCIN HYDROCHLORIDE,NDA208910,4c3d2e99-5351-4442-916a-d2001b0a5f5a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208910Orig1s000TOC.cfm,
2020,TIVICAY PD,DOLUTEGRAVIR SODIUM,NDA213983,63df5af3-b8ac-4e76-9830-2dbb340af922,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213983Orig1s000TOC.cfm,
2021,KLOXXADO,NALOXONE HCL,NDA212045,ebf0f833-c1c0-487c-8f29-01fa8c61b6cb,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212045Orig1s000TOC.cfm,
2024,BORUZU,BORTEZOMIB,NDA212782,b92628dd-fa09-4c3a-b6a3-66426025807c,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/212782Orig1s000TOC.cfm,
2023,ENTYVIO,VEDOLIZUMAB,BLA761133,6e94621c-1a95-4af9-98d1-52b9e6f1949c,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761133Orig1s000TOC.cfm,
2021,WEGOVY,SEMAGLUTIDE,NDA215256,ee06186f-2aa3-4990-a760-757579d8f77b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/215256Orig1s011.pdf,
2021,WEGOVY,SEMAGLUTIDE,NDA215256,ee06186f-2aa3-4990-a760-757579d8f77b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215256Orig1s000TOC.cfm,
1998,LOTEPREDNOL ETABONATE,LOTEPREDNOL ETABONATE,NDA020583,f09b1206-97c7-4f21-bda8-94f55128c5cb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/020583Orig1s027.pdf,
1998,LOTEPREDNOL ETABONATE,LOTEPREDNOL ETABONATE,NDA020583,f09b1206-97c7-4f21-bda8-94f55128c5cb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20583_Lotemax.cfm,
1998,LOTEPREDNOL ETABONATE,LOTEPREDNOL ETABONATE,NDA020583,f09b1206-97c7-4f21-bda8-94f55128c5cb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/020583Orig1s028.pdf,
1999,LIDOCAINE,LIDOCAINE,NDA020612,2ce8a4fe-8aa6-4dc5-ad0f-3984ae68c4bc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20612.cfm,
1999,LIDOCAINE,LIDOCAINE,NDA020612,2ce8a4fe-8aa6-4dc5-ad0f-3984ae68c4bc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020612_S002_Lidoderm Patch_APPROVAL PACKAGE.pdf,
1999,LIDOCAINE,LIDOCAINE,NDA020612,2ce8a4fe-8aa6-4dc5-ad0f-3984ae68c4bc,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020612_S003_Lidoderm Patch_APPROVAL PACKAGE.pdf,
1996,CLARITIN ALLERGY,LORATADINE,NDA020641,19afd658-8c67-af44-e063-6394a90abada,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/19670s18,20470s16,19658s18,20704s8,20641s9_Claritin.cfm",
1996,CLARITIN ALLERGY,LORATADINE,NDA020641,19afd658-8c67-af44-e063-6394a90abada,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-641s007_LoratadineClaritin.cfm,
1996,CLARITIN ALLERGY,LORATADINE,NDA020641,19afd658-8c67-af44-e063-6394a90abada,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/1998/019670_s012,19658s14,20470s7,20641s3,20704s4_ClaritinDTOC.cfml",
1996,CLARITIN ALLERGY,LORATADINE,NDA020641,19afd658-8c67-af44-e063-6394a90abada,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/1998/019670_s008,19658s10,20470s3,20641s120704s3_Claritin-DTOC.cfml",
2011,SPINOSAD,SPINOSAD,NDA022408,0d6e2507-3669-441e-b5ba-86087fd2955d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022408sOrig1s000TOC.cfm,
2011,SPINOSAD,SPINOSAD,NDA022408,0d6e2507-3669-441e-b5ba-86087fd2955d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/Natroba-Clinical-Review.pdf,
2011,SPINOSAD,SPINOSAD,NDA022408,0d6e2507-3669-441e-b5ba-86087fd2955d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/Natroba-Pharmacology-Review.pdf,
2011,SPINOSAD,SPINOSAD,NDA022408,0d6e2507-3669-441e-b5ba-86087fd2955d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/Natroba-Statistical-Review.pdf,
2011,SPINOSAD,SPINOSAD,NDA022408,0d6e2507-3669-441e-b5ba-86087fd2955d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/Natroba-Statistical-Review-(8-2010).pdf,
2011,SPINOSAD,SPINOSAD,NDA022408,0d6e2507-3669-441e-b5ba-86087fd2955d,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022408Orig1s000SumR.pdf,
2011,SPINOSAD,SPINOSAD,NDA022408,0d6e2507-3669-441e-b5ba-86087fd2955d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22408s005 spinosad clinical prea.pdf,
2011,SPINOSAD,SPINOSAD,NDA022408,0d6e2507-3669-441e-b5ba-86087fd2955d,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/22408s005 spinosad clinpharm prea.pdf,
2001,LOTRIMIN ULTRA ATHLETES FOOT,BUTENAFINE HYDROCHLORIDE,NDA021307,e258c4ac-53ef-4a99-b732-4985f890b938,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-307_Lotrimin.cfm,
2004,EPZICOM,ABACAVIR SULFATE AND LAMIVUDINE,NDA021652,f1139e7f-2db9-4961-9da3-9b7f2088736f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021652s000_EpzicomTOC.cfm,
2004,EPZICOM,ABACAVIR SULFATE AND LAMIVUDINE,NDA021652,f1139e7f-2db9-4961-9da3-9b7f2088736f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21652 abacavir  lamivudine clinical prea.pdf,
2004,EPZICOM,ABACAVIR SULFATE AND LAMIVUDINE,NDA021652,f1139e7f-2db9-4961-9da3-9b7f2088736f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21652 abacavir  lamivudine clinpharm.pdf,
2004,EPZICOM,ABACAVIR SULFATE AND LAMIVUDINE,NDA021652,f1139e7f-2db9-4961-9da3-9b7f2088736f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/21652 abacavir  lamivudine statistical prea.pdf,
2007,N/A,N/A,NDA022021,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022021TOC.cfm,
2010,CEFEPIME HYDROCHLORIDE AND DEXTROSE,CEFEPIME HYDROCHLORIDE,NDA050821,57517a0e-ec1b-4605-a7cc-7e3801158ec9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/050821_cefepime_toc.cfm,
2010,CEFEPIME HYDROCHLORIDE AND DEXTROSE,CEFEPIME HYDROCHLORIDE,NDA050821,57517a0e-ec1b-4605-a7cc-7e3801158ec9,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/050821s000SumR.pdf,
1981,LIDOCAINE HYDROCHLORIDE AND DEXTROSE,LIDOCAINE HYDROCHLORIDE,NDA018461,f21512ea-c7c3-4766-b976-b2c0b5616bf0,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/18-461S050_Lidocaine.pdf,
2002,REBIF,INTERFERON BETA-1A,BLA103780,c6fcb5d2-8fcd-44fa-a838-b84ee5f44f0f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/103780Orig1s5196.pdf,
2002,REBIF,INTERFERON BETA-1A,BLA103780,c6fcb5d2-8fcd-44fa-a838-b84ee5f44f0f,https://web.archive.org/web/20170118085129/http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080737.htm,
2002,REBIF,INTERFERON BETA-1A,BLA103780,c6fcb5d2-8fcd-44fa-a838-b84ee5f44f0f,https://web.archive.org/web/20120303004314/http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080739.htm,
1994,CLARITIN-D 12 HOUR,LORATADINE AND PSEUDOEPHEDRINE SULFATE,NDA019670,a7125705-01ff-4418-8c53-9209c2bbb484,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019670_S017_Claritin-DTOC.cfml,
1994,CLARITIN-D 12 HOUR,LORATADINE AND PSEUDOEPHEDRINE SULFATE,NDA019670,a7125705-01ff-4418-8c53-9209c2bbb484,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/019670_s015,018506s022_Claritin-DTOC.cfml",
1994,CLARITIN-D 12 HOUR,LORATADINE AND PSEUDOEPHEDRINE SULFATE,NDA019670,a7125705-01ff-4418-8c53-9209c2bbb484,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/019670_s013,20470s10,18506s018_Claritin-DTOC.cfml",
1994,CLARITIN-D 12 HOUR,LORATADINE AND PSEUDOEPHEDRINE SULFATE,NDA019670,a7125705-01ff-4418-8c53-9209c2bbb484,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/1998/019670_s008,19658s10,20470s3,20641s120704s3_Claritin-DTOC.cfml",
1994,CLARITIN-D 12 HOUR,LORATADINE AND PSEUDOEPHEDRINE SULFATE,NDA019670,a7125705-01ff-4418-8c53-9209c2bbb484,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/19670s18,20470s16,19658s18,20704s8,20641s9_Claritin.cfm",
1994,CLARITIN-D 12 HOUR,LORATADINE AND PSEUDOEPHEDRINE SULFATE,NDA019670,a7125705-01ff-4418-8c53-9209c2bbb484,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/019670_s014_Claritin-DTOC.cfml,
1994,CLARITIN-D 12 HOUR,LORATADINE AND PSEUDOEPHEDRINE SULFATE,NDA019670,a7125705-01ff-4418-8c53-9209c2bbb484,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/019670Orig1s020.pdf,
1994,CLARITIN-D 12 HOUR,LORATADINE AND PSEUDOEPHEDRINE SULFATE,NDA019670,a7125705-01ff-4418-8c53-9209c2bbb484,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/1998/019670_s012,19658s14,20470s7,20641s3,20704s4_ClaritinDTOC.cfml",
1994,CLARITIN-D 12 HOUR,LORATADINE AND PSEUDOEPHEDRINE SULFATE,NDA019670,a7125705-01ff-4418-8c53-9209c2bbb484,http://www.accessdata.fda.gov/drugsatfda_docs/nda/1999/019670_s009_Claritin-DTOC.cfml,
2015,ULTRAVATE,HALOBETASOL PROPIONATE,NDA208183,74e899db-1c1f-48b2-9913-5d32a14906ae,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208183Orig1s000TOC.cfm,
2015,ULTRAVATE,HALOBETASOL PROPIONATE,NDA208183,74e899db-1c1f-48b2-9913-5d32a14906ae,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208183Orig1s000SumR.pdf,
2018,N/A,N/A,NDA208912,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208912Orig1s000TOC.cfm,
1995,VALTREX,VALACYCLOVIR HYDROCHLORIDE,NDA020487,f8e0d8f8-cb73-4206-a484-88f5c4fbd719,http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20-487s004_ValtrexTOC.cfm,
1995,VALTREX,VALACYCLOVIR HYDROCHLORIDE,NDA020487,f8e0d8f8-cb73-4206-a484-88f5c4fbd719,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20-487s002_ValtrexTOC.cfm,
1995,VALTREX,VALACYCLOVIR HYDROCHLORIDE,NDA020487,f8e0d8f8-cb73-4206-a484-88f5c4fbd719,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020487s014s015_Valacyclovir_Clinical_BPCA.pdf,
1995,VALTREX,VALACYCLOVIR HYDROCHLORIDE,NDA020487,f8e0d8f8-cb73-4206-a484-88f5c4fbd719,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020487s014_Valacyclovir_Clinpharm_BPCA.pdf,
1995,VALTREX,VALACYCLOVIR HYDROCHLORIDE,NDA020487,f8e0d8f8-cb73-4206-a484-88f5c4fbd719,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020487S015_Valacyclovir_Clinpharm_BPCA.pdf,
1995,VALTREX,VALACYCLOVIR HYDROCHLORIDE,NDA020487,f8e0d8f8-cb73-4206-a484-88f5c4fbd719,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/20-487s005_ValtrexTOC.cfm,
1995,VALTREX,VALACYCLOVIR HYDROCHLORIDE,NDA020487,f8e0d8f8-cb73-4206-a484-88f5c4fbd719,http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/20-487s003_ValtrexTOC.cfm,
2023,RYZNEUTA,EFBEMALENOGRASTIM ALFA-VUXW,BLA761134,290ed754-758c-9cae-e063-6294a90ae68b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761134Orig1s000TOC.cfm,
2024,XROMI,HYDROXYUREA,NDA216593,4b37d336-86da-4363-aef1-34a7d3ba973b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/216593Orig1s000TOC.cfm,
2024,XROMI,HYDROXYUREA,NDA216593,4b37d336-86da-4363-aef1-34a7d3ba973b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/216593Orig1s000TOC.cfm,
2024,XROMI,HYDROXYUREA,NDA216593,4b37d336-86da-4363-aef1-34a7d3ba973b,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/216593Orig2s000TOC.cfm,
2023,IDOSE TR,TRAVOPROST INTRACAMERAL,NDA218010,92f6d3e2-8328-47df-972c-23008f4a1c1c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/218010Orig1s000TOC.cfm,
2010,SUBOXONE,"BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE",NDA022410,8a5edcf9-828c-4f97-b671-268ab13a8ecd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022410Orig1s016.pdf,
2010,SUBOXONE,"BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE",NDA022410,8a5edcf9-828c-4f97-b671-268ab13a8ecd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022410Orig1s014.pdf,
2010,SUBOXONE,"BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE",NDA022410,8a5edcf9-828c-4f97-b671-268ab13a8ecd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022410Orig1s006.pdf,
2010,SUBOXONE,"BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE",NDA022410,8a5edcf9-828c-4f97-b671-268ab13a8ecd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022410Orig1s007.pdf,
2010,SUBOXONE,"BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE",NDA022410,8a5edcf9-828c-4f97-b671-268ab13a8ecd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022410Orig1s000TOC.cfm,
2010,SUBOXONE,"BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE",NDA022410,8a5edcf9-828c-4f97-b671-268ab13a8ecd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022410Orig1s000SumR.pdf,
2010,SUBOXONE,"BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE",NDA022410,8a5edcf9-828c-4f97-b671-268ab13a8ecd,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022410Orig1s011.pdf,
1999,N/A,N/A,NDA020975,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20937_OptiMark.cfm,
1999,N/A,N/A,NDA020975,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/20-937s3,20-975s3,20-976s3_OptiMark.cfm",
2001,MONISTAT 1 COMBINATION PACK,MICONAZOLE NITRATE,NDA021308,97ff1c90-c250-4921-81af-6a56cc9cc7d2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021308_S009_MONISTAT 1.pdf,
2001,MONISTAT 1 COMBINATION PACK,MICONAZOLE NITRATE,NDA021308,97ff1c90-c250-4921-81af-6a56cc9cc7d2,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-308_Monistat.cfm,
2004,N/A,N/A,NDA021654,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-654_Omacor.cfm,
2004,N/A,N/A,NDA021654,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021654Orig1s018.pdf,
2004,N/A,N/A,NDA021654,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021853_021654s016_omacor_toc.cfm,
2008,EMEND,FOSAPREPITANT DIMEGLUMINE,NDA022023,8d66803a-6811-4c29-9c57-e16acfa87f21,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/022023Orig1s014.pdf,
2008,EMEND,FOSAPREPITANT DIMEGLUMINE,NDA022023,8d66803a-6811-4c29-9c57-e16acfa87f21,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022023Orig1s004.pdf,
2008,EMEND,FOSAPREPITANT DIMEGLUMINE,NDA022023,8d66803a-6811-4c29-9c57-e16acfa87f21,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/262_22023S017-fosaprepitant-clinical-bpca.pdf,
2008,EMEND,FOSAPREPITANT DIMEGLUMINE,NDA022023,8d66803a-6811-4c29-9c57-e16acfa87f21,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/261_22023S017-fosaprepitant-clinpharm-bpca.pdf,
2008,EMEND,FOSAPREPITANT DIMEGLUMINE,NDA022023,8d66803a-6811-4c29-9c57-e16acfa87f21,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/022023Orig1s017.pdf,
2008,EMEND,FOSAPREPITANT DIMEGLUMINE,NDA022023,8d66803a-6811-4c29-9c57-e16acfa87f21,http://www.accessdata.fda.gov/drugsatfda_docs/NDA/2008/022023s000TOC.cfm,
2008,EMEND,FOSAPREPITANT DIMEGLUMINE,NDA022023,8d66803a-6811-4c29-9c57-e16acfa87f21,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/022023Orig1s018.pdf,
2011,N/A,N/A,NDA050823,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/050823_ceftazidime_toc.cfm,
2011,N/A,N/A,NDA050823,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/050823Orig1s000SumR.pdf,
2013,VIZAMYL,FLUTEMETAMOL F-18,NDA203137,b3558f16-8f9a-4e55-8d9c-836427ebaa57,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203137_vizamyl_toc.cfm,
2012,TAZAROTENE,TAZAROTENE,NDA202428,0e337598-f589-483f-a2ae-be7c319d7454,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202428Orig1s000SumR.pdf,
2012,TAZAROTENE,TAZAROTENE,NDA202428,0e337598-f589-483f-a2ae-be7c319d7454,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202428_fabior_toc.cfm,
1995,PHOTOFRIN,PORFIMER SODIUM,NDA020451,5c4841b4-fbc0-4163-8ee1-cb28629cbfbf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020451Orig1s000rev.pdf,
1995,PHOTOFRIN,PORFIMER SODIUM,NDA020451,5c4841b4-fbc0-4163-8ee1-cb28629cbfbf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020415s012_021525_PhotofrinTOC.cfm,
2018,VITRAKVI,LAROTRECTINIB,NDA211710,9525f887-a055-4e33-8e92-898d42828cd1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210861Orig1s000_21171Orig1s000TOC.cfm,
2021,N/A,N/A,NDA213176,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213176Orig1Orig2s000TOC.cfm,
2019,REBLOZYL,LUSPATERCEPT,BLA761136,82f4d266-3f52-41eb-86ba-0abf3cf468e8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761136Orig1s000TOC.cfm,
2019,REBLOZYL,LUSPATERCEPT,BLA761136,82f4d266-3f52-41eb-86ba-0abf3cf468e8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761136Orig2s000TOC.cfm,
2010,N/A,N/A,NDA022411,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022411_oleptro_toc.cfm,
2010,N/A,N/A,NDA022411,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022411s000SumR.pdf,
1999,N/A,N/A,NDA020976,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/20-937s3,20-975s3,20-976s3_OptiMark.cfm",
1999,N/A,N/A,NDA020976,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20937_OptiMark.cfm,
2004,TRICOR,FENOFIBRATE,NDA021656,b693e68d-f812-4993-54b6-852e3517c344,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021656s000_TricorTOC.cfm,
2009,N/A,N/A,NDA022024,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022024_actoplus_met_xr_toc.cfm,
1983,SODIUM PHOSPHATES,"SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE AND SODIUM PHOSPHATE, DIBASIC, ANHYDROUS",NDA018892,6f044d16-295e-43ff-72a3-b045c387bc5c,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/018892Orig1s038.pdf,
1983,SODIUM PHOSPHATES,"SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE AND SODIUM PHOSPHATE, DIBASIC, ANHYDROUS",NDA018892,6f044d16-295e-43ff-72a3-b045c387bc5c,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/018892Orig1s037.pdf,
2015,LILETTA,LEVONORGESTREL,NDA206229,aaf0eb2a-f88a-4f26-a445-0fd30176c326,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206229Orig1s000TOC.cfm,
2015,LILETTA,LEVONORGESTREL,NDA206229,aaf0eb2a-f88a-4f26-a445-0fd30176c326,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/206229 levonorgestrel clinical prea.pdf,
2015,LILETTA,LEVONORGESTREL,NDA206229,aaf0eb2a-f88a-4f26-a445-0fd30176c326,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/206229 levonorgestrel clinpharm prea2.pdf,
2015,LILETTA,LEVONORGESTREL,NDA206229,aaf0eb2a-f88a-4f26-a445-0fd30176c326,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/206229 levonorgestrel statistical prea.pdf,
2020,TEPEZZA,TEPROTUMUMAB,BLA761143,3e6c54a1-cefd-4a5b-a855-ab9f268b6cce,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761143Orig1s024MedR.pdf,
2020,TEPEZZA,TEPROTUMUMAB,BLA761143,3e6c54a1-cefd-4a5b-a855-ab9f268b6cce,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761143Orig1s000TOC.cfm,
2020,TEPEZZA,TEPROTUMUMAB,BLA761143,3e6c54a1-cefd-4a5b-a855-ab9f268b6cce,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761143Orig1s023.pdf,
2021,OXBRYTA,VOXELOTOR,NDA216157,3c557fac-29ec-483f-b691-8a935d4decc3,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216157Orig1s000TOC.cfm,
2007,HYCAMTIN,TOPOTECAN,NDA020981,aa0815bb-8916-4c2c-9201-b04eb78e91fa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/020981s000_SumR.pdf,
2007,HYCAMTIN,TOPOTECAN,NDA020981,aa0815bb-8916-4c2c-9201-b04eb78e91fa,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/020981_hycamtin_toc.cfm,
2002,IDKIT HP ONE,CITRIC ACID ANHYDROUS AND 13C UREA,NDA021314,8baab7a7-5d20-46ad-9c4a-762992ef6b51,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021314s000_IDKitTOC.cfm,
2004,MENOPUR,MENOTROPINS,BLA021663,22c8db95-c3db-1770-8086-31356fbabe35,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-663_MenopurTOC.cfm,
2008,N/A,N/A,NDA022028,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022028_cosyntropin_toc.cfm,
2008,N/A,N/A,NDA022028,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022028s000_SumR.pdf,
1998,ENBREL,ETANERCEPT,BLA103795,a002b40c-097d-47a5-957f-7a7b1807af7f,https://web.archive.org/web/20170113111347/http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080570.htm,
1998,ENBREL,ETANERCEPT,BLA103795,a002b40c-097d-47a5-957f-7a7b1807af7f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/108_103795 etanercept clinical prea.pdf,
1998,ENBREL,ETANERCEPT,BLA103795,a002b40c-097d-47a5-957f-7a7b1807af7f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/110_103795 etanercept DD clinical prea.pdf,
1998,ENBREL,ETANERCEPT,BLA103795,a002b40c-097d-47a5-957f-7a7b1807af7f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/107_103795 etanercept CDTL clinical prea.pdf,
1998,ENBREL,ETANERCEPT,BLA103795,a002b40c-097d-47a5-957f-7a7b1807af7f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/109_103795 etanercept clinpharm prea.pdf,
1998,ENBREL,ETANERCEPT,BLA103795,a002b40c-097d-47a5-957f-7a7b1807af7f,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/111_103795 etanercept statistical prea.pdf,
1998,ENBREL,ETANERCEPT,BLA103795,a002b40c-097d-47a5-957f-7a7b1807af7f,https://web.archive.org/web/20170118085127/http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080536.htm,
1998,ENBREL,ETANERCEPT,BLA103795,a002b40c-097d-47a5-957f-7a7b1807af7f,https://web.archive.org/web/20160413105708/http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080578.htm,
1998,ENBREL,ETANERCEPT,BLA103795,a002b40c-097d-47a5-957f-7a7b1807af7f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/103795-5102_Enbrel.cfm,
1998,ENBREL,ETANERCEPT,BLA103795,a002b40c-097d-47a5-957f-7a7b1807af7f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/103795_S5097_ENBREL.pdf,
1998,ENBREL,ETANERCEPT,BLA103795,a002b40c-097d-47a5-957f-7a7b1807af7f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/103795_S5109_ENBREL.pdf,
1998,ENBREL,ETANERCEPT,BLA103795,a002b40c-097d-47a5-957f-7a7b1807af7f,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/103795s5123_EnbrelTOC.cfm,
2014,OBREDON,HYDROCODONE BITARTRATE AND GUAIFENESIN,NDA205474,f73fdec5-d330-4d8c-894b-d0bcf5490624,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205474Orig1s000SumR.pdf,
2014,OBREDON,HYDROCODONE BITARTRATE AND GUAIFENESIN,NDA205474,f73fdec5-d330-4d8c-894b-d0bcf5490624,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205474Orig1s000TOC.cfm,
2020,N/A,N/A,NDA208574,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/208574Orig1s000,Orig2s000TOC.cfm",
2020,N/A,N/A,NDA208574,N/A,"http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/208574Orig1s000,Orig2s000TOC.cfm",
2022,N/A,N/A,NDA214408,N/A,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/214408Orig1s000TOC.cfm,
2018,N/A,N/A,NDA211358,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211358Orig1s000TOC.cfm,
1995,COREG,CARVEDILOL,NDA020297,07c619c6-4a0c-445e-94fa-664a54f68a39,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/20-297s009_Coreg.cfm,
1995,COREG,CARVEDILOL,NDA020297,07c619c6-4a0c-445e-94fa-664a54f68a39,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-297S007_Coreg.cfm,
1995,COREG,CARVEDILOL,NDA020297,07c619c6-4a0c-445e-94fa-664a54f68a39,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020297Orig1s000rev.pdf,
1995,COREG,CARVEDILOL,NDA020297,07c619c6-4a0c-445e-94fa-664a54f68a39,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020297s022_carvedilol_Coreg-MedRev.pdf,
1995,COREG,CARVEDILOL,NDA020297,07c619c6-4a0c-445e-94fa-664a54f68a39,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020297s022_carvedilol_Coreg-StatsRev.pdf,
1995,COREG,CARVEDILOL,NDA020297,07c619c6-4a0c-445e-94fa-664a54f68a39,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020297s022_carvedilol_Coreg-ClinPharmRev.pdf,
1995,COREG,CARVEDILOL,NDA020297,07c619c6-4a0c-445e-94fa-664a54f68a39,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20297s4_Coreg.pdf,
2019,ENHERTU,FAM-TRASTUZUMAB DERUXTECAN-NXKI,BLA761139,7e67e73e-ddf4-4e4d-8b50-09d7514910b6,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761139Orig1s028.pdf,
2019,ENHERTU,FAM-TRASTUZUMAB DERUXTECAN-NXKI,BLA761139,7e67e73e-ddf4-4e4d-8b50-09d7514910b6,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761139Orig1s021.pdf,
2019,ENHERTU,FAM-TRASTUZUMAB DERUXTECAN-NXKI,BLA761139,7e67e73e-ddf4-4e4d-8b50-09d7514910b6,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761139Orig1s000TOC.cfm,
2013,APTIOM,ESLICARBAZEPINE ACETATE,NDA022416,3d0c9554-eaeb-4694-8089-00133fcadce3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022416Orig1s000TOC.cfm,
2013,APTIOM,ESLICARBAZEPINE ACETATE,NDA022416,3d0c9554-eaeb-4694-8089-00133fcadce3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022416Orig1s000TOC.cfm,
2013,APTIOM,ESLICARBAZEPINE ACETATE,NDA022416,3d0c9554-eaeb-4694-8089-00133fcadce3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/198_22416S009 eslicarbazepine CDTL clinical prea.pdf,
2013,APTIOM,ESLICARBAZEPINE ACETATE,NDA022416,3d0c9554-eaeb-4694-8089-00133fcadce3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/199_22416S009 eslicarbazepine clinical prea.pdf,
2013,APTIOM,ESLICARBAZEPINE ACETATE,NDA022416,3d0c9554-eaeb-4694-8089-00133fcadce3,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/200_22416S009 eslicarbazepine clinpharm prea.pdf,
1998,ZIAGEN,ABACAVIR SULFATE,NDA020978,ca73b519-015a-436d-aa3c-af53492825a1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20-977_Ziagen.cfm,
1998,ZIAGEN,ABACAVIR SULFATE,NDA020978,ca73b519-015a-436d-aa3c-af53492825a1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-978S-002_review.pdf,
1998,ZIAGEN,ABACAVIR SULFATE,NDA020978,ca73b519-015a-436d-aa3c-af53492825a1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020978_S009_ZIAGEN.pdf,
1998,ZIAGEN,ABACAVIR SULFATE,NDA020978,ca73b519-015a-436d-aa3c-af53492825a1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020978_S016_ZIAGEN.pdf,
1998,ZIAGEN,ABACAVIR SULFATE,NDA020978,ca73b519-015a-436d-aa3c-af53492825a1,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020978_S014_ZIAGEN.pdf,
2002,N/A,N/A,NDA021312,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021312_s007_clarinex red-tabs.pdf,
2002,N/A,N/A,NDA021312,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-312_Clarinex.cfm,
1978,BROMOCRIPTINE MESYLATE,BROMOCRIPTINE MESYLATE,NDA017962,17f3a343-1782-4799-95ba-31dfe93be2cf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/017962_s063_s064_ParlodelTOC.cfm,
1978,BROMOCRIPTINE MESYLATE,BROMOCRIPTINE MESYLATE,NDA017962,17f3a343-1782-4799-95ba-31dfe93be2cf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/017962_s063_s064_ParlodelTOC.cfm,
2018,ZEMDRI (PLAZOMICIN),PLAZOMICIN,NDA210303,1243fcd3-de84-428b-901e-d83d65e4d98c,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210303Orig1s000TOC.cfm,
2019,BACLOFEN,BACLOFEN,NDA208193,2422746c-afec-ad30-e063-6394a90a0403,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/208193Orig1s000TOC.cfm,
2022,XOFLUZA,BALOXAVIR MARBOXIL,NDA214410,e49e1a61-1b7c-4be5-ac84-af6240b511e7,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214410Orig2s000TOC.cfm,
2022,XOFLUZA,BALOXAVIR MARBOXIL,NDA214410,e49e1a61-1b7c-4be5-ac84-af6240b511e7,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214410Orig1s000, 210854Orig1s004, s010TOC.cfm",
1995,N/A,N/A,NDA020221,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20221-S012_Ethyol.cfm,
1995,N/A,N/A,NDA020221,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020221Orig1s000rev.pdf,
2025,VIZZ,ACECLIDINE,NDA218585,7aed8024-ad30-44d6-8f3b-63338ad3ce52,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/218585Orig1s000TOC.cfm,
2020,RIABNI,RITUXIMAB-ARRX,BLA761140,da1c4de7-0e5b-4f72-97ec-7a8d368f085f,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761140Orig1s000TOC.cfm,
2021,LOREEV XR,LORAZEPAM,NDA214826,227734c1-bf01-9607-73ea-5a1f38a89bd9,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214826Orig1s000TOC.cfm,
2010,NORVIR,RITONAVIR,NDA022417,2849298e-de6e-47bb-8194-56e075b33fc3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022417s000TOC.cfm,
2010,NORVIR,RITONAVIR,NDA022417,2849298e-de6e-47bb-8194-56e075b33fc3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022417s000_SumR.pdf,
1955,N/A,N/A,NDA010104,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/010104Orig1s000.pdf,
1950,LEVOPHED,NOREPINEPHRINE BITARTRATE,NDA007513,2c7dd2b0-cc10-4db6-bf56-6eb154ebeb10,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/007513Orig1s038.pdf,
2011,OXAYDO,OXYCODONE HYDROCHLORIDE,NDA202080,cff0c64a-63f5-4b3c-909a-cdecf6755cbe,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202080_oxecta_toc.cfm,
2013,SOVALDI,SOFOSBUVIR,NDA204671,80beab2c-396e-4a37-a4dc-40fdb62859cf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204671Orig1s000TOC.cfm,
2013,SOVALDI,SOFOSBUVIR,NDA204671,80beab2c-396e-4a37-a4dc-40fdb62859cf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204671Orig1s000SumR.pdf,
2013,SOVALDI,SOFOSBUVIR,NDA204671,80beab2c-396e-4a37-a4dc-40fdb62859cf,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/112_204671 S006 sofosbuvir CD clinical prea.pdf,
2013,SOVALDI,SOFOSBUVIR,NDA204671,80beab2c-396e-4a37-a4dc-40fdb62859cf,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/113_204671 S006 sofosbuvir clinpharm prea.pdf,
2017,OZEMPIC,SEMAGLUTIDE,NDA209637,adec4fd2-6858-4c99-91d4-531f5f2a2d79,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209637Orig1s000TOC.cfm,
2015,BENDEKA,BENDAMUSTINE HYDROCHLORIDE,NDA208194,ace9a43b-f9bd-4896-abfe-0ef4fec67ddf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208194Orig1s000TOC.cfm,
2015,BENDEKA,BENDAMUSTINE HYDROCHLORIDE,NDA208194,ace9a43b-f9bd-4896-abfe-0ef4fec67ddf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208194Orig1s004.pdf,
2015,BENDEKA,BENDAMUSTINE HYDROCHLORIDE,NDA208194,ace9a43b-f9bd-4896-abfe-0ef4fec67ddf,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208194Orig1s003.pdf,
2017,CINVANTI,APREPITANT,NDA209296,4c218d3a-a508-4abc-9ed8-a6e8e191d1b4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209296Orig1s000TOC.cfm,
1993,BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,NDA020186,27d52b23-e3e2-4339-b00e-cd0fec43ffbb,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/19982-S3_Zebeta.pdf,
2020,N/A,N/A,NDA213182,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213182Orig1s000TOC.cfm,
2020,UPLIZNA,INEBILIZUMAB,BLA761142,0ce5e7f6-eb97-4738-8b10-43b89e16b5b3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761142Orig1s000TOC.cfm,
2009,N/A,N/A,NDA022418,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022418_fibricor_toc.cfm,
2009,N/A,N/A,NDA022418,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022418s000_SumR.pdf,
1999,LAMISIL AT CREAM,TERBINAFINE HYDROCHLORIDE,NDA020980,9dea4789-bf1c-1577-e053-2a95a90a5381,http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20980.cfm,
2006,CLARINEX-D 12 HOUR,DESLORATADINE AND PSEUDOEPHEDRINE SULFATE,NDA021313,1af66b7a-4ab8-40d8-abdd-22d3310228a8,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021313s000TOC.cfm,
2005,ABRAXANE,PACLITAXEL,NDA021660,24d10449-2936-4cd3-b7db-a7683db721e4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021660Orig1s025.pdf,
2005,ABRAXANE,PACLITAXEL,NDA021660,24d10449-2936-4cd3-b7db-a7683db721e4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021660Orig1s031.pdf,
2005,ABRAXANE,PACLITAXEL,NDA021660,24d10449-2936-4cd3-b7db-a7683db721e4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021660Orig1s013.pdf,
2005,ABRAXANE,PACLITAXEL,NDA021660,24d10449-2936-4cd3-b7db-a7683db721e4,https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/500_21660S46 paclitaxel clinical bpca.pdf,
2005,ABRAXANE,PACLITAXEL,NDA021660,24d10449-2936-4cd3-b7db-a7683db721e4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021660Orig1s026.pdf,
2005,ABRAXANE,PACLITAXEL,NDA021660,24d10449-2936-4cd3-b7db-a7683db721e4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021660Orig1s022.pdf,
2005,ABRAXANE,PACLITAXEL,NDA021660,24d10449-2936-4cd3-b7db-a7683db721e4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021660Orig1s010.pdf,
2005,ABRAXANE,PACLITAXEL,NDA021660,24d10449-2936-4cd3-b7db-a7683db721e4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21660_AbraxaneTOC.cfm,
2005,ABRAXANE,PACLITAXEL,NDA021660,24d10449-2936-4cd3-b7db-a7683db721e4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021660Orig1s037.pdf,
2005,ABRAXANE,PACLITAXEL,NDA021660,24d10449-2936-4cd3-b7db-a7683db721e4,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021660Orig1s029.pdf,
2006,N/A,N/A,NDA022027,N/A,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022027_noxafil_toc.cfm,
